objective	O
:	O
to	O
test	O
the	O
hypothesis	O
that	O
tumor	O
necrosis	O
factor	O
(	O
tnf	O
)	O
-	O
alpha	O
may	O
mediate	O
the	O
loss	O
and	O
the	O
dedifferentiation	O
of	O
subcutaneous	O
fat	O
tissue	O
in	O
the	O
insulin	I-Treatment
-	O
induced	O
lipoatrophies	I-Test
of	O
a	O
diabetic	I-Problem
patient	O
who	O
presented	O
extensive	O
lesions	O
.	O

an	O
evaluation	I-Test
of	I-Test
ovarian	O
structure	O
and	O
function	O
should	O
be	O
considered	O
in	O
women	I-Background
of	I-Background
reproductive	I-Background
age	I-Background
being	O
treated	O
with	O
valproate	I-Treatment
for	I-Treatment
epilepsy	I-Problem
,	O
especially	O
if	O
they	O
develop	O
menstrual	I-Problem
cycle	I-Problem
disturbances	I-Problem
during	O
treatment	O
.	O

phenobarbital	I-Treatment
hepatotoxicity	I-Problem
in	O
an	I-Background
8	I-Background
-	I-Background
month	I-Background
-	I-Background
old	I-Background
infant	I-Background
.	O

the	O
authors	O
report	O
a	O
case	O
of	O
balint	I-Problem
syndrome	I-Problem
with	I-Problem
irreversible	I-Problem
posterior	I-Problem
leukoencephalopathy	I-Problem
on	I-Problem
mri	I-Problem
following	O
intrathecal	I-Treatment
methotrexate	I-Treatment
and	I-Treatment
cytarabine	I-Treatment
.	O

according	O
to	O
the	O
naranjo	O
probability	I-Test
scale	I-Test
,	O
flecainide	I-Treatment
was	O
the	O
probable	O
cause	O
of	O
the	I-Background
patient	I-Background
'	O
s	O
delirium	I-Problem
;	O
the	O
horn	I-Test
drug	I-Test
interaction	I-Test
probability	I-Test
scale	I-Test
indicates	O
a	O
possible	O
pharmacokinetic	O
drug	O
interaction	O
between	O
flecainide	I-Treatment
and	O
paroxetine	I-Treatment
.	O

contact	I-Problem
dermatitis	I-Problem
due	O
to	O
budesonide	I-Treatment
:	O
report	O
of	O
five	O
cases	O
and	O
review	O
of	O
the	O
japanese	O
literature	O
.	O

prolongation	I-Problem
of	I-Problem
the	I-Problem
qt	I-Problem
interval	I-Problem
observed	O
in	O
a	I-Background
japanese	I-Background
patient	I-Background
with	I-Background
vivax	I-Problem
malaria	I-Problem
following	O
treatment	O
with	O
halofantrine	I-Treatment
.	O

we	O
report	O
three	O
cases	I-Background
of	O
severe	I-Problem
hepatotoxicity	I-Problem
related	O
to	O
benzarone	I-Treatment
,	O
a	O
benzofuran	O
derivative	O
.	O

four	O
patients	I-Background
who	O
manifested	O
symptoms	O
of	O
the	O
antiepileptic	I-Treatment
drug	I-Treatment
(	I-Treatment
aed	I-Treatment
)	I-Treatment
hypersensitivity	I-Problem
syndrome	I-Problem
during	I-Treatment
therapy	I-Treatment
with	I-Treatment
carbamazepine	I-Treatment
are	O
reported	O
.	O

minocycline	I-Treatment
as	O
a	O
cause	O
of	O
drug	O
-	O
induced	O
autoimmune	I-Problem
hepatitis	I-Problem
.	O

secondary	I-Problem
acute	I-Problem
myeloid	I-Problem
leukemia	I-Problem
after	O
etoposide	I-Treatment
therapy	I-Treatment
for	O
haemophagocytic	I-Problem
lymphohistiocytosis	I-Problem
.	O

allergic	I-Problem
contact	I-Problem
angioedema	I-Problem
to	O
benzoyl	I-Treatment
peroxide	I-Treatment
.	O

a	I-Background
60	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
man	I-Background
with	I-Background
chronic	I-Problem
bronchitis	I-Problem
was	O
noted	O
to	O
develop	O
acute	I-Problem
respiratory	I-Problem
failure	I-Problem
and	I-Problem
metabolic	I-Problem
acidosis	I-Problem
four	I-Other
days	I-Other
after	I-Other
being	O
started	O
on	O
methazolamide	I-Treatment
(	I-Treatment
neptazane	I-Treatment
)	I-Treatment
for	O
an	O
ophthalmologic	I-Problem
problem	I-Problem
.	O

l	I-Treatment
-	I-Treatment
dopa	I-Treatment
-	O
induced	O
excessive	O
daytime	I-Problem
sleepiness	I-Problem
in	O
pd	O
:	O
a	O
placebo	O
-	O
controlled	O
case	O
with	O
mslt	O
assessment	I-Test
.	O

conclusions	O
:	O
it	O
is	O
probable	O
that	O
foscarnet	I-Treatment
contributed	O
to	O
the	O
electrolyte	I-Problem
disorders	I-Problem
and	I-Problem
symptomatology	I-Problem
in	O
this	I-Background
patient	I-Background
.	O

acute	I-Problem
drug	I-Problem
induced	I-Problem
hepatitis	I-Problem
due	O
to	O
erlotinib	I-Treatment
.	O

we	O
observed	O
3	O
diabetic	I-Problem
patients	I-Background
with	O
intolerable	I-Problem
dizziness	I-Problem
followed	I-Problem
by	I-Problem
nausea	I-Problem
and	I-Problem
vomiting	I-Problem
immediately	O
after	O
an	I-Treatment
initial	I-Treatment
administration	I-Treatment
of	I-Treatment
the	I-Treatment
alpha	I-Treatment
-	I-Treatment
glucosidase	I-Treatment
inhibitor	I-Treatment
,	I-Treatment
voglibose	I-Treatment
.	O

although	O
risk	O
factors	O
for	O
mtx	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
are	O
poorly	O
understood	O
,	O
the	I-Background
presence	I-Background
in	I-Background
3	O
out	O
of	O
5	O
of	I-Background
our	I-Background
patients	I-Background
of	I-Background
pre	I-Problem
-	I-Problem
existing	I-Problem
lung	I-Problem
disease	I-Problem
,	I-Problem
represented	I-Problem
by	I-Problem
diffuse	I-Problem
interstitial	I-Problem
changes	I-Problem
on	I-Problem
chest	I-Problem
x	I-Test
-	I-Test
ray	I-Test
,	I-Problem
and	I-Problem
mild	I-Problem
bronchial	I-Problem
asthma	I-Problem
in	I-Problem
two	I-Problem
ra	I-Problem
patients	I-Problem
and	I-Problem
by	I-Problem
pulmonary	I-Problem
silicosis	I-Problem
in	I-Problem
the	I-Problem
patient	I-Problem
with	I-Problem
psa	I-Problem
may	O
account	O
for	O
a	O
predisposition	O
to	O
the	O
development	O
of	O
mtx	O
pneumonitis	O
.	O

acute	O
esmolol	I-Treatment
toxicity	I-Problem
may	O
be	O
self	O
-	O
limiting	O
because	O
of	O
its	O
extremely	O
short	O
half	O
-	O
life	O
.	O

the	O
association	O
with	O
prolonged	I-Other
unopposed	I-Treatment
estrogen	I-Treatment
-	I-Treatment
like	I-Treatment
stimulation	I-Treatment
with	I-Treatment
tamoxifen	I-Treatment
as	O
a	O
possible	O
factor	O
in	O
the	O
development	I-Problem
of	I-Problem
ovarian	I-Problem
endometrioid	I-Problem
carcinoma	I-Problem
is	O
discussed	O
.	O

the	I-Background
other	I-Background
woman	I-Background
had	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
and	O
developed	O
acute	I-Problem
tubular	I-Problem
necrosis	I-Problem
after	O
treatment	O
with	O
gentamicin	I-Treatment
and	I-Treatment
cefoxitin	I-Treatment
.	O

one	O
patient	I-Background
who	O
received	O
clindamycin	I-Treatment
had	O
liver	O
biopsy	I-Test
findings	O
of	O
marked	I-Problem
cholestasis	I-Problem
,	I-Problem
portal	I-Problem
inflammation	I-Problem
,	I-Problem
bile	I-Problem
duct	I-Problem
injury	I-Problem
and	I-Problem
bile	I-Problem
duct	I-Problem
paucity	I-Problem
(	I-Problem
ductopenia	I-Problem
)	I-Problem
.	O

a	O
medline	I-Test
search	I-Test
(	O
1966	O
-	O
january	O
2009	O
)	O
revealed	O
one	O
in	I-Test
vivo	I-Test
pharmacokinetic	I-Test
study	I-Test
on	O
the	O
interaction	O
between	O
flecainide	O
,	O
a	O
cyp2d6	O
substrate	O
,	O
and	O
paroxetine	O
,	O
a	O
cyp2d6	O
inhibitor	O
,	O
as	O
well	O
as	O
3	O
case	I-Background
reports	I-Background
of	O
flecainide	I-Treatment
-	O
induced	O
delirium	I-Problem
.	O

as	O
these	O
cases	O
revealed	O
,	O
close	O
monitoring	I-Test
of	I-Test
blood	I-Test
chemistry	I-Test
is	O
mandatory	O
after	O
starting	O
spironolactone	I-Treatment
,	O
and	O
patients	I-Background
should	O
be	O
advised	O
to	O
stop	O
spironolactone	O
immediately	O
if	O
diarrhoea	I-Problem
develops	O
.	O

when	O
these	O
cells	O
are	O
exposed	O
to	O
nicotinic	I-Treatment
acid	I-Treatment
,	O
an	O
exaggerated	I-Problem
immune	I-Problem
response	I-Problem
is	O
produced	O
that	O
may	O
lead	O
to	O
pain	I-Problem
,	I-Problem
redness	I-Problem
,	I-Problem
and	I-Problem
swelling	I-Problem
at	I-Problem
the	I-Problem
injection	I-Problem
site	I-Problem
.	O

a	O
case	O
of	O
heatstroke	I-Problem
is	O
reported	O
in	O
a	I-Background
32	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
diagnosed	I-Background
with	I-Background
schizophrenia	I-Problem
and	O
on	O
clozapine	I-Treatment
monotherapy	I-Treatment
.	O

paraplegia	I-Problem
following	O
intrathecal	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
.	O

cimetidine	I-Treatment
-	O
induced	O
fever	I-Problem
.	O

this	I-Background
case	I-Background
report	O
illustrates	O
the	O
neurotoxicity	I-Problem
unique	I-Problem
to	O
hdarac	I-Treatment
.	O

agranulocytosis	I-Problem
associated	O
with	O
ticlopidine	I-Treatment
:	O
a	O
possible	O
benefit	O
with	O
filgastim	O
.	O

since	O
ss	O
is	O
a	O
clinical	O
diagnosis	O
,	O
heightened	O
clinician	O
awareness	O
of	O
the	O
possibility	O
of	O
ss	O
among	O
patients	I-Background
receiving	O
ssri	I-Treatment
or	I-Treatment
mirtazapine	I-Treatment
in	I-Treatment
combination	I-Treatment
with	I-Treatment
opioids	I-Treatment
may	O
lead	O
to	O
earlier	O
detection	O
and	O
avoidance	O
of	O
potentially	I-Problem
lethal	I-Problem
consequences	I-Problem
.	O

the	O
mechanism	O
by	O
which	O
sunitinib	I-Treatment
induces	O
gynaecomastia	I-Problem
is	O
thought	O
to	O
be	O
associated	O
with	O
an	O
unknown	O
direct	O
action	O
on	O
breast	O
hormonal	I-Test
receptors	I-Test
.	O

some	O
patients	I-Background
develop	O
hypersensitivity	I-Problem
rash	I-Problem
in	O
response	O
to	O
hcq	I-Treatment
.	O

to	O
report	O
a	O
case	O
of	O
serotonin	I-Problem
toxicity	I-Problem
,	O
presenting	O
in	O
the	O
postoperative	O
period	O
,	O
caused	O
by	O
an	O
interaction	O
between	O
paroxetine	I-Treatment
(	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
,	O
ssri	O
)	O
and	O
fentanyl	I-Treatment
(	O
a	O
phenylpiperidine	O
opioid	O
)	O
.	O

however	O
,	O
to	O
our	O
knowledge	O
,	O
in	O
newborns	I-Background
there	O
have	O
been	O
no	O
reported	O
cases	O
to	O
date	O
of	O
thrombocytosis	I-Problem
induced	O
by	O
enoxaparin	I-Treatment
.	O

the	O
case	O
presented	O
here	O
documents	O
adverse	I-Problem
cardiac	I-Problem
effects	I-Problem
in	O
a	O
28	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
who	O
intentionally	O
ingested	O
24	I-Treatment
mg	I-Treatment
of	I-Treatment
risperidone	I-Treatment
-	O
-	O
4	O
times	O
the	O
recommended	O
dose	O
.	O

anaphylaxis	I-Problem
to	O
cisplatin	I-Treatment
following	I-Treatment
nine	I-Other
previous	I-Other
uncomplicated	I-Other
cycles	I-Other
.	O

to	O
the	O
best	O
of	O
the	O
authors	O
'	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
propecia	I-Treatment
-	O
associated	O
cataract	I-Problem
.	O

serotonin	I-Problem
syndrome	I-Problem
caused	O
by	O
interaction	O
between	O
citalopram	I-Treatment
and	I-Treatment
fentanyl	I-Treatment
.	O

this	O
report	O
presents	O
a	O
case	O
of	O
acute	I-Problem
lung	I-Problem
injury	I-Problem
developing	O
within	I-Other
hours	I-Other
after	O
administration	I-Treatment
of	I-Treatment
mefloquine	I-Treatment
for	I-Treatment
a	I-Treatment
low	I-Problem
-	I-Problem
level	I-Problem
plasmodium	I-Problem
falciparum	I-Problem
malaria	I-Problem
,	O
which	O
was	O
persistent	I-Problem
despite	I-Problem
halofantrine	I-Treatment
therapy	I-Treatment
.	O

warfarin	I-Treatment
-	O
associated	O
bleeding	I-Problem
generally	O
is	O
considered	O
deleterious	O
;	O
however	O
,	O
in	O
our	O
patient	O
it	O
unmasked	O
an	O
early	O
stage	O
of	O
colon	O
cancer	O
and	O
thus	O
may	O
have	O
saved	O
the	O
patient	O
'	O
s	O
life	O
.	O

the	O
clinical	O
use	O
of	O
itraconazole	I-Treatment
in	O
patients	I-Background
receiving	I-Treatment
multiple	I-Treatment
doses	I-Treatment
of	I-Treatment
oxycodone	I-Treatment
for	O
pain	I-Problem
relief	I-Problem
may	O
increase	O
the	O
risk	O
of	O
opioid	I-Problem
-	I-Problem
associated	I-Problem
adverse	I-Problem
effects	I-Problem
.	O

three	O
cases	I-Background
of	O
gold	I-Treatment
-	O
related	O
neuropathy	I-Problem
are	O
reported	O
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
man	I-Background
,	O
treated	O
with	O
mesalazine	I-Treatment
for	O
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
who	O
developed	O
drug	I-Problem
-	I-Problem
induced	I-Problem
pericarditis	I-Problem
.	O

we	O
report	O
the	O
occurrence	O
of	O
spontaneous	I-Problem
intracranial	I-Problem
bleeding	I-Problem
in	O
an	I-Background
human	I-Background
immunodeficiency	I-Problem
virus	I-Problem
(	I-Problem
hiv	I-Problem
)	I-Problem
-	I-Problem
infected	I-Problem
adolescent	I-Problem
with	I-Problem
hemophilia	I-Problem
a	I-Problem
who	O
was	O
receiving	O
amprenavir	I-Treatment
(	I-Treatment
apv	I-Treatment
)	I-Treatment
.	O

under	O
the	O
suspicion	O
of	O
amiodarone	I-Treatment
-	O
induced	O
acute	I-Problem
pancreatitis	I-Problem
,	O
amiodarone	O
was	O
substituted	O
by	O
propafenone	O
.	O

evidence	O
is	O
shown	O
in	O
this	O
report	O
that	O
adenosine	I-Treatment
was	O
associated	O
with	O
dangerous	I-Problem
worsening	I-Problem
of	I-Problem
arrhythmia	I-Problem
in	O
patients	I-Background
with	I-Background
atrial	I-Problem
flutter	I-Problem
.	I-Problem

salicylate	I-Treatment
hepato	I-Problem
toxicity	I-Problem
in	O
rheumatic	I-Problem
fever	I-Problem
.	O

a	O
case	O
of	O
serotonin	I-Problem
syndrome	I-Problem
that	O
developed	O
during	O
concurrent	I-Treatment
linezolid	I-Treatment
and	I-Treatment
fluoxetine	I-Treatment
is	O
presented	O
.	O

herein	O
we	O
report	O
four	O
patients	I-Background
who	I-Background
underwent	I-Background
liver	I-Problem
transplantation	I-Problem
and	O
developed	O
neutropenia	I-Problem
while	O
receiving	O
mmf	I-Treatment
.	O

a	O
study	I-Test
of	O
in	O
vitro	O
reactivity	O
to	O
l	O
-	O
t4	O
,	O
as	O
assessed	O
by	O
peripheral	O
blood	I-Test
lymphocyte	I-Test
transformation	I-Test
,	O
was	O
carried	O
out	O
in	O
a	I-Background
patient	I-Background
with	I-Background
hashimoto	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
who	O
developed	O
leukopenia	I-Problem
during	O
treatment	O
with	O
l	I-Treatment
-	I-Treatment
t4	I-Treatment
.	O

methemoglobinemia	I-Problem
is	O
another	O
common	O
finding	O
among	O
patients	I-Background
receiving	O
dapsone	I-Treatment
therapy	I-Treatment
,	O
but	O
rarely	O
does	O
it	O
result	O
in	O
prominent	O
symptoms	O
other	O
than	O
transient	I-Problem
pallor	I-Problem
.	O

during	O
the	O
first	O
treatment	O
,	O
dysarthria	I-Problem
and	I-Problem
ataxia	I-Problem
were	O
seen	O
after	O
completion	O
of	O
the	I-Background
patient	I-Background
'	I-Background
s	I-Background
eighth	O
and	O
final	O
dose	O
of	O
hdarac	I-Treatment
.	O

four	O
weeks	O
earlier	O
she	I-Background
had	O
developed	O
hepatopathy	I-Problem
during	O
a	O
regimen	O
of	O
carbamazepine	I-Treatment
,	I-Treatment
lynestrenol	I-Treatment
and	I-Treatment
sodium	I-Treatment
valproate	I-Treatment
.	O

we	O
consider	O
asterixis	I-Problem
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	O
,	O
which	O
may	O
occur	O
even	I-Treatment
at	I-Treatment
low	I-Treatment
or	I-Treatment
moderate	I-Treatment
dosage	I-Treatment
levels	I-Treatment
,	O
if	O
certain	I-Treatment
drugs	I-Treatment
as	I-Treatment
lithium	I-Treatment
or	I-Treatment
clozapine	I-Treatment
are	I-Treatment
used	I-Treatment
in	I-Treatment
combination	I-Treatment
with	I-Treatment
cbz	I-Treatment
.	O

we	O
report	O
here	O
a	I-Background
rare	I-Background
case	I-Background
of	O
pleuropericarditis	I-Problem
due	O
to	O
methotrexate	I-Treatment
.	O

a	O
case	O
of	O
phenytoin	I-Treatment
-	O
induced	O
hepatitis	I-Problem
with	I-Problem
mononucleosis	I-Problem
is	O
reported	O
,	O
and	O
syndromes	O
associated	O
with	O
phenytoin	O
hypersensitivity	O
reactions	O
are	O
discussed	O
.	O

we	O
also	O
discuss	O
whether	O
screening	O
for	O
dpd	O
deficiency	O
is	O
warranted	O
to	O
identify	O
patients	I-Background
at	O
risk	O
for	O
severe	I-Problem
toxicities	I-Problem
from	O
5	I-Treatment
-	I-Treatment
fu	I-Treatment
treatment	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
reversible	I-Problem
encephalopathy	I-Problem
syndrome	I-Problem
in	O
a	I-Background
16	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
with	I-Background
acute	I-Problem
myelogenous	I-Problem
leukemia	I-Problem
(	I-Background
aml	I-Background
)	I-Background
,	O
who	O
is	O
undergoing	O
during	O
consolidation	I-Treatment
chemotherapy	I-Treatment
composed	I-Treatment
of	I-Treatment
bh	I-Treatment
-	I-Treatment
ac	I-Treatment
(	I-Treatment
n4	I-Treatment
-	I-Treatment
behenoyl	I-Treatment
-	I-Treatment
1	I-Treatment
-	I-Treatment
beta	I-Treatment
-	I-Treatment
d	I-Treatment
-	I-Treatment
arabinofuranosyl	I-Treatment
cytosine	I-Treatment
)	I-Treatment
and	I-Treatment
idarubicin	I-Treatment
.	O

concurrent	O
use	O
of	O
vismodegib	I-Treatment
and	I-Treatment
warfarin	I-Treatment
was	O
deemed	O
the	O
probable	O
cause	O
of	O
acute	I-Problem
inr	I-Problem
elevation	I-Problem
in	O
this	O
case	O
,	O
suggesting	O
the	O
need	O
for	O
close	O
monitoring	I-Test
of	I-Test
inr	O
values	I-Test
in	O
patients	O
receiving	O
this	O
combination	O
of	O
drugs	O
.	O

captopril	I-Treatment
is	O
an	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ace	O
)	O
inhibitor	O
and	O
their	O
cutaneous	I-Problem
side	I-Problem
-	I-Problem
effects	I-Problem
are	O
documented	O
,	O
but	O
little	O
has	O
been	O
published	O
concerning	O
the	O
usefulness	O
of	O
patch	O
test	I-Test
when	O
they	O
occur	O
.	O

high	I-Treatment
-	I-Treatment
dose	I-Treatment
methylprednisolone	I-Treatment
in	O
a	I-Background
pregnant	I-Background
woman	I-Background
with	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
and	O
adrenal	I-Problem
suppression	I-Problem
in	I-Problem
her	I-Problem
newborn	I-Problem
.	O

cardiac	I-Problem
hypersensitivity	I-Problem
and	I-Problem
myopericarditis	I-Problem
have	O
been	O
reported	O
during	O
long	I-Other
-	I-Other
term	I-Other
treatment	I-Treatment
with	I-Treatment
mesalazine	I-Treatment
.	O

it	O
is	O
concluded	O
that	O
'	O
cerebral	I-Problem
atrophy	I-Problem
'	O
on	O
ct	O
scans	I-Test
may	O
represent	O
an	O
accumulative	O
effect	O
of	O
acth	I-Treatment
and	O
that	O
acth	I-Treatment
should	O
be	O
given	O
with	O
the	O
utmost	O
discretion	O
,	O
and	O
in	O
as	O
low	O
a	O
dose	O
as	O
possible	O
.	O

two	O
cases	O
of	O
polymorphic	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
induced	O
by	O
the	O
administration	O
of	O
verapamil	I-Treatment
against	O
paroxysmal	I-Problem
supraventricular	I-Problem
tachycardia	I-Problem
.	O

fatal	I-Problem
acute	I-Problem
encephalomyelitis	I-Problem
after	O
a	O
single	I-Treatment
dose	I-Treatment
of	I-Treatment
intrathecal	I-Treatment
methotrexate	I-Treatment
.	O

the	O
authors	O
report	O
one	I-Background
case	I-Background
of	O
incomplete	I-Problem
posterior	I-Problem
hyaloid	I-Problem
detachment	I-Problem
(	I-Problem
phd	I-Problem
)	I-Problem
following	O
intravitreal	I-Treatment
pegaptanib	I-Treatment
to	O
treat	O
dme	I-Problem
.	O

pulmonary	I-Problem
edema	I-Problem
as	O
a	O
delayed	O
complication	O
of	O
ritodrine	I-Treatment
therapy	O
.	O

carbamazepine	I-Problem
toxicity	I-Problem
following	O
oxybutynin	I-Treatment
and	I-Treatment
dantrolene	I-Treatment
administration	O
:	O
a	O
case	O
report	O
.	O

multiple	I-Problem
seizures	I-Problem
after	O
bupropion	I-Treatment
overdose	I-Treatment
in	O
a	I-Background
small	I-Background
child	I-Background
.	O

sorafenib	I-Treatment
,	O
a	I-Treatment
multitargeted	I-Treatment
kinase	I-Treatment
inhibitor	I-Treatment
used	O
for	O
the	O
treatment	O
of	O
unresectable	I-Problem
hepatocellular	I-Problem
carcinoma	I-Problem
and	O
advanced	I-Problem
renal	I-Problem
cell	I-Problem
carcinomas	I-Problem
,	O
received	O
fda	O
approval	O
in	O
2005	O
.	O

triiodothyronine	I-Treatment
-	O
induced	O
thyrotoxicosis	I-Problem
in	O
ophthalmic	I-Problem
graves	I-Problem
disease	O
.	O

bleomycin	I-Treatment
induced	O
hyperpigmentation	I-Problem
with	I-Problem
yolk	I-Problem
sac	I-Problem
tumor	I-Problem
.	O

purpose	O
:	O
to	O
describe	O
bilateral	I-Problem
corneal	I-Problem
endothelial	I-Problem
dysfunction	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
parkinson	I-Problem
disease	I-Problem
who	O
was	O
treated	O
with	O
long	I-Other
-	I-Other
term	I-Other
amantadine	I-Treatment
.	O

a	O
case	O
of	O
severe	O
acute	I-Problem
hepatitis	I-Problem
caused	O
by	O
cyproterone	I-Treatment
acetate	I-Treatment
in	O
a	I-Background
71	I-Background
year	I-Background
old	I-Background
man	I-Background
with	I-Background
prostatic	I-Problem
carcinoma	I-Problem
is	O
reported	O
with	O
a	O
review	O
of	O
the	O
literature	O
on	O
hepatic	O
reactions	O
to	O
this	O
drug	O
.	O

insulin	I-Problem
-	I-Problem
dependent	I-Problem
diabetes	I-Problem
mellitus	I-Problem
associated	O
with	O
danazol	I-Treatment
.	O

conclusions	O
:	O
topical	I-Treatment
brimonidine	I-Treatment
may	O
be	O
associated	O
with	O
central	I-Problem
nervous	I-Problem
system	I-Problem
depression	I-Problem
in	O
infants	I-Background
.	O

flecainide	I-Treatment
-	O
associated	O
pneumonitis	I-Problem
with	I-Problem
acute	I-Problem
respiratory	I-Problem
failure	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
the	I-Background
leopard	I-Problem
syndrome	I-Problem
.	I-Problem

seizure	I-Problem
with	I-Problem
hyponatremia	I-Problem
in	O
a	I-Background
child	I-Background
prescribed	O
desmopressin	I-Treatment
for	O
nocturnal	I-Problem
enuresis	I-Problem
.	O

risks	O
and	O
benefits	O
of	O
co	O
-	O
treatment	O
should	O
be	O
carefully	O
considered	O
and	O
therapeutic	I-Treatment
alternatives	I-Treatment
to	I-Treatment
nsaids	I-Treatment
should	O
be	O
recommended	O
to	O
patients	I-Background
with	I-Background
central	I-Problem
di	I-Problem
in	I-Problem
order	I-Problem
to	I-Problem
improve	I-Problem
ddavp	I-Problem
safety	I-Problem
.	O

she	I-Background
had	O
been	O
treated	O
by	O
carbamazepine	I-Treatment
1000	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
for	O
neuropathic	I-Problem
pain	I-Problem
for	O
2	I-Other
years	I-Other
without	O
clinical	O
or	O
laboratory	O
signs	O
of	O
toxicity	O
.	O

after	O
a	O
second	I-Treatment
dose	I-Treatment
of	I-Treatment
metoclopramide	I-Treatment
,	O
these	O
symptoms	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	I-Problem
,	I-Problem
agitation	I-Problem
,	I-Problem
fever	I-Problem
,	I-Problem
diaphoresis	I-Problem
,	I-Problem
tachypnea	I-Problem
,	I-Problem
tachycardia	I-Problem
,	I-Problem
and	I-Problem
hypertension	I-Problem
.	O

we	O
report	O
the	O
first	O
case	O
of	O
tuberculous	I-Problem
uveitis	I-Problem
due	O
to	O
etanercept	I-Treatment
.	O

acute	I-Problem
hyperphosphatemia	I-Problem
caused	O
by	O
sodium	I-Treatment
phosphate	I-Treatment
enema	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
liver	I-Problem
dysfunction	I-Problem
and	I-Problem
chronic	I-Problem
renal	I-Problem
failure	I-Problem
.	O

we	O
discuss	O
the	O
association	O
between	O
carbamazepine	I-Treatment
and	O
hyponatremia	I-Problem
and	O
the	O
causes	O
of	O
hyponatremia	O
after	O
cardiopulmonary	O
bypass	O
.	O

use	O
of	O
the	O
naranjo	O
adverse	I-Test
drug	I-Test
reaction	I-Test
probability	I-Test
algorithm	I-Test
indicated	O
a	O
probable	O
relationship	O
between	O
serotonin	I-Problem
syndrome	I-Problem
and	O
treatment	I-Treatment
with	I-Treatment
lithium	I-Treatment
and	I-Treatment
venlafaxine	I-Treatment
.	O

the	O
exact	O
mechanism	O
of	O
ivig	I-Treatment
-	O
associated	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
remains	O
unclear	O
.	O

we	O
report	O
on	O
7	O
patients	I-Background
(	I-Background
2	I-Background
women	I-Background
,	I-Background
5	I-Background
men	I-Background
)	I-Background
with	I-Background
chronic	I-Problem
renal	I-Problem
failure	I-Problem
,	O
who	O
developed	O
under	O
a	I-Treatment
high	I-Treatment
dosage	I-Treatment
of	I-Treatment
the	I-Treatment
new	I-Treatment
diuretic	I-Treatment
muzolimine	I-Treatment
(	I-Treatment
range	I-Treatment
240	I-Treatment
to	I-Treatment
1440	I-Treatment
mg	I-Treatment
per	I-Other
day	I-Other
)	I-Treatment
fatal	I-Problem
neuromyeloencephalopathy	I-Problem
.	O

two	O
renal	I-Problem
transplant	I-Problem
patients	I-Background
developed	O
anemia	I-Problem
during	O
treatment	O
of	O
hypertension	I-Problem
with	O
enalapril	I-Treatment
medication	I-Treatment
.	O

the	O
development	O
of	O
cutaneous	I-Problem
ecchymosis	I-Problem
associated	O
with	O
a	I-Problem
sudden	I-Problem
fall	I-Problem
in	I-Problem
hemoglobin	I-Problem
after	O
the	O
administration	O
of	O
alteplase	I-Treatment
should	O
strongly	O
suggest	O
the	O
possibility	O
of	O
diffuse	I-Problem
subfascial	I-Problem
hematoma	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
papillary	I-Problem
necrosis	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
indinavir	I-Treatment
.	O

generalized	I-Problem
maculopapular	I-Problem
and	I-Problem
papular	I-Problem
purpuric	I-Problem
eruptions	I-Problem
are	O
perhaps	O
the	O
most	O
common	O
thionamide	I-Treatment
-	O
induced	O
reactions	I-Problem
.	O

imidazoline	I-Treatment
intoxication	I-Problem
due	O
to	O
overdose	I-Treatment
or	I-Treatment
accidental	I-Treatment
ingestion	I-Treatment
but	I-Treatment
also	I-Treatment
after	I-Treatment
normal	I-Treatment
therapeutic	I-Treatment
usage	I-Treatment
is	O
frequent	O
in	O
children	I-Background
.	O

a	I-Background
patient	I-Background
with	I-Background
intracranial	I-Problem
osteosarcoma	I-Problem
that	I-Background
arose	I-Background
16	I-Background
years	I-Background
after	I-Background
radiation	I-Background
therapy	I-Background
for	I-Background
hereditary	I-Problem
retinoblastoma	I-Problem
developed	O
fatal	O
cerebral	I-Problem
edema	I-Problem
and	I-Problem
brainstem	I-Problem
herniation	I-Problem
after	O
she	O
received	O
a	I-Other
single	I-Other
dose	I-Other
of	I-Treatment
intravenous	I-Treatment
methotrexate	I-Treatment
.	O

neutropenia	I-Problem
is	O
an	O
infrequent	O
complication	O
following	O
administration	O
of	O
the	I-Treatment
angiotensin	I-Treatment
-	I-Treatment
converting	I-Treatment
enzyme	I-Treatment
(	I-Treatment
ace	I-Treatment
)	I-Treatment
inhibitor	I-Treatment
,	I-Treatment
captopril	I-Treatment
.	O

introduction	O
:	O
we	O
describe	O
the	O
neurointensive	O
care	O
(	O
nic	O
)	O
management	O
of	O
a	O
patient	I-Background
with	O
severe	I-Problem
cerebral	I-Problem
swelling	I-Problem
and	I-Problem
raised	I-Problem
intracranial	I-Problem
pressure	I-Problem
(	I-Problem
icp	I-Problem
)	I-Problem
after	O
severe	O
sodium	I-Treatment
valproic	I-Treatment
acid	I-Treatment
(	I-Treatment
vpa	I-Treatment
)	I-Treatment
intoxication	I-Problem
.	O

lithium	I-Treatment
therapy	O
was	O
discontinued	O
because	O
of	O
poor	O
compliance	O
to	O
the	O
medication	O
and	O
intolerable	O
polyuria	I-Problem
.	O

both	O
pan	I-Treatment
and	I-Treatment
methotrexate	I-Treatment
have	O
been	O
independently	O
demonstrated	O
to	O
cause	O
sensorineural	I-Problem
hearing	I-Problem
loss	I-Problem
.	O

conclusion	O
:	O
a	I-Background
26	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
bipolar	I-Problem
disorder	I-Problem
developed	O
hyperammonemia	I-Problem
three	I-Other
weeks	I-Other
after	I-Treatment
initiating	I-Treatment
carbamazepine	I-Treatment
therapy	I-Treatment
.	O

we	O
report	O
two	O
adults	I-Background
who	O
received	O
gabapentin	I-Treatment
(	I-Treatment
gbp	I-Treatment
)	I-Treatment
and	O
subsequently	O
developed	O
behavioural	I-Problem
side	I-Problem
effects	I-Problem
.	O

we	O
can	O
conclude	O
that	O
in	O
this	I-Background
case	I-Background
,	O
as	O
in	O
many	O
others	O
,	O
akathisia	I-Problem
as	O
a	O
possible	O
adverse	O
effect	O
of	O
psychopharmacs	I-Treatment
was	O
very	O
hard	O
to	O
identify	O
.	O

although	O
haart	I-Treatment
is	O
very	O
important	O
in	O
the	O
treatment	O
of	O
hiv	I-Problem
,	O
its	O
side	O
effects	O
are	O
responsible	O
for	O
patients	I-Background
'	O
non	I-Problem
-	I-Problem
adherence	I-Problem
to	I-Problem
medications	I-Problem
.	O

a	O
case	O
of	O
acute	I-Problem
subdural	I-Problem
haematoma	I-Problem
originating	O
spontaneously	O
from	O
an	I-Background
angiomatous	I-Background
meningioma	I-Background
in	I-Background
a	I-Background
patient	I-Background
receiving	O
prophylactic	O
aspirin	I-Treatment
therapy	O
is	O
presented	O
.	O

long	O
known	O
to	O
psychiatrists	O
,	O
monoamine	I-Treatment
oxidase	I-Treatment
inhibitors	I-Treatment
(	I-Treatment
maois	I-Treatment
)	I-Treatment
and	O
complications	O
of	O
their	O
use	O
may	O
be	O
unfamiliar	O
to	O
medical	O
and	O
surgical	O
practitioners	O
who	O
may	O
thus	O
unwittingly	O
precipitate	O
a	O
hypertensive	I-Problem
crisis	I-Problem
or	I-Problem
serotonin	I-Problem
syndrome	I-Problem
.	O

according	O
to	O
the	O
naranjo	O
adverse	O
drug	O
reaction	O
probability	I-Test
scale	I-Test
,	O
the	O
likelihood	O
that	O
temozolomide	I-Treatment
was	O
responsible	O
for	O
the	O
adverse	O
drug	O
reaction	O
of	O
fever	I-Problem
was	O
probable	O
(	O
score	O
of	O
6	O
)	O
.	O

objective	O
:	O
to	O
describe	O
the	O
development	O
of	O
valproate	I-Treatment
-	O
related	O
reproductive	I-Problem
endocrine	I-Problem
disorders	I-Problem
in	O
women	I-Background
with	I-Background
epilepsy	I-Problem
.	O

alprazolam	I-Treatment
-	O
induced	O
mania	I-Problem
:	O
two	O
clinical	I-Background
cases	I-Background
.	O

bronchiolitis	I-Problem
obliterans	I-Problem
organising	I-Problem
pneumonia	I-Problem
associated	O
with	O
the	O
use	I-Treatment
of	I-Treatment
nitrofurantoin	I-Treatment
.	O

to	O
our	O
knowledge	O
,	O
this	O
recurrence	O
of	O
amiodarone	I-Treatment
pulmonary	I-Problem
toxicity	I-Problem
has	O
not	O
been	O
reported	O
previously	O
.	O

a	I-Background
patient	I-Background
treated	O
with	O
itraconazole	I-Treatment
(	I-Treatment
itcz	I-Treatment
)	I-Treatment
under	O
the	O
diagnosis	O
of	O
aspergillus	I-Problem
flavus	I-Problem
-	I-Problem
induced	I-Problem
chronic	I-Problem
hypertrophic	I-Problem
pachymeningitis	I-Problem
is	O
presented	O
.	O

severe	I-Problem
autoimmune	I-Problem
hemolytic	I-Problem
anemia	I-Problem
following	O
rituximab	I-Treatment
therapy	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
a	I-Background
lymphoproliferative	I-Problem
disorder	I-Problem
.	O

the	O
renal	O
consequences	O
of	O
indinavir	I-Treatment
-	O
associated	O
nephrotoxicity	I-Problem
are	O
uncertain	O
.	O

background	O
:	O
reports	O
on	O
delated	I-Problem
cutaneous	I-Problem
reactions	I-Problem
to	O
captopril	I-Treatment
have	O
been	O
seldom	O
reported	O
.	O

bismuth	I-Treatment
subsalicylate	I-Treatment
30	I-Treatment
ml	I-Treatment
every	I-Other
4	I-Other
hours	I-Other
was	O
prescribed	O
for	O
diarrhea	I-Problem
.	O

a	O
drug	O
interaction	O
between	O
the	O
alpha	O
(	O
2	O
)	O
-	O
adrenergic	O
agonist	O
medetomidine	O
and	O
lignocaine	O
is	O
suspected	O
and	O
highlights	O
the	O
potential	O
for	O
seizures	I-Problem
following	O
the	O
subcutaneous	I-Treatment
administration	I-Treatment
of	I-Treatment
relatively	I-Treatment
large	I-Treatment
doses	I-Treatment
of	I-Treatment
lignocaine	I-Treatment
under	I-Treatment
medetomidine	I-Treatment
sedation	I-Treatment
.	O

oesophageal	I-Problem
ulceration	I-Problem
due	O
to	O
emepronium	I-Treatment
bromide	I-Treatment
.	O

development	O
of	O
sarcoidosis	I-Problem
during	O
interferon	I-Treatment
alpha	I-Treatment
2b	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
combination	O
therapy	O
for	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
-	O
-	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

conclusion	O
:	O
the	O
findings	O
in	O
these	O
two	O
patients	I-Background
suggest	O
that	O
colchicine	I-Treatment
may	O
delay	I-Problem
corneal	I-Problem
wound	I-Problem
healing	I-Problem
.	O

gemcitabine	I-Treatment
-	O
associated	O
hemolytic	I-Problem
-	I-Problem
uremic	I-Problem
syndrome	I-Problem
.	O

case	O
study	O
:	O
adverse	I-Problem
response	I-Problem
to	O
clonidine	I-Treatment
.	O

in	O
this	O
report	O
,	O
a	I-Background
patient	I-Background
who	O
had	O
undergone	I-Treatment
a	I-Treatment
renal	I-Treatment
transplantation	I-Treatment
as	I-Treatment
a	I-Treatment
result	I-Treatment
of	I-Treatment
malignant	I-Treatment
hypertension	I-Treatment
,	O
and	O
who	O
was	O
on	I-Treatment
immunosuppressive	I-Treatment
therapy	I-Treatment
consisting	I-Treatment
of	I-Treatment
cyclosporin	I-Treatment
,	I-Treatment
prednisone	I-Treatment
and	I-Treatment
azathioprine	I-Treatment
,	O
developed	O
thrombosis	I-Problem
of	I-Problem
the	I-Problem
central	I-Problem
retinal	I-Problem
vein	I-Problem
5	I-Other
years	I-Other
following	O
the	O
transplantation	O
.	O

in	O
each	O
of	O
the	O
three	O
reported	I-Background
patients	I-Background
,	O
alteration	I-Problem
of	I-Problem
eyelid	I-Problem
appearance	I-Problem
with	I-Problem
deepening	I-Problem
of	I-Problem
the	I-Problem
lid	I-Problem
sulcus	I-Problem
was	O
evident	O
as	O
the	O
result	O
of	O
topical	I-Treatment
bimatoprost	I-Treatment
therapy	O
.	O

purpose	O
:	O
to	O
report	O
a	O
case	O
of	O
traumatic	I-Problem
flap	I-Problem
dehiscence	I-Problem
and	I-Problem
enterobacter	I-Problem
keratitis	I-Problem
34	I-Other
months	I-Other
after	I-Other
lasik	I-Treatment
.	O

conclusions	O
:	O
the	O
risk	O
of	O
drug	O
-	O
induced	O
rhabdomyolysis	I-Problem
due	O
to	O
the	O
potential	O
interaction	O
between	O
lovastatin	I-Treatment
and	O
azithromycin	I-Treatment
or	O
clarithromycin	I-Treatment
should	O
be	O
considered	O
before	O
the	O
concomitant	O
use	O
of	O
these	O
agents	O
.	O

ten	O
years	O
of	O
behavioral	O
data	I-Test
are	O
presented	O
to	O
support	O
the	O
hypothesis	O
that	O
phenobarbital	I-Treatment
was	O
exacerbating	O
maladaptive	I-Problem
behaviors	I-Problem
.	O

terbinafine	I-Treatment
-	O
induced	O
cholestatic	I-Problem
liver	I-Problem
disease	I-Problem
.	I-Problem

the	O
proteasome	I-Treatment
inhibitor	I-Treatment
bortezomib	I-Treatment
has	I-Treatment
been	I-Treatment
identified	I-Treatment
as	I-Treatment
a	I-Treatment
potent	I-Treatment
enhancer	I-Treatment
of	I-Treatment
trail	I-Treatment
-	O
induced	O
apoptosis	I-Problem
in	I-Problem
several	I-Problem
human	I-Problem
cancers	I-Problem
.	O

methods	O
:	O
a	O
retrospective	O
report	O
of	O
the	O
first	O
case	O
of	O
gemcitabine	I-Treatment
-	O
related	O
hus	I-Problem
,	O
in	O
a	I-Background
patient	I-Background
with	I-Background
metastatic	I-Problem
pancreatic	I-Problem
adenocarcinoma	I-Problem
,	I-Problem
treated	O
with	O
a	O
variety	O
of	O
standard	O
therapies	O
in	O
addition	O
to	O
rituximab	O
is	O
presented	O
.	O

their	I-Background
parkinsonism	I-Problem
improved	O
on	O
discontinuation	I-Treatment
of	I-Treatment
metoclopramide	I-Treatment
therapy	I-Treatment
.	O

lichen	I-Problem
planus	I-Problem
induced	O
by	O
hepatitis	I-Treatment
b	I-Treatment
vaccination	I-Treatment
:	O
a	O
new	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O

a	O
total	O
of	O
40	O
healthy	I-Background
volunteers	I-Background
were	O
planned	O
to	O
start	O
with	O
600	I-Treatment
mg	I-Treatment
rifampicin	I-Treatment
once	I-Other
daily	I-Other
from	I-Treatment
days	I-Treatment
1	I-Treatment
-	I-Treatment
5	I-Treatment
.	O

skin	I-Problem
necrosis	I-Problem
secondary	O
to	O
low	I-Treatment
-	I-Treatment
molecular	I-Treatment
weight	I-Treatment
heparin	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
antiphospholipid	I-Problem
antibody	I-Problem
syndrome	I-Problem
.	O

exacerbation	O
of	O
anthracycline	I-Treatment
-	O
induced	O
early	I-Problem
chronic	I-Problem
cardiomyopathy	I-Problem
with	I-Treatment
atra	I-Treatment
:	O
role	O
of	O
b	O
-	O
type	O
natriuretic	O
peptide	O
as	O
an	O
indicator	O
of	O
cardiac	O
dysfunction	O
.	O

fixed	I-Problem
drug	I-Problem
eruption	I-Problem
in	I-Problem
hands	I-Problem
caused	O
by	O
omeprazole	I-Treatment
.	O

fk506	I-Treatment
,	I-Treatment
which	I-Treatment
began	I-Treatment
to	I-Treatment
be	I-Treatment
administered	I-Treatment
12	I-Other
days	I-Other
earlier	I-Other
,	I-Treatment
rose	I-Treatment
to	I-Treatment
a	I-Treatment
level	I-Treatment
of	I-Treatment
44	I-Treatment
ng	I-Treatment
/	I-Treatment
ml	I-Treatment
(	I-Treatment
normal	I-Treatment
range	I-Treatment
,	I-Treatment
10	I-Treatment
-	I-Treatment
20	I-Treatment
ng	I-Treatment
/	I-Treatment
ml	I-Treatment
)	I-Treatment
1	O
day	O
before	O
neurologic	I-Problem
abnormalities	I-Problem
began	I-Problem
.	O

sweet	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
is	I-Problem
an	I-Problem
acute	I-Problem
febrile	I-Problem
neutrophilic	I-Problem
dermatosis	I-Problem
that	O
is	O
a	O
known	O
complication	O
of	O
the	O
administration	O
of	O
filgrastim	I-Treatment
,	O
a	O
drug	O
that	O
causes	O
increased	I-Problem
neutrophil	I-Problem
proliferation	I-Problem
and	I-Problem
differentiation	I-Problem
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	O
experienced	O
chronic	I-Problem
nausea	I-Problem
and	I-Problem
an	I-Problem
episode	I-Problem
of	I-Problem
confusion	I-Problem
while	O
treated	O
with	O
a	I-Treatment
small	I-Treatment
,	I-Treatment
stable	I-Treatment
dose	I-Treatment
of	I-Treatment
oral	I-Treatment
morphine	I-Treatment
in	O
the	O
setting	O
of	O
mild	I-Problem
renal	I-Problem
insufficiency	I-Problem
.	O

bulbar	I-Problem
and	I-Problem
pseudobulbar	I-Problem
palsy	I-Problem
complicating	O
therapy	O
with	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
in	O
children	I-Background
with	I-Background
leukemia	I-Problem
.	O

the	O
development	I-Problem
of	I-Problem
erythroid	I-Problem
leukemia	I-Problem
plus	I-Problem
carcinoma	I-Problem
in	O
these	O
two	O
men	I-Background
suggests	O
mutagenic	I-Problem
change	I-Problem
secondary	O
to	O
cyclophosphamide	I-Treatment
therapy	I-Treatment
.	O

administration	O
of	O
thiazide	I-Treatment
diuretics	I-Treatment
also	O
has	O
been	O
the	O
cause	O
of	O
hyponatremia	I-Problem
.	O

serotonin	I-Problem
syndrome	I-Problem
is	O
a	O
potentially	O
lethal	O
adverse	O
drug	O
reaction	O
that	O
may	O
occur	O
in	O
patients	I-Background
taking	O
proserotoninergic	I-Treatment
medications	I-Treatment
.	O

however	O
,	O
there	O
remain	O
questions	O
concerning	O
whether	O
these	O
drugs	O
,	O
especially	O
methimazole	I-Treatment
(	I-Treatment
mmi	I-Treatment
)	I-Treatment
,	O
may	O
be	O
associated	O
with	O
aplasia	I-Problem
cutis	I-Problem
congenita	I-Problem
(	O
acc	O
)	O
and	O
how	O
best	O
to	O
avoid	O
impairment	O
of	O
fetal	O
thyroid	O
function	O
during	O
their	O
use	O
.	O

an	I-Background
18	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
attention	I-Problem
-	I-Problem
deficit	I-Problem
-	I-Problem
hyperactivity	I-Problem
disorder	I-Problem
(	I-Problem
adhd	I-Problem
)	I-Problem
was	O
prescribed	O
varenicline	I-Treatment
for	O
smoking	I-Problem
cessation	I-Problem
.	O

the	O
condition	O
should	O
be	O
suspected	O
in	O
patients	I-Background
who	O
develop	O
unexplained	I-Problem
abdominal	I-Problem
pain	I-Problem
or	I-Problem
collapse	I-Problem
following	O
vasopressin	I-Treatment
treatment	O
.	O

the	O
present	O
observation	O
suggests	O
,	O
that	O
a	O
batch	O
of	O
different	O
testing	I-Test
doses	I-Test
,	O
including	O
lower	O
testing	O
doses	O
may	O
help	O
to	O
differentiate	O
between	O
an	I-Problem
allergic	I-Problem
type	I-Problem
of	I-Problem
contact	I-Problem
dermatitis	I-Problem
and	O
an	I-Problem
irritant	I-Problem
type	I-Problem
of	I-Problem
reaction	I-Problem
after	O
treatment	O
with	O
calcipotriol	I-Treatment
.	O

acute	I-Problem
erythroid	I-Problem
leukemia	I-Problem
after	O
cyclophosphamide	I-Treatment
therapy	I-Treatment
for	O
multiple	I-Problem
myeloma	I-Problem
:	O
report	O
of	O
two	O
cases	I-Background
.	O

a	O
combination	O
of	O
behavioural	O
and	O
cognitive	O
adverse	O
effects	O
is	O
illustrated	O
in	O
this	O
case	O
report	O
of	O
a	O
recurrent	O
triazolam	I-Treatment
-	O
induced	O
eating	I-Problem
disorder	I-Problem
.	O

5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
(	O
5	O
-	O
fu	O
)	O
-	O
associated	O
peripheral	I-Problem
neuropathy	I-Problem
is	O
an	O
uncommon	O
event	O
.	O

insulin	I-Treatment
-	O
induced	O
lipoatrophy	I-Problem
in	O
type	I-Problem
i	I-Problem
diabetes	I-Problem
.	O

this	O
article	O
describes	O
a	I-Background
patient	I-Background
with	O
suspected	O
ciprofloxacin	I-Treatment
-	O
induced	O
interstitial	I-Problem
nephritis	I-Problem
.	O

we	O
report	O
3	O
cases	I-Background
of	I-Background
hiv	I-Problem
-	I-Problem
1	I-Problem
infected	I-Background
patients	I-Background
who	O
experienced	O
symptomatic	I-Problem
angiolipomas	I-Problem
shortly	O
after	O
starting	O
antiretroviral	I-Treatment
therapy	I-Treatment
including	I-Treatment
the	I-Treatment
protease	I-Treatment
inhibitor	I-Treatment
indinavir	I-Treatment
.	O

depressive	I-Problem
symptoms	I-Problem
disappeared	O
after	O
interferon	I-Treatment
therapy	I-Treatment
was	O
stopped	O
.	O

coumarin	I-Treatment
is	O
reported	O
to	O
elevate	I-Problem
liver	I-Problem
function	I-Test
tests	I-Test
(	I-Test
lft	I-Test
)	I-Test
values	I-Test
.	O

decreased	I-Problem
plasma	I-Problem
cortisol	I-Problem
level	I-Problem
during	O
alprazolam	I-Treatment
treatment	O
of	O
panic	I-Problem
disorder	I-Problem
:	O
a	O
case	O
report	O
.	O

severe	O
diffuse	I-Problem
interstitial	I-Problem
pneumonitis	I-Problem
induced	O
by	O
carmustine	I-Treatment
(	I-Treatment
bcnu	I-Treatment
)	I-Treatment
.	O

fever	I-Problem
,	I-Problem
pulmonary	I-Problem
infiltrates	I-Problem
,	I-Problem
and	I-Problem
pleural	I-Problem
effusion	I-Problem
following	O
acyclovir	I-Treatment
therapy	I-Treatment
for	I-Treatment
herpes	I-Problem
zoster	I-Problem
ophthalmicus	I-Problem
.	O

we	O
propose	O
a	O
mechanism	O
of	O
vancomycin	I-Treatment
-	O
induced	O
mast	I-Problem
cell	I-Problem
degranulation	I-Problem
and	I-Problem
subsequent	I-Problem
release	I-Problem
of	I-Problem
eosinophil	I-Problem
chemotactic	I-Problem
factor	I-Problem
as	I-Problem
a	I-Problem
cause	I-Problem
of	I-Problem
csfe	I-Problem
.	O

within	I-Other
3	I-Other
weeks	I-Other
of	I-Other
beginning	I-Other
continuous	I-Treatment
daily	I-Other
isoniazid	I-Treatment
and	I-Treatment
rifampin	I-Treatment
therapy	O
for	O
pulmonary	I-Problem
tuberculosis	I-Problem
,	O
a	I-Background
patient	I-Background
developed	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
.	O

we	O
report	O
four	O
cases	I-Background
of	O
severe	O
corneal	I-Problem
ulceration	I-Problem
in	O
methamphetamine	I-Treatment
abusers	O
.	O

diagnosis	O
:	O
practolol	I-Treatment
induced	O
sclerosing	I-Problem
peritonitis	I-Problem
.	O

we	O
report	O
the	O
first	I-Test
biopsy	I-Test
confirmed	O
occurrence	O
of	O
acute	I-Problem
interstitial	I-Problem
nephritis	I-Problem
in	O
a	O
patient	I-Background
receiving	O
treatment	O
with	O
sunitinib	I-Treatment
for	O
metastatic	I-Problem
renal	I-Problem
cell	I-Problem
cancer	I-Problem
.	O

multiple	I-Problem
pulmonary	I-Problem
nodules	I-Problem
:	O
an	O
unusual	O
presentation	O
of	O
fludarabine	I-Treatment
pulmonary	O
toxicity	O
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
.	O

clozapine	I-Treatment
-	O
induced	O
tardive	I-Problem
dyskinesia	I-Problem
in	O
schizophrenic	I-Problem
patients	I-Background
taking	O
clozapine	O
as	O
a	O
first	O
-	O
line	O
antipsychotic	O
drug	O
.	O

recently	O
,	O
her	I-Background
serum	I-Test
theophylline	I-Test
levels	I-Test
had	I-Problem
increased	I-Problem
to	I-Problem
the	I-Problem
toxic	I-Problem
range	I-Problem
(	O
133	O
.	O
2	O
micromol	O
/	O
l	O
[	O
24	O
microg	O
/	O
ml	O
]	O
)	O
shortly	O
after	O
the	O
addition	O
of	O
zafirlukast	I-Treatment
(	O
accolate	O
,	O
zeneca	O
pharmaceuticals	O
,	O
wilmington	O
,	O
del	O
)	O
to	O
her	O
regimen	O
.	O

withdrawal	I-Problem
emergent	I-Problem
syndrome	I-Problem
in	O
an	I-Background
infant	I-Background
associated	O
with	O
maternal	I-Treatment
haloperidol	I-Treatment
therapy	I-Treatment
.	O

diphenylhydantoin	I-Treatment
apparently	O
adversely	I-Problem
affected	I-Problem
both	I-Problem
the	I-Problem
clinical	I-Problem
and	I-Problem
biochemical	I-Problem
parameters	I-Problem
of	I-Problem
the	I-Problem
acute	I-Problem
intermittent	I-Problem
porphyria	I-Problem
.	O

successful	O
recovery	O
from	O
interstitial	I-Problem
pneumonitis	I-Problem
,	O
induced	O
by	O
bicalutamide	I-Treatment
and	I-Treatment
leuprorelin	I-Treatment
acetate	I-Treatment
given	O
as	O
treatment	O
for	O
prostate	I-Problem
cancer	I-Problem
.	O

gold	I-Treatment
-	O
induced	O
pneumonitis	I-Problem
.	O

visceral	I-Problem
leishmaniasis	I-Problem
and	I-Problem
macrophagic	I-Problem
activation	I-Problem
syndrome	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
under	O
treatment	O
with	O
adalimumab	I-Treatment
.	O

he	I-Background
was	O
diagnosed	O
with	O
possible	I-Problem
serotonin	I-Problem
syndrome	I-Problem
;	O
his	O
symptoms	O
resolved	O
after	O
clomipramine	O
was	O
stopped	O
but	O
before	O
clozapine	I-Treatment
was	O
restarted	O
eight	O
days	O
later	O
.	O

disseminated	I-Problem
intravascular	I-Problem
coagulation	I-Problem
associated	I-Problem
with	I-Problem
acute	I-Problem
hemoglobinemia	I-Problem
or	I-Problem
hemoglobinuria	I-Problem
following	O
rh	I-Treatment
(	I-Treatment
0	I-Treatment
)	I-Treatment
(	I-Treatment
d	I-Treatment
)	I-Treatment
immune	I-Treatment
globulin	I-Treatment
intravenous	I-Treatment
administration	O
for	O
immune	I-Problem
thrombocytopenic	I-Problem
purpura	I-Problem
.	O

two	O
patients	O
had	O
ampicillin	I-Treatment
-	O
associated	O
seizures	I-Problem
.	O

a	I-Background
patient	I-Background
developed	O
restless	I-Problem
legs	I-Problem
symptoms	I-Problem
paralleling	O
the	O
course	O
of	O
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
(	I-Treatment
ifn	I-Treatment
alpha	I-Treatment
)	I-Treatment
therapy	I-Treatment
for	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

while	O
many	O
can	O
benefit	O
from	O
coadministration	I-Treatment
of	I-Treatment
serotonergic	I-Treatment
antidepressants	I-Treatment
and	I-Treatment
opioids	I-Treatment
,	O
it	O
appears	O
that	O
some	I-Background
individuals	I-Background
are	O
at	O
increased	O
risk	O
for	O
ss	I-Problem
.	O

stomatitis	I-Problem
,	O
diarrhea	I-Problem
,	O
dermatitis	I-Problem
,	O
and	O
myelosuppression	I-Problem
are	O
the	O
main	O
toxicities	O
of	O
5	I-Treatment
-	I-Treatment
fu	I-Treatment
.	O

after	O
treatment	O
with	O
cimetidine	I-Treatment
,	O
there	O
was	O
a	I-Problem
rapid	I-Problem
deterioration	I-Problem
with	I-Problem
decreased	I-Problem
oxygen	I-Problem
saturation	I-Problem
and	I-Problem
arterial	I-Problem
po2	I-Test
values	I-Test
.	O

we	O
describe	O
a	I-Background
case	I-Background
of	I-Background
advanced	I-Problem
ovarian	I-Problem
carcinoma	I-Problem
who	O
developed	O
difficulty	I-Problem
walking	I-Problem
because	I-Problem
of	I-Problem
marked	I-Problem
pain	I-Problem
in	I-Problem
the	I-Problem
lower	I-Problem
extremities	I-Problem
and	I-Problem
loss	I-Problem
of	I-Problem
proprioception	I-Problem
25	I-Other
days	I-Other
after	I-Treatment
treatment	I-Treatment
with	I-Treatment
weekly	I-Other
taxol	I-Treatment
(	I-Treatment
80	I-Treatment
mg	I-Treatment
/	I-Treatment
m	I-Treatment
(	I-Treatment
2	I-Treatment
)	I-Treatment
x3	I-Treatment
)	I-Treatment
.	O

agranulocytosis	I-Problem
and	I-Problem
granulocytopenia	I-Problem
associated	O
with	O
quetiapine	I-Treatment
.	O

the	O
multiple	I-Problem
comedones	I-Problem
and	I-Problem
ruptured	I-Problem
epidermoid	I-Problem
cysts	I-Problem
are	O
newly	O
reported	O
adverse	O
effects	O
of	O
imiquimod	I-Treatment
therapy	I-Treatment
.	O

we	O
conclude	O
that	O
neurosurgeons	O
and	O
neurologists	O
should	O
be	O
aware	O
of	O
calcium	I-Treatment
antagonist	I-Treatment
-	O
-	O
related	O
ileus	I-Problem
in	O
patients	I-Background
treated	O
with	O
nimodipine	I-Treatment
.	O

hyperpigmentation	I-Problem
during	O
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
therapy	I-Treatment
for	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
virus	I-Problem
infection	I-Problem
.	O

chlorambucil	I-Treatment
-	O
induced	O
chromosome	I-Problem
damage	I-Problem
to	O
human	O
lymphocytes	O
is	O
dose	O
-	O
dependent	O
and	O
cumulative	O
.	O

carbamazepine	I-Treatment
hypersensitivity	I-Problem
syndrome	I-Problem
is	O
a	O
rare	O
,	O
life	O
-	O
threatening	O
condition	O
.	O

case	O
report	O
:	O
dapsone	I-Treatment
hypersensitivity	I-Problem
syndrome	I-Problem
associated	O
with	O
treatment	O
of	O
the	O
bite	O
of	O
a	O
brown	O
recluse	O
spider	O
.	O

acute	I-Problem
asymptomatic	I-Problem
hepatitis	I-Problem
in	O
a	I-Background
healthy	I-Background
normal	I-Background
volunteer	I-Background
exposed	O
to	O
2	I-Treatment
oral	I-Treatment
doses	I-Treatment
of	I-Treatment
amodiaquine	I-Treatment
and	I-Treatment
artesunate	I-Treatment
.	O

the	O
authors	O
report	O
a	O
case	O
of	O
focal	I-Problem
myocardial	I-Problem
necrosis	I-Problem
,	I-Problem
presenting	I-Problem
clinically	I-Problem
as	I-Problem
an	I-Problem
acute	I-Problem
myocardial	I-Problem
infarction	I-Problem
during	O
the	O
administration	O
of	O
the	O
antineoplastic	O
drug	O
,	O
amsacrine	I-Treatment
,	O
in	O
a	I-Background
patient	I-Background
without	I-Background
coronary	I-Background
artery	I-Background
disease	I-Background
.	O

baclofen	I-Treatment
and	O
oxazepam	I-Treatment
were	O
prescribed	O
secondary	O
to	O
right	I-Problem
-	I-Problem
sided	I-Problem
hemiparesis	I-Problem
contractures	I-Problem
.	O

discussion	O
:	O
a	O
review	O
of	O
the	O
cases	O
of	O
ss	I-Problem
with	O
implication	O
of	O
mirtazapine	I-Treatment
as	O
the	O
cause	O
was	O
performed	O
.	O

a	O
small	O
number	O
of	O
oxaliplatin	I-Treatment
-	O
related	O
hemolytic	I-Problem
and	I-Problem
/	I-Problem
or	I-Problem
thrombocytopenic	I-Problem
reactions	I-Problem
have	O
been	O
reported	O
.	O

case	O
summary	O
:	O
a	I-Background
39	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
jewish	I-Background
schizophrenic	I-Problem
man	I-Background
treated	O
with	O
olanzapine	I-Treatment
developed	O
an	I-Problem
elevated	I-Problem
serum	I-Problem
ck	I-Problem
concentration	I-Problem
with	O
a	O
peak	O
concentration	O
of	O
4000	O
iu	O
/	O
l	O
(	O
normal	O
<	O
230	O
)	O
.	O

severe	I-Problem
water	I-Problem
intoxication	I-Problem
secondary	O
to	O
the	I-Treatment
concomitant	I-Treatment
intake	I-Treatment
of	I-Treatment
non	I-Treatment
-	I-Treatment
steroidal	I-Treatment
anti	I-Treatment
-	I-Treatment
inflammatory	I-Treatment
drugs	I-Treatment
and	I-Treatment
desmopressin	I-Treatment
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

an	O
apparent	O
link	O
is	O
described	O
between	O
the	O
use	O
of	O
mmf	I-Treatment
with	I-Treatment
prednisone	I-Treatment
to	I-Treatment
treat	I-Treatment
pemphigus	I-Problem
vulgaris	I-Problem
and	O
the	O
development	O
of	O
red	I-Problem
blood	I-Problem
cell	I-Problem
anemia	I-Problem
.	O

other	O
potential	O
causes	O
of	O
renal	O
failure	O
were	O
not	O
present	O
in	O
our	I-Background
patient	I-Background
and	O
his	I-Problem
renal	I-Problem
function	I-Problem
gradually	I-Problem
recovered	I-Problem
with	O
the	O
cessation	I-Treatment
of	I-Treatment
suramin	I-Treatment
treatment	I-Treatment
.	O

massive	I-Treatment
cbz	I-Test
od	I-Test
may	O
produce	O
a	O
reversible	I-Problem
encephalopathy	I-Problem
that	I-Problem
includes	I-Problem
cortical	I-Problem
hyperexcitability	I-Problem
,	I-Problem
a	I-Problem
profound	I-Problem
burst	I-Problem
-	I-Problem
suppression	I-Problem
eeg	I-Problem
pattern	I-Problem
,	I-Problem
and	I-Problem
cranial	I-Problem
nerve	I-Problem
areflexia	I-Problem
.	O

this	O
is	O
the	O
first	O
report	O
of	O
a	O
fluoxetine	I-Treatment
-	O
related	O
death	I-Problem
in	O
a	I-Background
child	I-Background
with	I-Background
a	I-Background
confirmed	I-Background
genetic	I-Problem
polymorphism	I-Problem
of	I-Problem
the	I-Problem
cyp2d6	I-Problem
gene	I-Problem
that	I-Problem
results	I-Problem
in	I-Problem
impaired	I-Problem
drug	I-Problem
metabolism	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
reversible	I-Problem
dka	I-Problem
and	I-Problem
new	I-Problem
-	I-Problem
onset	I-Problem
dm	I-Problem
that	O
developed	O
in	O
a	O
demented	I-Problem
patient	I-Background
who	O
was	O
treated	O
with	O
quetiapine	I-Treatment
for	I-Treatment
14	I-Other
days	I-Other
.	O

the	O
patient	I-Background
'	I-Background
s	I-Background
arthritis	I-Problem
flared	I-Problem
after	O
the	O
second	I-Other
infusion	I-Treatment
of	I-Treatment
infliximab	I-Treatment
,	O
which	O
was	O
discontinued	O
.	O

conclusion	O
:	O
marked	I-Problem
visual	I-Problem
field	I-Problem
constriction	I-Problem
appears	O
to	O
be	O
associated	O
with	O
vigabatrin	I-Treatment
therapy	I-Treatment
.	O

possible	O
serotonin	I-Problem
syndrome	I-Problem
associated	I-Problem
with	I-Problem
clomipramine	I-Treatment
after	O
withdrawal	I-Treatment
of	I-Treatment
clozapine	I-Treatment
.	O

a	I-Background
14	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
developed	O
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
(	I-Problem
sle	I-Problem
)	I-Problem
-	I-Problem
like	I-Problem
symptoms	I-Problem
,	I-Problem
rash	I-Problem
,	I-Problem
fever	I-Problem
,	I-Problem
leukopenia	I-Problem
and	I-Problem
positive	I-Problem
anti	I-Problem
-	I-Problem
nuclear	I-Problem
antibody	I-Problem
(	I-Problem
ana	I-Problem
)	I-Problem
two	O
weeks	O
after	O
administration	I-Treatment
of	I-Treatment
carbamazepine	I-Treatment
(	I-Treatment
cbz	I-Treatment
;	I-Treatment
tegretol	I-Treatment
)	I-Treatment
used	I-Treatment
against	I-Treatment
benign	I-Problem
rolandic	I-Problem
epilepsy	I-Problem
.	O

there	O
was	O
a	O
clear	O
relationship	O
between	O
restarting	O
the	O
accutane	I-Treatment
and	O
recurrence	I-Problem
of	I-Problem
the	I-Problem
transient	I-Problem
myopia	I-Problem
.	O

masculinization	I-Problem
of	I-Problem
a	I-Problem
female	I-Problem
fetus	I-Problem
occurred	O
in	O
5	O
of	O
39	O
(	O
12	O
.	O
8	O
%	O
)	O
exposed	O
to	O
norethisterone	I-Treatment
;	O
all	O
were	O
cases	O
of	O
clitoral	I-Problem
hypertrophy	I-Problem
not	O
requiring	O
surgical	O
treatment	O
.	O

she	I-Background
continued	I-Treatment
taking	I-Treatment
verapamil	I-Treatment
for	I-Other
6	I-Other
months	I-Other
,	I-Treatment
then	I-Treatment
,	I-Treatment
on	I-Treatment
her	I-Treatment
own	I-Treatment
,	I-Treatment
stopped	I-Treatment
all	I-Treatment
medications	I-Treatment
including	I-Treatment
the	I-Treatment
sustained	I-Treatment
-	I-Treatment
release	I-Treatment
verapamil	I-Treatment
,	O
and	O
her	O
asthma	I-Problem
symptoms	O
disappeared	O
.	O

conclusion	O
:	O
there	O
are	O
only	O
a	O
few	O
confirmed	O
cases	O
of	O
gemcitabine	I-Treatment
-	O
associated	O
hus	I-Problem
despite	O
the	O
widespread	O
use	O
of	O
the	O
drug	O
.	O

in	O
these	I-Background
patients	I-Background
,	O
long	I-Treatment
-	I-Treatment
acting	I-Treatment
octreotide	I-Treatment
may	O
trigger	O
serious	I-Problem
hypoglycemia	I-Problem
.	O

an	O
intertrigo	I-Problem
-	I-Problem
like	I-Problem
eruption	I-Problem
from	O
pegylated	I-Treatment
liposomal	I-Treatment
doxorubicin	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
neh	I-Problem
masquerading	I-Problem
as	I-Problem
cutaneous	I-Problem
vasculitis	I-Problem
in	O
a	I-Background
woman	I-Background
receiving	O
cyclophosphamide	I-Treatment
for	I-Background
lupus	I-Problem
nephritis	I-Problem
.	I-Problem

the	O
diagnosis	O
of	O
hypothermia	I-Problem
was	O
delayed	O
until	O
it	O
was	O
apparent	O
for	O
several	O
days	O
but	O
resolved	O
with	O
the	O
discontinuation	I-Treatment
of	I-Treatment
risperidone	I-Treatment
and	I-Treatment
continuation	I-Treatment
of	I-Treatment
clozapine	I-Treatment
.	O

unaccountable	I-Problem
severe	I-Problem
hypercalcemia	I-Problem
in	O
a	O
patient	I-Background
treated	O
for	O
hypoparathyroidism	I-Problem
with	O
dihydrotachysterol	I-Treatment
.	O

anaphylaxis	I-Problem
to	O
calcitonin	I-Treatment
.	O

however	O
,	O
he	I-Background
developed	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
,	I-Problem
hyperkalemia	I-Problem
,	I-Problem
and	I-Problem
hyperuricemia	I-Problem
30	I-Other
d	I-Other
after	O
receiving	O
the	O
sorafenib	I-Treatment
treatment	O
.	O

mycobacterium	I-Problem
marinum	I-Problem
infection	I-Problem
complicating	I-Problem
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
,	O
treated	O
with	O
infliximab	I-Treatment
.	O

current	I-Treatment
immunosuppressive	I-Treatment
therapies	I-Treatment
are	O
effective	O
but	O
can	O
be	O
associated	O
with	O
significant	I-Problem
adverse	I-Problem
reactions	I-Problem
.	I-Problem

this	O
report	O
describes	O
the	O
first	O
association	O
(	O
exclusive	O
of	O
drug	O
overdose	O
)	O
of	O
symptomatic	I-Problem
torsades	I-Problem
de	I-Problem
pointes	I-Problem
occurring	O
with	O
the	O
use	O
of	O
terfenadine	I-Treatment
in	O
a	I-Background
patient	I-Background
who	O
was	O
taking	I-Treatment
the	I-Treatment
recommended	I-Treatment
prescribed	I-Treatment
dose	I-Treatment
of	I-Treatment
this	I-Treatment
drug	I-Treatment
in	I-Treatment
addition	I-Treatment
to	I-Treatment
cefaclor	I-Treatment
,	I-Treatment
ketoconazole	I-Treatment
,	I-Treatment
and	I-Treatment
medroxyprogesterone	I-Treatment
.	O

tamoxifen	I-Treatment
is	O
suggested	O
to	O
be	O
carcinogenic	I-Problem
both	I-Problem
through	I-Problem
direct	I-Problem
genotoxic	I-Problem
and	I-Problem
epigenetic	I-Problem
mechanisms	I-Problem
.	O

discussion	O
:	O
colchicine	I-Treatment
,	O
the	O
most	O
important	O
drug	O
in	O
treatment	O
of	O
fmf	I-Problem
,	O
can	O
cause	O
myopathy	I-Problem
in	O
patients	I-Background
with	I-Background
impaired	I-Problem
renal	I-Problem
and	I-Problem
hepatic	I-Problem
function	I-Problem
.	O

in	O
the	O
presented	O
case	O
fluvoxamine	I-Background
-	I-Background
induced	I-Background
akathisia	I-Problem
in	I-Background
an	I-Background
ocd	I-Problem
patient	I-Background
was	O
partially	O
resistant	O
to	O
the	O
anticholinergic	O
agent	O
biperiden	O
,	O
and	O
was	O
successfully	O
treated	O
with	O
the	O
5	I-Treatment
-	I-Treatment
ht2a	I-Treatment
/	I-Treatment
5	I-Treatment
-	I-Treatment
ht2c	I-Treatment
antagonist	I-Treatment
mianserin	I-Treatment
.	O

subsequent	O
course	O
:	O
the	O
nephrosis	I-Problem
resolved	O
almost	O
completely	O
once	O
the	O
interferon	I-Treatment
was	I-Treatment
stopped	I-Treatment
and	I-Treatment
after	I-Treatment
immunosuppressive	I-Treatment
treatment	I-Treatment
.	O

in	I-Background
two	O
patients	I-Background
,	O
apomorphine	I-Treatment
remained	O
effective	O
in	O
the	O
morning	O
,	O
but	O
increased	O
the	O
intensity	I-Problem
of	I-Problem
the	I-Problem
dyskinesias	I-Problem
in	I-Problem
the	I-Problem
afternoon	I-Problem
.	O

transient	I-Problem
asymptomatic	I-Problem
bradycardia	I-Problem
in	O
patients	I-Background
on	O
infusional	I-Treatment
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
.	I-Treatment

in	O
2006	O
,	O
he	O
was	O
diagnosed	O
with	O
deep	I-Problem
vein	I-Problem
thrombosis	I-Problem
and	I-Problem
pulmonary	I-Problem
embolism	I-Problem
and	O
was	O
started	O
on	O
warfarin	I-Treatment
.	O

scleritis	I-Problem
complicating	O
zoledronic	I-Treatment
acid	I-Treatment
infusion	I-Treatment
.	O

a	I-Background
22	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
black	I-Background
man	I-Background
developed	O
fever	I-Problem
,	I-Problem
chills	I-Problem
,	I-Problem
fatigue	I-Problem
,	I-Problem
night	I-Problem
sweats	I-Problem
,	I-Problem
tender	I-Problem
lymphadenopathy	I-Problem
,	I-Problem
and	I-Problem
a	I-Problem
generalized	I-Problem
,	I-Problem
pruritic	I-Problem
,	I-Problem
macular	I-Problem
eruption	I-Problem
3	I-Other
weeks	I-Other
after	O
starting	O
minocycline	I-Treatment
therapy	I-Treatment
for	O
acne	I-Problem
.	O

ticlopidine	I-Treatment
-	O
induced	O
aplastic	I-Problem
anemia	I-Problem
:	O
two	O
new	O
case	O
reports	O
,	O
review	O
,	O
and	O
meta	O
-	I-Test
analysis	I-Test
of	O
55	O
additional	O
cases	O
.	O

this	O
is	O
the	O
second	O
report	O
of	O
acute	I-Problem
lung	I-Problem
injury	I-Problem
and	I-Problem
diffuse	I-Problem
alveolar	I-Problem
damage	I-Problem
caused	O
by	O
mefloquine	I-Treatment
.	O

a	O
case	O
of	O
erythema	I-Problem
multiforme	I-Problem
bullosum	I-Problem
in	O
patient	I-Background
of	I-Background
lepromatous	I-Problem
leprosy	I-Problem
with	I-Background
pulmonary	I-Problem
tuberculosis	I-Problem
due	O
to	O
rifampicin	I-Treatment
is	O
described	O
.	O

life	I-Problem
-	I-Problem
threatening	I-Problem
alterations	I-Problem
in	I-Problem
heart	I-Problem
rate	I-Problem
after	O
the	O
use	O
of	O
adenosine	I-Treatment
in	O
atrial	O
flutter	O
.	O

we	O
report	O
a	O
case	O
of	O
pancytopenia	I-Problem
in	O
a	I-Background
23	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
who	O
was	O
treated	O
with	O
5	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
(	I-Treatment
pentasa	I-Treatment
;	I-Treatment
nisshin	I-Treatment
,	I-Treatment
tokyo	I-Treatment
,	I-Treatment
japan	I-Treatment
)	I-Treatment
3	I-Treatment
.	I-Treatment
0	I-Treatment
g	I-Treatment
/	I-Treatment
day	I-Treatment
.	O

the	I-Problem
ampicillin	I-Treatment
rash	I-Problem
occurring	O
in	O
cases	O
of	O
infectious	I-Problem
mononucleosis	I-Problem
is	O
well	O
documented	O
.	O

the	O
major	O
side	O
effect	O
of	O
infliximab	I-Treatment
is	O
infection	I-Problem
.	O

an	I-Background
asymptomatic	I-Background
hiv	I-Problem
-	I-Background
infected	I-Background
woman	I-Background
experienced	O
right	I-Problem
-	I-Problem
sided	I-Problem
renal	I-Problem
colicky	I-Problem
pain	I-Problem
during	O
treatment	O
with	O
indinavir	I-Treatment
.	O

the	O
case	O
resembles	O
two	O
previously	O
reported	O
cases	O
of	O
optic	I-Problem
neuropathy	I-Problem
which	O
occurred	O
in	O
patients	I-Background
with	I-Background
wilson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
who	O
were	O
receiving	O
penicillamine	I-Treatment
.	O

cutaneous	I-Problem
ulceration	I-Problem
:	O
an	O
unusual	O
complication	O
of	O
intravenous	I-Treatment
pentamidine	I-Treatment
therapy	O
.	O

pulmonary	I-Problem
hemorrhage	I-Problem
is	O
an	O
uncommon	O
feature	O
in	O
the	O
hus	O
,	O
and	O
seems	O
to	O
appear	O
especially	O
in	O
the	O
hus	O
associated	O
with	O
mmc	I-Treatment
therapy	O
.	O

immunosuppression	O
elicited	O
by	O
the	O
extensive	I-Treatment
administration	I-Treatment
of	I-Treatment
prednisolone	I-Treatment
was	O
suspected	O
for	O
the	O
initiation	O
of	O
the	O
generalized	O
mite	I-Problem
infestation	I-Problem
.	O

the	I-Problem
episode	I-Problem
appeared	I-Problem
to	I-Problem
have	I-Problem
been	I-Problem
precipitated	I-Problem
by	I-Problem
toxicity	I-Problem
due	O
to	O
ingestion	O
of	O
a	I-Treatment
large	I-Treatment
amount	I-Treatment
of	I-Treatment
phenytoin	I-Treatment
.	I-Treatment

cardiopulmonary	I-Problem
arrest	I-Problem
following	O
intravenous	I-Treatment
phenytoin	I-Test
loading	I-Test
.	O

although	O
taxol	I-Treatment
has	O
shown	O
significant	O
activity	O
in	O
advanced	O
ovarian	O
cancer	O
,	O
peripheral	I-Problem
neuropathy	I-Problem
is	O
likely	O
to	O
become	O
the	O
major	O
dose	O
-	O
limiting	O
toxicity	O
.	O

syringotropic	I-Problem
hypersensitivity	I-Problem
reaction	I-Problem
associated	O
with	O
infliximab	I-Treatment
and	I-Treatment
leflunomide	I-Treatment
combination	I-Treatment
therapy	I-Treatment
in	O
a	I-Background
child	I-Background
with	I-Background
psoriatic	I-Problem
arthritis	I-Problem
.	O

corticosteroid	I-Treatment
therapy	O
was	O
continued	O
for	I-Other
8	I-Other
months	I-Other
since	O
there	O
was	O
still	O
improvement	O
of	O
pulmonary	I-Problem
function	I-Test
studies	I-Test
.	O

objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
sertraline	I-Treatment
-	O
induced	O
rhabdomyolysis	I-Problem
in	O
an	I-Background
elderly	I-Background
patient	I-Background
with	I-Background
dementia	I-Problem
and	I-Background
comorbidities	I-Problem
.	O

beyond	O
the	O
predictable	O
pharmacokinetic	O
drug	O
-	O
drug	O
interaction	O
requiring	O
a	O
significant	O
warfarin	O
dose	O
reduction	O
,	O
the	O
iodine	I-Treatment
-	I-Treatment
rich	I-Treatment
amiodarone	I-Treatment
affects	O
the	O
thyroid	O
gland	O
,	O
causing	O
overt	I-Problem
hypothyroidism	I-Problem
or	I-Problem
thyrotoxicosis	I-Problem
in	O
14	O
%	O
-	O
18	O
%	O
of	O
cases	O
.	O

toxic	I-Problem
epidermal	I-Test
necrolysis	I-Test
associated	O
with	O
interleukin	I-Treatment
-	I-Treatment
2	I-Treatment
.	O

the	O
pulmonary	I-Problem
toxicity	I-Problem
of	O
gold	I-Treatment
salts	I-Treatment
is	O
an	O
uncommon	O
cause	O
of	O
life	I-Problem
-	I-Problem
threatening	I-Problem
respiratory	I-Problem
failure	I-Problem
.	O

with	O
its	O
characteristics	O
,	O
tizanidine	I-Treatment
has	O
the	O
potential	O
to	O
compromise	I-Problem
hemodynamic	I-Problem
stability	I-Problem
during	I-Treatment
concomitant	I-Treatment
angiotensin	I-Treatment
-	I-Treatment
converting	I-Treatment
enzyme	I-Treatment
inhibitor	I-Treatment
use	I-Treatment
.	O

premature	I-Problem
closure	I-Problem
of	I-Problem
the	I-Problem
ductus	I-Problem
arteriosus	I-Problem
:	O
variable	O
response	O
among	O
monozygotic	I-Background
twins	I-Background
after	O
in	I-Treatment
utero	I-Treatment
exposure	I-Treatment
to	I-Treatment
indomethacin	I-Treatment
.	O

possible	O
mechanisms	O
by	O
which	O
clonidine	I-Treatment
decreases	O
spasticity	O
are	O
described	O
,	O
probable	O
mechanisms	O
of	O
induced	O
bradycardia	I-Problem
are	O
reviewed	O
,	O
and	O
specific	O
treatment	O
recommendations	O
for	O
the	O
use	O
of	O
clonidine	O
in	O
spinal	I-Problem
cord	I-Problem
injured	I-Problem
patients	O
are	O
presented	O
.	O

this	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
association	O
between	O
an	I-Problem
acute	I-Problem
cardiovascular	I-Problem
event	I-Problem
and	O
venlafaxine	I-Treatment
.	O

since	O
early	O
symptoms	O
of	O
the	O
toxic	O
effects	O
of	O
theophylline	O
can	O
mimic	O
peptic	O
ulcer	O
disease	O
,	O
cimetidine	I-Treatment
might	O
be	O
prescribed	O
for	O
the	O
gastrointestinal	I-Problem
symptoms	I-Problem
with	O
subsequent	O
worsening	O
of	O
theophylline	O
poisoning	O
.	O

acute	I-Problem
renal	I-Problem
failure	I-Problem
in	O
a	I-Background
patient	I-Background
receiving	O
treatment	O
with	O
suramin	I-Treatment
.	O

a	O
further	O
case	O
of	O
anaphylactoid	I-Problem
reaction	I-Problem
to	O
methylprednisolone	I-Treatment
is	O
reported	O
.	O

pulmonary	I-Problem
hemorrhage	I-Problem
as	O
a	O
clinical	O
manifestation	O
of	O
hemolytic	I-Problem
-	I-Problem
uremic	I-Problem
syndrome	I-Problem
associated	O
with	O
mitomycin	I-Treatment
c	I-Treatment
therapy	I-Treatment
.	O

eeg	I-Problem
abnormalities	I-Problem
were	O
observed	O
in	O
two	O
of	O
the	O
nine	O
children	I-Background
during	O
chlorambucil	I-Treatment
therapy	O
.	O

discontinuation	O
of	O
the	O
itraconazole	I-Treatment
caused	O
resolution	O
of	O
the	O
drug	I-Problem
eruption	I-Problem
.	O

the	I-Treatment
addition	I-Treatment
of	I-Treatment
intrathecal	I-Treatment
methotrexate	I-Treatment
to	I-Treatment
treatment	I-Treatment
protocols	I-Treatment
has	O
increased	O
survival	O
rates	O
in	I-Background
children	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
but	O
is	O
also	O
associated	O
with	O
varying	I-Problem
degrees	I-Problem
of	I-Problem
neurotoxicity	I-Problem
.	O

we	O
conclude	O
that	O
the	O
presence	O
of	O
this	I-Background
metabolic	I-Problem
defect	I-Problem
combined	O
with	O
topical	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
(	I-Treatment
a	I-Treatment
drug	I-Treatment
demonstrating	I-Treatment
a	I-Treatment
narrow	I-Treatment
therapeutic	I-Treatment
index	I-Treatment
)	I-Treatment
results	O
in	O
the	O
unusual	I-Problem
presentation	I-Problem
of	I-Problem
life	I-Problem
-	I-Problem
threatening	I-Problem
toxicity	I-Problem
after	O
treatment	O
with	O
a	O
topical	O
drug	O
.	O

six	O
patients	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
developed	O
a	O
syndrome	I-Problem
resembling	I-Problem
lupus	I-Problem
erythematosus	I-Problem
while	O
being	O
treated	O
with	O
penicillamine	I-Treatment
.	O

this	O
case	O
highlights	O
the	O
need	O
to	O
monitor	O
liver	O
enzymes	I-Test
in	O
patients	I-Background
treated	I-Background
with	I-Background
6	I-Background
-	I-Background
tg	I-Background
and	O
identifies	O
the	O
need	O
for	O
additional	O
research	O
focused	O
on	O
the	O
mechanism	O
of	O
thiopurine	I-Treatment
-	O
induced	O
hepatic	I-Problem
injury	I-Problem
.	O

5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
(	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
)	I-Treatment
is	I-Treatment
an	I-Treatment
analogue	I-Treatment
of	I-Treatment
pyrimidine	I-Treatment
nucleosides	I-Treatment
that	O
is	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
head	I-Problem
and	I-Problem
neck	I-Problem
,	I-Problem
breast	I-Problem
,	I-Problem
ovarian	I-Problem
,	I-Problem
and	I-Problem
colon	I-Problem
cancer	I-Problem
.	O

fulminant	I-Problem
fatal	I-Problem
cardiotoxicity	I-Problem
following	O
cyclophosphamide	I-Treatment
therapy	O
.	O

we	O
describe	O
the	O
exceptional	O
development	O
of	O
aml	I-Problem
and	O
lung	I-Problem
cancer	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
previously	I-Background
diagnosed	I-Background
cll	I-Problem
in	I-Problem
minimal	I-Problem
residual	I-Problem
disease	I-Problem
status	I-Problem
after	O
fludarabine	I-Treatment
treatment	O
followed	O
by	O
autologous	I-Treatment
peripheral	I-Treatment
blood	I-Treatment
stem	I-Treatment
-	I-Treatment
cell	I-Treatment
transplantation	I-Treatment
.	O

valproate	I-Treatment
-	O
induced	O
hyperammonemia	I-Problem
as	O
a	O
cause	O
of	O
altered	I-Problem
mental	I-Problem
status	I-Problem
.	O

we	O
report	O
5	O
cases	O
of	O
acute	I-Problem
reversible	I-Problem
renal	I-Problem
failure	I-Problem
coinciding	O
with	O
the	O
onset	O
of	O
treatment	O
with	O
captopril	I-Treatment
in	O
patients	I-Background
with	I-Background
severe	I-Problem
drug	I-Problem
-	I-Problem
resistant	I-Problem
hypertension	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
contact	I-Problem
dermatitis	I-Problem
due	O
to	O
sodium	I-Treatment
bisulfite	I-Treatment
in	O
tathion	O
eye	O
drops	O
.	O

the	I-Background
first	I-Background
patient	I-Background
is	O
undergoing	O
hemodialysis	O
and	O
,	O
though	O
responding	O
to	O
sunitinib	I-Treatment
,	O
is	O
having	O
significant	I-Problem
fatigue	I-Problem
and	I-Problem
hypertension	I-Problem
.	O

ccbs	I-Treatment
should	O
be	O
considered	O
in	O
the	O
treatment	O
of	O
5	O
-	O
fu	O
or	O
capecitabine	O
-	O
induced	O
headaches	I-Problem
.	O

furosemide	I-Treatment
,	I-Treatment
spironolactone	I-Treatment
,	I-Treatment
allopurinol	I-Treatment
,	I-Treatment
and	I-Treatment
hydroxyurea	I-Treatment
were	O
considered	O
possible	O
causes	O
of	O
the	O
reaction	I-Problem
and	O
were	O
discontinued	O
.	O

patients	O
:	O
one	O
patient	I-Background
with	O
mucositis	I-Problem
secondary	O
to	O
chemotherapy	I-Treatment
.	O

a	I-Background
patient	I-Background
with	I-Background
monocular	I-Problem
open	I-Problem
-	I-Problem
angle	I-Problem
glaucoma	I-Problem
had	O
trichiasis	I-Problem
,	O
a	O
condition	O
associated	O
with	O
the	O
use	O
of	O
a	I-Treatment
prostaglandin	I-Treatment
analog	I-Treatment
.	O

a	I-Background
53	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
african	I-Background
american	I-Background
male	I-Background
with	I-Background
hiv	I-Problem
was	O
prescribed	O
warfarin	I-Treatment
5	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
for	I-Treatment
12	I-Other
months	I-Other
after	O
diagnosis	O
of	O
idiopathic	I-Problem
deep	I-Problem
vein	I-Problem
thrombosis	I-Problem
and	I-Problem
bilateral	I-Problem
pulmonary	I-Problem
emboli	I-Problem
(	O
target	O
inr	I-Test
2	O
.	O
5	O
[	O
range	O
2	O
.	O
0	O
-	O
3	O
.	O
0	O
]	O
)	O
.	O

after	O
treatment	O
with	O
a	I-Treatment
beta	I-Treatment
-	I-Treatment
sympathomimetic	I-Treatment
drug	I-Treatment
(	I-Treatment
partusisten	I-Treatment
)	I-Treatment
one	I-Background
fetus	I-Background
developed	O
supraventricular	I-Problem
tachycardia	I-Problem
.	I-Problem

serotonin	I-Problem
syndrome	I-Problem
developed	O
in	O
a	I-Background
patient	I-Background
taking	O
concurrent	I-Treatment
linezolid	I-Treatment
and	I-Treatment
fluoxetine	I-Treatment
.	O

results	O
:	O
a	I-Background
male	I-Background
and	I-Background
a	I-Background
female	I-Background
patient	I-Background
with	I-Background
spasticity	I-Problem
treated	O
with	O
intrathecal	I-Treatment
baclofen	I-Treatment
were	O
recognized	O
to	O
have	O
sexual	I-Problem
dysfunction	I-Problem
side	O
effects	O
from	O
treatment	O
.	O

objective	O
:	O
to	O
describe	O
a	O
patient	I-Background
with	O
ifosfamide	I-Treatment
-	O
induced	O
nonconvulsive	I-Problem
status	I-Problem
epilepticus	I-Problem
.	O

upper	I-Problem
gastrointestinal	I-Problem
haemorrhage	I-Problem
is	O
a	O
serious	O
complication	O
of	O
aspirin	I-Treatment
and	I-Treatment
clopidogrel	I-Treatment
(	I-Treatment
dual	I-Treatment
)	I-Treatment
anti	O
-	O
platelet	O
therapy	O
with	O
a	O
high	O
morbidity	O
and	O
mortality	O
.	O

flecainide	I-Treatment
overdose	I-Treatment
can	O
rapidly	O
result	O
in	O
profound	I-Problem
cardiovascular	I-Problem
collapse	I-Problem
,	I-Problem
and	I-Problem
is	I-Problem
associated	I-Problem
with	I-Problem
a	I-Problem
relatively	I-Problem
high	I-Problem
mortality	I-Problem
.	O

sulfasalazine	I-Treatment
-	O
induced	O
lupus	I-Problem
erythematosus	I-Problem
.	O

reye	I-Problem
syndrome	I-Problem
(	I-Problem
rs	I-Problem
)	I-Problem
is	O
believed	O
to	O
occur	O
infrequently	O
among	O
children	I-Background
receiving	O
long	I-Treatment
-	I-Treatment
term	I-Treatment
aspirin	I-Treatment
therapy	O
.	O

propecia	I-Treatment
-	O
associated	O
bilateral	I-Problem
cataract	I-Problem
.	O

after	O
39	I-Other
hours	I-Other
on	O
argatroban	I-Treatment
,	O
the	O
infusion	O
was	O
stopped	O
when	O
minor	I-Problem
bleeding	I-Problem
was	I-Problem
observed	I-Problem
with	I-Problem
a	I-Problem
concurrent	I-Problem
activated	I-Test
partial	I-Problem
thromboplastin	I-Test
time	I-Test
(	I-Problem
aptt	I-Problem
)	I-Problem
of	I-Problem
100	I-Problem
seconds	I-Problem
.	O

anaphylactoid	I-Problem
reaction	I-Problem
to	O
methylprednisolone	I-Treatment
pulsed	I-Treatment
therapy	I-Treatment
for	O
multiple	I-Problem
sclerosis	I-Problem
.	O

surprisingly	O
,	O
we	O
found	O
that	O
three	O
patients	I-Background
appeared	O
to	O
develop	O
tardive	I-Problem
ogc	I-Problem
while	O
taking	O
clozapine	I-Treatment
.	O

we	O
report	O
a	O
fatal	O
case	O
of	O
toxic	I-Problem
epidermal	I-Problem
necrolysis	I-Problem
(	I-Problem
ten	I-Problem
)	I-Problem
resulting	O
from	O
a	O
high	I-Treatment
dose	I-Treatment
of	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
(	I-Treatment
ara	I-Treatment
-	I-Treatment
c	I-Treatment
)	I-Treatment
.	O

on	O
the	I-Other
fifth	I-Other
day	I-Other
after	O
administration	O
of	O
a	O
high	I-Treatment
dose	I-Treatment
of	I-Treatment
ara	I-Treatment
-	I-Treatment
c	I-Treatment
(	O
2	I-Treatment
g	I-Treatment
/	I-Treatment
m2	I-Treatment
intravenously	O
every	O
12	I-Other
hours	I-Other
)	O
,	O
she	O
developed	O
bullous	I-Problem
lesions	I-Problem
on	I-Problem
the	I-Problem
hands	I-Problem
and	I-Problem
soles	I-Problem
that	I-Problem
disseminated	I-Problem
,	I-Problem
evolving	I-Problem
to	I-Problem
necrosis	I-Problem
,	I-Problem
sepsis	I-Problem
,	I-Problem
and	I-Problem
death	I-Problem
on	O
the	I-Other
22nd	I-Other
day	I-Other
.	O

we	O
describe	O
2	O
patients	I-Background
with	I-Background
cutaneous	I-Problem
lupus	I-Problem
erythematosus	I-Problem
who	O
developed	O
severe	I-Problem
dapsone	I-Treatment
reaction	I-Problem
after	O
low	I-Treatment
dose	I-Treatment
therapy	I-Treatment
,	O
with	I-Problem
a	I-Problem
fatal	I-Problem
outcome	I-Problem
in	I-Problem
one	I-Problem
.	O

a	I-Background
patient	I-Background
with	I-Background
ulcerative	I-Problem
colitis	I-Problem
developed	O
skin	I-Problem
pigmentation	I-Problem
and	I-Problem
diffuse	I-Problem
pulmonary	I-Problem
shadowing	I-Problem
without	I-Problem
respiratory	I-Problem
symptomatology	I-Problem
,	O
while	O
taking	O
sulfasalazine	I-Treatment
.	O

this	O
is	O
a	O
case	O
report	O
involving	O
a	I-Background
patient	I-Background
who	O
was	O
treated	O
with	O
topical	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
cream	I-Treatment
and	O
subsequently	O
developed	O
a	I-Problem
severe	I-Problem
case	I-Problem
of	I-Problem
angioedema	I-Problem
.	O

cessation	I-Treatment
of	I-Treatment
d	I-Treatment
-	I-Treatment
pen	I-Treatment
and	I-Treatment
the	I-Treatment
start	I-Treatment
of	I-Treatment
corticosteroid	I-Treatment
therapy	I-Treatment
were	O
followed	O
by	O
recovery	I-Problem
from	I-Problem
bicytopenia	I-Problem
.	O

prevention	O
of	O
infection	I-Problem
by	O
immunization	I-Treatment
,	I-Treatment
together	I-Treatment
with	I-Treatment
early	I-Treatment
recognition	I-Treatment
and	I-Treatment
prompt	I-Treatment
antiviral	I-Treatment
treatment	I-Treatment
are	O
critical	O
.	O

a	I-Background
case	I-Background
of	O
normotensive	I-Problem
scleroderma	I-Problem
renal	I-Problem
crisis	I-Problem
after	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
methylprednisolone	I-Treatment
treatment	I-Treatment
.	O

objectives	O
:	O
a	O
delayed	I-Problem
stroke	I-Problem
-	I-Problem
like	I-Problem
leukoencephalopathy	I-Problem
has	O
been	O
observed	O
in	O
patients	I-Background
receiving	O
methotrexate	I-Treatment
(	I-Treatment
mtx	I-Treatment
)	I-Treatment
for	O
childhood	I-Problem
leukemia	I-Problem
.	O

duloxetine	I-Treatment
-	O
induced	O
hyponatremia	I-Problem
in	O
an	I-Background
elderly	I-Background
patient	I-Background
treated	I-Background
with	I-Background
thiazide	I-Treatment
diuretics	I-Treatment
.	O

the	O
following	O
is	O
a	O
case	I-Test
report	I-Test
analysis	I-Test
intended	O
to	O
draw	O
attention	O
to	O
the	O
need	O
for	O
better	O
care	O
coordination	O
by	O
describing	O
the	O
observed	O
relationship	O
of	O
olanzapine	I-Treatment
to	O
metabolic	I-Problem
changes	I-Problem
manifested	I-Problem
as	I-Problem
uncontrolled	I-Problem
diabetes	I-Problem
mellitus	I-Problem
and	I-Problem
weight	I-Problem
gain	I-Problem
.	O

arsenic	I-Treatment
trioxide	I-Treatment
has	O
recently	O
been	O
introduced	O
as	O
a	O
promising	O
new	O
agent	O
to	O
treat	O
refractory	I-Problem
acute	I-Problem
promyelocytic	I-Problem
leukemia	I-Problem
(	O
apl	O
)	O
.	O

although	O
the	I-Problem
t	I-Test
-	I-Test
aml	I-Test
developed	O
following	O
oral	I-Treatment
etoposide	I-Treatment
therapy	I-Treatment
,	O
the	I-Background
child	I-Background
had	O
previously	O
received	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
,	I-Treatment
multiagent	I-Treatment
chemotherapy	I-Treatment
,	O
and	O
rearrangement	O
of	I-Test
the	I-Test
mll	I-Test
gene	I-Test
was	O
not	O
demonstrated	O
.	O

heat	I-Problem
stroke	I-Problem
in	O
schizophrenia	I-Problem
during	O
clozapine	I-Treatment
treatment	O
:	O
rapid	O
recognition	O
and	O
management	O
.	O

the	O
same	I-Problem
symptoms	I-Problem
recurred	O
few	I-Other
days	I-Other
after	I-Other
taking	O
nitrendipine	I-Treatment
.	O

the	O
authors	O
report	O
two	O
cases	I-Background
of	O
acute	I-Problem
dystonic	I-Problem
reactions	I-Problem
(	I-Problem
adrs	I-Problem
)	I-Problem
as	O
a	O
side	O
effect	O
of	O
lamivudine	I-Treatment
.	O

isoniazid	I-Treatment
-	O
induced	O
anaphylaxis	I-Problem
.	O

histopathology	O
of	I-Test
the	I-Test
thyroid	I-Test
in	O
amiodarone	I-Treatment
-	O
induced	O
hypothyroidism	I-Problem
.	O

deepening	I-Problem
of	I-Problem
lid	I-Problem
sulcus	I-Problem
from	O
topical	O
bimatoprost	I-Treatment
therapy	O
.	O

gastro	I-Problem
-	I-Problem
oesophageal	I-Problem
reflux	I-Problem
associated	O
with	O
nifedipine	I-Treatment
.	O

case	O
summary	O
:	O
a	I-Background
68	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
developed	O
a	I-Problem
dry	I-Problem
,	I-Problem
irritating	I-Problem
cough	I-Problem
within	I-Other
one	I-Other
month	I-Other
of	O
starting	O
quinapril	I-Treatment
therapy	I-Treatment
for	O
the	O
treatment	O
of	O
essential	I-Problem
hypertension	I-Problem
.	O

sertraline	I-Treatment
-	O
induced	O
rhabdomyolysis	I-Problem
in	O
an	I-Background
elderly	I-Background
patient	I-Background
with	I-Background
dementia	I-Problem
and	I-Background
comorbidities	I-Problem
.	O

after	I-Treatment
the	I-Treatment
dose	I-Treatment
of	I-Treatment
methylprednisolone	I-Treatment
was	I-Treatment
reduced	I-Treatment
from	I-Treatment
40	I-Treatment
mg	I-Treatment
to	I-Treatment
20	I-Treatment
mg	I-Treatment
i	I-Treatment
.	I-Treatment
v	I-Treatment
.	I-Treatment
q6h	I-Treatment
and	I-Treatment
shifted	I-Treatment
to	I-Treatment
other	I-Treatment
anti	I-Treatment
-	I-Treatment
asthma	I-Treatment
treatment	I-Treatment
by	I-Treatment
procaterol	I-Treatment
metered	I-Treatment
dose	I-Treatment
inhaler	I-Treatment
via	I-Treatment
spacer	I-Treatment
,	O
the	O
psychotic	I-Problem
reaction	I-Problem
disappeared	O
a	I-Other
few	I-Other
hours	I-Other
later	I-Treatment
.	O

sirolimus	I-Treatment
works	I-Treatment
differently	I-Treatment
from	I-Treatment
the	I-Treatment
immunosuppressants	I-Treatment
currently	I-Treatment
available	I-Treatment
,	O
and	O
except	O
for	O
increased	I-Problem
lipid	I-Problem
levels	I-Problem
,	O
the	O
adverse	O
reaction	O
profile	O
of	O
sirolimus	I-Treatment
does	O
not	O
appear	O
to	O
overlap	O
to	O
any	O
great	O
extent	O
with	O
that	O
associated	O
with	O
cyclosporine	I-Treatment
or	O
tacrolimus	I-Treatment
.	O

patient	O
was	O
on	O
warfarin	I-Treatment
for	O
a	I-Problem
prior	I-Problem
deep	I-Problem
venous	I-Problem
thrombosis	I-Problem
.	O

quetiapine	I-Treatment
-	O
induced	O
myoclonus	I-Problem
.	O

dyspnea	I-Problem
possibly	O
associated	O
with	O
controlled	I-Treatment
-	I-Treatment
release	I-Treatment
morphine	I-Treatment
sulfate	I-Treatment
tablets	I-Treatment
.	O

the	O
incidence	O
of	O
are	I-Problem
suddenly	O
exceeded	O
10	O
%	O
of	O
the	O
patients	I-Background
treated	O
by	O
melarsoprol	I-Treatment
during	O
august	I-Other
1992	I-Other
and	I-Other
september	I-Other
1993	I-Other
.	O

a	I-Background
patient	I-Background
with	I-Background
disseminated	I-Problem
herpes	I-Problem
zoster	I-Problem
developed	O
a	O
syndrome	I-Problem
of	I-Problem
inappropriate	I-Problem
antidiuretic	I-Problem
hormone	I-Problem
and	I-Problem
profound	I-Problem
hyponatremia	I-Problem
secondary	O
to	O
the	O
administration	O
of	O
adenine	I-Treatment
arabinoside	I-Treatment
.	O

one	O
patient	I-Background
with	I-Background
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
developed	O
erythema	I-Problem
multiforme	I-Problem
after	O
taking	O
griseofulvin	I-Treatment
.	O

we	O
report	O
a	O
rare	O
case	O
of	O
colonic	I-Problem
mucosal	I-Problem
necrosis	I-Problem
following	O
kalimate	I-Treatment
(	I-Treatment
calcium	I-Treatment
polystryrene	I-Treatment
sulfonate	I-Treatment
)	I-Treatment
,	I-Treatment
an	I-Treatment
analogue	I-Treatment
of	I-Treatment
kayexalate	I-Treatment
without	I-Treatment
sorbitol	I-Treatment
in	O
a	I-Background
34	I-Background
-	I-Background
yr	I-Background
-	I-Background
old	I-Background
man	I-Background
.	O

bilateral	I-Problem
anterior	I-Problem
uveitis	I-Problem
associated	O
with	O
clomiphene	I-Treatment
citrate	I-Treatment
.	O

progressive	I-Problem
anemia	I-Problem
following	O
combination	I-Treatment
therapy	I-Treatment
with	I-Treatment
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
and	I-Treatment
interleukin	I-Treatment
-	I-Treatment
2	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
metastatic	I-Problem
renal	I-Problem
cell	I-Problem
carcinoma	I-Problem
.	O

metoclopramide	I-Treatment
-	O
induced	O
parkinsonism	I-Problem
.	O

a	O
12	I-Background
year	I-Background
old	I-Background
patient	I-Background
with	I-Background
atrial	I-Problem
flutter	I-Problem
is	O
presented	O
,	O
in	O
whom	O
intravenous	I-Treatment
adenosine	I-Treatment
was	O
followed	O
by	O
acceleration	I-Problem
of	I-Problem
the	I-Problem
heart	I-Problem
rate	I-Problem
to	I-Problem
a	I-Problem
potentially	I-Problem
dangerous	I-Problem
arrhythmia	I-Problem
.	O

similar	O
to	O
reports	O
in	O
patients	I-Background
receiving	O
gefitinib	I-Treatment
,	O
those	O
with	O
pathologic	O
findings	O
of	O
uip	O
on	O
resected	O
lung	I-Test
specimens	I-Test
or	O
known	O
pulmonary	O
fibrosis	O
may	O
be	O
at	O
particular	O
risk	O
for	O
erlotinib	I-Problem
pulmonary	I-Problem
toxicity	I-Problem
.	I-Problem

eleven	I-Other
days	I-Other
after	I-Treatment
increase	I-Treatment
of	I-Treatment
the	I-Treatment
trimipramine	I-Treatment
dosage	I-Treatment
to	I-Treatment
100	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
,	O
she	I-Background
was	O
hospitalized	O
because	O
of	O
seizures	I-Problem
suggesting	I-Problem
a	I-Problem
secondary	I-Problem
generalized	I-Problem
grand	I-Problem
-	I-Problem
mal	I-Problem
episode	I-Problem
.	O

aim	O
:	O
to	O
report	O
a	O
patient	I-Background
with	I-Background
diabetic	I-Problem
rubeosis	I-Problem
who	O
suffered	O
from	O
acute	I-Problem
retinal	I-Problem
ischemic	I-Problem
change	I-Problem
and	I-Problem
stroke	I-Problem
after	O
intravitreal	I-Treatment
injection	I-Treatment
of	I-Treatment
bevacizumab	I-Treatment
.	O

stevens	I-Problem
-	I-Problem
johnson	I-Problem
syndrome	I-Problem
caused	O
by	O
the	O
antiretroviral	I-Treatment
drug	I-Treatment
nevirapine	I-Treatment
.	O

from	O
these	O
data	O
,	O
acute	I-Problem
generalized	I-Problem
dystonia	I-Problem
with	I-Problem
brainstem	I-Problem
and	I-Problem
thalamic	I-Problem
lesions	I-Problem
may	O
occur	O
in	O
wd	I-Problem
patients	I-Background
after	O
an	I-Treatment
initial	I-Treatment
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
therapy	I-Treatment
.	O

although	O
this	O
combination	O
agent	O
has	O
been	O
associated	O
with	O
a	O
hypersensitivity	O
syndrome	O
involving	O
cutaneous	O
skin	O
eruptions	O
,	O
pediatric	I-Background
cases	I-Background
of	O
tmp	I-Treatment
-	I-Treatment
smx	I-Treatment
-	O
induced	O
hepatotoxicity	I-Problem
are	O
rare	O
.	O

drug	I-Problem
resistant	I-Problem
tuberculosis	I-Problem
requires	O
more	O
complex	I-Other
and	I-Other
longer	I-Other
treatment	I-Other
with	I-Treatment
alternative	I-Treatment
substances	I-Treatment
.	O

intracranial	I-Problem
haemorrhage	I-Problem
from	I-Problem
a	I-Problem
meningioma	I-Problem
in	O
a	I-Background
patient	I-Background
receiving	O
aspirin	I-Treatment
prophylaxis	O
:	O
a	O
case	O
report	O
.	O

the	O
objective	O
of	O
this	O
report	O
is	O
to	O
describe	O
a	O
case	O
of	O
fixed	I-Problem
drug	I-Problem
eruption	I-Problem
that	O
occurred	O
during	I-Treatment
omeprazole	I-Treatment
treatment	I-Treatment
.	O

case	O
2	O
:	O
a	I-Background
43	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
alcoholic	I-Problem
remained	O
completely	I-Treatment
abstinent	I-Treatment
with	I-Treatment
cyanamide	I-Treatment
treatment	I-Treatment
for	I-Treatment
5	I-Other
years	I-Other
and	O
complained	O
of	O
general	I-Problem
fatigue	I-Problem
.	O

delayed	I-Problem
hypersensitivity	I-Problem
to	O
flurbiprofen	I-Treatment
.	O

propafenone	I-Treatment
-	O
induced	O
ataxia	I-Problem
:	O
report	O
of	O
three	O
cases	I-Background
.	O

delavirdine	I-Treatment
and	I-Treatment
efavirenz	I-Treatment
(	I-Treatment
but	I-Treatment
not	I-Treatment
nevirapine	I-Treatment
)	I-Treatment
also	O
were	O
strong	O
inhibitors	O
of	O
cyp3a	O
,	O
consistent	O
with	O
clinical	I-Problem
hazards	I-Problem
of	O
initial	O
cotreatment	O
with	O
either	O
of	O
these	O
drugs	O
and	O
substrates	O
of	O
cyp3a	O
.	O

this	O
is	O
the	O
first	O
report	O
of	O
uft	I-Treatment
-	O
induced	O
scleroderma	I-Problem
-	I-Problem
like	I-Problem
reaction	I-Problem
.	O

can	O
roxithromycin	I-Treatment
and	I-Treatment
betamethasone	I-Treatment
induce	O
acute	I-Problem
pancreatitis	I-Problem
?	O
a	O
case	O
report	O
.	O

up	O
to	O
four	O
percent	O
of	I-Background
patients	I-Background
treated	O
with	O
imatinib	I-Treatment
may	O
develop	O
hepatotoxicity	I-Problem
,	O
which	O
usually	O
resolves	O
with	O
discontinuation	O
of	O
the	O
drug	O
.	O

schneiderian	I-Problem
first	I-Problem
-	I-Problem
rank	I-Problem
symptoms	I-Problem
associated	O
with	O
fluvoxamine	I-Treatment
treatment	O
:	O
a	O
case	O
report	O
.	O

peripheral	I-Problem
and	I-Problem
optic	I-Problem
neuropathy	I-Problem
was	O
usually	O
seen	O
after	O
several	I-Other
months	I-Other
of	I-Treatment
linezolid	I-Treatment
therapy	I-Treatment
(	I-Treatment
median	I-Treatment
5	I-Treatment
mo	I-Treatment
)	I-Treatment
,	O
lactic	I-Problem
acidosis	I-Problem
after	I-Problem
several	I-Problem
weeks	I-Problem
(	I-Problem
median	I-Problem
6	I-Problem
wks	I-Problem
)	I-Problem
,	I-Problem
and	I-Problem
serotonin	I-Problem
syndrome	I-Problem
after	I-Problem
several	I-Problem
days	I-Problem
(	I-Problem
median	I-Problem
4	I-Problem
days	I-Problem
)	I-Problem
.	O

muzolimine	I-Treatment
-	O
induced	O
severe	O
neuromyeloencephalopathy	I-Problem
:	O
report	O
of	O
seven	O
cases	O
.	O

we	O
conclude	O
peripheral	I-Problem
neuropathy	I-Problem
with	O
5	I-Treatment
-	I-Treatment
fu	I-Treatment
is	O
rare	O
.	O

additionally	O
,	O
danazol	I-Treatment
produces	O
hepatocellular	I-Problem
damage	I-Problem
in	O
approximately	O
10	O
%	O
of	I-Background
women	I-Background
.	O

conclusions	O
:	O
we	O
report	O
a	O
typical	I-Problem
symptoms	I-Problem
of	I-Problem
charles	I-Problem
-	I-Problem
bonnet	I-Problem
syndrome	I-Problem
(	I-Problem
cbs	I-Problem
)	I-Problem
in	O
patients	I-Background
with	I-Background
severe	I-Background
amd	I-Problem
after	O
intravitreal	I-Treatment
avastin	I-Treatment
-	I-Treatment
injections	I-Treatment
.	O

proconvulsive	I-Problem
tendency	I-Problem
of	O
imipenem	I-Treatment
/	I-Treatment
cilastatin	I-Treatment
is	O
one	O
of	O
its	O
well	O
-	O
known	O
side	O
effects	O
.	O

a	O
49	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
treated	O
with	O
prednisone	I-Treatment
and	I-Treatment
mesalamine	I-Treatment
(	I-Treatment
5	I-Treatment
-	I-Treatment
asa	I-Treatment
)	I-Treatment
developed	O
worsening	I-Problem
respiratory	I-Problem
distress	I-Problem
and	I-Problem
fever	I-Problem
.	I-Problem

objective	O
:	O
this	I-Background
case	I-Background
report	O
outlines	O
a	I-Problem
significant	I-Problem
type	I-Problem
of	I-Problem
morbidity	I-Problem
due	O
to	O
continued	O
use	O
of	O
gabapentin	I-Treatment
during	O
an	O
episode	O
of	O
acute	O
renal	O
failure	O
.	O

acute	I-Problem
delirium	I-Problem
resulting	O
from	O
levofloxacin	I-Treatment
therapy	O
is	O
an	O
exceedingly	O
rare	O
complication	O
that	O
has	O
been	O
thought	O
to	O
occur	O
more	O
commonly	O
in	O
elderly	I-Background
patients	I-Background
.	O

selective	O
estrogen	O
receptor	O
modulator	O
raloxifene	I-Treatment
-	O
associated	O
aggravation	I-Problem
of	I-Problem
nonalcoholic	I-Problem
steatohepatitis	I-Problem
.	O

the	I-Other
day	I-Other
after	I-Other
methotrexate	I-Treatment
administration	I-Treatment
,	O
the	O
patient	O
complained	O
of	O
severe	I-Problem
back	I-Problem
pain	I-Problem
and	I-Problem
urinary	I-Problem
retention	I-Problem
.	O

pulmonary	I-Problem
toxicity	I-Problem
secondary	O
to	O
procarbazine	I-Treatment
.	O

in	O
keeping	O
with	O
findings	O
in	O
the	O
literature	O
,	O
the	O
aortic	I-Problem
wall	I-Problem
in	I-Problem
this	I-Problem
case	I-Problem
was	I-Problem
damaged	I-Problem
by	O
secondary	O
changes	O
following	O
irradiation	I-Treatment
and	I-Treatment
bleomycin	I-Treatment
treatment	I-Treatment
.	I-Treatment

it	O
has	O
been	O
suggested	O
that	O
ppe	I-Problem
caused	O
by	O
cytarabine	I-Treatment
does	O
not	O
recur	O
with	O
subsequent	O
cytarabine	I-Test
re	O
-	O
challenge	O
.	O

conclusions	O
:	O
the	O
value	O
of	O
multihormonal	O
therapy	O
in	O
breast	O
carcinoma	O
is	O
not	O
established	O
,	O
and	O
the	O
addition	I-Treatment
of	I-Treatment
progestogens	I-Treatment
to	I-Treatment
tamoxifen	I-Treatment
may	O
not	O
reduce	O
of	O
developing	O
endometrial	I-Problem
lesions	I-Problem
,	O
including	O
carcinoma	I-Problem
.	O

inappropriate	I-Problem
antidiuretic	I-Problem
hormone	I-Problem
following	O
adenine	I-Treatment
arabinoside	I-Treatment
administration	O
.	O

ampicillin	I-Treatment
-	O
associated	O
seizures	I-Problem
.	O

we	O
describe	O
a	O
case	O
of	O
fibrosing	I-Problem
alveolitis	I-Problem
,	O
diagnosed	O
by	O
lung	O
biopsy	I-Test
,	O
in	O
a	I-Background
patient	I-Background
receiving	O
amiodarone	I-Treatment
which	I-Treatment
responded	I-Treatment
to	I-Treatment
corticosteroid	I-Treatment
therapy	I-Treatment
.	O

furosemide	I-Treatment
-	O
associated	O
fever	I-Problem
.	O

thymic	I-Problem
enlargement	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
juvenile	I-Background
idiopathic	I-Problem
arthritis	I-Problem
during	O
etanercept	I-Treatment
therapy	O
.	O

fatal	O
methylene	I-Treatment
blue	I-Treatment
associated	O
serotonin	I-Problem
toxicity	I-Problem
.	O

mannitol	I-Treatment
-	O
induced	O
arf	I-Problem
responds	O
promptly	O
to	O
hemodialysis	O
with	O
rapid	O
resolution	O
of	O
anuria	I-Problem
and	O
recovery	O
of	O
renal	I-Problem
failure	I-Problem
.	O

we	O
report	O
a	O
rare	O
case	O
of	O
recurrent	I-Problem
(	I-Problem
stuttering	I-Problem
)	I-Problem
priapism	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
protein	I-Problem
c	I-Problem
deficiency	I-Problem
while	O
maintained	I-Treatment
on	I-Treatment
warfarin	I-Treatment
therapy	I-Treatment
.	O

angioedema	I-Problem
and	I-Problem
maculopapular	I-Problem
eruptions	I-Problem
associated	O
with	O
carbamazepine	I-Treatment
administration	I-Treatment
.	I-Treatment

mental	I-Problem
nerve	I-Problem
neuropathy	I-Problem
as	O
a	O
result	O
of	O
hepatitis	I-Treatment
b	I-Treatment
vaccination	I-Treatment
.	I-Treatment

we	O
describe	O
a	I-Background
premenopausal	I-Background
woman	I-Background
who	O
,	O
while	O
having	O
tamoxifen	I-Treatment
due	O
to	O
a	O
diagnosis	O
of	O
in	I-Problem
situ	I-Problem
ductal	I-Problem
carcinoma	I-Problem
,	O
developed	O
endometriosis	I-Problem
requiring	O
surgery	O
.	O

disseminated	I-Problem
cellulitic	I-Problem
cryptococcosis	I-Problem
in	O
the	O
setting	O
of	O
prednisone	I-Treatment
monotherapy	I-Treatment
for	O
pemphigus	I-Problem
vulgaris	I-Problem
.	O

we	O
describe	O
a	I-Background
63	I-Background
year	I-Background
old	I-Background
woman	I-Background
with	I-Background
a	I-Background
suppurative	I-Problem
mediastinitis	I-Problem
,	O
treated	O
with	O
continuous	I-Treatment
pi	I-Treatment
irrigation	I-Treatment
who	O
developed	O
an	O
acute	I-Problem
oliguric	I-Problem
renal	I-Problem
failure	I-Problem
.	O

a	I-Background
young	I-Background
woman	I-Background
with	I-Background
epilepsy	I-Problem
had	O
tonic	I-Problem
-	I-Problem
clonic	I-Problem
seizures	I-Problem
during	O
antineoplastic	I-Treatment
therapy	I-Treatment
with	I-Treatment
adriamycin	I-Treatment
and	I-Treatment
cisplatin	I-Treatment
.	I-Treatment

conclusions	O
:	O
this	I-Background
patient	I-Background
'	O
s	O
rhabdomyolysis	I-Problem
was	O
probably	O
induced	O
by	O
sertraline	I-Treatment
therapy	O
.	O

nephrotic	I-Problem
syndrome	I-Problem
in	O
a	I-Background
multiple	I-Problem
sclerosis	I-Problem
patient	I-Background
treated	O
with	O
interferon	I-Treatment
beta	I-Treatment
1a	I-Treatment
.	O

in	O
our	I-Background
patient	I-Background
,	O
dian	I-Problem
possibly	O
was	O
related	O
to	O
cefuroxime	I-Treatment
,	O
but	O
the	O
patient	O
did	O
not	O
experience	O
associated	O
allergic	O
symptoms	O
.	O

we	O
describe	O
the	O
case	O
of	O
a	I-Background
nonatopic	I-Problem
17	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
with	I-Background
bronchial	I-Problem
asthma	I-Problem
and	I-Background
aspirin	I-Problem
intolerance	I-Problem
who	O
developed	O
a	I-Problem
dramatic	I-Problem
anaphylactic	I-Problem
reaction	I-Problem
to	O
oral	I-Treatment
prednisone	I-Treatment
.	O

case	O
summary	O
:	O
a	I-Background
10	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
girl	I-Background
with	I-Background
bilateral	I-Problem
optic	I-Problem
glioma	I-Problem
developed	O
a	O
hypersensitivity	I-Problem
reaction	I-Problem
to	O
carboplatin	I-Treatment
after	I-Treatment
nine	I-Other
courses	I-Other
.	O

liver	I-Problem
function	I-Problem
should	I-Problem
be	I-Problem
carefully	I-Problem
monitored	I-Problem
when	O
rifampicin	I-Treatment
and	I-Treatment
lopinavir	I-Treatment
/	I-Treatment
ritonavir	I-Treatment
are	I-Treatment
combined	I-Treatment
in	O
patients	I-Background
.	O

we	O
report	O
three	O
patients	I-Background
,	O
all	O
of	O
whom	O
had	O
preexisting	I-Problem
diabetic	I-Problem
dyslipidemia	I-Problem
,	O
who	O
showed	O
a	O
profound	I-Problem
reduction	I-Problem
in	I-Problem
plasma	I-Problem
hdl	I-Problem
cholesterol	I-Problem
and	I-Problem
apolipoprotein	I-Problem
ai	I-Problem
levels	I-Problem
soon	I-Other
after	I-Other
the	O
initiation	O
of	O
rosiglitazone	I-Treatment
therapy	I-Treatment
.	O

this	O
finding	O
suggests	O
that	O
fluvoxamine	I-Treatment
can	O
precipitate	O
schneiderian	I-Problem
first	I-Problem
-	I-Problem
rank	I-Problem
symptoms	I-Problem
in	O
some	I-Background
susceptible	I-Background
patients	I-Background
.	O

warfarin	I-Treatment
-	O
associated	O
thoracic	I-Problem
aortic	I-Problem
dissection	I-Problem
in	O
an	I-Background
elderly	I-Background
woman	I-Background
.	O

this	O
is	O
the	O
first	I-Background
report	I-Background
of	I-Background
an	I-Background
adverse	I-Background
effect	I-Background
of	I-Background
fetal	I-Problem
renal	I-Problem
circulation	I-Problem
by	O
maternal	I-Treatment
ingestion	I-Treatment
of	I-Treatment
nimesulide	I-Treatment
.	O

diarrhea	I-Problem
-	I-Problem
associated	I-Problem
over	I-Problem
-	I-Problem
anticoagulation	I-Problem
in	O
a	O
patient	I-Background
taking	O
warfarin	I-Treatment
:	O
therapeutic	O
role	O
of	O
cholestyramine	O
.	O

a	I-Background
72	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
man	I-Background
suddenly	O
developed	O
combative	I-Problem
behavior	I-Problem
,	I-Problem
refused	I-Problem
to	I-Problem
leave	I-Problem
his	I-Problem
room	I-Problem
,	I-Problem
stopped	I-Problem
eating	I-Problem
,	I-Problem
and	I-Problem
began	I-Problem
falling	I-Problem
to	I-Problem
the	I-Problem
floor	I-Problem
6	I-Other
weeks	I-Other
after	I-Treatment
being	I-Treatment
given	I-Treatment
ticlopidine	I-Treatment
.	O

the	O
case	O
history	O
confirms	O
that	O
gold	I-Treatment
treatment	O
,	O
even	O
in	I-Background
the	I-Background
same	I-Background
patient	I-Background
,	I-Background
can	O
give	O
rise	O
to	O
a	O
wide	I-Problem
range	I-Problem
of	I-Problem
skin	I-Problem
disturbances	I-Problem
,	I-Problem
which	I-Problem
in	I-Problem
many	I-Problem
cases	I-Problem
do	I-Problem
not	I-Problem
break	I-Problem
out	I-Problem
until	I-Problem
long	I-Problem
after	I-Problem
the	I-Problem
drug	I-Problem
has	I-Problem
been	I-Problem
withdrawn	I-Problem
.	O

lithium	I-Treatment
neurotoxicity	I-Problem
should	O
be	O
considered	O
in	O
creutzfeldt	I-Problem
-	I-Problem
jakob	I-Problem
disease	I-Problem
differential	O
diagnosis	O
,	O
serial	O
electroencephalograms	I-Test
being	O
the	O
most	O
valuable	O
.	O

the	O
authors	O
describe	O
a	O
case	O
of	O
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
that	O
occurred	O
in	O
a	I-Background
patient	I-Background
on	O
amitriptyline	I-Treatment
and	I-Treatment
lithium	I-Treatment
carbonate	I-Treatment
.	O

the	O
findings	O
were	O
judged	O
to	O
be	O
consistent	O
with	O
soft	I-Problem
-	I-Problem
tissue	I-Problem
injury	I-Problem
associated	O
with	O
intravenous	I-Treatment
administration	I-Treatment
of	I-Treatment
phenytoin	I-Treatment
,	O
also	O
termed	O
purple	O
glove	O
syndrome	O
.	O

however	O
,	O
as	O
illustrated	O
by	O
these	O
and	O
other	O
cases	O
reported	O
to	O
date	O
,	O
the	O
onset	O
of	O
troglitazone	I-Treatment
-	O
induced	O
liver	I-Problem
injury	I-Problem
is	I-Problem
insidious	I-Problem
and	I-Problem
temporally	I-Problem
variable	I-Problem
.	O

soon	O
after	O
its	O
introduction	O
in	O
1952	O
,	O
chlorpromazine	I-Treatment
was	O
noted	O
to	O
induce	O
symptoms	I-Problem
resembling	I-Problem
parkinson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
.	O

erythromycin	I-Treatment
is	O
a	O
macrolide	O
antibiotic	O
that	O
may	O
increase	I-Problem
the	I-Problem
risk	I-Problem
of	I-Problem
lovastatin	I-Treatment
-	I-Problem
induced	I-Problem
rhabdomyolysis	I-Problem
.	O

a	I-Background
23	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
male	I-Background
patient	I-Background
was	O
originally	O
admitted	O
to	O
receive	O
intravenous	I-Treatment
chemotherapy	I-Treatment
for	O
acute	I-Problem
myelogenous	I-Problem
leukemia	I-Problem
.	O

we	O
present	O
two	O
children	I-Background
with	I-Background
acute	I-Problem
lymphocytic	I-Problem
leukemia	I-Problem
who	O
developed	O
leukoencephalopathy	I-Problem
following	O
administration	I-Treatment
of	I-Treatment
a	I-Treatment
combination	I-Treatment
of	I-Treatment
intravenous	I-Treatment
ara	I-Treatment
=	I-Treatment
c	I-Treatment
and	I-Treatment
methotrexate	I-Treatment
during	I-Treatment
the	I-Treatment
consolidation	I-Treatment
phase	I-Treatment
of	I-Treatment
chemotherapy	I-Treatment
.	O

lethal	O
anuria	I-Problem
complicating	O
high	I-Treatment
dose	I-Treatment
ifosfamide	I-Treatment
chemotherapy	I-Treatment
in	O
a	I-Background
breast	I-Problem
cancer	I-Problem
patient	I-Background
with	I-Background
an	I-Problem
impaired	I-Problem
renal	I-Problem
function	I-Problem
.	O

when	O
pilsicainide	I-Treatment
is	O
prescribed	O
in	O
patients	I-Background
with	I-Background
coronary	I-Problem
artery	I-Problem
disease	I-Problem
or	I-Background
renal	I-Problem
dysfunction	I-Problem
,	I-Background
close	O
attention	O
must	O
be	O
paid	O
to	O
avoid	O
life	I-Problem
-	I-Problem
threatening	I-Problem
arrhythmias	I-Problem
due	O
to	O
high	O
plasma	O
concentrations	O
of	O
the	O
drug	O
.	O

we	O
describe	O
a	I-Background
case	I-Background
of	O
severe	I-Problem
aplastic	I-Problem
anemia	I-Problem
(	I-Problem
aa	I-Problem
)	I-Problem
that	O
was	O
probably	O
induced	O
by	O
lenalidomide	I-Treatment
.	O

we	O
present	O
a	O
case	O
report	O
of	O
a	I-Background
patient	I-Background
with	I-Background
typhoid	I-Problem
fever	I-Problem
who	O
experienced	O
a	O
hypersensitivity	I-Problem
reaction	I-Problem
subsequent	O
to	O
the	I-Treatment
infusion	I-Treatment
of	I-Treatment
chloramphenicol	I-Treatment
sodium	I-Treatment
succinate	I-Treatment
.	O

this	O
confirmed	O
the	O
history	O
of	O
captopril	I-Treatment
-	O
related	O
asthma	I-Problem
.	O

four	O
cases	I-Background
of	O
adverse	I-Problem
experiences	I-Problem
with	O
clonidine	I-Treatment
are	O
described	O
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
reversible	I-Problem
nonthrombocytopenic	I-Problem
palpable	I-Problem
purpura	I-Problem
associated	O
with	O
metoclopramide	I-Treatment
.	O

three	O
patients	I-Background
received	I-Treatment
respectively	I-Treatment
190	I-Treatment
mg	I-Treatment
,	I-Treatment
175	I-Treatment
mg	I-Treatment
,	I-Treatment
and	I-Treatment
196	I-Treatment
mg	I-Treatment
of	I-Treatment
methotrexate	I-Treatment
and	O
developed	O
bilateral	I-Problem
pulmonary	I-Problem
infiltrates	I-Problem
without	I-Problem
evidence	I-Problem
of	I-Problem
peripheral	I-Problem
blood	I-Problem
eosinophilia	I-Problem
.	O

clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
vinorelbine	I-Treatment
may	O
cause	O
siadh	I-Problem
and	I-Problem
possibly	I-Problem
hypokalemia	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
a	I-Background
34	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
on	O
carbamazepine	I-Treatment
for	O
complex	I-Problem
partial	I-Problem
seizures	I-Problem
who	O
developed	O
acute	I-Problem
liver	I-Problem
and	I-Problem
renal	I-Problem
failure	I-Problem
on	O
less	I-Treatment
than	I-Treatment
2	I-Treatment
.	I-Treatment
5	I-Treatment
grams	I-Treatment
a	I-Other
day	I-Other
of	I-Treatment
acetaminophen	I-Treatment
.	O

fever	I-Problem
and	I-Problem
maculopapular	I-Problem
rashes	I-Problem
appeared	O
at	O
10	I-Other
days	I-Other
after	O
phenytoin	I-Treatment
initiation	O
,	O
and	O
then	O
the	O
drug	O
was	O
discontinued	O
.	O

we	O
report	O
aza	I-Treatment
-	O
induced	O
drug	I-Problem
eruption	I-Problem
that	O
developed	O
in	O
two	O
cases	I-Background
of	I-Background
systemic	I-Problem
scleroderma	I-Problem
with	I-Problem
polymyositis	I-Problem
.	O

safety	O
aspects	O
of	O
a	O
coumarin	I-Treatment
-	I-Treatment
troxerutin	I-Treatment
combination	I-Treatment
regarding	O
liver	I-Problem
function	I-Problem
in	O
a	O
double	I-Test
-	I-Test
blind	I-Test
placebo	I-Test
-	I-Test
controlled	I-Test
study	I-Test
.	O

vogt	I-Problem
-	I-Problem
koyanagi	I-Problem
-	I-Problem
harada	I-Problem
disease	I-Problem
occurring	O
during	O
interferon	I-Treatment
alpha	I-Treatment
therapy	O
for	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

glucose	I-Treatment
and	I-Treatment
insulin	I-Treatment
exert	O
additive	I-Problem
ocular	I-Problem
and	I-Problem
renal	I-Problem
vasodilator	I-Problem
effects	I-Problem
on	O
healthy	I-Background
humans	I-Background
.	O

two	O
patients	I-Background
with	I-Background
osteomyelitis	I-Problem
who	O
developed	O
reversible	I-Problem
cholestatic	I-Problem
jaundice	I-Problem
during	O
treatment	O
with	O
oxacillin	I-Treatment
derivatives	O
are	O
described	O
.	O

data	O
synthesis	O
:	O
a	I-Background
49	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
symptoms	O
of	O
severe	O
psychosis	I-Problem
concomitant	O
with	O
ciprofloxacin	I-Treatment
(	O
250	I-Treatment
mg	I-Treatment
bid	I-Treatment
)	O
treatment	O
.	O

potential	O
causes	O
of	O
methamphetamine	I-Treatment
-	O
related	O
keratitis	I-Problem
can	O
be	O
divided	O
into	O
four	O
categories	O
resulting	O
from	O
(	O
a	O
)	O
direct	O
pharmacologic	O
and	O
physical	O
effects	O
of	O
methamphetamine	O
;	O
(	O
b	O
)	O
the	O
toxic	O
effects	O
of	O
diluting	O
or	O
"	O
cutting	O
"	O
agents	O
such	O
as	O
lidocaine	O
and	O
quinine	O
;	O
(	O
c	O
)	O
effects	O
related	O
to	O
the	O
route	O
of	O
drug	O
administration	O
(	O
intravenous	O
,	O
inhalation	O
,	O
smoking	O
)	O
;	O
and	O
(	O
d	O
)	O
manufacture	O
-	O
related	O
effects	O
of	O
exposure	O
to	O
unintentional	O
caustic	O
contaminants	O
in	O
the	O
final	O
product	O
.	O

pulmonary	I-Problem
oedema	I-Problem
after	O
hexoprenaline	I-Treatment
administration	O
in	O
preterm	I-Problem
labour	I-Problem
.	O

venlafaxine	I-Treatment
-	O
associated	O
seizures	I-Problem
at	O
therapeutic	O
doses	O
have	O
not	O
been	O
reported	O
in	O
the	O
literature	O
.	O

methotrexate	I-Treatment
-	O
induced	O
pneumonitis	I-Problem
in	O
patients	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
and	I-Background
psoriatic	I-Problem
arthritis	I-Problem
:	O
report	O
of	O
five	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

she	O
was	O
receiving	O
phenytoin	O
sodium	O
300	O
mg	O
/	O
day	O
;	O
carbamazepine	I-Treatment
200	I-Treatment
mg	I-Treatment
four	I-Other
times	I-Other
daily	I-Other
had	O
been	O
discontinued	O
four	O
days	O
before	O
admission	O
because	O
of	O
leukopenia	I-Problem
.	O

thoracoscopic	O
biopsy	I-Test
to	O
confirm	O
metastasis	O
revealed	O
instead	O
fibrotic	I-Problem
lesions	I-Problem
apparently	O
attributable	O
to	O
bleomycin	I-Treatment
or	I-Treatment
cyclophosphamide	I-Treatment
.	O

we	O
present	O
a	O
case	O
of	O
hemolytic	I-Problem
-	I-Problem
uremic	I-Problem
syndrome	I-Problem
that	O
developed	O
during	I-Treatment
the	I-Treatment
4th	I-Treatment
cycle	I-Treatment
of	I-Treatment
combination	I-Treatment
chemotherapy	I-Treatment
with	I-Treatment
oxaliplatin	I-Treatment
,	I-Treatment
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
and	I-Treatment
leucovorin	I-Treatment
.	O

we	O
report	O
the	O
case	O
of	O
a	O
lung	I-Problem
cancer	I-Problem
patient	I-Background
with	I-Background
bronquiloalveolar	I-Problem
carcinoma	I-Problem
(	I-Problem
bac	I-Problem
)	I-Problem
presenting	O
with	O
boop	I-Problem
after	O
chemotherapy	I-Treatment
with	I-Treatment
docetaxel	I-Treatment
and	I-Treatment
gemcitabine	I-Treatment
producing	I-Problem
severe	I-Problem
respiratory	I-Problem
insufficiency	I-Problem
,	I-Problem
and	I-Problem
simulating	I-Problem
a	I-Problem
progression	I-Problem
of	I-Problem
the	I-Problem
tumor	I-Problem
.	O

relapse	I-Problem
in	I-Problem
the	I-Problem
external	I-Problem
auditory	I-Problem
canal	I-Problem
of	I-Problem
acute	I-Problem
promyelocytic	I-Problem
leukemia	I-Problem
after	O
treatment	I-Treatment
with	I-Treatment
all	I-Treatment
-	I-Treatment
trans	I-Treatment
retinoic	I-Treatment
acid	I-Treatment
.	O

acute	I-Problem
neutrophilic	I-Problem
dermatosis	I-Problem
induced	O
by	O
all	I-Treatment
-	I-Treatment
trans	I-Treatment
-	I-Treatment
retinoic	I-Treatment
acid	I-Treatment
treatment	O
for	O
acute	I-Problem
promyelocytic	I-Problem
leukemia	I-Problem
.	O

fluphenazine	I-Treatment
-	O
induced	O
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
in	O
a	I-Background
schizophrenic	I-Problem
patient	I-Background
.	O

biopsy	O
-	O
proven	O
acute	I-Problem
interstitial	I-Problem
nephritis	I-Problem
associated	O
with	O
the	O
tyrosine	I-Treatment
kinase	I-Treatment
inhibitor	I-Treatment
sunitinib	I-Treatment
:	O
a	O
class	O
effect	O
?	O

we	O
describe	O
two	O
women	I-Background
who	O
developed	O
hus	I-Problem
after	O
mmc	I-Treatment
therapy	O
and	O
presented	O
massive	I-Problem
pulmonary	I-Problem
bleeding	I-Problem
.	O

alternating	I-Problem
sinus	I-Problem
rhythm	I-Problem
and	I-Problem
intermittent	I-Problem
sinoatrial	I-Problem
(	I-Problem
s	I-Problem
-	I-Problem
a	I-Problem
)	I-Problem
block	I-Problem
was	O
observed	O
in	O
a	I-Background
57	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
,	O
under	O
treatment	O
for	O
angina	I-Problem
with	O
80	I-Treatment
mg	I-Treatment
propranolol	I-Treatment
daily	I-Other
.	I-Treatment

these	O
case	O
reports	O
provide	O
evidence	O
that	O
5	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
may	O
induce	O
acute	I-Problem
pancreatitis	I-Problem
after	O
long	I-Other
term	I-Other
treatment	O
.	O

during	O
that	O
time	O
,	O
he	I-Background
had	O
also	O
been	O
taking	O
amphetamine	I-Treatment
-	I-Treatment
dextroamphetamine	I-Treatment
(	I-Treatment
adderall	I-Treatment
)	I-Treatment
on	O
work	O
days	O
for	O
his	O
adhd	I-Problem
.	O

therefore	O
,	O
we	O
diagnosed	O
her	I-Problem
eruption	I-Problem
as	I-Problem
contact	I-Problem
dermatitis	I-Problem
due	O
to	O
sodium	I-Treatment
bisulfite	I-Treatment
.	O

macular	I-Problem
infarction	I-Problem
after	O
endophthalmitis	I-Problem
treated	I-Treatment
with	I-Treatment
vitrectomy	I-Treatment
and	I-Treatment
intravitreal	I-Treatment
gentamicin	I-Treatment
.	O

since	O
tamoxifen	I-Treatment
therapy	I-Treatment
can	O
induce	O
endometrial	I-Problem
disorders	I-Problem
,	O
surveillance	O
schemes	O
of	O
women	I-Background
taking	O
tamoxifen	O
have	O
been	O
recommended	O
.	O

warfarin	I-Treatment
-	O
associated	O
bleeding	I-Problem
complication	I-Problem
saved	I-Problem
life	I-Problem
.	O

methods	O
/	O
results	O
:	O
this	O
paper	O
presents	O
a	O
new	I-Background
case	I-Background
of	O
rifabutin	I-Treatment
uveitis	I-Problem
and	O
a	O
review	O
of	O
the	O
various	O
published	O
reports	O
to	O
date	O
.	O

acute	I-Problem
abdomen	I-Problem
due	I-Problem
to	I-Problem
endometriosis	I-Problem
in	O
a	O
premenopausal	O
woman	O
taking	O
tamoxifen	I-Treatment
.	O

discussion	O
:	O
methotrexate	I-Treatment
-	O
induced	O
papular	I-Problem
eruption	I-Problem
is	O
rarely	O
reported	O
shortly	I-Other
after	I-Other
beginning	O
methotrexate	O
therapy	O
in	O
patients	I-Background
with	I-Background
acute	I-Problem
exacerbation	I-Problem
of	I-Problem
collagen	I-Problem
vascular	I-Problem
diseases	I-Problem
.	O

all	I-Background
patients	I-Background
had	O
taken	O
phenytoin	I-Treatment
for	I-Treatment
variable	I-Treatment
time	I-Treatment
periods	I-Treatment
(	I-Treatment
range	I-Treatment
16	I-Other
-	I-Other
80	I-Other
days	I-Other
;	I-Other
mean	I-Treatment
:	I-Treatment
40	I-Other
)	I-Treatment
and	O
were	O
on	O
the	O
medication	O
when	O
the	O
skin	I-Problem
lesions	I-Problem
first	O
appeared	O
.	O

one	O
should	O
therefore	O
be	O
aware	O
of	O
possible	O
extrapyramidal	I-Problem
side	I-Problem
effects	I-Problem
with	O
olanzapine	I-Treatment
that	O
are	O
reduced	O
compared	O
to	O
classical	O
neuroleptic	O
drugs	O
but	O
not	O
completely	O
eliminated	O
.	O

a	I-Background
patient	I-Background
who	O
had	O
been	O
treated	O
with	O
large	O
doses	O
of	O
thyroid	O
hormone	O
for	O
several	O
years	O
developed	O
features	O
of	O
secondary	I-Problem
hypothyroidism	I-Problem
after	O
thyroid	I-Treatment
hormone	I-Treatment
withdrawal	I-Treatment
.	O

this	O
article	O
discusses	O
the	O
possibility	O
that	O
simultaneous	O
use	O
of	O
valproic	I-Treatment
acid	I-Treatment
,	I-Treatment
lamotrigine	I-Treatment
,	I-Treatment
and	I-Treatment
phenytoin	I-Treatment
could	O
give	O
this	O
combination	O
of	O
toxicities	I-Problem
and	O
that	O
concurrent	I-Problem
viral	I-Problem
infection	I-Problem
may	O
increase	O
this	O
risk	O
.	O

a	O
second	O
patient	O
with	O
a	O
similar	O
glucose	O
tolerance	I-Test
test	I-Test
result	O
showed	O
postprandial	I-Problem
hyperglycemia	I-Problem
when	O
treated	O
similarly	O
with	O
betamethasone	I-Treatment
valerate	I-Treatment
cream	I-Treatment
0	I-Treatment
.	I-Treatment
1	I-Treatment
%	I-Treatment
.	O

phenytoin	I-Treatment
-	O
induced	O
hypersensitivity	I-Problem
reactions	I-Problem
.	I-Problem

a	I-Background
54	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
ten	I-Problem
4	I-Other
weeks	I-Other
after	I-Treatment
beginning	I-Treatment
lamotrigine	I-Treatment
for	O
complex	I-Problem
partial	I-Problem
seizures	I-Problem
related	I-Background
to	I-Background
a	I-Background
glioblastoma	I-Problem
multiforme	I-Problem
brain	I-Problem
tumor	I-Problem
.	O

the	O
occurrence	O
of	O
acute	I-Problem
hepatitis	I-Problem
is	O
best	O
known	O
for	O
ketoconazole	I-Treatment
.	O

optic	I-Problem
neuropathy	I-Problem
developed	O
in	O
a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
who	O
had	O
been	O
receiving	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
for	I-Treatment
about	I-Treatment
1	I-Other
year	I-Other
.	O

stupor	I-Problem
and	O
fast	I-Problem
activity	I-Problem
on	I-Problem
electroencephalography	I-Problem
in	O
a	I-Background
child	I-Background
treated	O
with	O
valproate	I-Treatment
.	O

during	O
her	O
third	O
cycle	O
,	O
she	I-Background
again	O
received	O
cisplatin	I-Treatment
100	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
over	I-Treatment
30	I-Other
minutes	I-Other
and	O
developed	O
palmar	I-Problem
pruritus	I-Problem
,	I-Problem
urticaria	I-Problem
,	I-Problem
and	I-Problem
edema	I-Problem
.	O

the	O
case	O
of	O
a	I-Background
patient	I-Background
with	I-Background
infectious	I-Problem
mononucleosis	I-Problem
treated	O
with	O
cephalexin	I-Treatment
who	O
later	O
showed	O
a	O
rash	I-Problem
is	O
presented	O
and	O
the	O
previous	O
literature	O
is	O
reviewed	O
.	O

after	I-Treatment
1	I-Other
week	I-Other
of	I-Treatment
nefazodone	I-Treatment
therapy	I-Treatment
the	O
patient	I-Background
experienced	O
headache	I-Problem
,	I-Problem
confusion	I-Problem
,	I-Problem
and	I-Problem
"	I-Problem
gray	I-Problem
areas	I-Problem
"	I-Problem
in	I-Problem
her	I-Problem
vision	I-Problem
,	I-Problem
without	I-Problem
abnormal	I-Problem
ophthalmologic	I-Problem
findings	I-Problem
.	O

nitrofurantoin	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
during	O
pregnancy	O
:	O
a	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O

methylphenidate	I-Treatment
-	O
associated	O
enuresis	I-Problem
in	O
attention	O
deficit	O
hyperactivity	O
disorder	O
.	O

to	O
our	O
knowledge	O
,	O
this	O
is	O
the	I-Background
first	I-Background
case	I-Background
report	O
that	O
demonstrates	O
the	O
occurrence	O
of	O
fever	I-Problem
with	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
amifostine	I-Treatment
therapy	O
without	O
the	O
manifestation	O
of	O
accompanying	O
rash	O
or	O
hypotension	O
.	O

administration	I-Treatment
of	I-Treatment
excessive	I-Treatment
insulin	I-Treatment
induced	O
hypoglycemia	I-Problem
within	O
4	I-Other
to	I-Other
8	I-Other
hours	I-Other
,	O
followed	O
by	O
rebound	I-Problem
hyperglycemia	I-Problem
.	O

in	O
both	O
cases	O
,	O
symptoms	I-Problem
of	I-Problem
autonomic	I-Problem
instability	I-Problem
and	I-Problem
severe	I-Problem
agitation	I-Problem
started	O
within	I-Other
hours	I-Other
of	I-Other
initiation	I-Other
of	I-Treatment
cyclobenzaprine	I-Treatment
and	O
fully	O
resolved	O
within	O
3	O
days	O
after	O
discontinuing	O
the	O
proserotoninergic	O
drugs	O
.	O

secondary	I-Problem
leukemia	I-Problem
in	O
a	I-Background
child	I-Background
with	I-Background
neuroblastoma	I-Problem
while	O
on	O
oral	I-Treatment
etoposide	I-Treatment
:	O
what	O
is	O
the	O
cause	O
?	O

atorvastatin	I-Treatment
induced	O
multiple	I-Problem
organ	I-Problem
failure	I-Problem
.	O

while	O
serotonin	I-Problem
syndrome	I-Problem
has	O
become	O
more	O
frequent	O
in	O
an	O
overdose	O
situation	O
and	O
when	O
an	O
interacting	O
drug	O
is	O
given	O
,	O
the	O
toxicity	O
of	O
ssirs	I-Treatment
is	O
less	O
than	O
that	O
of	O
most	O
other	O
psychiatric	O
drugs	O
.	O

a	I-Background
73	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
non	I-Problem
-	I-Problem
hodgkin	I-Problem
'	I-Problem
s	I-Problem
lymphoma	I-Problem
had	O
two	I-Problem
episodes	I-Problem
of	I-Problem
severe	I-Problem
,	I-Problem
bilateral	I-Problem
,	I-Problem
sensori	I-Problem
-	I-Problem
neural	I-Problem
hearing	I-Problem
loss	I-Problem
after	O
vincristine	I-Treatment
therapy	I-Treatment
.	O

severe	I-Problem
hemolytic	I-Problem
uremic	I-Problem
syndrome	I-Problem
in	O
an	I-Background
advanced	I-Background
ovarian	I-Problem
cancer	I-Problem
patient	I-Background
treated	O
with	O
carboplatin	I-Treatment
and	I-Treatment
gemcitabine	I-Treatment
.	O

ulcerative	I-Problem
proctitis	I-Problem
in	I-Problem
juvenile	I-Problem
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
after	O
ibuprofen	I-Treatment
treatment	O
.	O

acute	I-Problem
asthma	I-Problem
associated	O
with	O
sustained	I-Treatment
-	I-Treatment
release	I-Treatment
verapamil	I-Treatment
.	O

the	O
renal	I-Problem
insufficiency	I-Problem
of	O
three	O
patients	I-Background
and	O
the	O
timing	O
of	O
the	O
seizures	I-Problem
implicate	O
accumulation	I-Treatment
of	I-Treatment
ofloxacin	I-Treatment
as	O
a	O
contributing	O
factor	O
.	O

hemolytic	I-Problem
uremic	I-Problem
syndrome	I-Problem
in	O
a	I-Background
patient	I-Background
on	O
cis	I-Treatment
-	I-Treatment
platinum	I-Treatment
,	I-Treatment
vinblastine	I-Treatment
and	I-Treatment
bleomycin	I-Treatment
.	O

a	O
previous	O
review	O
described	O
data	O
on	O
15	O
patients	I-Background
who	O
experienced	O
acute	I-Problem
hemoglobinemia	I-Problem
or	I-Problem
hemoglobinuria	I-Problem
following	O
anti	I-Treatment
-	I-Treatment
d	I-Treatment
igiv	I-Treatment
administration	O
for	O
itp	I-Problem
or	I-Problem
secondary	I-Problem
thrombocytopenia	I-Problem
.	O

amiodarone	I-Treatment
was	O
discontinued	O
,	O
and	O
thyrotoxicosis	I-Problem
gradually	I-Problem
abated	I-Problem
.	O

de	I-Problem
novo	I-Problem
absence	I-Problem
status	I-Problem
of	I-Problem
late	I-Problem
onset	I-Problem
following	O
withdrawal	I-Treatment
of	I-Treatment
lorazepam	I-Treatment
:	O
a	O
case	O
report	O
.	O

tenofovir	I-Treatment
-	O
associated	O
nephrotoxicity	I-Problem
in	O
two	O
hiv	I-Problem
-	I-Problem
infected	I-Problem
adolescent	I-Background
males	I-Background
.	O

reports	O
of	O
colonic	I-Problem
perforation	I-Problem
as	O
a	O
result	O
of	O
the	O
administration	O
of	O
calcium	I-Treatment
polystyrene	I-Treatment
sulfonate	I-Treatment
and	O
sorbitol	I-Treatment
are	O
rare	O
.	O

improved	O
awareness	O
of	O
and	O
further	O
investigation	O
into	O
the	O
neurotoxic	I-Problem
effects	I-Problem
of	O
ofloxacin	I-Treatment
may	O
enhance	O
its	O
safe	O
use	O
.	O

atypical	I-Problem
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
associated	O
with	O
olanzapine	I-Treatment
.	O

objective	O
:	O
the	O
authors	O
described	O
a	O
case	O
of	O
interferon	I-Treatment
-	O
induced	O
psychosis	I-Problem
as	O
a	O
framework	O
to	O
review	O
the	O
literature	O
and	O
discuss	O
the	O
decision	O
to	O
pursue	O
antiviral	O
treatment	O
in	O
psychiatrically	I-Problem
ill	I-Problem
patients	I-Background
with	I-Background
hepatitis	I-Problem
c	I-Problem
.	I-Problem

we	O
believe	O
that	O
methotrexate	I-Treatment
represents	O
a	O
relatively	O
effective	O
alternative	O
to	O
surgery	O
in	O
patients	I-Background
with	I-Background
early	I-Problem
unruptured	I-Problem
tubal	I-Problem
pregnancy	I-Problem
,	O
but	O
suggest	O
that	O
it	O
be	O
used	O
with	O
caution	O
in	O
view	O
of	O
possible	O
systemic	I-Problem
toxicity	I-Problem
.	O

after	O
intravitreal	I-Treatment
injection	I-Treatment
of	I-Treatment
triamcinolone	I-Treatment
acetonide	I-Treatment
,	O
cataract	I-Problem
may	O
rapidly	O
develop	O
in	O
eyes	O
that	O
have	O
been	O
intensively	O
treated	O
,	O
topically	O
and	O
systemically	O
,	O
by	O
corticosteroids	O
for	O
several	O
years	O
.	O

acute	I-Problem
endophthalmitis	I-Problem
following	O
intravitreal	I-Treatment
bevacizumab	I-Treatment
(	I-Treatment
avastin	I-Treatment
)	I-Treatment
injection	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
bullous	I-Problem
eruption	I-Problem
,	I-Problem
one	I-Other
month	I-Other
after	O
starting	I-Treatment
nicardipine	I-Treatment
and	I-Treatment
lercanidipine	I-Treatment
.	I-Treatment

pulmonary	I-Problem
fibrosis	I-Problem
associated	O
with	O
nabumetone	I-Treatment
.	O

the	O
ability	O
of	O
tumor	I-Treatment
necrosis	I-Treatment
factor	I-Treatment
(	I-Treatment
tnf	I-Treatment
)	I-Treatment
-	I-Treatment
alpha	I-Treatment
inhibitors	I-Treatment
to	O
impair	O
pivotal	O
pro	O
-	O
inflammatory	O
host	O
defenses	O
may	O
facilitate	O
the	O
development	O
of	O
disseminated	I-Problem
cryptococcosis	I-Problem
.	O

this	O
was	O
accepted	O
as	O
evidence	O
for	O
propranolol	I-Treatment
being	O
the	O
cause	O
of	O
this	O
conduction	I-Problem
disorder	I-Problem
.	O

we	O
report	O
a	O
third	O
case	O
of	O
a	O
6	I-Background
-	I-Background
week	I-Background
-	I-Background
old	I-Background
infant	I-Background
with	I-Background
escherichia	I-Problem
coli	I-Problem
sepsis	I-Problem
who	O
received	I-Treatment
ampicillin	I-Treatment
and	I-Treatment
other	I-Treatment
antibiotics	I-Treatment
and	O
subsequently	O
developed	O
ten	I-Problem
.	O

purpose	O
:	O
to	O
report	O
a	O
case	I-Background
of	O
bilateral	I-Problem
anterior	I-Problem
uveitis	I-Problem
associated	O
with	O
ovulation	I-Treatment
induction	I-Treatment
therapy	I-Treatment
using	I-Treatment
clomiphene	I-Treatment
citrate	I-Treatment
.	O

a	I-Background
57	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
presented	O
with	O
a	O
3	O
-	O
week	O
history	O
of	O
dysphagia	I-Problem
for	I-Problem
solids	I-Problem
,	O
6	I-Other
months	I-Other
after	O
starting	O
treatment	O
with	O
nifedipine	I-Treatment
.	O

although	O
combinations	I-Treatment
of	I-Treatment
belladonna	I-Treatment
,	I-Treatment
ergotamine	I-Treatment
,	I-Treatment
and	I-Treatment
phenobarbital	I-Treatment
have	O
been	O
used	O
for	O
medical	O
treatment	O
of	O
menopausal	I-Problem
symptoms	I-Problem
since	O
the	O
1960s	O
,	O
this	O
is	O
the	O
first	O
known	O
case	O
report	O
of	O
its	O
association	O
with	O
anticonvulsant	I-Problem
hypersensitivity	I-Problem
syndrome	I-Problem
.	O

rifampin	I-Treatment
can	O
be	O
associated	O
with	O
severe	O
adverse	O
effects	O
such	O
as	O
hepatitis	I-Problem
,	I-Problem
acute	I-Problem
renal	I-Problem
failure	I-Problem
,	I-Problem
hemolytic	I-Problem
anemia	I-Problem
,	I-Problem
and	I-Problem
thrombocytopenia	I-Problem
.	O

it	O
is	O
believed	O
that	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
reversible	O
azathioprine	I-Treatment
-	O
induced	O
cholestasis	I-Problem
associated	O
with	O
histological	O
evidence	O
of	O
bile	O
duct	O
injury	O
.	O

we	O
present	O
a	O
fatal	O
case	O
of	O
subacute	O
methanol	I-Treatment
toxicity	O
with	O
associated	O
diffuse	I-Problem
brain	I-Problem
involvement	I-Problem
,	I-Problem
including	I-Problem
bilateral	I-Problem
putaminal	I-Problem
necrosis	I-Problem
and	I-Problem
cerebral	I-Problem
edema	I-Problem
with	I-Problem
ventricular	I-Problem
compression	I-Problem
.	O

patients	I-Background
with	I-Background
inoperable	I-Problem
or	I-Background
metastatic	I-Problem
colorectal	I-Problem
cancer	I-Problem
were	O
randomized	O
to	O
receive	O
monthly	I-Other
fu	I-Treatment
400	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
/	I-Treatment
day	I-Treatment
plus	I-Treatment
lv	I-Treatment
20	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
/	I-Treatment
day	I-Treatment
as	I-Treatment
intravenous	I-Treatment
push	I-Treatment
daily	I-Other
for	I-Treatment
five	I-Other
days	I-Other
,	O
or	O
fu	O
alone	O
.	O

the	O
present	O
report	O
suggests	O
that	O
clarithromycin	I-Treatment
coadministration	O
induces	O
increased	I-Problem
plasma	I-Problem
carbamazepine	I-Treatment
concentrations	I-Problem
,	O
which	O
may	O
result	O
in	O
carbamazepine	I-Treatment
toxicity	I-Problem
.	I-Problem

in	O
this	O
case	O
,	O
interferon	I-Treatment
alpha	I-Treatment
induced	O
polymyositis	I-Problem
and	I-Problem
cardiomyopathy	I-Problem
is	O
diagnosed	O
in	O
a	I-Background
33	I-Background
-	I-Background
yr	I-Background
-	I-Background
old	I-Background
male	I-Background
patient	I-Background
with	I-Background
history	I-Problem
of	I-Problem
chronic	I-Problem
hepatitis	I-Problem
b	I-Problem
.	I-Problem

to	O
describe	O
the	O
potential	O
for	O
interaction	O
between	O
opioids	I-Treatment
and	O
serotonergic	I-Treatment
antidepressants	I-Treatment
leading	O
to	O
the	O
development	O
of	O
serotonin	I-Problem
syndrome	I-Problem
(	O
ss	O
)	O
,	O
mechanism	O
of	O
the	O
interaction	O
,	O
and	O
the	O
spectrum	O
of	O
ss	O
in	O
elderly	I-Background
residents	I-Background
of	O
a	O
long	O
-	O
term	O
care	O
facility	O
.	O

erythema	I-Problem
multiforme	I-Problem
bullosum	I-Problem
due	O
to	O
rifampicin	I-Treatment
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
acute	I-Problem
leukemia	I-Problem
who	O
developed	O
horner	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
and	I-Problem
a	I-Problem
severe	I-Problem
demyelinating	I-Problem
peripheral	I-Problem
neuropathy	I-Problem
leading	I-Problem
to	I-Problem
death	I-Problem
after	O
receiving	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
.	I-Treatment

this	O
profile	O
should	O
trigger	O
a	O
"	O
red	O
flag	O
"	O
as	O
to	O
the	O
possibility	O
of	O
phenobarbital	I-Treatment
behavioral	I-Problem
side	I-Problem
effects	I-Problem
or	I-Problem
exacerbation	I-Problem
of	I-Problem
preexisting	I-Problem
maladaptive	I-Problem
behaviors	I-Problem
.	O

retinal	I-Problem
abnormalities	I-Problem
,	I-Problem
including	I-Problem
retinal	I-Problem
hemorrhage	I-Problem
and	I-Problem
"	I-Problem
cotton	I-Problem
-	I-Problem
wool	I-Problem
"	I-Problem
spots	I-Problem
,	O
often	O
occur	O
within	O
the	O
first	O
8	I-Other
weeks	I-Other
in	O
the	O
course	O
of	O
interferon	I-Treatment
therapy	O
in	O
patients	I-Background
with	I-Background
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

rapamycin	I-Treatment
/	I-Treatment
sirolimus	I-Treatment
-	O
induced	O
pneumonitis	I-Problem
has	O
been	O
described	O
previously	O
in	O
renal	O
transplant	O
recipients	O
,	O
and	O
this	O
report	O
describes	O
a	O
stable	O
heart	O
-	O
lung	O
transplant	O
recipient	O
who	O
developed	O
a	O
pulmonary	O
infiltrate	O
that	O
reversed	O
after	O
ceasing	O
sr	O
therapy	O
.	O

ifnalpha	I-Treatment
-	O
induced	O
recurrence	I-Problem
of	I-Problem
graves	I-Problem
'	I-Problem
disease	I-Problem
ten	I-Treatment
years	I-Treatment
after	I-Treatment
thyroidectomy	I-Treatment
in	O
chronic	I-Problem
viral	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

risperidone	I-Treatment
withdrawal	O
-	O
related	O
respiratory	I-Problem
dyskinesia	I-Problem
:	O
a	O
case	O
diagnosed	O
by	O
spirography	O
and	O
fibroscopy	O
.	O

paralytic	I-Problem
ileus	I-Problem
in	O
patients	I-Background
undergoing	O
bortezomib	I-Treatment
treatment	I-Treatment
has	O
been	O
reported	O
,	O
although	O
a	O
definite	O
attribution	O
to	O
bortezomib	O
administration	O
has	O
not	O
been	O
established	O
.	O

severe	O
serotonin	I-Problem
syndrome	I-Problem
induced	O
by	O
mirtazapine	I-Treatment
monotherapy	I-Treatment
.	O

three	I-Other
days	I-Other
after	I-Treatment
starting	I-Treatment
fluconazole	I-Treatment
,	O
she	O
developed	O
polyuria	I-Problem
and	I-Problem
polydipsia	I-Problem
and	I-Problem
was	I-Problem
found	I-Problem
to	I-Problem
have	I-Problem
severe	I-Problem
hyperglycemia	I-Problem
,	I-Problem
which	I-Problem
led	I-Problem
to	I-Problem
the	I-Problem
diagnosis	I-Problem
of	I-Problem
cushing	I-Problem
syndrome	I-Problem
.	O

postoperative	O
hypocalcemic	I-Problem
tetany	I-Problem
caused	O
by	O
fleet	I-Treatment
phospho	I-Treatment
-	I-Treatment
soda	I-Treatment
preparation	O
in	O
a	O
patient	I-Background
taking	O
alendronate	I-Treatment
sodium	I-Treatment
:	O
report	O
of	O
a	O
case	O
.	O

observations	O
in	O
our	O
patient	O
suggest	O
that	O
the	O
leukoencephalopathy	I-Problem
that	O
developed	O
in	O
previously	O
reported	O
patients	I-Background
who	O
received	O
5	O
-	O
fluorouracil	O
and	O
levamisole	O
may	O
have	O
been	O
caused	O
at	O
least	O
partly	O
by	O
levamisole	I-Treatment
.	O

we	O
describe	O
the	O
clinical	O
response	O
,	O
as	O
determined	O
by	O
increases	I-Problem
in	I-Problem
total	I-Problem
hb	I-Problem
and	I-Problem
decreased	I-Problem
transfusion	I-Problem
needs	I-Problem
,	O
in	I-Background
five	O
patients	I-Background
with	I-Background
thalassemia	I-Problem
intermedia	I-Problem
treated	O
with	O
hu	I-Treatment
alone	I-Treatment
or	I-Treatment
in	I-Treatment
combination	I-Treatment
with	I-Treatment
spb	I-Treatment
.	O

according	O
to	O
the	O
naranjo	O
et	O
al	O
.	O
adverse	O
-	I-Test
reaction	O
probability	I-Test
scale	I-Test
,	O
enoxaparin	I-Treatment
was	O
the	O
probable	O
cause	O
of	O
hepatotoxicity	I-Problem
in	O
this	I-Background
patient	I-Background
.	O

this	O
is	O
the	O
first	O
reported	O
case	O
of	O
hepatolithiasis	I-Problem
during	O
octreotide	I-Treatment
therapy	O
.	O

six	O
patients	I-Background
with	I-Background
no	I-Background
previous	I-Background
signs	I-Background
or	I-Background
symptoms	I-Background
suggestive	I-Background
of	I-Background
coronary	I-Background
artery	I-Background
disease	I-Background
developed	O
acute	I-Problem
coronary	I-Problem
ischemia	I-Problem
/	I-Problem
infarction	I-Problem
shortly	O
after	O
cis	I-Treatment
-	I-Treatment
diamine	I-Treatment
-	I-Treatment
dichloroplatinum	I-Treatment
ii	I-Treatment
(	I-Treatment
cisplatin	I-Treatment
)	I-Treatment
-	I-Treatment
based	I-Treatment
chemotherapy	I-Treatment
.	O

results	O
:	O
replacing	I-Treatment
valproate	I-Treatment
with	I-Treatment
lamotrigine	I-Treatment
resulted	O
in	O
a	I-Problem
decrease	I-Problem
in	I-Problem
serum	I-Problem
testosterone	I-Problem
concentrations	I-Problem
in	O
all	I-Background
3	O
women	I-Background
.	O

a	I-Background
65	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
,	I-Background
in	I-Background
the	I-Background
intensive	I-Background
care	I-Background
unit	I-Background
because	I-Background
of	I-Background
septic	I-Problem
shock	I-Problem
and	I-Background
acute	I-Problem
renal	I-Problem
failure	I-Problem
,	O
had	O
a	O
small	I-Problem
-	I-Problem
bowel	I-Problem
obstruction	I-Problem
due	O
to	O
amphojel	I-Treatment
concretions	I-Problem
.	O

after	O
the	O
first	O
oral	I-Treatment
dose	I-Treatment
of	I-Treatment
propranolol	I-Treatment
,	O
syncope	I-Problem
developed	O
together	O
with	O
atrioventricular	I-Problem
block	I-Problem
.	O

sorafenib	I-Treatment
induced	O
tumor	I-Problem
lysis	I-Problem
syndrome	I-Problem
in	O
an	I-Background
advanced	I-Background
hepatocellular	I-Problem
carcinoma	I-Problem
patient	I-Background
.	O

the	I-Problem
symptoms	I-Problem
did	I-Problem
not	I-Problem
recur	I-Problem
during	O
the	I-Treatment
36	I-Other
months	I-Other
of	I-Treatment
itraconazole	I-Treatment
treatment	I-Treatment
after	I-Treatment
discharge	I-Treatment
,	O
and	O
it	O
was	O
concluded	O
that	O
itcz	O
was	O
effective	O
for	O
a	I-Problem
.	I-Problem
flavus	I-Problem
hypertrophic	I-Problem
pachymeningitis	I-Problem
.	O

a	O
prospective	O
randomized	O
clinical	O
trial	I-Test
was	O
implemented	O
to	O
assess	O
whether	O
the	I-Treatment
concomitant	I-Treatment
or	I-Treatment
the	I-Treatment
sequential	I-Treatment
addition	I-Treatment
of	I-Treatment
tamoxifen	I-Treatment
to	I-Treatment
chemotherapy	I-Treatment
provides	O
improved	I-Problem
clinical	I-Problem
benefit	I-Problem
in	I-Problem
the	I-Problem
adjuvant	I-Problem
treatment	I-Problem
of	O
breast	I-Problem
cancer	I-Problem
in	O
postmenopausal	I-Problem
patients	I-Background
.	O

increased	I-Problem
libido	I-Problem
in	O
a	I-Background
woman	I-Background
treated	O
with	O
fluvoxamine	I-Treatment
:	O
a	O
case	O
report	O
.	O

in	O
the	O
following	O
case	O
report	O
,	O
a	O
patient	I-Background
developed	O
acute	I-Problem
interstitial	I-Problem
nephritis	I-Problem
with	I-Problem
renal	I-Problem
failure	I-Problem
and	I-Problem
exfoliative	I-Problem
dermatitis	I-Problem
following	O
ampicillin	I-Treatment
therapy	I-Treatment
.	O

severe	I-Problem
symptoms	I-Problem
associated	I-Problem
with	I-Problem
serotonin	I-Treatment
toxicity	I-Problem
were	O
shown	O
to	O
be	O
uncommon	O
in	O
patients	I-Background
receiving	O
linezolid	I-Treatment
and	I-Treatment
selected	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitors	I-Treatment
.	O

we	O
describe	O
the	O
side	I-Problem
effects	I-Problem
of	O
5	I-Treatment
-	I-Treatment
fu	I-Treatment
in	O
a	O
colon	I-Problem
cancer	I-Problem
patient	I-Background
who	I-Background
suffered	I-Background
severe	I-Background
mucositis	I-Problem
,	I-Background
desquamating	I-Problem
dermatitis	I-Problem
,	I-Background
prolonged	I-Background
myelosuppression	I-Problem
,	I-Background
and	I-Background
neurologic	I-Problem
toxicity	I-Problem
that	I-Background
required	I-Background
admission	I-Background
to	I-Background
the	I-Background
intensive	I-Background
care	I-Background
unit	I-Background
.	O

there	O
have	O
been	O
many	O
reports	O
of	O
probable	O
lithium	I-Treatment
-	O
induced	O
organic	I-Problem
brain	I-Problem
syndromes	I-Problem
occurring	O
when	I-Treatment
serum	I-Treatment
lithium	I-Test
levels	I-Test
are	I-Treatment
within	I-Treatment
or	I-Treatment
close	I-Treatment
to	I-Treatment
the	I-Treatment
therapeutic	I-Treatment
range	I-Treatment
.	O

the	O
patient	I-Background
was	O
enrolled	O
in	O
a	O
weight	O
-	O
loss	O
clinic	O
,	O
and	O
his	O
diabetes	O
medications	O
were	O
adjusted	O
.	O
subsequently	O
,	O
olanzapine	I-Treatment
was	I-Treatment
discontinued	I-Treatment
because	O
of	O
weight	I-Problem
gain	I-Problem
and	I-Problem
uncontrolled	I-Problem
diabetes	I-Problem
.	O

while	O
most	O
physicians	O
are	O
aware	O
of	O
heparin	I-Treatment
-	O
induced	O
thrombocytopenia	I-Problem
and	I-Problem
skin	I-Problem
necrosis	I-Problem
,	O
the	O
association	O
of	O
heparin	O
and	O
hyperkalemia	O
is	O
less	O
well	O
recognized	O
.	O

gefitinib	I-Treatment
(	O
iressa	I-Treatment
,	O
zd1839	I-Treatment
)	O
,	O
an	O
epidermal	I-Treatment
growth	I-Treatment
factor	I-Treatment
receptor	I-Treatment
tyrosine	I-Treatment
kinase	I-Treatment
inhibitor	I-Treatment
,	O
has	O
been	O
approved	O
in	O
several	O
countries	O
for	O
the	O
treatment	O
of	O
advanced	I-Problem
non	I-Problem
-	I-Problem
small	I-Problem
-	I-Problem
cell	I-Problem
lung	I-Problem
cancer	I-Problem
.	O

the	O
case	O
of	O
a	I-Background
4	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
with	O
valproate	I-Treatment
-	O
induced	O
stupor	I-Problem
and	I-Problem
electroencephalographic	I-Problem
pattern	I-Problem
of	I-Problem
increased	I-Problem
fast	I-Problem
activity	I-Problem
is	O
reported	O
.	O

prior	O
to	O
surgery	O
,	O
levodopa	I-Problem
induced	I-Problem
dyskinesia	I-Problem
had	O
improved	O
(	O
<	O
or	O
=	O
50	O
%	O
)	O
under	O
treatment	I-Treatment
with	I-Treatment
amantadine	I-Treatment
(	I-Treatment
400	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
,	I-Treatment
po	I-Treatment
)	I-Treatment
in	O
all	I-Background
three	O
patients	I-Background
.	O

foscarnet	I-Treatment
-	O
induced	O
severe	O
hypomagnesemia	I-Problem
and	I-Problem
other	I-Problem
electrolyte	I-Problem
disorders	I-Problem
.	O

a	O
case	O
is	O
reported	O
of	O
a	O
child	I-Background
with	I-Background
fatal	I-Problem
pulmonary	I-Problem
fibrosis	I-Problem
following	O
bcnu	I-Treatment
therapy	I-Treatment
.	O

a	I-Background
64	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
schizophrenia	I-Problem
developed	O
myoclonic	I-Problem
jerks	I-Problem
when	O
given	O
higher	I-Treatment
doses	I-Treatment
of	I-Treatment
quetiapine	I-Treatment
.	O

the	O
etiology	O
of	O
neurotoxicity	I-Problem
in	O
our	O
two	O
patients	I-Background
remains	O
unclear	O
;	O
however	O
,	O
as	O
cap	O
is	O
rapidly	O
metabolized	O
to	O
5	O
-	O
fu	O
in	O
patients	O
with	O
normal	O
liver	O
function	O
,	O
it	O
is	O
likely	O
that	O
5	I-Treatment
-	I-Treatment
fu	I-Treatment
or	I-Treatment
its	I-Treatment
active	I-Treatment
metabolites	I-Treatment
(	I-Treatment
fluoro	I-Treatment
-	I-Treatment
beta	I-Treatment
-	I-Treatment
alanine	I-Treatment
)	I-Treatment
were	O
contributing	O
factors	O
.	O

conclusions	O
:	O
amantadine	I-Treatment
can	O
cause	O
reversible	I-Problem
corneal	I-Problem
edema	I-Problem
but	O
can	O
irreversibly	O
reduce	O
the	O
density	O
of	O
endothelial	O
cells	O
.	O

after	O
gastric	I-Problem
-	I-Problem
outlet	I-Problem
obstruction	I-Problem
was	O
recognized	O
in	O
several	I-Background
infants	I-Background
who	O
received	O
prostaglandin	I-Treatment
e1	I-Treatment
,	O
we	O
studied	O
the	O
association	O
between	O
the	O
drug	O
and	O
this	O
complication	O
.	O

a	O
wide	O
variety	O
of	O
adverse	I-Problem
central	I-Problem
nervous	I-Problem
system	I-Problem
effects	I-Problem
have	O
been	O
reported	O
in	O
association	O
with	O
propafenone	I-Treatment
;	O
dizziness	I-Problem
is	O
the	O
most	O
common	O
.	O

iatrogenic	I-Problem
cushing	I-Problem
syndrome	I-Problem
has	O
been	O
reported	O
in	O
patients	I-Background
with	I-Background
cf	I-Problem
treated	O
concomitantly	O
,	O
and	O
for	O
extended	O
duration	O
,	O
with	O
inhaled	I-Treatment
corticosteroids	I-Treatment
and	I-Treatment
cyp3a4	I-Treatment
inhibitors	I-Treatment
.	O

red	I-Problem
blood	I-Problem
cell	I-Problem
anemia	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
pemphigus	I-Problem
vulgaris	I-Problem
induced	O
by	O
the	O
use	O
of	O
mycophenolate	I-Treatment
mofetil	I-Treatment
and	I-Treatment
prednisone	I-Treatment
.	O

induction	O
of	O
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
by	O
interferon	I-Treatment
-	I-Treatment
gamma	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
.	I-Problem

in	O
this	O
case	O
,	O
unlike	O
those	O
previously	O
reported	O
,	O
hyponatremia	I-Problem
recurred	O
5	I-Other
months	I-Other
after	O
switching	I-Treatment
from	I-Treatment
citalopram	I-Treatment
to	I-Treatment
mirtazapine	I-Treatment
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
safe	O
antidepressant	O
.	O

this	O
report	O
describes	O
a	O
case	O
of	O
acute	I-Problem
compromise	I-Problem
of	I-Problem
renal	I-Problem
function	I-Problem
associated	O
with	O
hypotension	I-Problem
in	O
a	I-Background
7	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
treated	O
with	O
the	O
ace	I-Treatment
inhibitor	I-Treatment
lisinopril	I-Treatment
and	I-Treatment
the	I-Treatment
arb	I-Treatment
losartan	I-Treatment
.	O

we	O
report	O
a	I-Background
male	I-Background
patient	I-Background
with	I-Background
advanced	I-Problem
aids	I-Problem
who	O
developed	O
hypercalcemia	I-Problem
2	I-Other
weeks	I-Other
after	I-Treatment
institution	I-Treatment
of	I-Treatment
rhgh	I-Treatment
therapy	I-Treatment
.	O

results	O
:	O
both	O
patients	I-Background
experienced	O
a	O
previously	O
unreported	O
side	O
effect	O
-	O
-	O
falling	I-Problem
backward	I-Problem
-	I-Problem
-	O
associated	O
with	O
bupropion	I-Treatment
use	O
.	O

a	O
second	O
episode	O
of	O
jaundice	I-Problem
followed	O
the	O
intravaginal	I-Treatment
administration	I-Treatment
of	I-Treatment
a	I-Treatment
mixture	I-Treatment
of	I-Treatment
furazolidone	I-Treatment
and	I-Treatment
nifuroxime	I-Treatment
.	O

clinicians	O
should	O
be	O
aware	O
that	O
an	I-Problem
erythematous	I-Problem
and	I-Problem
exfoliative	I-Problem
rash	I-Problem
may	O
be	O
induced	O
by	O
temozolomide	I-Treatment
,	O
and	O
be	O
familiar	O
with	O
the	O
pharmacologic	O
and	O
supportive	O
measures	O
necessary	O
for	O
its	O
treatment	O
.	O

captopril	I-Treatment
-	O
induced	O
bone	I-Problem
marrow	I-Problem
suppression	I-Problem
in	O
two	O
cardiac	I-Problem
patients	I-Background
with	I-Background
trisomy	I-Problem
21	I-Problem
.	O

a	I-Background
65	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
angina	I-Problem
pectoris	I-Problem
presented	O
with	O
syncope	I-Problem
after	O
sublingual	I-Treatment
ingestion	I-Treatment
of	I-Treatment
isosorbide	I-Treatment
dinitrate	I-Treatment
(	I-Treatment
5	I-Treatment
mg	I-Treatment
)	I-Treatment
.	O

the	O
authors	O
present	O
a	O
case	O
study	O
of	O
a	I-Background
mentally	I-Background
healthy	I-Background
man	I-Background
who	O
repeatedly	O
experienced	O
short	I-Problem
-	I-Problem
lived	I-Problem
,	I-Problem
obsessional	I-Problem
-	I-Problem
like	I-Problem
suicidal	I-Problem
ideas	I-Problem
and	I-Problem
images	I-Problem
after	O
ingestion	I-Treatment
of	I-Treatment
the	I-Treatment
anti	I-Treatment
-	I-Treatment
fungal	I-Treatment
drug	I-Treatment
ketoconazole	I-Treatment
.	O

flaccid	I-Problem
quadriparesis	I-Problem
was	O
noted	O
after	O
discontinuation	O
of	O
vecuronium	I-Treatment
.	O

aims	O
:	O
the	O
aim	O
of	O
this	O
study	I-Test
was	O
to	O
report	O
on	O
the	O
effectiveness	O
and	O
tumor	I-Problem
side	I-Problem
effects	I-Problem
of	O
topical	I-Treatment
interferon	I-Treatment
(	I-Treatment
inf	I-Treatment
)	I-Test
alpha	I-Treatment
2	I-Treatment
-	I-Treatment
beta	I-Treatment
in	O
a	O
case	O
of	O
conjunctiva	I-Problem
-	I-Problem
cornea	I-Problem
intraepithelial	I-Problem
neoplasia	I-Problem
(	I-Background
cin	I-Background
)	I-Background
of	I-Background
a	I-Background
patient	I-Background
that	I-Background
rejected	I-Background
any	I-Background
surgical	I-Background
procedure	I-Background
.	O

we	O
present	O
a	O
case	O
of	O
severe	I-Problem
unilateral	I-Problem
posterior	I-Problem
scleritis	I-Problem
associated	O
with	O
zoledronic	I-Treatment
acid	I-Treatment
administration	O
that	O
was	O
recognized	O
and	O
treated	O
in	O
a	O
timely	O
manner	O
.	O

the	O
patient	O
'	O
s	O
other	O
comorbidities	O
and	O
medications	O
have	O
not	O
been	O
suggested	O
as	O
possible	O
interactions	O
with	O
sertraline	I-Treatment
that	O
can	O
cause	O
rhabdomyolysis	I-Problem
.	O

l	I-Treatment
-	I-Treatment
asparaginase	I-Treatment
-	O
provoked	O
seizures	I-Problem
as	I-Problem
singular	I-Problem
expression	I-Problem
of	I-Problem
central	I-Problem
nervous	I-Problem
toxicity	I-Problem
.	O

acute	I-Problem
non	I-Problem
-	I-Problem
lymphocytic	I-Problem
leukemia	I-Problem
in	O
patients	I-Background
with	I-Background
ovarian	I-Problem
carcinoma	I-Problem
following	O
long	I-Treatment
-	I-Treatment
term	I-Treatment
treatment	I-Treatment
with	I-Treatment
treosulfan	I-Treatment
(	I-Treatment
=	I-Treatment
dihydroxybusulfan	I-Treatment
)	I-Treatment
.	O

children	I-Background
treated	O
with	O
thalidomide	I-Treatment
should	O
undergo	O
regular	O
neurophysiologic	I-Test
studies	I-Test
in	O
order	O
to	O
detect	O
presymptomatic	I-Problem
or	I-Problem
progressive	I-Problem
peripheral	I-Problem
neuropathy	I-Problem
.	O

nevirapine	I-Treatment
is	I-Treatment
a	I-Treatment
non	I-Treatment
-	I-Treatment
nucleoside	I-Treatment
reverse	I-Treatment
transcriptase	I-Treatment
inhibitor	I-Treatment
widely	I-Treatment
used	I-Treatment
in	I-Treatment
combination	I-Treatment
with	I-Treatment
other	I-Treatment
antiretroviral	I-Treatment
agents	I-Treatment
for	O
the	O
treatment	O
of	O
hiv	I-Problem
infection	I-Problem
.	O

the	O
case	O
is	O
presented	O
of	O
a	I-Background
72	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
hormone	I-Problem
-	I-Problem
refractory	I-Problem
prostate	I-Problem
cancer	I-Problem
and	O
weekly	I-Other
administration	I-Treatment
of	I-Treatment
30	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
docetaxel	I-Treatment
who	O
developed	O
subacute	I-Problem
interstitial	I-Problem
pneumonitis	I-Problem
-	I-Problem
related	I-Problem
pulmonary	I-Problem
fibrosis	I-Problem
after	O
seven	I-Treatment
doses	I-Treatment
and	I-Problem
died	I-Problem
despite	I-Treatment
mechanical	I-Treatment
ventilation	I-Treatment
and	I-Treatment
high	I-Treatment
-	I-Treatment
dose	I-Treatment
corticosteroid	I-Treatment
treatment	I-Treatment
.	O

in	O
this	O
case	O
,	O
it	O
was	O
suspected	O
that	O
a	O
combination	O
of	O
cigarette	O
smoking	O
,	O
pulmonary	I-Problem
fibrosis	I-Problem
,	O
and	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
therapy	I-Treatment
might	O
have	O
promoted	O
the	I-Problem
development	I-Problem
of	I-Problem
lung	I-Problem
cancer	I-Problem
.	O

rapid	O
onset	O
of	O
iatrogenic	I-Problem
adrenal	I-Problem
insufficiency	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
cystic	I-Problem
fibrosis	I-Problem
-	I-Problem
related	I-Problem
liver	I-Problem
disease	I-Problem
treated	O
with	O
inhaled	I-Treatment
corticosteroids	I-Treatment
and	I-Treatment
a	I-Treatment
moderate	I-Treatment
cyp3a4	I-Treatment
inhibitor	I-Treatment
.	I-Treatment

heparin	I-Treatment
-	O
associated	O
thrombocytopenia	I-Problem
and	I-Problem
thrombosis	I-Problem
is	O
a	O
severe	O
complication	O
of	O
systemic	O
heparin	I-Treatment
therapy	O
.	O

the	O
cause	O
of	O
his	O
bleeding	O
was	O
a	O
severe	O
thrombocytopoaenia	I-Problem
,	O
induced	O
by	O
chronic	I-Treatment
ingestion	I-Treatment
of	I-Treatment
quinine	I-Treatment
.	O

the	O
concomitant	I-Treatment
use	I-Treatment
of	I-Treatment
antidepressant	I-Treatment
drugs	I-Treatment
associated	I-Treatment
with	I-Treatment
lithium	I-Treatment
as	I-Treatment
a	I-Treatment
co	I-Treatment
-	I-Treatment
adjuvant	I-Treatment
seems	O
to	O
increase	O
the	O
risk	O
of	O
this	O
adverse	I-Problem
reaction	I-Problem
.	O

peripheral	I-Problem
nervous	I-Problem
system	I-Problem
disturbances	I-Problem
caused	O
by	O
cytosine	I-Treatment
arabinoside	I-Treatment
have	O
rarely	O
been	O
reported	O
.	O

we	O
report	O
an	O
unusually	O
short	O
lived	O
and	O
asymptomatic	O
episode	O
of	O
severe	O
cisplatin	I-Treatment
-	O
induced	O
renal	I-Problem
tubular	I-Problem
salt	I-Problem
wasting	I-Problem
in	O
a	I-Background
fit	I-Background
41	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
patient	I-Background
with	I-Background
malignant	I-Problem
teratoma	I-Problem
.	O

this	I-Background
case	I-Background
suggests	O
that	O
bh	I-Treatment
-	I-Treatment
ac	I-Treatment
,	I-Treatment
a	I-Treatment
derivative	I-Treatment
of	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
(	I-Treatment
1	I-Treatment
-	I-Treatment
beta	I-Treatment
-	I-Treatment
d	I-Treatment
-	I-Treatment
arabinofuranosylcytosine	I-Treatment
)	I-Treatment
could	O
be	O
a	O
cause	O
of	O
reversible	I-Problem
encephalopathy	I-Problem
syndrome	I-Problem
.	O

she	O
was	O
administered	O
metoclopramide	I-Treatment
because	O
of	O
nausea	I-Problem
and	O
,	O
within	I-Other
2	I-Other
hours	I-Other
,	O
developed	O
agitation	I-Problem
,	I-Problem
dysarthria	I-Problem
,	I-Problem
diaphoresis	I-Problem
,	I-Problem
and	I-Problem
a	I-Problem
movement	I-Problem
disorder	I-Problem
.	O

amprenavir	I-Treatment
is	O
a	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
hiv	O
-	O
1	O
)	O
protease	O
inhibitor	O
intended	O
to	O
be	O
used	O
to	O
treat	O
hiv	I-Problem
-	I-Problem
infected	I-Problem
children	I-Background
.	O

methotrexate	I-Treatment
-	O
induced	O
papular	I-Problem
eruption	I-Problem
following	O
treatment	O
of	O
psoriasis	O
has	O
not	O
been	O
previously	O
reported	O
.	O

on	O
day	O
7	O
of	O
linezolid	I-Treatment
treatment	O
,	O
the	I-Background
patient	I-Background
developed	O
severe	O
pruritus	I-Problem
,	I-Problem
macular	I-Problem
rash	I-Problem
,	I-Problem
facial	I-Problem
edema	I-Problem
,	I-Problem
eosinophilia	I-Problem
,	I-Problem
marked	I-Problem
increase	I-Problem
in	I-Problem
serum	I-Problem
creatinine	I-Problem
level	I-Problem
,	O
and	O
mild	O
hepatitis	I-Problem
.	O

we	O
report	O
a	O
fatal	O
case	O
of	O
acute	I-Problem
interstitial	I-Problem
pneumonitis	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
carmustine	I-Treatment
(	I-Treatment
bcnu	I-Treatment
)	I-Treatment
for	I-Background
a	I-Problem
brain	I-Problem
tumor	I-Problem
.	O

the	O
three	O
reported	I-Background
cases	I-Background
demonstrate	O
that	O
troglitazone	I-Treatment
is	O
an	O
idiosyncratic	O
hepatotoxin	O
that	O
can	O
lead	O
to	O
irreversible	I-Problem
liver	I-Problem
injury	I-Problem
.	O

high	I-Problem
-	I-Problem
grade	I-Problem
atrioventricular	I-Problem
block	I-Problem
during	O
dipyridamole	I-Treatment
stress	I-Test
testing	I-Test
.	O

we	O
describe	O
a	O
case	O
of	O
intraoperative	I-Treatment
gelatine	I-Treatment
-	O
induced	O
anaphylaxis	I-Problem
whose	O
diagnosis	O
was	O
delayed	O
as	O
the	O
use	O
of	O
gelatine	O
during	O
surgical	O
procedures	O
was	O
omitted	O
for	O
two	O
times	O
in	O
patient	O
'	O
s	O
medical	O
records	O
.	O

the	O
case	O
of	O
a	I-Background
29	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
suffering	I-Background
from	I-Background
falciparum	I-Problem
malaria	I-Problem
disease	I-Problem
who	O
got	O
a	O
reversible	I-Problem
hearing	I-Problem
loss	I-Problem
from	O
quinine	I-Treatment
therapy	O
is	O
presented	O
.	O

the	O
cases	O
of	O
two	O
asthmatic	I-Problem
patients	I-Background
who	O
became	O
hypokalemic	I-Problem
after	O
inhalation	I-Treatment
of	I-Treatment
normal	I-Treatment
doses	I-Treatment
of	I-Treatment
albuterol	I-Treatment
are	O
presented	O
.	O

this	O
article	O
presents	O
a	O
case	O
of	O
an	I-Problem
atypical	I-Problem
localized	I-Problem
cutaneous	I-Problem
eruption	I-Problem
with	I-Problem
an	I-Problem
unusual	I-Problem
course	I-Problem
and	I-Problem
protracted	I-Problem
resolution	I-Problem
time	I-Problem
associated	O
with	O
sorafenib	I-Treatment
therapy	I-Treatment
.	O

method	O
:	O
we	O
describe	O
two	O
patients	I-Background
who	O
presented	O
with	O
diabetic	I-Problem
ketoacidosis	I-Problem
after	O
treatment	O
with	O
quetiapine	I-Treatment
and	I-Treatment
risperidone	I-Treatment
,	O
respectively	O
.	O

we	O
suspect	O
that	O
nefazodone	I-Treatment
inhibits	O
metabolism	I-Problem
of	I-Problem
tacrolimus	I-Problem
.	O

our	O
review	I-Test
of	O
194	I-Background
ra	I-Background
patients	I-Background
and	I-Background
38	I-Background
psa	I-Background
patients	I-Background
receiving	I-Background
mtx	I-Background
has	I-Background
identified	I-Background
four	O
ra	I-Problem
patients	I-Background
and	I-Background
one	O
psa	I-Problem
patient	I-Background
with	O
mtx	I-Treatment
-	O
induced	O
pneumonitis	I-Problem
,	O
giving	O
a	O
prevalence	O
of	O
2	O
.	O
1	O
%	O
and	O
0	O
.	O
03	O
%	O
,	O
respectively	O
.	O

a	O
case	O
report	O
of	O
fatal	O
dapsone	I-Treatment
-	O
induced	O
agranulocytosis	I-Problem
in	O
an	I-Background
indian	I-Background
mid	I-Problem
-	I-Problem
borderline	I-Problem
leprosy	I-Problem
patient	I-Background
.	O

autoimmune	I-Problem
thyroid	I-Problem
disease	I-Problem
is	O
a	O
common	O
side	O
-	O
effect	O
of	O
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
(	I-Treatment
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
)	I-Treatment
treatment	O
of	O
viral	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

the	O
side	O
effects	O
of	O
mmf	I-Treatment
,	O
such	O
as	O
bone	I-Problem
marrow	I-Problem
toxicity	I-Problem
,	O
have	O
been	O
reported	O
.	O

he	I-Background
developed	O
a	O
late	I-Problem
secondary	I-Problem
infection	I-Problem
in	O
some	O
sites	O
treated	O
with	O
imiquimod	I-Treatment
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
51	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
in	O
whom	O
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
treatment	I-Treatment
was	O
followed	O
by	O
recurrence	I-Problem
of	I-Problem
graves	I-Problem
'	I-Problem
disease	I-Problem
10	I-Treatment
years	I-Treatment
after	I-Treatment
thyroidectomy	I-Treatment
was	O
performed	O
and	O
the	O
patient	O
was	O
declared	O
cured	O
.	O

we	O
report	O
2	O
cases	O
of	O
maculopapular	I-Problem
eruption	I-Problem
and	I-Problem
fever	I-Problem
in	O
patients	I-Background
infected	O
with	O
human	I-Problem
immunodeficiency	I-Problem
virus	I-Problem
(	O
hiv	O
)	O
on	O
the	O
2nd	I-Other
day	I-Other
of	I-Other
first	I-Other
administration	I-Other
of	O
ritonavir	I-Treatment
,	O
a	O
protease	O
inhibitor	O
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
woman	I-Background
who	O
developed	O
photo	I-Problem
-	I-Problem
onycholysis	I-Problem
on	I-Problem
multiple	I-Problem
nails	I-Problem
after	I-Other
uptake	I-Other
of	I-Treatment
olanzapine	I-Treatment
.	O

cimetidine	I-Treatment
is	O
a	O
rare	O
cause	O
of	O
drug	O
-	O
induced	O
fever	I-Problem
.	O

reversible	O
methotrexate	I-Treatment
-	O
associated	O
lymphoproliferative	I-Problem
disorder	I-Problem
resembling	O
advanced	O
gastric	O
cancer	O
in	O
a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
.	O

the	O
field	I-Problem
defects	I-Problem
and	I-Problem
some	I-Problem
electrophysiological	I-Problem
abnormalities	I-Problem
persist	I-Problem
when	O
vigabatrin	I-Treatment
therapy	I-Treatment
is	I-Treatment
withdrawn	I-Treatment
.	O

a	I-Background
possible	I-Background
case	I-Background
of	O
carbamazepine	I-Treatment
induced	O
pancreatitis	I-Problem
.	O

subsequent	O
to	O
the	O
first	O
dose	O
of	O
mirtazapine	I-Treatment
the	I-Background
patient	I-Background
experienced	O
seizures	I-Problem
,	I-Problem
bradycardia	I-Problem
and	I-Problem
prolonged	I-Problem
qrs	I-Problem
as	I-Problem
well	I-Problem
as	I-Problem
qtc	I-Problem
intervals	I-Problem
on	I-Problem
ekg	I-Problem
.	O

stuttering	I-Problem
priapism	I-Problem
complicating	O
warfarin	I-Treatment
therapy	O
in	O
a	I-Background
patient	I-Background
with	I-Background
protein	I-Problem
c	I-Problem
deficiency	I-Problem
.	O

she	O
had	O
been	O
on	O
a	O
combined	O
treatment	O
of	O
steroid	I-Treatment
and	I-Treatment
lobenzarit	I-Treatment
disodium	I-Treatment
for	I-Treatment
the	I-Treatment
first	I-Treatment
3	I-Other
years	I-Other
,	I-Treatment
and	I-Treatment
then	I-Treatment
continued	I-Treatment
with	I-Treatment
a	I-Treatment
combined	I-Treatment
treatment	I-Treatment
of	I-Treatment
steroid	I-Treatment
and	I-Treatment
bucillamine	I-Treatment
for	I-Other
the	I-Other
following	I-Other
years	I-Other
until	O
she	O
was	O
found	O
to	O
have	O
pulmonary	I-Problem
tuberculosis	I-Problem
,	O
at	O
which	O
time	O
the	O
steroid	O
was	O
suspended	O
10	O
months	O
before	O
she	O
visited	O
the	O
authors	O
'	O
clinic	O
.	O

we	O
describe	O
a	I-Background
rare	I-Background
case	I-Background
of	O
severe	O
drug	O
-	O
drug	O
interaction	O
between	O
propafenone	I-Treatment
and	I-Treatment
mirtazapine	I-Treatment
leading	O
to	O
propafenone	I-Problem
toxicity	I-Problem
.	O

because	O
the	O
combination	O
of	O
bleomycin	I-Treatment
and	O
vinca	I-Treatment
alkaloids	I-Treatment
is	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
aids	O
-	O
related	O
kaposi	O
'	O
s	O
sarcoma	O
,	O
clinicians	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
provoking	O
acral	I-Problem
necrosis	I-Problem
in	O
patients	O
who	O
develop	O
raynaud	I-Problem
'	I-Problem
s	I-Problem
phenomenon	I-Problem
under	O
chemotherapy	O
.	O

the	O
psychotic	I-Problem
behavior	I-Problem
resolved	O
completely	O
soon	I-Other
after	I-Other
the	O
discontinuation	I-Treatment
of	I-Treatment
levetiracetam	I-Treatment
.	O

male	I-Background
volunteers	I-Background
(	I-Background
n	O
=	O
12	O
)	I-Background
participated	O
in	O
a	O
randomised	O
,	O
two	O
-	O
period	O
,	O
crossover	O
trial	O
evaluating	O
the	O
effect	O
of	O
multiple	I-Treatment
doses	I-Treatment
of	I-Treatment
600	I-Treatment
mg	I-Treatment
rifampicin	I-Treatment
once	I-Other
daily	I-Other
for	I-Treatment
7	I-Other
days	I-Other
on	O
repaglinide	I-Problem
metabolism	I-Problem
.	O

this	O
report	O
suggests	O
that	O
anemia	I-Problem
can	O
occur	O
due	O
to	O
mmf	I-Treatment
,	O
in	O
particular	O
when	O
it	O
is	O
given	O
with	O
prednisone	I-Treatment
,	O
a	O
side	O
effect	O
well	O
documented	O
in	O
the	O
transplantation	O
literature	O
when	O
the	O
triple	O
combination	O
of	O
mmf	O
,	O
cyclosporine	O
and	O
prednisone	O
is	O
used	O
.	O

warfarin	I-Treatment
was	I-Treatment
initiated	I-Treatment
for	I-Treatment
deep	I-Problem
vein	I-Problem
thrombosis	I-Problem
prophylaxis	O
due	O
to	O
the	O
patient	I-Background
'	I-Background
s	I-Background
inability	I-Problem
to	I-Problem
ambulate	I-Problem
.	O

we	O
report	O
a	O
case	O
with	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
(	I-Problem
chc	I-Problem
)	I-Problem
who	O
developed	O
sarcoidosis	I-Problem
after	O
the	O
treatment	I-Treatment
by	I-Treatment
interferon	I-Treatment
alpha	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
.	O

the	O
relation	O
between	O
tacrolimus	O
treatment	O
and	O
staining	O
was	O
suggested	O
by	O
the	O
appearance	I-Problem
of	I-Problem
pigmentation	I-Problem
during	O
topical	I-Treatment
tacrolimus	I-Treatment
treatment	O
and	O
its	O
clinical	O
disappearance	O
when	O
treatment	O
was	O
stopped	O
.	O

though	O
hypotension	O
,	O
dry	O
mouth	O
,	O
and	O
constipation	O
are	O
well	O
-	O
documented	O
possible	O
adverse	O
effects	O
,	O
the	O
possibility	O
of	O
clonidine	I-Treatment
-	O
induced	O
bradycardia	I-Problem
is	O
less	O
well	O
recognized	O
and	O
is	O
rare	O
.	O

several	O
hypersensitivity	I-Problem
reactions	O
to	O
cloxacillin	I-Treatment
have	O
been	O
reported	O
,	O
although	O
ige	O
-	O
mediated	O
allergic	O
reactions	O
to	O
the	O
drug	O
are	O
rare	O
and	O
there	O
is	O
little	O
information	O
about	O
possible	O
tolerance	O
to	O
other	O
semisynthetic	O
penicillins	O
or	O
cephalosporins	O
in	O
patients	O
with	O
cloxacillin	O
allergy	O
.	O

brugada	I-Problem
type	I-Problem
electrocardiographic	I-Problem
changes	I-Problem
induced	O
by	O
concomitant	I-Treatment
use	I-Treatment
of	I-Treatment
lithium	I-Treatment
and	I-Treatment
propafenone	I-Treatment
in	O
patient	I-Background
with	I-Background
wolff	I-Problem
-	I-Problem
parkinson	I-Problem
-	I-Problem
white	I-Problem
syndrome	I-Problem
.	O

docetaxel	I-Treatment
-	O
induced	O
meibomian	I-Problem
duct	I-Problem
inflammation	I-Problem
and	I-Problem
blockage	I-Problem
leading	I-Problem
to	I-Problem
chalazion	I-Problem
formation	I-Problem
.	O

allergic	O
side	O
effects	O
of	O
aza	O
are	O
rare	O
,	O
and	O
reported	O
allergic	I-Problem
skin	I-Problem
eruptions	I-Problem
from	O
aza	I-Treatment
are	O
very	O
limited	O
in	O
japan	O
.	O

quetiapine	O
and	O
obsessive	I-Problem
-	I-Problem
compulsive	I-Problem
symptoms	I-Problem
(	I-Problem
ocs	I-Problem
)	I-Problem
:	O
case	O
report	O
and	O
review	O
of	O
atypical	O
antipsychotic	I-Treatment
-	O
induced	O
ocs	I-Problem
.	O

outcome	O
of	O
pregnancy	I-Problem
in	I-Background
women	I-Background
treated	O
with	O
all	I-Treatment
-	I-Treatment
trans	I-Treatment
retinoic	I-Treatment
acid	I-Treatment
;	O
a	O
case	O
report	O
and	O
review	O
of	O
literature	O
.	O

the	O
potential	O
development	O
of	O
sjs	I-Problem
/	I-Problem
ten	I-Problem
,	I-Problem
a	I-Problem
severe	I-Problem
life	I-Problem
-	I-Problem
threatening	I-Problem
illness	I-Problem
,	O
emphasizes	O
the	O
need	O
for	O
judicious	O
use	O
of	O
tmp	O
-	O
sx	O
and	O
close	O
monitoring	I-Test
and	O
follow	O
-	O
up	O
for	O
patients	I-Background
who	O
were	O
given	O
tmp	I-Treatment
-	I-Treatment
sx	I-Treatment
for	O
sstis	I-Problem
.	O

a	O
case	O
history	O
of	O
a	I-Background
15	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
who	O
developed	O
incapacitating	I-Problem
tardive	I-Problem
dyskinesia	I-Problem
that	O
resolved	O
during	O
treatment	O
with	O
deanol	I-Treatment
is	O
presented	O
.	O

drug	I-Treatment
-	O
induced	O
mammary	I-Problem
hyperplasias	I-Problem
have	O
been	O
reported	O
as	O
rare	O
complications	O
of	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
and	I-Treatment
neothetazone	I-Treatment
.	O

the	O
purpose	O
of	O
this	O
report	O
is	O
to	O
document	O
a	O
new	O
case	O
of	O
in	O
utero	O
cp	I-Treatment
exposure	O
with	O
multiple	I-Problem
congenital	I-Problem
anomalies	I-Problem
and	O
to	O
establish	O
an	O
apparent	O
cp	I-Problem
embryopathy	I-Problem
phenotype	O
.	O

aim	O
:	O
the	O
aim	O
of	O
this	O
article	O
is	O
to	O
present	O
the	O
clinical	O
characteristics	O
and	O
management	O
of	O
an	O
oral	O
adverse	I-Problem
effect	I-Problem
stemming	O
from	O
the	O
use	O
of	O
the	O
antiretroviral	I-Treatment
medication	I-Treatment
nevirapine	I-Treatment
(	I-Treatment
nvp	I-Treatment
)	I-Treatment
.	O

a	I-Background
27	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
who	I-Background
had	I-Background
a	I-Background
history	I-Background
of	I-Background
bronchial	I-Problem
asthma	I-Problem
,	I-Background
eosinophilic	I-Problem
enteritis	I-Problem
,	I-Background
and	I-Background
eosinophilic	I-Problem
pneumonia	I-Problem
presented	O
with	O
fever	I-Problem
,	I-Problem
skin	I-Problem
eruptions	I-Problem
,	I-Problem
cervical	I-Problem
lymphadenopathy	I-Problem
,	I-Problem
hepatosplenomegaly	I-Problem
,	I-Problem
atypical	I-Problem
lymphocytosis	I-Problem
,	I-Problem
and	I-Problem
eosinophilia	I-Problem
two	I-Other
weeks	I-Other
after	I-Other
receiving	O
trimethoprim	I-Treatment
(	I-Treatment
tmp	I-Treatment
)	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
(	I-Treatment
smx	I-Treatment
)	I-Treatment
treatment	O
.	O

treatment	I-Treatment
with	I-Treatment
infliximab	I-Treatment
is	O
known	O
to	O
produce	O
an	O
increase	I-Problem
of	I-Problem
autoantibodies	I-Problem
(	I-Problem
antinuclear	I-Problem
antibodies	I-Problem
,	I-Problem
anti	I-Problem
-	I-Problem
double	I-Problem
-	I-Problem
stranded	I-Problem
dna	I-Test
)	I-Problem
,	I-Problem
but	I-Problem
not	I-Problem
clinical	I-Problem
disease	I-Problem
.	O

serotonin	I-Problem
syndrome	I-Problem
,	I-Problem
which	O
occurs	O
as	O
a	O
result	O
of	O
enhanced	O
serotonin	O
concentration	O
in	O
the	O
central	O
nervous	O
system	O
,	O
is	O
a	O
well	O
-	O
known	O
adverse	O
effect	O
of	O
serotonin	I-Treatment
-	I-Treatment
active	I-Treatment
medications	I-Treatment
.	O

despite	O
the	O
risk	O
of	O
needle	O
-	O
track	O
seeding	O
,	O
pei	I-Treatment
remains	O
useful	O
in	O
the	O
treatment	O
of	O
hcc	I-Problem
.	O

trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
-	O
induced	O
hepatotoxicity	I-Problem
in	O
a	I-Background
pediatric	I-Background
patient	I-Background
.	O

imidazoline	I-Treatment
intoxication	I-Problem
in	O
children	I-Background
.	O

concomitant	O
administration	O
of	O
cytarabine	I-Treatment
might	O
have	O
affected	O
his	O
liver	I-Problem
function	I-Problem
and	O
there	O
might	O
have	O
been	O
interaction	O
between	O
the	O
drugs	O
.	O

the	O
probability	O
of	O
developing	O
acute	I-Problem
leukemia	I-Problem
in	O
this	O
study	I-Test
was	O
not	O
significantly	O
correlated	O
to	O
the	I-Treatment
total	I-Treatment
cumulative	I-Treatment
dosage	I-Treatment
of	I-Treatment
treosulfan	I-Treatment
.	O

intraventricular	I-Treatment
vancomycin	I-Treatment
-	O
induced	O
cerebrospinal	I-Problem
fluid	I-Problem
eosinophilia	I-Problem
:	O
report	O
of	O
two	O
patients	I-Background
.	I-Background

this	O
case	O
supports	O
the	O
view	O
that	O
in	I-Problem
gold	I-Treatment
-	I-Problem
induced	I-Problem
pneumonitis	I-Problem
a	I-Treatment
prolonged	I-Treatment
treatment	I-Treatment
with	I-Treatment
corticosteroids	I-Treatment
may	O
be	O
necessary	O
,	O
as	O
lung	O
function	O
continued	O
to	O
improve	O
.	O

massive	I-Problem
plasmocytosis	I-Problem
due	O
to	O
methimazole	I-Treatment
-	O
induced	O
bone	I-Problem
marrow	I-Problem
toxicity	I-Problem
.	O

a	O
reversible	I-Problem
toxic	I-Problem
liver	I-Problem
damage	I-Problem
was	O
observed	O
in	O
a	I-Background
non	I-Problem
-	I-Problem
alcoholic	I-Problem
woman	I-Background
treated	O
with	O
disulfiram	I-Treatment
.	O

a	I-Background
60	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
chronic	I-Problem
renal	I-Problem
failure	I-Problem
developed	O
acute	I-Problem
proximal	I-Problem
muscle	I-Problem
weakness	I-Problem
after	O
receiving	O
a	O
regular	I-Treatment
dosage	I-Treatment
of	I-Treatment
colchicine	I-Treatment
.	O

the	O
cause	O
of	O
these	O
previously	O
unreported	O
side	O
effects	O
of	O
niacin	I-Treatment
therapy	O
is	O
uncertain	O
but	O
may	O
be	O
related	O
to	O
prostaglandin	I-Problem
-	I-Problem
mediated	I-Problem
vasodilatation	I-Problem
,	I-Problem
hyperalgesia	I-Problem
of	I-Problem
sensory	I-Problem
nerve	I-Problem
receptors	I-Problem
,	I-Problem
and	I-Problem
potentiation	I-Problem
of	I-Problem
inflammation	I-Problem
in	I-Problem
the	I-Problem
gingiva	I-Problem
with	I-Problem
referral	I-Problem
of	I-Problem
pain	I-Problem
to	I-Problem
the	I-Problem
teeth	I-Problem
.	O

nocardia	I-Problem
is	O
an	O
important	O
opportunistic	O
infectious	O
agent	O
in	O
immunocompromised	I-Problem
hosts	I-Background
,	O
i	O
.	O
e	O
.	O
in	O
patients	O
taking	O
corticosteroids	I-Treatment
.	O

hepatobiliary	I-Problem
disorders	I-Problem
associated	O
with	O
orally	I-Treatment
administered	I-Treatment
terbinafine	I-Treatment
have	O
rarely	O
been	O
reported	O
.	O

we	O
report	O
a	I-Background
patient	I-Background
in	O
whom	O
the	O
anti	O
-	O
depressant	O
trazodone	I-Treatment
hydrochloride	I-Treatment
(	I-Treatment
molipaxin	I-Treatment
,	I-Treatment
roussel	I-Treatment
)	I-Treatment
,	O
a	O
serotonin	O
antagonist	O
,	O
provoked	O
generalized	I-Problem
pustular	I-Problem
psoriasis	I-Problem
(	I-Problem
gpp	I-Problem
)	I-Problem
.	O

early	I-Treatment
recognition	I-Treatment
of	I-Treatment
hereditary	I-Treatment
motor	I-Treatment
and	I-Treatment
sensory	I-Treatment
neuropathy	I-Treatment
type	I-Treatment
1	I-Treatment
can	O
avoid	O
life	O
-	O
threatening	O
vincristine	O
neurotoxicity	O
.	O

probable	O
enoxaparin	I-Treatment
-	O
induced	O
hepatotoxicity	I-Problem
.	O

interstitial	I-Problem
pneumonitis	I-Problem
associated	O
with	O
sirolimus	I-Treatment
:	O
a	O
dilemma	O
for	O
lung	O
transplantation	O
.	O

he	I-Background
had	O
also	O
developed	O
elevated	I-Problem
serum	I-Problem
ammonia	I-Problem
levels	I-Problem
while	O
on	O
valproic	I-Treatment
acid	I-Treatment
.	O

cutaneous	I-Problem
rashes	I-Problem
and	I-Problem
eruptions	I-Problem
can	O
be	O
caused	O
by	O
many	O
medications	O
,	O
including	O
carbamazepine	I-Treatment
.	O

in	O
this	O
case	O
,	O
the	I-Problem
increase	I-Problem
in	I-Problem
the	I-Problem
inr	I-Test
value	I-Test
with	I-Problem
associated	I-Problem
bruising	I-Problem
after	O
the	O
addition	O
of	O
amoxycillin	I-Treatment
suggests	O
a	O
drug	O
interaction	O
between	O
acenocoumarol	I-Treatment
and	O
amoxycillin	I-Treatment
,	O
other	O
possible	O
causes	O
having	O
been	O
eliminated	O
.	O

oncologists	O
supervising	O
future	O
clinical	O
trials	O
for	O
lung	I-Problem
cancer	I-Problem
should	O
be	O
alert	O
to	O
the	O
fact	O
that	O
sorafenib	I-Treatment
can	O
potentially	O
induce	O
serious	I-Problem
interstitial	I-Problem
lung	I-Problem
disease	I-Problem
,	O
although	O
this	O
might	O
depend	O
on	O
racial	O
differences	O
.	O

summary	O
:	O
a	I-Background
26	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
bipolar	I-Problem
disorder	I-Problem
,	I-Background
seizures	I-Problem
,	I-Background
and	I-Background
mild	I-Problem
mental	I-Problem
retardation	I-Problem
secondary	I-Problem
to	I-Problem
a	I-Problem
traumatic	I-Problem
brain	I-Problem
injury	I-Problem
began	O
treatment	O
with	O
carbamazepine	I-Treatment
for	O
aggression	I-Problem
and	O
seizure	I-Problem
control	O
.	O

serotonin	I-Problem
toxicity	I-Problem
precipitated	O
by	O
fentanyl	I-Treatment
is	O
unusual	O
and	O
has	O
not	O
previously	O
been	O
described	O
in	O
combination	O
with	O
ssris	I-Treatment
in	O
the	O
perioperative	O
setting	O
.	O

it	O
may	O
cause	O
a	I-Problem
severe	I-Problem
adverse	I-Problem
drug	I-Problem
reaction	I-Problem
with	O
multiorgan	O
involvement	O
known	O
as	O
dapsone	I-Treatment
hypersensitivity	I-Problem
syndrome	I-Problem
.	O

visual	I-Problem
system	I-Problem
side	I-Problem
effects	I-Problem
caused	I-Problem
by	I-Problem
parasympathetic	I-Problem
dysfunction	I-Problem
after	O
botulinum	I-Treatment
toxin	I-Treatment
type	I-Treatment
b	I-Treatment
injections	I-Treatment
.	O

renal	I-Problem
failure	I-Problem
associated	O
with	O
acetazolamide	I-Treatment
therapy	I-Treatment
for	O
glaucoma	I-Problem
.	O

acute	I-Problem
onset	I-Problem
of	I-Problem
nephrotic	I-Problem
syndrome	I-Problem
during	O
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
retreatment	I-Treatment
for	O
chronic	I-Problem
active	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

a	I-Background
16	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
developed	O
fever	I-Problem
,	I-Problem
generalized	I-Problem
rigidity	I-Problem
,	I-Problem
leukocytosis	I-Problem
,	I-Problem
and	I-Problem
increased	I-Problem
serum	I-Problem
transaminase	I-Problem
and	I-Problem
creatine	I-Problem
kinase	I-Problem
levels	I-Problem
while	O
receiving	O
treatment	O
with	O
olanzapine	I-Treatment
and	I-Treatment
lithium	I-Treatment
.	O

the	O
hyperpigmentation	I-Problem
was	I-Problem
diffuse	I-Problem
scattered	I-Problem
,	I-Problem
flagellate	I-Problem
like	I-Problem
and	I-Problem
linear	I-Problem
streaking	I-Problem
which	O
was	O
thought	O
to	O
be	O
mainly	O
related	O
to	O
the	O
skin	O
toxicity	O
of	O
bleomycin	I-Treatment
.	O

exacerbation	O
of	O
5	I-Treatment
-	I-Treatment
fu	I-Treatment
dermatologic	I-Problem
toxicities	I-Problem
in	O
patients	O
with	O
preexisting	O
conditions	O
suggests	O
the	O
importance	O
of	O
aggressive	O
ocular	O
prophylaxis	O
,	O
using	O
frequent	O
ocular	O
lubrication	O
and	O
topical	O
steroid	O
preparations	O
with	O
concurrent	O
medical	O
management	O
of	O
pre	O
-	O
existing	O
dermatologic	O
conditions	O
.	O

bowel	I-Problem
perforation	I-Problem
associated	O
with	O
intraperitoneal	I-Treatment
chromic	I-Treatment
phosphate	I-Treatment
instillation	I-Treatment
.	O

a	I-Background
62	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
who	I-Background
was	I-Background
being	I-Background
treated	I-Background
for	I-Background
squamous	I-Problem
cell	I-Problem
carcinoma	I-Problem
of	I-Problem
the	I-Problem
head	I-Problem
and	I-Problem
neck	I-Problem
developed	O
a	I-Problem
chemotherapy	I-Problem
-	I-Problem
related	I-Problem
hemolytic	I-Problem
-	I-Problem
uremic	I-Problem
syndrome	I-Problem
during	O
the	I-Treatment
second	I-Treatment
cycle	I-Treatment
of	I-Treatment
neoadjuvant	I-Treatment
chemotherapy	I-Treatment
consisting	I-Treatment
of	I-Treatment
cisplatin	I-Treatment
,	I-Treatment
bleomycin	I-Treatment
,	I-Treatment
and	I-Treatment
methotrexate	I-Treatment
.	O

these	O
data	O
confirm	O
the	O
therapeutic	O
value	O
of	O
arsenic	I-Treatment
trioxide	I-Treatment
in	O
relapsed	I-Problem
/	I-Problem
resistant	I-Problem
apl	I-Problem
.	O

avascular	I-Problem
necrosis	I-Problem
of	I-Problem
the	I-Problem
femoral	I-Problem
head	I-Problem
in	O
patients	I-Background
with	I-Background
prostate	I-Problem
cancer	I-Problem
treated	O
with	O
cyproterone	I-Treatment
acetate	I-Treatment
and	I-Treatment
radiotherapy	I-Treatment
.	O

ectropion	I-Problem
secondary	O
to	O
bolus	I-Treatment
injection	I-Treatment
of	I-Treatment
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
.	O

metoclopramide	I-Treatment
-	O
induced	O
parkinsonism	I-Problem
is	O
not	O
rare	O
,	O
and	O
appropriate	O
dose	O
reduction	O
in	O
patients	I-Background
with	I-Background
renal	I-Problem
failure	I-Problem
will	O
help	O
reduce	O
the	O
incidence	O
of	O
this	O
morbidity	O
.	O

posterior	I-Problem
reversible	I-Problem
encephalopathy	I-Problem
syndrome	I-Problem
associated	O
with	O
methotrexate	I-Treatment
neurotoxicity	I-Treatment
:	O
conventional	O
magnetic	I-Test
resonance	I-Test
and	O
diffusion	O
-	I-Test
weighted	I-Test
imaging	I-Test
findings	O
.	O

a	I-Background
6	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
(	I-Background
weight	I-Background
:	I-Background
16	I-Background
kg	I-Background
,	I-Background
at	I-Background
the	I-Background
start	I-Background
of	I-Background
treatment	I-Background
)	I-Background
began	O
sodium	I-Treatment
valproate	I-Treatment
(	I-Treatment
valproate	I-Treatment
syrup	I-Treatment
5	I-Treatment
%	I-Treatment
)	I-Treatment
treatment	O
for	O
epilepsy	I-Problem
in	O
february	O
2012	O
.	O

pharmacokinetic	O
determinants	O
of	O
6	I-Treatment
-	I-Treatment
mercaptopurine	I-Treatment
myelotoxicity	I-Problem
and	I-Problem
therapeutic	I-Problem
failure	I-Problem
in	O
children	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
.	O

we	O
report	O
the	O
case	O
histories	O
of	O
identical	I-Background
twin	I-Background
brothers	I-Background
who	O
developed	O
concordant	O
acute	O
lymphoblastic	O
leukemia	O
at	O
the	O
age	O
of	O
4	O
years	O
and	O
who	O
later	O
developed	O
leukoencephalopathy	I-Problem
and	I-Problem
hydrocephalus	I-Problem
related	O
to	O
central	O
nervous	O
system	O
prophylaxis	O
by	O
,	O
in	O
the	O
first	O
case	O
intrathecally	I-Treatment
administered	I-Treatment
methotrexate	I-Treatment
and	O
,	O
in	O
the	O
second	O
by	O
intrathecally	I-Treatment
administered	I-Treatment
methotrexate	I-Treatment
and	I-Treatment
cranial	I-Treatment
irradiation	I-Treatment
.	O

considering	O
the	O
increasing	O
use	O
of	O
tmz	I-Treatment
,	O
which	O
is	O
regarded	O
as	O
a	O
drug	O
with	O
moderate	I-Problem
toxicity	I-Problem
,	O
careful	O
follow	O
-	O
up	O
with	O
routine	O
blood	I-Test
testing	I-Test
is	O
vital	O
.	O

to	O
report	O
a	I-Background
case	I-Background
of	O
serotonin	I-Problem
syndrome	I-Problem
associated	O
with	O
interaction	I-Treatment
between	I-Treatment
fentanyl	I-Treatment
and	I-Treatment
citalopram	I-Treatment
,	O
as	O
evidenced	O
by	O
medication	O
history	O
,	O
clinical	O
features	O
and	O
reversal	O
following	O
discontinuation	O
of	O
fentanyl	O
.	O

we	O
report	O
a	O
case	O
of	O
ibuprofen	I-Treatment
-	O
induced	O
meningitis	I-Problem
in	O
an	I-Background
otherwise	I-Background
healthy	I-Background
individual	I-Background
.	O

the	O
reported	O
cases	O
of	O
in	I-Treatment
utero	I-Treatment
exposure	I-Treatment
to	I-Treatment
cyclosposphamide	I-Treatment
shared	O
the	O
following	O
manifestations	O
with	O
our	O
patient	I-Background
:	O
growth	I-Problem
deficiency	I-Problem
,	I-Problem
developmental	I-Problem
delay	I-Problem
,	I-Problem
craniosynostosis	I-Problem
,	I-Problem
blepharophimosis	I-Problem
,	I-Problem
flat	I-Problem
nasal	I-Problem
bridge	I-Problem
,	I-Problem
abnormal	I-Problem
ears	I-Problem
,	I-Problem
and	I-Problem
distal	I-Problem
limb	I-Problem
defects	I-Problem
including	I-Problem
hypoplastic	I-Problem
thumbs	I-Problem
and	I-Problem
oligodactyly	I-Problem
.	O

l	I-Treatment
-	I-Treatment
thyroxine	I-Treatment
-	O
induced	O
leukopenia	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
hashimoto	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
:	O
involvement	O
of	O
suppressor	O
-	O
cytotoxic	O
t	O
cells	O
.	O

carbamazepine	I-Treatment
-	O
induced	O
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
-	I-Problem
like	I-Problem
disease	I-Problem
.	O

conclusions	O
:	O
this	O
case	O
describes	O
the	O
clinically	O
significant	O
increase	I-Problem
of	I-Problem
inr	I-Problem
in	O
an	I-Background
elderly	I-Background
patient	I-Background
after	O
adding	O
a	O
chemotherapy	O
regimen	O
of	O
levamisole	I-Treatment
and	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
to	O
a	O
previous	O
regimen	O
of	O
warfarin	I-Treatment
alone	O
.	O

these	O
results	O
suggest	O
that	O
the	O
hepatoxicity	I-Problem
of	O
ethanol	O
in	O
alcoholic	I-Treatment
beverages	O
is	O
enhanced	O
by	O
interaction	O
with	O
its	O
congeners	O
and	O
acetaldehyde	O
;	O
they	O
also	O
suggest	O
that	O
alcoholic	O
beverages	O
are	O
not	O
equivalent	O
in	O
their	O
potential	O
to	O
cause	O
liver	O
damage	O
.	O

the	O
dermatology	O
literature	O
heretofore	O
has	O
not	O
noted	O
that	O
anemia	I-Problem
is	O
a	O
side	O
effect	O
of	O
patients	I-Background
taking	O
mmf	I-Treatment
to	O
treat	O
pemphigus	I-Problem
.	O

the	O
9	O
other	O
reported	O
cases	O
of	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
induced	O
rapidly	I-Problem
progressive	I-Problem
glomerulonephritis	I-Problem
have	O
been	O
reviewed	O
.	O

we	O
describe	O
a	I-Background
heroin	I-Problem
abuser	I-Problem
in	O
whom	O
clinical	O
and	O
laboratory	O
manifestations	O
of	O
acute	I-Problem
hepatitis	I-Problem
b	I-Problem
and	I-Problem
c	I-Problem
appeared	O
a	O
few	O
days	O
after	O
the	O
insertion	O
of	O
a	O
subcutaneous	I-Treatment
naltrexone	I-Treatment
implant	I-Treatment
.	O

ciprofloxacin	I-Treatment
-	O
induced	O
psychosis	I-Problem
.	O

thalidomide	I-Treatment
was	O
withdrawn	O
from	O
world	O
markets	O
in	O
1961	O
following	O
recognition	O
of	O
its	O
teratogenic	I-Problem
effects	I-Problem
.	O

weekly	I-Other
auc2	I-Treatment
carboplatin	I-Treatment
in	O
acquired	O
platinum	I-Problem
-	I-Problem
resistant	I-Problem
ovarian	I-Problem
cancer	I-Problem
with	I-Treatment
or	I-Treatment
without	I-Treatment
oral	I-Treatment
phenoxodiol	I-Treatment
,	O
a	O
sensitizer	O
of	O
platinum	O
cytotoxicity	O
:	O
the	O
phase	I-Test
iii	I-Test
ovature	I-Test
multicenter	I-Test
randomized	I-Test
study	I-Test
.	O

we	O
suggest	O
the	O
use	O
of	O
esmolol	I-Treatment
for	O
treatment	O
of	O
dysrhythmias	I-Problem
secondary	O
to	O
caffeine	I-Treatment
toxicity	O
;	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
use	O
of	O
esmolol	I-Treatment
has	O
not	O
been	O
reported	O
for	O
this	O
purpose	O
.	O

to	O
date	O
,	O
there	O
have	O
been	O
few	O
reports	O
of	O
visual	I-Problem
disturbances	I-Problem
associated	O
with	O
btx	I-Treatment
-	I-Treatment
b	I-Treatment
use	O
.	O

our	O
objective	O
is	O
to	O
present	O
a	O
retrospective	I-Test
analysis	I-Test
of	O
the	O
dwi	I-Test
findings	I-Test
in	O
four	O
patients	I-Background
who	O
suffered	O
subacute	I-Problem
neurotoxicity	I-Problem
after	O
intrathecal	I-Treatment
mtx	I-Test
.	O

we	O
report	O
a	O
case	O
of	O
st	I-Problem
elevation	I-Problem
in	I-Problem
right	I-Problem
precordial	I-Problem
leads	I-Problem
compatible	I-Problem
with	I-Problem
type	I-Problem
1	I-Problem
brugada	I-Problem
syndrome	I-Problem
following	O
administration	I-Treatment
of	I-Treatment
propafenone	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
wolff	I-Problem
-	I-Problem
parkinson	I-Problem
-	I-Problem
white	I-Problem
syndrome	I-Problem
who	O
was	O
receiving	I-Treatment
lithium	I-Treatment
at	I-Treatment
concentrations	I-Treatment
within	I-Treatment
therapeutic	I-Treatment
levels	I-Treatment
.	O

the	O
spectrum	O
of	O
cutaneous	I-Problem
eruptions	I-Problem
associated	O
with	O
dihydropyridines	I-Treatment
is	O
extensive	O
,	O
varying	O
from	O
exanthemas	I-Problem
to	O
severe	O
adverse	O
events	O
.	O

polymyositis	I-Problem
after	O
propylthiouracil	I-Treatment
treatment	O
for	O
hyperthyroidism	I-Problem
.	O

methamphetamine	I-Treatment
'	I-Treatment
s	I-Treatment
extensive	O
physiologic	O
effects	O
,	O
inconsistent	O
street	O
purity	O
,	O
and	O
multiple	O
routes	O
of	O
administration	O
offer	O
many	O
possibilities	O
for	O
injury	I-Problem
to	I-Problem
the	I-Problem
cornea	I-Problem
.	O

since	O
ethambutol	I-Treatment
is	O
actively	O
excreted	O
via	O
the	O
renal	O
system	O
,	O
compromise	O
of	O
renal	O
function	O
such	O
as	O
due	O
to	O
renal	O
tuberculosis	O
may	O
lead	O
to	O
serum	I-Problem
concentration	I-Problem
elevations	I-Problem
of	I-Problem
ethambutol	I-Problem
sufficient	I-Problem
to	I-Problem
produce	I-Problem
optic	I-Problem
neuropathy	I-Problem
.	O

renal	I-Problem
failure	I-Problem
appeared	O
8	I-Other
to	I-Other
17	I-Other
days	I-Other
after	O
beginning	O
gentamicin	I-Treatment
therapy	I-Treatment
and	O
was	O
characterized	O
by	O
creatinine	I-Problem
clearances	I-Test
4	I-Problem
to	I-Problem
10	I-Problem
ml	I-Problem
/	I-Problem
min	I-Problem
,	I-Problem
urine	I-Problem
to	I-Test
plasma	I-Test
creatinine	I-Test
ratios	I-Test
less	I-Problem
than	I-Problem
20	I-Problem
,	I-Problem
urinary	I-Problem
sodium	I-Test
concentrations	I-Test
16	I-Problem
to	I-Problem
60	I-Problem
meq	I-Problem
/	I-Problem
liter	I-Problem
,	I-Problem
proteinuria	I-Problem
,	I-Problem
and	I-Problem
cylindruria	I-Problem
.	O

seizures	I-Problem
associated	O
with	O
ofloxacin	I-Treatment
therapy	O
.	O

cutaneous	I-Problem
seeding	I-Problem
after	O
ultrasound	I-Treatment
-	I-Treatment
guided	I-Treatment
percutaneous	I-Treatment
ethanol	I-Treatment
injection	I-Treatment
for	O
treatment	O
of	O
hepatocellular	I-Problem
carcinoma	I-Problem
.	O

two	O
patients	I-Background
who	O
developed	O
decreased	I-Problem
visual	I-Problem
acuity	I-Problem
after	O
several	O
months	O
of	O
ethambutol	I-Treatment
treatment	O
for	O
mycobacterium	I-Problem
avium	I-Problem
-	I-Problem
intracellulare	I-Problem
infection	I-Problem
had	O
bitemporal	I-Problem
visual	I-Problem
field	I-Problem
defects	I-Problem
that	O
suggested	O
optic	I-Problem
chiasm	I-Problem
damage	I-Problem
.	O

conclusions	O
:	O
metoclopramide	I-Treatment
may	O
cause	O
reversible	I-Problem
nonthrombocytopenic	I-Problem
vascular	I-Problem
-	I-Problem
type	I-Problem
palpable	I-Problem
purpura	I-Problem
.	O

conclusions	O
:	O
life	O
-	O
threatening	O
adrenal	O
suppression	O
,	O
requiring	O
hydrocortisone	I-Treatment
supplementation	I-Treatment
and	I-Treatment
intensive	I-Treatment
therapy	I-Treatment
,	O
was	O
observed	O
and	O
successfully	I-Problem
treated	I-Problem
in	O
a	I-Background
newborn	I-Background
,	I-Background
whose	I-Background
mother	I-Background
had	I-Background
received	I-Background
high	I-Background
-	I-Background
dose	I-Background
methylprednisolone	I-Background
in	I-Background
late	I-Background
pregnancy	I-Background
.	O

a	O
case	O
of	O
extrapyramidal	I-Problem
symptoms	I-Problem
(	I-Problem
eps	I-Problem
)	I-Problem
following	O
administration	O
of	O
aripiprazole	I-Treatment
to	O
a	I-Background
man	I-Background
with	I-Background
developmental	I-Problem
disabilities	I-Problem
who	I-Background
had	I-Background
never	I-Background
received	I-Background
antipsychotic	I-Background
medications	I-Background
and	I-Background
had	I-Background
no	I-Background
history	I-Background
of	I-Background
movement	I-Background
disorders	I-Background
is	I-Background
presented	I-Background
.	O

although	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
has	O
been	O
shown	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
primary	I-Problem
osteogenic	I-Problem
sarcoma	I-Problem
,	O
the	O
tumoricidal	O
effects	O
of	O
therapy	O
appear	O
to	O
have	O
caused	O
a	I-Problem
fatal	I-Problem
rise	I-Problem
in	I-Problem
intracranial	I-Problem
pressure	I-Problem
.	O

this	O
case	O
had	O
radiation	O
fibrosis	O
,	O
so	O
we	O
suggest	O
that	O
radiation	O
fibrosis	O
may	O
be	O
another	O
contributor	O
of	O
the	O
occurrence	I-Problem
of	I-Problem
ild	I-Problem
in	O
patients	I-Background
taking	I-Treatment
erlotinib	I-Treatment
.	O

lithium	I-Treatment
-	O
associated	O
transient	I-Problem
thyrotoxicosis	I-Problem
in	O
4	O
chinese	I-Background
women	I-Background
with	I-Background
autoimmune	I-Problem
thyroiditis	I-Problem
.	O

a	I-Background
patient	I-Background
,	O
while	O
on	O
intravenous	I-Treatment
ritodrine	I-Treatment
therapy	I-Treatment
for	O
preterm	O
labor	O
,	O
experienced	O
an	I-Problem
episode	I-Problem
of	I-Problem
acute	I-Problem
chest	I-Problem
pain	I-Problem
.	O

subsequent	O
in	I-Test
vivo	I-Test
/	I-Test
vitro	I-Test
studies	I-Test
clearly	O
demonstrated	O
that	O
the	O
neurological	I-Problem
effects	I-Problem
were	O
due	O
to	O
a	O
synergistic	O
action	O
of	O
desferrioxamine	I-Treatment
and	I-Treatment
prochlorperazine	I-Treatment
,	O
probably	O
resulting	O
in	O
exceptional	O
fluxes	O
of	O
intra	O
/	O
extra	O
cellular	O
iron	O
/	O
copper	O
disturbing	O
noradrenergic	O
and	O
serotonergic	O
systems	O
.	O

favorable	O
outcome	O
of	O
de	O
novo	O
hepatitis	I-Problem
b	I-Problem
infection	I-Problem
after	I-Treatment
liver	I-Treatment
transplantation	I-Treatment
with	I-Treatment
lamivudine	I-Treatment
and	I-Treatment
adefovir	I-Treatment
therapy	I-Treatment
.	O

pemphigus	I-Problem
foliaceus	I-Problem
was	O
seen	O
in	O
a	I-Background
patient	I-Background
with	I-Background
pulmonary	I-Problem
tuberculosis	I-Problem
during	O
rifampicin	I-Treatment
therapy	O
.	O

conclusions	O
:	O
clinicians	O
should	O
be	O
aware	O
of	O
a	O
risk	O
of	O
serotonin	I-Problem
syndrome	I-Problem
with	I-Problem
serious	I-Problem
extrapyramidal	I-Problem
reactions	I-Problem
in	O
patients	I-Background
receiving	O
sertraline	I-Treatment
or	I-Treatment
venlafaxine	I-Treatment
when	I-Treatment
metoclopramide	I-Treatment
is	I-Treatment
coadministered	I-Treatment
even	I-Treatment
in	I-Treatment
a	I-Treatment
single	I-Treatment
,	I-Treatment
conventional	I-Treatment
dose	I-Treatment
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
patient	I-Background
who	O
developed	O
polyserositis	I-Problem
(	I-Problem
pericardial	I-Problem
effusion	I-Problem
,	I-Problem
pleural	I-Problem
effusion	I-Problem
,	I-Problem
and	I-Problem
pericarditis	I-Problem
)	I-Problem
after	O
being	O
started	I-Treatment
on	I-Treatment
clozapine	I-Treatment
,	O
and	O
whose	O
symptoms	O
remitted	O
upon	O
discontinuation	O
of	O
clozapine	O
.	O

three	I-Other
years	I-Other
later	I-Other
,	O
treatment	O
with	O
ampicillin	I-Treatment
caused	O
another	O
episode	O
of	O
cholestatic	I-Problem
hepatitis	I-Problem
with	I-Problem
cholestasis	I-Problem
and	I-Problem
duct	I-Problem
paucity	I-Problem
on	I-Problem
rebiopsy	I-Problem
.	O

methods	O
:	O
a	I-Background
patient	I-Background
who	O
developed	O
dramatic	O
,	O
permanent	I-Problem
vision	I-Problem
loss	I-Problem
after	O
a	O
9	I-Other
-	I-Other
month	I-Other
course	I-Treatment
of	I-Treatment
treatment	I-Treatment
with	I-Treatment
ethambutol	I-Treatment
and	I-Treatment
isoniazid	I-Treatment
for	O
pulmonary	I-Problem
tuberculosis	I-Problem
is	O
presented	O
.	O

the	O
authors	O
report	O
a	O
case	O
of	O
urinary	I-Problem
incontinence	I-Problem
(	I-Problem
ui	I-Problem
)	I-Problem
that	O
occurred	O
in	O
a	I-Background
woman	I-Background
after	O
administration	O
of	O
venlafaxine	I-Treatment
.	O

the	O
possibility	O
can	O
be	O
raised	O
that	O
m	I-Treatment
-	I-Treatment
csf	I-Treatment
accelerated	O
the	O
underlying	I-Problem
renal	I-Problem
disease	I-Problem
in	I-Problem
this	I-Problem
case	I-Problem
through	I-Problem
enhancing	I-Problem
macrophage	I-Problem
accumulation	I-Problem
into	I-Problem
the	I-Problem
glomerulus	I-Problem
,	I-Problem
leading	I-Problem
to	I-Problem
the	I-Problem
development	I-Problem
of	I-Problem
nephrotic	I-Problem
syndrome	I-Problem
.	O

we	O
describe	O
two	O
elbw	I-Problem
infants	I-Background
affected	I-Background
by	I-Background
hyperkalaemia	I-Problem
,	O
treated	O
with	O
kayexalate	I-Treatment
,	O
who	O
developed	O
serious	I-Problem
hypernatraemia	I-Problem
,	O
that	O
has	O
never	O
been	O
reported	O
before	O
in	O
preterm	O
infants	O
.	O

discussion	O
:	O
electrolyte	I-Problem
disorders	I-Problem
associated	O
with	O
foscarnet	I-Treatment
are	O
reviewed	O
.	O

we	O
report	O
two	O
cases	I-Background
that	O
developed	O
acute	I-Problem
myeloid	I-Problem
leukaemia	I-Problem
(	I-Problem
aml	I-Problem
)	I-Problem
during	O
tamoxifen	I-Treatment
therapy	I-Treatment
for	I-Treatment
breast	I-Problem
cancer	I-Problem
.	O

our	O
patient	O
was	O
a	I-Background
72	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
advanced	I-Problem
parkinson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
(	I-Problem
pd	I-Problem
)	I-Problem
who	O
received	O
levodopa	I-Treatment
and	I-Treatment
anti	I-Treatment
-	I-Treatment
cholinergic	I-Treatment
drugs	I-Treatment
and	O
whose	O
head	O
had	O
become	O
almost	O
completely	I-Problem
bald	I-Problem
.	O

the	O
patient	O
experienced	O
hallucinations	I-Problem
,	I-Problem
agitation	I-Problem
,	I-Problem
vomiting	I-Problem
,	I-Problem
tachycardia	I-Problem
and	I-Problem
seizures	I-Problem
after	O
ingestion	I-Treatment
of	I-Treatment
1050	I-Treatment
(	I-Treatment
48	I-Treatment
mg	I-Treatment
/	I-Treatment
kg	I-Treatment
)	I-Treatment
of	I-Treatment
extended	I-Treatment
-	I-Treatment
release	I-Treatment
bupropion	I-Treatment
.	O

this	O
case	O
report	O
describes	O
a	O
38	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
in	O
whom	O
siadh	I-Problem
was	O
strongly	O
suspected	O
secondary	O
to	O
tegretol	I-Treatment
therapy	O
to	O
control	O
a	I-Background
seizure	I-Problem
disorder	I-Background
.	O

however	O
,	O
cyclosporine	I-Treatment
dependency	I-Treatment
is	O
associated	O
with	O
the	O
risk	O
of	O
nephrotoxicity	I-Problem
.	O

the	O
observations	I-Test
suggest	O
that	O
testicular	I-Problem
swelling	I-Problem
and	I-Problem
pain	I-Problem
are	O
side	O
effects	O
of	O
desipramine	I-Treatment
.	O

method	O
:	O
we	O
describe	O
three	O
case	O
-	O
reports	O
concerning	O
haematological	I-Problem
adverse	I-Problem
effects	I-Problem
of	O
quetiapine	I-Treatment
.	O

typically	O
,	O
drug	I-Problem
-	I-Problem
induced	I-Problem
neutropenia	I-Problem
occurs	O
in	O
a	I-Background
patient	I-Background
receiving	O
a	I-Treatment
semisynthetic	I-Treatment
penicillin	I-Treatment
for	I-Treatment
two	I-Other
weeks	I-Other
or	I-Treatment
more	I-Treatment
.	O

peripheral	I-Problem
nerve	I-Problem
dysfunction	I-Problem
is	O
a	O
potentially	O
serious	O
complication	O
of	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
.	O

tumor	I-Problem
-	I-Problem
volume	I-Problem
increase	I-Problem
at	O
beginning	I-Other
of	O
primary	I-Treatment
treatment	I-Treatment
with	I-Treatment
topical	I-Treatment
interferon	I-Treatment
alpha	I-Test
2	I-Treatment
-	I-Treatment
beta	I-Treatment
in	O
a	I-Background
case	I-Background
of	I-Background
conjunctiva	I-Problem
-	I-Problem
cornea	I-Problem
intraepithelial	I-Problem
neoplasia	I-Problem
.	O

l	I-Treatment
-	I-Treatment
asparaginase	I-Treatment
-	O
induced	O
posterior	I-Problem
reversible	I-Problem
encephalopathy	I-Problem
syndrome	I-Problem
during	O
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
treatment	O
in	O
children	I-Background
.	O

on	O
the	O
other	O
hand	O
,	O
mtx	I-Treatment
-	O
induced	O
pneumonitis	I-Problem
seems	O
to	O
be	O
very	O
rare	O
in	O
psoriatic	O
arthritis	O
(	O
psa	O
)	O
.	O

ototoxicity	I-Problem
as	O
a	O
result	O
of	O
cis	I-Treatment
-	I-Treatment
platinum	I-Treatment
administration	I-Treatment
is	O
well	O
documented	O
.	O

massive	I-Problem
subfascial	I-Problem
hematoma	I-Problem
after	O
alteplase	I-Treatment
therapy	I-Treatment
for	O
acute	I-Problem
myocardial	I-Problem
infarction	I-Problem
.	O

we	O
suggest	O
that	O
itraconazole	I-Treatment
should	O
be	O
added	O
to	O
the	O
list	O
of	O
drugs	O
that	O
may	O
be	O
responsible	O
for	O
a	O
drug	I-Problem
-	I-Problem
induced	I-Problem
vanishing	I-Problem
bile	I-Problem
duct	I-Problem
syndrome	I-Problem
.	O

the	O
cases	O
of	O
cbz	I-Treatment
-	O
induced	O
sle	I-Problem
reported	O
in	O
the	O
literature	O
were	O
reviewed	O
.	O

ciprofloxacin	I-Treatment
-	O
induced	O
hemorrhagic	I-Problem
vasculitis	I-Problem
.	O

interpretation	O
:	O
when	O
high	I-Treatment
doses	I-Treatment
of	I-Treatment
fluticasone	I-Treatment
propionate	I-Treatment
are	O
used	O
,	O
growth	I-Problem
may	I-Problem
be	I-Problem
retarded	I-Problem
and	I-Problem
adrenal	I-Problem
suppression	I-Problem
may	O
occur	O
.	O

to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
significant	O
hypotension	I-Problem
associated	O
with	O
intravenous	I-Treatment
valproate	I-Treatment
in	O
the	O
treatment	O
of	O
status	I-Problem
epilepticus	I-Problem
in	O
the	O
pediatric	I-Background
population	I-Background
.	O

while	O
undergoing	O
treatment	O
with	O
albendazole	I-Treatment
,	O
he	I-Background
developed	O
worsening	I-Problem
diarrhea	I-Problem
with	I-Problem
abdominal	I-Problem
pain	I-Problem
and	I-Problem
fever	I-Problem
.	O

linezolid	I-Treatment
-	O
associated	O
peripheral	I-Problem
and	I-Problem
optic	I-Problem
neuropathy	I-Problem
,	I-Problem
lactic	I-Problem
acidosis	I-Problem
,	I-Problem
and	I-Problem
serotonin	I-Problem
syndrome	I-Problem
.	I-Problem

bone	I-Problem
marrow	I-Problem
aplasia	I-Problem
and	I-Problem
severe	I-Problem
skin	I-Problem
rash	I-Problem
after	O
a	I-Treatment
single	I-Treatment
low	I-Treatment
dose	I-Treatment
of	I-Treatment
methotrexate	I-Treatment
.	O

a	I-Background
woman	I-Background
38	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
,	I-Background
suffering	I-Background
for	I-Background
about	I-Background
ten	I-Background
years	I-Background
from	I-Background
multiple	I-Problem
sclerosis	I-Problem
and	O
treated	O
with	O
repeated	I-Other
therapy	I-Treatment
cycles	I-Treatment
of	I-Treatment
intrathecal	I-Treatment
depo	I-Treatment
-	I-Treatment
medrol	I-Treatment
,	O
developed	O
a	I-Problem
spastic	I-Problem
paraparesis	I-Problem
at	I-Problem
the	I-Problem
lower	I-Problem
limbs	I-Problem
.	O

the	O
efficacy	O
of	O
single	I-Treatment
-	I-Treatment
dose	I-Treatment
disulfiram	I-Treatment
as	O
an	O
inhibitor	O
of	O
human	O
p450	O
2e1	O
suggests	O
that	O
this	O
modality	O
for	O
manipulating	O
clinical	O
p450	O
2e1	O
activity	O
may	O
provide	O
a	O
useful	O
probe	O
for	O
delineating	O
p450	O
2e1	O
participation	O
in	O
human	O
drug	O
biotransformation	O
or	O
for	O
the	O
treatment	O
of	O
poisoning	I-Problem
by	O
p450	I-Treatment
2e1	I-Treatment
-	I-Treatment
activated	I-Treatment
toxins	I-Treatment
.	O

to	O
develop	O
information	O
on	O
the	O
relative	O
rarity	O
or	O
frequency	O
of	O
neurologic	O
worsening	O
with	O
the	O
initiation	O
of	O
penicillamine	O
therapy	O
,	O
we	O
conducted	O
a	O
retrospective	O
survey	O
of	O
25	O
additional	I-Background
patients	I-Background
with	I-Background
wilson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
who	O
met	O
the	O
criteria	O
of	O
presenting	O
with	O
neurologic	I-Problem
disease	I-Problem
and	O
having	O
been	O
treated	O
with	O
penicillamine	I-Treatment
.	O

the	O
authors	O
present	O
a	O
case	O
of	O
t	I-Problem
-	I-Problem
aml	I-Problem
that	O
developed	O
in	O
a	I-Background
child	I-Background
with	I-Background
metastatic	I-Problem
neuroblastoma	I-Problem
18	I-Other
months	I-Other
after	O
he	O
received	O
oral	I-Treatment
etoposide	I-Treatment
,	O
given	O
for	O
palliation	O
purpose	O
.	O

mechanisms	O
and	O
triggering	O
factors	O
of	O
hypoglycaemia	I-Problem
induced	O
by	O
mefloquine	I-Treatment
and	I-Treatment
some	I-Treatment
other	I-Treatment
anti	I-Treatment
-	I-Treatment
malarial	I-Treatment
quinine	I-Treatment
analogues	I-Treatment
are	O
discussed	O
.	O

only	O
nondepolarizing	I-Treatment
muscle	I-Treatment
relaxants	I-Treatment
should	O
be	O
used	O
in	O
patients	I-Background
who	I-Background
are	I-Background
at	I-Background
risk	I-Background
for	I-Background
mucositis	I-Problem
.	O

conclusion	O
:	O
a	O
possible	O
pharmacokinetic	O
interaction	O
between	O
dantrolene	I-Treatment
and	O
oxybutynin	I-Treatment
should	O
be	O
borne	O
in	O
mind	O
when	O
considering	O
carbamazepine	I-Treatment
medication	I-Treatment
for	O
a	I-Background
patient	I-Background
with	O
a	I-Problem
spinal	I-Problem
cord	I-Problem
lesion	I-Problem
.	O

we	O
describe	O
a	I-Background
15	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
patient	I-Background
diagnosed	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
presenting	I-Problem
with	I-Problem
status	I-Problem
epilepticus	I-Problem
after	O
receiving	I-Treatment
intrathecal	I-Treatment
methotrexate	I-Treatment
.	O

duodenal	I-Problem
ulceration	I-Problem
:	O
a	O
complication	O
of	O
tolazoline	I-Treatment
therapy	O
.	O

hepatic	I-Problem
damage	I-Problem
after	O
danazol	I-Treatment
treatment	O
.	O

hepato	I-Problem
-	I-Problem
biliary	I-Problem
abnormalities	I-Problem
secondary	O
to	O
ceftriaxone	I-Treatment
use	I-Treatment
:	O
a	O
case	O
report	O
.	O

rhabdomyolysis	I-Problem
with	O
concurrent	O
atorvastatin	I-Treatment
and	O
diltiazem	I-Treatment
.	O

case	O
report	O
:	O
mannitol	I-Treatment
nephrotoxicity	I-Problem
syndrome	O
:	O
role	O
of	O
hemodialysis	O
and	O
postulate	O
of	O
mechanisms	O
.	O

uveitis	I-Problem
during	O
treatment	O
of	O
disseminated	I-Problem
mycobacterium	I-Problem
avium	I-Problem
-	I-Problem
intracellulare	I-Problem
complex	I-Problem
infection	I-Problem
with	O
the	O
combination	I-Treatment
of	I-Treatment
rifabutin	I-Treatment
,	I-Treatment
clarithromycin	I-Treatment
and	I-Treatment
ethambutol	I-Treatment
.	O

the	O
visual	I-Problem
loss	I-Problem
in	O
this	O
patient	I-Background
seems	O
to	O
result	O
from	O
phenol	I-Treatment
neurotoxicity	I-Problem
rather	O
than	O
mechanical	O
compression	O
of	O
the	O
intraorbital	O
optic	O
nerve	O
.	O

polysomnographic	O
and	O
pharmacokinetic	O
findings	O
in	O
levodopa	I-Treatment
-	O
induced	O
augmentation	I-Problem
of	I-Problem
restless	I-Problem
legs	I-Problem
syndrome	I-Problem
.	O

these	I-Background
cases	I-Background
highlight	O
the	O
occurrence	O
of	O
livedo	I-Problem
reticularis	I-Problem
as	O
an	O
uncommon	O
side	O
-	O
effect	O
of	O
interferon	I-Treatment
alpha	I-Treatment
treatment	O
.	O

so	O
far	O
,	O
few	O
cases	O
of	O
pulmonary	I-Problem
side	I-Problem
effects	I-Problem
caused	O
by	O
ticlopidine	I-Treatment
have	O
been	O
reported	O
.	O

abnormal	I-Problem
dexamethasone	I-Test
suppression	I-Test
tests	I-Test
in	O
a	O
rifampicin	I-Treatment
-	O
treated	O
patient	I-Background
with	I-Background
suspected	I-Background
cushing	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
.	O

gemcitabine	I-Treatment
therapy	O
has	O
been	O
associated	O
with	O
radiation	I-Problem
recall	I-Problem
reactions	I-Problem
when	O
used	O
in	O
the	O
treatment	O
of	O
carcinoma	I-Problem
.	O

increased	I-Problem
lash	I-Problem
length	I-Problem
,	I-Problem
thickness	I-Problem
,	I-Problem
and	I-Problem
pigmentation	I-Problem
are	O
well	O
-	O
documented	O
side	O
effects	O
of	O
prostaglandin	I-Treatment
analog	I-Treatment
glaucoma	I-Problem
drops	I-Treatment
.	O

bullous	I-Problem
eruption	I-Problem
associated	O
with	O
dihydropyridines	I-Treatment
with	O
cross	O
reactivity	I-Test
.	O

ritonavir	I-Treatment
acted	O
as	O
a	O
cyp3a4	I-Problem
inhibitor	I-Problem
,	I-Problem
diminishing	I-Problem
carbamazepine	I-Problem
metabolism	I-Problem
and	I-Problem
provoking	I-Problem
an	I-Problem
increase	I-Problem
in	I-Problem
serum	I-Problem
levels	I-Problem
and	I-Problem
clinical	I-Problem
toxicity	I-Problem
.	O

acute	I-Problem
generalized	I-Problem
exanthematous	I-Problem
pustulosis	I-Problem
induced	O
by	O
nimesulide	I-Treatment
.	O

quinine	I-Treatment
induced	O
coagulopathy	I-Problem
-	I-Problem
-	I-Problem
a	I-Problem
near	I-Problem
fatal	I-Problem
experience	I-Problem
.	O

a	I-Background
58	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
developed	O
lichen	I-Problem
planus	I-Problem
during	I-Problem
treatment	I-Treatment
with	I-Treatment
gold	I-Treatment
.	O

atenolol	I-Treatment
-	O
induced	O
pseudolymphoma	I-Problem
.	O

first	O
case	O
report	O
of	O
suspected	O
onset	O
of	O
convulsive	I-Problem
seizures	I-Problem
due	O
to	O
co	I-Treatment
-	I-Treatment
administration	I-Treatment
of	I-Treatment
valproic	I-Treatment
acid	I-Treatment
and	I-Treatment
tebipenem	I-Treatment
.	O

fluoxetine	I-Treatment
-	O
related	O
death	I-Problem
in	O
a	O
child	I-Background
with	I-Background
cytochrome	I-Problem
p	I-Problem
-	I-Problem
450	I-Problem
2d6	I-Problem
genetic	I-Problem
deficiency	I-Problem
.	O

aplastic	I-Problem
anemia	I-Problem
and	I-Problem
agranulocytosis	I-Problem
in	O
patients	I-Background
using	O
methazolamide	I-Treatment
for	O
glaucoma	I-Problem
.	O

we	O
report	O
a	O
44	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	O
t	I-Problem
-	I-Problem
mds	I-Problem
(	I-Problem
refractory	I-Problem
anemia	I-Problem
with	I-Problem
excess	I-Problem
blasts	I-Problem
)	I-Problem
following	O
treatment	I-Treatment
of	I-Treatment
recurrent	I-Problem
anaplastic	I-Problem
astrocytoma	I-Problem
with	I-Treatment
temozolomide	I-Treatment
(	I-Treatment
tmz	I-Treatment
)	I-Treatment
.	O

an	I-Background
infant	I-Background
who	O
developed	O
pancreatitis	I-Problem
during	O
meglumine	O
antimoniate	O
treatment	O
for	O
visceral	O
leishmaniasis	O
and	O
who	O
was	O
successfully	O
treated	O
with	O
a	I-Treatment
combination	I-Treatment
of	I-Treatment
allopurinol	I-Treatment
and	I-Treatment
ketoconazole	I-Treatment
is	O
reported	O
.	O

the	O
purpose	O
of	O
this	O
study	I-Test
was	O
to	O
examine	O
the	O
incidence	O
and	O
cause	O
of	O
clostridium	I-Problem
difficile	I-Problem
colitis	I-Problem
occurring	O
after	O
cisplatin	I-Treatment
-	I-Treatment
based	I-Treatment
combination	I-Treatment
chemotherapy	I-Treatment
in	O
ovarian	I-Problem
cancer	I-Problem
patients	I-Background
.	O

cerebral	I-Problem
demyelinating	I-Problem
disease	I-Problem
developed	O
in	O
a	I-Background
patient	I-Background
during	O
adjuvant	I-Treatment
therapy	I-Treatment
with	I-Treatment
levamisole	I-Treatment
for	O
malignant	I-Problem
melanoma	I-Problem
.	O

amoxapine	I-Treatment
-	O
induced	O
cognitive	I-Problem
impairment	I-Problem
in	O
two	O
patients	I-Background
.	O

granisetron	I-Treatment
hydrochloride	I-Treatment
(	I-Treatment
3	I-Treatment
mg	I-Treatment
on	I-Other
days	I-Other
1	I-Other
,	I-Other
8	I-Other
,	I-Other
and	I-Other
15	I-Other
)	I-Treatment
and	I-Treatment
dexamethasone	I-Treatment
(	I-Treatment
13	I-Treatment
.	I-Treatment
2	I-Treatment
mg	I-Treatment
on	I-Other
day	I-Other
1	I-Other
and	I-Other
6	I-Other
.	I-Treatment
6	I-Treatment
mg	I-Treatment
on	I-Other
days	I-Other
2	I-Other
,	I-Other
3	I-Other
,	I-Other
8	I-Other
,	I-Other
and	I-Other
15	I-Other
)	I-Treatment
were	O
used	O
prior	O
to	O
irinotecan	I-Treatment
administration	O
in	O
both	I-Background
patients	I-Background
.	O

visceral	I-Problem
herpesvirus	I-Problem
infections	I-Problem
in	O
leukemic	I-Problem
patients	I-Background
receiving	O
cytarabine	I-Treatment
.	I-Treatment

although	O
a	O
few	O
case	O
reports	O
link	O
metronidazole	I-Treatment
with	O
the	O
development	O
of	O
pseudomembranous	I-Problem
colitis	I-Problem
,	O
albendazole	O
has	O
not	O
been	O
associated	O
with	O
the	O
development	O
of	O
this	O
condition	O
.	O

conclusion	O
:	O
oral	I-Problem
mucositis	I-Problem
is	O
a	O
frequent	O
and	O
potentially	O
severe	O
complication	O
of	O
cancer	I-Problem
chemotherapy	I-Treatment
.	O

one	I-Background
case	I-Background
of	O
priapism	I-Problem
occurred	O
during	I-Treatment
heparin	I-Treatment
therapy	I-Treatment
for	O
a	O
previous	O
surgical	I-Problem
operation	I-Problem
to	I-Problem
the	I-Problem
knee	I-Problem
is	O
reported	O
.	O

while	O
both	O
amiodarone	I-Treatment
and	I-Treatment
digoxin	I-Treatment
can	O
cause	O
permanent	I-Problem
visual	I-Problem
changes	I-Problem
,	O
the	O
ocular	O
effects	O
are	O
often	O
reversible	O
.	O

aim	O
:	O
report	O
of	O
a	O
case	O
of	O
a	I-Background
woman	I-Background
patient	I-Background
who	O
developed	O
celiac	I-Problem
disease	I-Problem
after	O
pegylated	I-Treatment
interferon	I-Treatment
alpha	I-Treatment
-	I-Treatment
2a	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
use	I-Treatment
for	I-Treatment
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

differential	O
diagnoses	O
included	O
ocular	O
rosacea	O
with	O
cicatrizing	O
conjunctivitis	O
and	O
5	I-Treatment
-	I-Treatment
fu	I-Treatment
-	O
induced	O
ectropion	I-Problem
.	O

in	I-Background
rare	I-Background
cases	I-Background
mitomycin	I-Treatment
c	I-Treatment
(	I-Treatment
mmc	I-Treatment
)	I-Treatment
may	O
induce	O
cancer	I-Problem
-	I-Problem
associated	I-Problem
hemolytic	I-Problem
uremic	I-Problem
syndrome	I-Problem
,	O
which	O
is	O
characterized	O
by	O
hemolytic	I-Problem
anemia	I-Problem
,	I-Problem
thrombocytopenia	I-Problem
and	I-Problem
progressive	I-Problem
renal	I-Problem
failure	I-Problem
.	O

hemolytic	I-Problem
uremic	I-Problem
syndrome	I-Problem
following	O
the	O
infusion	O
of	O
oxaliplatin	I-Treatment
:	O
case	O
report	O
.	O

tacrolimus	I-Treatment
(	I-Treatment
fk506	I-Treatment
)	I-Treatment
-	O
induced	O
mutism	I-Problem
after	O
liver	O
transplant	O
.	O

though	O
proteinuria	I-Problem
and	I-Problem
nephrotic	I-Problem
syndrome	I-Problem
is	O
a	O
rare	O
adverse	O
effect	O
of	O
ifn	I-Treatment
-	I-Treatment
beta	I-Treatment
-	I-Treatment
1b	I-Treatment
therapy	O
,	O
physicians	O
treating	O
ms	I-Problem
patients	I-Background
with	O
this	O
agent	O
should	O
pay	O
careful	O
attention	O
to	O
new	O
clinical	O
symptoms	O
and	O
laboratory	O
findings	O
.	O

it	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine	I-Treatment
-	O
induced	O
lupus	I-Problem
,	I-Problem
which	I-Problem
manifested	I-Problem
with	I-Problem
serositis	I-Problem
and	I-Problem
pulmonary	I-Problem
parenchymal	I-Problem
involvement	I-Problem
in	I-Problem
the	I-Problem
absence	I-Problem
of	I-Problem
joint	I-Problem
symptoms	I-Problem
.	O

by	O
means	O
of	O
the	O
in	I-Test
vitro	I-Test
heparin	I-Test
-	I-Test
induced	O
platelet	O
activation	O
(	I-Test
hipa	O
)	I-Test
assay	I-Test
it	O
was	O
shown	O
that	O
standard	I-Treatment
heparin	I-Treatment
and	I-Treatment
the	I-Treatment
lmw	I-Treatment
heparins	I-Treatment
fragmin	I-Treatment
and	I-Treatment
fraxiparin	I-Treatment
(	I-Treatment
sanofi	I-Treatment
labaz	I-Treatment
,	I-Treatment
munich	I-Treatment
,	I-Treatment
frg	I-Treatment
)	I-Treatment
,	I-Treatment
as	I-Treatment
well	I-Treatment
as	I-Treatment
the	I-Treatment
enoxaparine	I-Treatment
clexane	I-Treatment
(	I-Treatment
nattermann	I-Treatment
,	I-Treatment
cologne	I-Treatment
,	I-Treatment
frg	I-Treatment
)	I-Treatment
,	O
all	O
induced	O
platelet	I-Problem
activation	I-Problem
with	O
the	O
patient	I-Test
'	I-Test
s	I-Test
serum	I-Test
.	O

discussion	O
:	O
this	I-Background
case	I-Background
shows	O
that	O
switching	O
to	O
zidovudine	I-Treatment
potentially	O
can	O
lead	O
to	O
a	O
hyperlactatemia	I-Problem
relapse	I-Problem
.	O

acute	I-Problem
leukaemia	I-Problem
during	O
tamoxifen	I-Treatment
therapy	I-Treatment
.	O

heparin	I-Treatment
-	O
associated	O
thrombocytopenia	I-Problem
:	O
successful	O
therapy	O
with	O
the	O
heparinoid	O
org	O
10172	O
in	O
a	I-Background
patient	I-Background
showing	O
cross	O
-	O
reaction	O
to	O
lmw	O
heparins	O
.	O

a	I-Background
patient	I-Background
presented	O
with	O
a	O
painful	I-Problem
,	I-Problem
oedematous	I-Problem
,	I-Problem
cyanosed	I-Problem
hand	I-Problem
having	O
injected	I-Treatment
a	I-Treatment
solution	I-Treatment
of	I-Treatment
diamorphine	I-Treatment
and	I-Treatment
methylphenidate	I-Treatment
into	I-Treatment
his	I-Treatment
radial	I-Treatment
artery	I-Treatment
.	O

we	O
conclude	O
that	O
vincristine	I-Treatment
and	I-Treatment
actinomycin	I-Treatment
d	I-Treatment
were	O
the	O
cause	O
of	O
this	O
rare	O
from	O
of	O
hepatotoxicity	I-Problem
and	O
that	O
chemotherapy	O
for	O
the	O
underlying	O
malignant	O
disease	O
could	O
be	O
given	O
safely	O
after	O
clinical	O
recovery	O
.	O

pure	I-Problem
red	I-Problem
cell	I-Problem
aplasia	I-Problem
associated	O
with	O
fenoprofen	I-Treatment
.	O

a	I-Background
56	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
woman	I-Background
with	I-Background
a	I-Background
diagnosis	I-Background
of	I-Background
reactive	I-Problem
depression	I-Problem
developed	O
severe	I-Problem
ui	I-Problem
after	O
a	O
30	I-Other
days	I-Other
'	I-Treatment
treatment	I-Treatment
with	I-Treatment
venlafaxine	I-Treatment
75	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
.	I-Treatment

patients	O
:	O
three	O
patients	I-Background
developed	O
a	O
reproductive	I-Problem
endocrine	I-Problem
disorder	I-Problem
during	O
treatment	O
with	O
valproate	I-Treatment
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
marked	I-Problem
elevation	I-Problem
of	I-Problem
serum	I-Problem
creatine	I-Problem
kinase	I-Problem
(	O
ck	O
)	O
associated	O
with	O
olanzapine	I-Treatment
therapy	O
.	O

severe	I-Problem
c	I-Problem
.	I-Problem
difficile	I-Problem
colitis	I-Problem
occurred	O
in	O
2	O
patients	I-Background
(	O
6	O
.	O
1	O
%	O
)	O
after	O
receiving	O
cisplatin	I-Treatment
-	I-Treatment
based	I-Treatment
combination	I-Treatment
chemotherapy	I-Treatment
for	O
ovarian	I-Problem
malignancies	I-Problem
.	O

a	I-Background
56	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
scleroderma	I-Problem
developed	O
rapidly	I-Problem
progressive	I-Problem
glomerulonephritis	I-Problem
with	I-Problem
epithelial	I-Problem
crescents	I-Problem
associated	I-Problem
with	I-Problem
hemoptysis	I-Problem
after	O
27	I-Other
months	I-Other
of	I-Treatment
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
therapy	I-Treatment
and	I-Treatment
a	I-Treatment
cumulative	I-Treatment
dose	I-Treatment
of	I-Treatment
1	I-Treatment
,	I-Treatment
200	I-Treatment
g	I-Treatment
.	I-Treatment

high	I-Treatment
-	I-Treatment
dose	I-Treatment
phosphate	I-Treatment
treatment	O
leads	O
to	O
hypokalemia	I-Problem
in	O
hypophosphatemic	I-Problem
osteomalacia	I-Problem
.	O

we	O
report	O
a	I-Background
patient	I-Background
who	O
developed	O
heparin	I-Treatment
associated	I-Problem
thrombocytopenia	I-Problem
during	O
continuous	I-Treatment
arteriovenous	I-Treatment
haemofiltration	I-Treatment
and	O
discuss	O
its	O
implications	O
and	O
alternative	O
anticoagulant	O
treatment	O
.	O

we	O
describe	O
a	O
detailed	O
case	O
of	O
fulminant	I-Problem
hepatitis	I-Problem
induced	O
by	O
nevirapine	I-Treatment
(	O
viramune	O
)	O
and	O
treated	O
by	O
liver	O
transplantation	O
.	O

the	O
literature	O
is	O
also	O
reviewed	O
for	O
arf	I-Problem
associated	O
with	O
mannitol	I-Treatment
infusion	I-Treatment
in	O
patients	I-Background
who	O
received	O
dialysis	O
and	O
those	O
who	O
did	O
not	O
receive	O
dialysis	O
;	O
and	O
the	O
possible	O
mechanism	O
(	O
s	O
)	O
of	O
mannitol	O
nephrotoxicity	O
are	O
discussed	O
.	O

in	O
this	O
case	O
report	O
,	O
we	O
present	O
clinical	O
and	O
laboratory	O
findings	O
of	O
a	O
case	I-Background
with	I-Background
chronic	I-Problem
hepatitis	I-Problem
b	I-Problem
that	O
developed	O
acute	I-Problem
dystonia	I-Problem
soon	O
after	O
the	I-Treatment
first	I-Treatment
dose	I-Treatment
of	I-Treatment
pegylated	I-Treatment
interferon	I-Treatment
alpha	I-Treatment
.	I-Treatment

trichiasis	I-Problem
associated	O
with	O
prostaglandin	I-Treatment
analog	I-Treatment
use	O
.	O

the	O
possible	O
development	O
of	O
a	O
drug	I-Problem
-	I-Problem
induced	I-Problem
vasculitis	I-Problem
or	I-Problem
lupus	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
should	O
be	O
added	O
to	O
the	O
list	O
of	O
rare	O
toxic	O
effects	O
of	O
vancomycin	I-Treatment
.	O

healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
the	O
possible	O
development	O
of	O
serotonin	I-Problem
syndrome	I-Problem
as	O
a	O
complication	O
of	O
initiation	O
of	O
fentanyl	I-Treatment
and	I-Treatment
other	I-Treatment
phenylpiperidine	I-Treatment
opioids	I-Treatment
in	O
patients	I-Background
treated	I-Treatment
with	I-Treatment
ssris	I-Treatment
.	O

acute	I-Problem
myocardial	I-Problem
ischemia	I-Problem
following	O
accidental	I-Treatment
intravenous	I-Treatment
administration	I-Treatment
of	I-Treatment
epinephrine	I-Treatment
in	I-Treatment
high	I-Treatment
concentration	I-Treatment
.	O

bromide	I-Problem
intoxication	I-Problem
secondary	O
to	O
pyridostigmine	I-Treatment
bromide	I-Treatment
therapy	O
.	O

we	O
have	O
recently	O
encountered	O
a	O
patient	I-Background
with	I-Background
acquired	I-Problem
haemophilia	I-Problem
who	I-Background
developed	I-Background
a	I-Background
thrombotic	I-Problem
left	I-Problem
middle	I-Problem
cerebral	I-Problem
artery	I-Problem
distribution	I-Problem
stroke	I-Problem
while	O
being	O
treated	O
with	O
pfviii	I-Treatment
.	O

we	O
present	O
a	O
case	O
of	O
serotonin	I-Problem
syndrome	I-Problem
,	O
which	O
was	O
precipitated	O
by	O
this	O
medicine	O
in	O
a	I-Background
patient	I-Background
who	O
had	O
been	O
predisposed	O
by	O
long	I-Other
-	I-Other
term	I-Other
treatment	I-Treatment
with	I-Treatment
sertraline	I-Treatment
,	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
.	O

of	O
the	O
15	O
patients	I-Background
treated	O
with	O
tizanidine	I-Treatment
and	I-Treatment
mexiletine	I-Treatment
,	O
4	I-Background
suffered	O
tizanidine	I-Treatment
-	O
induced	O
adverse	O
effects	O
such	O
as	O
drowsiness	I-Problem
and	I-Problem
dry	I-Problem
mouth	I-Problem
in	O
the	O
retrospective	I-Test
survey	I-Test
.	O

type	I-Problem
i	I-Problem
second	I-Problem
-	I-Problem
degree	I-Problem
av	I-Problem
block	I-Problem
(	I-Problem
mobitz	I-Problem
type	I-Problem
i	I-Problem
,	I-Problem
wenckebach	I-Problem
av	I-Problem
block	I-Problem
)	I-Problem
during	O
ritodrine	I-Treatment
therapy	O
for	O
preterm	I-Problem
labor	I-Problem
.	O

after	O
other	O
potential	O
causes	O
of	O
liver	O
toxicity	O
were	O
excluded	O
,	O
tmp	I-Treatment
-	I-Treatment
smx	I-Test
was	O
determined	O
to	O
be	O
the	O
cause	O
of	O
his	O
acute	I-Problem
liver	I-Problem
toxicity	I-Problem
.	O

one	O
of	I-Background
the	I-Background
patients	I-Background
had	O
a	O
dexamethasone	I-Treatment
dependent	O
brain	I-Problem
metastatic	I-Problem
condition	I-Problem
.	O

biomicroscopy	I-Treatment
revealed	O
amiodarone	I-Problem
corneal	I-Problem
deposits	I-Problem
.	O

this	O
case	O
and	O
a	O
review	O
of	O
the	O
literature	O
show	O
the	O
severe	O
and	O
unpredictable	O
nature	O
of	O
ethambutol	I-Treatment
toxicity	O
and	O
its	O
potential	O
for	O
irreversible	I-Problem
vision	I-Problem
loss	I-Problem
despite	O
careful	O
ophthalmologic	I-Test
monitoring	I-Test
.	O

recently	O
,	O
some	O
studies	O
have	O
also	O
reported	O
association	O
between	O
patients	I-Background
with	I-Background
juvenile	I-Problem
rheumatoid	I-Problem
arthritis	I-Problem
(	I-Background
jra	I-Background
)	O
treated	O
with	O
methotrexate	I-Treatment
(	I-Treatment
mtx	I-Treatment
)	I-Treatment
and	O
malignant	I-Problem
lymphoma	I-Problem
developing	O
.	O

the	I-Background
two	O
middle	I-Background
aged	I-Background
women	I-Background
presented	O
with	O
respiratory	I-Problem
symptoms	I-Problem
after	O
prolonged	I-Other
treatment	I-Other
with	I-Treatment
nitrofurantoin	I-Treatment
.	O

objective	O
:	O
1	O
)	O
to	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
receiving	O
adalimumab	I-Treatment
who	O
developed	O
fever	I-Problem
,	I-Problem
pancytopenia	I-Problem
,	I-Problem
splenomegaly	I-Problem
,	I-Problem
and	I-Problem
extreme	I-Problem
hyperferritinemia	I-Problem
.	O

visual	I-Problem
hallucinations	I-Problem
associated	O
with	O
zonisamide	I-Treatment
.	O

milk	I-Problem
-	I-Problem
alkali	I-Problem
syndrome	I-Problem
induced	O
by	O
1	I-Treatment
,	I-Treatment
25	I-Treatment
(	I-Treatment
oh	I-Treatment
)	I-Treatment
2d	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
hypoparathyroidism	I-Problem
.	I-Background

we	O
report	O
the	O
case	O
of	O
a	I-Background
female	I-Background
acromegalic	I-Problem
patient	I-Background
in	O
whom	O
multiple	O
hepatic	I-Problem
adenomas	I-Problem
appeared	O
soon	O
after	O
danazol	I-Treatment
treatment	I-Treatment
for	O
uterine	I-Problem
fibromatosis	I-Problem
.	I-Problem

carbamazepine	I-Treatment
toxicity	I-Problem
induced	O
by	O
clarithromycin	I-Treatment
coadministration	O
in	O
psychiatric	I-Problem
patients	I-Background
.	O

thrombolytic	O
therapy	O
with	O
tissue	I-Treatment
plasminogen	I-Treatment
activator	I-Treatment
(	O
tpa	O
)	O
for	O
acute	I-Problem
myocardial	I-Problem
infarction	I-Problem
may	O
result	O
in	O
major	O
bleeding	O
complications	O
such	O
as	O
gastrointestinal	I-Problem
or	I-Problem
intracranial	I-Problem
bleeding	I-Problem
.	O

conclusion	O
:	O
the	O
hemolytic	I-Problem
-	I-Problem
uremic	I-Problem
syndrome	I-Problem
may	O
be	O
a	O
rare	O
complication	O
of	O
oxaliplatin	I-Treatment
-	I-Treatment
based	I-Treatment
chemotherapy	I-Treatment
.	O

however	O
,	O
recurrent	O
staphylococcus	I-Problem
aureus	I-Problem
sepsis	I-Problem
developed	O
during	O
cya	I-Treatment
therapy	I-Treatment
.	O

nabumetone	I-Treatment
-	O
associated	O
interstitial	I-Problem
nephritis	I-Problem
.	O

a	O
short	O
review	O
on	O
imatinib	I-Treatment
-	O
related	O
hepatotoxicity	I-Problem
is	O
also	O
presented	O
.	O

fatal	I-Problem
interstitial	I-Problem
pneumonitis	I-Problem
associated	O
with	O
docetaxel	I-Treatment
administration	O
in	O
a	I-Background
patient	I-Background
with	I-Background
hormone	I-Problem
-	I-Problem
refractory	I-Problem
prostate	I-Problem
cancer	I-Problem
.	O

background	O
:	O
etanercept	I-Treatment
is	O
a	I-Treatment
tumor	I-Treatment
necrosis	I-Treatment
factor	I-Treatment
(	I-Treatment
tnf	I-Treatment
)	I-Treatment
inhibitor	I-Treatment
that	O
has	O
been	O
licensed	O
in	O
the	O
united	O
states	O
for	O
the	O
treatment	O
of	O
adult	I-Problem
and	I-Problem
juvenile	I-Problem
rheumatoid	I-Problem
arthritis	I-Problem
as	I-Background
well	I-Background
as	I-Background
psoriatic	I-Problem
arthritis	I-Problem
.	O

reye	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
following	O
treatment	O
with	O
the	O
pantothenic	O
acid	O
antagonist	O
,	O
calcium	I-Treatment
hopantenate	I-Treatment
.	O

sudden	I-Problem
death	I-Problem
in	O
an	I-Background
infant	I-Background
from	O
methemoglobinemia	I-Problem
after	O
administration	O
of	O
"	O
sweet	I-Treatment
spirits	I-Treatment
of	I-Treatment
nitre	I-Treatment
"	O
.	O

findings	O
:	O
six	O
children	I-Background
with	I-Background
growth	I-Problem
retardation	I-Problem
noted	O
after	O
treatment	O
with	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
fluticasone	I-Treatment
propionate	I-Treatment
were	O
found	O
to	O
have	O
adrenal	I-Problem
suppression	I-Problem
.	O

methotrexate	I-Treatment
-	O
associated	O
nephropathy	I-Problem
is	O
a	O
rare	O
complication	O
in	O
pediatric	O
oncology	O
,	O
and	O
a	O
review	O
of	O
the	O
literature	O
suggests	O
that	O
exposure	O
to	O
nephrotoxic	O
agents	O
may	O
be	O
a	O
significant	O
but	O
perhaps	O
underrecognized	O
risk	O
factor	O
for	O
its	O
development	O
.	O

four	O
cases	I-Background
of	O
oesophageal	I-Problem
damage	I-Problem
associated	O
with	O
ingestion	I-Treatment
of	I-Treatment
the	I-Treatment
urinary	I-Treatment
anti	I-Treatment
-	I-Treatment
spasmodic	I-Treatment
agent	I-Treatment
emepronium	I-Treatment
bromide	I-Treatment
are	O
described	O
.	O

a	I-Background
66	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
japanese	I-Background
woman	I-Background
with	I-Background
severe	I-Problem
scleroderma	I-Problem
developed	O
anemia	I-Problem
and	I-Problem
thrombocytopenia	I-Problem
due	O
to	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
(	I-Treatment
d	I-Treatment
-	I-Treatment
pen	I-Treatment
)	I-Treatment
treatment	I-Treatment
,	O
although	O
the	O
leukopenia	O
was	O
not	O
markedly	O
severe	O
.	O

corticosteroid	I-Treatment
injections	I-Treatment
are	O
commonly	O
used	O
as	O
effective	O
treatments	O
for	O
a	O
variety	O
of	O
pain	I-Problem
disorders	I-Problem
.	O

we	O
present	O
two	O
cases	O
of	O
anaphylaxis	I-Problem
under	I-Problem
anaesthesia	I-Problem
where	O
return	I-Problem
of	I-Problem
spontaneous	I-Problem
circulation	I-Problem
was	O
refractory	O
to	O
epinephrine	I-Treatment
,	O
but	O
occurred	O
following	O
the	O
administration	I-Treatment
of	I-Treatment
the	I-Treatment
alpha	I-Treatment
-	I-Treatment
agonist	I-Treatment
metaraminol	I-Treatment
.	O

a	I-Background
51	I-Background
-	I-Background
yr	I-Background
-	I-Background
old	I-Background
nonsmoking	I-Background
male	I-Background
patient	I-Background
without	I-Background
any	I-Background
history	I-Background
of	I-Background
previous	I-Background
allergies	I-Background
,	I-Background
asthma	I-Background
,	I-Background
hay	I-Background
fever	I-Background
,	I-Background
or	I-Background
urticaria	I-Background
developed	O
attacks	I-Problem
of	I-Problem
asthma	I-Problem
when	O
captopril	I-Treatment
was	I-Treatment
added	I-Treatment
to	I-Treatment
the	I-Treatment
nadolol	I-Treatment
and	I-Treatment
dyazide	I-Treatment
treatment	O
for	O
his	O
high	I-Problem
blood	I-Problem
pressure	I-Problem
.	O

after	I-Treatment
ticlopidine	I-Treatment
was	I-Treatment
discontinued	I-Treatment
,	O
the	O
patient	O
was	O
rechallenged	I-Treatment
with	I-Treatment
the	I-Treatment
same	I-Treatment
dose	I-Treatment
of	I-Treatment
phenytoin	I-Treatment
without	O
symptoms	O
of	O
toxicity	I-Problem
.	O

rhabdomyolysis	I-Problem
due	O
to	O
an	O
uncommon	O
interaction	I-Treatment
of	I-Treatment
ciprofloxacin	I-Treatment
with	I-Treatment
simvastatin	I-Treatment
.	O

after	O
receiving	O
3	O
doses	O
of	O
ifosfamide	I-Treatment
/	I-Treatment
mesna	I-Treatment
,	O
she	I-Background
was	O
found	O
to	O
be	O
unresponsive	I-Problem
.	O

symptomatic	I-Problem
hypoglycemia	I-Problem
secondary	O
to	O
a	O
glipizide	I-Treatment
-	I-Treatment
trimethoprim	I-Treatment
/	I-Treatment
sulfamethoxazole	I-Treatment
drug	I-Treatment
interaction	I-Treatment
.	O

a	I-Background
51	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
type	I-Problem
1	I-Problem
diabetes	I-Problem
mellitus	I-Problem
following	O
24	I-Other
weeks	I-Other
of	I-Treatment
treatment	I-Treatment
with	I-Treatment
recombinant	I-Treatment
alpha	I-Treatment
-	I-Treatment
2b	I-Treatment
peginterferon	I-Treatment
plus	I-Treatment
ribavirin	I-Treatment
for	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

paroxysmal	I-Problem
supraventricular	I-Problem
tachycardia	I-Problem
during	O
treatment	O
with	O
cisplatin	I-Treatment
and	I-Treatment
etoposide	I-Treatment
combination	I-Treatment
.	O

conversely	O
,	O
diffuse	I-Problem
interstitial	I-Problem
pulmonary	I-Problem
fibrosis	I-Problem
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
patients	I-Background
receiving	O
methotrexate	I-Treatment
who	O
develop	O
bilateral	I-Problem
pulmonary	I-Problem
infiltrates	I-Problem
seen	O
on	O
chest	O
roentgenograms	I-Test
.	O

an	I-Background
83	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
receiving	I-Treatment
glipizide	I-Treatment
10	I-Treatment
mg	I-Treatment
bid	O
developed	O
symptomatic	I-Problem
hypoglycemia	I-Problem
within	O
three	I-Other
days	I-Other
of	I-Treatment
adding	I-Treatment
trimethoprim	I-Treatment
/	I-Treatment
sulfamethoxazole	I-Treatment
(	I-Treatment
tmp	I-Treatment
/	I-Treatment
smx	I-Treatment
)	I-Treatment
to	O
his	O
regimen	O
.	O

in	O
this	O
case	O
senna	I-Treatment
was	O
likely	O
the	O
cause	O
of	O
a	I-Problem
subacute	I-Problem
cholestatic	I-Problem
hepatitis	I-Problem
exemplifying	O
again	O
the	O
potential	O
role	O
of	O
herbal	I-Problem
related	I-Problem
liver	I-Problem
injury	I-Problem
.	O

early	O
peritoneal	O
dialysis	O
has	O
not	O
previously	O
been	O
reported	O
for	O
lisinopril	I-Treatment
induced	O
multiorgan	I-Problem
failure	I-Problem
.	O

various	O
case	O
reports	O
concerning	O
dapsone	I-Treatment
-	O
induced	O
agranulocytosis	I-Problem
are	O
reviewed	O
.	O

we	O
report	O
the	O
first	O
case	O
of	O
a	I-Background
54	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
turkish	I-Background
woman	I-Background
who	O
presented	O
with	O
ceftriaxone	I-Treatment
-	O
induced	O
fde	I-Problem
.	O

in	O
all	O
cases	O
,	O
seizures	I-Problem
were	O
controlled	O
by	O
withdrawal	I-Treatment
of	I-Treatment
phenytoin	I-Treatment
and	I-Treatment
reduction	I-Treatment
of	I-Treatment
drug	I-Treatment
levels	I-Treatment
.	O

this	O
case	O
describes	O
fulminant	I-Problem
hepatic	I-Problem
failure	I-Problem
in	O
a	I-Background
patient	I-Background
taking	O
disulfiram	I-Treatment
with	O
no	O
previous	O
liver	O
disease	O
and	O
report	O
of	O
being	O
compliant	O
with	O
alcohol	O
abstinence	O
.	O

fungal	I-Problem
infection	I-Problem
is	O
a	O
significant	O
comorbidity	O
in	O
patients	I-Background
with	I-Background
diabetes	I-Problem
mellitus	I-Problem
,	O
and	O
ketoconazole	I-Treatment
,	O
an	O
antifungal	O
agent	O
,	O
causes	O
a	I-Problem
number	I-Problem
of	I-Problem
drug	I-Problem
interactions	I-Problem
with	I-Problem
coadministered	I-Problem
drugs	I-Problem
.	O

dorzolamide	I-Treatment
-	O
induced	O
choroidal	I-Problem
detachment	I-Problem
in	O
a	I-Background
surgically	I-Background
untreated	I-Background
eye	I-Background
.	O

idiosyncratic	O
factors	O
involving	O
vasopressin	I-Treatment
receptor	I-Test
affinity	I-Test
and	O
distribution	O
,	O
vasopressin	O
-	O
associated	O
vasodilation	O
in	O
some	O
vascular	O
beds	O
,	O
and	O
the	O
effect	O
of	O
vasopressin	O
on	O
the	O
renin	O
-	O
angiotensin	O
system	O
may	O
further	O
contribute	O
to	O
impaired	I-Problem
tissue	I-Problem
perfusion	I-Problem
.	O

a	I-Background
66	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
mand	I-Background
suffering	I-Background
from	I-Background
severe	I-Background
coronary	I-Problem
heart	I-Problem
disease	I-Problem
took	O
digoxin	I-Treatment
with	O
suicidal	O
intent	O
an	O
was	O
treated	O
for	O
the	O
ensuing	O
complete	I-Problem
atrioventricular	I-Problem
block	I-Problem
with	O
digoxin	O
-	O
specific	O
antibody	O
fragments	O
.	O

epoprostenol	I-Treatment
may	O
be	O
associated	O
rarely	O
with	O
severe	I-Problem
erythroderma	I-Problem
.	I-Problem

we	O
report	O
the	O
case	O
of	O
a	I-Background
patient	I-Background
with	O
increased	I-Problem
cerebral	I-Problem
cortical	I-Problem
excitability	I-Problem
following	O
intoxication	O
with	O
flupirtine	I-Treatment
,	O
a	O
centrally	O
acting	O
analgesic	O
and	O
antispastic	O
drug	O
.	O

this	O
case	O
represents	O
the	O
third	O
example	O
of	O
erythroid	I-Problem
aplasia	I-Problem
associated	O
with	O
an	O
anti	O
-	O
inflammatory	O
agent	O
and	O
the	O
first	O
instance	O
due	O
to	O
fenoprofen	I-Treatment
.	O

lichenoid	I-Problem
drug	I-Problem
eruption	I-Problem
to	O
salsalate	I-Treatment
.	O

two	O
pediatric	I-Background
oncology	I-Background
patients	I-Background
with	I-Background
ewing	I-Problem
'	I-Problem
s	I-Problem
sarcoma	I-Problem
and	I-Background
one	O
with	I-Background
mixed	I-Problem
germ	I-Problem
cell	I-Problem
tumor	I-Problem
were	O
treated	O
with	O
drug	I-Treatment
regimens	I-Treatment
that	I-Treatment
included	I-Treatment
bleomycin	I-Treatment
or	I-Treatment
cyclophosphamide	I-Treatment
.	O

although	O
retinoic	I-Treatment
acid	I-Treatment
is	O
well	O
tolerated	O
by	O
the	O
majority	O
of	O
patients	O
with	O
this	O
disease	O
,	O
a	O
potentially	O
fatal	I-Problem
complication	I-Problem
of	O
this	O
kind	O
of	O
treatment	O
has	O
been	O
reported	O
:	O
"	O
the	O
retinoic	O
acid	O
syndrome	O
"	O
.	O

three	O
of	O
38	O
children	I-Background
given	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
therapy	O
developed	O
a	O
previously	O
undescribed	O
complication	I-Problem
.	O

a	O
case	O
of	O
aseptic	I-Problem
pleuropericarditis	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
chronic	I-Problem
plaque	I-Problem
psoriasis	I-Problem
under	O
methotrexate	I-Treatment
therapy	I-Treatment
.	O

linezolid	I-Treatment
-	O
induced	O
dyserythropoiesis	I-Problem
:	O
chloramphenicol	O
toxicity	O
revisited	O
.	O

conclusion	O
:	O
the	O
present	O
findings	O
suggest	O
that	O
fluvoxamine	I-Treatment
can	O
cause	O
increased	I-Problem
libido	I-Problem
in	O
some	I-Background
patients	I-Background
.	O

a	O
unique	O
case	O
of	O
a	I-Problem
transient	I-Problem
,	I-Problem
nonpigmenting	I-Problem
fixed	I-Problem
drug	I-Problem
eruption	I-Problem
caused	O
by	O
the	O
radiopaque	O
contrast	O
medium	O
iothalamate	I-Treatment
is	O
reported	O
.	O

mucosal	I-Problem
pigmentation	I-Problem
after	O
oral	I-Problem
lichen	I-Problem
planus	I-Problem
treatment	O
with	O
topical	I-Treatment
tacrolimus	I-Treatment
.	O

we	O
now	O
report	O
the	O
first	O
known	O
cancer	I-Problem
patient	I-Background
who	O
developed	O
life	I-Problem
-	I-Problem
threatening	I-Problem
complications	I-Problem
after	O
treatment	O
with	O
topical	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
and	O
was	O
shown	O
subsequently	O
to	O
have	I-Problem
profound	I-Problem
dpd	I-Problem
deficiency	I-Problem
.	O

when	O
the	O
acute	I-Problem
manic	I-Problem
state	I-Problem
is	I-Problem
characterized	I-Problem
by	I-Problem
marked	I-Problem
psychotic	I-Problem
symptoms	I-Problem
and	I-Problem
intense	I-Problem
anxiety	I-Problem
,	O
it	O
may	O
be	O
associated	O
with	O
increased	O
vulnerability	O
to	O
the	O
development	O
of	O
severe	O
lithium	I-Treatment
neurotoxicity	O
.	O

clinicians	O
who	O
manage	O
cachectic	I-Problem
patients	I-Background
,	O
particularly	O
those	O
with	I-Background
protracted	I-Problem
diarrhoea	I-Problem
and	O
/	O
or	O
receiving	O
anti	I-Treatment
-	I-Treatment
malarial	I-Treatment
drugs	I-Treatment
including	I-Treatment
mefloquine	I-Treatment
,	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
severe	I-Problem
hypoglycaemia	I-Problem
.	O

arrhythmias	I-Problem
and	I-Problem
cardiac	I-Problem
arrest	I-Problem
have	O
been	O
reported	O
during	O
amphotericin	I-Treatment
b	I-Treatment
administration	I-Treatment
but	O
no	O
effective	O
technique	O
has	O
been	O
described	O
to	O
prevent	O
them	O
.	O

based	O
upon	O
the	O
literature	I-Test
review	I-Test
,	O
the	I-Problem
hypotension	I-Problem
in	O
this	I-Background
patient	I-Background
was	O
possibly	O
due	O
to	O
the	I-Treatment
interaction	I-Treatment
between	I-Treatment
tizanidine	I-Treatment
and	I-Treatment
lisinopril	I-Treatment
.	O

baclofen	I-Treatment
withdrawal	I-Treatment
:	O
a	O
cause	O
of	O
prolonged	I-Problem
fever	I-Problem
in	O
the	O
intensive	O
care	O
unit	O
.	O

interstitial	I-Problem
pneumonitis	I-Problem
and	I-Problem
alveolar	I-Problem
hemorrhage	I-Problem
complicating	O
use	O
of	O
rituximab	I-Treatment
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

we	O
introduce	O
a	O
case	O
of	O
a	I-Background
sixty	I-Background
years	I-Background
old	I-Background
woman	I-Background
with	O
several	I-Problem
previous	I-Problem
episodes	I-Problem
of	I-Problem
rhinitis	I-Problem
,	I-Problem
conjunctivitis	I-Problem
and	I-Problem
perspiration	I-Problem
immediately	I-Problem
after	O
the	O
administration	O
of	O
salmon	I-Treatment
calcitonin	I-Treatment
with	I-Treatment
nasal	I-Treatment
spray	I-Treatment
or	I-Treatment
intramuscular	I-Treatment
administration	I-Treatment
(	I-Treatment
calsynar	I-Treatment
)	I-Treatment
.	O

eighty	O
-	O
two	O
patients	I-Background
with	I-Background
various	I-Problem
malignancies	I-Problem
who	O
received	O
imipenem	I-Treatment
/	I-Treatment
cilastatin	I-Treatment
143	I-Treatment
times	I-Treatment
for	I-Treatment
neutropenic	I-Problem
fever	I-Problem
between	O
march	O
1994	O
and	O
october	O
1999	O
in	O
department	O
of	O
pediatric	O
oncology	O
,	O
gazi	O
university	O
,	O
were	O
identified	O
.	O

the	O
present	O
report	O
first	O
highlights	O
the	O
potentially	I-Problem
life	I-Problem
-	I-Problem
threatening	I-Problem
side	I-Problem
effects	I-Problem
associated	O
with	O
over	O
-	O
the	O
-	O
counter	O
nsaids	I-Treatment
during	O
ddavp	I-Treatment
replacement	O
therapy	O
for	O
central	O
di	O
.	O

case	O
report	O
:	O
lack	O
of	O
control	O
of	O
diabetes	I-Problem
and	O
weight	I-Problem
gain	I-Problem
in	O
a	I-Background
patient	I-Background
on	O
initiation	O
and	O
rechallenge	O
of	O
therapy	O
with	O
olanzapine	I-Treatment
.	O

intravenous	O
azithromycin	I-Treatment
-	O
induced	O
ototoxicity	I-Problem
.	O

orally	I-Treatment
delivered	I-Treatment
pxd	I-Treatment
showed	O
no	O
evidence	O
of	O
clinical	O
activity	O
,	O
when	O
combined	O
with	O
weekly	I-Other
auc2	I-Test
-	I-Test
carboplatin	I-Treatment
in	I-Test
proc	I-Problem
.	O

we	O
report	O
such	O
a	O
series	O
of	I-Background
patients	I-Background
who	O
had	O
transient	I-Problem
asymptomatic	I-Problem
bradycardia	I-Problem
after	O
being	O
treated	O
with	O
continuous	I-Other
infusion	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
.	O

consolidation	I-Treatment
therapy	I-Treatment
with	I-Treatment
bortezomib	I-Treatment
/	I-Treatment
lenalidomide	I-Treatment
/	I-Treatment
dexamethasone	I-Treatment
versus	I-Treatment
bortezomib	I-Treatment
/	I-Treatment
dexamethasone	I-Treatment
after	I-Treatment
a	I-Treatment
dexamethasone	I-Treatment
-	I-Treatment
based	I-Treatment
induction	I-Treatment
regimen	I-Treatment
in	O
patients	I-Background
with	I-Background
multiple	I-Problem
myeloma	I-Problem
:	O
a	O
randomized	O
phase	O
iii	O
trial	O
.	O

based	O
on	O
prior	O
data	O
suggesting	O
that	O
scheduling	O
alterations	O
of	O
platinum	O
would	O
increase	O
activity	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	I-Test
was	O
to	O
assess	O
the	O
potential	I-Problem
therapeutic	I-Problem
benefit	I-Problem
of	O
phenoxodiol	I-Treatment
(	I-Treatment
pxd	I-Treatment
)	I-Treatment
,	I-Treatment
a	I-Treatment
novel	I-Treatment
biomodulator	I-Treatment
shown	I-Treatment
to	I-Treatment
have	I-Treatment
chemoresistance	I-Treatment
reversing	I-Treatment
potential	I-Treatment
,	I-Treatment
when	I-Treatment
combined	I-Treatment
with	I-Treatment
weekly	I-Other
auc2	I-Treatment
-	I-Treatment
carboplatin	I-Treatment
in	O
proc	I-Problem
patients	I-Background
.	O

we	O
also	O
describe	O
a	O
new	O
,	O
noninvasive	O
method	O
to	O
assess	O
magnesium	I-Treatment
-	O
induced	O
neuromuscular	I-Problem
block	I-Problem
when	O
curariform	I-Treatment
muscle	I-Treatment
relaxant	I-Treatment
was	I-Treatment
given	I-Treatment
simultaneously	I-Treatment
.	O

our	O
series	O
of	O
3	O
patients	I-Background
supports	O
a	O
causal	O
connection	O
between	O
bleomycin	I-Treatment
and	O
scleroderma	I-Problem
.	O

in	O
this	O
paper	O
,	O
we	O
report	O
a	I-Background
patient	I-Background
with	O
primary	O
anti	I-Problem
-	I-Problem
phospholipid	I-Problem
syndrome	I-Problem
treated	O
by	O
corticosteroid	I-Treatment
,	O
who	O
developed	O
disseminated	I-Problem
nocardiosis	I-Problem
.	O

eye	I-Problem
movement	I-Problem
disorders	I-Problem
in	O
bone	I-Problem
marrow	I-Problem
transplant	I-Problem
patients	I-Background
on	O
cyclosporin	I-Treatment
and	I-Treatment
ganciclovir	I-Treatment
.	O

prolonged	I-Problem
severe	I-Problem
cholestasis	I-Problem
induced	O
by	O
oxacillin	I-Treatment
derivatives	I-Treatment
.	O

cisplatin	I-Treatment
was	O
the	O
common	O
drug	O
in	O
the	I-Background
cases	I-Background
presented	O
and	O
therefore	O
could	O
be	O
related	O
to	O
the	O
inr	I-Problem
elevations	I-Problem
.	O

5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
cardiotoxicity	I-Problem
complicating	O
treatment	O
of	O
stage	O
iib	O
cervical	I-Problem
cancer	I-Problem
-	O
-	O
case	O
report	O
.	O

results	O
:	O
a	O
clinical	O
diagnosis	O
of	O
fixed	I-Problem
drug	I-Problem
eruption	I-Problem
owing	O
to	O
use	O
of	O
the	O
pde5	I-Treatment
inhibitor	I-Treatment
tadalafil	I-Treatment
(	I-Treatment
cialis	I-Treatment
)	I-Treatment
was	O
made	O
.	O

pancytopenia	I-Problem
associated	O
with	O
5	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
use	O
in	O
a	I-Background
patient	I-Background
with	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
.	O

fludarabine	I-Problem
induced	I-Problem
lung	I-Problem
toxicity	I-Problem
must	O
be	O
considered	O
in	O
all	I-Background
patients	I-Background
who	I-Background
develop	I-Background
unexplained	I-Background
lung	I-Problem
disease	I-Problem
while	O
receiving	O
fludarabine	I-Treatment
.	O

although	O
other	O
nitrites	O
induce	O
methemoglobinemia	O
,	O
exposure	O
to	O
methyl	I-Treatment
nitrite	I-Treatment
during	O
phenylpropanolamine	O
production	O
appears	O
to	O
be	O
a	O
new	O
cause	O
of	O
occupational	I-Problem
methemoglobinemia	I-Problem
.	O

we	O
report	O
four	O
cases	I-Background
of	O
sensorimotor	I-Problem
axonal	I-Problem
neuropathy	I-Problem
in	O
children	I-Background
aged	I-Background
10	I-Background
-	I-Background
15	I-Background
years	I-Background
,	O
treated	O
with	O
thalidomide	I-Treatment
for	O
myxopapillary	I-Problem
ependymoma	I-Problem
,	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
and	I-Background
recurrent	I-Problem
giant	I-Problem
aphthous	I-Problem
ulceration	I-Problem
.	O

the	I-Background
patient	I-Background
died	I-Problem
of	I-Problem
respiratory	I-Problem
failure	I-Problem
after	I-Other
8	I-Other
days	I-Other
of	I-Treatment
steroid	I-Treatment
infusion	I-Treatment
and	I-Treatment
erlotinib	I-Treatment
discontinuation	I-Treatment
.	I-Treatment

hypo	I-Problem
-	I-Problem
oestrogenic	I-Problem
and	I-Problem
anabolic	I-Problem
/	I-Problem
androgenic	I-Problem
side	O
-	O
effects	O
of	O
danazol	I-Treatment
are	O
well	O
known	O
by	O
the	O
gynaecologist	O
and	O
some	O
of	O
them	O
are	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
being	O
treated	O
for	O
endometriosis	I-Problem
.	O

we	O
believe	O
that	O
this	O
is	O
the	O
first	O
description	O
of	O
acute	I-Problem
hepatitis	I-Problem
caused	O
by	O
an	O
idiosyncratic	O
adverse	O
reaction	O
to	O
gliclazide	I-Treatment
or	O
to	O
one	O
of	O
its	O
metabolites	O
.	O

in	O
view	O
of	O
our	O
experience	O
in	O
the	O
present	O
case	O
,	O
it	O
should	O
be	O
stressed	O
that	O
close	O
monitoring	I-Test
of	I-Test
coagulation	I-Test
capacity	I-Test
is	O
necessary	O
in	O
critically	O
ill	O
patients	O
in	O
order	O
to	O
avoid	O
fatal	O
haemorrhage	I-Problem
after	O
initiating	I-Treatment
warfarin	I-Treatment
therapy	I-Treatment
regardless	I-Treatment
of	I-Treatment
the	I-Treatment
dosage	I-Treatment
.	O

we	O
report	O
a	I-Background
patient	I-Background
who	O
developed	O
acute	I-Problem
pancreatitis	I-Problem
during	O
amiodarone	I-Treatment
therapy	O
.	O

we	O
report	O
a	O
76	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
who	O
developed	O
an	O
acute	I-Problem
blistering	I-Problem
eruption	I-Problem
following	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
penicillin	I-Treatment
treatment	I-Treatment
for	O
pneumococcal	I-Problem
septicaemia	I-Problem
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
colchicine	I-Treatment
-	O
induced	O
myopathy	I-Problem
in	O
a	I-Background
teenager	I-Background
with	I-Background
familial	I-Problem
mediterranean	I-Problem
fever	I-Problem
(	I-Background
fmf	I-Background
)	I-Background
.	O

we	O
believe	O
that	O
mucositis	I-Problem
was	O
a	O
contributing	O
factor	O
to	O
this	O
case	O
of	O
fatal	I-Problem
hyperkalemia	I-Problem
after	O
administration	O
of	O
succinylcholine	I-Treatment
,	O
with	O
a	O
mechanism	O
similar	O
to	O
that	O
reported	O
with	O
thermal	O
injury	O
.	O

our	O
experience	O
supports	O
hemodialysis	I-Treatment
for	O
esrf	I-Problem
patients	I-Background
with	I-Background
atenolol	I-Problem
toxicity	I-Problem
.	O

epirubicin	I-Treatment
-	I-Treatment
cyclophosphamide	I-Treatment
adjuvant	I-Treatment
chemotherapy	I-Treatment
plus	I-Treatment
tamoxifen	I-Treatment
administered	I-Treatment
concurrently	I-Treatment
versus	O
sequentially	O
:	O
randomized	O
phase	O
iii	O
trial	O
in	O
postmenopausal	I-Background
node	I-Problem
-	I-Problem
positive	I-Problem
breast	I-Problem
cancer	I-Problem
patients	I-Background
.	O

rupture	I-Problem
of	I-Problem
a	I-Problem
cerebral	I-Problem
aneurysm	I-Problem
associated	O
with	O
nifedipine	I-Treatment
treatment	O
.	O

an	O
immediate	I-Problem
hemolytic	I-Problem
reaction	I-Problem
induced	O
by	O
repeated	I-Other
administration	I-Treatment
of	I-Treatment
oxaliplatin	I-Treatment
.	O

patient	I-Background
b	I-Background
developed	O
perioral	I-Problem
and	I-Problem
upper	I-Problem
extremity	I-Problem
paresthesias	I-Problem
during	O
the	I-Other
fourth	I-Other
cycle	I-Other
of	I-Treatment
cap	I-Treatment
alone	I-Treatment
(	I-Treatment
2500	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
)	I-Treatment
.	O

we	O
describe	O
four	O
patients	I-Background
who	O
had	O
seizures	I-Problem
while	O
receiving	O
ofloxacin	I-Treatment
;	O
no	O
other	O
causes	O
were	O
evident	O
.	O

the	O
case	O
history	O
and	O
toxicological	O
findings	O
of	O
an	I-Background
infant	I-Problem
fatality	I-Problem
involving	O
pseudoephedrine	I-Treatment
,	I-Treatment
brompheniramine	I-Treatment
,	I-Treatment
and	I-Treatment
dextromethorphan	I-Treatment
are	O
presented	O
.	O

a	O
drug	I-Problem
interaction	I-Problem
between	O
zafirlukast	I-Treatment
and	I-Treatment
theophylline	I-Treatment
.	O

dipyrone	I-Treatment
,	I-Treatment
also	I-Treatment
known	I-Treatment
as	I-Treatment
metamizole	I-Treatment
,	O
is	O
an	O
analgesic	O
and	O
antipyretic	O
drug	O
that	O
was	O
banned	O
by	O
the	O
united	O
states	O
food	O
and	O
drug	O
administration	O
because	O
of	O
its	O
association	O
with	O
agranulocytosis	I-Problem
.	O

a	I-Background
fatal	I-Background
case	I-Background
of	O
pancytopenia	I-Problem
due	O
to	O
levomepromazine	I-Treatment
.	O

reversible	I-Problem
heart	I-Problem
failure	I-Problem
in	O
a	I-Background
patient	I-Background
receiving	O
etanercept	I-Treatment
for	O
ankylosing	I-Problem
spondylitis	I-Problem
.	O

the	O
most	O
likely	O
cause	O
of	O
liver	I-Problem
failure	I-Problem
in	O
this	O
patient	O
was	O
,	O
therefore	O
,	O
clarithromycin	I-Treatment
,	O
which	O
undergoes	O
hepatic	O
metabolism	O
and	O
has	O
been	O
reported	O
to	O
cause	O
fulminant	O
hepatic	O
failure	O
.	O

localized	I-Problem
panniculitis	I-Problem
and	I-Problem
subsequent	I-Problem
lipoatrophy	I-Problem
with	O
subcutaneous	I-Treatment
glatiramer	I-Treatment
acetate	I-Treatment
(	I-Treatment
copaxone	I-Treatment
)	I-Treatment
injection	I-Treatment
for	O
the	O
treatment	O
of	O
multiple	I-Problem
sclerosis	I-Problem
.	O

glycopyrrolate	I-Treatment
(	I-Treatment
5	I-Treatment
.	I-Treatment
0	I-Treatment
microg	I-Treatment
/	I-Treatment
kg	I-Treatment
)	I-Treatment
not	O
only	O
resulting	O
in	O
resolution	I-Problem
of	I-Problem
bradycardia	I-Problem
but	O
also	O
resulting	O
in	O
an	I-Problem
exaggerated	I-Problem
increase	I-Problem
of	I-Problem
arterial	I-Problem
blood	I-Problem
pressure	I-Problem
.	O

conclusion	O
:	O
patients	I-Background
with	I-Background
insulin	I-Problem
allergy	I-Problem
may	O
not	O
have	O
complete	O
resolution	O
of	O
their	O
symptoms	O
after	O
standard	I-Treatment
desensitization	I-Treatment
,	O
particularly	O
those	O
patients	O
with	O
concomitant	I-Background
protamine	I-Problem
allergy	I-Problem
.	O

to	O
our	O
knowledge	O
,	O
the	O
syndrome	O
of	O
fever	I-Problem
,	I-Problem
pulmonary	I-Problem
infiltrates	I-Problem
,	I-Problem
and	I-Problem
pleural	I-Problem
effusion	I-Problem
following	O
use	O
of	O
acyclovir	I-Treatment
has	O
not	O
been	O
previously	O
reported	O
.	O

we	O
are	O
concerned	O
that	O
the	O
macular	I-Problem
lesion	I-Problem
was	O
a	O
retinal	O
toxic	O
effect	O
of	O
gentamicin	I-Treatment
because	O
of	O
the	O
recent	O
description	O
of	O
similar	O
lesions	O
occurring	O
after	O
the	O
inadvertent	O
intraocular	O
injection	O
of	O
massive	O
doses	O
of	O
this	O
drug	O
.	O

acute	I-Problem
myocardial	I-Problem
infarction	I-Problem
during	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
methylprednisolone	I-Treatment
therapy	I-Treatment
for	O
graves	I-Problem
'	I-Problem
ophthalmopathy	I-Problem
.	O

with	O
itraconazole	I-Treatment
,	O
hepatotoxic	I-Problem
reactions	O
have	O
only	O
very	O
rarely	O
been	O
reported	O
,	O
and	O
histologic	O
data	I-Test
are	O
lacking	O
.	O

we	O
describe	O
in	O
detail	O
the	O
first	O
u	O
.	O
s	O
.	O
case	O
report	O
,	O
of	O
a	O
4	O
(	O
1	O
/	O
2	I-Background
)	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
who	O
experienced	O
angioedema	I-Problem
during	O
treatment	O
with	O
oxcarbazepine	I-Treatment
.	O

caution	I-Problem
should	O
be	O
used	O
when	O
coadministering	I-Treatment
enfuvirtide	I-Treatment
and	I-Treatment
niacin	I-Treatment
to	O
hiv	I-Problem
-	I-Background
infected	I-Background
patients	I-Background
.	O

several	O
case	I-Background
reports	O
of	O
aplastic	I-Problem
anemia	I-Problem
with	O
use	O
of	O
acetazolamide	I-Treatment
,	O
and	O
two	O
cases	O
with	O
use	O
of	O
methazolamide	O
,	O
have	O
appeared	O
in	O
the	O
literature	O
.	O

ssris	I-Treatment
and	I-Treatment
fentanyl	I-Treatment
are	I-Treatment
commonly	I-Treatment
co	I-Treatment
-	I-Treatment
administered	I-Treatment
,	O
especially	O
in	O
the	O
setting	O
of	O
chronic	I-Problem
or	I-Problem
malignant	I-Problem
pain	I-Problem
,	O
as	O
underlying	I-Problem
depression	I-Problem
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
pain	O
.	O

in	O
this	O
report	O
we	O
present	O
four	O
patients	I-Background
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	O
drugs	O
,	O
in	O
whom	O
asterixis	I-Problem
was	O
triggered	O
either	O
by	O
adding	O
carbamazepine	I-Treatment
(	O
cbz	O
)	O
to	O
a	O
treatment	O
regimen	O
,	O
or	O
by	O
increasing	O
its	O
dosage	O
.	O

squamous	I-Problem
-	I-Problem
cell	I-Problem
carcinoma	I-Problem
arising	I-Problem
in	O
a	O
basal	O
-	O
cell	O
epithelioma	O
treated	O
with	O
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
.	O

the	I-Background
case	I-Background
of	I-Background
a	I-Background
bipolar	I-Problem
patient	I-Background
who	O
developed	O
thyrotoxicosis	I-Problem
with	I-Problem
severe	I-Problem
exophthalmos	I-Problem
while	O
on	O
lithium	I-Treatment
therapy	O
is	O
described	O
.	O

the	I-Background
patient	I-Background
received	O
only	O
the	O
ophthalmic	I-Treatment
sulfonamide	I-Treatment
,	I-Treatment
and	I-Treatment
it	I-Treatment
was	I-Treatment
used	I-Treatment
for	I-Treatment
one	I-Other
day	I-Other
,	O
but	O
he	I-Background
developed	O
stevens	I-Problem
-	I-Problem
johnson	I-Problem
syndrome	I-Problem
.	O

papillary	I-Problem
necrosis	I-Problem
associated	O
with	O
the	O
hiv	I-Problem
protease	O
inhibitor	O
indinavir	I-Treatment
.	O

a	O
case	O
is	O
reported	O
of	O
a	I-Background
40	I-Background
year	I-Background
old	I-Background
woman	I-Background
treated	O
with	O
intraventricular	I-Treatment
il	I-Treatment
-	I-Treatment
2	I-Treatment
for	O
leptomeningeal	I-Problem
disease	I-Problem
who	O
developed	O
progressive	I-Problem
cognitive	I-Problem
dysfunction	I-Problem
.	O

we	O
document	O
the	O
abrupt	O
development	O
of	O
an	O
extensive	I-Problem
choroidal	I-Problem
detachment	I-Problem
after	O
initiation	O
of	O
dorzolamide	I-Treatment
therapy	I-Treatment
in	O
a	O
surgically	I-Problem
untreated	I-Problem
eye	I-Problem
with	I-Problem
primary	I-Problem
open	I-Problem
-	I-Problem
angle	I-Problem
glaucoma	I-Problem
.	O

serotonin	I-Treatment
toxicity	I-Problem
as	O
a	O
consequence	O
of	O
linezolid	I-Treatment
use	I-Treatment
in	I-Treatment
revision	I-Treatment
hip	I-Treatment
arthroplasty	I-Treatment
.	O

gallstones	I-Problem
and	I-Problem
bile	I-Problem
sludge	I-Problem
are	O
common	O
side	O
effects	O
of	O
octreotide	I-Treatment
therapy	I-Treatment
but	O
rarely	O
become	O
symptomatic	O
or	O
require	O
treatment	O
.	O

the	O
authors	O
'	O
results	O
suggest	O
that	O
l	I-Treatment
-	I-Treatment
dopa	I-Treatment
may	O
cause	O
daytime	I-Problem
somnolence	I-Problem
in	O
some	I-Background
patients	I-Background
with	I-Background
parkinson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
.	O

seventy	O
-	O
four	O
per	O
cent	O
of	I-Background
patients	I-Background
with	I-Background
epileptogenic	I-Problem
disorders	I-Background
seen	O
at	O
the	O
emergency	O
unit	O
at	O
groote	O
schuur	O
hospital	O
were	O
on	O
phenytoin	I-Treatment
and	O
11	O
.	O
6	O
%	O
of	I-Background
these	I-Background
had	O
blood	I-Problem
levels	I-Test
in	I-Problem
the	I-Problem
toxic	I-Problem
range	I-Problem
.	O

based	O
on	O
the	O
history	O
and	O
clinical	O
features	O
,	O
a	O
diagnosis	O
of	O
insulin	I-Treatment
-	O
induced	O
lipohypertrophy	I-Problem
was	O
made	O
.	O

an	O
unusual	O
presentation	O
of	O
spontaneous	I-Problem
sub	I-Problem
-	I-Problem
conjunctival	I-Problem
haematoma	I-Problem
in	O
a	I-Background
patient	I-Background
receiving	O
warfarin	I-Treatment
.	O

he	O
developed	O
congestive	I-Problem
heart	I-Problem
failure	I-Problem
5	I-Other
days	I-Other
after	I-Treatment
administration	I-Treatment
of	I-Treatment
cyclophosphamide	I-Treatment
.	O

fulminant	I-Problem
liver	I-Problem
failure	I-Problem
associated	O
with	O
clarithromycin	I-Treatment
.	O

nifedipine	I-Treatment
may	O
induce	O
,	O
or	O
aggravate	O
,	O
pre	O
-	O
existing	O
,	O
gastro	I-Problem
-	I-Problem
oesophageal	I-Problem
reflux	I-Problem
.	O

rifampin	I-Treatment
-	O
associated	O
thrombocytopenia	I-Problem
secondary	I-Problem
to	I-Problem
poor	I-Problem
compliance	I-Problem
.	O

conclusions	O
:	O
there	O
was	O
a	O
temporal	O
relationship	O
between	O
the	O
onset	I-Problem
of	I-Problem
nonconvulsive	I-Problem
status	I-Problem
epilepticus	I-Problem
and	O
initiation	I-Treatment
of	I-Treatment
ifosfamide	I-Treatment
infusion	I-Treatment
.	O

gemcitabine	I-Treatment
-	O
induced	O
pericardial	I-Problem
effusion	I-Problem
and	I-Problem
tamponade	I-Problem
after	O
unblocked	I-Problem
cardiac	I-Problem
irradiation	I-Problem
.	O

although	O
useful	O
in	O
the	O
management	O
of	O
chronic	I-Problem
alcoholism	I-Problem
,	O
disulfiram	I-Treatment
is	O
being	O
increasingly	O
associated	O
with	O
a	I-Problem
wide	I-Problem
spectrum	I-Problem
of	I-Problem
side	I-Problem
effects	I-Problem
and	I-Problem
untoward	I-Problem
medical	I-Problem
sequelae	I-Problem
,	I-Problem
which	I-Problem
now	I-Problem
include	I-Problem
catatonia	I-Problem
.	O

discussion	O
:	O
the	O
naranjo	I-Test
probability	I-Test
scale	I-Test
indicated	O
a	O
probable	O
relationship	O
between	O
sertraline	I-Treatment
treatment	O
and	O
the	O
onset	O
of	O
rhabdomyolysis	I-Problem
.	O

severe	O
raynaud	I-Problem
'	I-Problem
s	I-Problem
phenomenon	I-Problem
with	O
yohimbine	I-Treatment
therapy	O
for	O
erectile	I-Problem
dysfunction	I-Problem
.	O

possible	O
theophylline	I-Problem
toxicity	I-Problem
during	O
anesthesia	I-Treatment
.	O

calcification	I-Problem
and	I-Problem
ossification	I-Problem
of	I-Problem
the	I-Problem
spinal	I-Problem
arachnoid	I-Problem
after	O
intrathecal	I-Treatment
administration	I-Treatment
of	I-Treatment
depo	I-Treatment
-	I-Treatment
medrol	I-Treatment
.	O

circulating	O
anticoagulant	O
in	O
the	O
procainamide	I-Treatment
-	O
induced	O
lupus	I-Problem
syndrome	I-Problem
.	O

this	O
report	O
describes	O
a	I-Background
case	I-Background
of	O
bilateral	I-Problem
ptosis	I-Problem
induced	O
by	O
chloroquine	I-Treatment
.	O

when	O
the	O
data	O
of	O
the	O
57	O
patients	I-Background
are	O
evaluated	O
,	O
a	O
reversible	O
direct	O
cytotoxic	I-Problem
effect	I-Problem
of	O
ticlopidine	I-Treatment
on	O
the	O
pluripotent	O
/	O
bipotent	O
hematopoietic	O
progenitor	O
stem	O
cell	O
is	O
proposed	O
.	O

we	O
report	O
a	I-Background
child	I-Background
with	I-Background
yolk	I-Problem
sac	I-Problem
tumor	I-Problem
who	O
developed	O
localized	I-Problem
pigmentation	I-Problem
after	O
the	I-Other
first	I-Other
course	I-Other
of	I-Treatment
chemotherapy	I-Treatment
regimen	I-Treatment
that	I-Treatment
included	I-Treatment
cisplatin	I-Treatment
,	I-Treatment
etoposide	I-Treatment
and	I-Treatment
bleomycin	I-Treatment
.	O

except	O
hypothyroidism	I-Problem
after	O
radioiodine	I-Treatment
treatment	I-Treatment
(	I-Treatment
euthyroid	I-Treatment
under	I-Treatment
substitutional	I-Treatment
therapy	I-Treatment
)	I-Treatment
,	O
she	I-Background
suffered	O
from	O
no	O
other	O
diseases	O
.	O

late	I-Problem
lethal	I-Problem
hepatitis	I-Problem
b	I-Problem
virus	I-Problem
reactivation	I-Problem
after	O
rituximab	I-Treatment
treatment	O
of	O
low	I-Problem
-	I-Problem
grade	I-Problem
cutaneous	I-Problem
b	I-Problem
-	I-Problem
cell	I-Problem
lymphoma	I-Problem
.	O

despite	O
the	O
low	I-Treatment
dosage	I-Treatment
of	I-Treatment
warfarin	I-Treatment
,	O
international	I-Problem
normalized	I-Test
ratio	I-Test
(	I-Problem
inr	I-Problem
)	I-Problem
was	I-Problem
markedly	I-Problem
elevated	I-Problem
from	O
1	I-Treatment
.	I-Treatment
15	I-Treatment
to	I-Treatment
11	I-Treatment
.	O
28	I-Treatment
for	O
only	O
4	I-Other
days	I-Other
,	O
and	O
bleeding	I-Problem
symptoms	I-Problem
concurrently	O
developed	O
.	O

the	O
possible	O
role	O
of	O
interferon	I-Treatment
beta	I-Treatment
in	O
the	O
pathogenesis	O
of	O
sarcoidosis	I-Problem
in	O
this	I-Background
patient	I-Background
is	O
discussed	O
.	O

we	O
hypothesize	O
that	O
a	O
pharmacodynamic	O
or	O
pharmacokinetic	O
drug	O
interaction	O
between	O
venlafaxine	I-Treatment
and	I-Treatment
trimipramine	I-Treatment
involving	O
the	O
cyp2d6	O
isoenzyme	O
may	O
have	O
played	O
a	O
role	O
in	O
inducing	O
the	O
seizures	I-Problem
.	O

a	O
case	O
is	O
described	O
of	O
severe	I-Problem
splenic	I-Problem
hemorrhage	I-Problem
and	I-Problem
rupture	I-Problem
which	O
developed	O
3	I-Other
h	I-Other
after	I-Treatment
completion	I-Treatment
of	I-Treatment
tpa	I-Treatment
infusion	I-Treatment
for	O
suspected	I-Problem
acute	I-Problem
myocardial	I-Problem
infarction	I-Problem
.	O

three	O
weeks	O
later	O
,	O
the	O
decerebrate	I-Problem
rigidity	I-Problem
and	I-Problem
high	I-Problem
bp	I-Problem
remained	O
,	O
and	O
tizanidine	I-Treatment
was	O
initiated	O
to	O
see	O
whether	O
the	O
decrease	O
in	O
muscle	O
tone	O
could	O
facilitate	O
hypertension	I-Problem
control	I-Problem
and	I-Problem
motor	I-Problem
recovery	I-Problem
.	O

conclusions	O
:	O
the	O
administration	O
of	O
prostaglandin	I-Treatment
e1	I-Treatment
to	O
neonates	I-Background
can	O
cause	O
gastric	I-Problem
-	I-Problem
outlet	I-Problem
obstruction	I-Problem
due	I-Problem
to	I-Problem
antral	I-Problem
hyperplasia	I-Problem
.	O

during	I-Other
and	I-Other
after	I-Other
ifn	I-Treatment
therapy	I-Treatment
we	O
should	O
consider	O
the	O
possibility	O
of	O
occurrence	O
of	O
iddm	I-Problem
as	I-Problem
well	I-Problem
as	I-Problem
other	I-Problem
autoimmune	I-Problem
diseases	I-Problem
and	O
observe	O
the	O
clinical	O
course	O
carefully	O
.	O

captopril	I-Treatment
-	O
related	O
(	O
and	O
-	O
induced	O
?	O
)	O
asthma	I-Problem
.	O

according	O
to	O
the	O
naranjo	O
probability	I-Test
scale	I-Test
,	O
the	O
papular	I-Problem
eruption	I-Problem
was	O
probably	O
caused	O
by	O
methotrexate	I-Treatment
.	O

the	O
patient	O
'	O
s	O
defects	O
may	O
be	O
due	O
to	O
methimazole	I-Treatment
teratogenicity	I-Problem
or	O
could	O
represent	O
a	O
previously	O
undescribed	O
syndrome	O
affecting	O
ectodermal	O
structures	O
.	O

conclusions	O
:	O
itraconazole	I-Treatment
-	O
induced	O
liver	I-Problem
injury	I-Problem
presents	I-Problem
with	I-Problem
a	I-Problem
cholestatic	I-Problem
pattern	I-Problem
of	I-Problem
injury	I-Problem
with	I-Problem
damage	I-Problem
to	I-Problem
the	I-Problem
interlobular	I-Problem
bile	I-Problem
ducts	I-Problem
,	I-Problem
possibly	I-Problem
leading	I-Problem
to	I-Problem
ductopenia	I-Problem
.	O

rhabdomyolysis	I-Problem
resulting	O
from	O
the	O
drug	O
interaction	O
between	O
diltiazem	I-Treatment
and	I-Treatment
other	I-Treatment
hmg	I-Treatment
-	I-Treatment
coa	I-Treatment
reductase	I-Treatment
inhibitors	I-Treatment
has	O
been	O
described	O
in	O
the	O
literature	O
.	O

acute	O
angioedema	I-Problem
response	O
to	O
topical	O
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
therapy	O
.	O

hypersensitivity	I-Problem
reactions	I-Problem
due	O
to	O
chloramphenicol	I-Treatment
are	O
rarely	O
reported	O
in	O
the	O
literature	O
.	O

diagnosis	O
of	O
sclerosing	I-Problem
glomerulonephritis	I-Problem
occurred	O
in	O
this	O
patient	I-Background
during	O
anastrozole	I-Treatment
use	O
,	O
suggesting	O
a	O
newly	O
defined	O
side	O
effect	O
of	O
anastrozole	O
.	O

a	I-Background
patient	I-Background
with	I-Background
coccidioidal	I-Problem
meningitis	I-Problem
was	O
treated	O
with	O
intrathecally	I-Treatment
administered	I-Treatment
amphotericin	I-Treatment
b	I-Treatment
,	O
and	O
an	I-Problem
acute	I-Problem
toxic	I-Problem
delirium	I-Problem
with	I-Problem
eeg	I-Problem
abnormalities	I-Problem
developed	O
.	O

this	O
case	O
raises	O
important	O
questions	O
about	O
non	I-Problem
-	I-Problem
ketotic	I-Problem
,	I-Problem
hyperosmolar	I-Problem
diabetic	I-Problem
coma	I-Problem
with	O
antipsychotics	I-Treatment
,	O
the	O
possible	O
association	O
between	O
hyperglycaemia	I-Problem
and	I-Problem
hyperthermia	I-Problem
,	O
and	O
the	O
direction	O
of	O
causality	O
in	O
this	O
,	O
the	O
recognition	O
of	O
either	O
syndrome	O
when	O
they	O
co	O
-	O
exist	O
and	O
management	O
issues	O
in	O
such	O
patients	O
.	O

conclusions	O
:	O
reversible	I-Problem
lupus	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
appears	O
to	O
be	O
a	O
rare	O
but	O
significant	O
side	O
effect	O
of	O
5	I-Treatment
-	I-Treatment
asa	I-Treatment
compounds	O
.	O

a	I-Background
patient	I-Background
with	I-Background
chronic	I-Problem
myeloid	I-Problem
leukaemia	I-Problem
treated	O
with	O
busulphan	I-Treatment
for	I-Treatment
4	I-Other
-	I-Other
5	I-Other
years	I-Other
,	O
developed	O
signs	O
of	O
busulphan	I-Problem
toxicity	I-Problem
and	I-Problem
portal	I-Problem
hypertension	I-Problem
with	I-Problem
ascites	I-Problem
,	I-Problem
oesophageal	I-Problem
varices	I-Problem
and	I-Problem
jaundice	I-Problem
.	O

several	O
cases	O
of	O
lithium	I-Treatment
-	O
induced	O
creutzfeldt	I-Problem
-	I-Problem
jakob	I-Problem
syndrome	I-Problem
have	O
been	O
reported	O
to	O
date	O
;	O
all	O
of	O
them	O
were	O
elderly	I-Background
patients	I-Background
and	O
a	O
half	O
had	O
"	I-Treatment
therapeutic	I-Treatment
"	I-Treatment
lithium	I-Test
serum	I-Test
levels	I-Test
.	O

there	O
is	O
,	O
however	O
,	O
currently	O
no	O
data	O
on	O
the	O
effect	O
of	O
combined	I-Background
hyperglycaemia	I-Treatment
and	I-Background
hyperinsulinaemia	I-Treatment
on	O
the	O
renal	I-Test
and	I-Problem
ocular	I-Test
blood	I-Test
flow	I-Test
seen	O
in	O
diabetic	I-Problem
patients	I-Background
on	O
insulin	I-Treatment
therapy	I-Treatment
.	O

pemphigus	I-Problem
vulgaris	I-Problem
precipitated	O
by	O
glibenclamide	I-Treatment
therapy	O
.	O

methimazole	I-Treatment
-	O
associated	O
cholestatic	I-Problem
liver	I-Problem
injury	I-Problem
:	O
case	O
report	O
and	O
brief	O
literature	O
review	O
.	O

the	O
most	O
likely	O
cause	O
of	O
such	O
hyponatremic	I-Problem
episode	I-Problem
is	O
vinblastine	I-Treatment
.	O

anti	O
-	O
tuberculous	O
drugs	O
had	O
been	O
stopped	O
on	O
the	O
2nd	O
day	O
of	O
therapy	O
due	O
to	O
development	O
of	O
optic	I-Problem
neuritis	I-Problem
secondary	I-Problem
to	O
ethambutol	I-Treatment
administration	O
at	O
another	O
hospital	O
.	O

based	O
on	O
this	O
experience	O
,	O
we	O
suggest	O
that	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
ketamine	I-Treatment
added	I-Treatment
to	I-Treatment
propofol	I-Treatment
may	O
be	O
associated	O
with	O
prevention	O
of	O
ea	I-Problem
in	O
children	I-Background
with	I-Background
a	I-Background
history	I-Background
of	I-Background
ea	I-Problem
with	I-Problem
propofol	I-Problem
tiva	I-Problem
.	O

tetany	I-Problem
in	O
a	I-Background
child	I-Background
with	I-Background
aids	I-Problem
receiving	O
intravenous	I-Treatment
tobramycin	I-Treatment
.	O

sideroblastic	I-Problem
anemia	I-Problem
due	O
to	O
linezolid	I-Treatment
in	O
a	O
patient	I-Background
with	I-Background
a	I-Background
left	I-Problem
ventricular	I-Problem
assist	I-Problem
device	I-Problem
.	O

oral	I-Treatment
dapsone	I-Treatment
has	O
been	O
available	O
for	O
over	O
60	O
years	O
and	O
has	O
been	O
used	O
to	O
treat	O
severe	O
acne	O
vulgaris	O
;	O
however	O
,	O
the	O
oral	O
formulation	O
is	O
known	O
to	O
cause	O
dose	I-Problem
-	I-Problem
dependent	I-Problem
haematological	I-Problem
reactions	I-Problem
and	O
is	O
currently	O
indicated	O
only	O
for	O
diseases	O
such	O
as	O
dermatitis	I-Problem
herpetiformis	I-Problem
and	O
hansen	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
.	O

enalapril	I-Treatment
-	O
induced	O
anemia	I-Problem
in	O
two	I-Background
kidney	I-Problem
transplant	I-Problem
recipients	I-Background
.	O

purpose	O
:	O
to	O
report	O
two	O
cases	O
in	O
which	O
topical	I-Treatment
brimonidine	I-Treatment
resulted	O
in	O
apparent	I-Problem
central	I-Problem
nervous	I-Problem
system	I-Problem
depression	I-Problem
and	I-Problem
unresponsiveness	I-Problem
in	O
an	I-Background
infant	I-Background
.	O

background	O
:	O
interferon	I-Treatment
beta	I-Treatment
has	O
become	O
standard	O
therapy	O
for	O
reducing	O
relapse	O
frequency	O
in	O
relapsing	I-Problem
/	I-Problem
remitting	I-Problem
multiple	I-Problem
sclerosis	I-Problem
(	O
rrms	O
)	O
.	O

in	O
this	O
article	O
lithium	O
is	O
not	O
discussed	O
,	O
although	O
there	O
are	O
a	O
number	O
of	O
concerns	O
about	O
lithium	O
'	O
s	O
potential	O
teratogenicity	O
,	O
and	O
it	O
has	O
been	O
implicated	O
in	O
epstein	I-Problem
'	I-Problem
s	I-Problem
anomaly	I-Problem
,	O
a	O
congenital	O
heart	O
defect	O
among	O
infants	O
born	O
to	O
women	O
taking	O
lithium	I-Treatment
;	O
as	O
with	O
other	O
medications	O
,	O
however	O
,	O
the	O
data	O
have	O
specific	O
limitations	O
.	O

hepatotoxicity	I-Problem
of	O
paracetamol	I-Treatment
enhanced	O
by	O
ingestion	I-Treatment
of	I-Treatment
alcohol	I-Treatment
:	O
report	O
of	O
two	O
cases	I-Background
.	I-Background

cancer	I-Problem
patients	I-Background
who	O
are	O
receiving	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
treatment	O
and	O
are	I-Background
dpd	I-Problem
deficient	I-Problem
can	O
develop	O
severe	I-Problem
side	I-Problem
effects	I-Problem
.	O

a	I-Background
patient	I-Background
is	O
described	O
who	O
developed	O
a	O
poorly	I-Problem
differentiated	I-Problem
sarcoma	I-Problem
after	O
cyclophosphamide	I-Treatment
was	O
used	O
to	O
treat	O
his	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
.	O

photo	I-Problem
-	I-Test
onycholysis	I-Test
caused	O
by	O
olanzapine	I-Treatment
and	I-Treatment
aripiprazole	I-Treatment
.	O

we	O
observed	O
5	O
reactions	O
in	O
3	O
patients	I-Background
that	O
appear	O
to	O
be	O
related	O
to	O
a	O
high	I-Treatment
dose	I-Treatment
-	I-Test
infusion	I-Treatment
time	I-Treatment
ratio	I-Treatment
,	O
indicating	O
that	O
dose	O
and	O
rate	O
of	O
infusion	O
may	O
be	O
important	O
factors	O
in	O
precipitating	O
anaphylactoid	I-Problem
reactions	I-Problem
with	O
cisplatin	I-Treatment
.	O

conclusion	O
:	O
fixed	I-Problem
drug	I-Problem
eruption	I-Problem
is	O
associated	O
with	O
many	O
drugs	O
but	O
this	O
is	O
the	O
first	O
such	O
report	O
with	O
omeprazole	I-Treatment
.	O

one	O
type	O
of	O
smon	I-Problem
is	O
associated	O
with	O
acrodermatitis	I-Problem
enteropathica	I-Problem
which	O
has	O
a	O
very	O
high	O
frequency	O
of	O
occurrence	O
in	O
association	O
with	O
administration	O
of	O
clioquinol	I-Treatment
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
amiodarone	I-Treatment
-	O
induced	O
thyrotoxicosis	I-Problem
of	O
protracted	O
duration	O
,	O
unresponsive	O
to	O
conventional	O
thionamide	O
therapy	O
,	O
with	O
therapy	O
limited	O
by	O
severe	O
adverse	O
drug	O
reactions	O
.	O

the	O
addition	O
of	O
ciprofloxacin	I-Treatment
to	O
chronic	I-Treatment
simvastatin	I-Treatment
therapy	O
led	O
to	O
the	O
development	O
of	O
rhabdomyolysis	I-Problem
.	O

nephropathy	I-Problem
caused	O
by	O
methicillin	I-Treatment
therapy	I-Treatment
for	I-Treatment
staphylococcal	I-Problem
septicemia	I-Problem
.	O

four	O
patients	I-Background
in	O
whom	O
pulmonary	I-Problem
oedema	I-Problem
developed	O
during	O
tocolysis	I-Treatment
with	I-Treatment
hexoprenaline	I-Treatment
are	O
described	O
and	O
the	O
aetiological	O
factors	O
and	O
pathogenesis	O
of	O
this	O
potentially	O
lethal	O
complication	O
discussed	O
.	O

a	O
case	O
of	O
skeletal	I-Problem
fluorosis	I-Problem
induced	O
by	O
prolonged	O
treatment	O
with	O
niflumic	I-Treatment
acid	I-Treatment
,	O
a	O
fast	O
-	O
acting	O
non	O
-	O
steroid	O
antiinflammatory	O
agent	O
,	O
is	O
reported	O
in	O
a	I-Background
35	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
suffering	I-Background
from	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
and	O
treated	O
,	O
in	I-Treatment
addition	I-Treatment
,	I-Treatment
with	I-Treatment
corticosteroids	I-Treatment
.	O

a	I-Background
65	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
on	O
warfarin	I-Treatment
therapy	I-Treatment
with	O
a	I-Problem
sudden	I-Problem
spontaneous	I-Problem
onset	I-Problem
of	I-Problem
sub	I-Problem
-	I-Problem
conjunctival	I-Problem
haematoma	I-Problem
associated	I-Problem
with	I-Problem
bloody	I-Problem
tears	I-Problem
was	O
assessed	O
in	O
the	O
clinic	O
following	O
a	O
referral	O
from	O
an	O
optometrist	O
.	O

this	O
case	O
report	O
describes	O
the	O
development	O
of	O
asymptomatic	I-Problem
visual	I-Problem
field	I-Problem
defects	I-Problem
(	O
vfds	O
)	O
in	O
a	O
psychiatric	O
patient	I-Background
with	O
bipolar	I-Problem
disorder	I-Problem
receiving	O
adjunctive	O
tiagabine	I-Treatment
treatment	O
.	O

cardiorespiratory	I-Problem
toxicity	I-Problem
due	O
to	O
miconazole	I-Treatment
.	O

lovastatin	I-Treatment
-	O
induced	O
rhabdomyolysis	I-Problem
possibly	O
associated	O
with	O
clarithromycin	I-Treatment
and	O
azithromycin	I-Treatment
.	O

for	O
prevention	O
of	O
cyp2e1	O
-	O
mediated	O
bioactivation	O
,	O
depending	O
on	O
protoxicant	I-Treatment
disposition	O
,	O
a	I-Treatment
second	I-Treatment
dsf	I-Treatment
dose	I-Treatment
might	O
be	O
necessary	O
to	O
completely	O
prevent	O
toxicity	O
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
treated	O
with	O
gold	I-Treatment
salts	I-Treatment
,	O
who	O
developed	O
bilateral	I-Problem
interstitial	I-Problem
pulmonary	I-Problem
abnormalities	I-Problem
and	O
showed	O
a	O
dramatic	O
response	O
on	O
corticosteroid	I-Treatment
therapy	O
.	O

pneumonitis	I-Problem
is	O
emerging	O
as	O
one	O
of	O
the	O
most	O
unpredictable	O
and	O
potentially	O
serious	O
,	O
adverse	O
effects	O
of	O
treatment	O
with	O
mtx	I-Treatment
.	O

a	O
chronic	O
reaction	O
associated	O
with	O
long	I-Treatment
-	I-Treatment
term	I-Treatment
treatment	I-Treatment
with	I-Treatment
nitrofurantoin	I-Treatment
has	O
also	O
been	O
reported	O
and	O
causes	O
irreversible	I-Problem
pulmonary	I-Problem
fibrosis	I-Problem
.	O

nitrofurantoin	I-Treatment
-	O
induced	O
acute	I-Problem
liver	I-Problem
damage	I-Problem
in	O
pregnancy	I-Background
.	O

a	I-Background
58	I-Background
-	I-Background
yr	I-Background
-	I-Background
old	I-Background
male	I-Background
patient	I-Background
with	I-Background
essential	I-Problem
thrombocythaemia	I-Problem
(	I-Problem
et	I-Problem
)	I-Problem
developed	O
chronic	I-Problem
myeloid	I-Problem
leukaemia	I-Problem
(	I-Problem
cml	I-Problem
)	I-Problem
after	O
continuous	I-Treatment
uneventful	I-Treatment
treatment	I-Treatment
with	I-Treatment
hydroxyurea	I-Treatment
for	I-Treatment
18	I-Other
yr	I-Other
.	O

a	I-Background
64	I-Background
year	I-Background
old	I-Background
man	I-Background
with	I-Background
recurrent	I-Problem
metastatic	I-Problem
squamous	I-Problem
cell	I-Problem
carcinoma	I-Problem
of	I-Problem
the	I-Problem
head	I-Problem
and	I-Problem
neck	I-Problem
developed	O
severe	O
skin	I-Problem
rash	I-Problem
and	I-Problem
bone	I-Problem
marrow	I-Problem
aplasia	I-Problem
4	I-Other
and	I-Other
7	I-Other
days	I-Other
,	O
respectively	O
,	O
following	O
a	I-Other
single	I-Other
dose	I-Other
of	I-Treatment
40	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
methotrexate	I-Treatment
(	I-Treatment
mtx	I-Treatment
)	I-Treatment
.	O

we	O
present	O
four	O
cases	I-Background
in	O
which	O
the	O
use	O
of	O
heparin	I-Treatment
was	O
associated	O
with	O
hyperkalemia	I-Problem
and	O
discuss	O
the	O
pathophysiology	O
.	O

three	O
cycles	O
of	O
chemotherapy	I-Treatment
had	O
been	O
administered	O
without	O
complications	O
when	O
,	O
at	I-Treatment
the	I-Treatment
beginning	I-Treatment
of	I-Treatment
the	I-Treatment
fourth	I-Other
cycle	I-Other
,	O
the	I-Background
patient	I-Background
developed	O
clinical	O
and	O
laboratory	O
abnormalities	O
consistent	O
with	O
the	O
development	O
of	O
the	O
hemolytic	I-Problem
-	I-Problem
uremic	I-Problem
syndrome	I-Problem
.	I-Problem

keratitis	I-Problem
in	O
methamphetamine	I-Treatment
abusers	I-Treatment
.	O

a	O
rechallenge	I-Test
,	O
performed	O
in	O
both	I-Background
patients	I-Background
,	O
confirmed	O
the	O
diagnosis	O
of	O
mesalamine	I-Treatment
-	O
induced	O
pancreatitis	I-Problem
.	O

central	I-Problem
nervous	I-Problem
system	I-Problem
toxicity	I-Problem
associated	O
with	O
meperidine	I-Treatment
use	O
in	O
hepatic	I-Problem
disease	I-Problem
.	O

to	O
our	O
knowledge	O
,	O
this	O
case	O
is	O
the	O
first	O
published	O
report	O
of	O
levofloxacin	I-Treatment
-	O
induced	O
ten	I-Problem
.	O

on	O
the	O
second	O
day	O
of	O
hospitalization	O
,	O
it	O
was	O
noted	O
that	O
the	O
patient	I-Background
'	O
s	O
dyspnea	I-Problem
and	I-Problem
sinus	I-Problem
bradycardia	I-Problem
could	O
be	O
related	O
to	O
a	I-Treatment
recent	I-Treatment
increase	I-Treatment
in	I-Treatment
his	I-Treatment
timolol	I-Treatment
dosage	I-Treatment
.	O

three	I-Other
months	I-Other
following	I-Treatment
splenectomy	I-Treatment
,	O
multiple	I-Problem
abscesses	I-Problem
occurred	I-Problem
in	I-Problem
the	I-Problem
muscles	I-Problem
of	I-Problem
both	I-Problem
thighs	I-Problem
while	O
the	I-Background
patient	I-Background
was	O
receiving	O
the	O
third	I-Treatment
course	I-Treatment
of	I-Treatment
the	I-Treatment
chop	I-Treatment
regimen	I-Treatment
.	O

methylene	I-Treatment
blue	I-Treatment
is	O
used	O
in	O
a	O
variety	O
of	O
surgical	O
settings	O
as	O
well	O
as	O
for	O
treatment	O
of	O
various	O
types	O
of	O
hypotensive	I-Problem
shock	I-Problem
and	O
methemoglobinaemia	I-Problem
.	O

methanol	I-Treatment
toxicity	I-Treatment
can	O
cause	O
severe	O
central	I-Problem
nervous	I-Problem
system	I-Problem
insult	I-Problem
in	O
which	O
a	O
characteristic	O
pattern	O
of	O
bilateral	O
putaminal	O
injury	O
is	O
noted	O
on	O
brain	O
imaging	I-Test
studies	I-Test
.	O

we	O
believe	O
that	O
these	O
skin	I-Problem
eruptions	I-Problem
belong	O
to	O
a	O
spectrum	O
of	O
neutrophilic	O
dermatoses	O
that	O
can	O
be	O
induced	O
or	O
aggravated	O
by	O
g	I-Treatment
-	I-Treatment
csf	I-Treatment
therapy	O
.	O

although	O
adverse	O
reactions	O
to	O
protamine	O
are	O
reported	O
infrequently	O
and	O
are	O
usually	O
mild	O
,	O
we	O
recently	O
observed	O
the	O
first	O
fatal	I-Problem
case	I-Problem
of	I-Problem
type	I-Problem
i	I-Problem
anaphylaxis	I-Problem
resulting	O
from	O
protamine	I-Treatment
.	O

we	O
have	O
reported	O
six	O
cases	I-Background
of	O
metoclopramide	I-Treatment
-	O
induced	O
parkinsonism	I-Problem
seen	O
in	O
consultation	O
over	O
a	O
two	O
-	O
year	O
period	O
.	O

neutrophilic	I-Problem
eccrine	I-Problem
hidradenitis	I-Problem
mimicking	O
cutaneous	O
vasculitis	O
in	O
a	I-Background
lupus	I-Problem
patient	I-Background
:	O
a	O
complication	O
of	O
cyclophosphamide	I-Treatment
.	O

gliclazide	I-Treatment
-	O
induced	O
acute	I-Problem
hepatitis	I-Problem
.	O

a	I-Background
16	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
male	I-Background
with	I-Background
acute	I-Problem
biphenotypic	I-Problem
leukemia	I-Problem
developed	O
evidence	O
of	O
the	O
eosinophilia	I-Problem
myalgia	I-Problem
syndrome	I-Problem
associated	O
with	O
total	I-Treatment
parenteral	I-Treatment
nutritional	I-Treatment
support	I-Treatment
with	I-Treatment
solutions	I-Treatment
containing	I-Treatment
tryptophan	I-Treatment
,	I-Treatment
which	I-Treatment
were	I-Treatment
given	I-Treatment
during	I-Treatment
his	I-Treatment
initial	I-Treatment
induction	I-Treatment
chemotherapy	I-Treatment
and	I-Treatment
also	I-Treatment
after	I-Treatment
autologous	I-Treatment
marrow	I-Treatment
transplantation	I-Treatment
.	O

subacute	I-Problem
cholestatic	I-Problem
hepatitis	I-Problem
likely	O
related	O
to	O
the	O
use	I-Treatment
of	I-Treatment
senna	I-Treatment
for	O
chronic	I-Problem
constipation	I-Problem
.	I-Problem

palmar	I-Problem
-	I-Problem
plantar	I-Problem
erythrodysaesthesia	I-Problem
(	I-Problem
ppe	I-Problem
)	I-Problem
is	O
an	I-Problem
uncommon	I-Problem
cutaneous	I-Problem
complication	I-Problem
of	O
cytotoxic	I-Treatment
chemotherapy	I-Treatment
which	O
generally	O
presents	O
as	O
a	I-Problem
painful	I-Problem
erythema	I-Problem
involving	I-Problem
the	I-Problem
palms	I-Problem
and	I-Problem
soles	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
an	I-Background
11	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
who	O
experienced	O
an	I-Problem
anaphylactic	I-Problem
reaction	I-Problem
after	I-Treatment
administration	I-Treatment
of	I-Treatment
bacitracin	I-Treatment
ointment	I-Treatment
.	O

the	I-Background
patient	I-Background
was	O
found	O
to	O
have	O
no	I-Problem
motile	I-Problem
sperm	I-Problem
with	I-Problem
a	I-Problem
normal	I-Problem
sperm	I-Problem
count	I-Problem
,	O
while	O
taking	O
a	O
dose	O
of	O
400	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
of	I-Treatment
carbamazepine	I-Treatment
.	O

a	I-Problem
fatal	I-Problem
pancytopenia	I-Problem
occurred	O
in	O
a	I-Background
patient	I-Background
with	I-Background
an	I-Background
history	I-Background
of	I-Background
depression	I-Problem
with	I-Background
hypomanic	I-Problem
rebounds	I-Problem
,	O
admitted	O
for	O
a	I-Problem
manic	I-Problem
episode	I-Problem
and	O
treated	I-Treatment
with	I-Treatment
levomepromazine	I-Treatment
,	I-Treatment
diazepam	I-Treatment
and	I-Treatment
lithium	I-Treatment
carbonate	I-Treatment
.	O

oxatomide	I-Treatment
is	O
an	O
antiallergic	O
drug	O
used	O
for	O
the	O
treatment	O
of	O
diseases	I-Problem
mediated	I-Problem
by	I-Problem
type	I-Problem
i	I-Problem
allergy	I-Problem
.	O

toxic	I-Problem
hepatitis	I-Problem
induced	O
by	O
disulfiram	I-Treatment
in	O
a	I-Background
non	I-Background
-	I-Background
alcoholic	I-Background
.	O

accordingly	O
,	O
camptocormia	I-Problem
is	O
a	O
dose	O
-	O
dependent	O
side	O
effect	O
of	O
valproate	I-Treatment
.	O

the	O
uncomplicated	O
long	I-Other
-	I-Other
term	I-Other
use	I-Treatment
of	I-Treatment
adequately	I-Treatment
-	I-Treatment
dosed	I-Treatment
aza	I-Treatment
and	I-Treatment
stable	I-Treatment
non	I-Treatment
-	I-Treatment
toxic	I-Treatment
metabolite	I-Treatment
levels	I-Treatment
could	I-Treatment
not	I-Treatment
acknowledge	I-Treatment
tpmt	I-Treatment
deficiency	I-Treatment
as	O
a	O
primary	O
cause	O
of	O
the	O
leukopenia	I-Problem
.	O

case	O
summary	O
:	O
a	O
65	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
patient	I-Background
chronically	I-Other
treated	I-Treatment
with	I-Treatment
the	I-Treatment
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitor	I-Treatment
(	I-Treatment
ssri	I-Treatment
)	I-Treatment
citalopram	I-Treatment
developed	O
confusion	I-Problem
,	I-Problem
agitation	I-Problem
,	I-Problem
tachycardia	I-Problem
,	I-Problem
tremors	I-Problem
,	I-Problem
myoclonic	I-Problem
jerks	I-Problem
and	I-Problem
unsteady	I-Problem
gait	I-Problem
,	I-Problem
consistent	I-Problem
with	I-Problem
serotonin	I-Problem
syndrome	I-Problem
,	O
following	I-Treatment
initiation	I-Treatment
of	I-Treatment
fentanyl	I-Treatment
,	O
and	O
all	O
symptoms	O
and	O
signs	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
.	O

such	O
a	O
case	O
induced	O
by	O
hypothyroidism	I-Problem
complicating	O
long	I-Other
-	I-Other
term	I-Other
therapy	I-Treatment
with	I-Treatment
amiodarone	I-Treatment
in	O
a	I-Background
45	I-Background
year	I-Background
old	I-Background
woman	I-Background
with	I-Background
pre	I-Problem
-	I-Problem
excitation	I-Problem
is	O
presented	O
.	O

the	O
diagnosis	O
was	O
based	O
on	O
the	O
rapid	I-Problem
onset	I-Problem
of	I-Problem
renal	I-Problem
failure	I-Problem
,	I-Problem
presence	I-Problem
of	I-Problem
eosinophilia	I-Problem
,	I-Problem
skin	I-Problem
rash	I-Problem
,	I-Problem
and	I-Problem
characteristic	I-Problem
renal	I-Problem
biopsy	I-Problem
finding	O
,	O
following	O
the	O
administration	O
of	O
ampicillin	I-Treatment
.	O

46	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
developed	O
painful	I-Problem
ulcers	I-Problem
over	I-Problem
her	I-Problem
lower	I-Problem
abdomen	I-Problem
in	I-Problem
the	I-Problem
form	I-Problem
of	I-Problem
reticulate	I-Problem
erythema	I-Problem
after	O
injecting	I-Treatment
interferon	I-Treatment
beta	I-Treatment
-	I-Treatment
1b	I-Treatment
subcutaneously	I-Treatment
for	O
multiple	I-Problem
sclerosis	I-Problem
.	O

lupus	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
caused	O
by	O
5	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
in	O
patients	I-Background
with	I-Background
inflammatory	I-Problem
bowel	I-Problem
disease	I-Problem
.	O

fatal	O
acute	I-Problem
tubular	I-Problem
necrosis	I-Problem
occurred	O
in	O
1	O
patient	I-Background
in	O
whom	O
intravesical	I-Treatment
formalin	I-Treatment
was	O
used	O
to	O
control	O
massive	I-Problem
persistent	I-Problem
hemorrhage	I-Problem
from	I-Problem
radiation	I-Problem
cystitis	I-Problem
.	O

the	O
hypercalcemia	I-Problem
responded	O
to	O
discontinuation	I-Treatment
of	I-Treatment
rhgh	I-Treatment
and	I-Treatment
a	I-Treatment
single	I-Treatment
dose	I-Treatment
of	I-Treatment
intravenous	I-Treatment
pamidronate	I-Treatment
disodium	I-Treatment
and	O
has	I-Problem
not	I-Problem
recurred	I-Problem
in	I-Problem
8	I-Problem
months	I-Problem
of	I-Problem
follow	I-Problem
-	I-Problem
up	I-Problem
.	O

the	O
authors	O
describe	O
three	O
families	I-Background
in	O
whom	O
the	O
occurrence	O
of	O
fvs	I-Problem
in	O
all	I-Background
the	I-Background
siblings	I-Background
strongly	O
suggests	O
hereditary	O
susceptibility	O
to	O
valproic	I-Treatment
acid	I-Treatment
-	I-Treatment
induced	I-Treatment
adverse	O
outcome	O
.	O

we	O
hypothesize	O
that	O
capecitabine	I-Treatment
-	O
induced	O
headache	I-Problem
is	O
vascular	O
in	O
nature	O
.	O

a	I-Problem
lupus	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
associated	O
with	O
infliximab	I-Treatment
therapy	O
.	O

a	O
case	O
report	O
of	O
a	I-Background
patient	I-Background
with	I-Background
probable	I-Problem
cisplatin	I-Problem
and	O
bleomycin	I-Treatment
-	O
induced	O
tma	I-Problem
is	O
presented	O
.	O

in	O
some	O
cases	O
this	O
seems	O
to	O
happen	O
because	O
spironolactone	I-Treatment
causes	O
diarrhoea	I-Problem
.	O

painful	I-Problem
neutrophilic	I-Problem
skin	I-Problem
lesions	I-Problem
were	O
observed	O
in	O
two	O
children	I-Background
receiving	O
granulocyte	I-Treatment
colony	I-Treatment
-	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
(	I-Treatment
g	I-Treatment
-	I-Treatment
csf	I-Treatment
)	I-Treatment
for	O
treatment	O
of	O
idiopathic	I-Problem
neutropenia	I-Problem
.	O

apparent	I-Problem
central	I-Problem
nervous	I-Problem
system	I-Problem
depression	I-Problem
in	O
infants	I-Background
after	O
the	O
use	O
of	O
topical	I-Treatment
brimonidine	I-Treatment
.	O

to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
insulin	I-Treatment
-	O
induced	O
lipohypertrophy	I-Problem
with	O
detailed	O
histological	I-Test
examinations	I-Test
.	O

tigecycline	I-Treatment
-	O
induced	O
acute	I-Problem
pancreatitis	I-Problem
:	O
case	O
report	O
and	O
literature	O
review	O
.	O

polymyositis	I-Problem
is	O
a	O
rare	O
complication	O
of	O
interferon	I-Treatment
alpha	I-Treatment
treatment	I-Treatment
as	O
a	O
result	O
of	O
immune	O
-	O
modulating	O
role	O
of	O
the	O
drug	O
itself	O
.	O

sodium	I-Treatment
thiosulfate	I-Treatment
is	I-Treatment
a	I-Treatment
neutralizing	I-Treatment
agent	I-Treatment
for	I-Treatment
cisplatin	I-Treatment
that	O
protects	I-Problem
against	I-Problem
renal	I-Problem
damage	I-Problem
.	O

anaphylactic	I-Problem
reaction	O
to	O
bacitracin	I-Treatment
ointment	I-Treatment
.	O

severe	I-Problem
bleomycin	I-Treatment
lung	I-Problem
toxicity	I-Problem
:	O
reversal	O
with	O
high	O
dose	O
corticosteroids	O
.	O

conclusions	O
:	O
although	O
mirtazapine	I-Treatment
offers	O
clinicians	O
a	O
combination	O
of	O
strong	O
efficacy	O
and	O
good	O
safety	O
,	O
we	O
suggest	O
bearing	O
ss	I-Problem
in	O
mind	O
when	O
prescribing	O
this	O
drug	O
,	O
especially	O
in	O
frail	I-Background
,	I-Background
elderly	I-Background
patients	I-Background
with	I-Background
underlying	I-Problem
chronic	I-Problem
conditions	I-Problem
.	O

five	O
cases	O
of	O
clindamycin	I-Treatment
-	O
associated	O
pseudomembranous	I-Problem
colitis	I-Problem
in	O
leukaemic	I-Problem
patients	I-Background
are	O
reported	O
.	O

three	O
days	O
after	O
receiving	O
intravitreal	I-Treatment
injection	I-Treatment
of	I-Treatment
bevacizumab	I-Treatment
(	I-Treatment
1	I-Treatment
.	I-Treatment
25	I-Treatment
mg	I-Treatment
in	I-Treatment
0	I-Treatment
.	I-Treatment
1	I-Treatment
ml	I-Treatment
)	I-Treatment
,	I-Treatment
he	I-Background
developed	O
acute	I-Problem
vision	I-Problem
loss	I-Problem
and	I-Problem
change	I-Problem
of	I-Problem
consciousness	I-Problem
.	O

the	O
proposed	O
cause	O
of	O
the	O
nausea	I-Problem
and	I-Problem
anorexia	I-Problem
was	I-Problem
digoxin	I-Treatment
toxicity	I-Problem
secondary	O
to	O
a	O
drug	O
-	O
drug	O
interaction	O
with	O
ciprofloxacin	I-Treatment
.	O

mitomycin	I-Treatment
c	I-Treatment
(	I-Treatment
mmc	I-Treatment
)	I-Treatment
is	O
an	O
alkylating	O
agent	O
that	O
has	O
been	O
recently	O
associated	O
with	O
the	I-Problem
hemolytic	I-Problem
-	I-Problem
uremic	I-Problem
syndrome	I-Problem
(	I-Problem
hus	I-Problem
)	I-Problem
.	O

muscle	O
biopsy	I-Test
revealed	O
variation	I-Problem
in	I-Problem
muscle	I-Problem
fiber	I-Problem
size	I-Problem
and	I-Problem
few	I-Problem
vacuolated	I-Problem
fibers	I-Problem
which	O
were	O
features	O
of	O
colchicine	I-Treatment
-	O
induced	O
myopathy	I-Problem
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	O
developed	O
neh	I-Problem
on	O
three	O
separate	O
occasions	O
provoked	O
by	O
two	O
different	O
chemotherapeutic	O
agents	O
-	O
-	O
cytarabine	I-Treatment
and	I-Treatment
mitoxantrone	I-Treatment
.	O

orofacial	I-Problem
dyskinesia	I-Problem
appeared	O
5	I-Other
hours	I-Other
after	I-Other
methylphenidate	I-Treatment
administration	O
,	O
persisted	O
for	O
10	O
hours	O
,	O
and	O
had	O
completely	O
resolved	O
within	O
2	O
days	O
.	O

present	O
results	O
suggested	O
that	O
coadministration	I-Treatment
of	I-Treatment
mexiletine	I-Treatment
increased	I-Treatment
blood	I-Treatment
tizanidine	I-Treatment
concentrations	I-Treatment
and	O
enhanced	O
tizanidine	I-Problem
pharmacodynamics	I-Problem
in	I-Problem
terms	I-Problem
of	I-Problem
reduction	I-Problem
in	I-Problem
blood	I-Problem
pressure	I-Problem
and	I-Problem
adverse	I-Problem
symptoms	I-Problem
.	O

bilateral	I-Problem
acoustic	I-Problem
(	I-Problem
viii	I-Problem
)	I-Problem
nerve	I-Problem
palsy	I-Problem
in	O
this	I-Background
patient	I-Background
was	O
most	O
likely	O
a	O
manifestation	O
of	O
vincristine	I-Treatment
neurotoxicity	I-Problem
.	O

acute	I-Problem
leukopenia	I-Problem
associated	O
with	O
silver	I-Treatment
sulfadiazine	I-Treatment
therapy	O
.	O

we	O
describe	O
two	O
cases	I-Background
of	I-Background
psvt	I-Problem
that	O
changed	O
to	O
non	I-Problem
-	I-Problem
sustained	I-Problem
polymorphic	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
after	O
administration	I-Treatment
of	I-Treatment
verapamil	I-Treatment
.	I-Treatment

we	O
described	O
the	O
occurrence	O
of	O
l	I-Treatment
-	I-Treatment
dopa	I-Treatment
-	O
induced	O
myoclonus	I-Problem
and	I-Problem
seizures	I-Problem
in	O
a	O
case	I-Background
of	I-Background
parkinsonism	I-Problem
with	O
its	O
seps	O
findings	O
.	O

retrospectively	O
,	O
bucillamine	I-Treatment
was	O
believed	O
to	O
be	O
the	O
cause	O
of	O
the	O
giant	I-Problem
hypertrophy	I-Problem
because	O
of	O
its	O
structural	O
similarity	O
to	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
,	O
which	O
was	O
the	O
subject	O
of	O
an	O
abundance	O
of	O
reports	O
of	O
mammary	O
hyperplasia	O
.	O

we	O
speculate	O
that	O
platelet	O
activation	O
induced	O
by	O
pfviii	I-Treatment
may	O
have	O
contributed	O
to	O
thrombosis	I-Problem
and	O
suggest	O
that	O
pfviii	O
be	O
used	O
with	O
caution	O
in	O
elderly	O
patients	O
with	O
pre	O
-	O
existing	O
cardiovascular	I-Problem
risk	O
factors	O
.	O

restoration	I-Problem
of	I-Problem
vancomycin	I-Treatment
susceptibility	I-Problem
in	I-Problem
enterococcus	I-Problem
faecalis	I-Problem
by	O
antiresistance	I-Treatment
determinant	I-Treatment
gene	I-Treatment
transfer	I-Treatment
.	O

dental	I-Problem
and	I-Problem
gingival	I-Problem
pain	I-Problem
as	O
side	O
effects	O
of	O
niacin	I-Treatment
therapy	O
.	O

we	O
describe	O
a	O
case	O
of	O
significant	I-Problem
elevation	I-Problem
of	I-Problem
serum	I-Problem
transaminases	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
6	I-Treatment
-	I-Treatment
tg	I-Treatment
for	O
a	O
flare	O
of	O
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
.	O

a	I-Background
patient	I-Background
developed	O
transient	I-Problem
,	I-Problem
acute	I-Problem
myopia	I-Problem
while	O
on	O
isotretinoin	I-Treatment
(	I-Treatment
accutane	I-Treatment
)	I-Treatment
therapy	O
for	O
acne	I-Problem
.	O

conclusions	O
:	O
the	O
pathogenesis	O
of	O
methotrexate	I-Treatment
-	O
induced	O
papular	I-Problem
eruption	I-Problem
in	O
collagen	I-Problem
vascular	I-Problem
diseases	I-Problem
may	O
suggest	O
cutaneous	O
small	O
-	O
vessel	O
vasculitis	O
.	O

aminophylline	I-Problem
hypersensitivity	I-Problem
apparently	O
due	O
to	O
ethylenediamine	I-Treatment
.	O

the	O
main	O
clinical	O
features	O
of	O
this	I-Background
58	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
patient	O
were	O
laboratory	O
evidence	O
of	O
leucopenia	I-Problem
and	I-Problem
cholestasis	I-Problem
,	I-Problem
and	I-Problem
biopsy	I-Problem
features	I-Test
of	I-Problem
fatty	I-Problem
liver	I-Problem
parenchyma	I-Problem
degeneration	I-Problem
with	I-Problem
granulocytic	I-Problem
portal	I-Problem
infiltration	I-Problem
and	I-Problem
bile	I-Problem
stasis	I-Problem
,	O
demonstrated	O
20	I-Other
days	I-Other
after	I-Other
the	O
initiation	O
of	O
antithyroid	I-Treatment
therapy	I-Treatment
with	I-Treatment
20	I-Treatment
mg	I-Treatment
methimazole	I-Treatment
daily	I-Other
.	O

excluding	O
other	O
causes	O
,	O
pentasa	I-Treatment
-	O
associated	O
pancytopenia	I-Problem
was	O
considered	O
.	O

results	O
:	O
a	I-Problem
patient	I-Problem
developed	O
a	O
bilaterally	I-Problem
symmetric	I-Problem
bull	I-Problem
'	I-Problem
s	I-Problem
-	I-Problem
eye	I-Problem
maculopathy	I-Problem
45	I-Other
years	I-Other
after	I-Other
taking	I-Treatment
quinacrine	I-Treatment
for	I-Treatment
18	I-Other
months	I-Other
as	O
prophylaxis	O
against	O
malaria	I-Problem
.	O

possible	O
digoxin	I-Treatment
toxicity	I-Problem
associated	O
with	O
concomitant	O
ciprofloxacin	I-Treatment
therapy	O
.	O

the	O
exophthalmos	I-Problem
improved	O
dramatically	O
within	I-Other
72	I-Other
hours	I-Other
of	I-Treatment
the	I-Treatment
withdrawal	I-Treatment
of	I-Treatment
lithium	I-Treatment
.	O

we	O
report	O
two	O
cases	I-Background
of	I-Background
neutropenia	I-Problem
following	O
captopril	I-Treatment
use	I-Treatment
in	O
cardiac	I-Problem
patients	I-Background
with	I-Background
trisomy	I-Problem
21	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
hyponatremia	I-Problem
associated	I-Problem
with	I-Problem
a	I-Problem
grand	I-Problem
mal	I-Problem
seizure	I-Problem
in	O
a	I-Background
28	I-Background
month	I-Background
-	I-Background
old	I-Background
child	I-Background
after	O
intra	I-Treatment
-	I-Treatment
nasal	I-Treatment
desmopressin	I-Treatment
administration	I-Treatment
for	O
high	I-Problem
fluid	I-Problem
intake	I-Problem
with	I-Problem
nocturnal	I-Problem
enuresis	I-Problem
.	O

he	I-Background
developed	O
fever	I-Problem
,	I-Problem
nausea	I-Problem
,	I-Problem
diarrhea	I-Problem
,	I-Problem
and	I-Problem
malaise	I-Problem
and	O
stopped	O
taking	O
on	O
the	O
third	I-Other
day	I-Other
after	O
commencing	O
pentasa	I-Treatment
.	O

livedo	I-Problem
reticularis	I-Problem
associated	O
with	O
interferon	I-Treatment
alpha	I-Treatment
therapy	I-Treatment
in	O
two	O
melanoma	I-Problem
patients	I-Background
.	O

a	I-Background
60	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
diabetes	I-Problem
mellitus	I-Problem
(	I-Problem
type	I-Problem
2	I-Problem
)	I-Problem
developed	O
an	I-Problem
acute	I-Problem
icteric	I-Problem
hepatitis	I-Problem
-	I-Problem
like	I-Problem
illness	I-Problem
6	I-Other
weeks	I-Other
after	I-Treatment
the	I-Treatment
initiation	I-Treatment
of	I-Treatment
gliclazide	I-Treatment
therapy	I-Treatment
.	O

thus	O
cabergoline	I-Treatment
may	O
cause	O
similar	O
pleuropulmonary	I-Problem
abnormalities	I-Problem
to	O
bromocriptine	I-Treatment
.	O

although	O
the	O
existence	O
of	O
an	O
acute	O
pericarditis	O
or	O
an	O
acute	O
myocarditis	O
as	O
possible	O
causes	O
of	O
the	O
st	O
elevation	O
can	O
not	O
be	O
fully	O
ruled	O
out	O
,	O
the	O
sudden	O
onset	O
,	O
prominent	O
magnitude	O
,	O
and	O
brief	O
duration	O
of	O
the	O
st	O
elevation	O
are	O
perhaps	O
more	O
indicative	O
of	O
an	O
acute	O
ischemic	O
event	O
,	O
possibly	O
related	O
to	O
a	O
transient	I-Problem
coronary	I-Problem
vasoconstriction	I-Problem
induced	O
by	O
the	O
dopamine	I-Treatment
infusion	O
.	O

acute	I-Problem
sensorineural	I-Problem
hearing	I-Problem
loss	I-Problem
following	O
intravenous	I-Treatment
ketoralac	I-Treatment
administration	O
.	O

trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
-	O
induced	O
hypersensitivity	I-Problem
syndrome	I-Problem
associated	I-Problem
with	I-Problem
reactivation	I-Problem
of	I-Problem
human	I-Problem
herpesvirus	I-Problem
-	I-Problem
6	I-Problem
.	O

a	I-Background
patient	I-Background
is	O
described	O
who	O
developed	O
a	O
rapid	O
onset	O
of	O
pulmonary	I-Problem
fibrosis	I-Problem
following	O
treatment	O
with	O
a	O
new	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
nabumetone	I-Treatment
.	O

to	O
report	O
a	O
case	O
of	O
increased	I-Problem
international	I-Problem
normalized	I-Problem
ratio	I-Problem
(	I-Problem
inr	I-Problem
)	I-Problem
in	O
a	I-Background
geriatric	I-Background
patient	I-Background
receiving	O
warfarin	I-Treatment
and	I-Treatment
ropinirole	I-Treatment
.	O

there	O
is	O
documentation	O
of	O
ocular	I-Problem
toxicity	I-Problem
with	O
ethambutol	I-Treatment
when	O
administered	O
at	O
dosages	O
generally	O
pronounced	O
as	O
being	O
safe	O
.	O

k	I-Problem
bipolar	I-Problem
manic	I-Problem
-	I-Problem
depressive	I-Problem
patient	I-Background
,	O
developed	O
while	O
on	O
lithium	I-Treatment
prophylaxis	O
,	O
akathisia	I-Problem
at	I-Treatment
therapeutic	I-Treatment
serum	I-Test
lithium	I-Test
levels	I-Treatment
and	O
subsequently	O
bucco	I-Problem
-	I-Problem
linguo	I-Problem
-	I-Problem
masticatory	I-Problem
dyskinesia	I-Problem
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	O
had	O
a	O
systemic	I-Problem
allergic	I-Problem
contact	I-Problem
dermatitis	I-Problem
to	I-Problem
8	I-Problem
-	I-Problem
mop	I-Problem
develop	O
during	O
her	O
second	O
course	O
of	O
puva	I-Treatment
treatment	O
for	O
psoriasis	I-Problem
.	O

seizures	I-Problem
were	O
treated	O
with	O
diazepam	I-Treatment
.	O

paradoxical	I-Problem
seizures	I-Problem
in	O
phenytoin	I-Treatment
toxicity	I-Treatment
.	O

case	O
summary	O
:	O
two	O
children	I-Background
with	I-Background
attention	I-Problem
deficit	I-Problem
disorder	I-Problem
treated	O
with	O
methylphenidate	I-Treatment
as	I-Treatment
a	I-Treatment
simple	I-Treatment
drug	I-Treatment
developed	O
fixed	I-Problem
drug	I-Problem
eruption	I-Problem
of	I-Problem
the	I-Problem
scrotum	I-Problem
.	O

while	O
the	O
patient	O
was	O
receiving	O
both	O
drugs	O
,	O
platelet	O
aggregation	I-Test
studies	I-Test
revealed	O
less	I-Problem
platelet	I-Problem
inhibition	I-Problem
than	I-Problem
would	I-Problem
be	I-Problem
expected	I-Problem
in	O
a	I-Background
patient	I-Background
not	O
taking	I-Treatment
a	I-Treatment
concomitant	I-Treatment
inducer	I-Treatment
of	I-Treatment
ticagrelor	I-Treatment
metabolism	I-Treatment
.	I-Treatment

metformin	I-Treatment
-	O
associated	O
lactic	I-Problem
acidosis	I-Problem
precipitated	O
by	O
diarrhea	O
.	O

to	O
date	O
,	O
only	O
1	O
death	I-Problem
attributable	O
to	O
risperidone	I-Treatment
overdose	I-Treatment
has	O
been	O
reported	O
.	O

systemic	I-Problem
allergic	I-Problem
contact	I-Problem
dermatitis	I-Problem
to	O
8	I-Treatment
-	I-Treatment
methoxypsoralen	I-Treatment
(	I-Treatment
8	I-Treatment
-	I-Treatment
mop	I-Treatment
)	I-Treatment
.	O

a	O
case	O
of	O
a	I-Background
21	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
who	O
had	O
developed	O
mild	I-Problem
hepatotoxicity	I-Problem
while	O
receiving	O
choline	I-Treatment
magnesium	I-Treatment
trisalicylate	I-Treatment
therapy	O
is	O
described	O
.	O

early	O
ritonavir	I-Treatment
-	O
induced	O
maculopapular	I-Problem
eruption	I-Problem
.	O

in	O
our	I-Background
patient	I-Background
,	O
an	O
objective	I-Test
causality	O
scale	I-Test
showed	O
that	O
therapeutic	I-Treatment
doses	I-Treatment
of	I-Treatment
colchicine	I-Treatment
for	I-Treatment
fmf	I-Problem
were	O
the	O
definite	O
cause	O
of	O
myopathy	I-Problem
,	O
even	O
though	O
his	I-Background
renal	I-Test
and	I-Background
hepatic	I-Background
function	I-Test
were	I-Background
normal	I-Background
.	O

thrombocytosis	I-Problem
induced	O
by	O
enoxaparin	I-Treatment
has	O
been	O
reported	O
as	O
a	O
rare	O
adverse	O
effect	O
of	O
this	O
medication	O
in	O
adults	O
.	O

a	I-Background
woman	I-Background
with	I-Background
a	I-Background
20	I-Background
-	I-Background
year	I-Background
history	I-Background
of	I-Background
acral	I-Problem
pustular	I-Problem
psoriasis	I-Problem
of	I-Problem
hallopeau	I-Problem
and	I-Problem
recurrent	I-Problem
pustular	I-Problem
lesions	I-Problem
of	I-Problem
the	I-Problem
forearms	I-Problem
and	I-Problem
lower	I-Problem
legs	I-Problem
,	O
developed	O
a	I-Problem
b	I-Problem
-	I-Problem
cell	I-Problem
lymphoma	I-Problem
of	I-Problem
the	I-Problem
lip	I-Problem
following	I-Other
4	I-Other
1	I-Other
/	I-Other
2	I-Other
years	I-Other
of	I-Treatment
treatment	I-Treatment
with	I-Treatment
razoxane	I-Treatment
.	O

the	O
evidence	O
of	O
high	O
plasmatic	O
levels	O
of	O
cbz	I-Treatment
and	O
the	O
absence	O
of	O
other	O
aetiologic	O
factors	O
lead	O
the	O
authors	O
to	O
conclude	O
that	O
the	O
overdose	I-Treatment
of	I-Treatment
cbz	I-Treatment
could	O
have	O
represented	O
the	O
precipitating	O
of	O
the	O
episode	O
of	O
acute	I-Problem
pancreatitis	I-Problem
.	O

in	O
this	O
report	O
,	O
we	O
describe	O
a	O
fatal	O
gemcitabine	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
gallbladder	I-Problem
metastatic	I-Problem
adenocarcinoma	I-Problem
.	O

progressive	I-Problem
interstitial	I-Problem
fibrosis	I-Problem
with	I-Problem
roentgenographic	I-Problem
honeycombing	I-Problem
developed	O
in	O
the	O
case	O
of	O
a	I-Background
psoriatic	I-Problem
patient	I-Background
who	O
had	O
been	O
on	O
a	I-Treatment
regimen	I-Treatment
of	I-Treatment
methotrexate	I-Treatment
for	I-Treatment
18	I-Other
years	I-Other
.	O

in	O
this	O
report	O
,	O
one	O
patient	I-Background
who	O
developed	O
gangrene	I-Problem
after	O
bleomycin	I-Treatment
and	I-Treatment
vincristine	I-Treatment
/	I-Treatment
vinblastine	I-Treatment
chemotherapy	O
for	O
aids	O
-	O
related	O
kaposi	O
'	O
s	O
sarcoma	O
and	O
another	O
hiv	O
-	O
infected	O
patient	O
who	O
exhibited	O
symptoms	O
of	O
severe	O
raynaud	O
'	O
s	O
phenomenon	O
related	O
to	O
the	O
same	O
regimen	O
are	O
presented	O
.	O

these	O
multiple	O
overlapping	O
factors	O
probably	O
lead	O
to	O
rhabdomyolysis	I-Problem
in	O
a	O
minority	O
of	O
patients	I-Background
receiving	O
vasopressin	I-Treatment
infusion	O
.	O

due	O
to	O
the	O
increasing	O
use	O
of	O
tmp	I-Treatment
-	I-Treatment
smx	I-Treatment
in	O
children	I-Background
,	O
clinicians	O
should	O
be	O
aware	O
of	O
this	O
potentially	O
life	I-Problem
-	I-Problem
threatening	I-Problem
,	I-Problem
immunemediated	I-Problem
hypersensitivity	I-Problem
reaction	O
.	O

given	O
that	O
discontinuation	O
of	O
nitrofurantoin	O
and	O
introduction	O
of	O
methylprednisolon	O
therapy	O
significantly	O
lowered	O
liver	O
enzyme	I-Test
levels	I-Test
,	O
restoring	O
most	O
of	O
them	O
to	O
normal	O
,	O
we	O
concluded	O
that	O
this	O
was	O
probably	O
the	O
case	O
of	O
toxic	I-Problem
liver	I-Problem
damage	I-Problem
caused	O
by	O
nitrofurantoin	I-Treatment
.	O

slow	I-Problem
acetylators	I-Problem
,	O
who	O
comprise	O
roughly	O
50	O
%	O
of	O
the	O
south	O
african	O
population	O
,	O
are	O
likely	O
to	O
develop	O
clinical	I-Problem
and	I-Problem
biochemical	I-Problem
features	I-Problem
of	I-Problem
phenytoin	I-Treatment
toxicity	I-Problem
when	O
this	O
drug	O
is	O
given	O
together	I-Treatment
with	I-Treatment
antituberculosis	I-Treatment
therapy	O
.	O

therefore	O
there	O
is	O
the	O
potential	O
for	O
significant	I-Problem
concentration	I-Problem
-	I-Problem
related	I-Problem
adverse	I-Problem
effects	I-Problem
when	O
phenytoin	I-Treatment
is	O
coadministered	O
with	O
other	I-Treatment
cyp2c9	I-Treatment
substrates	I-Treatment
.	O

putaminal	I-Problem
infarct	I-Problem
in	I-Problem
methanol	I-Treatment
intoxication	I-Problem
:	O
case	O
report	O
and	O
role	O
of	O
brain	O
imaging	I-Test
studies	I-Test
.	O

progressive	I-Problem
interstitial	I-Problem
lung	I-Problem
disease	I-Problem
from	O
prolonged	I-Other
methotrexate	I-Treatment
therapy	I-Treatment
.	O

the	O
case	O
reported	O
here	O
is	O
of	O
a	I-Background
child	I-Background
given	O
a	I-Treatment
large	I-Treatment
dose	I-Treatment
of	I-Treatment
intravenous	I-Treatment
iron	I-Treatment
sucrose	I-Treatment
(	O
16	I-Treatment
mg	I-Treatment
/	I-Treatment
kg	I-Treatment
)	O
over	O
3	I-Other
hours	I-Other
,	O
who	O
subsequently	O
developed	O
features	O
of	O
systemic	I-Problem
iron	I-Problem
toxicity	I-Problem
.	O

we	O
report	O
a	I-Background
patient	I-Background
with	I-Background
advanced	I-Problem
colonic	I-Problem
carcinoma	I-Problem
who	I-Background
was	I-Background
treated	I-Background
with	I-Background
concomitant	I-Treatment
chemoirradiation	I-Treatment
with	I-Background
oxaliplatin	I-Treatment
and	O
developed	O
a	I-Problem
peculiar	I-Problem
dermnatitis	I-Problem
in	I-Problem
the	I-Problem
irradiated	I-Problem
field	I-Problem
after	O
being	O
exposed	I-Treatment
to	I-Treatment
subsequent	I-Treatment
chemotherapy	I-Treatment
with	I-Treatment
oxaliplatin	I-Treatment
.	O

recombinant	I-Treatment
human	I-Treatment
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
several	O
cancers	I-Problem
,	O
but	O
there	O
have	O
been	O
several	O
reports	O
that	O
it	O
may	O
exacerbate	I-Problem
psoriasis	I-Problem
or	O
trigger	O
off	O
its	O
onset	O
.	O

this	O
is	O
the	O
first	O
case	O
of	O
hbv	I-Problem
reactivation	I-Problem
occurring	O
during	O
the	I-Treatment
year	I-Other
following	I-Other
rituximab	I-Treatment
monotherapy	I-Treatment
in	I-Treatment
the	I-Treatment
absence	I-Treatment
of	I-Treatment
any	I-Treatment
other	I-Treatment
immunosuppressive	I-Treatment
factor	I-Treatment
.	O

systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
during	O
penicillamine	I-Treatment
therapy	I-Treatment
for	O
rheumatoid	I-Problem
arthritis	I-Problem
.	I-Problem

in	O
the	O
absence	O
of	O
mucositis	O
or	O
diarrhea	O
,	O
severe	O
dermatologic	I-Problem
toxicity	I-Problem
following	O
a	I-Treatment
single	I-Treatment
low	I-Treatment
dose	I-Treatment
of	I-Treatment
the	I-Treatment
drug	I-Treatment
suggests	O
an	I-Problem
'	I-Problem
allergic	I-Problem
'	I-Problem
or	I-Problem
acute	I-Problem
hypersensitivity	I-Problem
reaction	I-Problem
to	O
mtx	I-Treatment
in	O
this	I-Background
patient	I-Background
.	O

erosion	I-Problem
of	I-Problem
psoriatic	I-Problem
plaques	I-Problem
after	O
chronic	O
methotrexate	I-Treatment
administration	O
.	O

cardiac	I-Problem
decompensation	I-Problem
following	O
verapamil	I-Treatment
therapy	I-Treatment
in	O
infants	I-Background
with	I-Background
supraventricular	I-Problem
tachycardia	I-Problem
.	O

we	O
report	O
two	O
cases	O
of	O
tenofovir	I-Treatment
(	I-Treatment
tdf	I-Treatment
)	I-Treatment
-	O
associated	O
nephrotoxicity	I-Problem
in	O
perinatally	I-Background
hiv	I-Problem
-	I-Background
infected	I-Background
adolescents	I-Background
.	O

results	O
:	O
including	O
our	O
own	O
patient	O
,	O
a	O
total	O
of	O
26	O
cases	O
of	O
gemcitabine	I-Treatment
-	O
associated	O
hus	I-Problem
were	O
identified	O
.	O

even	O
though	O
only	O
a	O
few	O
cases	O
of	O
this	O
adverse	O
event	O
have	O
been	O
reported	O
in	O
the	O
literature	O
,	O
severe	O
docetaxel	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
needs	O
to	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
when	O
such	O
patients	O
present	O
with	O
respiratory	I-Problem
symptoms	I-Problem
.	O

the	O
first	O
case	O
concerns	O
a	O
70	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
who	O
developed	O
severe	I-Problem
aplastic	I-Problem
anemia	I-Problem
7	I-Other
weeks	I-Other
after	I-Treatment
treatment	I-Treatment
with	I-Treatment
500	I-Treatment
mg	I-Treatment
of	I-Treatment
ticlopidine	I-Treatment
daily	I-Other
.	O

case	O
report	O
:	O
a	I-Background
six	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
with	I-Background
transfusion	I-Problem
-	I-Problem
dependent	I-Problem
beta	I-Problem
-	I-Problem
thalassaemia	I-Problem
developed	O
a	I-Problem
unilateral	I-Problem
hearing	I-Problem
loss	I-Problem
shortly	I-Other
after	I-Other
commencing	I-Treatment
desferrioxamine	I-Treatment
therapy	I-Treatment
.	O

syncope	I-Problem
in	O
a	I-Background
65	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
after	O
nitrate	I-Treatment
ingestion	I-Treatment
.	O

both	O
the	O
longitudinal	I-Problem
melanonychia	I-Problem
and	I-Problem
the	I-Problem
multiple	I-Problem
skin	I-Problem
cancers	I-Problem
first	O
appeared	O
after	O
approximately	I-Treatment
6	I-Other
months	I-Other
of	I-Treatment
hydroxyurea	I-Treatment
treatment	I-Treatment
.	O

multifocal	I-Problem
inflammatory	I-Problem
leukoencephalopathy	I-Problem
associated	O
with	O
levamisole	I-Treatment
therapy	I-Treatment
.	O

the	O
observation	O
of	O
cutaneous	I-Problem
vasculitis	I-Problem
during	O
administration	O
of	O
propylthiouracil	I-Treatment
suggested	O
that	O
clinical	O
awareness	O
of	O
this	O
complication	O
should	O
be	O
of	O
considerable	O
importance	O
.	O

physicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
developing	O
a	O
gemcitabine	I-Treatment
-	O
induced	O
radiation	I-Problem
recall	I-Problem
reaction	I-Problem
resulting	I-Problem
in	I-Problem
hemodynamically	I-Problem
significant	I-Problem
pericardial	I-Problem
effusion	I-Problem
.	O

objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
cefazolin	I-Treatment
-	O
induced	O
leukopenia	I-Problem
in	O
a	I-Background
critically	I-Problem
ill	I-Problem
patient	I-Background
who	O
developed	O
this	O
adverse	O
reaction	O
upon	O
rechallenge	O
with	O
cefoxitin	O
.	O

the	I-Background
second	I-Background
patient	I-Background
suffered	I-Background
from	I-Background
high	I-Problem
blood	I-Problem
pressure	I-Problem
,	O
which	O
was	O
controlled	O
with	O
beta	I-Treatment
-	I-Treatment
blocker	I-Treatment
drugs	I-Treatment
.	O

the	I-Background
female	I-Background
patient	I-Background
received	O
clozapine	I-Treatment
in	I-Treatment
a	I-Treatment
daily	I-Other
dose	I-Treatment
of	I-Treatment
400	I-Treatment
mg	I-Treatment
,	O
which	O
induced	O
agranulocytosis	I-Problem
after	I-Treatment
2	I-Other
months	I-Other
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
interstitial	I-Problem
pulmonary	I-Problem
disease	I-Problem
that	O
occurred	O
together	O
with	O
lymphocytic	I-Problem
colitis	I-Problem
during	O
treatment	O
with	O
ticlopidine	I-Treatment
.	O

increased	I-Problem
ocular	I-Problem
pressure	I-Problem
in	O
two	O
patients	I-Background
with	I-Background
narrow	I-Problem
angle	I-Problem
glaucoma	I-Problem
treated	O
with	O
venlafaxine	I-Treatment
.	O

although	O
they	O
had	O
complex	O
medical	O
problems	O
,	O
the	O
high	O
serum	O
concentrations	O
of	O
ampicillin	O
at	O
the	O
time	O
of	O
seizures	O
without	O
their	O
recurrence	O
after	O
discontinuing	O
the	O
antibiotic	O
suggest	O
that	O
the	O
seizures	I-Problem
were	O
related	O
to	O
the	O
ampicillin	I-Treatment
therapy	I-Treatment
.	O

glaucoma	I-Problem
secondary	O
to	O
epithelial	O
downgrowth	O
and	O
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
.	O

of	O
particular	O
interest	O
in	O
this	I-Background
patient	I-Background
is	O
the	O
fluctuation	I-Problem
of	I-Problem
the	I-Problem
qt	I-Problem
interval	I-Problem
at	O
a	I-Treatment
stable	I-Treatment
dose	I-Treatment
of	I-Treatment
methadone	I-Treatment
,	O
suggesting	O
that	O
a	O
single	I-Test
normal	I-Test
electrocardiogram	I-Test
(	O
ecg	I-Test
)	O
does	O
not	O
guarantee	O
that	O
the	O
patient	O
is	O
not	O
at	O
risk	O
of	O
ventricular	O
arrhythmias	O
.	O

this	O
is	O
the	O
first	O
report	O
of	O
acute	I-Problem
kidney	I-Problem
injury	I-Problem
due	I-Problem
to	I-Problem
zonisamide	I-Treatment
-	O
induced	O
dress	I-Problem
/	I-Problem
dihs	I-Problem
.	O

although	O
both	O
the	O
spontaneous	O
occurrence	O
of	O
sle	O
and	O
the	O
psychosis	O
as	O
a	O
sign	O
of	O
cns	O
involvement	O
of	O
sle	O
can	O
not	O
be	O
excluded	O
,	O
sle	I-Problem
could	O
be	O
considered	O
as	O
an	O
adverse	O
effect	O
of	O
carbamazepine	I-Treatment
.	O

background	O
:	O
cyanamide	I-Treatment
,	O
an	O
aversive	O
agent	O
widely	O
used	O
in	O
japan	O
,	O
is	O
known	O
to	O
induce	O
various	I-Problem
degrees	I-Problem
of	I-Problem
hepatic	I-Problem
lesion	I-Problem
with	I-Problem
ground	I-Problem
-	I-Problem
glass	I-Problem
inclusion	I-Problem
bodies	I-Problem
.	O

oxcarbazepine	I-Treatment
-	O
associated	O
angioedema	I-Problem
manifested	I-Problem
by	I-Problem
swelling	I-Problem
of	I-Problem
the	I-Problem
face	I-Problem
,	I-Problem
eyes	I-Problem
,	I-Problem
lips	I-Problem
,	I-Problem
or	I-Problem
tongue	I-Problem
or	I-Problem
difficulty	I-Problem
swallowing	I-Problem
or	I-Problem
breathing	I-Problem
(	I-Problem
or	I-Problem
both	I-Problem
)	I-Problem
is	O
a	O
rare	O
but	O
potentially	O
life	O
-	O
threatening	O
reaction	O
for	O
which	O
early	O
recognition	O
and	O
management	O
are	O
vital	O
.	O

the	O
combination	I-Treatment
therapy	I-Treatment
of	I-Treatment
interferon	I-Treatment
alpha	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
was	O
given	O
to	O
a	I-Background
50	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
with	I-Background
chc	I-Problem
who	I-Background
had	I-Background
not	I-Background
responded	I-Background
to	I-Background
a	I-Background
previous	I-Background
treatment	I-Background
by	I-Background
interferon	I-Background
alpha	I-Background
.	O

peripheral	I-Problem
neuropathy	I-Problem
associated	O
with	O
capecitabine	I-Treatment
.	I-Treatment

design	O
:	O
we	O
reviewed	O
the	O
medical	I-Background
records	I-Background
of	I-Background
four	O
patients	I-Background
,	O
who	O
were	O
seen	O
by	O
us	O
between	O
july	O
2000	O
and	O
february	O
2004	O
for	O
sudden	O
onset	O
of	O
a	I-Problem
central	I-Problem
neurological	I-Problem
syndrome	I-Problem
within	I-Other
days	I-Other
of	O
intrathecal	O
mtx	I-Test
.	O

prothipendylhydrochloride	I-Treatment
-	O
induced	O
priapism	I-Problem
:	O
case	O
report	O
.	O

interstitial	I-Problem
pneumonia	I-Problem
probably	O
associated	O
with	O
sorafenib	I-Treatment
treatment	I-Treatment
:	I-Treatment
an	O
alert	O
of	O
an	O
adverse	O
event	O
.	O

he	O
had	O
hypokalemia	I-Problem
(	I-Problem
k	I-Problem
2	I-Problem
.	I-Problem
3	I-Problem
mmol	I-Problem
/	I-Problem
l	I-Problem
)	I-Problem
induced	O
by	O
licorice	I-Treatment
and	I-Treatment
also	I-Treatment
had	I-Treatment
received	I-Treatment
disopyramide	I-Treatment
for	I-Treatment
arrhythmia	I-Problem
,	I-Treatment
bicalutamide	I-Treatment
for	I-Treatment
prostate	I-Problem
cancer	I-Problem
,	I-Treatment
and	I-Treatment
silodosin	I-Treatment
for	I-Treatment
prostate	I-Problem
hypertrophy	I-Problem
.	O

use	O
of	O
the	O
naranjo	O
adverse	O
drug	I-Test
reaction	I-Test
probability	I-Test
scale	I-Test
indicated	O
a	O
probable	O
relationship	O
(	O
score	O
of	O
5	O
)	O
between	O
the	O
patient	I-Background
'	I-Background
s	I-Background
development	O
of	O
hepatotoxicity	I-Problem
and	O
the	O
tmp	I-Treatment
-	I-Treatment
smx	I-Treatment
therapy	I-Treatment
.	O

since	O
its	O
introduction	O
in	O
2012	O
,	O
vismodegib	I-Treatment
has	O
been	O
implicated	O
as	O
a	O
possible	O
factor	O
in	O
seven	O
reports	I-Background
of	I-Background
patient	I-Background
deaths	I-Problem
.	O

acceleration	I-Problem
of	I-Problem
ventricular	I-Problem
response	I-Problem
to	O
atrial	I-Problem
flutter	I-Problem
after	O
intravenous	I-Treatment
adenosine	I-Treatment
.	I-Treatment

possible	O
induction	O
of	O
diabetes	I-Problem
by	O
treatment	O
of	O
hypertension	I-Problem
with	O
indapamide	I-Treatment
(	O
with	O
four	O
case	O
reports	O
)	O
.	O

physicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
the	O
development	O
of	O
rs	I-Problem
among	O
children	I-Background
who	O
are	O
receiving	O
long	I-Treatment
-	I-Treatment
term	I-Treatment
aspirin	I-Treatment
therapy	I-Treatment
for	O
the	O
treatment	O
of	O
systemic	I-Problem
inflammatory	I-Problem
illnesses	I-Problem
.	O

while	O
a	O
lower	O
systemic	O
steroid	O
dosage	O
may	O
have	O
been	O
the	O
provoking	O
factor	O
,	O
we	O
feel	O
that	O
an	O
adverse	I-Problem
reaction	I-Problem
to	O
oleic	I-Treatment
acid	I-Treatment
,	O
a	O
dispersing	O
agent	O
in	O
the	O
aerosol	O
freon	O
vehicle	O
,	O
is	O
a	O
strong	O
possibility	O
.	O

baclofen	I-Problem
withdrawal	I-Problem
syndrome	I-Problem
resulting	O
from	O
underdosing	I-Treatment
of	I-Treatment
oral	I-Treatment
baclofen	I-Treatment
should	O
be	O
considered	O
as	O
a	O
potential	O
source	O
of	O
prolonged	I-Problem
fever	I-Problem
in	I-Problem
the	I-Problem
intensive	I-Problem
care	I-Problem
unit	I-Problem
.	O

we	O
present	O
a	I-Background
case	I-Background
of	O
sotalol	I-Treatment
-	O
induced	O
bradycardia	I-Problem
reversed	O
by	O
glucagon	O
.	O

hyperammonemia	I-Problem
has	O
been	O
described	O
as	O
a	O
complication	O
of	O
valproic	I-Treatment
acid	I-Treatment
therapy	I-Treatment
but	O
may	O
often	O
be	O
overlooked	O
as	O
a	O
cause	O
of	O
lethargy	O
in	O
the	O
postictal	O
patient	O
who	O
presents	O
to	O
the	O
emergency	O
department	O
.	O

methylene	I-Treatment
blue	I-Treatment
has	O
been	O
found	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
monoamine	O
oxidase	O
(	O
mao	O
)	O
,	O
and	O
several	I-Background
cases	I-Background
of	O
serotonin	I-Problem
toxicity	I-Problem
have	O
been	O
reported	O
recently	O
following	O
its	O
administration	O
.	O

she	O
had	O
just	O
finished	O
a	I-Treatment
3	I-Other
-	I-Other
week	I-Other
course	I-Other
of	I-Treatment
intravenous	I-Treatment
tobramycin	I-Treatment
for	O
bronchiectasis	I-Problem
and	O
had	O
an	O
elevated	I-Problem
serum	I-Problem
tobramycin	I-Problem
trough	I-Problem
level	I-Problem
1	I-Problem
week	I-Problem
before	I-Problem
the	I-Problem
onset	I-Problem
of	I-Problem
tetany	I-Problem
.	O

in	O
a	O
postural	I-Test
challenge	I-Test
test	I-Test
after	O
administration	I-Treatment
of	I-Treatment
isosorbide	I-Treatment
dinitrate	I-Treatment
(	I-Treatment
5	I-Treatment
mg	I-Treatment
)	I-Treatment
,	O
blood	I-Problem
pressure	I-Test
decreased	I-Problem
from	O
120	O
/	O
67	O
to	O
65	O
/	O
35	O
mmhg	O
,	O
followed	O
by	O
syncope	I-Problem
with	O
a	I-Problem
sudden	I-Problem
decrease	I-Problem
in	I-Problem
pulse	I-Problem
rate	I-Problem
from	O
85	O
to	O
60	O
beats	O
/	O
min	O
.	O

the	O
condition	I-Problem
improved	I-Problem
slowly	O
after	O
stopping	O
medication	O
and	O
systemic	O
steroids	I-Treatment
.	O

acetaminophen	I-Treatment
is	O
a	O
widely	O
used	O
analgesic	O
that	O
can	O
cause	O
acute	I-Problem
liver	I-Problem
failure	I-Problem
when	O
consumed	O
above	O
a	O
maximum	O
daily	O
dose	O
.	O

patients	I-Background
treated	O
with	O
5	I-Treatment
-	I-Treatment
asa	I-Treatment
compounds	I-Treatment
who	I-Background
experience	I-Background
acute	I-Background
inflammatory	I-Background
symptoms	I-Background
or	I-Background
clinical	I-Background
deterioration	I-Background
not	I-Background
related	I-Background
to	I-Background
their	I-Background
gastrointestinal	I-Problem
disease	I-Problem
should	O
be	O
screened	O
to	O
rule	O
out	O
a	O
lupus	I-Problem
-	I-Problem
like	I-Problem
reaction	I-Problem
.	O

successful	O
treatment	O
with	O
arsenic	I-Treatment
trioxide	I-Treatment
of	O
a	I-Background
patient	I-Background
with	I-Background
atra	I-Problem
-	I-Problem
resistant	I-Problem
relapse	I-Problem
of	I-Problem
acute	I-Problem
promyelocytic	I-Problem
leukemia	I-Problem
.	O

drug	I-Problem
rash	I-Problem
with	I-Problem
eosinophilia	I-Problem
and	I-Problem
systemic	I-Problem
symptoms	I-Problem
after	O
chlorambucil	I-Treatment
treatment	O
in	O
chronic	I-Problem
lymphocytic	I-Problem
leukaemia	I-Problem
.	O

she	I-Background
manifested	O
all	I-Problem
the	I-Problem
clinical	I-Problem
symptoms	I-Problem
and	I-Problem
signs	I-Problem
of	I-Problem
caffeine	I-Treatment
toxicity	I-Problem
.	I-Problem

quinine	I-Treatment
-	O
induced	O
hearing	I-Problem
loss	I-Problem
.	O

ezetimibe	I-Treatment
-	O
induced	O
acute	I-Problem
pancreatitis	I-Problem
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
drug	O
-	O
induced	O
pemphigus	I-Problem
caused	O
by	O
an	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
,	O
captopril	I-Treatment
.	O

we	O
conclude	O
that	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
hu	I-Treatment
therapy	I-Treatment
in	I-Background
patients	I-Background
with	I-Background
thalassemia	I-Problem
intermedia	I-Problem
may	O
increase	I-Problem
total	I-Problem
hb	I-Test
levels	I-Test
sufficiently	O
to	O
eliminate	O
the	O
need	O
for	O
transfusions	O
.	O

there	O
is	O
the	O
risk	O
of	O
convulsions	I-Problem
occurring	O
in	O
susceptible	I-Background
patients	I-Background
following	O
the	I-Treatment
use	I-Treatment
of	I-Treatment
the	I-Treatment
new	I-Treatment
anaesthetic	I-Treatment
agents	I-Treatment
which	I-Treatment
are	I-Treatment
capable	I-Treatment
of	I-Treatment
inducing	I-Treatment
cns	I-Treatment
excitability	I-Treatment
.	O

a	I-Background
patient	I-Background
with	I-Background
psoriasis	I-Problem
is	I-Background
described	I-Background
who	I-Background
had	I-Background
an	I-Problem
abnormal	I-Problem
response	I-Problem
to	I-Problem
the	I-Problem
glucose	I-Test
tolerance	I-Test
test	I-Test
without	I-Problem
other	I-Problem
evidence	I-Problem
of	I-Problem
diabetes	I-Problem
and	O
then	O
developed	O
postprandial	I-Problem
hyperglycemia	I-Problem
and	I-Problem
glycosuria	I-Problem
during	O
a	I-Treatment
period	I-Treatment
of	I-Treatment
topical	I-Treatment
administration	I-Treatment
of	I-Treatment
a	I-Treatment
corticosteroid	I-Treatment
cream	I-Treatment
,	I-Treatment
halcinonide	I-Treatment
cream	I-Treatment
0	I-Treatment
.	I-Treatment
1	I-Treatment
%	I-Treatment
,	I-Treatment
under	I-Treatment
occlusion	I-Treatment
.	O

a	I-Background
young	I-Background
woman	I-Background
developed	O
galactorrhea	I-Problem
during	I-Treatment
treatment	I-Treatment
with	I-Treatment
a	I-Treatment
new	I-Treatment
dibenzoxazepine	I-Treatment
antidepressant	I-Treatment
,	I-Treatment
amoxapine	I-Treatment
.	O

after	O
ruling	O
out	O
a	O
hydrotelluric	O
source	O
of	O
fluorine	O
,	O
the	I-Background
patient	I-Background
'	I-Background
s	I-Background
fluorosis	I-Problem
was	O
linked	O
to	O
chronic	I-Other
use	I-Treatment
of	I-Treatment
niflumic	I-Treatment
acid	I-Treatment
,	O
following	O
the	O
publication	O
in	O
1978	O
of	O
the	O
2	O
previously	O
reported	O
cases	O
affected	O
by	O
this	O
drug	O
.	O

the	O
hospital	O
course	O
of	O
the	O
acute	O
renal	O
failure	O
is	O
presented	O
with	O
a	O
review	O
of	O
the	O
literature	O
on	O
cases	O
of	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
after	O
ivig	I-Treatment
.	O

we	O
report	O
3	O
cases	I-Background
of	I-Background
children	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
who	O
developed	O
seizures	I-Problem
and	I-Problem
altered	I-Problem
sensorium	I-Problem
after	O
l	I-Treatment
-	I-Treatment
asparaginase	I-Treatment
therapy	O
.	O

caution	O
with	O
use	O
of	O
cimetidine	O
in	O
tolazoline	I-Treatment
induced	O
upper	I-Problem
gastrointestinal	I-Problem
bleeding	I-Problem
.	O

other	O
thiazolidinediones	I-Treatment
currently	O
in	O
clinical	O
trials	O
may	O
be	O
able	O
to	O
provide	O
the	O
therapeutic	O
benefits	O
of	O
troglitazone	O
without	O
significant	O
hepatotoxicity	O
.	O

objective	O
:	O
to	O
report	O
a	I-Problem
case	I-Problem
of	I-Problem
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
(	I-Problem
nms	I-Problem
)	I-Problem
associated	O
with	O
fluphenazine	I-Treatment
in	O
a	O
schizophrenic	I-Problem
patient	I-Background
and	O
review	O
the	O
literature	O
related	O
to	O
this	O
condition	O
.	O

conclusions	O
:	O
because	O
of	O
its	O
structural	O
similarity	O
to	O
the	O
other	O
vinca	O
alkaloids	O
,	O
vinorelbine	I-Treatment
is	O
believed	O
to	O
be	O
responsible	O
for	O
siadh	I-Problem
in	O
our	O
patient	O
.	O

abnormal	I-Problem
retinal	I-Problem
function	I-Problem
associated	O
with	O
isotretinoin	I-Treatment
therapy	O
for	O
acne	I-Problem
.	O

to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	I-Background
case	I-Background
of	O
bromide	I-Problem
intoxication	I-Problem
due	O
to	O
pyridostigmine	I-Treatment
bromide	I-Treatment
administration	O
.	O

in	O
deciding	O
if	O
tamoxifen	I-Treatment
therapy	O
is	O
warranted	O
,	O
all	O
potentially	I-Problem
life	I-Problem
-	I-Problem
threatening	I-Problem
adverse	I-Problem
events	I-Problem
associated	O
with	O
tamoxifen	I-Treatment
should	O
be	O
considered	O
,	O
including	I-Problem
endometrial	I-Problem
adenocarcinoma	I-Problem
or	I-Problem
uterine	I-Problem
sarcoma	I-Problem
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
patient	I-Background
with	I-Background
chronic	I-Problem
lymphocytic	I-Problem
leukemia	I-Problem
(	I-Background
cll	I-Background
)	I-Background
who	O
developed	O
fatal	I-Problem
intravascular	I-Problem
autoimmune	I-Problem
hemolytic	I-Problem
anemia	I-Problem
(	I-Problem
aiha	I-Problem
)	I-Problem
after	O
fludarabine	I-Treatment
treatment	I-Treatment
.	O

a	I-Background
59	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
myasthenia	I-Problem
gravis	I-Problem
who	O
received	O
a	I-Treatment
large	I-Treatment
dose	I-Treatment
of	I-Treatment
pyridostigmine	I-Treatment
bromide	I-Treatment
developed	O
postoperative	I-Problem
psychosis	I-Problem
and	I-Problem
was	I-Problem
diagnosed	I-Problem
as	I-Problem
having	I-Problem
bromide	I-Problem
intoxication	I-Problem
.	I-Problem

this	O
is	O
a	O
report	O
of	O
a	I-Background
renal	I-Problem
transplant	I-Problem
patient	I-Background
with	I-Background
pneumocystis	I-Problem
pneumonia	I-Problem
who	O
developed	O
chemical	I-Problem
cellulitis	I-Problem
and	I-Problem
ulceration	I-Problem
following	O
the	O
extravasation	O
of	O
intravenous	I-Treatment
pentamidine	I-Treatment
into	I-Treatment
the	I-Treatment
soft	I-Treatment
tissues	I-Treatment
of	I-Treatment
the	I-Treatment
left	I-Treatment
hand	I-Treatment
and	I-Treatment
forearm	I-Treatment
.	O

attempts	O
were	O
made	O
to	O
stop	O
and	O
then	O
restart	O
the	O
theophylline	I-Treatment
therapy	I-Treatment
at	O
progressively	O
lower	O
doses	O
;	O
however	O
,	O
with	O
each	O
attempt	O
,	O
the	O
patient	I-Test
'	I-Test
s	I-Test
reaction	I-Test
to	I-Problem
the	I-Problem
drug	I-Problem
became	I-Problem
more	I-Problem
toxic	I-Problem
,	O
with	O
serum	O
theophylline	I-Test
levels	I-Test
ranging	O
between	O
99	O
.	O
9	O
and	O
149	I-Treatment
.	I-Treatment
9	I-Treatment
micromol	I-Treatment
/	I-Treatment
l	I-Treatment
(	O
18	I-Treatment
and	I-Treatment
27	I-Treatment
microg	I-Treatment
/	I-Treatment
ml	I-Treatment
)	O
.	O

dyspnea	I-Problem
,	I-Problem
hypoxemia	I-Problem
,	I-Problem
and	I-Problem
pleuritic	I-Problem
chest	I-Problem
pain	I-Problem
occurred	O
within	O
24	I-Other
hours	I-Other
of	O
rituximab	I-Treatment
administration	I-Treatment
,	O
and	O
there	O
was	O
no	O
other	O
apparent	O
explanation	O
.	O

dermatitis	I-Problem
to	O
captopril	I-Treatment
.	O

histological	O
examination	I-Test
of	I-Test
the	O
dacryolith	I-Test
suggested	O
its	O
derivation	O
from	O
breakdown	I-Treatment
products	I-Treatment
of	I-Treatment
adrenaline	I-Treatment
.	O

two	O
patients	I-Background
developed	O
diabetic	I-Problem
coma	I-Problem
when	O
taking	O
a	I-Treatment
combination	I-Treatment
of	I-Treatment
a	I-Treatment
thiazide	I-Treatment
diuretic	I-Treatment
and	I-Treatment
propranolol	I-Treatment
.	O

platinum	I-Problem
-	I-Problem
resistant	I-Problem
ovarian	I-Problem
cancer	I-Problem
(	I-Problem
proc	I-Problem
)	I-Problem
constitutes	O
a	O
therapeutic	O
dilemma	O
with	O
limited	I-Problem
efficacy	I-Problem
from	O
traditional	I-Treatment
cytotoxic	I-Treatment
agents	I-Treatment
.	O

a	I-Background
patient	I-Background
suffering	O
from	O
heparin	O
-	O
associated	O
thrombocytopenia	I-Problem
(	I-Problem
hat	I-Problem
)	I-Problem
,	I-Problem
recurrent	I-Problem
arteriothromboses	I-Problem
,	I-Problem
and	I-Problem
acute	I-Problem
renal	I-Problem
failure	I-Problem
after	O
treatment	O
with	O
standard	I-Treatment
heparin	I-Treatment
is	O
described	O
.	O

despite	O
minimal	O
short	O
-	O
term	O
side	O
effects	O
and	O
apparent	O
efficacy	O
,	O
chronic	O
treatment	O
of	O
mg	I-Problem
with	I-Treatment
mm	I-Treatment
may	O
be	O
associated	O
with	O
increased	I-Problem
risk	I-Problem
of	I-Problem
lymphoproliferative	I-Problem
disorders	O
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
patient	I-Background
with	I-Background
multiple	I-Problem
myeloma	I-Problem
who	O
developed	O
acute	I-Problem
life	I-Problem
-	I-Problem
threatening	I-Problem
water	I-Problem
intoxication	I-Problem
following	O
treatment	O
with	O
oral	I-Treatment
indomethacin	I-Treatment
and	I-Treatment
low	I-Treatment
dose	I-Treatment
intravenous	I-Treatment
cyclophosphamide	I-Treatment
.	O

multifocal	O
electroretinographic	O
abnormalities	O
in	O
ethambutol	I-Treatment
-	O
induced	O
visual	I-Problem
loss	I-Problem
.	O

she	I-Background
was	O
on	O
etanercept	I-Treatment
and	I-Treatment
methotrexate	I-Treatment
for	O
rheumatoid	I-Problem
arthritis	I-Problem
.	O

central	O
nervous	O
system	O
effects	O
secondary	I-Treatment
to	I-Treatment
ciprofloxacin	I-Treatment
treatment	I-Treatment
are	O
uncommon	O
and	O
usually	O
consist	O
only	O
of	O
minor	I-Problem
dizziness	I-Problem
or	I-Problem
mild	I-Problem
headache	I-Problem
,	I-Problem
although	I-Problem
rare	I-Problem
occurrences	I-Problem
of	I-Problem
seizures	I-Problem
and	I-Problem
hallucinations	I-Problem
have	O
been	O
reported	O
.	O

we	O
present	O
a	O
case	O
of	O
a	I-Background
20	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
who	O
ingested	O
900	I-Treatment
mg	I-Treatment
of	I-Treatment
glyburide	I-Treatment
causing	O
refractory	I-Problem
hypoglycemia	I-Problem
resistant	O
to	O
treatment	O
with	O
intravenous	O
dextrose	O
,	O
glucagon	O
,	O
and	O
diazoxide	O
.	O

etoposide	I-Treatment
-	O
related	O
myocardial	I-Problem
infarction	I-Problem
.	O

contrary	O
to	O
previous	O
recommendations	O
,	O
our	O
experience	O
cautions	O
against	O
the	O
further	O
use	O
of	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytarabine	I-Treatment
in	O
patients	O
who	O
develop	O
ppe	I-Problem
,	O
and	O
is	O
a	O
timely	O
reminder	O
of	O
the	O
potential	O
toxicity	O
of	O
this	O
agent	O
,	O
which	O
is	O
now	O
increasingly	O
being	O
used	O
as	O
first	O
-	O
line	O
treatment	O
in	O
the	O
management	O
of	O
haematologic	I-Problem
malignancies	I-Problem
.	O

she	O
had	O
been	O
on	O
copaxone	I-Treatment
20	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
treatment	I-Treatment
for	I-Treatment
2	I-Other
years	I-Other
when	O
she	I-Background
first	O
exhibited	O
gastrointestinal	I-Problem
symptoms	I-Problem
.	O

the	O
authors	O
present	O
an	O
elderly	I-Background
patient	I-Background
with	I-Background
mixed	I-Problem
dementia	I-Problem
who	O
developed	O
td	I-Problem
at	I-Problem
multiple	I-Problem
sites	I-Problem
,	I-Problem
(	I-Problem
including	I-Problem
respiratory	I-Problem
dyskinesia	I-Problem
[	I-Problem
rd	I-Problem
]	I-Problem
,	I-Problem
limb	I-Problem
dyskinesia	I-Problem
,	I-Problem
and	I-Problem
orofacial	I-Problem
dyskinesia	I-Problem
)	I-Problem
following	O
abrupt	I-Treatment
withdrawal	I-Treatment
of	I-Treatment
risperidone	I-Treatment
therapy	I-Treatment
.	O

interferon	I-Treatment
-	O
based	O
treatments	O
have	O
the	O
potential	O
to	O
decrease	O
the	O
burden	O
of	O
disease	O
,	O
but	O
are	O
complicated	O
by	O
side	O
effects	O
,	O
including	O
neuropsychiatric	I-Problem
symptoms	I-Problem
.	O

long	O
-	O
term	O
efficacy	O
of	O
adding	I-Treatment
fenofibric	I-Treatment
acid	I-Treatment
to	I-Treatment
moderate	I-Treatment
-	I-Treatment
dose	I-Treatment
statin	I-Treatment
therapy	I-Treatment
in	O
patients	I-Background
with	I-Background
persistent	I-Problem
elevated	I-Problem
triglycerides	I-Problem
.	O

type	I-Problem
1	I-Problem
diabetes	I-Problem
mellitus	I-Problem
provoked	O
by	O
peginterferon	I-Treatment
alpha	I-Treatment
-	I-Treatment
2b	I-Treatment
plus	I-Treatment
ribavirin	I-Treatment
treatment	I-Treatment
for	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

a	I-Background
61	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
early	I-Problem
diffuse	I-Problem
cutaneous	I-Problem
scleroderma	I-Problem
with	I-Problem
myositis	I-Problem
and	I-Background
progressive	I-Problem
interstitial	I-Problem
pneumonia	I-Problem
developed	O
generalized	I-Problem
erythema	I-Problem
with	I-Problem
high	I-Problem
fever	I-Problem
3	I-Other
weeks	I-Other
after	I-Other
taking	O
sulfamethoxazole	I-Treatment
/	I-Treatment
trimethoprim	I-Treatment
.	O

serotonin	I-Problem
toxicity	I-Problem
caused	O
by	O
an	I-Treatment
interaction	I-Treatment
between	I-Treatment
fentanyl	I-Treatment
and	I-Treatment
paroxetine	I-Treatment
.	O

the	O
sub	I-Problem
-	I-Problem
conjunctival	I-Problem
haematoma	I-Problem
in	O
a	O
patient	O
receiving	O
warfarin	I-Treatment
can	O
pose	O
a	O
significant	O
management	O
challenge	O
.	O

toxic	I-Problem
optic	I-Problem
neuropathy	I-Problem
associated	O
with	O
ethambutol	I-Treatment
:	O
implications	O
for	O
current	O
therapy	O
.	O

the	O
site	O
of	O
thrombosis	O
and	O
the	O
chronological	O
relationship	O
with	O
the	O
iir	O
implicates	O
a	O
hypersensitivity	O
to	O
infliximab	I-Treatment
in	O
the	O
causation	O
of	O
the	O
venous	I-Problem
thrombosis	I-Problem
in	O
this	O
case	O
.	O

one	I-Other
week	I-Other
after	I-Treatment
the	I-Treatment
initial	I-Treatment
-	I-Treatment
dose	I-Treatment
of	I-Treatment
adalimumab	I-Treatment
(	I-Treatment
160	I-Treatment
mg	I-Treatment
)	I-Treatment
,	O
which	O
was	O
initiated	O
due	O
to	O
an	I-Background
acute	I-Background
exacerbation	I-Background
of	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
,	I-Background
the	I-Background
patient	I-Background
developed	O
a	O
fulminant	I-Problem
cardiomyopathy	I-Problem
.	O

results	O
:	O
ethambutol	I-Treatment
,	O
and	O
to	O
a	O
lesser	O
extent	O
isoniazid	I-Treatment
,	O
are	O
both	O
implicated	O
in	O
the	O
development	O
of	O
visually	I-Problem
related	I-Problem
side	I-Problem
effects	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
an	O
inadvertent	I-Problem
increase	I-Problem
in	I-Problem
the	I-Problem
international	I-Problem
normalized	I-Problem
ratio	I-Problem
(	I-Problem
inr	I-Problem
)	I-Problem
after	O
the	O
addition	I-Treatment
of	I-Treatment
bismuth	I-Treatment
subsalicylate	I-Treatment
for	O
the	O
treatment	O
of	O
diarrhea	I-Problem
in	O
an	I-Background
enterally	I-Background
fed	I-Background
patient	I-Background
receiving	O
warfarin	I-Treatment
therapy	I-Treatment
.	O

oral	O
triazolam	I-Treatment
is	O
potentially	O
hazardous	I-Problem
to	O
patients	I-Background
receiving	O
systemic	O
antimycotics	O
ketoconazole	I-Treatment
or	O
itraconazole	I-Treatment
.	O

lft	O
elevation	O
is	O
transient	O
and	O
the	O
low	O
risk	O
of	O
the	O
sb	I-Treatment
-	I-Treatment
lot	I-Treatment
therapy	O
to	O
increase	I-Problem
lft	I-Problem
value	I-Test
can	O
be	O
limited	O
when	O
risk	O
factors	O
are	O
considered	O
.	O

nineteen	O
cases	I-Background
of	O
unusual	I-Problem
enhanced	I-Problem
vincristine	I-Problem
neurotoxicity	I-Problem
related	O
to	O
itraconazole	I-Treatment
have	O
been	O
reported	O
in	O
children	I-Background
.	O

extended	I-Treatment
-	I-Treatment
release	I-Treatment
tolterodine	I-Treatment
4	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
was	O
then	O
prescribed	O
to	O
manage	O
overactive	I-Problem
bladder	I-Problem
.	O

although	O
it	O
is	O
difficult	O
to	O
be	O
certain	O
of	O
the	O
direct	O
link	O
of	O
amiodarone	I-Treatment
on	O
the	O
basis	O
of	O
a	I-Background
single	O
case	I-Background
,	O
it	O
is	O
reasonable	O
to	O
presume	O
that	O
this	O
histopathology	O
is	O
associated	O
with	O
amiodarone	I-Treatment
-	O
induced	O
hypothyroidism	I-Problem
and	O
that	O
involution	O
changes	O
represent	O
the	O
hypofunctional	O
status	O
of	O
this	O
drug	O
-	O
induced	O
disorder	O
.	O

the	O
present	O
report	O
describes	O
the	I-Background
first	I-Background
case	I-Background
of	O
acute	I-Problem
pancreatitis	I-Problem
associated	O
with	O
danazol	I-Treatment
treatment	I-Treatment
of	I-Treatment
endometriosis	I-Problem
.	O

awareness	O
of	O
this	O
route	O
of	O
intoxication	O
might	O
be	O
important	O
in	O
patients	O
in	O
whom	O
neurologic	I-Problem
or	I-Problem
psychiatric	I-Problem
symptoms	I-Problem
develop	O
while	O
large	I-Treatment
amounts	I-Treatment
of	I-Treatment
lidocaine	I-Treatment
cream	I-Treatment
are	I-Treatment
being	I-Treatment
used	I-Treatment
.	O

cephalosporin	I-Treatment
-	O
induced	O
leukopenia	I-Problem
following	O
rechallenge	O
with	O
cefoxitin	I-Treatment
.	O

thrombotic	I-Problem
thrombocytopenic	I-Problem
purpura	I-Problem
induced	O
by	O
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
in	O
a	I-Background
jehovah	I-Background
'	I-Background
s	I-Background
witness	I-Background
.	O

this	O
eruption	I-Problem
appears	O
to	O
be	O
a	O
distinct	I-Problem
cutaneous	I-Problem
toxicity	I-Problem
of	O
pld	I-Treatment
.	O

granulocytopenia	I-Problem
and	I-Problem
agranulocytosis	I-Problem
are	O
considered	O
among	O
the	O
most	O
dangerous	O
adverse	O
effects	O
of	O
clozapine	I-Treatment
.	O

results	O
:	O
we	O
recently	O
experienced	O
a	O
case	O
of	O
fatal	O
erlotinib	I-Treatment
-	O
induced	O
ild	I-Problem
,	O
diagnosed	O
based	O
on	O
clinical	O
and	O
radiologic	O
findings	O
,	O
which	O
occurred	O
in	O
a	I-Background
patient	I-Background
with	I-Background
radiation	I-Problem
fibrosis	I-Problem
.	O

unusual	I-Problem
hypersensitivity	I-Problem
to	O
warfarin	I-Treatment
in	O
a	I-Background
critically	I-Problem
ill	I-Problem
patient	I-Background
.	O

we	O
report	O
a	O
case	O
of	O
seizure	I-Problem
associated	O
with	O
l	I-Treatment
-	I-Treatment
asparaginase	I-Treatment
therapy	I-Treatment
but	O
no	O
evidence	O
of	O
hemorrhagic	O
or	O
thrombotic	O
cerebrovascular	O
events	O
.	O

here	O
we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
who	O
developed	O
a	O
severe	I-Problem
infliximab	I-Problem
infusion	I-Problem
reaction	I-Problem
(	I-Problem
iir	I-Problem
)	I-Problem
,	I-Problem
complicated	I-Problem
1	I-Problem
day	I-Problem
later	I-Problem
by	I-Problem
severe	I-Problem
swelling	I-Problem
of	I-Problem
the	I-Problem
forearm	I-Problem
and	I-Problem
hand	I-Problem
ipsilateral	I-Problem
to	O
the	O
site	O
of	O
infliximab	I-Treatment
infusion	I-Treatment
.	O

she	O
died	I-Problem
within	I-Problem
six	I-Problem
weeks	I-Problem
of	I-Problem
developing	I-Problem
congestive	I-Problem
heart	I-Problem
failure	I-Problem
coupled	I-Problem
with	I-Problem
liver	I-Problem
failure	I-Problem
due	O
to	O
haemosiderosis	I-Problem
despite	O
regular	I-Treatment
use	I-Treatment
of	I-Treatment
desferrioxamine	I-Treatment
.	O

a	I-Background
56	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
caucasian	I-Background
man	I-Background
who	O
received	O
concomitant	I-Treatment
chemotherapy	I-Treatment
and	I-Treatment
radiation	I-Treatment
for	I-Treatment
head	I-Problem
and	I-Problem
neck	I-Problem
cancer	I-Problem
developed	O
fever	I-Problem
concurrent	I-Treatment
with	I-Treatment
the	I-Treatment
administration	I-Treatment
of	I-Treatment
amifostine	I-Treatment
.	O

in	O
this	O
study	I-Test
,	O
we	O
report	O
on	O
three	O
individual	I-Background
patients	I-Background
who	O
received	O
btx	I-Treatment
-	I-Treatment
b	I-Treatment
and	O
who	O
subsequently	O
developed	O
parasympathetic	I-Problem
dysfunction	I-Problem
of	I-Problem
the	I-Problem
visual	I-Problem
system	I-Problem
after	O
injections	O
of	O
btx	I-Treatment
-	I-Treatment
b	I-Treatment
at	O
remote	O
sites	O
.	O

minocycline	I-Treatment
-	O
induced	O
autoimmune	I-Problem
hepatitis	I-Problem
is	O
usually	O
identical	O
to	O
sporadic	I-Problem
autoimmune	I-Problem
hepatitis	I-Problem
.	O

background	O
:	O
reproductive	I-Problem
endocrine	I-Problem
disorders	I-Problem
characterized	I-Problem
by	I-Problem
menstrual	I-Problem
disorders	I-Problem
,	I-Problem
polycystic	I-Problem
ovaries	I-Problem
,	I-Problem
and	I-Problem
hyperandrogenism	I-Problem
seem	O
to	O
be	O
common	O
among	O
women	I-Background
treated	O
with	O
sodium	I-Treatment
valproate	I-Treatment
for	I-Treatment
epilepsy	I-Problem
.	O

two	O
cases	I-Background
of	I-Background
lepromatous	I-Problem
leprosy	I-Problem
with	I-Problem
erythema	I-Problem
nodosum	I-Problem
leprosum	I-Problem
who	O
were	O
on	O
high	I-Treatment
doses	I-Treatment
of	I-Treatment
clofazimine	I-Treatment
,	O
showed	O
discoloration	I-Problem
of	I-Problem
nail	I-Problem
plate	I-Problem
,	I-Problem
subungual	I-Problem
hyperkeratosis	I-Problem
and	I-Problem
onycholysis	I-Problem
.	O

doxycycline	I-Treatment
-	O
induced	O
photo	I-Problem
-	I-Problem
onycholysis	I-Problem
.	O

case	O
report	O
:	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
after	O
administering	I-Treatment
intravenous	I-Treatment
immunoglobulin	I-Treatment
.	O

sweet	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
associated	O
with	O
sargramostim	I-Treatment
(	I-Treatment
granulocyte	I-Treatment
-	I-Treatment
macrophage	I-Treatment
colony	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
)	I-Treatment
treatment	I-Treatment
.	O

this	O
is	O
a	O
rare	O
case	O
of	O
ards	I-Problem
associated	O
with	O
lithium	I-Treatment
intoxication	O
.	O

intravenous	I-Treatment
haloperidol	I-Treatment
is	O
generally	O
well	O
tolerated	O
,	O
but	O
multiform	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
has	O
been	O
reported	O
.	O

to	O
report	O
a	O
case	O
of	O
rhabdomyolysis	I-Problem
and	I-Problem
acute	I-Problem
hepatitis	I-Problem
associated	O
with	O
the	O
coadministration	I-Treatment
of	I-Treatment
atorvastatin	I-Treatment
and	I-Treatment
diltiazem	I-Treatment
.	O

ten	I-Other
hours	I-Other
after	I-Treatment
the	I-Treatment
second	I-Other
methotrexate	I-Treatment
injection	I-Treatment
,	O
the	I-Background
patient	I-Background
experienced	O
a	O
diffuse	I-Problem
pruritic	I-Problem
papular	I-Problem
eruption	I-Problem
located	I-Problem
mainly	I-Problem
on	I-Problem
the	I-Problem
limbs	I-Problem
.	O

flecainide	I-Treatment
and	I-Treatment
pharmacologically	I-Treatment
similar	I-Treatment
agents	I-Treatment
that	I-Treatment
interact	I-Treatment
with	I-Treatment
sodium	I-Treatment
channels	I-Treatment
may	O
cause	O
delirium	I-Problem
in	O
susceptible	I-Background
patients	I-Background
.	O

an	I-Background
elderly	I-Background
man	I-Background
with	O
procainamide	I-Treatment
hydrochloride	I-Treatment
-	O
induced	O
lupus	I-Problem
syndrome	O
had	O
a	O
circulating	O
anticoagulant	O
against	O
factor	O
xi	O
and	O
a	O
biologic	I-Test
false	O
-	O
positive	O
(	O
bfp	I-Test
)	I-Test
test	O
result	O
for	O
syphilis	O
.	O

in	O
one	O
patient	I-Background
,	O
treatment	O
with	O
dca	I-Treatment
was	O
associated	O
with	O
a	O
decrease	I-Problem
in	I-Problem
blood	I-Problem
lactate	I-Problem
levels	I-Problem
from	O
11	O
.	O
2	O
mm	O
before	O
treatment	O
to	O
0	O
.	O
8	O
mm	O
16	I-Other
h	I-Other
later	I-Other
.	O

we	O
report	O
a	O
case	O
of	O
noncardiogenic	I-Problem
pulmonary	I-Problem
edema	I-Problem
developed	O
after	O
therapeutic	O
trial	I-Test
of	O
eo	I-Treatment
as	O
sclerosing	O
agent	O
for	O
esophageal	I-Problem
varix	I-Problem
.	O

that	O
review	O
suggested	O
that	O
patients	I-Background
receiving	I-Treatment
anti	I-Treatment
-	I-Treatment
d	I-Treatment
igiv	I-Treatment
be	O
monitored	O
for	O
those	O
and	O
other	O
potential	O
complications	O
of	O
hemoglobinemia	I-Problem
,	I-Problem
particularly	I-Problem
disseminated	I-Problem
intravascular	I-Problem
coagulation	I-Problem
(	I-Problem
dic	I-Problem
)	I-Problem
.	O

seizures	I-Problem
associated	O
with	O
therapeutic	I-Treatment
doses	I-Treatment
of	I-Treatment
venlafaxine	I-Treatment
and	I-Treatment
trimipramine	I-Treatment
.	O

background	O
:	O
the	O
risk	O
/	O
benefit	O
ratio	O
of	O
warfarin	I-Treatment
therapy	I-Treatment
changes	O
in	O
the	O
over	I-Background
75s	I-Background
,	O
when	O
haemorrhagic	I-Problem
side	I-Problem
-	I-Problem
effects	I-Problem
become	O
more	O
common	O
.	O

norethisterone	I-Treatment
in	O
these	O
69	O
pregnancies	I-Background
accounted	O
for	O
33	O
.	O
3	O
%	O
(	O
5	O
of	O
15	O
)	O
cases	O
of	O
clitoral	I-Problem
hypertrophy	I-Problem
diagnosed	O
in	O
100	O
,	O
756	O
consecutive	O
births	O
.	O

interstitial	I-Problem
fibrosis	I-Problem
of	I-Problem
the	I-Problem
lung	I-Problem
is	O
a	O
potential	O
complication	O
of	O
methotrexate	I-Treatment
therapy	O
for	O
psoriasis	I-Problem
.	O

this	O
is	O
the	O
first	O
reported	O
fatality	O
due	O
to	O
this	O
drug	O
interaction	O
and	O
only	O
the	O
second	O
case	O
of	O
serotonin	I-Problem
syndrome	I-Problem
reported	O
with	O
oxcarbazepine	I-Treatment
.	O

purple	I-Problem
glove	I-Problem
syndrome	I-Problem
,	O
named	O
for	O
its	O
distinctive	O
purple	I-Problem
discoloration	I-Problem
and	I-Problem
swelling	I-Problem
of	I-Problem
the	I-Problem
hands	I-Problem
in	I-Problem
the	I-Problem
distribution	I-Problem
of	I-Problem
a	I-Problem
glove	I-Problem
,	O
is	O
an	O
uncommon	O
complication	O
of	O
intravenous	I-Treatment
phenytoin	I-Treatment
administration	I-Treatment
through	I-Treatment
small	I-Treatment
dorsal	I-Treatment
veins	I-Treatment
of	I-Treatment
the	I-Treatment
hands	I-Treatment
.	O

possible	O
linkage	O
of	O
amprenavir	I-Treatment
with	O
intracranial	I-Problem
bleeding	I-Problem
in	O
an	I-Background
hiv	I-Problem
-	I-Background
infected	I-Background
hemophiliac	I-Background
.	O

inadvertent	I-Treatment
subsequent	I-Treatment
rechallenge	I-Test
with	I-Treatment
celiprolol	I-Treatment
led	O
to	O
recurrence	I-Problem
of	I-Problem
the	I-Problem
pneumonitis	I-Problem
,	O
10	I-Other
weeks	I-Other
after	I-Treatment
drug	I-Treatment
readministration	I-Test
.	O

flecainide	I-Treatment
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atrial	I-Problem
fibrillation	I-Problem
.	O

in	O
the	O
absence	O
of	O
evidence	O
of	O
a	O
potential	O
role	O
for	O
concomitant	O
medication	O
i	O
.	O
e	O
.	O
hydroxychloroquine	O
sulfate	O
to	O
play	O
a	O
role	O
in	O
the	O
clinical	O
,	O
biochemical	O
and	O
morphological	O
picture	O
,	O
an	I-Treatment
interaction	I-Treatment
between	I-Treatment
the	I-Treatment
herbal	I-Treatment
preparation	I-Treatment
and	I-Treatment
tibolone	I-Treatment
was	O
suspected	O
as	O
the	O
likely	O
cause	O
of	O
liver	I-Problem
damage	I-Problem
.	O

its	O
overall	O
toxicity	O
is	O
considerably	O
less	O
compared	O
to	O
standard	O
induction	O
chemotherapy	O
;	O
however	O
,	O
it	O
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
a	O
potentially	O
fatal	O
symptom	I-Problem
complex	I-Problem
referred	I-Problem
to	I-Problem
as	I-Problem
"	I-Problem
retinoic	I-Problem
acid	I-Problem
syndrome	I-Problem
.	I-Problem
"	I-Problem
this	O
report	O
describes	O
a	I-Background
patient	I-Background
with	I-Background
apl	I-Problem
who	O
developed	O
the	O
syndrome	O
a	I-Other
few	I-Other
weeks	I-Other
after	I-Treatment
initiating	I-Treatment
induction	I-Treatment
therapy	I-Treatment
with	I-Treatment
atra	I-Treatment
despite	I-Treatment
being	I-Treatment
treated	I-Treatment
for	I-Treatment
hyperleukocytosis	I-Treatment
.	O

during	I-Treatment
intravenous	I-Treatment
treatment	I-Treatment
with	I-Treatment
terlipressin	I-Treatment
for	I-Treatment
recurrent	I-Problem
gastrointestinal	I-Problem
(	I-Treatment
gi	I-Treatment
)	I-Treatment
bleeding	I-Treatment
,	O
a	I-Background
50	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
with	I-Background
no	I-Background
history	I-Background
of	I-Background
heart	I-Background
disease	I-Background
developed	O
a	I-Problem
newly	I-Problem
prolonged	I-Problem
qt	I-Problem
interval	I-Problem
and	I-Problem
torsade	I-Problem
de	I-Problem
pointes	I-Problem
.	O

it	O
is	O
concluded	O
that	O
chloral	I-Treatment
hydrate	I-Treatment
and	I-Treatment
methaqualone	I-Treatment
may	O
be	O
administered	O
safely	O
without	O
additional	O
caution	O
in	O
prothrombin	O
test	I-Test
monitoring	I-Test
during	I-Treatment
oral	I-Treatment
anticoagulant	I-Treatment
therapy	I-Treatment
.	O

amiodarone	I-Treatment
hydrochloride	I-Treatment
,	O
a	O
new	O
antiarrhythmic	O
agent	O
,	O
has	O
been	O
associated	O
with	O
pulmonary	I-Problem
toxicity	I-Problem
characterized	I-Problem
by	I-Problem
cough	I-Problem
,	I-Problem
dyspnea	I-Problem
and	I-Problem
diffuse	I-Problem
pulmonary	I-Problem
infiltrates	I-Problem
.	O

although	O
major	O
hazards	O
of	O
treatment	O
of	O
hypophosphatemic	I-Problem
osteomalacia	I-Problem
with	I-Treatment
phosphate	I-Treatment
and	I-Treatment
calcitriol	I-Treatment
are	O
secondary	I-Problem
hyperparathyroidism	I-Problem
and	I-Problem
vitamin	I-Problem
d	I-Problem
intoxication	I-Problem
,	I-Problem
potassium	I-Problem
loss	I-Problem
also	O
should	O
be	O
kept	O
in	O
mind	O
.	O

he	O
had	O
priapism	I-Problem
following	O
the	O
use	O
of	O
olanzapine	I-Treatment
.	O

conclusion	O
:	O
our	O
case	O
shows	O
a	O
fatal	O
side	I-Problem
effect	I-Problem
of	O
erlotinib	I-Treatment
.	O

data	O
have	O
been	O
published	O
regarding	O
the	O
possibility	O
that	O
tamoxifen	I-Treatment
may	O
be	O
responsible	O
for	O
the	O
subsequent	I-Problem
development	I-Problem
of	I-Problem
carcinoma	I-Problem
of	I-Problem
the	I-Problem
corpus	I-Problem
uteri	I-Problem
in	O
these	I-Background
patients	I-Background
.	O

corticosteroids	I-Treatment
may	O
be	O
useful	O
for	O
therapy	O
of	O
some	O
features	O
of	O
this	O
syndrome	O
,	O
such	O
as	O
thrombocytopenia	I-Problem
.	O

eosinophilic	I-Problem
cystitis	I-Problem
after	O
bladder	I-Treatment
instillation	I-Treatment
with	I-Treatment
dimethyl	I-Treatment
sulfoxide	I-Treatment
.	O

beginning	O
ductopenia	I-Problem
was	O
present	O
in	O
two	I-Background
,	O
suggesting	O
that	O
itraconazole	I-Treatment
might	O
be	O
responsible	O
for	O
the	O
occurrence	O
of	O
prolonged	I-Problem
drug	I-Problem
-	I-Problem
induced	I-Problem
cholangiopathy	I-Problem
.	O

a	I-Problem
15	I-Problem
-	I-Problem
kg	I-Problem
weight	I-Problem
gain	I-Problem
developed	O
in	O
a	I-Background
patient	I-Background
during	O
the	I-Other
third	I-Other
week	I-Other
of	O
ibuprofen	I-Treatment
therapy	O
.	O

cefoxitin	I-Treatment
-	O
associated	O
renal	I-Problem
failure	I-Problem
.	O

two	O
of	I-Background
our	I-Background
patients	I-Background
developed	O
td	I-Problem
after	O
23	I-Other
months	I-Other
and	O
34	I-Other
months	I-Other
of	O
ziprasidone	I-Treatment
monotherapy	O
,	O
respectively	O
.	O

we	O
describe	O
two	O
dark	I-Background
-	I-Background
skinned	I-Background
patients	I-Background
who	O
developed	O
hyperpigmented	I-Problem
skin	I-Problem
and	I-Problem
tongue	I-Problem
lesions	I-Problem
during	O
combination	I-Treatment
therapy	I-Treatment
with	I-Treatment
ifn	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
.	I-Treatment

attenuation	I-Problem
of	I-Problem
asparaginase	I-Problem
-	I-Problem
induced	I-Problem
hyperglycemia	I-Problem
after	O
substitution	I-Treatment
of	I-Treatment
the	I-Treatment
erwinia	I-Treatment
carotovora	I-Treatment
for	I-Treatment
the	I-Treatment
escherichia	I-Treatment
coli	I-Treatment
enzyme	I-Treatment
preparation	I-Treatment
.	O

it	O
remains	O
to	O
be	O
seen	O
whether	O
the	O
hepatotoxicity	I-Problem
associated	O
with	O
troglitazone	I-Treatment
is	O
a	O
drug	O
-	O
class	O
effect	O
or	O
specific	O
to	O
troglitazone	O
.	O

ampicillin	I-Treatment
-	O
induced	O
interstitial	I-Problem
nephritis	I-Problem
with	I-Problem
generalised	I-Problem
exfoliative	I-Problem
dermatitis	I-Problem
.	O

high	I-Treatment
-	I-Treatment
dose	I-Treatment
intravenous	I-Treatment
mannitol	I-Treatment
infusion	I-Treatment
in	O
various	O
clinical	O
settings	O
may	O
result	O
in	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
(	O
arf	O
)	O
.	O

a	I-Background
7	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
developed	I-Background
a	I-Problem
severe	I-Problem
unilateral	I-Problem
grand	I-Problem
mal	I-Problem
seizure	I-Problem
at	I-Treatment
the	I-Treatment
age	I-Treatment
of	I-Treatment
5	I-Treatment
years	I-Treatment
(	I-Treatment
phenobarbitone	I-Treatment
therapy	I-Treatment
)	I-Treatment
;	I-Treatment
1	I-Other
.	I-Other
5	I-Other
years	I-Other
later	I-Other
valproate	I-Treatment
(	I-Treatment
2	I-Treatment
-	I-Treatment
propylpentanoic	I-Treatment
acid	I-Treatment
,	I-Treatment
vpa	I-Treatment
)	I-Treatment
was	I-Treatment
added	I-Treatment
to	I-Treatment
the	I-Treatment
therapy	I-Treatment
.	I-Treatment

we	O
report	O
the	O
first	O
case	O
of	O
rhabdomyolysis	I-Problem
related	O
to	O
the	O
administration	I-Treatment
of	I-Treatment
clarithromycin	I-Treatment
without	I-Treatment
concurrent	I-Treatment
use	I-Treatment
of	I-Treatment
other	I-Treatment
medications	I-Treatment
.	O

the	O
authors	O
report	O
a	I-Background
further	I-Background
case	I-Background
of	O
methimazole	I-Treatment
-	O
associated	O
liver	I-Problem
damage	I-Problem
and	O
present	O
a	O
brief	O
review	O
of	O
eleven	O
previous	I-Background
cases	I-Background
found	O
in	O
the	O
literature	O
.	O

a	I-Background
67	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
patient	I-Background
,	I-Background
with	I-Background
primary	I-Problem
polymyositis	I-Problem
and	I-Background
without	I-Background
previous	I-Background
evidence	I-Background
of	I-Background
liver	I-Background
disease	I-Background
,	O
developed	O
clinical	O
and	O
biochemical	O
features	O
of	O
severe	O
cholestasis	I-Problem
3	I-Other
months	I-Other
after	I-Treatment
initiation	I-Treatment
of	I-Treatment
azathioprine	I-Treatment
therapy	O
.	O

hypersensitivity	I-Problem
reaction	I-Problem
following	O
chloramphenicol	I-Treatment
administration	O
in	O
a	I-Background
patient	I-Background
with	I-Background
typhoid	I-Problem
fever	I-Problem
.	O

allergic	O
and	O
irritant	O
contact	I-Problem
dermatitis	I-Problem
to	O
calcipotriol	I-Treatment
.	O

a	I-Background
23	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
had	O
a	O
severe	O
hypersensitivity	I-Problem
reaction	I-Problem
to	O
the	O
drug	O
ibuprofen	I-Treatment
.	O

we	O
present	O
the	O
first	O
case	O
of	O
wes	I-Problem
in	O
an	I-Background
infant	I-Background
born	I-Background
to	I-Background
a	I-Background
mother	I-Background
taking	O
haloperidol	I-Treatment
during	O
her	O
pregnancy	O
.	O

despite	O
treatment	O
with	O
levofloxacin	I-Treatment
,	I-Treatment
acyclovir	I-Treatment
,	I-Treatment
and	I-Treatment
voriconazole	I-Treatment
,	O
the	O
patient	I-Background
developed	O
high	I-Problem
fevers	I-Problem
.	O

the	I-Background
5	O
patients	I-Background
had	I-Background
severe	I-Background
renovascular	I-Problem
disease	I-Problem
which	O
might	O
thus	O
represent	O
a	O
significant	O
risk	O
factor	O
in	O
the	O
development	O
of	O
captopril	I-Treatment
-	O
induced	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
.	O

methods	O
:	O
growth	I-Problem
retardation	I-Problem
was	O
observed	O
in	O
six	O
severely	I-Problem
asthmatic	I-Problem
children	I-Background
after	O
introduction	I-Treatment
of	I-Treatment
high	I-Treatment
-	I-Treatment
dose	I-Treatment
fluticasone	I-Treatment
propionate	I-Treatment
treatment	I-Treatment
(	I-Treatment
dry	I-Treatment
powder	I-Treatment
)	I-Treatment
.	O

the	O
toxic	I-Problem
effects	I-Problem
of	O
methotrexate	I-Treatment
included	O
elevated	I-Problem
liver	I-Problem
transaminases	I-Problem
(	I-Problem
3	I-Problem
/	I-Problem
4	I-Problem
)	I-Problem
,	I-Problem
nausea	I-Problem
(	I-Problem
2	I-Problem
/	I-Problem
4	I-Problem
)	I-Problem
,	I-Problem
abdominal	I-Problem
pain	I-Problem
(	I-Problem
2	I-Problem
/	I-Problem
4	I-Problem
)	I-Problem
,	I-Problem
bone	I-Problem
pain	I-Problem
(	I-Problem
2	I-Problem
/	I-Problem
4	I-Problem
)	I-Problem
,	I-Problem
mild	I-Problem
neutropenia	I-Problem
(	I-Problem
1	I-Problem
/	I-Problem
4	I-Problem
)	I-Problem
,	I-Problem
and	I-Problem
mild	I-Problem
pruritus	I-Problem
(	I-Problem
1	I-Problem
/	I-Problem
4	I-Problem
)	I-Problem
.	O

conclusion	O
:	O
zidovudine	I-Treatment
is	O
well	O
a	O
known	O
cause	O
of	O
anaemia	I-Problem
and	O
thus	O
should	O
be	O
used	O
with	O
caution	O
in	O
the	O
initiation	O
of	O
antiretroviral	O
therapy	O
.	O

a	I-Background
60	I-Background
-	I-Background
yr	I-Background
-	I-Background
old	I-Background
woman	I-Background
,	O
established	O
on	O
paroxetine	I-Treatment
for	O
depression	I-Problem
,	O
underwent	I-Treatment
excision	I-Treatment
of	I-Treatment
a	I-Treatment
chest	I-Treatment
wall	I-Treatment
myxofibrosarcoma	I-Problem
and	I-Treatment
chest	I-Treatment
wall	I-Treatment
reconstruction	I-Treatment
.	O

papilloedema	I-Problem
and	I-Problem
hepatic	I-Problem
dysfunction	I-Problem
apparently	O
induced	O
by	O
perhexiline	I-Treatment
maleate	I-Treatment
(	I-Treatment
pexid	I-Treatment
)	I-Treatment
.	O

the	O
volatile	I-Treatment
anesthetic	I-Treatment
halothane	I-Treatment
undergoes	O
substantial	O
biotransformation	O
generating	O
metabolites	O
that	O
mediate	O
hepatotoxicity	I-Problem
.	O

case	O
4	O
:	O
a	O
61	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
alcoholic	I-Problem
who	I-Background
remained	I-Background
completely	I-Background
abstinent	I-Background
while	O
taking	O
cyanamide	I-Treatment
for	I-Treatment
3	I-Other
years	I-Other
showed	O
slight	O
elevation	I-Problem
of	I-Problem
serum	I-Problem
transaminases	I-Problem
.	O

these	O
observations	O
indicate	O
that	O
submassive	I-Problem
hepatic	I-Problem
necrosis	I-Problem
may	O
result	O
from	O
treatment	O
with	O
propylthiouracil	I-Treatment
and	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
sensitization	O
mechanisms	O
may	O
be	O
responsible	O
for	O
the	O
hepatic	O
injury	O
induced	O
by	O
this	O
drug	O
.	O

two	O
children	I-Background
with	I-Background
rheumatic	I-Problem
fever	I-Problem
developed	O
anicteric	I-Problem
hepatitis	I-Problem
while	O
on	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
aspirin	I-Treatment
therapy	O
.	O

the	O
authors	O
describe	O
valproate	I-Treatment
-	O
induced	O
hyperammonemia	I-Problem
and	I-Problem
mental	I-Problem
status	I-Problem
changes	I-Problem
in	O
an	I-Background
88	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
,	O
the	O
first	O
known	O
reported	O
case	O
in	O
an	O
elderly	O
patient	O
.	O

the	O
mechanism	O
of	O
the	O
decrease	I-Problem
in	I-Problem
plasma	I-Problem
potassium	I-Problem
induced	O
by	O
phosphate	I-Treatment
treatment	I-Treatment
was	O
investigated	O
in	O
a	I-Background
24	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
hypertensive	I-Problem
patient	I-Background
with	I-Background
hypophosphatemic	I-Problem
osteomalacia	I-Problem
,	I-Background
who	I-Background
was	I-Background
the	I-Background
youngest	I-Background
of	I-Background
four	I-Background
patients	I-Background
,	I-Background
belonging	I-Background
to	I-Background
a	I-Background
23	I-Background
number	I-Background
kindred	I-Background
of	I-Background
five	I-Background
generations	I-Background
.	O

adrenaline	I-Treatment
dacryolith	I-Problem
:	O
detection	O
by	O
ultrasound	O
examination	I-Test
of	I-Test
the	I-Test
nasolacrimal	I-Test
duct	I-Test
.	O

ten	O
days	O
after	O
itraconazole	I-Treatment
was	O
started	O
,	O
he	O
developed	O
paralytic	I-Problem
ileus	I-Problem
,	I-Problem
neurogenic	I-Problem
bladder	I-Problem
,	I-Problem
mild	I-Problem
left	I-Problem
ptosis	I-Problem
,	I-Problem
and	I-Problem
absence	I-Problem
of	I-Problem
deep	I-Problem
reflexes	I-Problem
,	I-Problem
with	I-Problem
severe	I-Problem
paralysis	I-Problem
of	I-Problem
the	I-Problem
lower	I-Problem
extremities	I-Problem
and	I-Problem
mild	I-Problem
weakness	I-Problem
of	I-Problem
the	I-Problem
upper	I-Problem
extremities	I-Problem
.	O

objective	O
:	O
the	O
aim	O
of	O
this	O
paper	O
is	O
to	O
describe	O
a	I-Background
case	I-Background
of	O
increased	I-Problem
libido	I-Problem
during	O
fluvoxamine	I-Treatment
therapy	I-Treatment
.	I-Treatment

an	I-Background
8	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
child	I-Background
with	O
familial	I-Problem
mediterranean	I-Problem
fever	I-Problem
exhibited	O
signs	O
of	O
colchicine	I-Treatment
intoxication	I-Problem
while	O
receiving	O
prophylactic	I-Treatment
doses	I-Treatment
of	I-Treatment
the	I-Treatment
drug	I-Treatment
.	O

furthermore	O
,	O
the	I-Treatment
warfarin	I-Treatment
dose	I-Treatment
was	I-Treatment
again	I-Treatment
increased	I-Treatment
after	I-Treatment
discontinuation	I-Treatment
of	I-Treatment
ropinirole	I-Treatment
due	O
to	O
common	O
gastrointestinal	I-Problem
adverse	I-Problem
effects	I-Problem
.	O

serotonin	I-Problem
syndrome	I-Problem
following	O
metaxalone	I-Treatment
overdose	I-Treatment
and	O
therapeutic	O
use	O
of	O
a	O
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitor	I-Treatment
.	O

the	O
aim	O
of	O
this	O
report	O
is	O
to	O
describe	O
the	O
clinical	O
and	O
electroencephalographic	O
findings	O
seen	O
in	O
an	I-Background
elderly	I-Background
woman	I-Background
without	O
previous	O
history	O
of	O
seizures	O
who	O
developed	O
a	O
nonconvulsive	I-Problem
generalized	I-Problem
status	I-Problem
epilepticus	I-Problem
following	O
acute	I-Treatment
withdrawal	I-Treatment
of	I-Treatment
lorazepam	I-Treatment
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
androgen	I-Problem
-	I-Problem
independent	I-Problem
prostate	I-Problem
cancer	I-Problem
in	O
whom	O
psa	I-Problem
continued	I-Problem
to	I-Problem
decrease	I-Problem
for	I-Problem
a	I-Problem
period	I-Problem
of	I-Problem
15	I-Problem
months	I-Problem
after	O
flutamide	I-Treatment
withdrawal	I-Treatment
.	O

acute	I-Problem
renal	I-Problem
failure	I-Problem
following	O
intravenous	I-Treatment
immunoglobulin	I-Treatment
therapy	I-Treatment
in	O
a	I-Background
hiv	I-Problem
-	I-Background
infected	I-Background
patient	I-Background
.	O

after	O
a	I-Treatment
total	I-Treatment
of	I-Treatment
four	I-Treatment
doses	I-Treatment
of	I-Treatment
linezolid	I-Treatment
,	O
the	I-Background
patient	I-Background
reported	O
further	I-Problem
discomfort	I-Problem
.	O

although	O
moderate	O
myelosuppression	O
is	O
not	O
uncommonly	O
seen	O
in	O
patients	O
treated	O
with	O
lenalidomide	I-Treatment
,	O
aplastic	I-Problem
anemia	I-Problem
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
agent	O
.	O

this	O
paper	O
contributed	O
to	O
the	O
identification	O
of	O
possible	O
reactions	I-Problem
in	I-Problem
the	I-Problem
oral	I-Problem
cavity	I-Problem
due	O
to	O
antiretroviral	I-Treatment
medication	I-Treatment
.	O

persistent	I-Problem
light	I-Problem
reactivity	I-Problem
from	O
systemic	I-Treatment
quinine	I-Treatment
.	O

based	O
on	O
the	O
clinical	O
status	O
of	O
the	I-Background
patient	I-Background
,	O
it	O
was	O
suspected	O
that	O
several	O
conditions	O
contributed	O
to	O
the	O
abnormal	I-Problem
hypersensitivity	I-Problem
to	O
warfarin	I-Treatment
.	O

treatment	O
of	O
apl	O
in	O
pregnancy	O
is	O
controversial	O
as	O
the	O
use	O
of	O
atra	O
has	O
been	O
questioned	O
due	O
to	O
the	O
teratogenic	I-Problem
effect	I-Problem
of	O
retinoids	I-Treatment
.	O

diazepam	I-Treatment
use	O
by	O
pregnant	O
women	O
can	O
be	O
associated	O
with	O
a	O
later	I-Problem
presentation	I-Problem
of	I-Problem
withdrawal	I-Problem
symptoms	I-Problem
in	I-Problem
the	I-Problem
neonate	I-Problem
than	O
that	O
induced	O
by	O
the	O
use	O
of	O
other	O
drugs	O
.	O

a	I-Background
65	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
patient	I-Background
chronically	I-Other
treated	I-Treatment
with	I-Treatment
the	I-Treatment
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitor	I-Treatment
(	I-Treatment
ssri	I-Treatment
)	I-Treatment
citalopram	I-Treatment
developed	O
confusion	I-Problem
,	I-Problem
agitation	I-Problem
,	I-Problem
tachycardia	I-Problem
,	I-Problem
tremors	I-Problem
,	I-Problem
myoclonic	I-Problem
jerks	I-Problem
and	I-Problem
unsteady	I-Problem
gait	I-Problem
,	I-Problem
consistent	I-Problem
with	I-Problem
serotonin	I-Problem
syndrome	I-Problem
,	O
following	I-Treatment
initiation	I-Treatment
of	I-Treatment
fentanyl	I-Treatment
,	O
and	O
all	O
symptoms	O
and	O
signs	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	O
.	O

this	O
case	O
highlights	O
rapid	I-Problem
onset	I-Problem
of	I-Problem
adrenal	I-Problem
insufficiency	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
cf	I-Problem
-	I-Problem
related	I-Problem
liver	I-Problem
disease	I-Problem
treated	O
briefly	I-Treatment
with	I-Treatment
a	I-Treatment
moderate	I-Treatment
cyp3a4	I-Treatment
inhibitor	I-Treatment
.	O

the	O
biochemistry	O
of	O
paracetamol	O
hepatotoxicity	O
is	O
outlined	O
and	O
the	O
increased	O
susceptibility	O
of	O
alcoholic	I-Background
patients	I-Background
to	O
the	O
hepatotoxic	I-Problem
effects	I-Problem
of	O
paracetamol	I-Treatment
is	O
remarked	O
upon	O
.	O

the	O
newborn	I-Background
manifested	O
a	O
four	I-Problem
day	I-Problem
course	I-Problem
of	I-Problem
lethargy	I-Problem
with	I-Problem
unexplained	I-Problem
high	I-Problem
lithium	I-Treatment
levels	I-Problem
in	O
the	O
adult	O
toxic	O
range	O
.	O

the	O
occurrence	O
of	O
severe	I-Problem
aiha	I-Problem
in	O
cll	I-Problem
patients	I-Background
treated	O
with	O
fludarabine	I-Treatment
has	O
been	O
reported	O
by	O
several	O
authors	O
.	O

corneal	I-Problem
endothelial	I-Problem
dysfunction	I-Problem
associated	O
with	O
amantadine	I-Treatment
toxicity	O
.	O

we	O
describe	O
the	O
development	O
of	O
cutaneous	I-Problem
scleroderma	I-Problem
in	O
3	O
patients	I-Background
coincident	O
with	O
the	I-Treatment
use	I-Treatment
of	I-Treatment
bleomycin	I-Treatment
in	I-Treatment
low	I-Treatment
cumulative	I-Treatment
doses	I-Treatment
of	I-Treatment
less	I-Treatment
than	I-Treatment
100	I-Treatment
u	I-Treatment
.	I-Treatment

this	O
case	O
suggests	O
that	O
sarcoidosis	O
and	O
pravastatin	I-Treatment
,	O
two	O
entities	O
not	O
frequently	O
associated	O
with	O
myotonia	O
,	O
may	O
interact	O
in	O
a	O
synergistic	O
manner	O
to	O
produce	O
severe	I-Problem
clinical	I-Problem
myotonia	I-Problem
in	O
humans	I-Background
.	I-Background

disopyramide	I-Treatment
-	O
induced	O
heart	I-Problem
block	I-Problem
.	O

telescoped	I-Problem
digits	I-Problem
of	I-Problem
the	I-Problem
hands	I-Problem
and	I-Problem
feet	I-Problem
developed	O
in	O
a	I-Background
69	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
with	I-Background
severe	I-Problem
chronic	I-Problem
tophaceous	I-Problem
gout	I-Problem
during	O
allopurinol	I-Treatment
treatment	I-Treatment
.	O

we	O
describe	O
a	I-Background
relatively	I-Background
healthy	I-Background
,	I-Background
9	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
who	O
developed	O
a	O
ca	I-Problem
-	I-Problem
mrsa	I-Problem
skin	I-Problem
and	I-Problem
soft	I-Problem
tissue	I-Problem
infection	I-Problem
and	O
was	O
treated	O
with	O
tmp	I-Treatment
-	I-Treatment
smx	I-Treatment
.	O

recurrent	I-Problem
septicemia	I-Problem
with	I-Problem
lethal	I-Problem
outcome	I-Problem
during	O
and	O
after	O
cyclosporine	I-Treatment
therapy	O
in	O
severe	I-Problem
ulcerative	I-Problem
colitis	I-Problem
.	O

amifostine	I-Treatment
-	O
induced	O
fever	I-Problem
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

we	O
report	O
a	I-Background
patient	I-Background
who	O
developed	O
spontaneous	I-Problem
splenic	I-Problem
infarction	I-Problem
after	O
the	O
use	O
of	O
sumatriptan	I-Treatment
for	O
the	O
treatment	O
of	O
migraine	I-Problem
headache	I-Problem
.	O

hepatotoxicity	I-Problem
associated	O
with	O
6	I-Treatment
-	I-Treatment
thioguanine	I-Treatment
therapy	O
for	O
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
.	O

neuropathy	I-Problem
is	O
a	O
significant	O
side	O
effect	O
of	O
thalidomide	I-Treatment
therapy	O
,	O
which	O
may	O
limit	O
its	O
clinical	O
use	O
.	O

a	O
possible	O
mechanism	O
for	O
focal	I-Problem
neurological	I-Problem
deficit	I-Problem
in	O
brain	I-Problem
-	I-Problem
damaged	I-Problem
patients	I-Background
on	O
phenytoin	I-Treatment
therapy	I-Treatment
is	O
discussed	O
.	O

pulmonary	I-Problem
toxicity	I-Problem
with	O
mefloquine	I-Treatment
.	O

ciprofloxacin	I-Treatment
is	O
one	O
drug	O
that	O
has	O
been	O
reported	O
to	O
cause	O
interstitial	I-Problem
nephritis	I-Problem
.	O

acute	I-Problem
renal	I-Problem
failure	I-Problem
during	O
lisinopril	I-Treatment
and	I-Treatment
losartan	I-Treatment
therapy	O
for	O
proteinuria	I-Problem
.	O

we	O
present	O
the	O
first	O
case	O
of	O
a	I-Background
patient	I-Background
with	O
priapism	I-Problem
after	O
oral	I-Treatment
intake	I-Treatment
of	I-Treatment
the	I-Treatment
phenothiazine	I-Treatment
prothipendylhydrochloride	I-Treatment
.	O

however	O
,	O
because	O
diphenhydramine	I-Treatment
also	I-Problem
exhibits	I-Problem
type	I-Problem
ia	I-Problem
sodium	I-Problem
channel	I-Problem
blockade	I-Problem
,	I-Problem
cardiac	I-Problem
toxicity	I-Problem
is	O
also	O
possible	O
.	O

ticlopidine	I-Treatment
-	O
induced	O
interstitial	I-Problem
pulmonary	I-Problem
disease	I-Problem
:	O
a	O
case	O
report	O
.	O

linezolid	I-Treatment
is	O
a	O
popular	O
choice	O
of	O
antibiotic	O
,	O
especially	O
for	O
the	O
treatment	O
of	O
orthopedic	I-Problem
-	I-Problem
related	I-Problem
mrsa	I-Problem
infections	I-Problem
.	O

we	O
present	O
a	O
case	O
of	O
photo	I-Problem
-	I-Problem
onycholysis	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
doxycycline	I-Treatment
for	O
acne	I-Problem
vulgaris	I-Problem
.	O

anticonvulsant	I-Problem
hypersensitivity	I-Problem
syndrome	I-Problem
associated	O
with	O
bellamine	I-Treatment
s	I-Treatment
,	I-Treatment
a	I-Treatment
therapy	I-Treatment
for	I-Treatment
menopausal	I-Problem
symptoms	I-Problem
.	I-Problem

case	O
summary	O
:	O
a	I-Background
66	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
woman	I-Background
with	I-Background
a	I-Background
10	I-Background
-	I-Background
year	I-Background
history	I-Background
of	I-Background
hypertension	I-Problem
and	I-Background
bronchial	I-Problem
asthma	I-Problem
was	O
switched	I-Treatment
from	I-Treatment
immediate	I-Treatment
-	I-Treatment
release	I-Treatment
verapamil	I-Treatment
hydrocloride	I-Treatment
40	I-Treatment
mg	I-Treatment
tid	I-Treatment
to	I-Treatment
sustained	I-Treatment
-	I-Treatment
release	I-Treatment
verapamil	I-Treatment
240	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
po	I-Treatment
for	O
better	O
hypertension	I-Problem
control	O
.	O

due	O
to	O
the	O
severity	O
of	O
the	O
rash	I-Problem
,	O
temozolomide	I-Treatment
was	O
permanently	O
discontinued	O
.	O

ovarian	I-Problem
endometrioid	I-Problem
carcinoma	I-Problem
and	I-Problem
endometriosis	I-Problem
developing	O
in	O
a	I-Background
postmenopausal	I-Problem
breast	I-Problem
cancer	I-Problem
patient	I-Background
during	O
tamoxifen	I-Treatment
therapy	I-Treatment
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

conclusion	O
:	O
the	I-Treatment
new	I-Treatment
quinolone	I-Treatment
derivatives	I-Treatment
(	I-Treatment
levofloxacin	I-Treatment
,	I-Treatment
sparfloxacin	I-Treatment
,	I-Treatment
grepafloxacin	I-Treatment
,	I-Treatment
trovafloxacin	I-Treatment
,	I-Treatment
gatifloxacin	I-Treatment
and	I-Treatment
moxifloxacin	I-Treatment
)	I-Treatment
,	I-Treatment
also	I-Treatment
called	I-Treatment
gyrase	I-Treatment
inhibitors	I-Treatment
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	I-Problem
nervous	I-Problem
system	I-Problem
-	I-Problem
related	I-Problem
adverse	I-Problem
effects	I-Problem
,	I-Problem
including	I-Problem
headache	I-Problem
,	I-Problem
dizziness	I-Problem
and	I-Problem
insomnia	I-Problem
.	O

terlipressin	I-Treatment
-	O
induced	O
ventricular	I-Problem
arrhythmia	I-Problem
.	O

case	O
report	O
:	O
we	O
report	O
a	O
case	O
of	O
acute	I-Problem
severe	I-Problem
hepatitis	I-Problem
resulting	O
from	O
erlotinib	I-Treatment
monotherapy	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
locally	I-Problem
advanced	I-Problem
pancreatic	I-Problem
cancer	I-Problem
.	O

we	O
highlight	O
two	O
instances	I-Background
of	O
systemic	I-Problem
allergic	I-Problem
reaction	I-Problem
,	O
and	O
discuss	O
the	O
potential	I-Problem
side	I-Problem
effects	I-Problem
of	O
local	O
aprotinin	I-Treatment
injections	O
in	O
the	O
orthopaedic	O
setting	O
as	O
well	O
as	O
the	O
evidence	O
base	O
for	O
its	O
use	O
.	O

acute	I-Problem
pancreatitis	I-Problem
associated	O
with	O
danazol	I-Treatment
treatment	I-Treatment
for	O
endometriosis	I-Problem
.	O

case	O
report	O
:	O
we	O
report	O
the	O
case	O
of	O
a	I-Background
58	I-Background
year	I-Background
old	I-Background
patient	I-Background
who	O
,	O
after	I-Treatment
2	I-Other
days	I-Other
of	I-Treatment
treatment	I-Treatment
with	I-Treatment
roxithromycin	I-Treatment
and	O
betamethasone	I-Treatment
,	O
manifested	O
acute	I-Problem
pancreatitis	I-Problem
.	O

it	O
should	O
be	O
recognized	O
that	O
ibuprofen	I-Treatment
may	O
be	O
associated	O
with	O
salt	I-Problem
and	I-Problem
water	I-Problem
retention	I-Problem
in	O
the	O
same	O
fashion	O
as	O
previously	O
described	O
with	O
phenylbutazone	I-Treatment
and	O
indomethacin	I-Treatment
.	O

gastric	I-Problem
tumor	I-Problem
,	I-Problem
endometrial	I-Problem
carcinoma	I-Problem
and	I-Problem
cervical	I-Problem
adenocarcinoma	I-Problem
in	I-Problem
situ	I-Problem
were	O
detected	O
after	O
treatment	O
with	O
tamoxifen	I-Treatment
for	O
breast	I-Problem
cancer	I-Problem
.	O

this	O
therapy	O
was	O
also	O
complicated	O
by	O
warfarin	I-Treatment
-	O
induced	O
skin	I-Problem
necrosis	I-Problem
.	O

immobilization	O
,	O
while	O
paget	O
'	O
s	O
bone	O
disease	O
was	O
present	O
,	O
and	O
perhaps	O
enhanced	O
activation	O
of	O
dihydrotachysterol	I-Treatment
by	O
rifampicin	O
,	O
could	O
have	O
led	O
to	O
increased	I-Problem
calcium	I-Problem
-	I-Problem
release	I-Problem
into	O
the	O
circulation	O
.	O

although	O
neurotoxicity	I-Problem
is	O
a	O
frequent	O
complication	O
of	O
methotrexate	I-Treatment
therapy	I-Treatment
,	O
fatal	O
acute	O
neurotoxicity	O
is	O
extremely	O
uncommon	O
,	O
especially	O
in	O
adults	O
.	O

allopurinol	I-Treatment
-	O
associated	O
hand	I-Problem
and	I-Problem
foot	I-Problem
deformities	I-Problem
in	O
chronic	I-Problem
tophaceous	I-Problem
gout	I-Problem
.	O

the	O
intramuscular	I-Test
challenge	I-Test
test	I-Test
with	O
25	I-Treatment
ui	I-Treatment
of	I-Treatment
miacalcic	I-Treatment
was	O
positive	O
with	O
an	O
immediate	I-Other
anaphylactic	I-Problem
reaction	I-Problem
.	O

there	O
are	O
several	O
documented	I-Background
case	I-Background
reports	O
of	O
serotonin	I-Treatment
toxicity	I-Problem
when	O
used	O
with	O
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitors	I-Treatment
.	O

a	O
literature	O
review	I-Test
revealed	O
83	O
other	I-Background
reported	I-Background
cases	I-Background
of	O
rifampicin	I-Treatment
-	O
induced	O
renal	I-Problem
insufficiency	I-Problem
.	O

complete	O
regression	O
of	O
iatrogenic	O
kaposi	I-Problem
'	I-Problem
s	I-Problem
sarcoma	I-Problem
due	O
to	O
corticosteroid	I-Treatment
treatment	O
in	O
a	I-Background
patient	I-Background
with	I-Background
tubercular	I-Problem
pericarditis	I-Problem
.	O

diagnosis	O
:	O
severe	O
temozolomide	I-Treatment
-	O
induced	O
immunosuppression	I-Problem
,	O
exacerbated	I-Treatment
by	I-Treatment
corticosteroids	I-Treatment
,	O
with	O
profound	O
t	I-Problem
-	I-Problem
cell	I-Problem
lymphocytopenia	I-Problem
and	O
simultaneous	O
opportunistic	O
infections	O
with	O
pneumocystis	I-Problem
jiroveci	I-Problem
pneumonia	I-Problem
,	O
brain	I-Problem
abscess	I-Problem
with	I-Problem
listeria	I-Problem
monocytogenes	I-Problem
,	O
and	O
cutaneous	I-Problem
kaposi	I-Problem
'	I-Problem
s	I-Problem
sarcoma	I-Problem
.	O

the	O
use	O
of	O
cyclosporin	I-Treatment
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
cholelithiasis	I-Problem
in	O
transplant	I-Problem
recipients	I-Background
.	O

rifampicin	I-Treatment
-	O
induced	O
adrenal	I-Problem
insufficiency	I-Problem
in	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
:	O
difficulties	O
in	O
diagnosis	O
and	O
treatment	O
.	O

bisphosphonate	I-Treatment
-	O
related	O
osteonecrosis	I-Problem
of	I-Problem
the	I-Problem
skull	I-Problem
base	I-Problem
.	O

angioedema	I-Problem
and	I-Problem
dysphagia	I-Problem
caused	O
by	O
contact	I-Problem
allergy	I-Problem
to	O
inhaled	O
budesonide	I-Treatment
.	O

emergence	I-Problem
of	I-Problem
philadelphia	I-Problem
positive	I-Problem
chronic	I-Problem
myeloid	I-Problem
leukaemia	I-Problem
during	O
treatment	O
with	O
hydroxyurea	I-Treatment
for	O
philadelphia	I-Problem
negative	I-Problem
essential	I-Problem
thrombocythaemia	I-Problem
.	O

ciprofloxacin	I-Treatment
greatly	O
increases	O
concentrations	I-Problem
and	I-Problem
hypotensive	I-Problem
effect	I-Problem
of	I-Problem
tizanidine	I-Treatment
by	O
inhibiting	O
its	O
cytochrome	I-Test
p450	I-Test
1a2	O
-	O
mediated	O
presystemic	O
metabolism	O
.	O

2	I-Treatment
-	I-Treatment
cda	I-Treatment
induces	O
lymphocytopenia	I-Problem
,	O
which	O
may	O
explain	O
the	O
improvement	O
in	O
this	O
patient	I-Background
'	I-Background
s	I-Background
psoriasis	I-Problem
.	O

there	O
is	O
a	O
dose	O
-	O
effect	O
relationship	O
between	O
doxorubicin	I-Treatment
and	O
the	O
incidence	O
of	O
symptomatic	I-Problem
cardiac	I-Problem
failure	I-Problem
.	O

these	O
are	O
the	O
first	O
reported	O
patients	O
to	O
show	O
mferg	O
abnormalities	O
that	O
correspond	O
to	O
bitemporal	O
visual	O
field	O
defects	O
and	O
add	O
to	O
the	O
growing	O
evidence	O
that	O
ethambutol	I-Treatment
damages	I-Problem
the	I-Problem
retina	I-Problem
.	O

two	I-Other
days	I-Other
after	I-Treatment
administration	I-Treatment
of	I-Treatment
kalimate	I-Treatment
enema	I-Treatment
,	O
he	I-Background
had	O
profuse	I-Problem
hematochezia	I-Problem
,	O
and	O
a	O
sigmoidoscopy	I-Test
showed	O
diffuse	I-Problem
colonic	I-Problem
mucosal	I-Problem
necrosis	I-Problem
in	I-Problem
the	I-Problem
rectum	I-Problem
and	O
sigmoid	O
colon	O
.	O

conventional	O
and	I-Test
diffusion	I-Test
-	I-Test
weighted	I-Test
mri	I-Test
findings	I-Test
of	O
methotrexate	I-Treatment
related	O
sub	I-Problem
-	I-Problem
acute	I-Problem
neurotoxicity	I-Problem
.	O

scleromyxedema	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
multiple	I-Problem
sclerosis	I-Problem
and	I-Background
monoclonal	I-Problem
gammopathy	I-Problem
on	O
interferon	I-Treatment
beta	I-Treatment
-	I-Treatment
1a	I-Treatment
.	O

the	O
literature	I-Test
search	I-Test
revealed	O
22	O
cases	I-Background
of	O
hypersensitivity	I-Problem
reaction	I-Problem
to	O
cyclosporine	I-Treatment
.	O

the	O
presence	O
of	O
a	I-Problem
lymphocyte	I-Problem
alveolitis	I-Problem
with	I-Problem
a	I-Problem
predominance	I-Problem
of	I-Problem
cd4	I-Problem
+	I-Problem
t	I-Problem
cells	I-Problem
in	O
3	O
ra	I-Problem
patients	I-Background
and	O
cd8	I-Problem
+	I-Problem
t	I-Problem
cells	I-Test
with	I-Problem
a	I-Problem
concomitant	I-Problem
increase	I-Problem
in	I-Problem
neutrophils	I-Problem
in	O
another	O
case	O
suggests	O
that	O
immunologically	O
mediated	O
reactions	O
may	O
be	O
one	O
damage	O
mechanism	O
in	O
mtx	I-Treatment
-	O
induced	O
pneumonitis	I-Problem
.	O

the	O
authors	O
report	O
two	O
cases	O
of	O
delayed	I-Problem
elimination	I-Problem
of	O
methotrexate	I-Treatment
in	O
patients	I-Background
receiving	I-Background
ciprofloxacin	I-Background
,	O
with	O
severe	O
toxicity	O
.	O

severe	I-Problem
acute	I-Problem
encephalopathy	I-Problem
following	O
inadvertent	O
intrathecal	I-Treatment
doxorubicin	I-Treatment
administration	I-Treatment
.	O

porcine	I-Treatment
factor	I-Treatment
viii	I-Treatment
(	I-Treatment
pfviii	I-Treatment
)	I-Treatment
,	O
which	O
is	O
used	O
to	O
control	O
bleeding	I-Problem
in	O
patients	I-Background
with	I-Background
congenital	I-Problem
or	I-Problem
acquired	I-Problem
haemophilia	I-Problem
who	I-Background
have	I-Background
high	I-Problem
-	I-Problem
titre	I-Problem
neutralizing	I-Problem
antibodies	I-Problem
to	I-Problem
human	I-Problem
fviii	I-Problem
,	O
is	O
not	O
known	O
to	O
increase	O
the	O
risk	I-Problem
of	I-Problem
arterial	I-Problem
or	I-Problem
venous	I-Problem
thrombosis	I-Problem
.	I-Problem

in	O
all	I-Background
the	I-Background
patients	I-Background
,	O
pellagra	I-Problem
symptoms	I-Problem
appeared	O
during	O
isoniazid	I-Treatment
therapy	I-Treatment
.	O

fatal	O
gemcitabine	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
in	O
metastatic	I-Problem
gallbladder	I-Problem
adenocarcinoma	I-Problem
.	O

olanzapine	I-Treatment
-	O
induced	O
hyperglycaemic	I-Problem
coma	I-Problem
and	I-Problem
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
.	O

neurologic	I-Problem
symptoms	I-Problem
resolved	I-Problem
after	O
stopping	I-Treatment
cap	I-Treatment
for	I-Treatment
4	I-Other
weeks	I-Other
in	O
patient	O
a	O
,	O
with	O
no	O
recurrence	O
after	O
reinitiating	O
cap	O
alone	O
at	O
2000	O
mg	O
/	O
m2	O
.	O

objective	O
:	O
to	O
report	O
a	I-Background
case	I-Background
of	O
serotonin	I-Problem
syndrome	I-Problem
associated	O
with	O
interaction	O
between	O
fentanyl	I-Treatment
and	I-Treatment
citalopram	I-Treatment
,	O
as	O
evidenced	O
by	O
medication	O
history	O
,	O
clinical	O
features	O
and	O
reversal	O
following	O
discontinuation	O
of	O
fentanyl	O
.	O

we	O
report	O
(	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
in	O
a	O
child	O
)	O
the	O
emergence	O
of	O
psychosis	I-Problem
in	O
a	I-Background
12	I-Background
-	I-Background
year	I-Background
old	I-Background
white	I-Background
girl	I-Background
with	O
an	O
increased	I-Treatment
efavirenz	I-Treatment
concentration	I-Treatment
and	O
heterozygous	I-Background
gene	I-Background
polymorphism	I-Background
of	I-Background
the	I-Background
cyp2b6	I-Background
-	I-Background
g516t	I-Background
.	I-Background

severe	I-Problem
erythroderma	I-Problem
as	O
a	O
complication	O
of	O
continuous	I-Other
epoprostenol	I-Treatment
therapy	O
.	O

case	O
summary	O
:	O
a	I-Background
58	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
woman	I-Background
developed	O
fulminant	I-Problem
liver	I-Problem
failure	I-Problem
while	O
being	O
treated	O
with	O
the	O
macrolide	I-Treatment
antibiotic	I-Treatment
clarithromycin	I-Treatment
for	I-Treatment
pneumonia	I-Problem
.	O

conclusions	O
:	O
marked	I-Problem
elevation	I-Problem
of	I-Problem
serum	I-Problem
ck	I-Problem
may	O
be	O
a	O
possible	O
complication	O
of	O
olanzapine	I-Treatment
therapy	I-Treatment
.	O

objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
severe	O
skin	I-Problem
necrosis	I-Problem
resulting	O
from	O
peripheral	I-Treatment
intravenous	I-Treatment
administration	I-Treatment
of	I-Treatment
low	I-Treatment
-	I-Treatment
dose	I-Treatment
vasopressin	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
catecholamine	I-Problem
-	I-Problem
resistant	I-Problem
septic	I-Problem
shock	I-Problem
.	O

although	O
the	O
essential	O
cause	O
of	O
pv	I-Problem
is	O
unclear	O
,	O
its	O
onset	O
has	O
occasionally	O
been	O
associated	O
with	O
drug	O
therapy	O
,	O
in	O
particular	O
penicillamine	I-Treatment
.	O

recurrent	I-Problem
hypotension	I-Problem
immediately	I-Problem
after	I-Problem
seizures	I-Problem
in	O
nortriptyline	I-Treatment
overdose	I-Treatment
.	O

we	O
report	O
a	I-Background
patient	I-Background
with	O
recurrent	I-Problem
,	I-Problem
increasingly	I-Problem
severe	I-Problem
episodes	I-Problem
of	I-Problem
ppe	I-Problem
,	I-Problem
ultimately	I-Problem
complicated	I-Problem
by	I-Problem
a	I-Problem
severe	I-Problem
bullous	I-Problem
eruption	I-Problem
,	O
following	O
successive	O
cycles	I-Treatment
of	I-Treatment
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytarabine	I-Treatment
for	I-Treatment
the	I-Treatment
treatment	I-Treatment
of	I-Treatment
acute	I-Problem
lymphoblastic	I-Problem
leukaemia	I-Problem
.	O

intravenous	I-Treatment
diazepam	I-Treatment
exacerbated	O
the	O
seizures	I-Problem
.	O

after	O
nine	O
previous	O
uncomplicated	O
cycles	O
she	I-Background
developed	O
severe	I-Problem
anaphylaxis	I-Problem
to	O
cisplatin	I-Treatment
.	O

cefuroxime	I-Treatment
-	O
induced	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
.	O

we	O
describe	O
the	O
clinical	I-Test
and	I-Test
liver	I-Test
biopsy	I-Test
morphologic	I-Test
features	I-Test
for	O
4	O
patients	I-Background
with	O
minocycline	I-Treatment
-	O
induced	O
autoimmune	I-Problem
hepatitis	I-Problem
(	O
group	O
1	O
)	O
.	O

we	O
report	O
a	O
case	O
of	O
a	I-Background
29	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
liver	I-Problem
transplant	I-Problem
patient	I-Background
who	O
suffered	O
liver	I-Problem
injury	I-Problem
most	O
likely	O
induced	O
by	O
drug	I-Treatment
interaction	I-Treatment
between	I-Treatment
capecitabine	I-Treatment
and	I-Treatment
warfarin	I-Treatment
.	O

discussion	O
:	O
patients	I-Background
with	I-Background
5	I-Treatment
-	I-Treatment
fu	I-Treatment
-	I-Background
induced	I-Background
ectropion	I-Problem
experience	O
tender	I-Problem
,	I-Problem
red	I-Problem
,	I-Problem
scaled	I-Problem
lids	I-Problem
,	O
making	O
contact	O
lens	O
wear	O
difficult	O
.	O

restless	I-Problem
legs	I-Problem
syndrome	I-Problem
may	O
thus	O
be	O
an	O
adverse	O
effect	O
of	O
ifn	I-Treatment
alpha	I-Treatment
treatment	I-Treatment
.	I-Treatment

treatment	O
of	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
with	O
interferon	I-Treatment
alpha	I-Treatment
(	I-Treatment
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
)	I-Treatment
is	O
relatively	O
contraindicated	O
in	O
patients	I-Background
with	I-Background
psychiatric	I-Problem
disorders	I-Problem
because	O
of	O
possible	I-Problem
severe	I-Problem
psychiatric	I-Problem
side	I-Problem
effects	I-Problem
.	O

methods	O
:	O
we	O
report	O
a	I-Background
patient	I-Background
who	O
had	O
an	O
anaphylactic	I-Problem
reaction	I-Problem
during	O
the	O
intravenous	I-Treatment
infusion	I-Treatment
of	I-Treatment
cyclosporine	I-Treatment
.	O

gabapentin	I-Treatment
toxicity	O
in	O
renal	I-Problem
failure	I-Problem
:	O
the	O
importance	O
of	O
dose	O
adjustment	O
.	O

we	O
describe	O
a	O
case	O
of	O
a	I-Background
man	I-Background
treated	O
with	O
an	O
egfr	I-Treatment
-	I-Treatment
inhibitor	I-Treatment
(	I-Treatment
erlotinib	I-Treatment
)	I-Treatment
for	O
a	O
cell	I-Problem
lung	I-Problem
cancer	I-Problem
who	O
developed	O
skin	I-Problem
manifestations	I-Problem
localized	I-Problem
in	I-Problem
an	I-Problem
uncommon	I-Problem
area	I-Problem
and	I-Problem
with	I-Problem
an	I-Problem
atypical	I-Problem
evolution	I-Problem
.	O

we	O
describe	O
a	O
case	O
of	O
clozapine	I-Treatment
-	O
induced	O
seizures	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
treatment	I-Problem
-	I-Problem
resistant	I-Problem
schizophrenia	I-Problem
.	O

two	O
fatal	I-Background
cases	I-Background
of	O
poisoning	I-Problem
by	O
paracetamol	I-Treatment
are	O
described	O
.	O

the	O
neurotoxicity	I-Problem
seen	O
with	O
hdarac	I-Treatment
is	O
dose	O
-	O
related	O
and	O
has	O
occurred	O
in	O
up	O
to	O
60	O
percent	O
of	I-Background
treated	I-Background
patients	I-Background
.	O

the	O
hiv	I-Treatment
protease	I-Treatment
inhibitor	I-Treatment
indinavir	I-Treatment
may	O
cause	O
nephrolithiasis	I-Problem
and	I-Problem
interstitial	I-Problem
nephritis	I-Problem
.	O

background	O
:	O
colchicine	I-Treatment
has	O
a	O
known	O
adverse	O
effect	O
on	O
wound	I-Problem
healing	I-Problem
through	O
its	O
inhibitory	O
effect	O
on	O
tubulin	O
-	O
dependent	O
cell	O
functions	O
and	O
through	O
collagenase	O
activation	O
.	O

pneumocystis	I-Problem
carinii	I-Problem
pneumonia	I-Problem
as	O
a	O
complication	O
of	O
methotrexate	I-Treatment
treatment	O
of	O
asthma	I-Problem
.	O

2	I-Treatment
-	I-Treatment
cda	I-Treatment
typically	O
causes	O
a	I-Problem
long	I-Problem
-	I-Problem
lasting	I-Problem
state	I-Problem
of	I-Problem
immunodeficiency	I-Problem
and	O
the	O
profound	O
influence	O
of	O
this	O
drug	O
on	O
the	O
immune	O
system	O
has	O
raised	O
questions	O
concerning	O
the	O
emergence	I-Problem
of	I-Problem
secondary	I-Problem
neoplasms	I-Problem
after	I-Problem
its	I-Problem
use	I-Problem
.	O

conclusions	O
:	O
topiramate	I-Treatment
may	O
be	O
associated	O
with	O
ciliochoroidal	O
effusion	O
with	O
forward	O
displacement	O
of	O
the	O
lens	O
-	O
iris	O
diaphragm	O
and	O
anterior	O
chamber	O
shallowing	O
,	O
resulting	O
in	O
acute	I-Problem
myopia	I-Problem
and	I-Problem
angle	I-Problem
-	I-Problem
closure	I-Problem
glaucoma	I-Problem
.	O

increased	O
awareness	O
is	O
needed	O
on	O
the	O
possible	O
occurrence	O
of	O
lpd	I-Problem
resembling	O
gastric	O
cancer	O
in	O
rheumatoid	I-Problem
arthritis	I-Problem
patients	I-Background
treated	O
with	O
mtx	I-Treatment
.	O

a	O
dapsone	I-Treatment
hypersensitivity	I-Problem
syndrome	I-Problem
,	I-Problem
consisting	I-Problem
of	I-Problem
fever	I-Problem
,	I-Problem
headache	I-Problem
,	I-Problem
nausea	I-Problem
,	I-Problem
vomiting	I-Problem
,	I-Problem
lymphadenopathy	I-Problem
,	I-Problem
hepatitis	I-Problem
,	I-Problem
hemolysis	I-Problem
,	I-Problem
leukopenia	I-Problem
,	I-Problem
and	I-Problem
mononucleosis	I-Problem
,	O
has	O
been	O
described	O
in	O
patients	I-Background
treated	O
with	O
the	O
drug	O
for	O
leprosy	I-Problem
.	O

conclusions	O
:	O
intravitreal	I-Treatment
injection	I-Treatment
of	I-Treatment
triamcinolone	I-Treatment
acetonide	I-Treatment
may	O
be	O
an	O
additional	O
tool	O
in	O
the	O
treatment	O
of	O
therapy	I-Problem
-	I-Problem
resistant	I-Problem
cystoid	I-Problem
macular	I-Problem
edema	I-Problem
after	O
penetrating	O
keratoplasty	O
.	O

since	O
its	O
fda	O
approval	O
in	O
2002	O
,	O
there	O
are	O
no	O
known	O
citations	O
of	O
ezetimibe	I-Treatment
-	O
induced	O
pancreatitis	I-Problem
.	O

acute	I-Problem
acoustic	I-Problem
nerve	I-Problem
palsy	I-Problem
associated	O
with	O
vincristine	I-Treatment
therapy	I-Treatment
.	O

review	O
of	O
all	O
reported	O
cases	O
of	O
the	O
use	O
of	O
atra	I-Treatment
in	I-Background
pregnancy	I-Problem
revealed	O
no	O
serious	O
adverse	I-Problem
outcomes	I-Problem
or	I-Problem
congenital	I-Problem
anomalies	I-Problem
although	O
only	O
very	O
few	O
cases	O
had	O
exposure	O
in	O
the	O
first	O
trimester	O
.	O

the	O
first	O
patient	O
was	O
a	I-Background
57	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
hiv	I-Problem
and	I-Background
bipolar	I-Problem
disease	I-Problem
who	O
developed	O
rapid	I-Problem
and	I-Problem
severe	I-Problem
weight	I-Problem
gain	I-Problem
when	O
quetiapine	I-Treatment
was	I-Treatment
added	I-Treatment
to	I-Treatment
a	I-Treatment
stable	I-Treatment
atazanavir	I-Treatment
-	I-Treatment
ritonavir	I-Treatment
-	I-Treatment
based	I-Treatment
antiretroviral	I-Treatment
regimen	I-Treatment
.	O

a	I-Background
43	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
multiple	I-Problem
sclerosis	I-Problem
(	I-Background
ms	I-Background
)	I-Background
had	O
nephrotic	I-Problem
syndrome	I-Problem
21	I-Other
months	I-Other
after	I-Treatment
starting	I-Treatment
treatment	I-Treatment
with	I-Treatment
interferon	I-Treatment
(	I-Treatment
ifn	I-Treatment
)	I-Treatment
-	I-Treatment
beta	I-Treatment
-	I-Treatment
1b	I-Treatment
(	I-Treatment
subcutaneous	I-Treatment
administration	I-Treatment
)	I-Treatment
.	O

results	O
:	O
an	I-Background
81	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
a	I-Background
history	I-Background
of	I-Background
neoplasies	I-Problem
of	I-Problem
the	I-Problem
colon	I-Problem
and	I-Problem
prostate	I-Problem
and	O
anticoagulant	I-Treatment
treatment	O
was	O
referred	O
for	O
treatment	O
of	O
an	I-Problem
ocular	I-Problem
surface	I-Problem
neoplasia	I-Problem
on	I-Problem
his	I-Problem
left	I-Problem
eye	I-Problem
.	O

conclusion	O
:	O
the	O
present	O
findings	O
suggest	O
that	O
:	O
(	O
i	O
)	O
amantadine	I-Treatment
probably	O
exerts	O
its	O
anti	I-Problem
-	I-Problem
dyskinetic	I-Problem
effect	I-Problem
by	O
acting	O
on	O
the	O
"	O
indirect	O
"	O
pathway	O
;	O
(	O
ii	O
)	O
the	O
pathophysiological	O
mechanisms	O
of	O
subthalamotomy	O
induced	O
dyskinesias	O
may	O
differ	O
from	O
those	O
involved	O
in	O
l	O
-	O
dopa	O
induced	O
dyskinesias	O
;	O
(	O
iii	O
)	O
dyskinesias	O
induced	O
by	O
stn	O
surgery	O
resolve	O
spontaneously	O
as	O
compensatory	O
mechanisms	O
develop	O
.	O

we	O
report	O
a	O
case	O
of	O
a	I-Background
previously	I-Background
healthy	I-Background
,	I-Background
postmenopausal	I-Background
woman	I-Background
who	O
developed	O
anticonvulsant	I-Problem
hypersensitivity	I-Problem
syndrome	I-Problem
while	O
taking	O
bellamine	I-Treatment
s	I-Treatment
(	I-Treatment
belladonna	I-Treatment
alkaloids	I-Treatment
;	I-Treatment
ergotamine	I-Treatment
;	I-Treatment
phenobarbital	I-Treatment
)	I-Treatment
for	O
hot	I-Problem
flashes	I-Problem
.	O

skin	I-Problem
rash	I-Problem
began	O
after	O
2	I-Other
weeks	I-Other
of	O
treatment	O
,	O
and	O
signs	O
of	O
hepatocellular	I-Problem
failure	I-Problem
developed	O
3	I-Other
weeks	I-Other
after	O
phenobarbital	I-Treatment
had	O
been	O
started	O
.	O

ceftriaxone	O
was	O
approved	O
in	O
1997	O
for	O
the	O
treatment	O
of	O
otitis	I-Problem
media	I-Problem
despite	O
previous	O
studies	I-Test
that	O
documented	O
an	O
association	O
of	O
ceftriaxone	I-Treatment
with	O
elevated	I-Problem
hepato	I-Problem
-	I-Problem
biliary	I-Problem
enzymes	I-Problem
and	I-Problem
transient	I-Problem
biliary	I-Problem
stasis	I-Problem
.	O

a	I-Background
rare	I-Background
case	I-Background
of	I-Background
advanced	I-Problem
ovarian	I-Problem
carcinoma	I-Problem
who	O
developed	O
difficulty	I-Problem
walking	I-Problem
25	I-Other
days	I-Other
after	I-Treatment
treatment	I-Treatment
with	I-Treatment
weekly	I-Other
paclitaxel	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
cough	I-Problem
following	O
the	I-Treatment
administration	I-Treatment
of	I-Treatment
quinapril	I-Treatment
,	O
with	O
complete	O
resolution	O
after	O
changing	O
to	O
the	O
alternative	O
ace	O
inhibitor	O
fosinopril	O
in	O
a	O
patient	I-Background
with	I-Background
essential	I-Background
hypertension	I-Problem
.	O

liver	I-Problem
disease	I-Problem
induced	O
by	O
perhexiline	I-Treatment
maleate	I-Treatment
.	O

objective	O
:	O
to	O
report	O
the	O
occurrence	O
of	O
anaphylactoid	I-Problem
reactions	I-Problem
to	O
intraperitoneal	I-Treatment
cisplatin	I-Treatment
in	O
3	O
patients	I-Background
.	I-Background

in	O
a	O
female	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
,	O
inadvertent	I-Treatment
doxorubicin	I-Treatment
administration	I-Treatment
intrathecally	I-Treatment
caused	O
severe	I-Problem
,	I-Problem
life	I-Problem
-	I-Problem
threatening	I-Problem
,	I-Problem
acute	I-Problem
encephalopathy	I-Problem
with	I-Problem
high	I-Problem
-	I-Problem
pressure	I-Problem
hydrocephalus	I-Problem
.	O

these	O
skin	I-Problem
lesions	I-Problem
may	O
be	O
induced	O
or	O
worsened	O
during	O
antiviral	I-Treatment
therapy	I-Treatment
with	I-Treatment
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
(	I-Treatment
ifn	I-Treatment
)	I-Treatment
.	I-Treatment

clinicians	O
should	O
be	O
aware	O
of	O
the	O
proepileptogenic	O
effect	O
of	O
venlafaxine	I-Treatment
and	I-Treatment
trimipramine	I-Treatment
at	I-Treatment
therapeutic	I-Treatment
doses	I-Treatment
and	O
that	O
this	O
combination	O
may	O
eventually	O
increase	I-Problem
the	I-Problem
risk	I-Problem
of	I-Problem
seizures	I-Problem
.	O

we	O
report	O
the	I-Background
case	I-Background
of	I-Background
a	I-Background
43	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
itp	I-Problem
refractory	I-Problem
to	I-Problem
steroids	I-Problem
and	I-Problem
intravenous	I-Problem
immunoglobulin	I-Problem
who	O
developed	O
acute	I-Problem
respiratory	I-Problem
distress	I-Problem
syndrome	I-Problem
(	I-Problem
ards	I-Problem
)	I-Problem
after	O
a	O
single	I-Treatment
infusion	I-Treatment
of	I-Treatment
rituximab	I-Treatment
.	O

she	O
had	O
been	O
prescribed	I-Treatment
two	I-Treatment
mood	I-Treatment
stabilizers	I-Treatment
and	O
suffered	O
from	O
anticholinergic	I-Problem
adverse	I-Problem
effects	I-Problem
and	I-Problem
the	I-Problem
movement	I-Problem
disorder	I-Problem
tardive	I-Problem
dyskinesia	I-Problem
(	I-Problem
td	I-Problem
)	I-Problem
.	O

case	O
report	O
:	O
we	O
describe	O
here	O
a	I-Background
case	I-Background
of	I-Background
a	I-Background
60	I-Background
year	I-Background
old	I-Background
female	I-Background
that	O
experienced	O
a	O
relapse	I-Problem
of	I-Problem
symptomatic	I-Problem
hyperlactatemia	I-Problem
after	O
being	O
switched	I-Treatment
from	I-Treatment
stavudine	I-Treatment
to	I-Treatment
zidovudine	I-Treatment
and	O
how	O
the	O
case	O
was	O
managed	O
at	O
the	O
infectious	O
diseases	O
institute	O
,	O
kampala	O
,	O
uganda	O
.	O

this	O
report	O
describes	O
two	O
patients	I-Background
who	O
developed	O
acute	I-Problem
myelocytic	I-Problem
leukemia	I-Problem
only	O
after	O
exposure	I-Treatment
to	I-Treatment
cyclophosphamide	I-Treatment
,	I-Treatment
methotrexate	I-Treatment
,	I-Treatment
and	I-Treatment
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
adjuvant	I-Treatment
therapy	I-Treatment
.	O

reversible	I-Problem
corneal	I-Problem
keratinization	I-Problem
following	O
trabeculectomy	O
and	O
treatment	O
with	O
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
.	I-Treatment

case	O
:	O
we	O
report	O
a	O
case	O
of	O
a	O
woman	I-Background
with	O
severe	I-Problem
human	I-Problem
insulin	I-Problem
-	I-Problem
induced	I-Problem
lipoatrophy	I-Problem
who	O
has	O
been	O
treated	O
exclusively	O
with	O
recombinant	I-Treatment
dna	I-Treatment
human	I-Treatment
insulin	I-Treatment
since	O
the	O
onset	O
of	O
iddm	O
.	O

method	O
:	O
case	O
analysis	I-Test
of	O
a	I-Treatment
poly	I-Treatment
-	I-Treatment
drug	I-Treatment
overdose	I-Treatment
(	I-Treatment
venlafaxine	I-Treatment
,	I-Treatment
topiramate	I-Treatment
,	I-Treatment
divalproex	I-Treatment
sodium	I-Treatment
,	I-Treatment
risperidone	I-Treatment
,	I-Treatment
and	I-Treatment
carbamazepine	I-Treatment
)	I-Treatment
presenting	O
with	O
mixed	I-Problem
ss	I-Problem
/	I-Problem
nms	I-Problem
features	I-Problem
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
ss	O
/	O
nms	O
in	O
critical	O
care	O
settings	O
.	O

hyperpigmentation	I-Problem
is	O
one	O
of	O
the	O
cutaneous	O
side	O
effects	O
of	O
chemotherapautic	I-Treatment
agents	I-Treatment
,	O
but	O
it	O
is	O
usually	O
accepted	O
as	O
a	O
cosmetic	O
problem	O
.	O

pancreatitis	O
is	O
a	O
very	O
rare	O
adverse	O
effect	O
associated	O
with	O
the	O
use	O
of	O
amiodarone	O
,	O
and	O
only	O
four	O
cases	I-Background
of	O
amiodarone	I-Treatment
-	O
induced	O
pancreatitis	I-Problem
have	O
been	O
reported	O
in	O
literature	O
.	O

the	O
latter	O
form	O
(	O
macrodantin	I-Treatment
)	O
is	O
reported	O
to	O
engender	O
less	I-Problem
gastrointestinal	I-Problem
intolerance	I-Problem
but	O
it	O
can	O
produce	O
the	O
same	O
adverse	O
effects	O
as	O
the	O
conventional	O
form	O
-	O
-	O
liver	I-Problem
damage	I-Problem
,	I-Problem
acute	I-Problem
and	I-Problem
chronic	I-Problem
pulmonary	I-Problem
reactions	I-Problem
,	I-Problem
peripheral	I-Problem
neuropathy	I-Problem
,	I-Problem
blood	I-Problem
dyscrasias	I-Problem
and	I-Problem
allergic	I-Problem
reactions	I-Problem
-	I-Problem
-	O
and	O
does	O
so	O
just	O
as	O
rapidly	O
and	O
floridly	O
;	O
one	O
such	I-Background
case	I-Background
is	O
reported	O
here	O
.	O

case	O
report	O
:	O
a	I-Background
29	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
black	I-Background
man	I-Background
,	I-Background
hiv	I-Problem
-	I-Background
infected	I-Background
since	I-Background
1996	I-Background
,	O
began	O
highly	I-Treatment
active	I-Treatment
antiretroviral	I-Treatment
therapy	I-Treatment
(	I-Treatment
haart	I-Treatment
)	I-Treatment
with	I-Treatment
zidovudine	I-Treatment
,	I-Treatment
lamivudine	I-Treatment
,	I-Treatment
and	I-Treatment
indinavir	I-Treatment
.	O

method	O
:	O
the	O
authors	O
followed	O
a	I-Background
patient	I-Background
with	I-Background
chronic	I-Problem
hcv	I-Problem
who	O
received	O
interferon	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
and	O
who	O
developed	O
hallucinations	I-Problem
ultimately	O
requiring	O
psychiatric	O
hospitalization	O
.	O

this	O
case	O
of	O
linezolid	I-Treatment
-	O
associated	O
acute	I-Problem
interstitial	I-Problem
nephritis	I-Problem
within	I-Problem
the	I-Problem
context	I-Problem
of	I-Problem
a	I-Problem
drug	I-Problem
rash	I-Problem
with	I-Problem
eosinophilia	I-Problem
and	I-Problem
systemic	I-Problem
symptoms	I-Problem
(	I-Problem
dress	I-Problem
)	I-Problem
syndrome	I-Problem
in	O
a	O
patient	O
treated	O
with	O
linezolid	O
raises	O
concerns	O
about	O
the	O
presumed	O
renal	O
safety	O
of	O
this	O
drug	O
.	O

easily	O
reversible	O
hypoxemia	I-Problem
and	I-Problem
hypotension	I-Problem
induced	O
by	O
nimodipine	I-Treatment
.	O

adverse	O
effects	O
of	O
amiodarone	I-Treatment
including	O
pulmonary	I-Problem
toxicity	I-Problem
,	I-Problem
hepatotoxicity	I-Problem
,	I-Problem
aggravation	I-Problem
of	I-Problem
arrhythmia	I-Problem
,	I-Problem
and	I-Problem
thyroid	I-Problem
diseases	I-Problem
are	O
well	O
understood	O
.	O

chronic	I-Problem
photosensitivity	I-Problem
associated	O
with	O
hydrochlorothiazide	I-Treatment
ingestion	I-Treatment
occurred	O
in	O
four	O
patients	I-Background
.	O

chlorambucil	I-Treatment
central	I-Problem
nervous	I-Problem
toxicity	I-Problem
:	O
a	O
significant	O
side	O
effect	O
of	O
chlorambucil	O
therapy	O
in	O
childhood	I-Problem
nephrotic	I-Problem
syndrome	I-Problem
.	O

the	O
mechanism	O
of	O
action	O
of	O
this	O
centrally	I-Treatment
acting	I-Treatment
muscle	I-Treatment
relaxant	I-Treatment
is	O
unknown	O
;	O
however	O
,	O
the	O
observation	O
of	O
serotonin	I-Problem
syndrome	I-Problem
in	O
patients	I-Background
with	O
metaxalone	I-Treatment
overdose	I-Treatment
suggests	O
a	O
role	O
in	O
the	O
serotonergic	O
pathway	O
.	O

in	O
general	O
,	O
angiotensin	I-Treatment
converting	I-Treatment
enzyme	I-Treatment
(	I-Treatment
ace	I-Treatment
)	I-Treatment
inhibitors	I-Treatment
should	O
be	O
discontinued	O
in	O
pregnancy	I-Problem
,	O
as	O
they	O
can	O
induce	O
an	O
ace	I-Problem
fetopathy	I-Problem
.	O

of	I-Background
371	O
patients	I-Background
treated	I-Treatment
with	I-Treatment
8mop	I-Treatment
,	O
three	O
(	O
0	O
.	O
8	O
%	O
)	O
developed	O
an	O
acute	I-Problem
dermatitis	I-Problem
in	O
the	O
puva	O
-	O
treated	O
areas	O
.	O

there	O
is	O
a	O
putative	O
role	O
of	O
liothyronine	I-Treatment
administration	O
in	O
precipitating	O
or	O
activating	O
hyperthyroidism	I-Problem
.	O

neutropenic	I-Problem
colitis	I-Problem
during	O
standard	I-Treatment
dose	I-Treatment
combination	I-Treatment
chemotherapy	I-Treatment
with	I-Treatment
nedaplatin	I-Treatment
and	I-Treatment
irinotecan	I-Treatment
for	I-Treatment
testicular	I-Problem
cancer	I-Problem
.	O

brain	I-Problem
metastases	I-Problem
are	O
a	O
frequent	O
finding	O
in	O
patients	I-Background
with	I-Background
advanced	I-Problem
non	I-Problem
-	I-Problem
small	I-Problem
cell	I-Problem
lung	I-Problem
cancer	I-Problem
and	O
concomitant	I-Treatment
administration	I-Treatment
of	I-Treatment
antiepileptic	I-Treatment
and	I-Treatment
chemotherapeutic	I-Treatment
drugs	I-Treatment
or	I-Treatment
epidermal	I-Treatment
growth	I-Treatment
factor	I-Treatment
receptor	I-Treatment
(	I-Treatment
egfr	I-Treatment
)	I-Treatment
inhibitor	I-Treatment
is	O
necessary	O
in	O
many	O
cases	O
.	O

a	I-Background
female	I-Background
patient	I-Background
with	I-Background
her2	I-Problem
positive	I-Problem
,	I-Problem
metastatic	I-Problem
breast	I-Problem
cancer	I-Problem
presented	O
with	O
pulmonary	I-Problem
infiltrates	I-Problem
,	I-Problem
and	I-Problem
a	I-Problem
plural	I-Problem
effusion	I-Problem
dyspnoea	I-Problem
after	O
several	I-Other
months	I-Other
of	O
trastuzumab	I-Treatment
treatment	O
.	O

thrombocytosis	I-Problem
under	O
ciprofloxacin	I-Treatment
and	I-Treatment
tazobactam	I-Treatment
/	I-Treatment
piperacillin	I-Treatment
.	O

quinine	I-Treatment
and	I-Treatment
its	I-Treatment
isomer	I-Treatment
quinidine	I-Treatment
are	O
well	O
-	O
known	O
causes	O
of	O
iatrogenic	I-Problem
hypoglycaemia	I-Problem
,	I-Problem
due	I-Problem
to	I-Problem
excessive	I-Problem
insulin	I-Problem
secretion	I-Problem
.	O

hyperammonemia	I-Problem
secondary	O
to	O
valproic	I-Treatment
acid	I-Treatment
as	O
a	O
cause	O
of	O
lethargy	O
in	O
a	I-Background
postictal	I-Background
patient	I-Background
.	O

objective	O
:	O
to	O
report	O
on	O
the	O
possible	O
development	O
of	O
serotonin	I-Problem
syndrome	I-Problem
in	O
a	O
patient	I-Background
receiving	O
clomipramine	I-Treatment
after	O
clozapine	I-Treatment
was	O
withdrawn	O
from	O
the	O
treatment	O
regimen	O
.	O

fatal	I-Problem
ventricular	I-Problem
fibrillation	I-Problem
after	O
treatment	O
with	O
digoxin	I-Treatment
in	O
a	I-Background
27	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
mitral	I-Problem
leaflet	I-Problem
prolapse	I-Problem
syndrome	I-Problem
.	O

clostridium	I-Problem
difficile	I-Problem
colitis	I-Problem
associated	O
with	O
cisplatin	I-Treatment
-	I-Treatment
based	I-Treatment
chemotherapy	I-Treatment
in	O
ovarian	I-Problem
cancer	I-Problem
patients	I-Background
.	I-Background

lithium	I-Treatment
-	O
induced	O
creutzfeldt	I-Problem
-	I-Problem
jakob	I-Problem
syndrome	I-Problem
.	O

it	O
is	O
concluded	O
that	O
simultaneous	I-Treatment
administration	I-Treatment
of	I-Treatment
ciprofloxacin	I-Treatment
and	I-Treatment
tazobactam	I-Treatment
/	I-Treatment
piperacillin	I-Treatment
may	O
cause	O
marked	I-Problem
thrombocytosis	I-Problem
.	O

alone	I-Treatment
or	I-Treatment
in	I-Treatment
combination	I-Treatment
with	I-Treatment
corticosteroids	I-Treatment
,	I-Treatment
cyclosporine	I-Treatment
is	O
an	O
effective	O
drug	O
of	O
choice	O
for	O
the	O
resistant	I-Background
patients	I-Background
.	O

bull	I-Problem
'	I-Problem
s	I-Problem
-	I-Problem
eye	I-Problem
maculopathy	I-Problem
associated	O
with	O
quinacrine	I-Treatment
therapy	O
for	O
malaria	I-Problem
.	O

physicians	O
should	O
be	O
aware	O
that	O
indinavir	I-Treatment
nephrolithiasis	I-Treatment
may	O
cause	O
papillary	I-Problem
necrosis	I-Problem
.	O

following	O
the	O
institution	O
of	O
intravenous	O
therapy	O
with	O
acyclovir	I-Treatment
,	O
the	I-Background
patient	I-Background
developed	O
fever	I-Problem
,	I-Problem
hemoptysis	I-Problem
,	I-Problem
and	I-Problem
a	I-Problem
pleural	I-Problem
friction	I-Problem
rub	I-Problem
.	O

due	O
to	O
discomfort	I-Problem
,	I-Problem
diplopia	I-Problem
and	I-Problem
lagophthalmos	I-Problem
,	I-Problem
the	I-Problem
haematoma	I-Problem
necessitated	O
suspension	O
of	O
warfarin	I-Treatment
therapy	I-Treatment
and	I-Treatment
a	I-Treatment
surgical	I-Treatment
evacuation	I-Treatment
.	O

acute	I-Problem
dystonia	I-Problem
with	I-Problem
thalamic	I-Problem
and	I-Problem
brainstem	I-Problem
lesions	I-Problem
after	O
initial	O
penicillamine	I-Treatment
treatment	O
in	O
wilson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
.	O

fatal	I-Problem
agranulocytosis	I-Problem
in	O
an	O
indian	I-Background
male	I-Background
receiving	O
100	I-Treatment
mg	I-Treatment
of	I-Treatment
dapsone	I-Treatment
daily	I-Other
,	O
hospitalized	O
for	O
mid	I-Problem
-	I-Problem
borderline	I-Problem
leprosy	I-Problem
in	I-Problem
type	I-Problem
i	I-Problem
reaction	I-Problem
with	I-Problem
triple	I-Problem
nerve	I-Problem
paralysis	I-Problem
is	O
reported	O
.	O

the	O
authors	O
presented	O
a	O
case	O
of	O
pulmonary	I-Problem
hypertension	I-Problem
during	O
lithium	I-Treatment
therapy	I-Treatment
,	O
while	O
she	I-Background
has	O
been	O
on	O
lithium	O
for	O
6	I-Other
years	I-Other
.	O

background	O
:	O
oxaliplatin	I-Treatment
is	I-Treatment
a	I-Treatment
platinum	I-Treatment
derivative	I-Treatment
,	O
which	O
is	O
used	O
in	O
the	O
treatment	O
of	O
colorectal	I-Problem
cancer	I-Problem
.	O

after	O
having	O
received	I-Treatment
gemcitabine	I-Treatment
on	I-Treatment
day	I-Treatment
1	I-Treatment
of	I-Treatment
the	I-Treatment
second	I-Treatment
course	I-Treatment
,	O
the	I-Background
patient	I-Background
developed	O
dry	I-Problem
cough	I-Problem
,	I-Problem
subfebrile	I-Problem
temperatures	I-Problem
and	I-Problem
dyspnea	I-Problem
within	I-Other
48	I-Other
h	I-Other
.	I-Other

as	O
linezolid	I-Treatment
has	O
been	O
shown	O
to	O
have	O
hematologic	I-Problem
side	I-Problem
effects	I-Problem
,	O
blood	O
count	I-Test
monitoring	I-Test
is	O
recommended	O
in	O
patients	O
receiving	O
this	O
drug	O
for	O
long	I-Other
-	I-Other
term	I-Other
therapy	O
.	O

the	O
role	O
of	O
adriamycin	I-Treatment
in	O
the	O
production	O
of	O
cardiotoxicity	I-Problem
is	O
reviewed	O
.	O

he	O
began	O
taking	O
propafenone	I-Treatment
only	O
6	O
days	O
prior	O
to	O
admission	O
because	O
of	O
uncontrolled	O
atrial	I-Problem
fibrillation	I-Problem
and	O
symptoms	O
of	O
fatigue	I-Problem
.	O

a	I-Background
53	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
nms	I-Problem
without	I-Problem
rigidity	I-Problem
while	O
taking	O
olanzapine	I-Treatment
.	O

we	O
report	O
on	O
a	I-Background
14	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
with	I-Background
severe	I-Background
haemophilia	I-Problem
a	I-Problem
who	O
developed	O
a	I-Problem
portal	I-Problem
vein	I-Problem
thrombosis	I-Problem
during	O
continuous	I-Other
infusion	I-Treatment
of	I-Treatment
f	I-Treatment
viii	I-Treatment
.	O

suxamethonium	I-Problem
apnoea	I-Problem
terminated	O
with	O
commercial	I-Treatment
serumcholinesterase	I-Treatment
.	O

fatal	O
multiple	I-Problem
drug	I-Problem
intoxication	I-Problem
following	O
acute	I-Treatment
sertraline	I-Treatment
use	I-Treatment
.	O

observations	O
:	O
we	O
observed	O
aggravation	I-Problem
and	I-Problem
spreading	I-Problem
of	I-Problem
a	I-Problem
psoriatic	I-Problem
plaque	I-Problem
when	O
treated	O
topically	O
with	O
the	I-Treatment
toll	I-Treatment
-	I-Treatment
like	I-Treatment
receptor	I-Treatment
(	I-Treatment
tlr	I-Treatment
)	I-Treatment
7	I-Treatment
agonist	I-Treatment
imiquimod	I-Treatment
.	O

hypercalcemia	I-Problem
in	O
an	I-Background
aids	I-Problem
patient	I-Background
treated	O
with	O
growth	I-Treatment
hormone	I-Treatment
.	O

significant	O
drug	O
interaction	O
:	O
phenytoin	I-Problem
toxicity	I-Problem
due	O
to	O
erlotinib	I-Treatment
.	O

a	I-Problem
pharmacokinetic	I-Problem
interaction	I-Problem
between	O
the	I-Treatment
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitor	I-Treatment
citalopram	I-Treatment
and	I-Treatment
a	I-Treatment
tricyclic	I-Treatment
antidepressant	I-Treatment
,	I-Treatment
clomipramine	I-Treatment
,	O
was	O
noted	O
in	O
a	I-Background
patient	I-Background
treated	I-Background
for	I-Background
major	I-Background
depression	I-Problem
and	I-Background
obsessive	I-Problem
-	I-Problem
compulsive	I-Problem
disorder	I-Problem
.	O

they	O
continued	O
to	O
rise	O
for	O
five	O
more	O
days	O
before	O
salicylate	I-Treatment
hepatotoxicity	I-Problem
was	O
suspected	O
.	O

the	O
occurrence	O
of	O
neuromuscular	I-Problem
blockade	I-Problem
and	O
the	O
resulting	O
potentiation	I-Problem
of	I-Problem
muscle	I-Problem
relaxants	I-Problem
during	O
magnesium	I-Treatment
sulfate	I-Treatment
(	I-Treatment
mgso4	I-Treatment
)	I-Treatment
administration	O
is	O
well	O
known	O
.	O

gabapentin	I-Treatment
-	O
induced	O
mood	I-Problem
changes	I-Problem
with	I-Problem
hypomanic	I-Problem
features	I-Problem
in	O
adults	I-Background
.	O

drug	I-Problem
induced	I-Problem
polymyositis	I-Problem
secondary	O
to	O
leuprolide	I-Treatment
acetate	I-Treatment
(	I-Treatment
lupron	I-Treatment
)	I-Treatment
therapy	I-Treatment
for	O
prostate	I-Problem
carcinoma	I-Problem
.	O

incomplete	I-Problem
posterior	I-Problem
hyaloid	I-Problem
detachment	I-Problem
after	O
intravitreal	I-Treatment
pegaptanib	I-Treatment
injection	I-Treatment
in	I-Treatment
diabetic	I-Problem
macular	I-Problem
edema	I-Problem
.	O

this	O
paper	O
reports	O
a	O
case	O
of	O
fatal	O
perhexiline	I-Treatment
maleate	I-Treatment
liver	I-Problem
injury	I-Problem
.	O

during	O
the	O
second	O
hospitalization	O
it	O
is	O
possible	O
that	O
antipsychotic	I-Treatment
treatment	I-Treatment
combined	I-Treatment
with	I-Treatment
an	I-Treatment
antidepressant	I-Treatment
caused	O
akathisia	I-Problem
or	O
there	O
were	O
symptoms	O
of	O
agitated	O
depression	O
and	O
akathisia	O
present	O
at	O
the	O
same	O
time	O
,	O
which	O
is	O
very	O
difficult	O
to	O
determine	O
in	O
everyday	O
clinical	O
practice	O
.	O

objectives	O
:	O
to	O
describe	O
the	O
presentation	O
and	O
treatment	O
of	O
acute	O
isoniazid	I-Treatment
(	I-Treatment
inh	I-Treatment
)	I-Treatment
neurotoxicity	I-Problem
appearing	O
at	O
an	O
inner	O
-	O
city	O
municipal	O
hospital	O
.	O

clozapine	I-Treatment
,	O
an	O
atypical	O
antipsychotic	O
,	O
can	O
be	O
toxic	I-Problem
at	O
doses	I-Treatment
4	I-Treatment
times	I-Treatment
a	I-Treatment
moderate	I-Treatment
dose	I-Treatment
.	O

this	O
article	O
presents	O
a	I-Background
3	I-Background
(	I-Background
1	I-Background
/	I-Background
2	I-Background
)	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
child	I-Background
on	O
valproic	I-Treatment
acid	I-Treatment
,	I-Treatment
lamotrigine	I-Treatment
,	I-Treatment
and	I-Treatment
phenytoin	I-Treatment
who	O
developed	O
simultaneous	I-Problem
hepatotoxicity	I-Problem
and	I-Problem
bone	I-Problem
marrow	I-Problem
toxicity	I-Problem
during	O
a	O
parainfluenza	O
virus	O
type	O
3	O
infection	O
.	O

reversible	I-Problem
cholestasis	I-Problem
with	I-Problem
bile	I-Problem
duct	I-Problem
injury	I-Problem
following	O
azathioprine	I-Treatment
therapy	O
.	O

the	O
authors	O
report	O
five	O
cases	O
of	O
tremor	I-Problem
related	O
to	O
itraconazole	I-Treatment
therapy	I-Treatment
,	I-Treatment
which	O
occurred	O
within	I-Other
1	I-Other
-	I-Other
12	I-Other
months	I-Other
of	O
initiating	O
treatment	O
and	O
resolved	O
gradually	O
following	O
itraconazole	O
withdrawal	O
.	O

objective	O
:	O
to	O
report	O
a	I-Background
case	I-Background
of	I-Background
phenolphthalein	I-Treatment
-	O
induced	O
toxic	I-Problem
epidermal	I-Problem
necrolysis	I-Problem
(	I-Problem
ten	I-Problem
)	I-Problem
in	O
a	I-Background
patient	I-Background
maintained	I-Treatment
on	I-Treatment
several	I-Treatment
other	I-Treatment
medications	I-Treatment
more	I-Treatment
commonly	I-Treatment
known	I-Treatment
to	I-Treatment
be	I-Treatment
associated	I-Treatment
with	I-Treatment
ten	I-Treatment
.	O

clinical	I-Problem
symptoms	I-Problem
and	I-Problem
leukopenia	I-Problem
normalized	I-Problem
after	O
discontinuation	I-Treatment
of	I-Treatment
cbz	I-Treatment
and	I-Treatment
administration	I-Treatment
of	I-Treatment
prednisolone	I-Treatment
at	I-Treatment
40	I-Treatment
mg	I-Treatment
.	O

a	I-Background
patient	I-Background
with	I-Background
alcoholic	I-Problem
cerebellar	I-Problem
degeneration	I-Problem
had	O
periodic	I-Problem
alternating	I-Problem
nystagmus	I-Problem
during	O
a	O
period	O
of	O
phenytoin	I-Treatment
intoxication	O
.	O

extensive	I-Problem
forearm	I-Problem
deep	I-Problem
venous	I-Problem
thrombosis	I-Problem
following	O
a	O
severe	O
infliximab	I-Treatment
infusion	I-Problem
reaction	I-Problem
.	O

severe	I-Problem
acidosis	I-Problem
from	O
acetazolamide	I-Treatment
in	O
a	I-Background
diabetic	I-Problem
patient	I-Background
.	O

conclusions	O
:	O
clinicians	O
should	O
be	O
aware	O
that	O
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
is	O
a	O
potential	O
novel	O
adverse	O
drug	O
effect	O
of	O
copaxone	I-Treatment
.	O

adr	O
induced	O
by	O
drug	O
treatment	O
can	O
be	O
a	O
side	O
effect	O
of	O
treatment	O
with	O
antipsychotic	O
drugs	O
and	O
other	O
drugs	O
;	O
however	O
,	O
there	O
have	O
been	O
no	O
reports	O
of	O
lamivudine	I-Treatment
-	O
induced	O
adr	I-Problem
in	O
the	O
english	O
literature	O
.	O

serotonin	I-Problem
syndrome	I-Problem
from	O
the	O
interaction	I-Treatment
of	I-Treatment
cyclobenzaprine	I-Treatment
with	I-Treatment
other	I-Treatment
serotoninergic	I-Treatment
drugs	I-Treatment
.	O

however	O
,	O
a	O
recent	I-Test
post	I-Test
-	I-Test
marketing	I-Test
survey	I-Test
in	O
japan	O
revealed	O
that	O
interstitial	I-Problem
pneumonia	I-Problem
occurred	O
in	O
4	O
among	O
approximately	O
2	O
000	O
japanese	I-Background
patients	I-Background
treated	O
with	O
sorafenib	I-Treatment
.	O

the	I-Background
other	I-Background
patient	I-Background
developed	O
transient	I-Problem
intraoperative	I-Problem
hypertension	I-Problem
immediately	I-Problem
after	O
inadvertent	I-Treatment
submucosal	I-Treatment
injection	I-Treatment
of	I-Treatment
concentrated	I-Treatment
epinephrine	I-Treatment
.	O

pneumonitis	I-Problem
with	I-Problem
pleural	I-Problem
and	I-Problem
pericardial	I-Problem
effusion	I-Problem
and	I-Problem
neuropathy	I-Problem
during	O
amiodarone	I-Treatment
therapy	I-Treatment
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
interstitial	I-Problem
pneumonitis	I-Problem
induced	O
by	O
bicalutamide	I-Treatment
and	I-Treatment
/	I-Treatment
or	I-Treatment
leuprorelin	I-Treatment
acetate	I-Treatment
given	I-Treatment
as	I-Treatment
therapy	I-Treatment
for	I-Treatment
prostate	I-Problem
cancer	I-Problem
,	O
in	O
which	O
the	O
pneumonitis	O
was	O
successfully	O
managed	O
by	O
steroid	O
treatment	O
.	O

for	O
those	O
patients	I-Background
with	I-Background
a	I-Problem
history	I-Problem
of	I-Problem
nms	I-Problem
,	O
or	O
even	O
of	O
isolated	I-Problem
serum	I-Problem
ck	I-Problem
elevation	I-Problem
during	O
antipsychotic	I-Treatment
therapy	I-Treatment
,	O
follow	O
-	O
up	O
should	O
be	O
stricter	O
.	O

children	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
(	I-Problem
all	I-Problem
)	I-Problem
,	O
treated	O
with	O
l	I-Treatment
-	I-Treatment
asparaginase	I-Treatment
are	O
at	O
risk	O
for	O
cerebral	I-Problem
thrombosis	I-Problem
or	I-Problem
hemorrhage	I-Problem
because	O
of	O
coagulation	I-Problem
protein	I-Problem
deficiencies	I-Problem
.	O

dexamethasone	O
treatment	O
of	O
amiodarone	I-Treatment
-	O
induced	O
thyrotoxicosis	I-Problem
(	I-Problem
ait	I-Problem
)	I-Problem
with	O
or	O
without	O
persistent	O
administration	O
of	O
the	O
drug	O
.	O

acyclovir	I-Treatment
neurotoxicity	I-Problem
:	O
clinical	O
experience	O
and	O
review	O
of	O
the	O
literature	O
.	O

inadvertent	I-Problem
exaggerated	I-Problem
anticoagulation	I-Problem
following	O
use	O
of	O
bismuth	I-Treatment
subsalicylate	I-Treatment
in	O
an	I-Background
enterally	I-Background
fed	I-Background
patient	I-Background
receiving	O
warfarin	I-Treatment
therapy	I-Treatment
.	O

we	O
report	O
the	O
specifics	O
of	O
12	O
cases	I-Background
of	O
severe	O
hypertension	I-Problem
after	O
the	O
intraoperative	I-Treatment
use	I-Treatment
of	I-Treatment
topical	I-Treatment
phenylephrine	I-Treatment
,	I-Treatment
submucosal	I-Treatment
epinephrine	I-Treatment
,	I-Treatment
or	I-Treatment
both	I-Treatment
.	O

the	O
patient	I-Background
experienced	O
muscle	I-Problem
twitches	I-Problem
,	I-Problem
tremulousness	I-Problem
,	I-Problem
and	I-Problem
anxiety	I-Problem
on	I-Other
day	I-Other
17	I-Other
of	O
foscarnet	I-Treatment
therapy	I-Treatment
.	O

a	O
case	O
of	O
timolol	I-Treatment
-	O
associated	O
heart	I-Problem
failure	I-Problem
in	O
a	I-Background
73	I-Background
-	I-Background
year	I-Background
old	I-Background
white	I-Background
man	I-Background
is	O
reported	O
.	O

in	O
december	O
,	O
he	I-Background
was	O
prescribed	O
160	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
tebipenem	I-Treatment
pivoxil	I-Treatment
by	O
an	O
otolaryngologist	O
for	O
inflammation	I-Problem
of	I-Problem
the	I-Problem
tympanic	I-Problem
membrane	I-Problem
.	O

a	I-Background
65	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
patient	I-Background
presented	O
with	O
jaundice	I-Problem
followed	I-Problem
2	I-Problem
days	I-Problem
later	I-Problem
by	I-Problem
severe	I-Problem
dyspnea	I-Problem
and	I-Problem
tachypnea	I-Problem
which	I-Problem
worsened	I-Problem
when	I-Problem
patient	I-Problem
was	I-Problem
lying	I-Problem
flat	I-Problem
,	O
1	I-Other
week	I-Other
after	I-Other
the	I-Treatment
fourth	I-Treatment
dose	I-Treatment
of	I-Treatment
adalimumab	I-Treatment
.	O

renal	I-Problem
failure	I-Problem
is	O
a	O
rare	O
complication	O
associated	O
with	O
the	O
use	O
of	O
rifampicin	I-Treatment
for	O
the	O
treatment	O
of	O
tuberculosis	I-Problem
,	O
usually	O
occurring	O
well	O
into	O
the	O
course	O
of	O
therapy	O
.	O

an	I-Background
autopsy	I-Test
case	I-Background
of	O
multiple	I-Treatment
psychotropic	I-Treatment
drug	I-Treatment
poisoning	I-Problem
.	O

severe	O
heparin	I-Treatment
associated	O
thrombocytopenia	I-Problem
is	O
a	O
rare	O
complication	O
of	O
heparin	O
therapy	O
.	O

six	O
patients	I-Background
at	O
steady	O
state	O
in	O
treatment	O
with	O
indinavir	I-Treatment
participated	O
in	O
the	O
study	I-Test
.	O

results	O
:	O
a	I-Background
52	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
parkinson	I-Problem
disease	I-Problem
who	O
had	O
taken	I-Treatment
amantadine	I-Treatment
for	I-Treatment
6	I-Other
years	I-Other
had	O
bilateral	I-Problem
corneal	I-Problem
edema	I-Problem
for	I-Problem
2	I-Problem
months	I-Problem
at	I-Problem
baseline	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
a	I-Background
patient	I-Background
with	I-Background
pulmonary	I-Problem
hypertension	I-Problem
and	I-Background
undifferentiated	I-Problem
connective	I-Problem
tissue	I-Problem
disease	I-Problem
who	O
,	O
after	I-Other
2	I-Other
months	I-Other
of	I-Treatment
treatment	I-Treatment
with	I-Treatment
epoprostenol	I-Treatment
,	O
presented	O
with	O
rapidly	I-Problem
progressive	I-Problem
erythema	I-Problem
,	I-Problem
scaling	I-Problem
,	I-Problem
nausea	I-Problem
and	I-Problem
vomiting	I-Problem
,	I-Problem
and	I-Problem
fever	I-Problem
.	O

neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
in	O
an	O
adolescent	I-Background
receiving	O
olanzapine	I-Treatment
-	I-Treatment
lithium	I-Treatment
combination	I-Treatment
therapy	I-Treatment
.	O

a	O
lethal	O
complication	I-Problem
of	O
peripheral	I-Treatment
vein	I-Treatment
vasopressin	I-Treatment
infusion	I-Treatment
.	O

cutaneous	I-Problem
eruptions	I-Problem
occur	O
in	O
3	O
%	O
of	O
individuals	O
administered	O
carbamazepine	I-Treatment
.	O

a	I-Background
27	I-Background
year	I-Background
old	I-Background
female	I-Background
with	I-Background
a	I-Background
complex	I-Background
history	I-Background
of	I-Background
congenital	I-Problem
heart	I-Problem
disease	I-Problem
,	I-Background
cardiac	I-Problem
surgery	I-Problem
,	I-Background
heart	I-Problem
failure	I-Problem
,	I-Background
and	I-Background
arrhythmias	I-Problem
was	O
admitted	O
for	O
a	I-Problem
pseudomonas	I-Problem
aeruginosa	I-Problem
sternal	I-Problem
wound	I-Problem
infection	I-Problem
and	O
treated	O
with	O
intravenous	I-Treatment
antibiotics	I-Treatment
.	O

hyperkalaemia	I-Problem
with	I-Problem
renal	I-Problem
tubular	I-Problem
dysfunction	I-Problem
by	O
oral	I-Treatment
therapy	I-Treatment
of	I-Treatment
sulfamethoxazole	I-Treatment
-	I-Treatment
trimethoprim	I-Treatment
(	I-Treatment
co	I-Treatment
-	I-Treatment
trimoxazole	I-Treatment
)	I-Treatment
is	O
described	O
in	O
2	O
elderly	I-Background
japanese	I-Background
patients	I-Background
with	I-Background
lymphoid	I-Problem
malignancy	I-Problem
,	O
who	O
developed	O
pneumocystis	I-Problem
carinii	I-Problem
pneumonia	I-Problem
and	O
improved	O
.	O

this	O
is	O
the	O
first	O
report	O
on	O
the	O
histopathological	O
findings	O
of	O
thyroid	O
tissue	O
from	O
a	O
patient	O
with	O
amiodarone	I-Treatment
-	O
induced	O
hypothyroidism	I-Problem
.	O

acute	I-Problem
pulmonary	I-Problem
reactions	I-Problem
to	O
nitrofurantoin	I-Treatment
are	O
an	O
uncommon	O
side	O
effect	O
of	O
therapy	O
and	O
can	I-Problem
cause	I-Problem
minor	I-Problem
or	I-Problem
life	I-Problem
-	I-Problem
threatening	I-Problem
pulmonary	I-Problem
dysfunction	I-Problem
.	O

high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
may	O
benefit	O
patients	I-Background
with	I-Background
refractory	I-Problem
acute	I-Problem
leukemia	I-Problem
.	O

life	O
-	O
threatening	O
hyponatremia	I-Problem
caused	O
by	O
vinblastine	I-Treatment
.	O

we	O
report	O
a	I-Background
myeloma	I-Problem
patient	I-Background
who	O
developed	O
severe	O
paralytic	I-Problem
ileus	I-Problem
during	O
bortezomib	I-Treatment
therapy	I-Treatment
,	O
which	O
presented	I-Problem
in	I-Problem
the	I-Problem
context	I-Problem
of	I-Problem
progressive	I-Problem
constipation	I-Problem
without	I-Problem
other	I-Problem
known	I-Problem
causes	I-Problem
and	I-Problem
which	I-Problem
regressed	I-Problem
promptly	I-Problem
with	I-Problem
medical	I-Problem
management	I-Problem
after	I-Problem
drug	I-Problem
cessation	I-Problem
,	O
suggesting	O
a	O
direct	O
causal	O
relationship	O
.	O

here	O
,	O
we	O
report	O
on	O
the	O
drug	O
safety	O
of	O
coumarin	I-Treatment
with	O
special	O
respect	O
to	O
liver	I-Problem
reaction	I-Problem
.	O

however	O
,	O
eo	I-Treatment
-	O
induced	O
noncardiogenic	I-Problem
pulmonary	I-Problem
edema	I-Problem
has	O
not	O
been	O
reported	O
in	O
human	I-Background
.	O

since	O
the	I-Problem
thrombocyte	I-Test
count	I-Test
started	I-Problem
to	I-Problem
increase	I-Problem
immediately	I-Problem
after	I-Problem
initiation	I-Problem
and	I-Problem
dropped	I-Problem
immediately	I-Problem
after	O
discontinuation	I-Treatment
of	I-Treatment
ciprofloxacin	I-Treatment
and	I-Treatment
tazobactam	I-Treatment
/	I-Treatment
piperacillin	I-Treatment
and	O
all	O
other	O
drugs	O
were	O
discontinued	O
already	O
before	O
or	O
were	O
started	O
after	O
the	O
nadir	O
of	O
the	O
thrombocyte	I-Test
count	I-Test
,	O
these	O
two	O
antibiotics	O
were	O
regarded	O
causative	O
.	O

however	O
,	O
in	O
1993	O
,	O
a	O
clinical	I-Test
study	I-Test
involving	O
400	O
patients	I-Background
on	I-Background
the	I-Background
thai	I-Background
-	I-Background
burmese	I-Background
border	I-Background
revealed	O
cardiac	I-Problem
effects	I-Problem
of	O
antimalarial	I-Treatment
treatment	I-Treatment
with	O
halofantrine	I-Treatment
,	O
including	O
one	O
sudden	I-Problem
death	I-Problem
after	O
the	O
treatment	O
.	O

tetracycline	I-Treatment
-	O
induced	O
benign	I-Problem
intracranial	I-Problem
hypertension	I-Problem
.	O

only	O
one	O
case	I-Background
of	O
a	O
generalized	I-Problem
maculopapular	I-Problem
rash	I-Problem
with	O
enoxaparin	I-Treatment
has	O
been	O
reported	O
in	O
europe	O
.	O

after	O
3	I-Other
-	I-Other
to	I-Other
13	I-Other
-	I-Other
month	I-Other
period	I-Treatment
of	I-Treatment
therapy	I-Treatment
without	I-Treatment
indapamide	I-Treatment
,	O
glucose	I-Problem
levels	I-Test
of	I-Problem
all	I-Problem
patients	I-Problem
decreased	I-Problem
and	I-Problem
diabetes	I-Problem
disappeared	I-Problem
.	O

the	O
favourable	O
outcome	O
in	O
these	O
two	O
patients	I-Background
contrasts	O
with	O
the	O
fatal	O
outcome	O
of	O
the	O
two	O
other	O
reported	O
cases	O
of	O
nitrofurantoin	I-Treatment
induced	O
boop	I-Problem
.	O

skin	I-Problem
necrosis	I-Problem
after	O
extravasation	O
of	O
low	O
-	O
dose	O
vasopressin	I-Treatment
administered	O
for	O
septic	I-Problem
shock	I-Problem
.	O

the	I-Background
patient	I-Background
was	O
previously	I-Treatment
on	I-Treatment
phenytoin	I-Treatment
and	O
was	O
initiated	I-Treatment
on	I-Treatment
ticagrelor	I-Treatment
for	O
antiplatelet	I-Problem
therapy	I-Problem
following	I-Treatment
stent	I-Treatment
placement	I-Treatment
.	O

clonidine	I-Treatment
-	O
induced	O
bradycardia	I-Problem
in	O
patients	I-Background
with	I-Background
spinal	I-Problem
cord	I-Problem
injury	I-Problem
.	O

mi	I-Problem
related	O
to	O
the	O
use	O
of	O
activated	I-Treatment
and	I-Treatment
non	I-Treatment
-	I-Treatment
activated	I-Treatment
pccs	I-Treatment
predominantly	O
affects	O
young	I-Background
patients	I-Background
who	I-Background
often	I-Background
have	I-Background
no	I-Background
preceding	I-Background
history	I-Background
of	I-Background
,	I-Background
or	I-Background
risk	I-Background
factors	I-Background
for	I-Background
,	I-Background
mi	I-Background
and	O
tends	O
to	O
be	O
associated	O
with	O
large	I-Treatment
cumulative	I-Treatment
doses	I-Treatment
of	I-Treatment
concentrate	I-Treatment
.	O

to	O
our	O
knowledge	O
,	O
we	O
describe	O
the	O
first	O
reported	O
case	O
of	O
isolated	I-Problem
paresthesia	I-Problem
and	I-Problem
peripheral	I-Problem
neuropathy	I-Problem
,	O
without	O
systemic	O
involvement	O
,	O
secondary	O
to	O
sulindac	I-Treatment
administration	I-Treatment
.	O

to	O
report	O
a	I-Background
probable	I-Background
case	I-Background
of	O
ticlopidine	I-Treatment
-	O
induced	O
phenytoin	I-Treatment
toxicity	I-Problem
.	O

two	O
patients	I-Background
are	O
described	O
in	O
whom	O
subtle	I-Problem
cognitive	I-Problem
impairments	I-Problem
are	O
associated	O
with	O
therapeutic	I-Treatment
doses	I-Treatment
of	I-Treatment
amoxapine	I-Treatment
.	O

itraconazole	I-Treatment
is	O
particularly	O
attractive	O
in	O
fungal	I-Problem
prophylaxis	O
for	O
cancer	I-Problem
patients	I-Background
due	O
to	O
its	O
broad	O
spectrum	O
,	O
including	O
candida	O
and	O
aspergillus	O
.	O

the	O
authors	O
think	O
that	O
although	O
lamivudine	I-Treatment
is	O
widely	O
used	O
and	O
well	O
tolerated	O
,	O
it	O
can	O
cause	O
adrs	I-Problem
,	O
which	O
are	O
reversible	O
after	O
drug	O
withdrawal	O
.	O

psoriasis	I-Problem
induced	O
by	O
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
.	O

we	O
report	O
the	I-Background
first	I-Background
case	I-Background
of	O
iha	I-Problem
associated	O
with	O
cefuroxime	I-Treatment
administration	O
.	O

we	O
report	O
a	I-Background
16	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
who	O
developed	O
nephrotic	I-Problem
syndrome	I-Problem
related	I-Problem
to	I-Problem
membranous	I-Problem
glomerulopathy	I-Problem
with	I-Problem
clinical	I-Problem
and	I-Problem
serological	I-Problem
evidence	I-Problem
of	I-Problem
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
after	O
treatment	I-Treatment
with	I-Treatment
griseofulvin	I-Treatment
.	O

conclusion	O
:	O
in	O
some	I-Background
abstainers	I-Background
who	O
take	I-Treatment
cyanamide	I-Treatment
for	I-Treatment
several	I-Other
years	I-Other
,	O
thin	I-Problem
septum	I-Problem
-	I-Problem
like	I-Problem
liver	I-Problem
fibrosis	I-Problem
progresses	I-Problem
along	I-Problem
with	I-Problem
the	I-Problem
emergence	I-Problem
of	I-Problem
ground	I-Problem
-	I-Problem
glass	I-Problem
hepatocytes	I-Problem
.	O

metabolic	I-Problem
acidosis	I-Problem
induced	O
by	O
acetazolamide	I-Treatment
.	O

valproic	I-Treatment
acid	I-Treatment
also	I-Treatment
displaces	I-Treatment
warfarin	I-Treatment
from	I-Treatment
the	I-Treatment
protein	I-Treatment
binding	I-Treatment
sites	I-Treatment
resulting	O
in	O
significant	I-Problem
inr	I-Problem
changes	I-Problem
but	O
this	O
type	O
of	O
drug	O
interaction	O
is	O
less	O
well	O
known	O
.	O

therapy	I-Treatment
with	I-Treatment
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
may	O
be	O
associated	O
with	O
a	O
number	O
of	O
neuropsychiatric	I-Problem
symptoms	I-Problem
,	I-Problem
such	I-Problem
as	I-Problem
parkinsonism	I-Problem
,	I-Problem
akathisia	I-Problem
,	I-Problem
seizure	I-Problem
,	I-Problem
and	I-Problem
depressive	I-Problem
disorders	I-Problem
.	O

discussion	O
:	O
the	O
main	O
adverse	O
effects	O
of	O
leflunomide	I-Treatment
consist	O
of	O
diarrhea	I-Problem
,	I-Problem
nausea	I-Problem
,	I-Problem
liver	I-Problem
enzyme	I-Problem
elevation	I-Problem
,	I-Problem
hypertension	I-Problem
,	I-Problem
alopecia	I-Problem
,	I-Problem
and	I-Problem
allergic	I-Problem
skin	I-Problem
reactions	I-Problem
.	O

in	O
a	O
single	O
practice	O
during	O
the	O
21	O
years	O
1971	O
-	O
1991	O
,	O
the	O
incidence	O
of	O
gestational	I-Problem
diabetes	I-Problem
in	O
pregnancies	I-Background
in	O
which	O
norethisterone	I-Treatment
was	O
prescribed	O
was	O
32	O
.	O
4	O
%	O
(	O
22	O
of	O
69	O
)	O
in	O
comparison	O
with	O
7	O
.	O
1	O
%	O
in	O
pregnancies	O
in	O
which	O
the	O
women	O
did	O
not	O
take	O
norethisterone	O
(	O
137	O
of	O
1	O
,	O
684	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

the	O
development	O
of	O
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
(	O
sle	O
)	O
after	I-Other
38	I-Other
months	I-Other
of	O
therapy	O
with	O
recombinant	I-Treatment
human	I-Treatment
interferon	I-Treatment
gamma	I-Treatment
(	O
rifn	O
-	O
gamma	I-Test
)	O
was	O
observed	O
in	O
a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
.	I-Problem

to	O
the	O
best	O
of	O
our	O
knowledge	O
no	O
comparable	O
case	O
and	O
no	O
discussion	O
of	O
possible	O
complications	O
of	O
aspirin	I-Treatment
prophylaxis	I-Treatment
in	O
patients	I-Background
with	I-Background
brain	I-Problem
tumours	I-Problem
have	O
been	O
published	O
.	O

case	O
report	O
:	O
we	O
present	O
a	O
case	O
of	O
a	O
28	I-Background
-	I-Background
yr	I-Background
-	I-Background
old	I-Background
male	I-Background
who	O
developed	O
a	O
severe	O
case	O
of	O
nephrotic	I-Problem
syndrome	I-Problem
while	O
being	O
treated	O
for	O
relapsing	I-Problem
/	I-Problem
remitting	I-Problem
multiple	I-Problem
sclerosis	I-Problem
(	I-Background
rrms	I-Background
)	I-Background
with	O
weekly	I-Other
injections	I-Treatment
of	I-Treatment
interferon	I-Treatment
beta	I-Treatment
1a	I-Treatment
.	O

this	O
is	O
the	O
third	O
report	O
of	O
reversible	I-Problem
hepatic	I-Problem
decompensation	I-Problem
associated	O
with	O
prolonged	O
mtx	I-Treatment
therapy	O
in	O
patients	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
.	O

conclusions	O
:	O
acute	I-Problem
severe	I-Problem
hepatitis	I-Problem
though	O
rare	O
is	O
occasionally	O
observed	O
with	O
egfr	I-Treatment
inhibitors	I-Treatment
gefitinib	I-Treatment
or	I-Treatment
erlotinib	I-Treatment
.	O

propafenone	I-Treatment
is	O
an	O
established	O
class	O
ic	O
antiarrhythmic	O
drug	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
atrial	I-Problem
fibrillation	I-Problem
.	O

reversible	I-Problem
nonthrombocytopenic	I-Problem
palpable	I-Problem
purpura	I-Problem
associated	O
with	O
metoclopramide	I-Treatment
.	O

physicians	O
who	O
use	O
sulfasalazine	I-Treatment
to	O
treat	O
patients	O
with	O
inflammatory	I-Problem
bowel	I-Problem
disease	I-Problem
should	O
be	O
aware	O
of	O
the	O
signs	O
of	O
sulfasalazine	I-Treatment
-	O
induced	O
lupus	I-Problem
syndrome	I-Problem
.	O

transient	I-Problem
hemiparesis	I-Problem
caused	O
by	O
phenytoin	I-Treatment
toxicity	I-Treatment
.	O

sensorineural	I-Problem
hearing	I-Problem
loss	I-Problem
due	O
to	O
quinine	I-Treatment
therapy	O
for	O
malaria	I-Problem
has	O
frequently	O
been	O
mentioned	O
in	O
the	O
literature	O
but	O
has	O
not	O
been	O
a	O
subject	O
of	O
research	O
during	O
the	O
last	O
decades	O
.	O

we	O
report	O
a	I-Background
78	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
who	O
had	O
acute	I-Problem
unilateral	I-Problem
total	I-Problem
visual	I-Problem
loss	I-Problem
after	O
retrogasserian	I-Treatment
phenol	I-Treatment
injection	I-Treatment
for	O
the	O
treatment	O
of	O
trigeminal	I-Problem
neuralgia	I-Problem
.	O

four	I-Other
months	I-Other
after	I-Background
receiving	I-Background
an	I-Background
orthotopic	I-Background
liver	I-Background
transplant	I-Background
,	I-Background
a	I-Background
51	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
was	O
admitted	O
for	O
progressive	I-Problem
liver	I-Problem
failure	I-Problem
and	I-Problem
severe	I-Problem
hepatocellular	I-Problem
necrosis	I-Problem
thought	O
to	O
be	O
due	O
to	O
tacrolimus	I-Treatment
.	O

patients	I-Background
receiving	O
neutral	I-Treatment
protamine	I-Treatment
hagedorn	I-Treatment
(	I-Treatment
nph	I-Treatment
)	I-Treatment
insulin	I-Treatment
are	O
at	O
increased	O
risk	O
for	O
the	O
development	O
of	O
protamine	I-Problem
hypersensitivity	I-Problem
.	O

the	I-Background
second	I-Background
patient	I-Background
,	O
who	O
developed	O
cholestasis	I-Problem
after	O
receiving	O
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
,	O
had	O
marked	O
duct	I-Problem
paucity	I-Problem
in	O
the	O
liver	I-Test
biopsy	I-Test
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	O
became	O
hypothyroid	I-Problem
while	O
taking	O
ferrous	I-Treatment
sulfate	I-Treatment
.	O

allergy	I-Problem
to	O
cloxacillin	I-Treatment
with	O
normal	O
tolerance	O
to	O
amoxicillin	I-Treatment
and	O
cefuroxime	I-Treatment
.	O

triazolam	I-Treatment
-	O
induced	O
nocturnal	I-Problem
bingeing	I-Problem
with	I-Problem
amnesia	I-Problem
.	O

ticlopidine	I-Treatment
-	O
induced	O
aplastic	I-Problem
anemia	I-Problem
(	I-Problem
tiaa	I-Problem
)	I-Problem
is	O
considered	O
very	O
uncommon	O
.	O

one	O
case	I-Background
report	O
describes	O
an	O
interaction	O
between	O
simvastatin	I-Treatment
and	I-Treatment
the	I-Treatment
anticoagulant	I-Treatment
acenocoumarol	I-Treatment
,	O
which	O
resulted	O
in	O
an	O
elevated	I-Problem
inr	I-Problem
.	O

a	I-Background
35	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
presented	O
with	O
neurotoxicity	I-Problem
correlated	O
to	O
an	I-Treatment
i	I-Treatment
.	I-Treatment
v	I-Treatment
.	I-Treatment
regimen	I-Treatment
of	I-Treatment
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
as	O
episodes	O
of	O
acute	I-Problem
confusional	I-Problem
state	I-Problem
and	I-Problem
abnormalities	I-Problem
of	I-Problem
symmetrically	I-Problem
restricted	I-Problem
diffusion	I-Problem
in	I-Problem
the	I-Problem
periventricular	I-Problem
white	I-Problem
matter	I-Problem
and	I-Problem
corpus	I-Problem
callosum	I-Problem
.	O

ampicillin	I-Treatment
may	O
aggravate	O
clinical	O
and	O
experimental	O
myasthenia	I-Problem
gravis	I-Problem
.	O

in	O
the	O
present	O
paper	O
,	O
we	O
discuss	O
the	O
first	O
japanese	I-Background
vivax	I-Problem
malaria	I-Problem
patient	I-Background
whose	O
qt	I-Problem
interval	I-Problem
was	I-Problem
prolonged	I-Problem
after	O
treatment	O
with	O
halofantrine	I-Treatment
.	O

the	O
center	O
for	O
disease	O
control	O
has	O
received	O
numerous	O
reports	O
of	O
an	O
eosinophilia	I-Problem
-	I-Problem
myalgia	I-Problem
syndrome	I-Problem
related	O
to	O
products	I-Treatment
containing	I-Treatment
l	I-Treatment
-	I-Treatment
tryptophan	I-Treatment
.	O

disopyramide	I-Treatment
(	I-Treatment
norpace	I-Treatment
)	I-Treatment
-	O
induced	O
hypoglycemia	I-Problem
.	O

a	O
case	O
report	O
of	O
the	O
hypersensitivity	I-Problem
syndrome	I-Problem
occurring	O
in	O
a	I-Background
patient	I-Background
being	O
treated	O
with	O
dapsone	I-Treatment
for	O
a	O
brown	I-Problem
recluse	I-Problem
spider	I-Problem
bite	I-Problem
is	O
presented	O
.	O

aims	O
:	O
to	O
present	O
a	O
case	O
of	O
piloerection	I-Problem
after	O
replacing	O
fluvoxamine	I-Treatment
maleate	I-Treatment
with	O
milnacipran	I-Treatment
hydrochloride	I-Treatment
,	O
and	O
to	O
analyse	O
this	O
effect	O
based	O
on	O
receptor	O
occupancy	O
theory	O
.	O

serotonin	I-Problem
syndrome	I-Problem
after	O
concomitant	O
linezolid	I-Treatment
and	I-Treatment
meperidine	I-Treatment
therapy	O
has	O
not	O
been	O
described	O
.	O

she	I-Background
presented	O
to	O
clinic	O
with	O
nausea	I-Problem
and	I-Problem
anorexia	I-Problem
within	I-Other
a	I-Other
few	I-Other
days	I-Other
of	O
addition	I-Treatment
of	I-Treatment
ciprofloxacin	I-Treatment
to	I-Treatment
her	I-Treatment
current	I-Treatment
regimen	I-Treatment
of	I-Treatment
medications	I-Treatment
,	I-Treatment
which	I-Treatment
included	I-Treatment
digoxin	I-Treatment
.	O

disulfiram	I-Treatment
-	O
induced	O
fulminant	I-Problem
hepatic	I-Problem
failure	I-Problem
in	O
an	I-Background
active	I-Background
duty	I-Background
soldier	I-Background
.	O

background	O
:	O
we	O
report	O
six	O
cases	I-Background
of	O
psychosis	I-Problem
in	O
patients	I-Background
with	I-Background
akinetic	I-Problem
-	I-Problem
rigid	I-Problem
syndromes	I-Problem
who	O
were	O
treated	O
with	O
risperidone	I-Treatment
.	O

colonic	I-Problem
necrosis	I-Problem
is	O
known	O
as	O
a	O
rare	O
complication	O
following	O
the	O
administration	O
of	O
kayexalate	I-Treatment
(	I-Treatment
sodium	I-Treatment
polystryrene	I-Treatment
sulfonate	I-Treatment
)	I-Treatment
in	I-Treatment
sorbitol	I-Treatment
.	O

anaphylaxis	I-Problem
to	O
cisplatin	I-Treatment
is	O
an	O
infrequent	O
life	O
-	O
threatening	O
complication	O
which	O
may	O
occur	O
even	O
in	O
patients	I-Background
who	O
have	O
received	O
prior	O
treatment	O
with	O
cisplatin	O
.	O

piloerection	I-Problem
induced	O
by	O
replacing	I-Treatment
fluvoxamine	I-Treatment
with	I-Treatment
milnacipran	I-Treatment
.	O

ethambutol	I-Treatment
is	O
an	O
antimicrobial	O
agent	O
used	O
frequently	O
to	O
treat	O
tuberculosis	I-Problem
.	O

the	O
purpose	O
of	O
this	O
review	O
is	O
to	O
increase	O
awareness	O
among	O
physicians	O
and	O
other	O
health	O
care	O
professionals	O
that	O
dic	I-Problem
may	O
be	O
a	O
rare	O
but	O
potentially	O
severe	O
complication	O
of	O
anti	I-Treatment
-	I-Treatment
d	I-Treatment
igiv	I-Treatment
treatment	O
.	O

four	O
chinese	I-Background
female	I-Background
patients	I-Background
who	I-Background
suffered	I-Background
from	I-Background
manic	I-Problem
-	I-Problem
depressive	I-Problem
disorder	I-Problem
and	I-Background
underlying	I-Problem
autoimmune	I-Problem
thyroiditis	I-Problem
developed	O
transient	I-Problem
episodes	I-Problem
of	I-Problem
thyrotoxicosis	I-Problem
during	O
maintenance	I-Treatment
lithium	I-Treatment
therapy	I-Treatment
.	O

neurointensive	O
care	O
management	O
of	O
raised	I-Problem
intracranial	I-Problem
pressure	I-Problem
caused	O
by	O
severe	O
valproic	I-Treatment
acid	I-Treatment
intoxication	O
.	O

primary	I-Problem
ovarian	I-Problem
large	I-Problem
b	I-Problem
-	I-Problem
cell	I-Problem
lymphoma	I-Problem
in	O
patient	I-Background
with	I-Background
juvenile	I-Problem
rheumatoid	I-Problem
arthritis	I-Problem
treated	O
with	O
low	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
.	O

asterixis	I-Problem
induced	O
by	O
carbamazepine	I-Treatment
therapy	O
.	O

ifosfamide	I-Treatment
is	O
a	O
known	O
nephrotoxic	O
drug	O
with	O
demonstrated	O
tubulopathies	I-Problem
.	O

a	I-Background
case	I-Background
of	O
noncardiogenic	I-Problem
pulmonary	I-Problem
edema	I-Problem
by	O
ethanolamine	I-Treatment
oleate	I-Treatment
.	O

a	I-Background
boy	I-Background
with	I-Background
chronic	I-Problem
neutropenia	I-Problem
and	I-Problem
recurrent	I-Problem
inflammatory	I-Problem
skin	I-Problem
lesions	I-Problem
developed	O
multiple	I-Problem
erythematous	I-Problem
nodules	I-Problem
following	O
administration	O
of	O
g	I-Treatment
-	I-Treatment
csf	I-Treatment
.	O

fulminant	I-Problem
hepatitis	I-Problem
and	O
lymphocyte	I-Problem
sensitization	I-Problem
due	O
to	O
propylthiouracil	I-Treatment
.	O

we	O
report	O
on	O
three	O
patients	I-Background
with	I-Background
acute	I-Problem
schizophrenia	I-Problem
,	O
who	O
developed	O
severe	O
akathisia	I-Problem
during	O
treatment	O
with	O
olanzapine	I-Treatment
(	I-Treatment
20	I-Treatment
-	I-Treatment
25	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
)	I-Treatment
.	O

aims	O
/	O
hypothesis	O
:	O
there	O
is	O
evidence	O
that	O
insulin	I-Treatment
and	I-Treatment
glucose	I-Treatment
cause	O
renal	I-Problem
and	I-Problem
ocular	I-Problem
vasodilation	I-Problem
.	O

a	O
cause	O
-	O
effect	O
relationship	O
to	O
capecitabine	I-Treatment
was	O
suggested	O
due	O
to	O
resolution	O
of	O
headache	I-Problem
with	O
capecitabine	O
withdrawal	O
and	O
reappearance	O
with	O
capecitabine	O
rechallenge	O
.	O

this	O
is	O
a	O
report	O
of	O
a	I-Background
case	I-Background
of	O
anuric	I-Problem
arf	I-Problem
after	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
mannitol	I-Treatment
infusion	I-Treatment
for	O
treatment	O
of	O
narrow	I-Problem
-	I-Problem
angle	I-Problem
glaucoma	I-Problem
that	O
readily	O
responded	O
to	O
acute	O
hemodialysis	O
.	O

she	I-Background
was	O
treated	O
with	O
sorafenib	I-Treatment
at	I-Treatment
400	I-Treatment
mg	I-Treatment
daily	I-Other
.	O

the	O
clinical	O
course	O
suggested	O
that	O
recombinant	I-Treatment
alpha	I-Treatment
-	I-Treatment
2b	I-Treatment
peginterferon	I-Treatment
plus	I-Treatment
ribavirin	I-Treatment
provoked	O
type	I-Problem
1	I-Problem
diabetes	I-Problem
mellitus	I-Problem
,	O
therefore	O
,	O
in	O
patients	O
who	O
are	O
candidates	O
for	O
interferon	O
therapy	O
the	O
presence	O
of	O
pancreatic	O
autoantibodies	O
and	O
the	O
fasting	O
plasma	O
glucose	O
level	O
should	O
be	O
investigated	O
before	O
and	O
during	O
treatment	O
.	O

rhabdomyolysis	I-Problem
following	O
clarithromycin	I-Treatment
monotherapy	I-Treatment
.	O

in	O
addition	O
to	O
its	O
known	O
effect	O
on	O
gallbladder	I-Problem
stasis	I-Problem
,	O
octreotide	I-Treatment
alters	I-Problem
bile	I-Problem
acid	I-Test
composition	I-Test
and	I-Problem
may	I-Problem
thus	I-Problem
hasten	I-Problem
intrahepatic	I-Problem
sludge	I-Problem
and	I-Problem
stone	I-Problem
formation	I-Problem
.	O

a	O
17	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
developed	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
within	I-Other
48	I-Other
h	I-Other
of	O
an	O
intravenous	I-Treatment
high	I-Treatment
-	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
(	I-Treatment
5	I-Treatment
g	I-Treatment
/	I-Treatment
m2	I-Treatment
)	I-Treatment
infusion	I-Treatment
.	O

splenic	I-Problem
hemorrhage	I-Problem
:	O
a	O
complication	O
of	O
tissue	I-Treatment
plasminogen	I-Treatment
activator	I-Treatment
treatment	I-Treatment
.	O

conclusions	O
:	O
cefazolin	I-Treatment
was	O
a	O
probable	O
cause	O
of	O
this	O
patient	I-Background
'	O
s	O
leukopenia	I-Problem
.	O

paradoxical	I-Problem
cerebral	I-Problem
cortical	I-Problem
hyperexcitability	I-Problem
following	O
flupirtine	I-Treatment
overdose	I-Treatment
.	O

autopsy	O
evidence	O
of	O
herpesvirus	I-Problem
infection	I-Problem
was	O
found	O
in	O
visceral	O
organs	O
of	O
four	O
leukemic	I-Problem
patients	I-Background
who	O
had	O
received	O
large	I-Treatment
doses	I-Treatment
of	I-Treatment
cytarabine	I-Treatment
(	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
;	I-Treatment
ara	I-Treatment
-	I-Treatment
c	I-Treatment
)	I-Treatment
shortly	O
before	O
their	O
death	O
.	O

heparin	I-Treatment
-	O
induced	O
hyperkalemia	I-Problem
.	O

although	O
myelosuppression	I-Problem
is	O
mild	O
,	O
immunosuppression	I-Problem
and	I-Problem
superinfection	I-Problem
are	O
potential	O
hazards	O
of	O
treatment	O
with	O
dcf	I-Treatment
.	O

the	O
photosensitivity	I-Problem
is	I-Problem
still	I-Problem
present	I-Problem
3	I-Problem
years	I-Problem
after	O
the	O
withdrawal	I-Treatment
of	I-Treatment
quinine	I-Treatment
.	O

interference	I-Problem
with	I-Problem
the	I-Problem
cortisol	I-Problem
axis	I-Problem
by	O
the	O
microtubule	O
antagonist	O
,	O
cph82	I-Treatment
.	O

physicians	O
should	O
be	O
aware	O
of	O
the	O
possible	O
association	O
between	O
the	O
use	O
of	O
alteplase	I-Treatment
and	O
the	O
development	O
of	O
subfascial	I-Problem
hemorrhage	I-Problem
.	O

the	O
clinical	O
findings	O
and	O
laboratory	O
studies	O
suggested	O
an	I-Problem
autoimmune	I-Problem
cell	I-Problem
-	I-Problem
mediated	I-Problem
hypersensitivity	I-Problem
reaction	I-Problem
triggered	O
by	O
phenobarbital	I-Treatment
.	O

anaphylactic	I-Problem
reaction	I-Problem
to	O
oral	I-Treatment
prednisone	I-Treatment
:	O
a	I-Background
case	I-Background
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

prolonged	I-Problem
prostate	I-Problem
-	I-Problem
specific	I-Problem
antigen	I-Problem
response	I-Problem
in	O
flutamide	I-Treatment
withdrawal	O
syndrome	O
despite	O
disease	O
progression	O
.	O

none	O
of	O
them	O
had	O
a	O
history	O
of	O
cardiac	O
disease	O
,	O
and	O
with	O
the	O
possible	O
exception	O
of	O
one	O
case	O
of	O
cardiac	I-Problem
arrest	I-Problem
,	O
where	O
the	I-Background
patient	I-Background
received	O
doxorubicin	I-Treatment
,	O
no	O
predisposing	O
factors	O
could	O
be	O
found	O
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
iddm	I-Problem
which	O
occurred	O
during	O
interferon	I-Treatment
therapy	I-Treatment
for	O
chronic	I-Problem
hepatitis	I-Problem
.	I-Problem

though	O
physicians	O
treating	O
large	O
populations	O
of	O
patients	I-Background
with	I-Background
hiv	I-Problem
are	O
well	O
aware	O
of	O
this	O
complication	O
,	O
only	O
one	O
other	O
report	O
of	O
nevirapine	I-Treatment
-	O
associated	O
sjs	I-Problem
has	O
been	O
documented	O
in	O
the	O
dermatology	O
literature	O
.	O

we	O
report	O
a	O
case	O
of	O
baclofen	I-Problem
withdrawal	I-Problem
syndrome	I-Problem
resulting	O
from	O
oral	I-Treatment
baclofen	I-Treatment
underdosing	I-Treatment
.	O

a	I-Background
35	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
nephrotic	I-Problem
man	I-Background
developed	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
with	I-Problem
serum	I-Problem
creatinine	I-Test
to	I-Problem
1543	I-Problem
micromol	I-Problem
/	I-Problem
l	I-Problem
after	O
a	I-Other
month	I-Other
of	I-Treatment
therapy	I-Treatment
with	I-Treatment
enalapril	I-Treatment
.	O

comparable	O
adverse	O
effects	O
,	O
such	O
as	O
disorientation	I-Problem
and	I-Problem
temporary	I-Problem
amnesia	I-Problem
,	O
have	O
been	O
reported	O
in	O
patients	I-Background
in	O
the	O
analogous	O
agent	O
,	O
propranolol	I-Treatment
.	O

this	O
is	O
an	O
image	O
and	O
brief	O
case	O
report	O
of	O
a	I-Background
13	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
who	O
presented	O
with	O
severe	I-Problem
rash	I-Problem
and	I-Problem
systemic	I-Problem
symptoms	I-Problem
after	O
starting	O
oxcarbazepine	I-Treatment
.	O

renal	I-Problem
damage	I-Problem
associated	O
with	O
long	O
term	O
use	O
of	O
lithium	I-Treatment
carbonate	I-Treatment
.	I-Treatment

triamcinolone	I-Treatment
acetonide	I-Treatment
induced	O
secondary	I-Problem
adrenal	I-Problem
insufficiency	I-Problem
related	O
to	O
impaired	O
cyp3a4	O
metabolism	O
by	O
coadministration	I-Treatment
of	I-Treatment
nefazodone	I-Treatment
.	O

hepatocellular	I-Problem
damage	I-Problem
following	O
therapeutic	O
intravenous	I-Treatment
iron	I-Treatment
sucrose	I-Treatment
infusion	I-Treatment
in	O
a	I-Background
child	I-Background
.	O

we	O
report	O
a	I-Background
43	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
who	O
developed	O
sore	I-Problem
throat	I-Problem
,	I-Problem
swelling	I-Problem
of	I-Problem
the	I-Problem
lips	I-Problem
and	I-Problem
oral	I-Problem
cavity	I-Problem
and	I-Problem
dysphagia	I-Problem
,	O
2	I-Other
weeks	I-Other
after	I-Other
the	I-Treatment
use	I-Treatment
of	I-Treatment
budesonide	I-Treatment
spray	I-Treatment
(	I-Treatment
budefat	I-Treatment
)	I-Treatment
for	O
treatment	O
of	O
bronchial	I-Problem
asthma	I-Problem
.	I-Problem

among	O
the	O
risk	O
factors	O
studied	O
,	O
two	O
appear	O
to	O
increase	I-Problem
the	I-Problem
risk	I-Problem
of	I-Problem
are	I-Problem
:	O
the	O
prescription	I-Treatment
of	I-Treatment
thiabendazole	I-Treatment
to	O
treat	O
strongyloidiasis	I-Problem
during	I-Treatment
the	I-Treatment
melarsoprol	I-Treatment
cure	I-Treatment
and	O
the	O
bad	O
general	O
clinical	O
conditions	O
of	O
patients	O
.	O

a	O
second	O
possibility	O
is	O
an	O
interaction	I-Treatment
between	I-Treatment
clarithromycin	I-Treatment
and	I-Treatment
isradipine	I-Treatment
,	O
potentially	O
increasing	O
the	O
hepatic	I-Problem
toxicity	I-Problem
of	O
isradipine	O
.	O

we	O
report	O
two	O
cases	I-Background
of	O
cerebrospinal	I-Problem
fluid	I-Problem
eosinophilia	I-Problem
(	I-Problem
csfe	I-Problem
)	I-Problem
secondary	O
to	O
the	O
intraventricular	I-Treatment
administration	I-Treatment
of	I-Treatment
vancomycin	I-Treatment
.	O

we	O
describe	O
two	O
patients	I-Background
who	O
experienced	O
serious	I-Problem
quetiapine	I-Problem
adverse	I-Problem
effects	I-Problem
potentially	O
mediated	O
through	O
an	O
interaction	O
with	O
ritonavir	I-Treatment
-	I-Treatment
boosted	I-Treatment
atazanavir	I-Treatment
.	O

the	O
patient	I-Background
was	O
diagnosed	O
with	O
carbamazepine	I-Problem
toxicity	I-Problem
related	O
to	O
the	O
introduction	O
of	O
ritonavir	I-Treatment
.	O

caution	O
should	O
be	O
exercised	O
,	O
especially	O
in	O
patients	I-Background
who	O
are	O
given	O
voriconazole	I-Treatment
or	O
fluconazole	I-Treatment
during	O
long	O
-	O
lasting	O
fentanyl	I-Treatment
treatment	O
,	O
because	O
insidiously	O
elevated	O
fentanyl	I-Treatment
concentration	O
may	O
lead	O
to	O
respiratory	I-Problem
depression	I-Problem
.	O

this	O
review	O
presents	O
the	O
first	O
case	O
series	O
of	O
dic	I-Problem
associated	I-Problem
with	I-Problem
acute	I-Problem
hemoglobinemia	I-Problem
or	I-Problem
hemoglobinuria	I-Problem
following	O
anti	I-Treatment
-	I-Treatment
d	I-Treatment
igiv	I-Treatment
administration	I-Treatment
for	O
itp	I-Problem
.	O

risperidone	I-Treatment
is	O
a	O
frequently	O
used	O
member	O
of	O
a	O
new	O
class	O
of	O
atypical	O
antipsychotics	O
-	O
the	O
serotonin	O
-	O
dopamine	O
antagonists	O
(	O
sdas	O
)	O
-	O
due	O
to	O
its	O
comparatively	O
high	O
efficacy	O
and	O
low	O
d2	O
/	I-Test
5ht2	O
binding	O
ratio	O
,	O
which	O
results	O
in	O
a	O
low	O
incidence	O
of	O
extrapyramidal	O
side	O
effects	O
including	O
tardive	I-Problem
dyskinesia	I-Problem
(	O
td	O
)	O
.	O

a	I-Background
5	I-Background
-	I-Background
month	I-Background
-	I-Background
old	I-Background
infant	I-Background
became	O
lethargic	I-Problem
and	I-Problem
poorly	I-Problem
responsive	I-Problem
after	O
receiving	I-Treatment
1	I-Treatment
drop	I-Treatment
of	I-Treatment
brimonidine	I-Treatment
in	I-Treatment
each	I-Treatment
eye	I-Treatment
.	O

the	O
authors	O
report	O
2	O
cases	I-Background
of	O
renal	I-Problem
damage	I-Problem
associated	O
with	O
lithium	I-Treatment
carbonate	I-Treatment
treatment	I-Treatment
.	O

it	O
was	O
hypothesized	O
that	O
valproic	I-Treatment
acid	I-Treatment
may	I-Treatment
interfere	I-Treatment
with	I-Treatment
glucuronidation	I-Treatment
of	I-Treatment
lamotrigine	I-Treatment
,	O
leading	O
to	O
increased	I-Problem
serum	I-Problem
lamotrigine	I-Problem
levels	I-Problem
,	I-Problem
or	I-Problem
perhaps	I-Problem
alter	I-Problem
the	I-Problem
drug	I-Problem
'	I-Problem
s	I-Problem
metabolism	I-Problem
,	I-Problem
resulting	I-Problem
in	I-Problem
accumulation	I-Problem
of	I-Problem
a	I-Problem
toxic	I-Problem
intermediate	I-Problem
metabolite	I-Problem
.	O

a	I-Background
healthy	I-Background
,	I-Background
30	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
,	O
exposed	O
to	O
sulindac	I-Treatment
on	O
two	O
separate	O
occasions	O
,	O
had	O
an	O
incapacitating	I-Problem
isolated	I-Problem
idential	I-Problem
sensory	I-Problem
neuropathy	I-Problem
.	O

clofibrate	I-Treatment
-	O
induced	O
myopathy	I-Problem
in	O
patients	I-Background
with	I-Background
diabetes	I-Problem
insipidus	I-Problem
.	O

this	O
is	O
the	I-Background
first	I-Background
histologically	I-Background
confirmed	I-Background
case	I-Background
of	O
nash	I-Problem
that	O
was	O
aggravated	O
by	O
raloxifene	I-Treatment
.	O

to	O
date	O
,	O
eight	O
cases	O
of	O
ten	I-Problem
and	O
one	O
of	O
sjs	I-Problem
related	O
to	O
lamotrigine	I-Treatment
administration	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

ara	I-Treatment
-	I-Treatment
c	I-Treatment
is	O
frequently	O
associated	O
with	O
dermatologic	I-Problem
toxicity	I-Problem
,	O
but	O
this	O
is	O
only	O
the	O
second	O
case	O
of	O
toxic	O
epidermal	O
necrolysis	O
described	O
in	O
connection	O
with	O
this	O
drug	O
.	O

hyperglycemia	I-Problem
and	I-Problem
diabetic	I-Problem
coma	I-Problem
:	O
possible	O
relationship	O
to	O
diuretic	O
-	O
propranolol	I-Treatment
therapy	O
.	O

potential	O
mechanisms	O
involved	O
in	O
the	O
occurrence	O
of	O
ischemic	I-Problem
colitis	I-Problem
in	O
patients	I-Background
receiving	O
tegaserod	I-Treatment
are	O
also	O
discussed	O
.	O

anaphylaxis	I-Problem
to	O
intravenous	I-Treatment
cyclosporine	I-Treatment
and	O
tolerance	O
to	O
oral	O
cyclosporine	O
:	O
case	I-Background
report	O
and	O
review	O
.	O

case	O
report	O
:	O
a	I-Background
woman	I-Background
of	I-Background
80	I-Background
years	I-Background
,	O
on	I-Treatment
long	I-Other
-	I-Other
term	I-Other
warfarin	I-Treatment
therapy	O
presented	O
with	O
an	O
acute	I-Problem
dissecting	I-Problem
thoracic	I-Problem
aortic	I-Problem
aneurysm	I-Problem
;	O
on	O
investigation	O
the	O
only	O
precipitating	O
factor	O
found	O
was	O
an	O
international	O
normalised	O
ratio	O
of	O
4	O
.	O
8	O
.	O

a	I-Background
patient	I-Background
with	I-Background
an	I-Background
allergy	I-Problem
to	I-Problem
a	I-Problem
macrolide	I-Problem
antibiotic	I-Problem
was	O
given	I-Treatment
tacrolimus	I-Treatment
and	O
developed	O
a	O
sudden	I-Problem
cutaneous	I-Problem
reaction	I-Problem
.	O

this	O
case	O
suggests	O
the	O
importance	O
of	O
careful	O
observation	I-Test
for	O
extramedullary	I-Problem
relapse	I-Problem
in	O
patients	I-Background
who	O
are	O
treated	O
with	O
atra	I-Treatment
.	O

olanzapine	I-Treatment
-	O
associated	O
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
.	O

acute	I-Problem
dystonia	I-Problem
induced	O
by	O
lamivudine	I-Treatment
.	O

we	O
report	O
in	O
detail	O
an	O
unusual	O
adverse	O
reaction	O
to	O
infliximab	I-Treatment
therapy	O
,	O
a	O
drug	O
-	O
induced	O
lupus	I-Problem
-	I-Problem
like	I-Problem
clinical	I-Problem
syndrome	I-Problem
.	O

oral	I-Treatment
intake	I-Treatment
and	I-Treatment
acarbose	I-Treatment
were	O
withheld	O
and	O
the	I-Problem
ileus	I-Problem
spontaneously	I-Problem
resolved	I-Problem
after	O
2	O
days	O
.	O

no	O
explanation	O
for	O
this	O
delay	O
was	O
found	O
,	O
other	O
than	O
the	O
possibility	O
that	O
magnesium	I-Treatment
sulfate	I-Treatment
treatment	O
impeded	O
lactogenesis	I-Problem
.	O

although	O
its	O
side	O
effects	O
are	O
few	O
,	O
tamoxifen	I-Treatment
increases	O
the	O
incidence	I-Problem
of	I-Problem
proliferative	I-Problem
lesions	I-Problem
of	I-Problem
the	I-Problem
endometrium	I-Problem
,	O
which	O
theoretically	O
should	O
be	O
preventable	O
with	O
progestational	O
agents	O
.	O

three	O
senile	I-Background
patients	I-Background
developed	O
fatal	O
acute	O
encephalopathy	I-Problem
while	O
receiving	O
calcium	I-Treatment
hopantenate	I-Treatment
.	O

renal	I-Problem
injury	I-Problem
due	O
to	O
anastrozole	I-Treatment
has	O
not	O
been	O
published	O
in	O
the	O
english	O
literature	O
.	O

facial	I-Problem
,	I-Problem
tongue	I-Problem
,	I-Problem
and	I-Problem
arm	I-Problem
movements	I-Problem
were	O
first	O
reported	O
approximately	O
five	I-Other
weeks	I-Other
after	O
the	O
initiation	I-Treatment
of	I-Treatment
aripiprazole	I-Treatment
.	O

restless	I-Problem
legs	I-Problem
syndrome	I-Problem
due	O
to	O
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
.	O

hus	I-Problem
has	O
been	O
reported	O
after	O
several	I-Treatment
anticancer	I-Treatment
chemotherapies	I-Treatment
and	I-Treatment
most	I-Treatment
often	I-Treatment
after	I-Treatment
mitomycin	I-Treatment
c	I-Treatment
-	I-Treatment
based	I-Treatment
chemotherapy	I-Treatment
regimens	I-Treatment
.	O

although	O
the	O
association	O
between	O
sjs	I-Problem
/	I-Problem
ten	I-Problem
and	O
the	O
sulfonamide	I-Treatment
class	I-Treatment
of	I-Treatment
antibiotics	I-Treatment
is	O
well	O
established	O
,	O
the	O
increasing	O
prevalence	O
of	O
ca	I-Problem
-	I-Problem
mrsa	I-Problem
has	O
left	O
practitioners	O
with	O
limited	O
regimens	O
to	O
effectively	O
treat	O
skin	I-Problem
and	I-Problem
soft	I-Problem
tissue	I-Problem
infections	I-Problem
(	I-Problem
sstis	I-Problem
)	I-Problem
in	O
the	O
outpatient	O
setting	O
.	O

acute	I-Problem
non	I-Problem
-	I-Problem
lymphocytic	I-Problem
leukemia	I-Problem
occurred	O
in	O
eight	O
women	I-Background
following	O
long	O
-	O
term	O
treatment	O
with	O
treosulfan	I-Treatment
(	I-Treatment
=	I-Treatment
dihydroxybusulfan	I-Treatment
)	I-Treatment
for	O
ovarian	I-Problem
carcinoma	I-Problem
.	O

elderly	I-Background
patients	I-Background
for	O
whom	O
nitrate	I-Treatment
has	O
been	O
prescribed	O
should	O
be	O
warned	O
of	O
the	O
occurrence	O
of	O
hypotension	I-Problem
,	O
leading	O
to	O
unconsciousness	I-Problem
.	O

a	O
patient	O
receiving	O
vancomycin	I-Treatment
for	O
a	O
serious	I-Problem
staphylococcal	I-Problem
infection	I-Problem
had	O
a	I-Problem
lupus	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
characterized	I-Problem
by	I-Problem
a	I-Problem
malar	I-Problem
rash	I-Problem
,	I-Problem
pain	I-Problem
and	I-Problem
erythema	I-Problem
of	I-Problem
the	I-Problem
cartilage	I-Problem
of	I-Problem
both	I-Problem
ears	I-Problem
,	I-Problem
and	I-Problem
tender	I-Problem
erythematous	I-Problem
and	I-Problem
hemorrhagic	I-Problem
lesions	I-Problem
of	I-Problem
the	I-Problem
finger	I-Problem
tips	I-Problem
.	O

seven	O
patients	I-Background
with	I-Background
hematologic	I-Problem
malignancies	I-Problem
who	O
were	O
treated	O
with	O
miconazole	I-Treatment
for	O
either	O
suspected	O
or	O
proven	O
fungal	I-Problem
infections	I-Problem
developed	O
eight	I-Problem
episodes	I-Problem
of	I-Problem
major	I-Problem
adverse	I-Problem
cardiorespiratory	I-Problem
and	I-Problem
anaphylactic	I-Problem
reactions	I-Problem
.	O

we	O
report	O
the	O
first	O
case	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
rituximab	I-Treatment
-	O
related	O
autoimmune	I-Problem
hemolytic	I-Problem
anemia	I-Problem
.	O

anaphylactoid	I-Problem
reactions	I-Problem
with	O
intraperitoneal	I-Treatment
cisplatin	I-Test
.	O

tremor	I-Problem
:	O
a	O
newly	O
described	O
adverse	O
event	O
with	O
long	I-Other
-	I-Other
term	I-Other
itraconazole	I-Treatment
therapy	I-Treatment
.	O

treatment	O
-	O
related	O
myelodysplastic	I-Problem
syndrome	I-Problem
after	O
temozolomide	I-Treatment
for	O
recurrent	I-Problem
high	I-Problem
-	I-Problem
grade	I-Problem
glioma	I-Problem
.	O

it	O
occasionally	O
accompanies	O
the	O
heparin	I-Treatment
-	O
associated	O
thrombocytopenia	I-Problem
and	I-Problem
thrombosis	I-Problem
syndrome	I-Problem
.	O

we	O
report	O
an	I-Background
unusual	I-Background
case	I-Background
of	O
massive	I-Treatment
fluoxetine	I-Treatment
ingestion	I-Treatment
resulting	O
in	O
neurological	I-Problem
and	I-Problem
cardiovascular	I-Problem
toxicity	I-Problem
resulting	I-Problem
in	I-Problem
death	I-Problem
.	O

although	O
dyspnea	O
associated	O
with	O
verapamil	O
administration	O
has	O
been	O
reported	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	I-Background
elderly	I-Background
asymptomatic	I-Problem
asthmatic	I-Problem
patient	I-Background
with	I-Background
hypertension	I-Problem
who	O
developed	O
an	I-Problem
acute	I-Problem
asthma	I-Problem
attack	I-Problem
following	O
sustained	I-Treatment
-	I-Treatment
release	I-Treatment
verapamil	I-Treatment
administration	I-Treatment
.	O

the	I-Problem
bleeding	I-Problem
resolved	O
on	O
discontinuation	I-Treatment
of	I-Treatment
apv	I-Treatment
.	O

we	O
describe	O
a	O
case	O
of	O
infection	I-Problem
with	I-Problem
mycobacterium	I-Problem
abscessus	I-Problem
in	O
a	I-Background
67	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
receiving	O
infliximab	I-Treatment
as	I-Treatment
a	I-Treatment
component	I-Treatment
of	I-Treatment
her	I-Treatment
therapy	I-Treatment
for	O
ra	I-Problem
.	O

renal	I-Problem
toxicities	I-Problem
have	O
been	O
reported	O
in	O
less	O
than	O
one	O
percent	O
of	I-Background
the	I-Background
patients	I-Background
receiving	O
ciprofloxacin	I-Treatment
therapy	I-Treatment
.	I-Treatment

taxane	I-Treatment
-	O
induced	O
glaucoma	I-Problem
.	O

ciprofloxacin	I-Treatment
-	O
induced	O
toxic	I-Problem
epidermal	I-Problem
necrolysis	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
.	I-Background

hypotension	I-Problem
due	O
to	O
interaction	I-Treatment
between	I-Treatment
lisinopril	I-Treatment
and	I-Treatment
tizanidine	I-Treatment
.	O

development	O
of	O
an	O
extensive	I-Problem
skin	I-Problem
rash	I-Problem
following	O
a	O
single	O
dose	O
of	O
mtx	I-Treatment
may	O
be	O
an	O
early	O
warning	O
sign	O
for	O
life	O
-	O
threatening	O
bone	O
marrow	O
aplasia	O
.	O

anaphylactoid	I-Problem
reaction	I-Problem
to	O
50	I-Treatment
%	I-Treatment
solution	I-Treatment
of	I-Treatment
dextrose	I-Treatment
.	O

hypokalemia	I-Problem
after	O
normal	I-Treatment
doses	I-Treatment
of	I-Treatment
neubulized	I-Treatment
albuterol	I-Treatment
(	I-Treatment
salbutamol	I-Treatment
)	I-Treatment
.	O

although	O
praziquantel	I-Treatment
administration	O
may	O
have	O
been	O
effective	O
in	O
killing	O
the	O
parasite	I-Problem
in	I-Background
both	O
patients	I-Background
,	O
we	O
are	O
concerned	O
about	O
the	O
production	O
of	O
marked	I-Problem
inflammation	I-Problem
as	O
a	O
result	O
of	O
treatment	O
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	O
developed	O
granulocytopenia	I-Problem
and	I-Problem
fever	I-Problem
after	O
taking	I-Treatment
dipyrone	I-Treatment
and	O
discuss	O
the	O
available	O
literature	O
.	O

spectral	O
-	I-Test
domain	I-Test
optical	I-Test
coherence	I-Test
tomography	I-Test
and	O
adaptive	O
optics	I-Test
may	O
detect	O
hydroxychloroquine	I-Treatment
retinal	O
toxicity	O
before	O
symptomatic	I-Problem
vision	I-Problem
loss	I-Problem
.	O

a	I-Background
64	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
presented	O
with	O
proteinuria	I-Problem
during	O
postoperative	I-Treatment
interferon	I-Treatment
(	I-Treatment
ifn	I-Treatment
)	I-Treatment
-	I-Treatment
beta	I-Treatment
therapy	I-Treatment
against	O
malignant	I-Problem
melanoma	I-Problem
.	O

ethambutol	I-Treatment
toxicity	O
manifesting	O
as	O
acute	I-Problem
onset	I-Problem
psychosis	I-Problem
.	O

cholesterol	I-Problem
crystal	I-Problem
embolization	I-Problem
-	I-Problem
associated	I-Problem
renal	I-Problem
failure	I-Problem
after	O
therapy	I-Treatment
with	I-Treatment
recombinant	I-Treatment
tissue	I-Treatment
-	I-Treatment
type	I-Treatment
plasminogen	I-Treatment
activator	I-Treatment
.	O

methods	O
:	O
a	I-Background
76	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
primary	I-Background
open	I-Problem
-	I-Problem
angle	I-Problem
glaucoma	I-Problem
and	I-Background
no	I-Background
history	I-Background
of	I-Background
ocular	I-Background
surgery	I-Background
developed	O
a	O
choroidal	I-Problem
detachment	I-Problem
12	I-Other
hours	I-Other
after	I-Treatment
initiation	I-Treatment
of	I-Treatment
therapy	I-Treatment
with	I-Treatment
dorzolamide	I-Treatment
eye	I-Treatment
drops	I-Treatment
.	O

life	O
-	O
threatening	O
hyperkalemia	I-Problem
induced	O
by	O
arginine	I-Treatment
.	O

we	O
report	O
on	O
three	O
patients	I-Background
who	O
developed	O
acute	I-Problem
liver	I-Problem
damage	I-Problem
during	O
therapy	O
with	O
itraconazole	I-Treatment
,	O
and	O
in	O
whom	O
liver	O
biopsy	I-Test
specimens	I-Test
were	O
obtained	O
.	O

methods	O
:	O
a	I-Background
68	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
intense	I-Problem
conjunctival	I-Problem
hyperemia	I-Problem
and	I-Problem
cystoid	I-Problem
macula	I-Problem
edema	I-Problem
after	O
switching	O
from	O
latanoprost	O
to	O
bimatoprost	I-Treatment
9	O
months	O
after	O
cataract	I-Problem
surgery	I-Problem
in	O
an	O
eye	O
at	O
low	O
-	O
risk	O
for	O
this	O
cystoid	O
macular	O
edema	O
.	O

tacrolimus	I-Treatment
(	I-Treatment
fk506	I-Treatment
)	I-Treatment
,	I-Treatment
an	I-Treatment
immunosuppressant	I-Treatment
,	O
has	O
been	O
associated	O
with	O
mutism	I-Problem
in	O
adults	I-Background
after	I-Background
liver	I-Problem
transplant	I-Problem
.	I-Problem

gemcitabine	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
is	O
usually	O
a	O
dramatic	O
condition	O
.	O

however	O
,	O
the	O
amount	O
of	O
prednisone	I-Treatment
required	O
to	I-Treatment
maintain	I-Treatment
normotension	I-Treatment
resulted	O
in	O
cushingoid	I-Problem
features	I-Problem
and	O
has	O
been	O
discontinued	O
.	O

we	O
present	O
the	O
case	O
of	O
a	I-Background
woman	I-Background
undergoing	O
treatment	O
with	O
acenocoumarol	I-Treatment
for	O
deep	I-Problem
vein	I-Problem
thrombosis	I-Problem
,	O
who	O
maintained	O
an	O
international	O
normalized	O
ratio	O
(	O
inr	O
)	O
of	O
between	O
2	O
.	O
5	O
and	O
4	O
for	O
2	O
months	O
.	O

development	I-Problem
of	I-Problem
tics	I-Problem
in	O
a	I-Background
thirteen	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
following	O
atomoxetine	I-Treatment
use	O
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
chronic	I-Problem
,	I-Problem
nonproductive	I-Problem
cough	I-Problem
secondary	I-Problem
to	I-Problem
the	I-Problem
angiotensin	I-Problem
-	I-Problem
converting	I-Problem
enzyme	I-Problem
(	I-Problem
ace	I-Problem
)	I-Problem
inhibitor	I-Problem
quinapril	I-Problem
,	O
with	O
complete	O
resolution	O
after	O
switching	I-Treatment
to	I-Treatment
another	I-Treatment
ace	I-Treatment
inhibitor	I-Treatment
,	I-Treatment
fosinopril	I-Treatment
.	O

cholelithiasis	I-Problem
and	I-Problem
thrombosis	I-Problem
of	I-Problem
the	I-Problem
central	I-Problem
retinal	I-Problem
vein	I-Problem
in	O
a	I-Background
renal	I-Problem
transplant	I-Problem
recipient	I-Background
treated	O
with	O
cyclosporin	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
hepatolithiasis	I-Problem
(	I-Problem
intrahepatic	I-Problem
stone	I-Problem
)	I-Problem
complicated	I-Problem
by	I-Problem
gram	I-Problem
-	I-Problem
negative	I-Problem
sepsis	I-Problem
in	O
a	I-Background
37	I-Background
year	I-Background
old	I-Background
male	I-Background
with	I-Background
acromegaly	I-Problem
being	O
treated	O
with	O
octreotide	I-Treatment
.	O

proliferation	I-Problem
of	I-Problem
abnormal	I-Problem
bone	I-Problem
marrow	I-Problem
histiocytes	I-Problem
,	O
an	O
undesired	O
effect	O
of	O
granulocyte	I-Treatment
macrophage	I-Treatment
-	I-Treatment
colony	I-Treatment
-	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
therapy	O
in	O
a	I-Background
patient	I-Background
with	I-Background
hurler	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
undergoing	O
bone	O
marrow	O
transplantation	O
.	O

described	O
here	O
are	O
2	O
patients	I-Background
who	O
developed	O
thrombotic	I-Problem
microangiopathy	I-Problem
of	I-Problem
the	I-Problem
kidneys	I-Problem
after	O
receiving	O
high	I-Treatment
cumulative	I-Treatment
doses	I-Treatment
of	O
the	O
new	O
anticancer	O
drug	O
gemcitabine	I-Treatment
.	O

conclusions	O
:	O
an	O
objective	I-Test
causality	I-Test
assessment	I-Test
revealed	O
that	O
fluphenazine	I-Treatment
was	O
the	O
probable	O
cause	O
of	O
nms	I-Problem
in	O
this	O
patient	I-Background
.	O

like	O
other	O
atypical	O
neuroleptics	O
olanzapine	I-Treatment
is	O
considered	O
to	O
show	O
a	O
reduced	I-Problem
prevalence	I-Problem
of	I-Problem
extrapyramidal	I-Problem
side	I-Problem
effects	I-Problem
when	O
compared	O
to	O
classical	O
neuroleptic	I-Treatment
drugs	I-Treatment
.	I-Treatment

based	O
on	O
our	O
experience	O
and	O
on	O
previously	O
published	O
data	O
,	O
serum	O
ammonia	I-Test
levels	I-Test
appear	O
to	O
be	O
indicated	O
in	O
all	I-Background
ed	I-Problem
patients	I-Background
on	O
valproic	I-Treatment
acid	I-Treatment
therapy	I-Treatment
who	O
present	O
with	O
altered	I-Problem
mental	I-Problem
status	I-Problem
.	O

rapamycin	I-Treatment
/	I-Treatment
sirolimus	I-Treatment
(	I-Treatment
sr	I-Treatment
)	I-Treatment
,	I-Treatment
trade	I-Treatment
named	I-Treatment
rapammune	I-Treatment
(	I-Treatment
wyeth	I-Treatment
-	I-Treatment
ayerst	I-Treatment
,	I-Treatment
sydney	I-Treatment
,	I-Treatment
australia	I-Treatment
)	I-Treatment
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	I-Problem
,	I-Problem
hypertension	I-Problem
,	I-Problem
hyperlipidemia	I-Problem
,	I-Problem
and	I-Problem
infection	I-Problem
.	O

enoxaparin	I-Treatment
-	O
induced	O
generalized	I-Problem
exanthem	I-Problem
.	O

our	O
cases	O
constitute	O
the	O
most	O
severe	O
cases	O
of	O
benzarone	I-Treatment
hepatotoxicity	I-Problem
reported	O
so	O
far	O
,	O
and	O
comprise	O
the	O
first	O
cases	O
of	O
(	I-Problem
sub	I-Problem
)	I-Problem
fulminant	I-Problem
hepatitis	I-Problem
and	I-Problem
cirrhosis	I-Problem
related	O
to	O
benzarone	I-Treatment
.	O

within	I-Treatment
3	I-Other
days	I-Other
after	I-Treatment
starting	I-Treatment
bismuth	I-Treatment
subsalicylate	I-Treatment
therapy	I-Treatment
,	O
the	I-Background
patient	I-Test
'	I-Test
s	I-Test
inr	I-Test
increased	I-Problem
from	I-Problem
2	I-Problem
.	I-Problem
56	I-Problem
to	I-Problem
3	I-Problem
.	I-Problem
54	I-Problem
and	I-Problem
minor	I-Problem
bleeding	I-Problem
was	I-Problem
noted	I-Problem
from	I-Problem
the	I-Problem
patient	I-Problem
'	I-Problem
s	I-Problem
tracheostomy	I-Problem
site	I-Problem
.	O

after	I-Treatment
three	I-Other
weeks	I-Other
of	I-Treatment
carbamazepine	I-Treatment
therapy	I-Treatment
,	O
the	O
patient	I-Background
arrived	O
at	O
the	O
emergency	O
department	O
(	O
ed	O
)	O
with	O
severe	I-Problem
agitation	I-Problem
and	I-Problem
aggressive	I-Problem
behavior	I-Problem
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
ciprofloxacin	I-Treatment
-	O
induced	O
psychosis	I-Problem
and	O
to	O
discuss	O
occurrence	O
rates	O
,	O
risk	O
factors	O
,	O
possible	O
etiologies	O
,	O
preventive	O
measures	O
,	O
and	O
treatment	O
courses	O
for	O
this	O
adverse	O
reaction	O
.	O

a	I-Background
77	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
ankle	I-Problem
,	I-Problem
hand	I-Problem
,	I-Problem
and	I-Problem
facial	I-Problem
swelling	I-Problem
2	I-Other
weeks	I-Other
after	I-Treatment
starting	I-Treatment
rosiglitazone	I-Treatment
.	O

although	O
rare	O
,	O
massive	I-Problem
pulmonary	I-Problem
embolus	I-Problem
must	O
be	O
considered	O
to	O
be	O
a	O
major	O
risk	O
of	O
thrombolytic	I-Treatment
therapy	O
for	O
deep	O
venous	O
thrombosis	O
.	O

we	O
report	O
a	O
case	O
of	O
hypoglycaemia	I-Problem
after	O
mefloquine	I-Treatment
therapy	I-Treatment
(	I-Treatment
1	I-Treatment
,	I-Treatment
500	I-Treatment
mg	I-Treatment
over	I-Treatment
two	I-Treatment
days	I-Treatment
)	I-Treatment
for	O
severe	I-Problem
gastrointestinal	I-Problem
cryptosporidiasis	I-Problem
in	O
a	I-Background
cachectic	I-Problem
aids	I-Problem
patient	I-Background
with	I-Background
protracted	I-Problem
diarrhoea	I-Problem
.	O

objective	O
:	O
to	O
describe	O
onset	O
of	O
syndrome	I-Problem
of	I-Problem
inappropriate	I-Problem
antidiuretic	I-Problem
hormone	I-Problem
(	I-Problem
siadh	I-Problem
)	I-Problem
associated	O
with	O
vinorelbine	I-Treatment
therapy	O
for	O
advanced	I-Problem
breast	I-Problem
cancer	I-Problem
.	O

the	O
thiazolidinediones	I-Treatment
(	O
rosiglitazone	O
and	O
pioglitazone	O
)	O
,	O
a	O
new	O
class	O
of	O
oral	O
antidiabetic	O
agents	O
,	O
are	O
"	O
insulin	O
sensitizers	O
"	O
and	O
exert	O
direct	O
effects	O
on	O
the	O
mechanisms	O
of	O
insulin	I-Problem
resistance	I-Problem
.	O

the	O
exacerbation	I-Problem
of	I-Problem
psoriasis	I-Problem
was	O
accompanied	O
by	O
a	I-Problem
massive	I-Problem
induction	I-Problem
of	I-Problem
lesional	I-Problem
type	I-Problem
i	I-Problem
interferon	I-Problem
activity	I-Problem
,	O
detected	O
by	O
mxa	O
expression	I-Test
after	O
imiquimod	I-Treatment
therapy	O
.	O

two	O
patients	I-Background
treated	O
with	O
alprazolam	I-Treatment
had	O
histories	O
suggestive	O
of	O
a	I-Problem
bipolar	I-Problem
disorder	I-Problem
and	O
developed	O
lithium	I-Problem
-	I-Problem
responsive	I-Problem
manic	I-Problem
episodes	I-Problem
.	O

cerebrovascular	I-Problem
complications	I-Problem
of	O
l	I-Treatment
-	I-Treatment
asparaginase	I-Treatment
therapy	O
in	O
children	I-Background
with	I-Background
leukemia	I-Problem
:	O
aphasia	I-Problem
and	I-Problem
other	I-Problem
neuropsychological	I-Problem
deficits	I-Problem
.	O

we	O
report	O
two	O
patients	I-Background
who	O
developed	O
intense	I-Problem
livedo	I-Problem
reticularis	I-Problem
clearly	O
related	O
to	O
the	O
administration	O
of	O
interferon	I-Treatment
alpha	I-Treatment
2b	I-Treatment
as	I-Treatment
an	I-Treatment
adjuvant	I-Treatment
therapy	I-Treatment
for	I-Treatment
melanoma	I-Problem
.	O

a	O
case	O
of	O
siadh	I-Problem
associated	O
with	O
desipramine	I-Treatment
treatment	I-Treatment
in	O
an	I-Background
elderly	I-Background
depressed	I-Problem
woman	I-Background
is	O
described	O
.	O

niflumic	I-Treatment
acid	I-Treatment
-	O
induced	O
skeletal	I-Problem
fluorosis	I-Problem
:	O
iatrogenic	O
disease	O
or	O
therapeutic	O
perspective	O
for	O
osteoporosis	O
?	O

both	I-Background
patients	I-Background
developed	O
severe	I-Problem
complications	I-Problem
when	O
treated	O
with	O
aminoglutethimide	I-Treatment
as	O
a	O
cancer	I-Problem
hormonal	O
therapy	O
.	O

an	I-Background
11	I-Background
-	I-Background
day	I-Background
-	I-Background
old	I-Background
infant	I-Background
became	O
lethargic	I-Problem
and	I-Problem
apneic	I-Problem
after	O
a	I-Treatment
single	I-Treatment
drop	I-Treatment
of	I-Treatment
brimonidine	I-Treatment
.	O

investigations	O
suggested	O
that	O
the	O
dextrose	I-Treatment
,	O
rather	O
than	O
any	O
additives	O
,	O
was	O
responsible	O
for	O
the	I-Problem
reaction	I-Problem
.	O

correction	O
of	O
serum	O
electrolyte	O
imbalance	O
prevents	O
cardiac	I-Problem
arrhythmia	I-Problem
during	O
amphotericin	I-Treatment
b	I-Treatment
administration	I-Treatment
.	O

acute	I-Problem
myopathy	I-Problem
with	I-Problem
selective	I-Problem
degeneration	I-Problem
of	I-Problem
myosin	I-Problem
filaments	I-Problem
following	O
status	O
asthmaticus	I-Problem
treated	O
with	O
methylprednisolone	I-Treatment
and	O
vecuronium	I-Treatment
.	O

presented	O
is	O
a	O
case	O
of	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
induced	O
by	O
acetazolamide	I-Treatment
therapy	I-Treatment
for	I-Treatment
glaucoma	I-Problem
.	O

cyanamide	I-Treatment
-	O
induced	O
liver	I-Problem
dysfunction	I-Problem
after	O
abstinence	I-Background
in	I-Background
alcoholics	I-Background
:	O
a	O
long	O
-	O
term	O
follow	I-Test
-	O
up	O
study	I-Test
on	O
four	O
cases	O
.	O

fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	I-Treatment
alone	O
than	O
when	O
receiving	O
desipramine	I-Treatment
with	O
cinacalcet	I-Treatment
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	I-Problem
and	I-Problem
headache	I-Problem
)	O
have	O
been	O
reported	O
for	O
patients	I-Background
treated	O
with	O
either	O
desipramine	I-Treatment
or	I-Treatment
cinacalcet	I-Treatment
.	O

three	O
patients	I-Background
developed	O
proteinuria	I-Problem
following	O
gold	I-Treatment
therapy	O
for	O
rheumatoid	I-Problem
arthritis	I-Problem
.	O

the	O
authors	O
report	O
a	I-Background
case	I-Background
of	I-Background
a	I-Background
patient	I-Background
who	O
received	O
alteplase	I-Treatment
for	O
acute	I-Problem
myocardial	I-Problem
infarction	I-Problem
and	O
developed	O
spontaneous	I-Problem
subfascial	I-Problem
hematoma	I-Problem
without	I-Problem
any	I-Problem
evidence	I-Problem
of	I-Problem
direct	I-Problem
trauma	I-Problem
.	O

ticlopidine	I-Treatment
-	O
induced	O
marrow	I-Problem
aplasia	I-Problem
treated	O
with	O
cyclosporine	O
.	O

dural	I-Problem
sinus	I-Problem
thrombosis	I-Problem
developed	O
in	O
two	O
children	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
during	O
induction	I-Treatment
treatment	I-Treatment
with	I-Treatment
vincristine	I-Treatment
sulfate	I-Treatment
,	I-Treatment
prednisone	I-Treatment
,	I-Treatment
and	I-Treatment
asparaginase	I-Treatment
.	O

zolpidem	I-Treatment
(	I-Treatment
ambien	I-Treatment
)	I-Treatment
,	O
a	O
relatively	O
new	O
nonbenzodiazepine	O
sedative	O
-	O
hypnotic	O
,	O
was	O
involved	O
in	O
the	O
death	I-Problem
of	O
a	I-Background
39	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
obese	I-Problem
male	I-Background
who	O
was	O
being	O
treated	O
for	O
depression	I-Problem
and	I-Problem
insomnia	I-Problem
.	O

a	O
medline	I-Test
search	I-Test
identified	O
all	O
the	O
reported	O
cases	O
of	O
hypersensitivity	I-Problem
reactions	I-Problem
to	O
cyclosporine	I-Treatment
.	O

methods	O
:	O
a	I-Background
79	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
being	O
treated	O
with	O
imiquimod	I-Treatment
5	I-Other
days	I-Other
per	I-Other
week	I-Other
for	O
a	O
nodular	I-Problem
basal	I-Problem
cell	I-Problem
developed	O
a	O
verrucous	I-Problem
plaque	I-Problem
over	O
the	O
treatment	O
area	O
after	I-Treatment
7	I-Other
weeks	I-Other
of	O
therapy	O
.	O

oxcarbazepine	I-Treatment
,	O
a	O
metabolite	O
of	O
carbamazepine	O
,	O
is	O
used	O
as	O
an	O
antiepileptic	I-Problem
,	I-Problem
analgesic	I-Problem
for	O
neuropathic	I-Problem
pain	I-Problem
and	O
in	O
the	O
treatment	O
of	O
affective	I-Problem
disorders	I-Problem
.	O

patient	O
and	O
method	O
:	O
a	I-Background
34	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
,	I-Background
genotype	I-Problem
3	I-Problem
,	O
receiving	O
pegylated	I-Treatment
interferon	I-Treatment
alpha	I-Treatment
-	I-Treatment
2a	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
for	I-Treatment
6	I-Other
months	I-Other
,	O
developed	O
progressive	I-Problem
malaise	I-Problem
and	I-Problem
anemia	I-Problem
6	I-Other
months	I-Other
after	O
the	O
end	O
of	O
treatment	O
.	O

we	O
report	O
on	O
three	O
cases	O
wherein	O
treatment	I-Treatment
of	I-Treatment
dexmedetomidine	I-Treatment
-	O
induced	O
bradycardia	I-Problem
with	I-Problem
i	I-Problem
.	I-Problem
v	I-Problem
.	O

esmolol	I-Treatment
,	I-Treatment
an	I-Treatment
ultrashort	I-Treatment
-	I-Treatment
acting	I-Treatment
beta	I-Treatment
1	I-Treatment
-	I-Treatment
selective	I-Treatment
antagonist	I-Treatment
,	O
controlled	O
her	I-Background
multiple	I-Problem
dysrhythmias	I-Problem
and	I-Problem
symptoms	I-Problem
of	I-Problem
sympathetic	I-Problem
nervous	I-Problem
system	I-Problem
hyperstimulation	I-Problem
.	O

(	O
case	O
1	O
)	O
a	I-Background
29	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	O
overdose	I-Treatment
of	O
metaxalone	I-Treatment
presented	O
to	O
the	O
emergency	O
department	O
with	O
altered	I-Problem
mental	I-Problem
status	I-Problem
,	I-Problem
seizure	I-Problem
-	I-Problem
like	I-Problem
activity	I-Problem
,	I-Problem
hyperthermia	I-Problem
,	I-Problem
rigidity	I-Problem
in	I-Problem
the	I-Problem
lower	I-Problem
extremities	I-Problem
,	I-Problem
myoclonus	I-Problem
,	I-Problem
and	I-Problem
hyperreflexia	I-Problem
.	O

warfarin	I-Treatment
and	O
boceprevir	I-Treatment
interaction	O
causing	O
subtherapeutic	I-Problem
international	I-Problem
normalized	I-Problem
ratio	I-Problem
:	O
a	O
case	O
report	O
.	O

a	O
brief	O
review	O
of	O
reported	O
cases	O
of	O
chloramphenicol	I-Treatment
hypersensitivity	I-Problem
in	O
the	O
english	O
-	O
language	O
literature	O
,	O
as	O
well	O
as	O
possible	O
alternative	O
explanations	O
in	O
this	O
case	O
,	O
are	O
provided	O
.	O

possible	O
recurrence	O
of	O
amiodarone	I-Treatment
pulmonary	I-Problem
toxicity	I-Problem
following	O
corticosteroid	I-Treatment
therapy	O
.	O

in	O
the	O
present	O
study	O
,	O
arsenic	I-Treatment
trioxide	I-Treatment
was	O
given	O
intravenously	O
for	O
42	I-Other
days	I-Other
to	O
a	O
56	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
patient	I-Background
suffering	O
from	O
chemotherapy	I-Problem
/	I-Problem
atra	I-Problem
-	I-Problem
resistant	I-Problem
apl	I-Problem
,	O
with	O
43	O
%	O
apl	O
blasts	O
in	O
the	O
bone	O
marrow	O
and	O
elevated	O
d	O
-	O
dimers	O
.	O

we	O
assume	O
that	O
rifn	I-Treatment
-	I-Treatment
gamma	I-Treatment
induced	O
the	I-Problem
de	I-Problem
novo	I-Problem
development	I-Problem
of	I-Problem
sle	I-Problem
in	O
our	I-Background
patient	I-Background
.	O

interstitial	I-Problem
pneumopathy	I-Problem
and	O
low	I-Treatment
-	I-Treatment
dosage	I-Treatment
amiodarone	I-Treatment
.	O

conclusions	O
:	O
these	O
results	O
suggest	O
that	O
clozapine	I-Treatment
may	O
cause	O
td	I-Problem
;	O
however	O
,	O
the	O
prevalence	O
is	O
low	O
and	O
the	O
severity	O
is	O
relatively	O
mild	O
,	O
with	O
no	O
or	O
mild	O
self	O
-	O
reported	O
discomfort	O
.	O

hepatotoxicity	I-Problem
resolved	O
once	O
erlotinib	I-Treatment
was	O
discontinued	O
and	O
serum	O
transaminases	I-Test
returned	O
to	O
baseline	O
normal	O
values	O
.	O

conclusions	O
:	O
sustained	I-Treatment
-	I-Treatment
release	I-Treatment
verapamil	I-Treatment
is	O
thought	O
to	O
be	O
the	O
cause	O
of	O
the	O
asthma	I-Problem
attack	I-Problem
in	O
this	O
patient	O
because	O
she	O
was	O
not	O
taking	O
any	O
other	O
preparations	O
;	O
the	O
symptoms	O
started	O
with	O
the	O
administration	O
of	O
sustained	O
-	O
release	O
verapamil	O
and	O
were	O
relieved	O
after	O
its	O
discontinuation	O
.	O

a	O
patient	O
developed	O
cholestatic	I-Problem
hepatitis	I-Problem
while	O
being	O
treated	O
with	O
nitrofurantoin	I-Treatment
.	O

severe	O
apnea	I-Problem
in	O
an	I-Background
infant	I-Background
exposed	O
to	O
lamotrigine	I-Treatment
in	O
breast	O
milk	O
.	O

pneumonitis	I-Problem
,	I-Problem
bilateral	I-Problem
pleural	I-Problem
effusions	I-Problem
,	I-Problem
echocardiographic	I-Problem
evidence	I-Test
of	I-Problem
cardiac	I-Problem
tamponade	I-Problem
,	I-Problem
and	I-Problem
positive	I-Problem
autoantibodies	I-Problem
developed	O
in	O
a	I-Background
43	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
,	O
who	O
was	O
receiving	O
long	I-Treatment
-	I-Treatment
term	I-Treatment
sulfasalazine	I-Treatment
therapy	O
for	O
chronic	I-Problem
ulcerative	I-Problem
colitis	I-Problem
.	O

bone	I-Problem
formation	I-Problem
induced	O
in	O
an	I-Background
infant	I-Background
by	O
systemic	I-Treatment
prostaglandin	I-Treatment
-	I-Treatment
e2	I-Treatment
administration	I-Treatment
.	O

angioedema	I-Problem
,	O
a	O
rare	O
side	O
effect	O
of	O
carbamazepine	I-Treatment
,	O
involves	I-Problem
vascular	I-Problem
leakage	I-Problem
in	I-Problem
dermis	I-Problem
and	I-Problem
subcutis	I-Problem
mediated	I-Problem
by	I-Problem
immunoglobulin	I-Problem
e	I-Test
and	I-Problem
/	I-Problem
or	I-Problem
bradykinins	I-Problem
.	O

a	O
diagnosis	O
of	O
trastuzumab	I-Treatment
-	O
induced	O
pneumonitis	I-Problem
was	O
made	O
.	O

several	I-Problem
such	I-Problem
hbv	I-Problem
reactivations	I-Problem
were	O
reported	O
after	O
combined	I-Treatment
rituximab	I-Treatment
and	I-Treatment
multiagent	I-Treatment
chemotherapy	I-Treatment
for	O
b	I-Problem
-	I-Problem
cell	I-Problem
lymphomas	I-Problem
.	O

thus	O
,	O
the	O
eosinophilia	I-Problem
myalgia	I-Problem
syndrome	I-Problem
can	O
be	O
associated	O
with	O
parenteral	I-Treatment
tryptophan	I-Treatment
administration	O
.	O

generalized	I-Problem
pustular	I-Problem
psoriasis	I-Problem
precipitated	O
by	O
trazodone	I-Treatment
in	O
the	O
treatment	O
of	O
depression	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
sweet	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
in	O
association	O
with	O
sargramostim	I-Treatment
treatment	I-Treatment
following	I-Treatment
chemotherapy	I-Treatment
for	O
acute	I-Problem
myelogenous	I-Problem
leukemia	I-Problem
.	O

this	O
regimen	O
could	O
prove	O
useful	O
for	O
other	O
patients	I-Background
who	O
develop	O
hypersensitivity	I-Problem
reactions	I-Problem
to	O
carboplatin	I-Treatment
and	O
allow	O
therapy	O
to	O
continue	O
.	O

we	O
present	O
a	I-Background
neonate	I-Background
with	I-Background
a	I-Background
seizure	I-Problem
disorder	I-Problem
who	O
acutely	O
developed	O
pupillary	I-Problem
mydriasis	I-Problem
secondary	O
to	O
lidocaine	I-Treatment
overdose	I-Treatment
.	O

based	O
on	O
the	O
naranjo	I-Test
algorithm	I-Test
,	O
the	O
adverse	O
reaction	O
observed	O
was	O
probably	O
related	O
to	O
the	O
hydroxyurea	I-Treatment
treatment	O
(	O
score	O
=	O
6	O
)	O
;	O
however	O
,	O
the	O
hydroxyurea	I-Treatment
chemotherapy	I-Treatment
could	O
not	O
be	O
discontinued	O
because	O
of	O
the	O
myeloproliferative	I-Problem
disorder	I-Problem
.	O

extrapyramidal	I-Problem
side	I-Problem
effects	I-Problem
induced	O
by	O
some	I-Treatment
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitors	I-Treatment
(	I-Treatment
ssris	I-Treatment
)	I-Treatment
,	I-Treatment
i	I-Treatment
.	I-Treatment
e	I-Treatment
.	I-Treatment
fluoxetine	I-Treatment
and	I-Treatment
sertraline	I-Treatment
,	O
have	O
been	O
previously	O
reported	O
in	O
patients	I-Background
with	I-Background
depression	I-Problem
and	I-Background
obsessive	I-Problem
-	I-Problem
compulsive	I-Problem
disorder	I-Problem
(	I-Problem
ocd	I-Problem
)	I-Problem
.	O

ten	I-Other
-	I-Other
17	I-Other
days	I-Other
after	I-Treatment
receiving	I-Treatment
chemotherapy	I-Treatment
,	O
five	O
patients	I-Background
(	I-Background
4	I-Background
males	I-Background
and	I-Background
1	I-Background
female	I-Background
)	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
developed	O
incapacitating	I-Problem
myalgias	I-Problem
in	I-Problem
neck	I-Problem
,	I-Problem
thighs	I-Problem
and	I-Problem
arms	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
a	O
potential	O
drug	O
-	O
drug	O
interaction	O
in	O
a	I-Background
woman	I-Background
treated	O
by	O
a	I-Treatment
first	I-Treatment
injection	I-Treatment
of	I-Treatment
high	I-Treatment
-	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
for	O
a	I-Problem
t	I-Problem
-	I-Problem
lymphoblastic	I-Problem
lymphoma	I-Problem
.	O

we	O
conclude	O
that	O
myocardial	I-Problem
infarction	I-Problem
may	O
develop	O
in	O
patients	I-Background
treated	O
with	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
glucocorticoids	I-Treatment
for	O
graves	I-Problem
'	I-Problem
ophthalmopathy	I-Problem
,	O
and	O
increased	I-Problem
blood	I-Problem
pressure	I-Problem
may	O
herald	O
this	O
complication	O
.	O

a	O
40	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
relapsing	I-Problem
-	I-Problem
remitting	I-Problem
multiple	I-Problem
sclerosis	I-Problem
(	I-Problem
ms	I-Problem
)	I-Problem
developed	O
primary	I-Problem
central	I-Problem
nervous	I-Problem
system	I-Problem
lymphoma	I-Problem
(	I-Problem
pcnsl	I-Problem
)	I-Problem
after	O
having	O
received	O
21	I-Treatment
doses	I-Treatment
of	I-Treatment
natalizumab	I-Treatment
monotherapy	I-Treatment
.	O

serotonin	I-Problem
syndrome	I-Problem
caused	O
by	O
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
-	I-Treatment
inhibitors	I-Treatment
-	I-Treatment
metoclopramide	I-Treatment
interaction	I-Treatment
.	O

this	O
is	O
the	O
first	I-Background
reported	I-Background
case	I-Background
of	O
suspected	O
dian	I-Problem
due	O
to	O
cefuroxime	I-Treatment
.	O

we	O
report	O
a	I-Background
cae	I-Background
of	O
paranoid	I-Problem
psychosis	I-Problem
following	O
use	O
of	O
a	O
decongestant	I-Treatment
containing	I-Treatment
ppa	I-Treatment
and	O
summarize	O
the	O
case	O
report	O
literature	O
of	O
psychiatric	O
adverse	O
effects	O
to	O
ppa	O
in	O
which	O
doses	O
were	O
known	O
and	O
stated	O
to	O
be	O
within	O
recommended	O
guidelines	O
.	O

liver	I-Problem
transplantation	I-Problem
for	I-Problem
fulminant	I-Problem
hepatitis	I-Problem
related	O
to	O
nevirapine	I-Treatment
therapy	I-Treatment
.	O

we	O
describe	O
a	I-Background
case	I-Background
of	O
prolonged	I-Treatment
terbinafine	I-Treatment
-	O
induced	O
cholestatic	I-Problem
liver	I-Problem
disease	I-Problem
.	O

we	O
describe	O
a	O
case	O
of	O
interstitial	I-Problem
hypoxaemiant	I-Problem
pneumonitis	I-Problem
probably	O
related	O
to	O
flecainide	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
the	I-Background
leopard	I-Problem
syndrome	I-Problem
,	O
a	O
rare	O
congenital	O
disorder	O
.	O

this	I-Background
case	I-Background
showed	O
sequential	O
manifestation	O
from	O
transient	O
thyrotoxicosis	O
to	O
the	O
appearance	O
of	O
tsh	O
-	O
receptor	O
autoantibodies	O
,	O
and	O
then	O
the	O
occurrence	O
of	O
graves	I-Problem
'	I-Problem
hyperthyroidism	I-Problem
during	O
ifn	I-Treatment
therapy	I-Treatment
.	O

halothane	I-Problem
hepatitis	I-Problem
and	O
prompt	O
resolution	O
with	O
methionine	I-Treatment
therapy	O
:	O
case	I-Background
report	O
.	O

this	O
report	O
describes	O
an	O
unexpected	O
drug	O
-	O
induced	O
hepatitis	I-Problem
in	O
a	I-Background
previously	I-Background
healthy	I-Background
young	I-Background
woman	I-Background
exposed	O
to	O
2	I-Treatment
doses	I-Treatment
of	I-Treatment
amodiaquine	I-Treatment
and	I-Treatment
artesunate	I-Treatment
.	O

it	O
was	O
restarted	O
6	O
weeks	O
later	O
,	O
and	O
10	I-Other
weeks	I-Other
after	I-Other
that	O
,	O
the	I-Background
patient	I-Background
presented	O
with	O
fulminant	I-Problem
hepatic	I-Problem
failure	I-Problem
,	O
which	O
resolved	O
rapidly	O
after	O
cessation	O
of	O
nicotinic	I-Treatment
acid	I-Treatment
therapy	O
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
the	I-Background
antiphospholipid	I-Problem
syndrome	I-Problem
who	O
had	O
skin	I-Problem
necrosis	I-Problem
develop	O
from	O
low	I-Treatment
-	I-Treatment
molecular	I-Treatment
weight	I-Treatment
heparin	I-Treatment
therapy	I-Treatment
at	I-Treatment
sites	I-Treatment
distant	I-Treatment
from	I-Treatment
injection	I-Treatment
sites	I-Treatment
.	O

while	O
cyp	O
form	O
induction	O
by	O
pyrethrins	I-Treatment
,	I-Treatment
phenobarbital	I-Treatment
and	I-Treatment
related	I-Treatment
compounds	I-Treatment
can	O
be	O
associated	O
with	O
liver	I-Problem
and	I-Problem
thyroid	I-Problem
gland	I-Problem
tumour	I-Problem
formation	I-Problem
in	I-Problem
rodents	I-Problem
,	O
epidemiological	O
data	I-Test
for	O
phenobarbital	O
suggests	O
that	O
such	O
effects	O
do	O
not	O
occur	O
in	O
humans	O
.	O

disulfiram	I-Treatment
encephalopathy	I-Problem
as	O
a	O
cause	O
of	O
the	O
catatonia	I-Problem
syndrome	I-Problem
.	O

little	O
has	O
been	O
studied	O
of	O
the	O
adverse	I-Problem
effects	I-Problem
of	I-Problem
the	I-Problem
exposure	I-Problem
of	I-Problem
the	I-Problem
liver	I-Problem
to	O
the	O
interaction	O
of	O
ethanol	I-Treatment
with	I-Treatment
its	I-Treatment
congeners	I-Treatment
and	I-Treatment
acetaldehyde	I-Treatment
,	O
coexisting	O
in	O
the	O
contents	O
of	O
alcoholic	O
beverages	O
.	O

fatal	O
serotonin	I-Problem
syndrome	I-Problem
precipitated	O
by	O
oxcarbazepine	I-Treatment
in	O
a	I-Background
patient	I-Background
using	O
an	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
.	O

this	O
eruption	I-Problem
emerged	O
after	I-Treatment
1	I-Other
month	I-Other
of	I-Treatment
therapy	I-Treatment
with	I-Treatment
salsalate	I-Treatment
,	O
persisted	O
for	O
as	O
long	O
as	O
salsalate	O
was	O
administered	O
,	O
and	O
cleared	O
within	O
3	O
weeks	O
of	O
discontinuing	O
the	O
medication	O
.	O

a	O
case	O
report	O
is	O
presented	O
concerning	O
the	O
administration	O
of	O
ketanserin	O
in	O
the	O
treatment	O
of	O
pulmonary	I-Problem
vasoconstriction	I-Problem
and	I-Problem
right	I-Problem
ventricular	I-Problem
failure	I-Problem
following	O
the	O
infusion	I-Treatment
of	I-Treatment
protamine	I-Treatment
in	O
a	I-Background
patient	I-Background
undergoing	I-Treatment
coronary	I-Treatment
artery	I-Treatment
bypass	I-Treatment
surgery	I-Treatment
and	I-Treatment
mitral	I-Treatment
valve	I-Treatment
replacement	I-Treatment
.	O

when	O
cyanamide	I-Treatment
-	I-Background
treated	I-Background
alcoholics	I-Problem
relapse	O
into	O
drinking	O
,	O
more	O
severe	O
inflammation	I-Problem
develops	O
in	O
the	O
liver	O
.	O

acute	I-Problem
renal	I-Problem
failure	I-Problem
should	O
be	O
recognized	O
as	O
a	O
potential	O
complication	O
of	O
suramin	I-Treatment
treatment	I-Treatment
.	O

after	O
induction	I-Treatment
of	I-Treatment
general	I-Treatment
anesthesia	I-Treatment
and	I-Treatment
administration	I-Treatment
of	I-Treatment
a	I-Treatment
standard	I-Treatment
dose	I-Treatment
of	I-Treatment
intravenous	I-Treatment
esmolol	I-Treatment
hydrochloride	I-Treatment
,	O
her	I-Background
cardiac	I-Test
rhythm	I-Test
progressed	O
to	O
asystole	I-Problem
.	O

exacerbation	I-Problem
of	I-Problem
schizophrenia	I-Problem
associated	O
with	O
amantadine	I-Treatment
.	O

priapism	I-Problem
as	O
a	O
complication	O
of	O
heparin	I-Treatment
therapy	O
.	O

torsades	I-Problem
de	I-Problem
pointes	I-Problem
occurring	O
in	O
association	O
with	O
terfenadine	I-Treatment
use	O
.	O

protamine	I-Problem
allergy	I-Problem
as	O
a	O
complication	O
of	O
insulin	I-Treatment
hypersensitivity	I-Problem
:	O
a	O
case	O
report	O
.	O

we	O
report	O
a	O
case	O
of	O
recurrent	I-Problem
torsades	I-Problem
de	I-Problem
pointes	I-Problem
following	O
treatment	O
with	O
pentavalent	I-Treatment
antimonial	I-Treatment
drugs	I-Treatment
and	I-Treatment
amiodarone	I-Treatment
.	O

this	O
case	O
presentation	O
is	O
of	O
a	I-Background
patient	I-Background
who	O
had	O
the	O
clinical	I-Problem
appearance	I-Problem
of	I-Problem
epiglottitis	I-Problem
,	O
but	O
actually	I-Problem
had	I-Problem
an	I-Problem
oro	I-Problem
-	I-Problem
pharyngeal	I-Problem
dystonic	I-Problem
reaction	I-Problem
to	O
prochlorperazine	I-Treatment
.	O

localized	I-Problem
dyskeratotic	I-Problem
plaque	I-Problem
with	I-Problem
milia	I-Problem
associated	O
with	O
sorafenib	I-Treatment
.	O

the	O
authors	O
describe	O
a	O
case	O
of	O
the	O
catatonia	I-Problem
syndrome	I-Problem
associated	O
with	O
disulfiram	I-Treatment
therapy	I-Treatment
.	O

most	O
of	O
the	O
clinical	O
data	O
on	O
the	O
safety	O
profile	O
of	O
desmopressin	I-Treatment
(	I-Treatment
ddavp	I-Treatment
)	I-Treatment
,	O
which	O
is	O
an	O
effective	O
treatment	O
for	O
both	I-Background
polyuric	I-Problem
conditions	I-Problem
and	I-Background
bleeding	I-Problem
disorders	I-Problem
,	O
originate	O
from	O
studies	O
on	O
the	O
tailoring	O
of	O
drug	O
treatment	O
,	O
whereas	O
few	O
reports	O
exist	O
describing	O
severe	O
side	O
effects	O
secondary	O
to	O
drug	O
-	O
drug	O
interaction	O
.	O

propafenone	I-Treatment
'	O
s	O
distribution	O
,	O
clearance	O
,	O
and	O
structural	O
similarity	O
to	O
propranolol	I-Treatment
contribute	O
to	O
its	O
central	I-Problem
nervous	I-Problem
system	I-Problem
effects	I-Problem
.	O

risk	O
of	O
severe	O
serotonin	I-Problem
toxicity	I-Problem
following	O
co	I-Treatment
-	I-Treatment
administration	I-Treatment
of	I-Treatment
methylene	I-Treatment
blue	I-Treatment
and	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitors	I-Treatment
:	O
an	O
update	O
on	O
a	O
case	O
report	O
of	O
post	I-Problem
-	I-Problem
operative	I-Problem
delirium	I-Problem
.	O

cyclophosphamide	I-Treatment
-	O
induced	O
cardiotoxicity	I-Problem
occurred	O
,	O
even	O
though	O
the	I-Background
patient	I-Background
had	I-Background
both	I-Background
shown	I-Background
normal	I-Background
cardiac	I-Background
function	I-Background
before	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
chemotherapy	I-Treatment
and	I-Treatment
had	I-Treatment
received	I-Treatment
a	I-Treatment
lower	I-Treatment
dose	I-Treatment
of	I-Treatment
cyclophosphamide	I-Treatment
.	O

a	I-Background
64	I-Background
year	I-Background
old	I-Background
woman	I-Background
with	I-Background
previous	I-Background
history	I-Background
of	I-Background
coronary	I-Problem
stenting	I-Problem
five	I-Other
days	I-Other
before	I-Treatment
was	O
admitted	O
in	O
our	O
institution	O
for	O
intracranial	I-Problem
bleeding	I-Problem
while	O
receiving	O
aspirin	I-Treatment
and	I-Treatment
clopidogrel	I-Treatment
.	O

methods	O
:	O
a	O
case	O
is	O
presented	O
of	O
a	I-Background
45	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
on	O
prolonged	I-Other
gemcitabine	I-Treatment
treatment	I-Treatment
for	O
ovarian	I-Problem
cancer	I-Problem
who	O
developed	O
hus	I-Problem
and	O
recovered	O
after	O
drug	O
discontinuation	O
.	O

a	O
more	O
serious	O
development	I-Problem
of	I-Problem
adrenal	I-Problem
insufficiency	I-Problem
may	O
occur	O
upon	O
the	O
improper	O
replacement	O
of	O
systemic	I-Treatment
steroids	I-Treatment
.	O

we	O
describe	O
a	I-Background
case	I-Background
of	O
pneumonitis	I-Problem
following	O
local	I-Treatment
administration	I-Treatment
of	I-Treatment
methotrexate	I-Treatment
for	O
nonsurgical	O
termination	O
of	O
an	O
ectopic	I-Problem
pregnancy	I-Problem
.	O

carbamazepine	I-Treatment
-	O
induced	O
hyperammonemia	I-Problem
.	O

case	O
3	O
:	O
a	I-Background
29	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
alcoholic	I-Problem
complained	O
of	O
general	I-Problem
fatigue	I-Problem
and	I-Problem
a	I-Problem
slight	I-Problem
fever	I-Problem
after	I-Treatment
1	I-Other
.	I-Other
5	I-Other
years	I-Other
of	I-Treatment
abstinence	I-Treatment
with	I-Treatment
cyanamide	I-Treatment
treatment	O
.	O

caution	O
is	O
,	O
therefore	O
,	O
needed	O
to	O
prevent	O
undesired	O
accumulation	O
of	O
tca	I-Treatment
that	O
may	O
lead	O
to	O
protracted	I-Problem
cushing	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
.	O

unusual	I-Problem
pigmentary	I-Problem
changes	I-Problem
associated	O
with	O
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
therapy	O
.	O

syndrome	I-Problem
of	I-Problem
inappropriate	I-Problem
antidiuretic	I-Problem
hormone	I-Problem
associated	O
with	O
vinorelbine	I-Treatment
therapy	O
.	O

the	O
study	I-Test
showed	O
a	O
high	O
incidence	O
of	O
adverse	I-Problem
events	I-Problem
when	O
a	O
higher	I-Treatment
than	I-Treatment
standard	I-Treatment
dose	I-Treatment
of	I-Treatment
the	I-Treatment
new	I-Treatment
lopinavir	I-Treatment
/	I-Treatment
ritonavir	I-Treatment
tablets	I-Treatment
was	I-Treatment
combined	I-Treatment
with	I-Treatment
rifampicin	I-Treatment
.	O

onset	O
of	O
male	I-Background
gynaecomastia	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
sunitinib	I-Treatment
for	I-Treatment
metastatic	I-Problem
renal	I-Problem
cell	I-Problem
carcinoma	I-Problem
.	O

systemic	I-Problem
disease	I-Problem
,	I-Problem
most	I-Problem
commonly	I-Problem
renal	I-Problem
dysfunction	I-Problem
,	O
preceded	O
all	O
30	O
reported	I-Background
cases	I-Background
of	O
acyclovir	I-Treatment
neurotoxicity	I-Problem
.	O

rifampicin	I-Treatment
-	O
induced	O
renal	I-Problem
failure	I-Problem
.	O

a	O
case	I-Background
of	I-Background
high	I-Problem
-	I-Problem
grade	I-Problem
endometrial	I-Problem
stromal	I-Problem
sarcoma	I-Problem
,	I-Problem
confined	I-Problem
into	I-Problem
an	I-Problem
intrauterine	I-Problem
polypoid	I-Problem
growth	I-Problem
,	I-Background
in	I-Background
a	I-Background
woman	I-Background
with	I-Background
a	I-Background
history	I-Background
of	I-Background
breast	I-Problem
cancer	I-Problem
who	O
was	O
treated	O
with	O
adjuvant	I-Treatment
tamoxifen	I-Treatment
.	O

after	O
therapy	I-Treatment
for	I-Treatment
diabetic	I-Problem
coma	I-Problem
with	I-Treatment
insulin	I-Treatment
(	I-Treatment
containing	I-Treatment
the	I-Treatment
preservative	I-Treatment
cresol	I-Treatment
)	I-Treatment
and	I-Treatment
electrolyte	I-Treatment
solutions	I-Treatment
was	O
started	O
,	O
the	I-Background
patient	I-Background
complained	O
of	O
increasing	I-Problem
myalgia	I-Problem
,	I-Problem
developed	I-Problem
a	I-Problem
high	I-Problem
fever	I-Problem
and	I-Problem
respiratory	I-Problem
and	I-Problem
metabolic	I-Problem
acidosis	I-Problem
and	I-Problem
lost	I-Problem
consciousness	I-Problem
.	O

a	I-Background
case	I-Background
of	O
severe	I-Problem
aplastic	I-Problem
anemia	I-Problem
secondary	O
to	O
treatment	O
with	O
lenalidomide	I-Treatment
for	I-Treatment
multiple	I-Problem
myeloma	I-Problem
.	O

the	I-Treatment
introduction	I-Treatment
of	I-Treatment
para	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
(	I-Treatment
pas	I-Treatment
)	I-Treatment
led	O
to	O
hypoglycaemic	I-Problem
coma	I-Problem
.	O

the	O
risk	O
of	O
developing	O
saml	I-Problem
is	O
estimated	O
to	O
be	O
between	O
1	O
%	O
and	O
5	O
%	O
,	O
2	I-Other
-	I-Other
20	I-Other
years	I-Other
after	I-Treatment
exposure	I-Treatment
to	I-Treatment
etoposide	I-Treatment
but	O
may	O
also	O
be	O
related	O
to	O
cumulative	O
drug	O
doses	O
,	O
treatment	O
schedules	O
,	O
host	O
factors	O
and	O
co	O
-	O
administration	O
of	O
other	O
antineoplastic	O
agents	O
.	O

an	I-Problem
infant	I-Problem
girl	I-Problem
with	I-Problem
choanal	I-Problem
atresia	I-Problem
,	I-Problem
athelia	I-Problem
,	I-Problem
minor	I-Problem
anomalies	I-Problem
,	I-Problem
and	I-Problem
mild	I-Problem
to	I-Problem
moderate	I-Problem
mental	I-Problem
retardation	I-Problem
was	O
born	O
to	O
a	I-Background
woman	I-Background
treated	O
for	O
hyperthyroidism	I-Problem
throughout	O
pregnancy	O
with	O
methimazole	I-Treatment
and	I-Treatment
propranolol	I-Treatment
.	O

ethambutol	I-Treatment
is	O
frequently	O
used	O
in	O
the	O
treatment	O
of	O
tuberculosis	I-Problem
,	O
and	O
,	O
although	O
optic	O
neuropathies	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
ethambutol	O
,	O
this	O
adverse	O
side	O
effect	O
has	O
been	O
considered	O
to	O
be	O
rare	O
and	O
generally	O
reversible	O
with	O
discontinuation	O
of	O
the	O
medication	O
.	O

skin	O
manifestations	O
of	O
a	O
case	O
of	O
phenylbutazone	I-Treatment
-	O
induced	O
serum	I-Problem
sickness	I-Problem
-	I-Problem
like	I-Problem
reactions	I-Problem
.	O

development	O
of	O
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
multiple	I-Problem
sclerosis	I-Problem
treated	O
with	O
copaxone	I-Treatment
.	O

aliskiren	I-Treatment
-	O
associated	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
with	O
hyperkalemia	O
.	O

fever	I-Problem
caused	O
by	O
the	O
use	O
of	O
furosemide	I-Treatment
was	O
proved	O
;	O
the	O
fever	O
resolved	O
after	O
discontinuation	O
of	O
this	O
medication	O
and	O
recurred	O
after	O
its	O
reintroduction	O
.	O

the	O
use	O
of	O
methotrexate	I-Treatment
(	I-Treatment
mtx	I-Treatment
)	I-Treatment
has	O
been	O
contraindicated	O
for	O
treatment	O
of	O
severe	O
psoriasis	O
in	O
hiv	O
infection	O
on	O
the	O
basis	O
of	O
six	O
previously	O
reported	O
cases	O
in	O
which	O
mtx	I-Treatment
appeared	O
to	O
potentiate	O
opportunistic	O
infections	O
and	O
accelerate	O
hiv	I-Problem
disease	I-Problem
.	O

pharmacokinetics	O
of	O
dapsone	I-Treatment
gel	I-Treatment
,	I-Treatment
5	I-Treatment
%	I-Treatment
for	O
the	O
treatment	O
of	O
acne	I-Problem
vulgaris	I-Problem
.	O

to	O
our	O
knowledge	O
,	O
these	O
cases	O
represent	O
the	O
first	O
reports	O
of	O
tdf	I-Treatment
-	O
associated	O
irreversible	I-Problem
renal	I-Problem
failure	I-Problem
and	I-Problem
rickets	I-Problem
in	O
pediatric	I-Background
patients	I-Background
.	O

in	O
particular	O
,	O
this	O
adverse	I-Problem
effect	I-Problem
has	O
never	O
been	O
described	O
with	O
mefloquine	I-Treatment
(	I-Treatment
lariam	I-Treatment
)	I-Treatment
.	O

a	O
potential	O
role	O
for	O
renal	O
and	O
hepatic	O
impairment	O
in	O
the	O
observed	O
protracted	O
course	O
of	O
amiodarone	I-Treatment
-	O
induced	O
thyrotoxicosis	I-Problem
is	O
suggested	O
.	O

the	I-Background
patient	I-Background
completed	O
a	O
10	I-Other
-	I-Other
month	I-Other
follow	O
-	O
up	O
,	O
maintaining	O
a	O
complete	O
resolution	O
of	O
the	O
treated	O
skin	I-Problem
lesions	I-Problem
;	O
however	O
,	O
the	O
development	O
of	O
a	I-Problem
painful	I-Problem
hand	I-Problem
ulcer	I-Problem
,	O
possibly	O
associated	O
with	O
the	O
hydroxyurea	I-Treatment
,	O
and	O
new	I-Problem
skin	I-Problem
cancers	I-Problem
were	O
observed	O
at	O
the	O
last	O
follow	O
-	O
up	O
visit	O
.	O

potential	O
aripiprazole	I-Treatment
-	O
mediated	O
extrapyramidal	I-Problem
symptoms	I-Problem
in	O
an	I-Background
adult	I-Background
with	I-Background
developmental	I-Problem
disabilities	I-Problem
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
extranodal	I-Problem
non	I-Problem
-	I-Problem
hodgkin	I-Problem
lymphoma	I-Problem
who	O
developed	O
systemic	I-Problem
candidiasis	I-Problem
after	O
treatment	O
with	O
a	I-Treatment
cyclophosphamide	I-Treatment
-	I-Treatment
based	I-Treatment
chemotherapy	I-Treatment
regimen	I-Treatment
.	I-Treatment

we	O
describe	O
the	O
first	O
case	O
of	O
de	I-Problem
novo	I-Problem
asthma	I-Problem
following	O
treatment	O
with	O
the	I-Treatment
angiotensin	I-Treatment
converting	I-Treatment
enzyme	I-Treatment
(	I-Treatment
ace	I-Treatment
)	I-Treatment
inhibitor	I-Treatment
captopril	I-Treatment
.	O

a	I-Background
53	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
,	I-Background
without	I-Background
any	I-Background
prior	I-Background
history	I-Background
of	I-Background
psychosis	I-Background
,	O
developed	O
schizophrenia	I-Problem
4	I-Other
days	I-Other
after	I-Other
starting	I-Treatment
low	I-Treatment
-	I-Treatment
dose	I-Treatment
bromocriptine	I-Treatment
therapy	I-Treatment
for	O
a	O
macroprolactinoma	I-Problem
.	O

six	I-Other
days	I-Other
after	O
taking	O
erlotinib	I-Treatment
,	O
a	O
chest	I-Test
radiograph	I-Test
showed	O
rapid	I-Problem
progression	I-Problem
of	I-Problem
reticular	I-Problem
infiltration	I-Problem
in	I-Problem
both	I-Problem
lung	I-Problem
fields	I-Problem
.	O

because	O
of	O
suspected	O
drug	O
-	O
induced	O
seizures	I-Problem
,	O
both	O
antidepressants	I-Treatment
were	O
stopped	O
.	O

based	O
on	O
the	O
naranjo	O
probability	I-Test
scale	I-Test
,	O
serotonin	I-Problem
syndrome	I-Problem
was	O
a	O
probable	O
adverse	O
reaction	O
associated	O
with	O
co	I-Treatment
-	I-Treatment
administration	I-Treatment
of	I-Treatment
citalopram	I-Treatment
and	I-Treatment
fentanyl	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
a	O
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
treated	O
with	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
(	I-Treatment
15	I-Treatment
mg	I-Treatment
/	I-Treatment
week	I-Treatment
)	I-Treatment
who	O
developed	O
infection	I-Problem
with	I-Problem
both	I-Problem
m	I-Problem
.	I-Problem
tuberculosis	I-Problem
and	I-Problem
m	I-Problem
.	I-Problem
chelonae	I-Problem
after	O
the	O
revision	O
of	O
a	O
prosthetic	O
hip	O
.	O

thrombotic	I-Problem
microangiopathy	I-Problem
with	I-Problem
renal	I-Problem
failure	I-Problem
in	O
two	O
patients	I-Background
undergoing	O
gemcitabine	I-Treatment
chemotherapy	I-Treatment
.	O

despite	O
the	O
known	O
pulmonary	I-Problem
side	I-Problem
effects	I-Problem
of	O
nitrofurantoin	I-Treatment
,	O
there	O
is	O
no	O
report	O
of	O
this	O
toxicity	O
occurring	O
in	O
pregnant	O
patients	O
.	O

however	O
,	O
several	O
case	O
reports	O
have	O
suggested	O
that	O
clozapine	I-Treatment
could	O
also	O
cause	O
td	I-Problem
.	O

a	O
case	O
is	O
presented	O
in	O
which	O
a	O
68	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
became	O
delirious	I-Problem
after	O
being	O
withdrawn	I-Treatment
from	I-Treatment
a	I-Treatment
low	I-Treatment
dosage	I-Treatment
of	I-Treatment
alprazolam	I-Treatment
.	O

however	O
,	O
re	O
-	O
initiation	O
of	O
sunitinib	I-Treatment
treatment	O
was	O
followed	O
by	O
bilateral	I-Problem
breast	I-Problem
enlargement	I-Problem
again	O
.	O

background	O
:	O
hydroxyurea	I-Treatment
is	I-Treatment
a	I-Treatment
cytostatic	I-Treatment
agent	I-Treatment
used	O
to	O
treat	O
myeloproliferative	I-Problem
disorders	I-Problem
and	O
long	O
-	O
term	O
treatment	O
is	O
associated	O
with	O
mucocutaneous	I-Problem
adverse	I-Problem
events	I-Problem
and	I-Problem
nail	I-Problem
hyperpigmentation	I-Problem
.	O

captopril	I-Treatment
-	O
induced	O
acute	I-Problem
reversible	I-Problem
renal	I-Problem
failure	I-Problem
.	O

hence	O
,	O
hyperthyroidism	I-Problem
induced	O
by	O
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
could	O
correspond	O
to	O
the	O
first	O
phase	O
of	O
silent	O
thyroiditis	O
,	O
to	O
graves	O
'	O
disease	O
or	O
to	O
the	O
succession	O
of	O
both	O
.	O

the	O
epivodes	O
of	O
nms	I-Problem
occured	O
under	O
treatment	O
with	O
clozapine	I-Treatment
,	I-Treatment
risperidone	I-Treatment
,	I-Treatment
and	I-Treatment
amisulpride	I-Treatment
.	O

during	O
the	I-Other
first	I-Other
days	I-Other
of	I-Treatment
arsenic	I-Treatment
trioxide	I-Treatment
treatment	I-Treatment
a	I-Problem
rapid	I-Problem
decrease	I-Problem
in	I-Problem
the	I-Problem
d	I-Problem
-	I-Problem
dimers	I-Problem
was	I-Problem
seen	I-Problem
(	I-Problem
normal	I-Problem
values	I-Problem
reached	I-Problem
until	I-Problem
day	I-Problem
7	I-Problem
)	I-Problem
,	I-Problem
together	I-Problem
with	I-Problem
a	I-Problem
slight	I-Problem
decrease	I-Problem
in	I-Problem
peripheral	I-Problem
blood	I-Problem
leukocytes	I-Problem
.	O

in	O
contrast	O
to	O
chronic	O
or	O
subacute	O
thyroiditis	O
,	O
graves	I-Problem
'	I-Problem
disease	I-Problem
rarely	O
complicates	O
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
therapy	O
for	O
chronic	I-Problem
viral	I-Problem
c	I-Problem
hepatitis	I-Problem
.	O

mesalamine	I-Treatment
may	O
cause	O
hypersensitivity	I-Problem
pneumonitis	I-Problem
in	O
patients	I-Background
with	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
.	O

this	O
paper	O
reports	O
an	I-Background
autopsy	I-Background
case	I-Background
of	I-Background
a	I-Background
78	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
with	O
multiple	I-Problem
nodules	I-Problem
in	I-Problem
the	I-Problem
liver	I-Problem
developed	O
after	O
long	O
-	O
termed	O
administration	O
of	O
phosphate	I-Treatment
diethylstilbestrol	I-Treatment
(	I-Treatment
pdes	I-Treatment
)	I-Treatment
for	O
prostatic	I-Problem
cancer	I-Problem
.	O

fracture	I-Problem
of	I-Problem
the	I-Problem
femoral	I-Problem
neck	I-Problem
occurred	O
in	O
one	O
patient	I-Background
during	O
psl	I-Treatment
therapy	I-Treatment
,	O
although	O
the	O
relationship	O
between	O
the	O
fracture	O
and	O
psl	O
therapy	O
was	O
uncertain	O
.	O

this	O
panic	I-Problem
anxiety	I-Problem
was	O
not	O
relieved	O
by	O
taking	O
etizolam	I-Treatment
and	I-Treatment
flunitrazepam	I-Treatment
again	O
,	O
but	O
subsided	O
rapidly	O
by	O
the	O
re	O
-	O
administration	O
of	O
mianserin	I-Treatment
30	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
,	O
and	O
because	I-Problem
of	I-Problem
that	I-Problem
the	I-Problem
depressive	I-Problem
symptom	I-Problem
also	I-Problem
disappeared	I-Problem
.	O

when	O
co	I-Treatment
-	I-Treatment
trimoxazole	I-Treatment
was	O
stopped	O
the	O
red	I-Problem
cell	I-Problem
aplasia	I-Problem
resolved	I-Problem
.	O

interaction	I-Treatment
of	I-Treatment
sildenafil	I-Treatment
and	I-Treatment
indinavir	I-Treatment
when	O
co	O
-	O
administered	O
to	O
hiv	I-Problem
-	I-Problem
positive	I-Problem
patients	I-Background
.	O

cerebral	I-Problem
and	I-Problem
ocular	I-Problem
toxicity	I-Problem
induced	O
by	O
desferrioxamine	I-Treatment
.	O

a	I-Background
patient	I-Background
developed	O
papilloedema	I-Problem
and	I-Problem
hepatic	I-Problem
dysfunction	I-Problem
while	O
being	O
treated	O
with	O
perhexiline	I-Treatment
maleate	I-Treatment
.	O

we	O
describe	O
a	I-Background
case	I-Background
of	O
subcutaneous	I-Problem
metastasis	I-Problem
along	O
the	O
needle	O
track	O
after	O
percutaneous	I-Treatment
ethanol	I-Treatment
injection	I-Treatment
(	I-Treatment
pei	I-Treatment
)	I-Treatment
for	O
treatment	O
of	O
hepatocellular	I-Problem
carcinoma	I-Problem
.	O

he	O
developed	O
episodic	I-Problem
movements	I-Problem
possibly	I-Problem
consistent	I-Problem
with	I-Problem
eps	I-Problem
secondary	I-Treatment
to	I-Treatment
aripiprazole	I-Treatment
usage	I-Treatment
.	O

recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
terfenadine	I-Treatment
and	I-Treatment
astemizole	I-Treatment
,	O
which	O
have	O
antiallergic	O
actions	O
similar	O
to	O
those	O
of	O
oxatomide	O
,	O
show	O
side	I-Problem
effects	I-Problem
on	I-Problem
the	I-Problem
cardiovascular	I-Problem
system	I-Problem
,	I-Problem
such	I-Problem
as	I-Problem
qt	I-Problem
prolongation	I-Problem
,	I-Problem
ventricular	I-Problem
arrhythmia	I-Problem
and	I-Problem
cardiac	I-Problem
arrest	I-Problem
.	O

we	O
reported	O
3	O
patients	I-Background
who	O
developed	O
acute	I-Problem
generalized	I-Problem
dystonia	I-Problem
and	I-Problem
akinetic	I-Problem
rigid	I-Problem
syndrome	I-Problem
following	O
an	O
initial	O
therapy	O
with	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
125	I-Treatment
-	I-Treatment
500	I-Treatment
mg	I-Treatment
daily	I-Treatment
.	O

priapism	I-Problem
associated	O
with	O
olanzapine	I-Treatment
.	O

thus	O
,	O
an	O
immunological	O
mechanism	O
might	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
pirmenol	I-Treatment
-	O
induced	O
qt	I-Problem
prolongation	I-Problem
and	I-Problem
t	I-Problem
wave	I-Problem
inversion	I-Problem
on	O
the	O
electrocardiogram	I-Test
.	O

five	I-Other
months	I-Other
after	I-Treatment
initiating	I-Treatment
mirtazapine	I-Treatment
therapy	O
,	O
she	I-Background
developed	O
symptomatic	I-Problem
hyponatremia	I-Problem
.	O

the	I-Problem
renal	I-Test
biopsy	I-Test
showed	I-Problem
focal	I-Problem
segmental	I-Problem
glomerulosclerosis	I-Problem
,	O
which	O
has	O
only	O
been	O
previously	O
reported	O
in	O
two	O
cases	I-Background
of	O
cml	I-Problem
treated	O
with	O
ifnalpha	I-Treatment
.	O

sulindac	I-Treatment
(	I-Treatment
clinoril	I-Treatment
)	I-Treatment
,	O
a	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agent	O
,	O
has	O
few	O
reported	O
neurologic	I-Problem
toxic	I-Problem
effects	I-Problem
,	O
all	O
of	O
which	O
have	O
been	O
associated	O
with	O
systemic	O
disease	O
.	O

the	O
second	O
patient	O
was	O
a	I-Background
32	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
hiv	I-Problem
,	I-Background
anxiety	I-Problem
disorder	I-Problem
,	I-Background
and	I-Background
a	I-Background
history	I-Background
of	I-Background
intravenous	I-Problem
drug	I-Problem
abuse	I-Problem
who	O
developed	O
increased	I-Problem
sedation	I-Problem
and	I-Problem
mental	I-Problem
confusion	I-Problem
when	O
an	O
atazanavir	I-Treatment
-	I-Treatment
ritonavir	I-Treatment
-	I-Treatment
based	I-Treatment
antiretroviral	I-Treatment
regimen	I-Treatment
was	I-Treatment
added	I-Treatment
to	I-Treatment
her	I-Treatment
stable	I-Treatment
antianxiety	I-Treatment
drug	I-Treatment
regimen	I-Treatment
,	I-Treatment
which	I-Treatment
included	I-Treatment
quetiapine	I-Treatment
.	O

fulminant	I-Problem
hepatitis	I-Problem
associated	O
with	O
disulfiram	I-Treatment
.	O

anhedonic	I-Problem
ejaculation	I-Problem
with	O
desipramine	I-Treatment
.	O

serotonin	I-Problem
syndrome	I-Problem
induced	O
by	O
transitioning	O
from	O
phenelzine	I-Treatment
to	I-Treatment
venlafaxine	I-Treatment
:	O
four	I-Background
patient	I-Background
reports	O
.	O

lower	I-Problem
extremity	I-Problem
arterial	I-Problem
thrombosis	I-Problem
following	O
sonographically	O
guided	O
thrombin	I-Treatment
injection	I-Treatment
of	I-Treatment
a	I-Treatment
femoral	I-Problem
pseudoaneurysm	I-Problem
.	O

a	O
severe	O
form	O
of	O
exophthalmos	I-Problem
resulting	O
from	O
lithium	I-Treatment
therapy	O
has	O
not	O
been	O
described	O
in	O
the	O
literature	O
.	O

no	O
cases	O
of	O
renal	O
acidosis	O
,	O
and	O
only	O
one	O
case	O
of	O
nephrogenic	I-Problem
diabetes	I-Problem
insipidus	I-Problem
,	O
has	O
been	O
previously	O
reported	O
as	O
a	O
complication	O
of	O
foscarnet	I-Treatment
treatment	I-Treatment
.	O

cough	I-Problem
induced	O
by	O
quinapril	I-Treatment
with	O
resolution	O
after	O
changing	O
to	O
fosinopril	I-Treatment
.	O

we	O
report	O
a	O
case	O
in	O
which	O
a	I-Treatment
potential	I-Treatment
drug	I-Treatment
interaction	I-Treatment
resulted	O
in	O
elevated	I-Problem
phenytoin	I-Problem
levels	I-Problem
after	O
initiation	I-Treatment
of	I-Treatment
erlotinib	I-Treatment
therapy	I-Treatment
in	O
a	I-Background
patient	I-Background
who	O
was	O
receiving	I-Treatment
phenytoin	I-Treatment
.	O

anastrozole	I-Treatment
-	O
associated	O
sclerosing	I-Problem
glomerulonephritis	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
breast	I-Problem
cancer	I-Problem
.	I-Background

background	O
:	O
gemcitabine	O
has	O
mild	O
renal	I-Problem
toxicity	I-Problem
,	O
but	O
cases	I-Background
of	O
gemcitabine	I-Treatment
-	O
associated	O
hemolytic	I-Problem
-	I-Problem
uremic	I-Problem
syndrome	I-Problem
(	I-Problem
hus	I-Problem
)	I-Problem
have	O
been	O
reported	O
.	O

recurrent	O
palmar	I-Problem
-	I-Problem
plantar	I-Problem
erythrodysaesthesia	I-Problem
following	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytarabine	I-Treatment
treatment	O
for	O
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
.	O

conclusions	O
:	O
peripheral	I-Treatment
administration	I-Treatment
of	I-Treatment
low	I-Treatment
-	I-Treatment
dose	I-Treatment
vasopressin	I-Treatment
for	O
septic	I-Problem
shock	I-Problem
should	O
be	O
discouraged	O
because	O
of	O
the	O
risk	O
of	O
ischemic	I-Problem
skin	I-Problem
complications	I-Problem
.	O

many	O
types	O
of	O
medicaments	O
can	O
cause	O
akathisia	I-Problem
as	O
an	O
adverse	O
event	O
of	O
their	O
use	O
and	O
they	O
include	O
:	O
antipsychotics	I-Treatment
,	I-Treatment
antidepressants	I-Treatment
,	I-Treatment
antiemetics	I-Treatment
,	I-Treatment
antihistamines	I-Treatment
,	I-Treatment
and	I-Treatment
psychoactive	I-Treatment
substances	I-Treatment
.	I-Treatment

we	O
report	O
the	O
case	O
of	O
a	I-Background
60	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
who	O
developed	O
erythema	I-Problem
and	O
erosions	I-Problem
in	I-Problem
the	I-Problem
axilla	I-Problem
and	I-Problem
groin	I-Problem
while	O
on	O
pld	I-Treatment
for	O
breast	I-Problem
cancer	I-Problem
.	O

serotonin	I-Problem
syndrome	I-Problem
has	O
been	O
reported	O
with	O
administration	I-Treatment
of	I-Treatment
linezolid	I-Treatment
and	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitors	I-Treatment
.	O

we	O
suggest	O
that	O
the	O
treatment	O
of	O
hypoglycaemia	I-Problem
with	O
50	I-Treatment
%	I-Treatment
solution	I-Treatment
of	I-Treatment
dextrose	I-Treatment
is	O
associated	O
with	O
a	I-Problem
significant	I-Problem
risk	I-Problem
factor	I-Problem
in	O
those	O
diabetic	I-Problem
individuals	I-Background
who	I-Background
are	I-Background
either	I-Background
allergic	I-Background
or	I-Background
are	I-Background
receiving	I-Background
beta	I-Background
-	I-Background
adrenoreceptor	I-Background
blocking	I-Background
drugs	I-Background
.	O

a	O
case	O
of	O
phenobarbital	I-Treatment
exacerbation	I-Problem
of	I-Problem
a	I-Problem
preexisting	I-Problem
maladaptive	I-Problem
behavior	I-Problem
partially	I-Treatment
suppressed	I-Treatment
by	I-Treatment
chlorpromazine	I-Treatment
and	O
misinterpreted	O
as	O
chlorpromazine	O
efficacy	O
.	O

colchicine	I-Treatment
-	O
induced	O
myopathy	I-Problem
in	O
a	I-Background
teenager	I-Background
with	I-Background
familial	I-Background
mediterranean	I-Problem
fever	I-Problem
.	O

levofloxacin	I-Treatment
-	O
induced	O
delirium	I-Problem
with	I-Problem
psychotic	I-Problem
features	I-Problem
.	O

methemoglobinemia	I-Problem
:	O
an	O
occupational	O
hazard	O
of	O
phenylpropanolamine	I-Treatment
production	O
.	O

destructive	I-Problem
thyrotoxicosis	I-Problem
appeared	O
4	I-Other
-	I-Other
6	I-Other
months	I-Other
after	O
starting	O
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
,	O
followed	O
by	O
graves	I-Problem
'	I-Problem
hyperthyroidism	I-Problem
within	O
8	O
to	O
11	O
months	O
.	O

case	O
summaries	O
:	O
in	O
each	O
case	O
,	O
the	O
patients	I-Background
were	O
treated	O
over	O
5	I-Other
years	I-Other
with	I-Treatment
lovastatin	I-Treatment
and	O
developed	O
rhabdomyolysis	I-Problem
that	O
coincided	O
with	O
the	O
completion	O
of	O
a	O
prescribed	O
regimen	O
of	O
a	I-Treatment
newer	I-Treatment
macrolide	I-Treatment
antibiotic	I-Treatment
.	O

thrombotic	I-Problem
stroke	I-Problem
associated	O
with	O
the	O
use	O
of	O
porcine	I-Treatment
factor	I-Treatment
viii	I-Treatment
in	O
a	O
patient	I-Background
with	I-Background
acquired	I-Problem
haemophilia	I-Problem
.	O

purpose	O
:	O
the	I-Treatment
intravitreal	I-Treatment
application	I-Treatment
of	I-Treatment
triamcinolone	I-Treatment
acetonide	I-Treatment
as	O
treatment	O
of	O
long	O
-	O
standing	O
,	O
therapy	O
-	O
resistant	O
cystoid	I-Problem
macular	I-Problem
edema	I-Problem
after	O
penetrating	O
keratoplasty	O
is	O
reported	O
.	O

patients	I-Background
receiving	O
ciprofloxacin	I-Treatment
and	I-Treatment
digoxin	I-Treatment
should	O
be	O
monitored	O
closely	O
for	O
the	O
risk	O
of	O
digoxin	I-Problem
toxicity	I-Problem
.	O

to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
pancytopenia	I-Problem
due	O
to	O
mmi	I-Treatment
,	O
where	O
the	O
usual	O
hypoplasia	O
found	O
is	O
replaced	O
by	O
massive	O
plasmocytosis	O
.	O

the	O
following	O
is	O
a	O
report	O
of	O
2	O
cases	O
of	O
rifampicin	I-Treatment
-	O
induced	O
renal	I-Problem
insufficiency	I-Problem
.	O

fatal	I-Problem
eosinophilia	I-Problem
myalgia	I-Problem
syndrome	I-Problem
in	O
a	O
marrow	I-Background
transplant	I-Background
patient	I-Background
attributed	O
to	O
total	I-Treatment
parenteral	I-Treatment
nutrition	I-Treatment
with	I-Treatment
a	I-Treatment
solution	I-Treatment
containing	I-Treatment
tryptophan	I-Treatment
.	O

we	O
describe	O
a	O
43	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
who	O
developed	O
signs	O
and	O
symptoms	O
of	O
bilateral	I-Problem
optic	I-Problem
neuropathy	I-Problem
during	O
treatment	O
with	O
ethambutol	I-Treatment
.	O

the	I-Background
patient	I-Background
described	I-Background
in	I-Background
this	I-Background
paper	I-Background
was	I-Background
a	I-Background
78	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
diabetic	I-Problem
man	I-Background
who	O
developed	O
oral	I-Problem
lesions	I-Problem
of	I-Problem
pv	I-Problem
following	O
institution	I-Treatment
of	I-Treatment
glibenclamide	I-Treatment
therapy	O
.	O

since	O
elevated	O
cortisol	O
levels	O
in	O
cushing	O
'	O
s	O
disease	O
poses	O
a	O
threat	O
for	O
pancreatitis	O
,	O
there	O
is	O
a	O
possibility	O
that	O
patients	I-Background
with	I-Background
cushing	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
might	O
be	O
more	O
prone	O
to	O
acute	I-Problem
pancreatitis	I-Problem
following	O
propofol	I-Treatment
administration	O
.	O

ticlopidine	I-Treatment
is	I-Treatment
an	I-Treatment
oral	I-Treatment
antiplatelet	I-Treatment
agent	I-Treatment
frequently	O
utilized	O
in	O
the	O
treatment	O
of	O
cerebrovascular	I-Problem
disease	I-Problem
and	O
is	O
rarely	O
associated	O
with	O
severe	I-Problem
bone	I-Problem
marrow	I-Problem
suppression	I-Problem
,	I-Problem
typically	I-Problem
aplastic	I-Problem
anemia	I-Problem
.	O

moxifloxacin	I-Treatment
and	I-Treatment
lomefloxacin	I-Treatment
are	O
fluoroquinolone	I-Treatment
antibiotics	I-Treatment
used	O
in	O
treating	O
urinary	I-Problem
and	I-Problem
respiratory	I-Problem
tract	I-Problem
infections	I-Problem
.	O

to	O
our	O
knowledge	O
,	O
this	O
case	O
report	O
represents	O
only	O
the	O
third	O
description	O
of	O
laxative	I-Treatment
-	O
induced	O
ten	I-Problem
.	O

prompted	O
by	O
the	O
advent	O
of	O
potentially	O
life	I-Problem
-	I-Problem
threatening	I-Problem
neuromuscular	I-Problem
symptoms	I-Problem
following	O
initiation	O
of	O
linezolid	I-Treatment
therapy	O
in	O
two	O
patients	I-Background
receiving	O
treatment	O
with	I-Treatment
a	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitor	I-Treatment
antidepressant	I-Treatment
,	O
an	O
evaluation	I-Test
was	O
conducted	O
to	O
determine	O
the	O
incidence	O
and	O
characteristics	O
of	O
symptomatic	O
serotonin	O
toxicity	O
among	O
hospitalized	O
patients	O
receiving	O
combined	O
treatment	O
with	O
these	O
medications	O
.	O

celiac	I-Problem
disease	I-Problem
onset	O
after	O
pegylated	I-Treatment
interferon	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
treatment	I-Treatment
of	I-Treatment
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

hyperkalaemia	I-Problem
with	I-Problem
renal	I-Problem
tubular	I-Problem
dysfunction	I-Problem
by	O
sulfamethoxazole	I-Treatment
-	I-Treatment
trimethoprim	I-Treatment
for	I-Treatment
pneumocystis	I-Problem
carinii	I-Problem
pneumonia	I-Problem
in	O
patients	I-Background
with	I-Background
lymphoid	I-Problem
malignancy	I-Problem
.	O

following	O
7	I-Other
days	I-Other
of	I-Treatment
tigecycline	I-Treatment
she	I-Background
developed	O
severe	O
abdominal	I-Problem
pain	I-Problem
and	I-Problem
elevated	I-Problem
pancreatic	I-Problem
enzymes	I-Problem
suggesting	O
acute	O
pancreatitis	O
.	O

to	O
treat	O
hepatitis	I-Problem
b	I-Problem
,	O
interferon	I-Treatment
alpha	I-Treatment
was	O
administered	O
until	O
the	O
proximal	I-Problem
muscle	I-Problem
weakness	I-Problem
developed	O
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
the	O
serotonin	I-Problem
syndrome	I-Problem
during	O
treatment	O
with	O
lithium	I-Treatment
and	I-Treatment
venlafaxine	I-Treatment
,	O
an	O
antidepressant	O
with	O
a	O
dual	O
selective	O
re	O
-	O
uptake	O
inhibition	O
mechanism	O
,	O
and	O
review	O
the	O
literature	O
for	O
similar	O
cases	O
.	O

supratherapeutic	I-Treatment
flecainide	I-Test
plasma	I-Test
concentrations	I-Test
may	O
cause	O
delirium	I-Problem
.	O

at	O
the	O
end	O
of	O
his	O
fifth	I-Other
cycle	I-Other
of	I-Treatment
sunitinib	I-Treatment
therapy	I-Treatment
,	O
the	I-Background
patient	I-Background
complained	O
of	O
the	O
development	O
of	O
abnormally	I-Problem
large	I-Problem
mammary	I-Problem
glands	I-Problem
associated	I-Problem
with	I-Problem
pain	I-Problem
and	I-Problem
peri	I-Problem
-	I-Problem
areolar	I-Problem
erythema	I-Problem
.	O

this	O
is	O
a	O
case	O
report	O
of	O
possible	O
association	O
of	O
methylphenidate	I-Treatment
and	O
enuresis	I-Problem
in	O
an	I-Background
11	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
with	I-Background
attention	I-Problem
deficit	I-Problem
hyperactivity	I-Problem
disorder	I-Problem
.	O

this	O
report	O
describes	O
a	O
case	O
of	O
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
due	O
to	O
risperidone	I-Treatment
in	O
a	I-Background
child	I-Background
with	I-Background
joubert	I-Problem
syndrome	I-Problem
.	O

a	I-Background
47	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
hiv	I-Problem
-	I-Problem
infected	I-Problem
man	I-Background
with	I-Background
dilated	I-Problem
cardiomyopathy	I-Problem
and	I-Background
prolonged	I-Problem
qt	I-Problem
syndrome	I-Problem
with	I-Background
an	I-Background
automatic	I-Background
implantable	I-Background
cardiovascular	I-Background
defibrillator	I-Background
device	I-Background
was	O
prescribed	O
subcutaneous	I-Treatment
enfuvirtide	I-Treatment
90	I-Treatment
mg	I-Treatment
twice	I-Other
daily	I-Other
as	I-Treatment
part	I-Treatment
of	I-Treatment
his	I-Treatment
antiretroviral	I-Treatment
regimen	I-Treatment
and	I-Treatment
oral	I-Treatment
extended	I-Treatment
-	I-Treatment
release	I-Treatment
niacin	I-Treatment
500	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Other
for	I-Treatment
a	I-Treatment
high	I-Test
-	I-Treatment
density	I-Test
lipoprotein	I-Test
level	I-Test
of	I-Treatment
8	I-Treatment
mg	I-Treatment
/	I-Treatment
dl	I-Treatment
.	I-Treatment
after	O
1	I-Other
week	I-Other
of	O
concomitant	O
therapy	O
,	O
the	O
patient	O
began	O
experiencing	O
extreme	I-Problem
redness	I-Problem
,	I-Problem
edema	I-Problem
,	I-Problem
and	I-Problem
swelling	I-Problem
at	I-Problem
the	I-Problem
injection	I-Problem
site	I-Problem
that	I-Problem
corresponded	I-Problem
with	I-Problem
the	I-Problem
flushing	I-Problem
sensation	I-Problem
due	I-Problem
to	I-Problem
niacin	I-Problem
.	O

acute	O
inh	O
neurotoxicity	O
was	O
not	O
suspected	O
on	O
the	O
first	O
admission	O
;	O
however	O
,	O
when	O
readmitted	O
4	O
weeks	O
later	O
with	O
another	O
seizure	I-Problem
,	O
the	O
diagnosis	O
of	O
acute	I-Problem
inh	I-Treatment
neurotoxicity	I-Problem
was	O
made	O
.	O

levofloxacin	I-Treatment
-	O
induced	O
toxic	I-Problem
epidermal	I-Problem
necrolysis	I-Problem
in	O
an	I-Background
elderly	I-Background
patient	I-Background
.	I-Background

the	O
incidence	O
of	O
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
(	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
)	I-Treatment
-	O
related	O
cardiotoxicity	I-Problem
seems	O
to	O
be	O
dosage	I-Treatment
and	O
schedule	I-Treatment
dependent	O
.	O

torsades	I-Problem
de	I-Problem
pointes	I-Problem
induced	O
by	O
a	I-Treatment
combination	I-Treatment
of	I-Treatment
garenoxacin	I-Treatment
and	I-Treatment
disopyramide	I-Treatment
and	I-Treatment
other	I-Treatment
cytochrome	I-Test
p450	I-Test
,	I-Treatment
family	I-Treatment
3	I-Treatment
,	I-Treatment
subfamily	I-Treatment
a	I-Treatment
polypeptide	I-Treatment
-	I-Treatment
4	I-Treatment
-	I-Treatment
influencing	I-Treatment
drugs	I-Treatment
during	O
hypokalemia	O
due	O
to	O
licorice	O
.	O

ataxia	I-Problem
caused	O
by	O
propafenone	I-Treatment
has	O
been	O
reported	O
to	O
the	O
pharmaceutical	O
companies	O
and	O
drug	O
monitoring	O
agencies	O
,	O
but	O
has	O
not	O
been	O
well	O
described	O
or	O
emphasized	O
in	O
the	O
medical	O
literature	O
.	O

the	I-Background
first	I-Background
patient	I-Background
developed	O
mild	I-Problem
nitritoid	I-Problem
symptoms	I-Problem
and	I-Problem
pain	I-Problem
in	I-Problem
a	I-Problem
band	I-Problem
-	I-Problem
like	I-Problem
distribution	I-Problem
,	O
corresponding	O
to	O
t10	O
-	O
t12	O
dermatomes	O
,	O
shortly	O
after	O
gold	I-Treatment
sodium	I-Treatment
thiomalate	I-Treatment
(	I-Treatment
gstm	I-Treatment
)	I-Treatment
injection	I-Treatment
.	O

two	O
65	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
men	I-Background
with	I-Background
coronary	I-Problem
heart	I-Problem
disease	I-Problem
,	O
given	O
niacin	I-Treatment
therapy	I-Treatment
for	I-Treatment
dyslipidemia	I-Problem
for	I-Treatment
5	I-Other
months	I-Other
,	O
developed	O
intense	I-Problem
dental	I-Problem
and	I-Problem
gingival	I-Problem
pain	I-Problem
that	O
was	O
associated	O
with	O
increases	I-Treatment
in	I-Treatment
dose	I-Treatment
and	O
that	O
was	O
relieved	O
with	O
discontinuance	O
of	O
niacin	O
treatment	O
.	O

two	O
patients	I-Background
are	O
described	O
who	O
developed	O
testicular	I-Problem
swelling	I-Problem
and	I-Problem
pain	I-Problem
during	O
treatment	O
with	O
desipramine	I-Treatment
.	O

metabolic	O
balance	I-Test
studies	I-Test
and	O
rechallenge	O
with	O
hydrochlorothiazide	I-Treatment
were	O
undertaken	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
thiazide	I-Treatment
-	O
induced	O
hyponatremia	I-Problem
.	O

paradoxical	I-Problem
pulmonary	I-Problem
vasoconstriction	I-Problem
induced	O
by	O
nitroglycerin	I-Treatment
in	O
idiopathic	I-Problem
pulmonary	I-Problem
hypertension	I-Problem
.	O

although	O
visual	O
hallucinations	O
have	O
not	O
been	O
reported	O
as	O
an	O
adverse	O
effect	O
of	O
this	O
agent	O
,	O
we	O
describe	O
three	O
patients	O
who	O
experienced	O
complex	I-Problem
visual	I-Problem
hallucinations	I-Problem
and	I-Problem
altered	I-Problem
mental	I-Problem
status	I-Problem
after	O
zonisamide	I-Treatment
treatment	O
was	O
begun	O
or	O
its	O
dosage	O
increased	O
.	O

clinical	O
profile	O
of	O
oxcarbazepine	I-Treatment
-	O
related	O
angioneurotic	I-Problem
edema	I-Problem
:	O
case	I-Background
report	O
and	O
review	O
.	O

extra	O
caution	O
should	O
be	O
taken	O
in	O
using	O
octreotide	I-Treatment
or	I-Treatment
its	I-Treatment
long	I-Treatment
-	I-Treatment
acting	I-Treatment
analog	I-Treatment
in	O
patients	I-Background
otherwise	O
predisposed	O
to	O
intrahepatic	I-Problem
bile	I-Problem
stasis	I-Problem
.	O

background	O
:	O
fluoxetine	I-Treatment
,	O
a	O
highly	O
specific	O
serotonin	O
reuptake	O
inhibitor	O
,	O
has	O
been	O
reported	O
to	O
cause	O
sexual	I-Problem
dysfunction	I-Problem
in	O
a	O
minority	I-Background
of	I-Background
patients	I-Background
.	O

we	O
report	O
a	I-Background
45	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
chinese	I-Background
man	I-Background
with	I-Background
cml	I-Problem
and	I-Problem
chronic	I-Problem
hepatitis	I-Problem
b	I-Problem
virus	I-Background
infection	I-Background
,	O
on	I-Treatment
imatinib	I-Treatment
treatment	I-Treatment
,	O
presenting	O
with	O
herpetic	I-Problem
rash	I-Problem
and	I-Problem
acute	I-Problem
liver	I-Problem
failure	I-Problem
.	O

one	O
patient	I-Background
had	O
severe	O
temporary	I-Problem
weakness	I-Problem
after	O
an	I-Treatment
ampicillin	I-Test
sodium	I-Test
challenge	I-Test
.	O

acute	I-Problem
myeloid	I-Problem
leukemia	I-Problem
and	I-Problem
lung	I-Problem
cancer	I-Problem
occurring	O
in	O
a	I-Background
chronic	I-Problem
lymphocytic	I-Problem
leukemia	I-Problem
patient	I-Background
treated	O
with	O
fludarabine	I-Treatment
and	I-Treatment
autologous	I-Treatment
peripheral	I-Treatment
blood	I-Treatment
stem	I-Treatment
-	I-Treatment
cell	I-Treatment
transplantation	I-Treatment
.	O

despite	O
a	O
very	O
low	O
complication	O
rate	O
,	O
several	O
severe	O
arterial	I-Problem
thrombotic	I-Problem
events	O
have	O
been	O
reported	O
following	O
thrombin	I-Treatment
injection	I-Treatment
of	O
pseudoaneurysms	I-Problem
.	O

the	O
results	O
clearly	O
demonstrate	O
that	O
cph82	I-Treatment
was	O
associated	O
with	O
suppression	I-Problem
of	I-Problem
the	I-Problem
endogeneous	I-Problem
production	I-Problem
of	I-Problem
acth	I-Problem
and	I-Problem
cortisol	I-Problem
with	I-Problem
a	I-Problem
concomitant	I-Problem
paradoxical	I-Problem
picture	I-Problem
of	I-Problem
clinical	I-Problem
hypercortisolism	I-Problem
.	O

exposure	O
of	O
the	O
fetus	I-Background
to	O
indomethacin	I-Treatment
by	O
administration	O
of	O
the	O
drug	O
to	O
the	O
mother	O
may	O
cause	O
many	O
side	O
effects	O
,	O
including	O
premature	I-Problem
closure	I-Problem
of	I-Problem
the	I-Problem
ductus	I-Problem
arteriosus	I-Problem
.	O

she	I-Background
was	O
diagnosed	O
with	O
epstein	I-Problem
-	I-Problem
barr	I-Problem
virus	I-Problem
-	I-Problem
associated	I-Problem
polymorphic	I-Problem
lymphoproliferative	I-Problem
disorder	I-Problem
(	I-Problem
lpd	I-Problem
)	I-Problem
due	O
to	O
immunodeficiency	I-Treatment
caused	I-Treatment
by	I-Treatment
mtx	I-Treatment
administration	I-Treatment
.	O

pulmonary	I-Problem
hypertension	I-Problem
during	O
lithium	I-Treatment
therapy	I-Treatment
:	O
clinical	O
case	O
study	O
.	O

conclusions	O
:	O
clinicians	O
should	O
be	O
aware	O
of	O
this	O
adverse	O
reaction	O
when	O
facing	O
similar	O
complex	O
neurologic	I-Problem
symptoms	I-Problem
in	O
patients	I-Background
who	O
are	O
receiving	O
the	O
antibiotic	O
treatment	O
described	O
here	O
,	O
especially	O
vancomycin	I-Treatment
.	O

corneal	I-Problem
edema	I-Problem
recurred	O
when	O
the	I-Treatment
administration	I-Treatment
of	I-Treatment
amantadine	I-Treatment
was	I-Treatment
resumed	I-Treatment
.	O

vitamin	I-Treatment
k1	I-Treatment
caused	O
skin	I-Problem
rash	I-Problem
possibly	O
because	O
of	O
the	O
distribution	O
and	O
metabolism	O
characteristic	O
of	O
the	O
drug	O
in	O
this	O
patient	O
.	O

initial	O
treatment	O
with	O
heparin	O
was	O
substituted	O
with	O
thrombolysis	I-Treatment
,	O
which	O
resulted	O
in	O
clinical	O
improvement	O
and	O
dissolution	O
of	O
right	O
heart	O
thrombus	O
but	O
was	O
followed	O
by	O
fatal	I-Problem
intracerebral	I-Problem
haemorrhage	I-Problem
.	O

the	O
most	O
commonly	O
recognized	O
toxic	O
effect	O
of	O
ethambutol	I-Treatment
is	O
optic	I-Problem
neuropathy	I-Problem
,	O
which	O
generally	O
is	O
considered	O
uncommon	O
and	O
reversible	O
in	O
medical	O
literature	O
.	O

a	O
case	O
of	O
congestive	I-Problem
heart	I-Problem
failure	I-Problem
in	O
a	I-Background
child	I-Background
with	I-Background
wilms	I-Problem
'	I-Problem
tumor	I-Problem
treated	O
adriamycin	I-Treatment
is	O
presented	O
and	O
discussed	O
.	O

background	O
:	O
hypersensitivity	I-Problem
reactions	I-Problem
to	O
cyclosporine	I-Treatment
are	O
rare	O
.	O

this	O
is	O
the	O
first	I-Background
case	I-Background
of	O
tmp	I-Treatment
-	I-Treatment
smx	I-Treatment
-	O
induced	O
hypersensitivity	I-Problem
syndrome	I-Problem
associated	O
with	O
the	O
reactivation	I-Problem
of	I-Problem
a	I-Problem
latent	I-Problem
viral	I-Problem
infection	I-Problem
.	O

in	O
addition	O
,	O
single	I-Treatment
-	I-Treatment
agent	I-Treatment
weekly	I-Other
auc2	I-Treatment
-	I-Treatment
carboplatin	I-Treatment
appeared	O
to	O
be	O
inactive	O
by	O
response	O
criteria	O
in	O
a	I-Background
homogenously	I-Background
defined	I-Background
population	I-Background
of	I-Background
proc	I-Problem
.	O

conclusions	O
:	O
intrathecal	I-Treatment
baclofen	I-Treatment
can	O
impair	I-Problem
sexual	I-Problem
function	I-Problem
and	I-Problem
ejaculation	I-Problem
in	O
some	I-Background
patients	I-Background
.	O

serum	O
sickness	O
consists	O
of	O
a	O
systemic	O
reaction	O
resulting	O
from	O
the	O
formation	O
of	O
soluble	O
circulating	O
immunocomplexes	O
after	O
the	O
introduction	O
of	O
a	O
foreign	O
substance	O
into	O
the	O
body	O
we	O
studied	O
a	I-Background
38	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
diagnosed	I-Background
with	I-Background
anxiety	I-Problem
,	I-Problem
depression	I-Problem
and	I-Problem
right	I-Problem
sacroileitis	I-Problem
who	O
was	O
treated	O
with	O
phenylbutazone	I-Treatment
,	I-Treatment
ranitidine	I-Treatment
,	I-Treatment
clomipramine	I-Treatment
and	I-Treatment
levomepromazine	I-Treatment
.	O

the	O
symptomatology	O
of	O
18	O
other	I-Background
paediatric	I-Background
cases	I-Background
of	O
naphthylimidazoline	I-Treatment
exposure	I-Problem
reported	O
to	O
the	O
belgian	O
national	O
poison	O
centre	O
,	O
is	O
also	O
discussed	O
.	O

anterior	I-Problem
spinal	I-Problem
artery	I-Problem
syndrome	I-Problem
-	O
-	O
a	O
complication	O
of	O
cervical	I-Treatment
intrathecal	I-Treatment
phenol	I-Treatment
injection	I-Treatment
.	O

phenytoin	O
was	O
discontinued	O
after	O
admission	O
;	O
however	O
,	O
phenytoin	I-Treatment
1	I-Treatment
g	I-Treatment
i	I-Treatment
.	I-Treatment
v	I-Treatment
.	I-Treatment
was	O
given	O
for	O
a	I-Problem
tonic	I-Problem
-	I-Problem
clonic	I-Problem
seizure	I-Problem
two	O
days	O
after	O
admission	O
,	O
after	O
which	O
swelling	I-Problem
of	I-Problem
the	I-Problem
face	I-Problem
and	I-Problem
legs	I-Problem
and	I-Problem
pruritus	I-Problem
developed	O
.	O

to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
that	O
demonstrates	O
histological	I-Problem
abnormalities	I-Problem
of	I-Problem
the	I-Problem
glomerulus	I-Problem
associated	O
with	O
postoperative	I-Treatment
ifn	I-Treatment
-	I-Treatment
beta	I-Treatment
therapy	I-Treatment
for	O
the	O
malignant	I-Problem
melanoma	I-Problem
.	O

protease	I-Treatment
inhibitor	I-Treatment
-	O
induced	O
carbamazepine	I-Problem
toxicity	I-Problem
.	O

this	O
report	O
details	O
a	O
case	O
of	O
bilateral	I-Problem
avascular	I-Problem
necrosis	I-Problem
of	I-Problem
the	I-Problem
femoral	I-Problem
heads	I-Problem
in	O
a	I-Background
patient	I-Background
receiving	O
'	I-Treatment
standard	I-Treatment
'	I-Treatment
doses	I-Treatment
of	I-Treatment
dexamethasone	I-Treatment
as	O
part	O
of	O
the	O
antiemetic	O
regimen	O
used	O
in	O
cisplatin	O
-	O
based	O
combination	O
chemotherapy	O
.	O

he	I-Background
recovered	O
successfully	O
after	O
treatment	O
with	O
very	I-Treatment
high	I-Treatment
doses	I-Treatment
of	I-Treatment
corticosteroids	I-Treatment
and	I-Treatment
azathioprine	I-Treatment
.	O

marked	I-Problem
hyperkalemia	I-Problem
was	O
observed	O
during	I-Treatment
and	I-Treatment
immediately	I-Other
after	I-Treatment
an	I-Treatment
infusion	I-Treatment
of	I-Treatment
arginine	I-Treatment
monohydrochloride	I-Treatment
in	O
two	O
patients	I-Background
with	I-Background
severe	I-Background
hepatic	I-Problem
disease	I-Problem
and	I-Background
moderate	I-Problem
renal	I-Problem
insufficiency	I-Problem
.	O

finally	O
,	O
reserpine	I-Treatment
toxicity	I-Problem
,	I-Problem
in	I-Problem
particular	I-Problem
central	I-Problem
nervous	I-Problem
system	I-Problem
(	I-Problem
cns	I-Problem
)	I-Problem
disturbances	I-Problem
,	O
was	O
reported	O
more	O
frequently	O
in	O
patients	O
also	I-Treatment
receiving	I-Treatment
barbiturates	I-Treatment
,	I-Treatment
suggesting	O
additive	I-Problem
cns	I-Problem
effects	I-Problem
.	O

patients	O
receiving	O
amifostine	I-Treatment
who	O
develop	O
only	O
fever	I-Problem
should	O
be	O
evaluated	O
for	O
an	O
adverse	O
drug	O
reaction	O
,	O
as	O
well	O
as	O
for	O
sepsis	I-Problem
and	I-Problem
fevers	I-Problem
of	I-Problem
neutropenia	I-Problem
,	O
and	O
it	O
may	O
be	O
necessary	O
to	O
discontinue	O
the	O
drug	O
.	O

clinical	O
signs	O
of	O
hypermagnesemia	I-Problem
are	O
an	O
uncommon	O
complication	O
following	O
oral	I-Treatment
administration	I-Treatment
of	I-Treatment
magnesium	I-Treatment
sulfate	I-Treatment
.	O

markedly	I-Problem
increased	I-Problem
pigmementation	I-Problem
of	I-Problem
skin	I-Problem
immediately	I-Problem
overlying	I-Problem
veins	I-Problem
used	O
for	O
multiple	I-Treatment
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
infusions	I-Treatment
was	O
noted	O
.	O

severe	I-Problem
hepatitis	I-Problem
caused	O
by	O
cyproterone	I-Treatment
acetate	I-Treatment
.	O

erythema	I-Problem
multiforme	I-Problem
associated	O
with	O
phenytoin	I-Treatment
and	I-Treatment
cranial	I-Treatment
radiation	I-Treatment
therapy	I-Treatment
:	O
a	O
report	O
of	O
three	O
patients	I-Background
and	O
review	O
of	O
the	O
literature	O
.	O

chloroquine	I-Treatment
has	O
been	O
used	O
for	O
many	O
decades	O
in	O
the	O
prophylaxis	I-Problem
and	I-Problem
treatment	I-Problem
of	O
malaria	I-Problem
.	O

before	O
icu	O
admission	O
,	O
the	I-Background
patient	I-Background
had	I-Background
suffered	I-Background
from	I-Background
painful	I-Background
mucositis	I-Problem
causing	O
severe	I-Problem
dysphagia	I-Problem
and	I-Problem
bleeding	I-Problem
,	O
which	O
was	O
thought	O
to	O
be	O
the	O
result	O
of	O
chemotherapy	I-Treatment
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
patient	I-Background
with	I-Background
the	I-Background
acquired	I-Problem
immunodeficiency	I-Problem
syndrome	I-Problem
treated	O
with	O
rifampicin	I-Treatment
who	O
had	O
a	O
'	O
normal	O
'	O
screening	O
test	O
for	O
adrenal	O
insufficiency	O
,	O
yet	O
had	O
clinical	O
evidence	O
of	O
adrenal	I-Problem
failure	I-Problem
.	O

we	O
postulate	O
that	O
cyclosporin	I-Treatment
,	O
possibly	O
together	I-Treatment
with	I-Treatment
ganciclovir	I-Treatment
,	O
can	O
produce	O
transient	I-Problem
brain	I-Problem
stem	I-Problem
or	I-Problem
neuromuscular	I-Problem
dysfunction	I-Problem
with	I-Problem
eye	I-Problem
movement	I-Problem
abnormality	I-Problem
in	O
occasional	I-Background
patients	I-Background
.	O

three	O
patients	I-Background
,	O
in	O
whom	O
tumour	I-Problem
overkill	O
by	O
cytotoxic	I-Treatment
treatment	I-Treatment
,	I-Treatment
including	I-Treatment
high	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
with	I-Treatment
folinic	I-Treatment
acid	I-Treatment
rescue	I-Treatment
,	O
resulted	O
in	O
the	O
'	I-Problem
phosphate	I-Problem
shower	I-Problem
syndrome	I-Problem
'	I-Problem
(	I-Problem
hyper	I-Problem
-	I-Problem
uricaemia	I-Problem
,	I-Problem
hyperkalaemia	I-Problem
and	I-Problem
hyperphosphataemia	I-Problem
with	I-Problem
hypocalcaemia	I-Problem
and	I-Problem
tetany	I-Problem
,	I-Problem
with	I-Problem
metabolic	I-Problem
acidosis	I-Problem
and	I-Problem
acute	I-Problem
renal	I-Problem
impairment	I-Problem
)	I-Problem
are	O
described	O
.	O

methylene	I-Treatment
blue	I-Treatment
-	O
associated	O
serotonin	I-Problem
toxicity	I-Problem
has	O
been	O
described	O
before	O
but	O
usually	O
as	O
mild	O
toxicity	O
.	O

the	O
second	O
was	O
an	O
82	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
receiving	I-Treatment
ticlopidine	I-Treatment
for	I-Treatment
2	I-Other
years	I-Other
when	O
,	O
during	O
a	O
febrile	O
episode	O
,	O
he	O
was	O
found	O
neutropenic	I-Problem
with	I-Problem
marrow	I-Problem
aplasia	I-Problem
.	I-Problem

we	O
report	O
a	O
case	O
of	O
pediatric	I-Background
bupropion	I-Treatment
ingestion	I-Treatment
resulting	O
in	O
multiple	I-Problem
seizures	I-Problem
.	O

the	O
co	I-Treatment
-	I-Treatment
administration	I-Treatment
of	I-Treatment
ssris	I-Treatment
and	I-Treatment
fentanyl	I-Treatment
may	O
precipitate	O
serotonin	I-Problem
toxicity	I-Problem
.	O

three	I-Other
days	I-Other
after	I-Treatment
intravitreal	I-Treatment
injection	I-Treatment
of	I-Treatment
bevacizumab	I-Treatment
,	O
acute	I-Problem
ocular	I-Problem
ischemic	I-Problem
syndrome	I-Problem
occurred	O
.	O

calcipotriol	I-Treatment
(	O
daivonex	O
r	O
;	O
leo	O
pharmaceuticals	O
,	O
zurich	O
,	O
switzerland	O
)	O
may	O
cause	O
irritation	I-Problem
of	I-Problem
the	I-Problem
skin	I-Problem
,	O
whereas	O
allergic	O
reactions	O
are	O
less	O
common	O
.	O

after	O
discontinuation	I-Treatment
of	I-Treatment
danazol	I-Treatment
the	O
diabetes	I-Problem
completely	O
resolved	O
.	O

we	O
describe	O
the	O
development	O
of	O
ischemic	I-Problem
colitis	I-Problem
in	O
a	O
woman	I-Background
who	O
was	O
treated	O
with	O
tegaserod	I-Treatment
and	O
review	O
the	O
relationship	O
among	O
ischemic	O
colitis	O
,	O
tegaserod	O
use	O
,	O
and	O
irritable	O
bowel	O
syndrome	O
.	O

we	O
presented	O
the	O
case	O
of	O
a	I-Background
patient	I-Background
who	O
developed	O
a	O
cutaneous	I-Problem
reaction	I-Problem
induced	O
by	O
captopril	I-Treatment
with	O
positive	O
patch	O
test	O
.	O

this	O
latest	O
(	O
third	O
)	O
report	O
suggests	O
that	O
the	O
safety	O
profile	O
should	O
be	O
reexamined	O
and	O
at	O
least	O
raises	O
the	O
question	O
of	O
potential	I-Problem
renal	I-Problem
toxicity	I-Problem
of	O
interferons	I-Treatment
in	O
ms	I-Problem
.	I-Problem

co	I-Treatment
-	I-Treatment
trimoxazole	I-Treatment
red	I-Problem
cell	I-Problem
aplasia	I-Problem
in	O
leukaemia	I-Problem
.	O

interferon	I-Treatment
-	I-Test
alpha	I-Test
(	I-Test
ifn	I-Treatment
-	I-Test
alpha	I-Test
)	I-Treatment
may	O
precipitate	O
or	O
exacerbate	O
the	O
occurrence	O
of	O
mpgn	I-Problem
.	O

toxic	I-Problem
epidermal	I-Problem
necrolysis	I-Problem
after	O
the	O
use	O
of	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
.	O

we	O
describe	O
3	O
elderly	I-Background
patients	I-Background
with	O
moderate	I-Problem
to	I-Problem
severe	I-Problem
ataxia	I-Problem
that	O
occurred	O
while	O
they	O
were	O
taking	I-Treatment
propafenone	I-Treatment
.	O

gestational	I-Problem
diabetes	I-Problem
was	O
no	O
less	O
severe	O
(	O
degree	O
of	O
hyperglycaemia	O
,	O
need	O
for	O
insulin	O
therapy	O
)	O
when	O
associated	O
with	O
norethisterone	I-Treatment
.	O

however	O
,	O
follow	O
-	O
up	O
revealed	O
that	O
gestational	O
diabetes	O
when	O
associated	O
with	O
norethisterone	I-Treatment
had	O
a	O
lesser	O
risk	O
of	O
emerging	O
diabetes	I-Problem
mellitus	I-Problem
and	I-Problem
impaired	I-Problem
glucose	I-Problem
tolerance	I-Problem
.	O

because	O
the	O
cerebellar	I-Problem
toxicity	I-Problem
may	O
be	O
worsened	O
by	O
continuation	O
of	O
therapy	O
after	O
initial	O
onset	O
of	O
symptoms	O
,	O
prompt	O
termination	O
of	O
hdarac	I-Treatment
is	O
recommended	O
.	O

we	O
describe	O
a	O
case	O
of	O
ulcerative	I-Problem
proctitis	I-Problem
after	O
ibuprofen	I-Treatment
treatment	I-Treatment
in	O
a	I-Background
girl	I-Background
with	I-Background
juvenile	I-Problem
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
.	O

clinicians	O
should	O
include	O
phenolphthalein	I-Treatment
in	O
their	O
list	O
of	O
possible	O
causes	O
of	O
drug	O
-	O
induced	O
ten	I-Problem
.	O

methotrexate	I-Treatment
-	O
induced	O
diffuse	I-Problem
interstitial	I-Problem
pulmonary	I-Problem
fibrosis	I-Problem
.	O

abdominal	I-Problem
wall	I-Problem
ulceration	I-Problem
and	I-Problem
mucinosis	I-Problem
secondary	O
to	O
recombinant	I-Treatment
human	I-Treatment
interferon	I-Treatment
-	I-Treatment
beta	I-Treatment
-	I-Treatment
1b	I-Treatment
.	O

asthenozoospermia	I-Problem
:	O
possible	O
association	O
with	O
long	I-Other
-	I-Other
term	I-Other
exposure	I-Treatment
to	I-Treatment
an	I-Treatment
anti	I-Treatment
-	I-Treatment
epileptic	I-Treatment
drug	I-Treatment
of	I-Treatment
carbamazepine	I-Treatment
.	O

psoriasis	I-Problem
triggered	O
by	O
toll	O
-	O
like	I-Test
receptor	I-Test
7	O
agonist	O
imiquimod	I-Treatment
in	O
the	O
presence	O
of	O
dermal	I-Problem
plasmacytoid	I-Problem
dendritic	I-Problem
cell	I-Problem
precursors	I-Problem
.	O

a	I-Background
52	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
black	I-Background
woman	I-Background
on	O
phenytoin	I-Treatment
therapy	O
for	O
post	I-Problem
-	I-Problem
traumatic	I-Problem
epilepsy	I-Problem
developed	O
transient	I-Problem
hemiparesis	I-Problem
contralateral	I-Problem
to	I-Problem
the	I-Problem
injury	I-Problem
.	O

use	O
of	O
the	O
naranjo	O
probability	I-Test
scale	I-Test
determined	O
the	O
association	O
between	O
cephalosporin	I-Treatment
use	O
and	O
leukopenia	I-Problem
to	O
be	O
probable	O
.	O

sister	O
chromatid	I-Test
exchanges	I-Test
(	I-Test
sces	O
)	I-Test
,	O
a	O
sensitive	O
measure	O
of	O
chromosome	I-Problem
damage	I-Problem
,	O
were	O
counted	O
in	O
peripheral	O
-	O
blood	I-Test
lymphocytes	I-Test
from	O
10	O
patients	I-Background
with	I-Background
behcet	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
receiving	O
chlorambucil	I-Treatment
.	O

sarcoma	I-Problem
complicating	O
therapy	O
with	O
cyclophosphamide	I-Treatment
.	O

clozapine	I-Treatment
induced	O
polyserositis	I-Problem
.	O

fatal	O
interstitial	I-Problem
lung	I-Problem
disease	I-Problem
after	O
erlotinib	I-Treatment
administration	O
in	O
a	I-Background
patient	I-Background
with	I-Background
radiation	I-Problem
fibrosis	I-Problem
.	O

the	O
pharmaceutical	O
company	O
producing	O
halfan	I-Treatment
has	O
reported	O
8	I-Problem
cardiac	I-Problem
arrests	I-Problem
,	O
leading	O
to	O
6	I-Problem
deaths	I-Problem
,	O
when	I-Treatment
a	I-Treatment
higher	I-Treatment
dose	I-Treatment
than	I-Treatment
recommended	I-Treatment
was	I-Treatment
used	I-Treatment
,	O
there	O
was	O
recent	O
or	O
concomitant	O
treatment	O
with	O
mefloquine	I-Treatment
,	O
there	O
was	O
pre	O
-	O
existing	O
prolongation	O
of	O
the	O
qt	O
interval	O
or	O
the	O
patient	O
had	O
a	O
thiamine	O
deficiency	O
.	O

conclusions	O
:	O
fixed	I-Problem
drug	I-Problem
rash	I-Problem
induced	O
by	O
methylphenidate	I-Treatment
is	O
a	O
possible	O
but	O
rare	O
phenomenon	O
.	O

special	O
care	O
should	O
be	O
taken	O
when	O
pulmonary	I-Problem
symptoms	I-Problem
appear	O
in	O
association	O
with	O
ticlopidine	I-Treatment
treatment	I-Treatment
.	O

conclusion	O
:	O
although	O
a	O
definite	O
association	O
has	O
not	O
been	O
proven	O
,	O
clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
agranulocytosis	I-Problem
while	O
using	O
quetiapine	I-Treatment
.	O

acute	I-Problem
renal	I-Problem
failure	I-Problem
is	O
a	O
rare	O
complication	O
following	O
the	O
administration	O
of	O
intravenous	I-Treatment
immunoglobulin	I-Treatment
(	I-Treatment
ivig	I-Treatment
)	I-Treatment
.	O

reactivation	I-Problem
of	I-Problem
cytomegalovirus	I-Problem
probably	O
followed	O
the	O
treatment	O
of	O
wegener	I-Problem
'	I-Problem
s	I-Problem
granulomatosis	I-Problem
with	O
corticosteroids	I-Treatment
and	I-Treatment
azathioprine	I-Treatment
.	O

we	O
present	O
a	O
case	O
of	O
respiratory	I-Problem
failure	I-Problem
occurring	O
in	O
a	I-Background
woman	I-Background
at	I-Background
16	I-Problem
weeks	I-Problem
'	I-Problem
gestation	I-Problem
who	O
was	O
being	I-Treatment
treated	I-Treatment
with	I-Treatment
nitrofurantoin	I-Treatment
for	I-Treatment
a	I-Treatment
urinary	I-Problem
tract	I-Problem
infection	I-Problem
.	O

we	O
describe	O
a	I-Background
case	I-Background
of	I-Background
ege	I-Problem
manifested	O
as	O
an	O
allergy	I-Problem
to	O
gemfibrozil	I-Treatment
.	O

results	O
:	O
at	O
our	O
institution	O
,	O
no	O
children	I-Background
appeared	O
with	O
acute	O
inh	I-Treatment
neurotoxicity	I-Problem
in	O
the	O
period	O
1985	O
through	O
1990	O
,	O
whereas	O
seven	O
patients	O
were	O
treated	O
from	O
1991	O
through	O
1993	O
.	O

two	O
patients	I-Background
on	O
long	I-Treatment
-	I-Treatment
term	I-Treatment
lithium	I-Treatment
therapy	I-Treatment
developed	O
the	O
nephrotic	I-Problem
syndrome	I-Problem
.	O

acute	I-Problem
psychosis	I-Problem
associated	O
with	O
levetiracetam	I-Treatment
.	O

hypoglycemia	I-Problem
induced	O
by	O
long	I-Treatment
-	I-Treatment
acting	I-Treatment
somatostatin	I-Treatment
analogues	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
nonfunctional	I-Problem
neuroendocrine	I-Problem
tumor	I-Problem
.	O

case	O
report	O
:	O
we	O
report	O
a	I-Background
patient	I-Background
who	O
developed	I-Problem
a	I-Problem
dat	I-Problem
-	I-Problem
positive	I-Problem
hemolytic	I-Problem
episode	I-Problem
after	O
a	I-Treatment
red	I-Treatment
cell	I-Treatment
(	I-Treatment
rbc	I-Treatment
)	I-Treatment
transfusion	I-Treatment
was	I-Treatment
delivered	I-Treatment
during	I-Treatment
the	I-Treatment
infusion	I-Treatment
of	I-Treatment
her	I-Treatment
17th	I-Other
cycle	I-Other
of	I-Treatment
oxaliplatin	I-Treatment
.	O

regression	O
of	O
thyrotoxic	I-Problem
ophthalmopathy	I-Problem
following	O
lithium	I-Treatment
withdrawal	I-Treatment
.	O

mechanism	O
of	O
topiramate	I-Treatment
-	O
induced	O
acute	I-Problem
-	I-Problem
onset	I-Problem
myopia	I-Problem
and	I-Problem
angle	I-Problem
closure	I-Problem
glaucoma	I-Problem
.	O

the	O
clinical	O
symptoms	O
of	O
gastric	I-Problem
mucosa	I-Problem
foveolar	I-Problem
hyperplasia	I-Problem
due	O
to	O
long	I-Other
-	I-Other
term	I-Other
pge1	I-Treatment
therapy	I-Treatment
simulate	I-Problem
hypertrophic	I-Problem
pyloric	I-Problem
stenosis	I-Problem
.	O

aggressive	O
management	O
of	O
doxorubicin	I-Treatment
-	O
induced	O
cardiomyopathy	I-Problem
associated	O
with	O
'	I-Treatment
low	I-Treatment
'	I-Treatment
doses	I-Treatment
of	O
doxorubicin	O
.	O

generalized	I-Problem
argyria	I-Problem
after	O
habitual	I-Treatment
use	I-Treatment
of	I-Treatment
agno3	I-Treatment
.	O

the	O
authors	O
report	O
the	O
first	O
case	O
of	O
bucillamine	I-Treatment
-	O
induced	O
giant	I-Problem
mammary	I-Problem
hyperplasia	I-Problem
.	O

hydroxyurea	I-Treatment
(	I-Test
hu	I-Treatment
)	I-Test
and	I-Treatment
sodium	I-Treatment
phenylbutyrate	I-Test
(	I-Test
spb	I-Treatment
)	I-Treatment
have	O
been	O
shown	O
to	O
increase	O
fetal	O
hemoglobin	I-Test
(	I-Test
hb	I-Test
f	I-Test
)	I-Test
levels	I-Test
in	O
patients	I-Background
with	I-Background
thalassemia	I-Problem
intermedia	I-Problem
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
biopsy	O
proven	O
myositis	I-Problem
whose	O
symptoms	O
began	O
within	I-Treatment
10	I-Other
days	I-Other
of	I-Treatment
receiving	I-Treatment
leuprolide	I-Treatment
acetate	I-Treatment
therapy	I-Treatment
for	O
prostate	I-Problem
cancer	I-Problem
.	O

objective	O
:	O
to	O
report	O
2	O
cases	I-Background
of	O
serotonin	I-Problem
syndrome	I-Problem
with	I-Problem
serious	I-Problem
extrapyramidal	I-Problem
movement	I-Problem
disorders	I-Problem
occurring	O
when	O
metoclopramide	I-Treatment
was	I-Treatment
coadministered	I-Treatment
with	I-Treatment
sertraline	I-Treatment
or	I-Treatment
venlafaxine	I-Treatment
.	O

we	O
report	O
a	I-Background
31	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
women	I-Background
with	I-Background
recurrent	I-Problem
hodgkin	I-Problem
'	I-Problem
s	I-Problem
lymphoma	I-Problem
and	I-Background
unrecognized	I-Problem
hmsn	I-Problem
-	I-Problem
1	I-Problem
who	O
developed	O
severe	I-Problem
motor	I-Problem
neuropathy	I-Problem
3	I-Other
weeks	I-Other
after	I-Treatment
the	I-Treatment
first	I-Treatment
cycle	I-Treatment
of	I-Treatment
treatment	I-Treatment
including	I-Treatment
2	I-Treatment
mg	I-Treatment
of	I-Treatment
vincristine	I-Treatment
.	O

when	O
the	I-Background
patient	I-Background
was	O
treated	O
again	O
with	O
fludarabine	I-Treatment
nine	I-Other
months	I-Other
later	I-Other
,	O
the	I-Problem
dat	I-Test
became	I-Problem
positive	I-Problem
with	I-Problem
anti	I-Problem
-	I-Problem
igg	I-Problem
and	I-Problem
anti	I-Problem
-	I-Problem
c3d	I-Problem
antiglobulins	I-Problem
after	O
the	O
second	I-Treatment
course	I-Treatment
of	I-Treatment
treatment	I-Treatment
.	O

this	O
case	O
report	O
describes	O
a	O
patient	I-Background
who	O
was	O
previously	O
prescribed	O
alendronate	I-Treatment
(	I-Treatment
fosamax	I-Treatment
)	I-Treatment
and	O
presented	O
with	O
postoperative	I-Problem
hypophosphatemia	I-Problem
and	I-Problem
hypocalcemic	I-Problem
tetany	I-Problem
after	I-Treatment
bowel	I-Treatment
preparation	I-Treatment
with	I-Treatment
fleet	I-Treatment
phospho	I-Treatment
-	I-Treatment
soda	I-Treatment
.	O

acute	I-Problem
dystonic	I-Problem
reaction	I-Problem
with	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
pimozide	I-Treatment
.	O

there	O
are	O
,	O
however	O
,	O
case	O
studies	O
describing	O
patients	O
experiencing	O
recurrences	I-Problem
of	I-Problem
tics	I-Problem
following	O
treatment	I-Treatment
with	I-Treatment
atomoxetine	I-Treatment
.	O

nicotinic	I-Treatment
acid	I-Treatment
-	O
induced	O
fulminant	I-Problem
hepatic	I-Problem
failure	I-Problem
.	O

ketanserin	O
in	O
the	O
treatment	O
of	O
protamine	I-Treatment
-	O
induced	O
pulmonary	I-Problem
hypertension	I-Problem
.	I-Problem

lithium	I-Treatment
and	I-Treatment
venlafaxine	I-Treatment
interaction	I-Treatment
:	O
a	O
case	O
of	O
serotonin	I-Problem
syndrome	I-Problem
.	O

the	O
seizures	I-Problem
were	O
suspected	O
to	O
be	O
caused	O
by	O
a	O
reduced	I-Treatment
concentration	I-Treatment
of	I-Treatment
vpa	I-Treatment
in	I-Treatment
the	I-Treatment
blood	I-Treatment
.	O

d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
induced	O
crescentic	I-Problem
glomerulonephritis	I-Problem
:	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

we	O
offered	O
several	O
tentative	O
explanations	O
for	O
this	O
event	O
,	O
including	O
an	O
adverse	I-Problem
interaction	I-Problem
between	O
paroxetine	I-Treatment
and	I-Treatment
other	I-Treatment
agent	I-Treatment
(	I-Treatment
s	I-Treatment
)	I-Treatment
used	O
in	O
the	O
course	O
of	O
the	O
anaesthesia	I-Treatment
.	O

neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
is	O
an	O
uncommon	O
and	O
potentially	O
fatal	O
idiosynchratic	O
reaction	O
of	O
antipsychotic	I-Treatment
drugs	I-Treatment
,	O
in	O
which	O
the	O
clinical	O
scenario	O
encompass	O
muscular	I-Problem
rigidity	I-Problem
,	I-Problem
hyperthermia	I-Problem
,	I-Problem
autonomic	I-Problem
dysfunction	I-Problem
,	I-Problem
altered	I-Problem
consciousness	I-Problem
,	I-Problem
high	I-Problem
creatinine	I-Problem
phosphokinase	I-Problem
levels	I-Problem
,	I-Problem
and	I-Problem
leukocytosis	I-Problem
.	O

indinavir	I-Treatment
-	O
associated	O
nephrolithiasis	I-Problem
and	I-Problem
chronic	I-Problem
interstitial	I-Problem
nephritis	I-Problem
were	O
the	O
only	O
possible	O
causes	O
identified	O
in	O
this	O
patient	O
.	O

gemcitabine	I-Treatment
is	O
a	O
chemotherapy	O
agent	O
that	O
may	O
cause	O
unpredictable	I-Problem
side	I-Problem
effects	I-Problem
.	O

albendazole	I-Treatment
-	O
induced	O
pseudomembranous	I-Problem
colitis	I-Problem
.	O

tuberculous	I-Problem
uveitis	I-Problem
after	O
treatment	O
with	O
etanercept	I-Treatment
.	O

salicylate	I-Treatment
-	O
induced	O
hepatotoxicity	I-Problem
is	O
reviewed	O
.	O

to	O
describe	O
a	I-Background
case	I-Background
of	O
flecainide	I-Treatment
-	O
induced	O
delirium	I-Problem
associated	O
with	O
a	O
pharmacokinetic	O
drug	O
interaction	I-Treatment
with	I-Treatment
paroxetine	I-Treatment
.	O

we	O
report	O
on	O
a	I-Background
patient	I-Background
who	O
developed	O
hypersensitivity	I-Problem
pneumonitis	I-Problem
during	O
treatment	O
with	O
the	O
beta	O
-	O
blocker	O
,	O
celiprolol	I-Treatment
.	O

dexmedetomidine	I-Treatment
is	O
used	O
to	O
provide	I-Problem
sedation	I-Problem
for	O
pediatric	I-Background
patients	I-Background
undergoing	I-Background
nonpainful	I-Background
radiological	I-Test
imaging	I-Test
studies	I-Test
.	O

a	I-Background
71	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
developed	O
serotonin	I-Problem
syndrome	I-Problem
while	O
receiving	O
treatment	O
with	O
moderate	I-Treatment
doses	I-Treatment
of	I-Treatment
lithium	I-Treatment
and	I-Treatment
venlafaxine	I-Treatment
for	O
refractory	I-Problem
depression	I-Problem
.	O

four	I-Other
years	I-Other
after	I-Other
the	I-Treatment
beginning	I-Treatment
of	I-Treatment
ifn	I-Treatment
therapy	I-Treatment
,	O
he	I-Background
acutely	I-Problem
developed	I-Problem
moderate	I-Problem
hyperglycemia	I-Problem
and	I-Problem
severe	I-Problem
ketonuria	I-Problem
with	I-Problem
positive	I-Problem
islet	I-Problem
cell	I-Problem
antibody	I-Problem
,	O
and	O
then	O
28	O
units	O
/	O
day	O
of	O
insulin	O
injection	O
was	O
started	O
.	O

tardive	I-Problem
dyskinesia	I-Problem
in	O
2	O
patients	I-Background
treated	O
with	O
ziprasidone	I-Treatment
.	O

the	O
mean	O
time	O
from	O
starting	O
mmf	I-Treatment
to	O
the	O
development	O
of	O
neutropenia	I-Problem
was	O
4	O
months	O
.	O

fulminant	I-Problem
hepatic	I-Problem
failure	I-Problem
associated	O
with	O
bicalutamide	I-Treatment
.	O

a	O
complex	O
pattern	O
of	O
melanonychia	I-Problem
and	I-Problem
onycholysis	I-Problem
after	O
treatment	O
with	O
pemetrexed	I-Treatment
for	I-Treatment
lung	I-Problem
cancer	I-Problem
.	O

hypernatraemia	I-Problem
induced	O
by	O
sodium	I-Treatment
polystyrene	I-Treatment
sulphonate	I-Treatment
(	I-Treatment
kayexalate	I-Treatment
)	I-Treatment
in	O
two	O
extremely	I-Background
low	I-Background
birth	I-Background
weight	I-Background
newborns	I-Background
.	O

hypoxia	O
is	O
a	O
predisposing	O
factor	O
for	O
premature	I-Problem
ductal	I-Problem
closure	I-Problem
and	O
often	O
occurs	O
after	O
maternal	I-Treatment
indomethacin	I-Treatment
therapy	I-Treatment
.	O

severe	O
histological	I-Problem
osteomalacia	I-Problem
developed	O
in	O
a	I-Background
woman	I-Background
with	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
2	I-Treatment
years	I-Treatment
after	I-Treatment
ileal	I-Treatment
resection	I-Treatment
and	I-Treatment
the	I-Treatment
start	I-Other
of	I-Treatment
cholestyramine	I-Treatment
therapy	O
.	O

serotonin	I-Problem
syndrome	I-Problem
(	I-Problem
ss	I-Problem
)	I-Problem
and	I-Problem
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
(	I-Problem
nms	I-Problem
)	I-Problem
are	O
medical	O
emergencies	O
associated	O
with	O
psychotropic	I-Treatment
administration	I-Treatment
.	O

drug	I-Problem
eruption	I-Problem
caused	O
by	O
azathioprine	I-Treatment
:	O
value	O
of	O
using	O
the	O
drug	O
-	I-Test
induced	I-Test
lymphocytes	I-Test
stimulation	I-Test
test	I-Test
for	O
diagnosis	O
.	O

continuous	O
eeg	I-Test
monitoring	I-Test
is	O
helpful	O
in	O
managing	O
seizures	I-Problem
that	O
occur	O
as	O
a	I-Treatment
complication	I-Treatment
of	I-Treatment
cbz	I-Treatment
od	I-Treatment
,	O
after	O
the	O
course	O
of	O
recovery	O
or	O
worsening	O
,	O
and	O
in	O
providing	O
assistance	O
with	O
prognosis	O
.	O

the	O
fluorine	I-Treatment
contained	O
in	O
niflumic	I-Treatment
acid	I-Treatment
induced	O
a	O
marked	I-Problem
densification	I-Problem
of	I-Problem
trabecular	I-Problem
bone	I-Problem
in	O
all	I-Background
3	O
cases	I-Background
.	O

a	I-Background
17	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
with	I-Background
refractory	I-Problem
psoriatic	I-Problem
arthritis	I-Problem
and	I-Background
alpha	I-Problem
-	I-Problem
1	I-Problem
antitrypsin	I-Problem
deficiency	I-Problem
who	O
developed	O
a	O
syringotropic	I-Problem
hypersensitivity	I-Problem
reaction	I-Problem
after	O
9	I-Other
months	I-Other
of	I-Treatment
therapy	I-Treatment
with	I-Treatment
infliximab	I-Treatment
and	I-Treatment
leflunomide	I-Treatment
is	O
described	O
.	O

managing	O
cardiovascular	I-Problem
collapse	I-Problem
in	O
severe	I-Treatment
flecainide	I-Treatment
overdose	I-Treatment
without	O
recourse	O
to	O
extracorporeal	O
therapy	O
.	O

a	O
53	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
caucasian	I-Background
male	I-Background
victim	I-Background
of	I-Background
suicide	I-Background
was	O
suspected	O
of	O
overdose	I-Treatment
with	O
sertraline	I-Treatment
and	I-Treatment
alprazolam	I-Treatment
after	O
death	O
-	I-Test
scene	I-Test
investigation	I-Test
.	O

infliximab	I-Treatment
therapy	I-Treatment
may	O
cause	O
a	O
lupus	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
that	O
is	O
reversible	O
upon	O
discontinuing	O
this	O
agent	O
.	O

a	I-Background
7	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
with	I-Background
congenital	I-Problem
toxoplasmosis	I-Problem
who	O
took	O
pyrimethamine	I-Treatment
and	I-Treatment
sulfadiazine	I-Treatment
for	I-Treatment
reactivated	I-Problem
chorioretinitis	I-Problem
developed	O
fever	I-Problem
,	I-Problem
severe	I-Problem
cutaneous	I-Problem
involvement	I-Problem
,	I-Problem
swelling	I-Problem
,	I-Problem
abdominal	I-Problem
pain	I-Problem
and	I-Problem
transaminitis	I-Problem
,	O
persisting	O
weeks	O
after	O
withholding	O
medicines	O
.	O

pain	O
management	O
discussion	O
forum	O
:	O
serious	I-Problem
interaction	I-Problem
among	O
frequently	I-Other
used	I-Treatment
drugs	I-Treatment
for	O
chronic	I-Problem
pain	I-Problem
.	O

this	I-Problem
kind	I-Problem
of	I-Problem
reaction	I-Problem
is	O
seldom	O
mentioned	O
as	O
occurring	O
during	O
co	I-Treatment
-	I-Treatment
administration	I-Treatment
with	I-Treatment
tizanidine	I-Treatment
.	O

progressive	I-Problem
hypokalemia	I-Problem
developed	O
during	O
phosphate	I-Treatment
treatment	O
.	O

a	I-Background
69	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
pure	I-Problem
red	I-Problem
cell	I-Problem
aplasia	I-Problem
after	O
taking	I-Treatment
fenoprofen	I-Treatment
for	I-Treatment
ten	I-Other
months	I-Other
.	O

introduction	O
of	O
etanercept	I-Treatment
was	O
also	O
clinically	O
effective	O
but	O
followed	O
by	O
development	O
of	O
severe	I-Problem
heart	I-Problem
failure	I-Problem
.	I-Problem

minimal	I-Problem
change	I-Problem
nephrotic	I-Problem
syndrome	I-Problem
developing	O
during	O
postoperative	I-Treatment
interferon	I-Treatment
-	I-Treatment
beta	I-Treatment
therapy	I-Treatment
for	I-Treatment
malignant	I-Problem
melanoma	I-Problem
.	O

she	I-Background
was	I-Background
admitted	I-Background
following	I-Background
a	I-Background
fall	I-Problem
and	O
,	O
after	O
being	O
given	O
metoclopramide	I-Treatment
,	O
developed	O
movement	I-Problem
disorder	I-Problem
and	I-Problem
a	I-Problem
period	I-Problem
of	I-Problem
unresponsiveness	I-Problem
.	O

we	O
observed	O
transient	I-Problem
panhypogammaglobulinaemia	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
neuropsychiatric	I-Problem
sle	I-Problem
after	O
treatment	O
with	O
prednisolone	I-Treatment
and	I-Treatment
cyclophosphamide	I-Treatment
.	O

isoniazid	I-Treatment
inhibits	O
the	O
conversion	O
of	O
tryptophan	O
to	O
niacin	O
and	O
may	O
induce	O
pellagra	I-Problem
,	O
particularly	O
in	O
poorly	I-Problem
nourished	I-Problem
patients	I-Background
.	O

the	O
authors	O
suggest	O
that	O
in	O
patients	I-Background
with	I-Background
corneal	I-Problem
ulcers	I-Problem
refractory	O
to	O
conventional	O
treatment	O
who	O
are	O
receiving	O
colchicine	I-Treatment
,	O
cessation	O
of	O
colchicine	O
therapy	O
should	O
be	O
considered	O
.	O

after	O
the	O
patient	I-Treatment
discontinued	I-Treatment
rifampicin	I-Treatment
,	O
the	O
skin	I-Problem
lesions	I-Problem
cleared	I-Problem
completely	I-Problem
within	I-Other
5	I-Other
weeks	I-Other
without	O
any	O
systemic	O
medication	O
.	O

ziprasidone	I-Treatment
is	O
an	O
atypical	O
antipsychotic	I-Problem
drug	O
that	O
is	O
believed	O
to	O
have	O
a	O
low	O
propensity	O
for	O
inducing	O
extrapyramidal	I-Problem
symptoms	I-Problem
,	I-Problem
including	I-Problem
tardive	I-Problem
dyskinesia	I-Problem
(	I-Problem
td	I-Problem
)	I-Problem
.	O

acute	I-Problem
ischaemia	I-Problem
of	I-Problem
the	I-Problem
leg	I-Problem
following	O
accidental	O
intra	I-Treatment
-	I-Treatment
arterial	I-Treatment
injection	I-Treatment
of	I-Treatment
dissolved	I-Treatment
flunitrazepam	I-Treatment
tablets	I-Treatment
.	O

emphasis	O
is	O
given	O
to	O
the	O
differentiation	O
of	O
diphenylhydantoin	I-Treatment
induced	O
gingival	I-Problem
hyperplasia	I-Problem
from	O
the	I-Problem
angiomatous	I-Problem
enlargement	I-Problem
of	I-Problem
the	I-Problem
gingiva	I-Problem
before	O
any	O
treatment	O
is	O
planned	O
.	O

electro	O
-	I-Test
oculography	I-Test
,	O
electroretinography	O
,	O
visual	O
evoked	I-Test
potentials	I-Test
,	O
and	O
multifocal	O
electroretinography	I-Test
in	O
patients	I-Background
with	O
vigabatrin	I-Treatment
-	O
attributed	O
visual	I-Problem
field	I-Problem
constriction	I-Problem
.	O

case	O
summaries	O
:	O
two	O
patients	I-Background
with	I-Background
stable	I-Problem
hypothyroidism	I-Problem
experienced	O
symptoms	O
of	O
hypothyroidism	I-Problem
with	I-Problem
increased	I-Problem
serum	I-Problem
thyroid	I-Problem
-	I-Problem
stimulating	I-Problem
hormone	I-Problem
(	O
tsh	O
)	O
concentrations	O
after	O
switching	I-Treatment
from	I-Treatment
1	I-Treatment
levothyroxine	I-Treatment
product	I-Treatment
to	I-Treatment
another	I-Treatment
.	O

an	O
objective	I-Test
causality	I-Test
assessment	I-Test
indicated	O
a	O
probable	O
relationship	O
between	O
clotting	I-Problem
abnormality	I-Problem
and	O
warfarin	I-Treatment
administration	O
,	O
although	O
the	O
degree	O
of	O
elevation	O
of	O
the	O
inr	O
was	O
unusual	O
in	O
the	O
light	O
of	O
the	O
daily	O
warfarin	O
dose	O
and	O
duration	O
of	O
its	O
exposure	O
.	O

the	O
pathophysiological	O
mechanisms	O
remain	O
unknown	O
,	O
although	O
the	O
drug	O
could	O
act	O
through	O
massive	I-Problem
cytokines	I-Problem
liberation	I-Problem
after	O
destruction	I-Problem
of	I-Problem
cd20	I-Problem
positive	I-Problem
cells	I-Problem
by	O
rituximab	I-Treatment
.	O

the	O
more	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
effects	O
of	O
sunitinib	I-Treatment
include	O
hypertension	I-Problem
,	I-Problem
fatigue	I-Problem
,	I-Problem
hand	I-Problem
-	I-Problem
foot	I-Problem
syndrome	I-Problem
,	I-Problem
elevated	I-Problem
lipase	I-Problem
and	I-Problem
lymphopenia	I-Problem
.	O

we	O
report	O
a	O
45	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
psoriasis	I-Problem
patient	I-Background
who	O
developed	O
eruptive	I-Problem
mollusca	I-Problem
contagiosa	I-Problem
during	O
an	O
antipsoriatic	I-Treatment
treatment	I-Treatment
with	I-Treatment
efalizumab	I-Treatment
.	O

skin	I-Problem
necrosis	I-Problem
is	O
a	O
rare	O
complication	O
of	O
subcutaneous	I-Treatment
heparin	I-Treatment
therapy	I-Treatment
that	O
usually	O
occurs	O
at	O
injection	O
sites	O
.	O

epsilon	I-Treatment
-	I-Treatment
aminocaproic	I-Treatment
acid	I-Treatment
and	O
renal	I-Problem
complications	I-Problem
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

ibuprofen	I-Treatment
rarely	O
causes	O
lower	O
gastrointestinal	O
adverse	O
reactions	O
but	O
has	O
been	O
implicated	O
in	O
systemic	I-Problem
and	I-Problem
local	I-Problem
side	I-Problem
effects	I-Problem
in	I-Problem
patients	I-Problem
with	I-Problem
lupus	I-Problem
.	O

case	O
summaries	O
:	O
while	O
conducting	O
a	O
protocol	O
evaluating	O
the	O
efficacy	O
of	O
intraperitoneal	I-Treatment
cisplatin	I-Treatment
and	I-Treatment
hyperthermia	I-Treatment
in	O
the	O
treatment	O
of	O
recurrent	I-Problem
ovarian	I-Problem
cancer	I-Problem
,	O
3	O
patients	I-Background
were	O
noted	O
to	O
exhibit	O
anaphylactoid	I-Problem
reactions	I-Problem
.	O

perinatal	I-Problem
vasoconstrictive	I-Problem
renal	I-Problem
insufficiency	I-Problem
associated	O
with	O
maternal	I-Treatment
nimesulide	I-Treatment
use	I-Treatment
.	O

protease	I-Treatment
inhibitors	I-Treatment
(	I-Treatment
ritonavir	I-Treatment
and	I-Treatment
saquinavir	I-Treatment
)	I-Treatment
were	I-Treatment
added	I-Treatment
to	I-Treatment
the	I-Treatment
treatment	I-Treatment
and	O
the	I-Background
patient	I-Background
developed	O
progressive	I-Problem
ataxia	I-Problem
related	I-Problem
to	I-Problem
carbamazepine	I-Treatment
toxicity	I-Problem
.	O

the	O
medical	O
examiner	O
'	O
s	O
report	O
indicated	O
death	I-Problem
caused	O
by	O
fluoxetine	I-Treatment
toxicity	I-Treatment
.	O

hypertonic	I-Treatment
sodium	I-Treatment
bicarbonate	I-Treatment
is	O
recognized	O
as	O
effective	O
therapy	O
for	O
hypotension	I-Problem
and	I-Problem
arrhythmias	I-Problem
.	O

because	O
toxicity	I-Problem
may	O
occur	O
when	O
flecainide	I-Treatment
is	I-Treatment
prescribed	I-Treatment
with	I-Treatment
paroxetine	I-Treatment
and	I-Treatment
other	I-Treatment
potent	I-Treatment
cyp2d6	I-Treatment
inhibitors	I-Treatment
,	O
flecainide	O
plasma	I-Test
concentrations	I-Test
should	O
be	O
monitored	O
closely	O
with	O
commencement	O
of	O
cyp2d6	O
inhibitors	O
.	O

gentamicin	I-Treatment
-	O
associated	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
.	O

sulfasalazine	I-Problem
-	O
induced	O
lung	I-Problem
disorder	I-Problem
is	O
an	O
extremely	O
rare	O
entity	O
which	O
must	O
be	O
considered	O
in	O
all	O
ulcerative	O
colitis	O
patients	O
while	O
on	O
sulfasalazine	O
therapy	O
,	O
despite	O
the	O
absence	O
of	O
pulmonary	O
symptomatology	O
.	O

suspected	O
ciprofloxacin	I-Treatment
-	O
induced	O
interstitial	I-Problem
nephritis	I-Problem
.	O

tegaserod	I-Treatment
-	O
associated	O
ischemic	I-Problem
colitis	I-Problem
.	O

clinicians	O
should	O
be	O
aware	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
neurotoxicity	O
during	O
treatment	O
,	O
as	O
well	O
as	O
predisposing	O
factors	O
that	O
put	O
patients	I-Background
receiving	O
methotrexate	I-Treatment
at	O
risk	O
for	O
neurotoxic	I-Problem
effects	I-Problem
.	O

we	O
report	O
the	O
first	O
case	O
of	O
chlorambucil	I-Treatment
-	O
induced	O
dress	I-Problem
syndrome	I-Problem
in	O
a	I-Background
70	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
recently	O
diagnosed	O
with	O
chronic	I-Problem
lymphocytic	I-Problem
leukaemia	I-Problem
.	O

are	O
nasal	O
decongestants	O
safer	O
than	O
rhinitis	O
?	O
a	O
case	O
of	O
oxymetazoline	I-Treatment
-	O
induced	O
syncope	I-Problem
.	O

marked	I-Problem
elevation	I-Problem
of	I-Problem
serum	I-Problem
creatine	I-Problem
kinase	I-Problem
associated	O
with	O
olanzapine	I-Treatment
therapy	I-Treatment
.	O

after	O
cessation	I-Treatment
of	I-Treatment
amantadine	I-Treatment
,	O
the	I-Problem
edema	I-Problem
resolved	I-Problem
,	I-Problem
and	I-Problem
the	I-Problem
endothelial	I-Test
cell	I-Test
densities	I-Test
were	I-Problem
<	I-Treatment
or	I-Treatment
=	I-Treatment
600	I-Treatment
/	I-Treatment
mm	I-Treatment
.	O

discussion	O
:	O
olanzapine	I-Treatment
,	O
like	O
other	O
atypical	I-Treatment
antipsychotic	I-Treatment
drugs	I-Treatment
,	O
may	O
cause	O
muscle	I-Problem
injury	I-Problem
with	I-Problem
concomitant	I-Problem
elevations	I-Problem
of	I-Problem
serum	I-Problem
ck	I-Problem
of	I-Problem
muscle	I-Problem
origin	I-Problem
.	O

study	O
202	O
was	O
an	O
open	O
-	O
label	O
,	O
add	O
-	O
on	O
study	I-Test
in	O
patients	I-Background
with	I-Background
partial	I-Background
or	I-Background
generalized	I-Background
epilepsy	I-Background
treated	O
with	O
valproic	I-Treatment
acid	I-Treatment
(	I-Treatment
vpa	I-Treatment
)	I-Treatment
,	I-Treatment
carbamazepine	I-Treatment
(	I-Treatment
cbz	I-Treatment
)	I-Treatment
,	I-Treatment
phenytoin	I-Treatment
(	I-Treatment
pht	I-Treatment
)	I-Treatment
,	I-Treatment
or	I-Treatment
topiramate	I-Treatment
(	I-Treatment
tpm	I-Treatment
)	I-Treatment
as	I-Treatment
monotherapy	I-Treatment
.	O

dual	O
antiplatelet	O
therapy	O
with	O
aspirin	I-Treatment
and	I-Treatment
a	I-Treatment
p2y12	I-Treatment
receptor	I-Treatment
antagonist	I-Treatment
following	I-Treatment
placement	I-Treatment
of	I-Treatment
coronary	I-Treatment
stents	I-Treatment
is	O
critical	O
to	O
prevent	O
stent	I-Problem
thrombosis	I-Problem
and	I-Problem
subsequent	I-Problem
myocardial	I-Problem
infarction	I-Problem
.	O

organometals	I-Treatment
also	O
compromise	I-Problem
the	I-Problem
limbic	I-Problem
system	I-Problem
and	O
result	O
in	O
deficits	I-Problem
in	I-Problem
learning	I-Problem
and	I-Problem
memory	I-Problem
.	O

optic	I-Problem
neuropathy	I-Problem
associated	O
with	O
penicillamine	I-Treatment
therapy	O
in	O
a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
.	O

we	O
present	O
the	O
first	O
case	O
of	O
ovarian	I-Problem
endometrioid	I-Problem
carcinoma	I-Problem
and	I-Problem
endometriosis	I-Problem
in	O
a	O
postmenopausal	I-Background
patient	I-Background
who	O
was	O
treated	O
with	O
tamoxifen	I-Treatment
for	O
breast	I-Problem
cancer	I-Problem
.	I-Background

there	O
was	O
a	O
good	O
correlation	O
between	O
the	O
total	I-Treatment
dose	I-Treatment
of	I-Treatment
acth	I-Treatment
and	O
the	O
percentage	I-Problem
decrease	I-Problem
of	I-Problem
brain	I-Problem
parenchyma	I-Problem
.	O

we	O
noted	O
that	O
the	O
delirium	I-Problem
resembled	I-Problem
serotonin	I-Problem
toxicity	I-Problem
and	O
that	O
the	O
patient	O
had	O
been	O
taking	O
paroxetine	I-Treatment
until	I-Treatment
2	I-Treatment
days	I-Treatment
before	I-Treatment
surgery	I-Treatment
.	O

primary	I-Problem
central	I-Problem
nervous	I-Problem
system	I-Problem
lymphoma	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
natalizumab	I-Treatment
.	O

we	O
retrospectively	O
reviewed	O
the	O
records	O
of	O
7	O
pediatric	I-Background
oncology	I-Problem
patients	I-Background
who	O
received	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
ketamine	I-Treatment
in	I-Treatment
conjunction	I-Treatment
with	I-Treatment
propofol	I-Treatment
for	I-Treatment
total	I-Treatment
intravenous	I-Treatment
anesthesia	I-Treatment
(	I-Treatment
tiva	I-Treatment
)	I-Treatment
repeatedly	I-Treatment
for	I-Treatment
radiation	I-Treatment
therapy	I-Treatment
.	O

we	O
presume	O
the	O
cause	O
for	O
multiple	I-Problem
organ	I-Problem
failure	I-Problem
could	O
be	O
the	O
result	O
of	O
drug	O
-	O
drug	O
interaction	I-Treatment
,	I-Treatment
atorvastatin	I-Treatment
and	I-Treatment
verapamil	I-Treatment
,	O
as	O
verapamil	O
is	O
known	O
to	O
increase	O
the	O
serum	I-Test
concentration	I-Test
of	O
atorvastatin	O
significantly	O
.	O

hypersensitivity	I-Problem
to	O
zonisamide	I-Treatment
was	O
confirmed	O
by	O
the	O
skin	I-Test
patch	I-Test
test	I-Test
.	O

pulmonary	I-Problem
edema	I-Problem
occurred	O
24	I-Other
hours	I-Other
after	I-Treatment
intravenous	I-Treatment
ritodrine	I-Treatment
therapy	I-Treatment
and	I-Treatment
10	I-Other
hours	I-Other
after	I-Treatment
subcutaneous	I-Treatment
terbutaline	I-Treatment
therapy	I-Treatment
.	O

transient	I-Problem
acute	I-Problem
myopia	I-Problem
resulting	O
from	O
isotretinoin	I-Treatment
(	I-Treatment
accutane	I-Treatment
)	I-Treatment
therapy	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
fatal	I-Problem
fulminant	I-Problem
hepatitis	I-Problem
caused	O
by	O
the	O
use	O
of	O
disulfiram	I-Treatment
in	O
a	I-Background
man	I-Background
with	O
previously	O
normal	O
hepatocellular	O
function	O
.	O

objective	O
:	O
to	O
describe	O
two	O
cases	I-Background
of	O
rhabdomyolysis	I-Problem
in	O
patients	I-Background
taking	O
lovastatin	I-Treatment
that	I-Treatment
were	I-Treatment
precipitated	I-Treatment
by	I-Treatment
the	I-Treatment
use	I-Treatment
of	I-Treatment
the	I-Treatment
newer	I-Treatment
macrolide	I-Treatment
antibiotics	I-Treatment
clarithromycin	I-Treatment
and	I-Treatment
azithromycin	I-Treatment
.	O

neutrophilic	I-Problem
dermatoses	I-Problem
in	O
two	O
children	I-Background
with	I-Background
idiopathic	I-Problem
neutropenia	I-Problem
:	O
association	O
with	O
granulocyte	I-Treatment
colony	I-Treatment
-	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
(	I-Treatment
g	I-Treatment
-	I-Treatment
csf	I-Treatment
)	I-Treatment
therapy	I-Treatment
.	O

the	O
zinc	I-Treatment
/	I-Treatment
o	I-Treatment
-	I-Treatment
cymen	I-Treatment
-	I-Treatment
5	I-Treatment
-	I-Treatment
ol	I-Treatment
system	I-Treatment
has	O
direct	O
antimicrobial	I-Problem
effects	I-Problem
and	O
inhibits	I-Problem
oral	I-Problem
disease	I-Problem
-	I-Problem
related	I-Problem
processes	I-Problem
.	O

paroxetine	I-Treatment
is	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
possessing	O
anti	I-Problem
-	I-Problem
depressant	I-Problem
activity	I-Problem
.	O

a	I-Background
case	I-Background
of	O
polymyositis	I-Problem
with	I-Problem
dilated	I-Problem
cardiomyopathy	I-Problem
associated	O
with	O
interferon	I-Treatment
alpha	I-Treatment
treatment	O
for	O
hepatitis	I-Problem
b	I-Problem
.	I-Problem

phenytoin	I-Treatment
toxicity	O
:	O
an	O
easily	O
missed	O
cause	O
of	O
cerebellar	I-Problem
syndrome	I-Problem
.	O

hepatotoxicity	I-Problem
after	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
methylprednisolone	I-Treatment
for	O
demyelinating	I-Problem
disease	I-Problem
.	O

interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
-	O
induced	O
focal	I-Problem
segmental	I-Problem
glomerulosclerosis	I-Problem
in	I-Problem
chronic	I-Problem
myelogenous	I-Problem
leukemia	I-Problem
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

prior	O
reports	O
have	O
emphasized	O
the	O
tubular	I-Problem
and	I-Problem
interstitial	I-Problem
lesions	I-Problem
associated	O
with	O
intermittent	I-Treatment
or	I-Treatment
discontinuous	I-Treatment
rifampin	I-Treatment
therapy	I-Treatment
for	O
tuberculosis	I-Problem
.	O

transtentorial	I-Problem
herniation	I-Problem
caused	O
by	O
an	I-Problem
intracranial	I-Problem
mass	I-Problem
lesion	I-Problem
following	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
.	O

a	O
case	O
of	O
prolonged	I-Problem
suxamethonium	I-Treatment
apnoea	I-Problem
successfully	O
terminated	O
by	O
the	I-Treatment
infusion	I-Treatment
of	I-Treatment
a	I-Treatment
commercial	I-Treatment
preparation	I-Treatment
of	I-Treatment
serumcholinesterase	I-Treatment
is	O
reported	O
.	O

53	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
a	I-Background
history	I-Background
of	I-Background
deep	I-Problem
vein	I-Problem
thrombosis	I-Problem
and	I-Background
pulmonary	I-Problem
embolism	I-Problem
was	O
receiving	O
warfarin	I-Treatment
to	O
prevent	O
thromboembolic	I-Problem
complications	I-Problem
;	I-Problem
her	O
international	I-Test
normalized	I-Test
ratio	I-Test
(	O
inr	I-Test
)	O
had	O
been	O
stable	O
for	O
1	O
month	O
.	O

objective	O
:	O
to	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
asymptomatic	I-Problem
bronchial	I-Problem
asthma	I-Problem
and	I-Background
hypertension	I-Problem
who	O
developed	O
an	O
acute	I-Problem
asthma	I-Problem
attack	I-Problem
after	O
receiving	O
sustained	I-Treatment
-	I-Treatment
release	I-Treatment
verapamil	I-Treatment
.	O

severe	O
hepatotoxicity	I-Problem
related	O
to	O
benzarone	I-Treatment
:	O
a	O
report	O
of	O
three	O
cases	I-Background
with	O
two	O
fatalities	O
.	O

we	O
report	O
on	O
a	I-Background
56	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
who	O
exhibited	O
drug	I-Problem
refractory	I-Problem
paroxysmal	I-Problem
atrial	I-Problem
fibrillation	I-Problem
,	I-Problem
in	I-Problem
which	I-Problem
marked	I-Problem
prolongation	I-Problem
of	I-Problem
the	I-Problem
qt	I-Problem
interval	I-Problem
and	I-Problem
t	I-Problem
wave	I-Problem
inversion	I-Problem
on	O
electrocardiogram	O
was	O
demonstrated	O
reproducibly	O
shortly	O
after	O
the	O
administration	O
of	O
oral	O
pirmenol	I-Treatment
therapy	O
.	O

insulin	I-Treatment
-	O
induced	O
lipohypertrophy	I-Problem
:	O
report	O
of	O
a	O
case	O
with	O
histopathology	O
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
crest	I-Problem
syndrome	I-Problem
(	I-Problem
calcinosis	I-Problem
,	I-Problem
raynaud	I-Problem
'	I-Problem
s	I-Problem
phenomenon	I-Problem
,	I-Problem
esophageal	I-Problem
dysfunction	I-Problem
,	I-Problem
sclerodactyly	I-Problem
,	I-Problem
and	I-Problem
telangiectasia	I-Problem
)	I-Problem
who	O
paradoxically	O
experienced	O
worsening	I-Problem
of	I-Problem
raynaud	I-Problem
'	I-Problem
s	I-Problem
phenomenon	I-Problem
when	O
using	O
yohimbine	I-Treatment
for	O
ed	I-Problem
.	O

high	I-Treatment
-	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
-	O
associated	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
may	O
be	O
an	O
avoidable	O
complication	O
.	O

chronic	O
myelogenous	O
leukemia	O
(	O
cml	O
)	O
,	O
hepatitis	O
c	O
,	O
and	O
interferon	I-Treatment
alpha	I-Treatment
(	I-Treatment
ifnalpha	I-Treatment
)	I-Treatment
have	O
all	O
been	O
associated	O
with	O
renal	I-Problem
dysfunction	I-Problem
.	O

conclusions	O
:	O
infectious	I-Problem
endophthalmitis	I-Problem
is	O
a	O
potential	O
complication	O
of	O
intravitreal	I-Treatment
bevacizumab	I-Treatment
injection	I-Treatment
.	O

results	O
:	O
one	O
case	O
of	O
recurrent	I-Problem
primary	I-Problem
peritoneal	I-Problem
carcinoma	I-Problem
previously	O
treated	O
with	O
a	I-Treatment
carboplatin	I-Treatment
-	I-Treatment
based	I-Treatment
regimen	I-Treatment
,	O
developed	O
a	I-Problem
platinum	I-Problem
hypersensitivity	I-Problem
.	O

to	O
our	O
knowledge	O
,	O
these	O
cases	O
are	O
the	O
first	O
published	O
reports	O
of	O
lovastatin	I-Treatment
-	O
induced	O
rhabdomyolysis	I-Problem
associated	I-Treatment
with	I-Treatment
azithromycin	I-Treatment
and	I-Treatment
clarithromycin	I-Treatment
.	O

prick	O
tests	I-Test
and	O
intradermal	O
tests	I-Test
with	O
a	O
series	O
of	O
dilutions	O
of	O
carboplatin	O
and	O
cisplatin	O
were	O
performed	O
on	O
three	I-Background
patients	I-Background
who	O
had	O
exhibited	O
medium	I-Problem
and	I-Problem
severe	I-Problem
hypersensitivity	I-Problem
reactions	I-Problem
to	O
carboplatin	I-Treatment
.	O

a	O
case	O
of	O
sideroblastic	I-Problem
anemia	I-Problem
is	O
presented	O
in	O
a	I-Background
patient	I-Background
with	I-Background
a	I-Background
left	I-Problem
ventricular	I-Problem
assist	I-Problem
device	I-Problem
drive	I-Problem
-	I-Problem
line	I-Problem
infection	I-Problem
who	O
was	O
receiving	I-Treatment
linezolid	I-Treatment
,	O
an	O
antibiotic	O
used	O
for	O
serious	I-Problem
infections	I-Problem
with	I-Problem
gram	I-Problem
-	I-Problem
positive	I-Problem
organisms	I-Problem
.	O

development	O
of	O
nephrotic	I-Problem
syndrome	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
acute	I-Problem
myeloblastic	I-Problem
leukemia	I-Problem
after	O
treatment	O
with	O
macrophage	I-Treatment
-	I-Treatment
colony	I-Treatment
-	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
.	O

in	O
patients	O
with	O
a	O
known	O
access	O
to	O
inh	I-Treatment
,	O
seizures	I-Problem
should	O
be	O
considered	O
to	O
be	O
caused	O
by	O
inh	O
toxicity	O
unless	O
proved	O
otherwise	O
.	O

to	O
our	O
knowledge	O
,	O
this	O
is	O
the	I-Background
first	I-Background
case	I-Background
reported	O
in	O
the	O
english	O
literature	O
of	O
a	O
generalized	I-Problem
exanthem	I-Problem
due	O
to	O
subcutaneous	I-Treatment
injection	I-Treatment
of	I-Treatment
enoxaparin	I-Treatment
.	O

this	O
case	O
illustrates	O
the	O
potential	I-Problem
decoupling	I-Problem
of	I-Problem
psa	I-Problem
response	I-Problem
from	O
disease	O
status	O
in	O
flutamide	I-Treatment
withdrawal	I-Treatment
.	O

colonic	I-Problem
mucosal	I-Problem
necrosis	I-Problem
following	O
administration	O
of	O
calcium	I-Treatment
polystryrene	I-Treatment
sulfonate	I-Treatment
(	I-Treatment
kalimate	I-Treatment
)	I-Treatment
in	O
a	O
uremic	I-Problem
patient	I-Background
.	O

intracranial	I-Problem
hemorrhage	I-Problem
and	I-Problem
focal	I-Problem
seizures	I-Problem
secondary	O
to	O
use	O
of	O
l	I-Treatment
-	I-Treatment
asparaginase	I-Treatment
during	O
induction	O
therapy	O
of	O
acute	O
lymphocytic	O
leukemia	O
.	O

a	I-Problem
fatal	I-Problem
poisoning	I-Problem
case	I-Background
involving	O
etizolam	I-Treatment
,	I-Treatment
phenobarbital	I-Treatment
,	I-Treatment
promethazine	I-Treatment
and	I-Treatment
chlorpromazine	I-Treatment
is	O
presented	O
.	O

rituximab	O
-	O
based	O
therapy	O
for	O
gemcitabine	I-Treatment
-	O
induced	O
hemolytic	I-Problem
uremic	I-Problem
syndrome	I-Problem
in	O
a	O
patient	I-Background
with	I-Background
metastatic	I-Problem
pancreatic	I-Problem
adenocarcinoma	I-Problem
:	O
a	O
case	O
report	O
.	O

leukopenia	I-Problem
due	O
to	O
parvovirus	I-Problem
b19	I-Problem
in	I-Background
a	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
patient	I-Background
using	O
azathioprine	I-Treatment
.	O

fixed	I-Problem
drug	I-Problem
eruption	I-Problem
of	I-Problem
the	I-Problem
scrotum	I-Problem
due	O
to	O
methylphenidate	I-Treatment
.	O

cytarabine	I-Treatment
-	O
induced	O
cerebellar	I-Problem
syndrome	I-Problem
:	O
case	O
report	O
and	O
literature	O
review	O
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
glaucoma	I-Problem
induced	O
by	O
doxetaxel	I-Treatment
therapy	I-Treatment
for	I-Treatment
metastatic	I-Problem
breast	I-Problem
cancer	I-Problem
.	O

myoclonus	I-Problem
was	O
induced	O
and	O
enhanced	O
by	O
l	I-Treatment
-	I-Treatment
dopa	I-Treatment
,	O
developing	I-Problem
into	I-Problem
generalized	I-Problem
seizures	I-Problem
.	O

during	O
analysis	O
of	O
28	O
patients	O
receiving	O
cap	I-Treatment
with	I-Treatment
concomitant	I-Treatment
radiation	I-Treatment
(	I-Treatment
xrt	I-Test
)	I-Treatment
for	O
pancreatic	I-Problem
cancer	I-Problem
(	O
resected	O
or	O
locally	O
advanced	O
)	O
,	O
two	O
patients	I-Background
developed	O
signs	O
and	O
symptoms	O
consistent	O
with	O
peripheral	I-Problem
neuropathy	I-Problem
.	O

a	O
liver	I-Test
biopsy	I-Test
in	O
2012	O
revealed	O
marked	O
fibrosis	I-Problem
,	I-Background
leading	I-Background
the	I-Background
patient	I-Background
to	O
start	O
hepatitis	O
c	O
treatment	O
with	O
peginterferon	I-Treatment
alfa	I-Treatment
-	I-Treatment
2a	I-Treatment
,	I-Treatment
ribavirin	I-Treatment
and	I-Treatment
boceprevir	I-Treatment
.	O

knowledge	O
regarding	O
potential	O
adverse	O
effects	O
of	O
cap	I-Treatment
is	O
paramount	O
and	O
dose	O
modification	O
is	O
indicated	O
with	O
development	O
of	O
neurotoxicity	I-Problem
.	O

we	O
present	O
a	O
case	O
of	O
significant	O
over	O
-	O
anticoagulation	O
temporally	O
associated	O
with	O
a	O
bout	O
of	O
protracted	I-Problem
diarrhea	I-Problem
in	O
a	O
patient	O
on	O
warfarin	I-Treatment
therapy	O
.	O

new	O
oral	I-Treatment
therapies	I-Treatment
for	O
type	I-Problem
2	I-Problem
diabetes	I-Problem
mellitus	I-Problem
:	O

the	O
case	O
histories	O
are	O
presented	O
of	O
two	O
patients	I-Background
who	O
developed	O
lung	I-Problem
disease	I-Problem
associated	O
with	O
the	I-Treatment
use	I-Treatment
of	I-Treatment
nitrofurantoin	I-Treatment
with	I-Problem
histological	I-Problem
features	I-Problem
of	I-Problem
bronchiolitis	I-Problem
obliterans	I-Problem
organising	I-Problem
pneumonia	I-Problem
(	I-Problem
boop	I-Problem
)	I-Problem
,	O
a	O
rare	O
but	O
recognised	O
form	O
of	O
drug	O
induced	O
injury	O
.	O

a	I-Background
57	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
right	I-Problem
bundle	I-Problem
branch	I-Problem
block	I-Problem
+	I-Problem
lph	I-Problem
and	I-Background
ventricular	I-Problem
premature	I-Problem
contractions	I-Problem
developed	O
complete	I-Problem
heart	I-Problem
block	I-Problem
(	I-Problem
chb	I-Problem
)	I-Problem
following	O
administration	O
of	O
disopyramide	I-Treatment
phosphate	I-Treatment
(	I-Treatment
norpace	I-Treatment
)	I-Treatment
.	O

methods	O
:	O
in	O
an	O
institutional	O
practice	O
setting	O
,	O
two	O
women	I-Background
,	I-Background
aged	I-Background
25	I-Background
and	I-Background
45	I-Background
,	O
developed	O
acute	I-Problem
myopia	I-Problem
after	O
starting	O
topiramate	I-Treatment
for	O
epilepsy	I-Problem
.	O

diffusion	O
-	I-Test
weighted	I-Test
mri	I-Test
correlates	O
of	O
subacute	I-Problem
methotrexate	I-Treatment
-	O
related	O
neurotoxicity	I-Problem
.	O

ards	I-Problem
is	O
rarely	O
associated	O
with	O
rituximab	O
infusion	O
for	O
lympho	O
-	O
proliferative	O
disorders	O
,	O
but	O
it	O
should	O
be	O
considered	O
by	O
those	O
administering	O
rituximab	I-Treatment
,	O
especially	O
when	O
a	I-Background
patient	I-Background
develops	O
severe	I-Problem
pulmonary	I-Problem
symptoms	I-Problem
soon	O
after	O
infusion	I-Treatment
.	O

seven	I-Background
of	I-Background
the	I-Background
eight	O
cases	I-Background
of	O
acute	I-Problem
leukemia	I-Problem
occurred	O
in	O
a	O
series	O
of	O
553	O
patients	O
treated	O
with	O
treosulfan	I-Treatment
for	O
ovarian	I-Problem
cancer	I-Problem
in	O
the	O
period	O
from	O
1970	O
to	O
1977	O
and	O
followed	O
closely	O
for	O
a	O
total	O
of	O
1159	O
patient	O
-	O
years	O
up	O
to	O
february	O
1978	O
.	O

desipramine	I-Treatment
-	O
associated	O
siadh	I-Problem
in	O
an	I-Background
elderly	I-Background
woman	I-Background
:	O
case	O
report	O
.	O

can	O
propofol	I-Treatment
precipitate	O
pancreatitis	I-Problem
in	O
patients	I-Background
with	I-Background
cushing	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
?	I-Background

this	O
case	O
presents	O
the	O
possibility	O
of	O
anaphylaxis	I-Problem
to	O
topical	O
5	I-Treatment
-	I-Treatment
fu	I-Treatment
treatments	O
and	O
/	O
or	O
the	O
interaction	O
with	O
angiotensin	I-Treatment
converting	I-Treatment
enzyme	I-Treatment
inhibitors	I-Treatment
.	O

after	O
stopping	O
indapamide	I-Treatment
,	I-Treatment
glucose	I-Problem
tolerance	I-Problem
impairing	I-Problem
may	O
be	O
reversed	O
.	O

we	O
describe	O
a	O
case	O
of	O
needle	I-Problem
-	I-Problem
track	I-Problem
cutaneous	I-Problem
seeding	I-Problem
of	I-Problem
hepatocellular	I-Problem
carcinoma	I-Problem
(	O
hcc	O
)	O
after	O
sonographically	I-Treatment
guided	I-Treatment
percutaneous	I-Treatment
ethanol	I-Treatment
injection	I-Treatment
(	O
pei	O
)	O
.	O

zidovudine	I-Treatment
use	O
in	O
pregnancy	O
:	O
a	O
report	O
on	O
104	O
cases	O
and	O
the	O
occurrence	O
of	O
birth	I-Problem
defects	I-Problem
.	O

a	I-Background
patient	I-Background
with	I-Background
seropositive	I-Problem
rheumatoid	I-Problem
arthritis	I-Problem
developed	O
ascites	I-Problem
while	O
taking	I-Treatment
weekly	I-Other
doses	I-Treatment
of	I-Treatment
methotrexate	I-Treatment
(	I-Treatment
mtx	I-Treatment
)	I-Treatment
.	O

high	I-Problem
incidence	I-Problem
of	I-Problem
adverse	I-Problem
events	I-Problem
in	O
healthy	I-Background
volunteers	I-Background
receiving	O
rifampicin	I-Treatment
and	I-Treatment
adjusted	I-Treatment
doses	I-Treatment
of	I-Treatment
lopinavir	I-Treatment
/	I-Treatment
ritonavir	I-Treatment
tablets	I-Treatment
.	O

we	O
report	O
here	O
a	I-Background
case	I-Background
of	O
ten	I-Problem
after	O
administration	O
of	O
ciprofloxacin	I-Treatment
.	O

zidovudine	I-Treatment
induced	O
pure	I-Problem
red	I-Problem
cell	I-Problem
aplasia	I-Problem
:	O
a	I-Background
case	I-Background
report	O
.	O

a	I-Background
case	I-Background
of	O
recall	I-Problem
pneumonitis	I-Problem
induced	O
by	O
gemcitabine	I-Treatment
is	O
reported	O
.	O

albuterol	I-Treatment
-	O
induced	O
hypokalemia	I-Problem
and	I-Problem
its	I-Problem
potential	I-Problem
cardiac	I-Problem
toxicity	I-Problem
are	O
discussed	O
briefly	O
.	O

in	O
the	O
absence	O
of	O
an	O
ideal	O
dose	O
-	O
intense	O
fu	O
monotherapy	O
regimen	O
,	O
monthly	I-Other
fu	I-Treatment
with	I-Treatment
low	I-Treatment
-	I-Treatment
dose	I-Treatment
lv	I-Treatment
provides	O
a	O
simple	O
and	O
economical	O
means	O
by	O
which	O
to	O
achieve	O
adequate	O
fu	O
efficacy	O
in	O
the	O
treatment	O
of	O
advanced	I-Problem
colorectal	I-Problem
cancer	I-Problem
.	O

objective	O
:	O
to	O
report	O
a	I-Background
patient	I-Background
developing	O
fulminant	I-Problem
liver	I-Problem
failure	I-Problem
while	O
being	O
treated	O
with	O
clarithromycin	I-Treatment
for	O
pneumonia	I-Problem
.	O

the	O
abnormal	O
rhythm	O
disappeared	O
with	O
the	O
withdrawal	O
of	O
propranolol	I-Treatment
and	O
when	O
the	O
drug	O
was	O
restarted	O
a	O
2	I-Problem
/	I-Problem
1	I-Problem
s	I-Problem
-	I-Problem
a	I-Problem
block	I-Problem
was	O
seen	O
.	O

the	O
naranjo	I-Test
probability	I-Test
scale	I-Test
indicated	O
a	O
probable	O
relationship	O
between	O
apnea	I-Problem
and	O
exposure	O
to	O
lamotrigine	I-Treatment
through	I-Treatment
breast	I-Treatment
-	I-Treatment
feeding	I-Treatment
in	I-Background
this	I-Background
infant	I-Background
.	O

listeria	I-Problem
brain	I-Problem
abscess	I-Problem
,	I-Problem
pneumocystis	I-Problem
pneumonia	I-Problem
and	I-Problem
kaposi	I-Problem
'	I-Problem
s	I-Problem
sarcoma	I-Problem
after	O
temozolomide	I-Treatment
.	O

since	O
amiodarone	I-Treatment
was	O
first	O
marketed	O
in	O
1992	O
in	O
japan	O
,	O
the	O
incidence	O
of	O
amiodarone	I-Treatment
-	O
induced	O
thyrotoxicosis	I-Problem
(	I-Problem
ait	I-Problem
)	I-Problem
has	O
been	O
increasing	O
.	O

the	O
occurrence	O
of	O
a	O
myocardial	I-Problem
infarction	I-Problem
is	O
reported	O
after	O
chemotherapy	I-Treatment
containing	I-Treatment
etoposide	I-Treatment
,	O
in	O
a	I-Background
man	I-Background
with	I-Background
no	I-Background
risk	I-Background
factors	I-Background
for	I-Background
coronary	I-Background
heart	I-Background
disease	I-Background
.	O

the	O
use	O
of	O
beclomethasone	I-Treatment
diproprionate	I-Treatment
inhaler	I-Treatment
complicated	O
by	O
the	O
development	O
of	O
an	O
eosinophilic	I-Problem
pneumonia	I-Problem
reaction	I-Problem
.	O

nephrotic	I-Problem
syndrome	I-Problem
related	I-Problem
to	I-Problem
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
after	O
griseofulvin	I-Treatment
therapy	O
.	O

theoretical	O
basal	O
ganglia	O
toxicologic	O
mechanisms	O
of	O
methanol	I-Treatment
poisoning	I-Problem
are	O
reviewed	O
,	O
and	O
the	O
role	O
of	O
brain	O
imaging	I-Test
studies	I-Test
will	O
regard	O
to	O
diagnosis	O
,	O
prognosis	O
and	O
impact	O
on	O
management	O
is	O
discussed	O
.	O

we	O
report	O
a	I-Background
case	I-Background
of	I-Background
drug	O
-	O
induced	O
kaposi	I-Problem
'	I-Problem
s	I-Problem
sarcoma	I-Problem
(	I-Problem
ks	I-Problem
)	I-Problem
on	O
the	O
sole	O
of	O
the	O
right	O
foot	O
in	O
a	I-Background
71	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
,	O
treated	O
for	O
6	I-Other
months	I-Other
with	I-Treatment
corticosteroid	I-Treatment
therapy	I-Treatment
(	I-Treatment
prednisolone	I-Treatment
25	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
)	I-Treatment
for	I-Background
pericardial	I-Problem
effusion	I-Problem
.	O

we	O
present	O
a	O
case	O
of	O
acute	I-Treatment
epinephrine	I-Treatment
toxicity	O
resulting	O
in	O
acute	I-Problem
myocardial	I-Problem
ischemia	I-Problem
in	O
a	I-Background
young	I-Background
boy	I-Background
with	I-Background
combined	I-Problem
variable	I-Problem
immunodeficiency	I-Problem
syndrome	I-Problem
who	O
developed	O
severe	I-Problem
allergic	I-Problem
reaction	I-Problem
to	O
intravenous	I-Treatment
immunoglobulin	I-Treatment
,	I-Treatment
and	I-Treatment
was	I-Treatment
subsequently	I-Treatment
given	I-Treatment
epinephrine	I-Treatment
by	I-Treatment
mistake	I-Treatment
intravenously	I-Treatment
rather	I-Treatment
than	I-Treatment
subcutaneously	I-Treatment
.	O

albeit	O
rare	O
among	O
western	O
patients	O
,	O
such	O
lithium	I-Treatment
-	O
associated	O
thyroid	I-Problem
dysfunctions	I-Problem
appeared	O
to	O
be	O
more	O
likely	O
to	O
occur	O
in	O
hong	I-Background
kong	I-Background
chinese	I-Background
.	O

metaxalone	I-Treatment
has	O
only	O
recently	O
been	O
associated	O
with	O
serotonin	I-Problem
syndrome	I-Problem
.	O

bisphosphonate	I-Treatment
-	O
related	O
osteonecrosis	I-Problem
of	I-Problem
the	I-Problem
jaw	I-Problem
(	I-Problem
bronj	I-Problem
)	I-Problem
is	O
reported	O
in	O
up	O
to	O
18	O
.	O
6	O
%	O
of	I-Background
patients	I-Background
treated	O
with	O
intravenous	I-Treatment
bisphosphonates	I-Treatment
and	O
can	O
result	O
in	O
significant	O
morbidity	O
.	O

growth	I-Problem
and	I-Problem
adrenal	I-Problem
suppression	I-Problem
in	O
asthmatic	I-Problem
children	I-Background
treated	O
with	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
fluticasone	I-Treatment
propionate	I-Treatment
.	O

a	O
diagnosis	O
of	O
infliximab	I-Treatment
-	O
induced	O
lupus	I-Problem
was	O
made	O
and	O
the	O
drug	O
treatment	O
was	O
withdrawn	O
.	O

aims	O
:	O
to	O
identify	O
the	O
human	O
cytochrome	O
p450	I-Test
enzyme	O
(	O
s	O
)	O
involved	O
in	O
the	O
in	O
vitro	O
metabolism	O
of	O
rosiglitazone	I-Treatment
,	O
a	O
potential	O
oral	O
antidiabetic	O
agent	O
for	O
the	O
treatment	O
of	O
type	I-Problem
2	I-Problem
diabetes	I-Problem
-	I-Problem
mellitus	I-Problem
.	I-Problem

neurotoxicity	I-Problem
can	O
occur	O
at	O
any	O
time	O
using	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytosine	I-Treatment
therapy	O
.	O

the	O
possibility	O
of	O
phenytoin	I-Problem
hypersensitivity	I-Problem
reactions	O
should	O
be	O
considered	O
when	O
patients	O
receiving	O
phenytoin	I-Treatment
have	O
unusual	O
symptoms	O
,	O
particularly	O
fever	I-Problem
,	I-Problem
rash	I-Problem
,	I-Problem
and	I-Problem
lymphadenopathy	I-Problem
.	O

magnesium	I-Treatment
tocolysis	I-Treatment
as	O
the	O
cause	O
of	O
urinary	I-Problem
calculus	I-Problem
during	I-Problem
pregnancy	I-Problem
.	O

ocular	I-Treatment
ethambutol	I-Treatment
toxicity	I-Problem
.	O

fatal	I-Problem
intravascular	I-Problem
autoimmune	I-Problem
hemolytic	I-Problem
anemia	I-Problem
after	O
fludarabine	I-Treatment
treatment	I-Treatment
for	O
chronic	I-Problem
lymphocytic	I-Problem
leukemia	I-Problem
.	O

a	I-Background
74	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
patient	I-Background
with	I-Background
idiopathic	I-Problem
parkinson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
was	O
evaluated	O
for	O
unintended	I-Problem
sleep	I-Problem
episodes	I-Problem
that	O
occurred	O
after	O
long	I-Other
-	I-Other
term	I-Other
treatment	I-Other
with	I-Treatment
400	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
of	I-Treatment
l	I-Treatment
-	I-Treatment
dopa	I-Treatment
.	O

thrombotic	I-Problem
thrombocytopenic	I-Problem
purpura	I-Problem
(	I-Problem
ttp	I-Problem
)	I-Problem
developed	O
in	O
a	I-Background
patient	I-Background
with	I-Background
seropositive	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
(	I-Background
ra	I-Background
)	I-Background
after	O
2	I-Other
1	I-Other
/	I-Other
2	I-Other
months	I-Other
of	I-Treatment
treatment	I-Treatment
with	I-Treatment
penicillamine	I-Treatment
.	O

phenolphthalein	I-Treatment
-	O
induced	O
toxic	I-Problem
epidermal	I-Problem
necrolysis	I-Problem
.	O

physicians	O
should	O
be	O
aware	O
of	O
the	O
potentially	O
lethal	I-Problem
side	I-Problem
effects	I-Problem
of	O
dapsone	I-Treatment
.	O

acute	I-Problem
myocardial	I-Problem
necrosis	I-Problem
during	O
administration	O
of	O
amsacrine	I-Treatment
.	O

rapid	O
identification	I-Test
of	O
speech	I-Problem
loss	I-Problem
linked	O
to	O
fk506	I-Treatment
may	O
be	O
important	O
because	O
reduction	O
or	O
cessation	O
of	O
the	O
drug	O
may	O
be	O
associated	O
with	O
reverse	O
of	O
speech	O
loss	O
.	O

fatal	O
pulmonary	I-Problem
fibrosis	I-Problem
following	O
1	I-Treatment
,	I-Treatment
3	I-Treatment
-	I-Treatment
bis	I-Treatment
(	I-Treatment
2	I-Treatment
-	I-Treatment
chloroethyl	I-Treatment
)	I-Treatment
-	I-Treatment
1	I-Treatment
-	I-Treatment
nitrosourea	I-Treatment
(	I-Treatment
bcnu	I-Treatment
)	I-Treatment
therapy	I-Treatment
.	O

the	O
increasing	O
prevalence	O
of	O
methamphetamine	I-Treatment
abuse	I-Treatment
and	O
the	O
severity	O
of	O
the	O
associated	I-Problem
ulcers	I-Problem
should	O
alert	O
ophthalmologists	O
to	O
the	O
problem	O
of	O
methamphetamine	I-Treatment
-	O
related	O
keratitis	I-Problem
.	O

mds	I-Problem
was	O
diagnosed	O
8	I-Other
.	I-Other
4	I-Other
months	I-Other
after	I-Treatment
beginning	I-Treatment
tmz	I-Treatment
.	O

uveitis	I-Problem
associated	O
with	O
rifabutin	I-Treatment
therapy	I-Treatment
:	O
a	O
clinical	O
alert	O
.	O

we	O
report	O
a	O
case	O
of	O
a	I-Background
patient	I-Background
with	O
ciprofloxacin	I-Treatment
-	O
induced	O
sjs	I-Problem
and	O
acute	I-Problem
onset	I-Problem
of	I-Problem
vbds	I-Problem
,	O
and	O
reviewed	O
the	O
related	O
literature	O
.	O

this	O
case	O
supports	O
the	O
assessment	O
that	O
mh	O
and	O
diabetes	O
are	O
associated	O
diseases	O
and	O
that	O
cresol	I-Treatment
could	O
possibly	O
trigger	O
mh	I-Problem
.	O

neonatal	I-Problem
mydriasis	I-Problem
:	O
intravenous	O
lidocaine	I-Treatment
adverse	O
reaction	O
.	O

acute	I-Problem
renal	I-Problem
failure	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
by	O
continuous	I-Treatment
povidone	I-Treatment
-	I-Treatment
iodine	I-Treatment
mediastinal	I-Treatment
irrigation	I-Treatment
.	O

to	O
our	O
knowledge	O
,	O
this	O
is	O
the	I-Background
first	I-Background
case	I-Background
of	O
griseofulvin	I-Treatment
-	O
exacerbated	O
lupus	I-Problem
in	O
which	O
nephrotic	I-Problem
syndrome	I-Problem
has	O
been	O
observed	O
.	O

after	O
reviewing	O
the	O
literature	O
we	O
suggest	O
the	O
cpm	I-Problem
was	O
a	O
complication	O
of	O
lithium	I-Treatment
toxicity	I-Problem
which	O
affected	O
the	O
lateral	O
geniculate	O
nucleus	O
which	O
produced	O
blindness	I-Problem
.	O

a	I-Background
71	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
,	O
who	O
had	O
a	O
history	O
of	O
a	O
previous	O
bullous	I-Problem
drug	O
reaction	O
to	O
a	O
sulfonamide	I-Treatment
,	O
began	O
receiving	O
an	O
ophthalmic	O
preparation	O
that	O
contained	O
sulfacetamide	I-Treatment
sodium	I-Treatment
.	O

the	O
authors	O
report	O
on	O
two	O
patients	I-Background
with	O
corneal	I-Problem
ulcers	I-Problem
refractory	O
to	O
conventional	O
treatment	O
while	O
the	O
patients	O
were	O
undergoing	O
oral	I-Treatment
colchicine	I-Treatment
therapy	I-Treatment
.	O

vancomycin	I-Treatment
-	O
induced	O
vasculitis	I-Problem
.	O

based	O
on	O
our	O
findings	O
,	O
it	O
is	O
thus	O
concluded	O
that	O
cisplatin	I-Treatment
may	O
cause	O
c	I-Problem
.	I-Problem
difficile	I-Problem
colitis	I-Problem
.	O

nephrotic	I-Problem
syndrome	I-Problem
associated	O
with	O
lithium	I-Treatment
therapy	I-Treatment
.	O

we	O
report	O
2	O
patients	I-Background
who	O
developed	O
polyarteritis	I-Problem
nodosa	I-Problem
following	O
vaccination	I-Treatment
against	I-Treatment
hepatitis	I-Treatment
b	I-Treatment
.	I-Treatment

we	O
recommend	O
the	O
cautious	O
use	O
of	O
ketorolac	I-Treatment
in	O
patients	I-Background
with	I-Background
underlying	I-Problem
illnesses	I-Problem
where	O
nsaid	I-Problem
-	I-Problem
induced	I-Problem
ototoxicity	I-Problem
could	I-Problem
result	I-Problem
in	I-Problem
adverse	I-Problem
otologic	I-Problem
consequences	I-Problem
.	O

colitis	I-Problem
as	O
a	O
manifestation	O
of	O
infliximab	I-Treatment
-	O
associated	O
disseminated	O
cryptococcosis	O
.	O

a	I-Background
15	I-Background
-	I-Background
month	I-Background
-	I-Background
old	I-Background
girl	I-Background
with	I-Background
rhinopharyngitis	I-Problem
was	O
treated	O
with	O
a	I-Treatment
nasal	I-Treatment
solution	I-Treatment
containing	I-Treatment
the	I-Treatment
imidazoline	I-Treatment
derivative	I-Treatment
naphazoline	I-Treatment
.	O

three	O
diabetic	I-Problem
cases	I-Background
of	O
acute	I-Problem
dizziness	I-Problem
due	O
to	O
initial	I-Treatment
administration	I-Treatment
of	I-Treatment
voglibose	I-Treatment
.	O

fatal	I-Problem
cold	I-Treatment
medication	I-Treatment
intoxication	I-Problem
in	O
an	O
infant	I-Background
.	O

case	O
study	O
:	O
a	O
modified	O
topical	O
treatment	O
regimen	O
for	O
sodium	I-Treatment
warfarin	I-Treatment
-	O
induced	O
necrotizing	I-Problem
fasciitis	I-Problem
.	O

marked	I-Problem
qt	I-Problem
prolongation	I-Problem
and	I-Problem
torsades	I-Problem
de	I-Problem
pointes	I-Problem
secondary	I-Problem
to	I-Problem
acute	I-Problem
ischemia	I-Problem
in	O
an	I-Background
elderly	I-Background
man	I-Background
taking	O
dofetilide	I-Treatment
for	O
atrial	I-Problem
fibrillation	I-Problem
:	O
a	O
cautionary	O
tale	O
.	O

methylphenidate	I-Treatment
and	I-Treatment
dextroamphetamine	I-Treatment
-	O
induced	O
peripheral	I-Problem
vasculopathy	I-Problem
.	O

the	I-Treatment
reversal	I-Treatment
of	I-Treatment
heparin	I-Treatment
by	I-Treatment
protamine	I-Treatment
may	O
cause	O
severe	I-Problem
hemodynamic	I-Problem
deterioration	I-Problem
,	O
characterized	O
by	O
systemic	I-Problem
hypotension	I-Problem
,	I-Problem
pulmonary	I-Problem
hypertension	I-Problem
,	I-Problem
and	I-Problem
bronchoconstriction	I-Problem
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
severe	I-Problem
apnea	I-Problem
in	O
an	I-Background
infant	I-Background
exposed	I-Treatment
to	I-Treatment
lamotrigine	I-Treatment
through	I-Treatment
breast	I-Treatment
-	I-Treatment
feeding	I-Treatment
.	O

hemodynamic	I-Problem
collapse	I-Problem
following	O
labetalol	I-Treatment
administration	O
in	O
preeclampsia	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
a	O
35	I-Background
-	I-Background
year	I-Background
old	I-Background
female	I-Background
who	O
developed	O
new	O
onset	O
type	I-Problem
ii	I-Problem
diabetes	I-Problem
mellitus	I-Problem
with	I-Problem
hyperosmolar	I-Problem
hyperglycaemic	I-Problem
coma	I-Problem
and	I-Problem
acute	I-Problem
renal	I-Problem
failure	I-Problem
following	O
treatment	I-Treatment
with	I-Treatment
a	I-Treatment
sga	I-Treatment
for	O
a	O
first	O
manic	O
episode	O
.	O

we	O
report	O
the	O
occurrence	O
of	O
renal	I-Problem
failure	I-Problem
due	I-Problem
to	I-Problem
cholesterol	I-Problem
crystal	I-Problem
embolization	I-Problem
following	O
thrombolytic	I-Treatment
therapy	I-Treatment
with	I-Treatment
intravenous	I-Treatment
recombinant	I-Treatment
tissue	I-Treatment
-	I-Treatment
type	I-Treatment
plasminogen	I-Treatment
activator	I-Treatment
(	I-Treatment
t	I-Treatment
-	I-Treatment
pa	I-Treatment
)	I-Treatment
.	O

the	O
asthma	I-Problem
resolved	O
within	I-Other
24	I-Other
hours	I-Other
following	O
three	I-Treatment
albuterol	I-Treatment
inhalations	I-Treatment
.	O

administration	O
of	O
amantadine	I-Treatment
was	O
associated	O
with	O
psychotic	I-Problem
decompensations	I-Problem
in	O
two	O
schizophrenic	I-Problem
patients	I-Background
being	O
maintained	O
on	O
concomitant	I-Treatment
neuroleptic	I-Treatment
medication	I-Treatment
.	O

clinicians	O
should	O
be	O
aware	O
of	O
fasting	I-Problem
hypoglycemia	I-Problem
as	O
an	O
unusual	O
but	O
potentially	O
serious	O
complication	O
of	O
disopyramide	I-Treatment
therapy	O
.	O

to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
patient	I-Background
with	O
captopril	I-Treatment
-	O
induced	O
pemphigus	I-Problem
in	O
whom	O
no	O
new	O
lesions	O
developed	O
after	O
subsequent	O
treatment	O
with	O
enalapril	O
.	O

fortunately	O
,	O
a	O
hypersensitivity	I-Problem
reaction	I-Problem
to	O
one	I-Treatment
formulation	I-Treatment
of	I-Treatment
cyclosporine	I-Treatment
does	O
not	O
preclude	O
use	O
of	O
a	O
different	O
formulation	O
.	O

she	O
developed	O
a	O
severe	O
urticarial	I-Problem
rash	I-Problem
3	I-Other
weeks	I-Other
following	I-Other
initiation	O
of	O
therapy	O
with	O
enoxaparin	I-Treatment
.	O

fatal	I-Problem
toxic	I-Problem
epidermal	I-Problem
necrolysis	I-Problem
related	O
to	O
lamotrigine	I-Treatment
administration	I-Treatment
.	O

objective	O
:	O
to	O
document	O
a	I-Background
case	I-Background
of	O
serotonin	I-Problem
syndrome	I-Problem
(	I-Problem
ss	I-Problem
)	I-Problem
associated	O
with	O
mirtazapine	I-Treatment
monotherapy	I-Treatment
,	O
review	O
the	O
previously	O
reported	O
cases	O
of	O
ss	O
associated	O
with	O
this	O
tetracyclic	O
antidepressant	O
,	O
and	O
discuss	O
the	O
possible	O
pathogenic	O
mechanisms	O
leading	O
to	O
this	O
serious	O
adverse	O
drug	O
reaction	O
.	O

conclusion	O
:	O
therapy	O
with	O
indapamide	I-Treatment
may	O
induce	O
diabetes	I-Problem
in	O
essential	I-Problem
hypertension	I-Problem
patients	I-Background
.	O

placebo	O
-	O
controlled	I-Test
clinical	O
trials	I-Test
of	O
recombinant	I-Treatment
human	I-Treatment
interleukin	I-Test
-	I-Treatment
11	I-Treatment
(	I-Treatment
rhil	I-Treatment
-	I-Treatment
11	I-Treatment
,	I-Treatment
also	I-Treatment
known	I-Treatment
as	I-Treatment
oprelvekin	I-Treatment
[	I-Treatment
neumega	I-Treatment
]	I-Treatment
)	I-Treatment
in	O
patients	I-Background
with	I-Background
nonmyeloid	I-Problem
malignancies	I-Problem
have	O
demonstrated	O
significant	O
efficacy	O
in	O
preventing	O
postchemotherapy	I-Problem
platelet	I-Test
nadirs	I-Test
of	I-Problem
<	I-Problem
or	I-Problem
=	I-Problem
20	I-Problem
,	I-Problem
000	I-Problem
/	I-Problem
microl	I-Problem
,	O
and	O
reducing	O
the	O
need	O
for	O
platelet	O
transfusions	O
while	O
continuing	O
chemotherapy	O
without	O
dose	O
reductions	O
.	O

a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
developed	O
an	O
acute	I-Problem
intrahepatic	I-Problem
cholestasis	I-Problem
after	O
100	I-Treatment
mg	I-Treatment
of	I-Treatment
sodium	I-Treatment
aurothiomalate	I-Treatment
.	O

we	O
concluded	O
that	O
the	O
colonic	I-Problem
ulcer	I-Problem
and	I-Problem
the	I-Problem
sigmoidovesical	I-Problem
fistula	I-Problem
had	O
been	O
caused	O
by	O
the	O
administration	O
of	O
calcium	I-Treatment
polystyrene	I-Treatment
sulfonate	I-Treatment
and	I-Treatment
sorbitol	I-Treatment
.	O

rosiglitazone	I-Treatment
,	O
a	I-Treatment
thiazolidinedione	I-Treatment
antidiabetic	I-Treatment
medication	I-Treatment
used	O
in	O
the	O
treatment	O
of	O
type	I-Problem
2	I-Problem
diabetes	I-Problem
mellitus	I-Problem
,	O
is	O
predominantly	O
metabolized	O
by	O
the	O
cytochrome	O
p450	O
(	O
cyp	O
)	O
enzyme	O
cyp2c8	O
.	O

interstitial	I-Problem
lung	I-Problem
disease	I-Problem
(	I-Problem
ild	I-Problem
)	I-Problem
related	O
to	O
therapy	I-Treatment
with	I-Treatment
the	I-Treatment
drug	I-Treatment
gefitinib	I-Treatment
has	O
been	O
well	O
reported	O
.	O

according	O
to	O
the	O
naranjo	O
adverse	O
drug	O
reaction	O
probability	I-Test
scale	I-Test
,	O
tigecycline	I-Treatment
was	O
the	O
probable	O
cause	O
of	O
her	O
acute	I-Problem
pancreatitis	I-Problem
.	O

the	O
patient	O
'	O
s	O
movements	I-Problem
resolved	O
following	O
diphenhydramine	I-Treatment
administration	O
.	O

the	O
spectrum	O
of	O
nitrofurantoin	I-Treatment
lung	I-Problem
injury	I-Problem
continues	O
to	O
widen	O
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	O
a	O
complex	O
medication	O
regimen	O
who	O
was	O
admitted	O
for	O
rhabdomyolysis	I-Problem
and	I-Problem
accompanying	I-Problem
acute	I-Problem
renal	I-Problem
failure	I-Problem
,	I-Problem
along	I-Problem
with	I-Problem
acute	I-Problem
hepatitis	I-Problem
,	O
thought	O
to	O
be	O
secondary	O
to	O
a	O
drug	O
interaction	O
between	O
atorvastatin	I-Treatment
and	O
diltiazem	I-Treatment
.	O

the	O
current	O
study	I-Test
investigated	O
the	O
visual	O
fields	O
and	O
visual	O
electrophysiology	O
of	O
eight	O
patients	I-Background
with	O
known	O
vigabatrin	I-Treatment
-	O
attributed	O
visual	I-Problem
field	I-Problem
loss	I-Problem
,	O
three	O
of	O
whom	O
were	O
reported	O
previously	O
.	O

although	O
the	O
literature	O
on	O
the	O
use	I-Treatment
of	I-Treatment
risperidone	I-Treatment
in	O
elderly	I-Background
patients	I-Background
with	I-Background
dementia	I-Problem
consists	O
largely	O
of	O
uncontrolled	O
trials	I-Test
,	O
case	O
reports	O
,	O
and	O
chart	O
reviews	I-Test
,	O
it	O
appears	O
that	O
this	O
agent	O
is	O
effective	O
for	O
managing	O
agitation	O
in	O
this	O
population	O
and	O
does	O
so	O
with	O
a	O
low	O
frequency	O
of	O
extrapyramidal	O
symptoms	O
(	O
eps	O
)	O
.	O

temozolomide	I-Treatment
-	O
induced	O
desquamative	I-Problem
skin	I-Problem
rash	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
metastatic	I-Problem
melanoma	I-Problem
.	O

the	O
calcium	I-Treatment
channel	I-Treatment
blockers	I-Treatment
are	O
a	O
group	O
of	O
drugs	O
that	O
have	O
recently	O
become	O
available	O
for	O
the	O
treatment	O
of	O
angina	I-Problem
.	O

we	O
report	O
on	O
a	I-Background
young	I-Background
adolescent	I-Background
with	O
benign	I-Problem
intracranial	I-Problem
hypertension	I-Problem
which	O
we	O
attribute	O
to	O
the	O
use	O
of	O
minocycline	I-Treatment
for	O
acne	I-Problem
.	O

a	I-Background
10	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
asthmatic	I-Problem
boy	I-Background
began	O
to	O
suffer	O
from	O
urticarial	I-Problem
rash	I-Problem
and	I-Problem
moderately	I-Problem
severe	I-Problem
bronchospasm	I-Problem
after	O
8	I-Other
weeks	I-Other
'	I-Other
treatment	I-Treatment
with	I-Treatment
disodium	I-Treatment
cromoglycate	I-Treatment
.	O

panic	I-Problem
anxiety	I-Problem
after	O
abrupt	I-Treatment
discontinuation	I-Treatment
of	I-Treatment
mianserin	I-Treatment
.	O

this	I-Background
case	I-Background
and	O
other	O
published	O
evidence	O
should	O
alert	O
physicians	O
to	O
the	O
possibility	O
of	O
fatal	O
erlotinib	I-Treatment
-	O
induced	O
ild	I-Problem
.	O

recent	O
reports	O
suggest	O
that	O
concomitant	I-Treatment
administration	I-Treatment
of	I-Treatment
cyp3a	I-Treatment
inhibitors	I-Treatment
with	I-Treatment
fentanyl	I-Treatment
may	O
lead	O
to	O
dangerous	O
drug	I-Problem
interactions	I-Problem
.	O

post	O
-	O
exposure	O
prophylaxis	O
of	O
h1n1	I-Problem
with	O
oseltamivir	I-Treatment
was	O
safe	I-Problem
,	I-Problem
effective	I-Problem
and	I-Problem
well	I-Problem
tolerated	I-Problem
to	I-Problem
prevent	I-Problem
h1n1	I-Problem
influenza	I-Problem
a	I-Problem
virus	I-Problem
infection	I-Problem
in	O
newly	I-Background
transplanted	I-Problem
renal	I-Problem
allograft	I-Problem
recipient	I-Background
receiving	O
triple	O
immunosuppression	O
without	I-Treatment
any	I-Treatment
interaction	I-Treatment
with	I-Treatment
tacrolimus	I-Treatment
level	I-Test
.	O

discussion	O
:	O
central	I-Problem
nervous	I-Problem
system	I-Problem
(	I-Problem
cns	I-Problem
)	I-Problem
toxicity	I-Problem
has	O
been	O
described	O
with	O
ifosfamide	I-Treatment
,	O
with	O
most	O
cases	O
reported	O
in	I-Background
the	I-Background
pediatric	I-Background
population	I-Background
.	O

despite	O
the	O
underlying	O
hepatitis	O
c	O
,	O
this	I-Background
case	I-Background
represents	O
renal	I-Problem
abnormalities	I-Problem
consistent	O
with	O
ifnalpha	I-Treatment
therapy	I-Treatment
for	O
cml	I-Problem
.	O

conclusion	O
:	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
time	O
colchicine	I-Treatment
intoxication	I-Problem
in	O
this	O
age	O
group	O
has	O
been	O
described	O
in	O
the	O
english	O
literature	O
.	O

we	O
have	O
seen	O
a	O
case	O
of	O
terminal	I-Problem
malignant	I-Problem
melanoma	I-Problem
in	I-Problem
which	I-Problem
clinical	I-Problem
manifestations	I-Problem
,	I-Problem
indicative	I-Problem
of	I-Problem
anterior	I-Problem
spinal	I-Problem
artery	I-Problem
syndrome	I-Problem
,	O
developed	O
following	O
the	I-Treatment
injection	I-Treatment
of	I-Treatment
0	I-Treatment
.	I-Treatment
3	I-Treatment
ml	I-Treatment
of	I-Treatment
10	I-Treatment
%	I-Treatment
phenol	I-Treatment
-	I-Treatment
glycerine	I-Treatment
into	I-Treatment
the	I-Treatment
cervical	I-Treatment
subarachnoid	I-Treatment
space	I-Treatment
at	I-Treatment
the	I-Treatment
c4	I-Treatment
-	I-Treatment
-	I-Treatment
c5	I-Treatment
level	I-Treatment
for	O
the	O
control	O
of	O
severe	I-Problem
right	I-Problem
arm	I-Problem
pain	I-Problem
.	O

colchicine	I-Treatment
-	O
induced	O
myopathy	I-Problem
in	O
renal	I-Problem
failure	I-Problem
.	O

this	O
report	O
suggests	O
that	O
bleomycin	I-Treatment
lung	I-Problem
toxicity	I-Problem
may	O
be	O
reversible	O
if	O
treated	O
aggressively	O
.	O

discussion	O
:	O
nms	I-Problem
is	O
a	O
rare	O
but	O
potentially	O
fatal	O
reaction	O
associated	O
with	O
neuroleptic	I-Treatment
drugs	I-Treatment
.	O

scleroderma	I-Problem
in	O
association	O
with	O
the	O
use	O
of	O
bleomycin	I-Treatment
:	O
a	O
report	O
of	O
3	O
cases	I-Background
.	O

linezolid	I-Treatment
-	O
associated	O
acute	I-Problem
interstitial	I-Problem
nephritis	I-Problem
and	I-Problem
drug	I-Problem
rash	I-Problem
with	I-Problem
eosinophilia	I-Problem
and	I-Problem
systemic	I-Problem
symptoms	I-Problem
(	I-Problem
dress	I-Problem
)	I-Problem
syndrome	I-Problem
.	O

a	I-Background
3	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
diagnosed	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
received	O
induction	I-Treatment
chemotherapy	I-Treatment
.	O

interferon	I-Treatment
and	I-Treatment
other	I-Treatment
immunostimulatory	I-Treatment
medications	I-Treatment
can	O
lead	O
to	O
an	O
exacerbation	I-Problem
of	I-Problem
this	I-Problem
preexisting	I-Problem
low	I-Problem
-	I-Problem
grade	I-Problem
chronic	I-Problem
inflammation	I-Problem
that	O
is	O
quite	O
similar	O
to	O
interferon	O
-	O
triggered	O
sarcoidosis	O
.	O

intravenous	I-Treatment
cytarabine	I-Treatment
and	I-Treatment
methotrexate	I-Treatment
appear	O
to	O
act	O
synergistically	O
to	O
enhance	O
the	O
potential	O
for	O
central	I-Problem
nervous	I-Problem
system	I-Problem
toxicity	I-Problem
.	O

we	O
suggest	O
adding	O
this	O
side	I-Problem
effect	I-Problem
to	O
the	O
list	O
of	O
untoward	O
effects	O
of	O
lidocaine	O
and	O
to	O
the	O
differential	O
diagnosis	O
of	O
fixed	O
dilated	O
pupils	O
in	O
neonates	I-Background
treated	O
with	O
lidocaine	I-Treatment
.	O

conclusions	O
:	O
topical	I-Treatment
inf	I-Treatment
alpha	I-Treatment
2	I-Treatment
-	I-Treatment
beta	I-Treatment
is	O
a	O
valid	O
choice	O
for	O
the	O
treatment	O
of	O
cin	I-Problem
in	O
patients	I-Background
for	I-Background
whom	I-Background
surgery	I-Background
is	I-Background
not	I-Background
possible	I-Background
.	O

we	O
report	O
3	O
patients	I-Background
who	O
developed	O
cutaneous	I-Problem
vasculitis	I-Problem
which	O
is	O
a	O
rare	O
and	O
serious	O
side	O
-	O
effect	O
during	I-Treatment
antithyroid	I-Treatment
drug	I-Treatment
therapy	I-Treatment
.	O

prominent	I-Problem
eye	I-Problem
movements	I-Problem
during	I-Problem
nrem	I-Problem
sleep	I-Problem
and	I-Problem
rem	I-Problem
sleep	I-Problem
behavior	I-Problem
disorder	I-Problem
associated	O
with	O
fluoxetine	I-Treatment
treatment	I-Treatment
of	O
depression	I-Problem
and	I-Background
obsessive	I-Problem
-	I-Problem
compulsive	I-Problem
disorder	I-Problem
.	O

allergic	O
reaction	O
to	O
gemfibrozil	I-Treatment
manifesting	O
as	O
eosinophilic	I-Problem
gastroenteritis	I-Problem
.	O

we	O
suggest	O
that	O
sarcoidosis	I-Problem
may	O
develop	O
in	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
patients	I-Background
during	O
interferon	I-Treatment
alpha	I-Treatment
and	I-Treatment
/	I-Treatment
or	I-Treatment
ribavirin	I-Treatment
treatment	O
,	O
and	O
diagnostic	O
tests	I-Test
for	O
this	O
adverse	O
effect	O
should	O
be	O
performed	O
during	O
the	O
follow	O
-	O
ups	O
.	O

azole	I-Treatment
antifungals	I-Treatment
,	O
prescribed	O
prophylactically	O
to	O
avoid	O
severe	I-Problem
infections	I-Problem
in	O
immunosuppressed	I-Problem
organ	I-Problem
transplant	I-Problem
recipients	I-Background
,	O
can	O
interact	O
with	O
drug	I-Treatment
substrates	I-Treatment
of	I-Treatment
cyp3a4	I-Treatment
.	O

we	O
present	O
the	O
case	O
of	O
a	I-Background
5	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
who	O
developed	O
bilateral	I-Problem
vocal	I-Problem
cord	I-Problem
paralysis	I-Problem
following	O
preoperative	I-Treatment
peritonsillar	I-Treatment
bupivacaine	I-Treatment
infiltration	I-Treatment
.	O

one	O
patient	I-Background
suffered	O
coronary	I-Problem
artery	I-Problem
vasospasm	I-Problem
,	O
attributed	O
to	O
the	O
use	O
of	O
topical	I-Treatment
1	I-Treatment
:	I-Treatment
1000	I-Treatment
epinephrine	I-Treatment
during	I-Treatment
surgery	I-Treatment
.	O

trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
-	O
induced	O
aseptic	I-Problem
meningitis	I-Problem
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
metastatic	I-Problem
prostate	I-Problem
cancer	I-Problem
who	O
developed	O
nonoliguric	I-Problem
renal	I-Problem
failure	I-Problem
during	O
treatment	O
with	O
suramin	I-Treatment
.	O

in	O
conclusion	O
,	O
this	I-Background
case	I-Background
strongly	O
suggests	O
that	O
gliclazide	I-Treatment
can	O
induce	O
acute	I-Problem
icteric	I-Problem
liver	I-Problem
necro	I-Problem
-	I-Problem
inflammation	I-Problem
which	O
may	O
be	O
misdiagnosed	O
clinically	O
as	O
acute	O
viral	O
hepatitis	O
.	O

after	O
administration	O
of	O
oxybutynin	I-Treatment
concomitantly	I-Treatment
with	I-Treatment
an	I-Treatment
increase	I-Treatment
in	I-Treatment
the	I-Treatment
dose	I-Treatment
of	I-Treatment
dantrolene	I-Treatment
,	O
she	I-Background
presented	O
the	O
clinical	I-Problem
symptoms	I-Problem
and	I-Problem
laboratory	I-Problem
finding	I-Problem
of	I-Problem
carbamazepine	I-Treatment
intoxication	I-Problem
.	O

a	O
methotrexate	I-Treatment
overdosage	I-Problem
was	I-Problem
shown	I-Problem
at	I-Problem
36	I-Problem
h	I-Problem
after	I-Problem
infusion	I-Problem
associated	O
with	O
a	O
severe	I-Problem
renal	I-Problem
failure	I-Problem
.	O

ceftriaxone	I-Treatment
-	O
induced	O
fixed	I-Problem
drug	I-Problem
eruption	I-Problem
:	O
first	O
report	O
.	O

we	O
report	O
the	O
case	O
of	O
a	O
20	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
with	I-Background
polyarteritis	I-Problem
nodosa	I-Problem
(	I-Background
pan	I-Background
)	I-Background
who	O
developed	O
bilateral	I-Problem
sensorineural	I-Problem
hearing	I-Problem
loss	I-Problem
25	I-Other
minutes	I-Other
after	I-Other
receiving	O
30	I-Treatment
mg	I-Treatment
of	I-Treatment
intravenous	I-Treatment
ketoralac	I-Treatment
.	O

we	O
report	O
an	I-Background
82	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
who	O
developed	O
ventricular	I-Problem
tachycardia	I-Problem
and	I-Problem
torsades	I-Problem
de	I-Problem
pointes	I-Problem
(	I-Problem
tdp	I-Problem
)	I-Problem
after	O
oral	I-Treatment
administration	I-Treatment
of	I-Treatment
garenoxacin	I-Treatment
,	O
a	O
novel	O
quinolone	O
antibiotic	O
agent	O
that	O
differs	O
from	O
the	O
third	O
-	O
generation	O
quinolones	O
,	O
for	O
pneumonia	I-Problem
.	O

lethargy	I-Problem
in	O
a	I-Background
newborn	I-Background
:	O
lithium	I-Treatment
toxicity	O
or	O
lab	O
error	O
?	O

simultaneous	I-Problem
toxicities	I-Problem
in	O
a	I-Background
child	I-Background
on	O
multiple	I-Treatment
anticonvulsants	I-Treatment
.	I-Treatment

we	O
report	O
a	I-Background
71	I-Background
-	I-Background
year	I-Background
male	I-Background
with	I-Background
castration	I-Problem
-	I-Problem
resistant	I-Problem
metastatic	I-Problem
prostate	I-Problem
cancer	I-Problem
who	O
was	O
treated	O
with	O
weekly	I-Other
docetaxel	I-Treatment
for	I-Treatment
12	I-Other
weeks	I-Other
and	O
developed	O
significant	I-Problem
eye	I-Problem
irritation	I-Problem
and	I-Problem
dryness	I-Problem
during	O
treatment	O
.	O

in	O
addition	O
,	O
a	I-Background
31	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
obsessive	I-Problem
-	I-Problem
compulsive	I-Problem
disorder	I-Problem
developed	O
rbd	I-Problem
soon	I-Other
after	I-Other
starting	I-Other
fluoxetine	I-Treatment
therapy	I-Treatment
,	O
which	I-Problem
persisted	I-Problem
at	I-Problem
psg	I-Problem
study	I-Test
19	I-Problem
months	I-Problem
after	I-Problem
fluoxetine	I-Problem
discontinuation	I-Problem
.	O

propafenone	I-Treatment
associated	O
severe	O
central	I-Problem
nervous	I-Problem
system	I-Problem
and	I-Problem
cardiovascular	I-Problem
toxicity	I-Problem
due	O
to	O
mirtazapine	I-Treatment
:	O
a	O
case	O
of	O
severe	O
drug	O
interaction	O
.	O

neurotoxicity	I-Problem
of	O
intrathecal	I-Treatment
administration	I-Treatment
of	I-Treatment
amphotericin	I-Treatment
b	I-Treatment
.	I-Treatment

parenteral	O
pyridoxine	O
,	O
the	O
specific	O
antidote	O
for	O
inh	I-Treatment
-	O
induced	O
refractory	I-Problem
seizures	I-Problem
,	O
should	O
be	O
readily	O
available	O
in	O
every	O
emergency	O
department	O
in	O
the	O
areas	O
similarly	O
experiencing	O
increasing	O
trends	O
of	O
tb	O
.	O

discussion	O
:	O
rhabdomyolysis	I-Problem
is	I-Problem
a	I-Problem
clinical	I-Problem
syndrome	I-Problem
resulting	I-Problem
from	I-Problem
the	I-Problem
destruction	I-Problem
of	I-Problem
skeletal	I-Problem
muscle	I-Problem
that	I-Problem
may	I-Problem
progress	I-Problem
to	I-Problem
renal	I-Problem
failure	I-Problem
several	O
drugs	O
have	O
been	O
associated	O
with	O
rhabdomyolysis	O
,	O
including	O
lovastatin	I-Treatment
,	I-Treatment
a	I-Treatment
hydroxymethylglutaryl	I-Treatment
-	I-Treatment
coenzyme	I-Treatment
a	I-Treatment
reductase	I-Treatment
inhibitor	I-Treatment
.	O

thrombocytosis	I-Problem
associated	O
with	O
enoxaparin	I-Treatment
:	O
a	O
very	O
rare	O
cause	O
in	O
newborns	I-Background
.	O

the	I-Problem
spectrum	I-Problem
of	I-Problem
renal	I-Problem
lesions	I-Problem
occurring	I-Problem
during	O
antituberculous	I-Treatment
therapy	I-Treatment
,	I-Treatment
particularly	I-Treatment
in	I-Treatment
association	I-Treatment
with	I-Treatment
rifampin	I-Treatment
,	O
may	O
be	O
wider	O
than	O
previously	O
suspected	O
.	O

native	I-Problem
arterial	I-Problem
thrombosis	I-Problem
,	O
though	O
recognized	O
as	O
a	O
severe	O
complication	O
of	O
thrombin	I-Treatment
injection	I-Treatment
,	O
has	O
not	O
been	O
well	O
described	O
in	O
the	O
literature	O
.	O

acute	I-Problem
hepatitis	I-Problem
with	I-Problem
prolonged	I-Problem
cholestasis	I-Problem
and	I-Problem
disappearance	I-Problem
of	I-Problem
interlobular	I-Problem
bile	I-Problem
ducts	I-Problem
following	O
tibolone	I-Treatment
and	I-Treatment
hypericum	I-Treatment
perforatum	I-Treatment
(	I-Treatment
st	I-Treatment
.	I-Treatment
john	I-Treatment
'	I-Treatment
s	I-Treatment
wort	I-Treatment
)	I-Treatment
.	O

methods	O
:	O
five	O
cases	I-Background
of	O
contact	I-Problem
dermatitis	I-Problem
due	O
to	O
budesonide	I-Treatment
,	O
a	O
nonhalogenated	O
steroid	O
,	O
are	O
described	O
.	O

this	O
sulfonamide	O
like	O
nephropathy	O
should	O
be	O
differentiated	O
from	O
acetazolamide	I-Treatment
-	O
related	O
calcium	I-Problem
phosphate	I-Problem
nephrolithiasis	I-Problem
.	I-Problem

aripiprazole	I-Treatment
was	O
subsequently	O
discontinued	O
secondary	O
to	O
its	O
lack	O
of	O
efficacy	O
for	O
ocd	I-Problem
and	O
the	O
development	O
of	O
a	I-Problem
movement	I-Problem
disorder	I-Problem
.	O

gigantomastia	I-Problem
induced	O
by	O
bucillamine	I-Treatment
.	O

hypersensitivity	I-Problem
to	O
carboplatin	I-Treatment
has	O
been	O
reported	O
in	O
up	O
to	O
44	I-Background
%	I-Background
of	I-Background
patients	I-Background
receiving	O
this	O
antineoplastic	O
agent	O
,	O
usually	O
occurring	O
after	I-Treatment
several	I-Treatment
courses	I-Treatment
of	I-Treatment
treatment	I-Treatment
.	O

conclusions	O
:	O
in	O
our	O
reported	I-Background
case	I-Background
,	O
a	O
local	I-Problem
hyperproduction	I-Problem
of	I-Problem
tnf	I-Problem
-	I-Problem
alpha	I-Problem
from	I-Problem
macrophages	I-Problem
that	O
was	O
induced	O
by	O
the	O
injected	I-Treatment
insulin	I-Treatment
could	O
explain	O
the	O
dedifferentiation	I-Problem
of	I-Problem
the	I-Problem
adipocytes	I-Problem
of	I-Problem
the	I-Problem
subcutaneous	I-Problem
tissue	I-Problem
and	O
the	O
reversion	O
that	O
was	O
induced	O
by	O
the	O
local	O
injection	O
of	O
dexamethasone	O
.	O

both	O
venlafaxine	I-Treatment
and	I-Treatment
trimipramine	I-Treatment
have	O
been	O
associated	O
with	O
seizures	I-Problem
,	O
mainly	O
after	O
overdose	I-Treatment
.	O

thirty	O
-	O
six	O
patients	O
with	O
al	O
received	O
,	O
in	O
a	O
three	I-Other
-	I-Other
month	I-Other
period	O
,	O
51	O
cycles	O
of	O
combined	O
chemotherapy	I-Treatment
which	O
included	O
,	O
in	O
all	O
of	O
them	O
,	O
cytosine	I-Treatment
arabinoside	I-Treatment
(	I-Treatment
ara	I-Treatment
-	I-Treatment
c	I-Treatment
)	I-Treatment
;	O
among	O
them	O
,	O
along	O
with	O
myelosuppression	O
,	O
five	O
experienced	O
fever	I-Problem
,	I-Problem
infectious	I-Problem
complications	I-Problem
,	I-Problem
gastrointestinal	I-Problem
tract	I-Problem
symptoms	I-Problem
and	I-Problem
severe	I-Problem
myalgias	I-Problem
.	O

infliximab	I-Treatment
-	O
induced	O
lupus	I-Problem
in	O
crohn	O
'	O
s	O
disease	O
:	O
a	I-Background
case	I-Background
report	O
.	O

the	O
infection	I-Problem
tended	I-Problem
to	O
subside	O
with	O
the	O
amph	I-Treatment
administration	I-Treatment
.	O

context	O
:	O
acute	I-Problem
drug	I-Problem
induced	I-Problem
hepatitis	I-Problem
has	O
not	O
been	O
commonly	O
associated	O
with	O
epidermal	I-Treatment
growth	I-Treatment
factor	I-Treatment
receptor	I-Treatment
(	I-Treatment
egfr	I-Treatment
)	I-Treatment
inhibitors	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
fatal	O
pulmonary	I-Problem
toxicity	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
advanced	I-Problem
non	I-Problem
-	I-Problem
small	I-Problem
cell	I-Problem
lung	I-Problem
cancer	I-Problem
who	O
received	O
erlotinib	I-Treatment
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
idiopathic	I-Problem
rls	I-Problem
who	O
developed	O
augmentation	I-Problem
after	I-Treatment
8	I-Other
months	I-Other
of	I-Treatment
levodopa	I-Treatment
treatment	I-Treatment
.	O

this	O
communication	O
describes	O
a	I-Background
patient	I-Background
who	O
developed	O
schneiderian	I-Problem
first	I-Problem
-	I-Problem
rank	I-Problem
symptoms	I-Problem
in	O
the	O
course	O
of	O
treatment	O
with	O
fluvoxamine	I-Treatment
.	O

in	O
addition	O
to	O
the	O
recognized	O
arrhythmic	O
complications	O
,	O
the	O
authors	O
emphasize	O
myocardial	I-Problem
necrosis	I-Problem
as	O
a	O
possible	O
further	O
manifestation	O
of	O
amsacrine	I-Treatment
-	O
related	O
cardiotoxicity	I-Problem
.	O

the	O
authors	O
caution	O
that	O
treatment	I-Treatment
with	I-Treatment
alprazolam	I-Treatment
may	O
be	O
complicated	O
by	O
the	O
induction	O
of	O
mania	I-Problem
.	O

the	O
use	O
of	O
rituximab	I-Treatment
has	O
been	O
uncommonly	O
associated	O
with	O
delayed	I-Problem
pulmonary	I-Problem
toxicity	I-Problem
.	O

we	O
believe	O
that	O
the	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
in	O
our	O
patient	I-Background
was	O
associated	O
with	O
anastrozole	I-Treatment
.	O

on	I-Treatment
the	I-Other
fifth	I-Other
day	I-Other
of	I-Treatment
tocolysis	I-Treatment
with	I-Treatment
magnesium	I-Treatment
sulfate	I-Treatment
,	I-Treatment
nifedipine	I-Treatment
,	I-Treatment
terbutaline	I-Treatment
and	I-Treatment
betamethasone	I-Treatment
,	O
edema	I-Problem
developed	O
in	I-Problem
both	I-Problem
labia	I-Problem
.	O

two	O
patients	I-Background
with	I-Background
extrinsic	I-Problem
asthma	I-Problem
and	I-Background
coexistent	I-Background
insulin	I-Problem
-	I-Problem
dependent	I-Problem
diabetes	I-Problem
mellitus	I-Problem
sustained	O
an	O
anaphylactoid	I-Problem
reaction	I-Problem
after	O
the	O
intravenous	I-Treatment
administration	I-Treatment
of	I-Treatment
50	I-Treatment
%	I-Treatment
solution	I-Treatment
of	I-Treatment
dextrose	I-Treatment
.	O

cardiac	I-Problem
arrest	I-Problem
after	O
esmolol	I-Treatment
administration	O
:	O
a	O
review	O
of	O
acute	O
beta	O
-	O
blocker	O
toxicity	O
.	O

we	O
suggest	O
that	O
nicotinic	I-Treatment
acid	I-Treatment
was	O
the	O
cause	O
of	O
his	O
liver	I-Problem
disease	I-Problem
,	O
that	O
this	O
case	O
is	O
of	O
particular	O
note	O
because	O
of	O
the	O
rather	O
short	O
period	O
of	O
therapy	O
before	O
the	O
onset	O
of	O
liver	O
injury	O
and	O
the	O
severity	O
of	O
the	O
hepatic	O
failure	O
,	O
and	O
that	O
the	O
probable	O
increased	O
use	O
of	O
nicotinic	O
acid	O
for	O
serum	O
cholesterol	O
control	O
makes	O
it	O
especially	O
important	O
for	O
physicians	O
and	O
their	O
patients	O
to	O
be	O
alert	O
to	O
the	O
signs	O
of	O
hepatotoxicity	O
.	O

methods	O
:	O
two	O
patients	I-Background
with	O
exudative	I-Problem
age	I-Problem
-	I-Problem
related	I-Problem
macular	I-Problem
degeneration	I-Problem
were	O
treated	O
sequentially	O
with	O
an	O
intravitreal	I-Treatment
injection	I-Treatment
of	I-Treatment
bevacizumab	I-Treatment
and	O
developed	O
signs	O
of	O
severe	O
but	O
painless	O
infectious	I-Problem
endophthalmitis	I-Problem
2	I-Other
days	I-Other
later	I-Other
.	I-Other

ibuprofen	I-Treatment
-	O
induced	O
meningitis	I-Problem
:	O
detection	O
of	O
intrathecal	O
igg	O
synthesis	O
and	O
immune	O
complexes	O
.	O

tardive	I-Problem
oculogyric	I-Problem
crisis	I-Problem
during	O
treatment	O
with	O
clozapine	I-Treatment
:	O
report	O
of	O
three	O
cases	I-Background
.	O

myasthenia	I-Problem
gravis	I-Problem
during	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
therapy	I-Treatment
for	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

we	O
herein	O
report	O
this	O
rare	O
case	O
of	O
acute	I-Problem
onset	I-Problem
of	I-Problem
nephrotic	I-Problem
syndrome	I-Problem
during	O
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
retreatment	O
.	O

para	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
-	O
induced	O
hypoglycaemia	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
diabetic	I-Problem
nephropathy	I-Problem
.	O

ischaemia	I-Problem
following	O
selfadministered	I-Treatment
intra	I-Treatment
-	I-Treatment
arterial	I-Treatment
injection	I-Treatment
of	I-Treatment
methylphenidate	I-Treatment
and	I-Treatment
diamorphine	I-Treatment
.	O

mitomycin	I-Treatment
c	I-Treatment
-	O
related	O
hemolytic	I-Problem
uremic	I-Problem
syndrome	I-Problem
in	O
cancer	I-Problem
patients	I-Background
.	O

acute	I-Problem
bilateral	I-Problem
phrenic	I-Problem
neuropathy	I-Problem
following	O
treatment	O
with	O
adalimumab	I-Treatment
.	O

hypoxemia	I-Problem
improved	I-Treatment
during	I-Treatment
continuous	I-Treatment
tolazoline	I-Treatment
infusion	I-Treatment
,	O
but	O
gastrointestinal	I-Problem
bleeding	I-Problem
occurred	O
.	O

background	O
:	O
nvp	I-Treatment
is	O
a	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
used	O
in	O
the	O
treatment	O
of	O
human	I-Problem
immunodeficiency	I-Problem
virus	I-Problem
(	I-Problem
hiv	I-Problem
)	I-Problem
infection	I-Problem
.	O

a	I-Background
patient	I-Background
with	I-Background
acute	I-Problem
esophageal	I-Problem
variceal	I-Problem
bleeding	I-Problem
developed	O
fatal	I-Problem
rhabdomyolysis	I-Problem
during	O
treatment	O
with	O
a	O
continuous	I-Treatment
intravenous	I-Treatment
infusion	I-Treatment
of	I-Treatment
vasopressin	I-Treatment
.	O

preliminary	O
results	O
suggest	O
that	O
the	O
higher	I-Treatment
concentrations	I-Treatment
of	I-Treatment
dextrose	I-Treatment
induce	O
increased	I-Problem
histamine	I-Problem
release	I-Problem
from	I-Problem
blood	I-Problem
cells	I-Problem
,	O
and	O
that	O
this	O
phenomenon	O
is	O
more	O
marked	O
in	O
diabetic	I-Problem
,	I-Background
and	I-Background
particularly	I-Background
diabetic	I-Problem
-	I-Problem
allergic	I-Problem
,	I-Background
individuals	I-Background
.	O

all	I-Background
patients	I-Background
beginning	O
hmg	I-Treatment
-	I-Treatment
coa	I-Treatment
reductase	I-Treatment
inhibitor	I-Treatment
therapy	O
should	O
be	O
counseled	O
regarding	O
the	I-Problem
signs	I-Problem
and	I-Problem
symptoms	I-Problem
of	I-Problem
muscle	I-Problem
injury	I-Problem
;	O
particular	O
attention	O
should	O
be	O
paid	O
to	O
those	O
patients	O
who	O
are	O
taking	O
medications	O
that	O
may	O
interact	O
.	O

interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
-	O
induced	O
hyperthyroidism	I-Problem
:	O
a	O
three	O
-	O
stage	O
evolution	O
from	O
silent	O
thyroiditis	O
towards	O
graves	I-Problem
'	I-Problem
disease	I-Problem
.	O

acute	I-Problem
severe	I-Problem
intoxication	I-Problem
with	O
carbamazepine	I-Treatment
is	O
associated	O
with	O
seizures	O
,	O
coma	O
and	O
respiratory	O
depression	O
.	O

conclusion	O
:	O
we	O
have	O
introduced	O
a	I-Background
case	I-Background
of	O
anaphylaxis	I-Problem
by	O
calcitonin	I-Treatment
that	O
suggest	O
an	O
ige	O
mediated	O
hypersensitivity	O
reaction	O
.	O

purpose	O
:	O
to	O
describe	O
transient	I-Problem
structured	I-Problem
visual	I-Problem
hallucinations	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
vascular	I-Problem
age	I-Problem
-	I-Problem
related	I-Problem
macular	I-Problem
degeneration	I-Problem
(	I-Problem
amd	I-Problem
)	I-Problem
,	O
following	O
an	I-Treatment
intravitreal	I-Treatment
avastin	I-Treatment
-	I-Treatment
injection	I-Treatment
.	O

bortezomib	I-Treatment
-	O
induced	O
paralytic	I-Problem
ileus	I-Problem
is	O
a	O
potential	O
gastrointestinal	O
side	O
effect	O
of	O
this	O
first	O
-	O
in	O
-	O
class	O
anticancer	O
proteasome	O
inhibitor	O
.	O

it	O
is	O
suggested	O
that	O
the	O
fatal	O
stroke	I-Problem
may	O
have	O
resulted	O
from	O
arterial	I-Problem
spasm	I-Problem
caused	O
by	O
ergotamine	I-Treatment
overdosage	I-Treatment
and	O
possibly	O
complicated	O
by	O
thrombosis	O
.	O

during	O
the	O
anti	O
-	O
tuberculous	O
therapy	O
,	O
visual	I-Problem
loss	I-Problem
can	O
be	O
related	O
to	O
ethambutol	I-Treatment
toxicity	O
or	O
the	O
tuberculosis	I-Problem
infection	I-Problem
itself	O
.	O

elevated	I-Problem
international	I-Problem
normalized	I-Problem
ratio	I-Problem
in	O
a	I-Background
patient	I-Background
concurrently	O
using	O
warfarin	I-Treatment
and	I-Treatment
vismodegib	I-Treatment
.	O

occurrence	O
of	O
iddm	I-Problem
during	O
interferon	I-Treatment
therapy	I-Treatment
for	O
chronic	I-Problem
viral	I-Problem
hepatitis	I-Problem
.	O

pseudomembranous	I-Problem
colitis	I-Problem
readily	O
occurs	O
in	O
at	O
least	O
certain	I-Background
population	I-Background
groups	I-Background
receiving	O
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
.	O

results	O
:	O
budesonide	I-Treatment
use	O
can	O
cause	O
contact	I-Problem
dermatitis	I-Problem
.	O

hypertension	I-Problem
develops	O
in	O
most	O
patients	I-Background
after	I-Treatment
transplantation	I-Treatment
when	O
immunosuppression	I-Treatment
is	I-Treatment
based	I-Treatment
on	I-Treatment
cyclosporine	I-Treatment
and	I-Treatment
prednisone	I-Treatment
.	O

it	O
was	O
concluded	O
that	O
potassium	I-Problem
loss	I-Problem
occurred	O
by	O
a	O
non	O
-	O
renal	O
(	O
intestinal	O
)	O
route	O
in	O
phosphate	I-Treatment
-	O
induced	O
hypokalemia	I-Problem
.	O

we	O
have	O
described	O
three	O
patients	I-Background
with	I-Background
hepatitis	I-Problem
c	I-Problem
for	O
whom	O
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
were	O
prescribed	O
and	O
who	O
developed	O
two	I-Problem
successive	I-Problem
phases	I-Problem
of	I-Problem
silent	I-Problem
thyroiditis	I-Problem
followed	I-Problem
by	I-Problem
hyperthryroidism	I-Problem
relapse	I-Problem
due	I-Problem
to	I-Problem
graves	I-Problem
'	I-Problem
disease	I-Problem
.	O

hepatotoxicity	I-Problem
associated	O
with	O
choline	I-Treatment
magnesium	I-Treatment
trisalicylate	I-Treatment
:	O
case	I-Background
report	O
and	O
review	O
of	O
salicylate	O
-	O
induced	O
hepatotoxicity	O
.	O

conclusions	O
:	O
the	I-Background
3	O
cases	I-Background
presented	O
here	O
illustrate	O
the	O
development	O
of	O
reproductive	I-Problem
endocrine	I-Problem
disorders	I-Problem
after	I-Treatment
the	I-Treatment
initiation	I-Treatment
of	I-Treatment
valproate	I-Treatment
therapy	I-Treatment
in	O
women	I-Background
with	I-Background
epilepsy	I-Problem
.	O

a	I-Background
43	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
man	I-Background
developed	O
a	O
shallow	I-Problem
erosion	I-Problem
of	I-Problem
a	I-Problem
psoriatic	I-Problem
plaque	I-Problem
after	O
chronic	I-Other
administration	I-Treatment
of	I-Treatment
methotrexate	I-Treatment
.	O

conclusions	O
:	O
sd	O
-	O
oct	O
and	O
ao	O
detected	O
abnormalities	O
that	O
correlate	O
topographically	O
with	O
visual	I-Problem
field	I-Problem
loss	I-Problem
from	O
hydroxychloroquine	I-Treatment
toxicity	O
as	O
demonstrated	O
by	O
hvf	O
10	O
-	O
2	O
and	O
may	O
be	O
useful	O
in	O
the	O
detection	O
of	O
subclinical	O
abnormalities	O
that	O
precede	O
symptoms	O
or	O
objective	O
visual	O
field	O
loss	O
.	O

leflunomide	I-Treatment
-	O
induced	O
toxic	I-Problem
epidermal	I-Problem
necrolysis	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
.	O

delayed	I-Problem
bowel	I-Problem
injury	I-Problem
is	O
an	O
infrequently	O
observed	O
complication	O
of	O
chromic	I-Treatment
phosphate	I-Treatment
administration	I-Treatment
.	O

therefore	O
,	O
amantadine	I-Treatment
was	O
permanently	O
discontinued	O
and	O
the	O
cornea	I-Problem
cleared	I-Problem
again	O
.	O

spontaneous	I-Problem
splenic	I-Problem
infarction	I-Problem
associated	O
with	O
sumatriptan	I-Treatment
use	O
.	O

discussion	O
:	O
anaphylactoid	I-Problem
reactions	I-Problem
have	O
been	O
described	O
previously	O
with	O
cisplatin	I-Treatment
administration	O
.	O

the	O
current	O
report	O
describes	O
a	I-Background
man	I-Background
who	O
was	O
prescribed	O
zonisamide	I-Treatment
for	I-Treatment
epilepsy	I-Problem
and	O
subsequently	O
developed	O
widespread	I-Problem
skin	I-Problem
rash	I-Problem
,	I-Problem
acute	I-Problem
kidney	I-Problem
injury	I-Problem
,	I-Problem
high	I-Problem
-	I-Problem
grade	I-Problem
fever	I-Problem
,	I-Problem
eosinophilia	I-Problem
,	I-Problem
liver	I-Problem
dysfunction	I-Problem
,	I-Problem
lymphadenopathy	I-Problem
and	I-Problem
an	I-Problem
increase	I-Problem
in	I-Problem
antihuman	I-Problem
herpesvirus	I-Problem
-	I-Problem
6	I-Problem
immunoglobulin	I-Problem
g	I-Test
titer	I-Test
.	O

the	O
toxicity	I-Problem
of	O
cadmium	I-Treatment
,	I-Treatment
zinc	I-Treatment
,	I-Treatment
and	I-Treatment
cadmium	I-Treatment
/	I-Treatment
zinc	I-Treatment
mixtures	I-Treatment
at	I-Treatment
concentrations	I-Treatment
ranging	I-Treatment
from	I-Treatment
10000	I-Treatment
to	I-Treatment
10	I-Treatment
microg	I-Treatment
/	I-Treatment
l	I-Treatment
was	O
investigated	O
.	O

we	O
present	O
a	O
case	O
of	O
an	I-Background
elderly	I-Background
woman	I-Background
with	I-Background
a	I-Background
pre	I-Background
-	I-Background
existing	I-Background
history	I-Background
of	I-Background
ischaemic	I-Problem
heart	I-Problem
disease	I-Problem
,	O
who	O
was	O
treated	O
with	O
venlafaxine	I-Treatment
,	O
and	O
developed	O
acute	I-Problem
myocardial	I-Problem
ischaemia	I-Problem
within	I-Other
the	I-Other
first	I-Other
week	I-Other
of	I-Problem
treatment	I-Problem
.	O

here	O
,	O
we	O
describe	O
a	I-Background
case	I-Background
of	O
vogt	I-Problem
-	I-Problem
koyanagi	I-Problem
-	I-Problem
harada	I-Problem
disease	I-Problem
occurring	O
4	I-Other
months	I-Other
after	I-Treatment
the	I-Treatment
start	I-Treatment
of	I-Treatment
interferon	I-Treatment
alpha	I-Treatment
treatment	O
,	O
probably	O
induced	O
by	O
the	O
immunomodulatory	O
effects	O
of	O
interferon	O
.	O

capecitabine	I-Treatment
-	O
induced	O
headache	I-Problem
responding	O
to	O
diltiazem	O
.	O

serotonin	I-Problem
syndrome	I-Problem
after	O
concomitant	I-Treatment
treatment	I-Treatment
with	I-Treatment
linezolid	I-Treatment
and	I-Treatment
meperidine	I-Treatment
.	O

we	O
report	O
on	O
a	I-Background
child	I-Background
with	O
fatal	O
valproate	I-Treatment
-	O
related	O
hepatotoxic	I-Problem
effects	I-Problem
despite	O
this	O
supplementation	O
.	O

acute	I-Problem
isoniazid	I-Treatment
neurotoxicity	I-Problem
in	O
an	O
urban	O
hospital	O
.	O

in	O
vitro	I-Problem
inhibition	I-Problem
of	I-Problem
hematopoiesis	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
systemic	I-Problem
sclerosis	I-Problem
treated	O
with	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
.	O

rhabdomyolysis	I-Problem
has	O
been	O
reported	O
in	O
patients	I-Background
receiving	O
hydroxymethylglutaryl	I-Treatment
coenzyme	I-Treatment
a	I-Treatment
(	I-Treatment
hmg	I-Treatment
-	I-Treatment
coa	I-Treatment
)	I-Treatment
reductase	I-Treatment
inhibitors	I-Treatment
when	I-Treatment
coadministered	I-Treatment
with	I-Treatment
agents	I-Treatment
that	I-Treatment
may	I-Treatment
inhibit	I-Treatment
their	I-Treatment
metabolism	I-Treatment
.	O

a	I-Background
55	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
presented	O
an	O
episode	O
of	O
acute	I-Problem
urticaria	I-Problem
and	I-Problem
labial	I-Problem
angioedema	I-Problem
60	I-Other
minutes	I-Other
after	O
ingesting	I-Treatment
500	I-Treatment
mg	I-Treatment
of	I-Treatment
cloxacillin	I-Treatment
for	O
a	I-Background
skin	I-Problem
abscess	I-Problem
.	O

acne	I-Problem
provoked	O
by	O
gold	I-Treatment
seems	O
not	O
to	O
have	O
been	O
described	O
elsewhere	O
.	O

taxanes	I-Treatment
are	O
widely	O
used	O
chemotherapeutic	O
agents	O
with	O
the	O
potential	O
to	O
induce	O
pulmonary	I-Problem
injury	I-Problem
through	O
a	O
variety	O
of	O
mechanisms	O
.	O

purpose	O
:	O
to	O
report	O
two	O
cases	I-Background
of	O
acute	I-Problem
endophthalmitis	I-Problem
following	O
intravitreal	I-Treatment
bevacizumab	I-Treatment
injection	I-Treatment
.	O

this	O
is	O
a	O
case	O
report	O
of	O
subtle	O
,	O
mild	I-Problem
hypothermia	I-Problem
in	O
a	I-Background
54	I-Background
-	I-Background
year	I-Background
old	I-Background
female	I-Background
patient	I-Background
receiving	O
risperidone	I-Treatment
for	O
schizophrenia	I-Problem
.	O

mycophenolate	I-Treatment
mofetil	I-Treatment
-	O
induced	O
neutropenia	I-Problem
in	I-Problem
liver	I-Problem
transplantation	I-Problem
.	O

according	O
to	O
the	O
literature	O
,	O
chlorambucil	I-Treatment
central	I-Problem
nervous	I-Problem
toxicity	I-Problem
is	O
found	O
almost	O
exclusively	O
in	O
childhood	I-Background
nephrotic	I-Problem
syndrome	I-Problem
.	O

administration	I-Treatment
of	I-Treatment
lamotrigine	I-Treatment
,	O
especially	O
in	O
combination	O
with	I-Treatment
valproic	I-Treatment
acid	I-Treatment
,	O
may	O
lead	O
to	O
the	O
development	O
of	O
ten	I-Problem
.	O

docetaxel	I-Treatment
induced	O
meibomian	I-Problem
duct	I-Problem
inflammation	I-Problem
and	I-Problem
blockage	I-Problem
is	O
the	O
likely	O
cause	O
of	O
this	O
presentation	O
in	O
a	I-Background
patient	I-Background
with	I-Background
no	I-Background
history	I-Background
of	I-Background
eyelid	I-Background
masses	I-Background
in	I-Background
the	I-Background
past	I-Background
.	O

we	O
describe	O
a	O
unique	O
case	O
of	O
disseminated	O
cryptococcosis	O
presenting	O
as	O
colitis	O
that	O
mimicked	O
an	I-Problem
exacerbation	I-Problem
of	I-Problem
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
in	O
a	I-Treatment
tnf	I-Treatment
-	I-Treatment
alpha	I-Treatment
inhibitor	I-Treatment
recipient	I-Background
.	O

rhabdomyolysis	I-Problem
associated	O
with	O
the	O
use	O
of	O
intravenous	I-Treatment
vasopressin	I-Treatment
.	O

administration	O
of	O
intravenous	I-Treatment
nitroglycerin	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
idiopathic	I-Problem
pulmonary	I-Problem
hypertension	I-Problem
resulted	O
in	O
an	O
increase	I-Problem
in	I-Problem
pulmonary	I-Problem
artery	I-Problem
pressure	I-Problem
associated	I-Problem
with	I-Problem
a	I-Problem
decrease	I-Problem
in	I-Problem
blood	I-Problem
flow	I-Problem
that	I-Problem
is	I-Problem
best	I-Problem
explained	I-Problem
by	I-Problem
an	I-Problem
increase	I-Problem
in	I-Problem
pulmonary	I-Problem
vascular	I-Problem
resistance	I-Problem
.	O

the	O
increased	I-Problem
libido	I-Problem
disappeared	O
after	O
fluvoxamine	I-Treatment
was	O
discontinued	O
.	O

coadministration	I-Treatment
of	I-Treatment
antidepressant	I-Treatment
agents	I-Treatment
such	I-Treatment
as	I-Treatment
nefazodone	I-Treatment
,	I-Treatment
or	I-Treatment
any	I-Treatment
other	I-Treatment
drug	I-Treatment
that	I-Treatment
inhibits	I-Treatment
the	I-Treatment
cyp3a4	I-Treatment
isoenzyme	I-Treatment
subfamily	I-Treatment
,	O
should	O
be	O
anticipated	O
to	O
interfere	O
with	O
tacrolimus	I-Treatment
metabolism	I-Problem
.	O

conclusions	O
:	O
we	O
conclude	O
that	O
a	I-Treatment
high	I-Treatment
dose	I-Treatment
combined	I-Treatment
with	I-Treatment
a	I-Treatment
short	I-Treatment
infusion	I-Treatment
time	I-Treatment
increases	O
the	O
risk	O
of	O
anaphylactoid	I-Problem
reactions	I-Problem
with	O
the	O
administration	I-Treatment
of	I-Treatment
intraperitoneal	I-Treatment
cisplatin	I-Treatment
.	O

human	I-Treatment
insulin	I-Treatment
-	O
induced	O
lipoatrophy	I-Problem
.	O

severe	I-Problem
hepatotoxicity	I-Problem
from	O
phenobarbital	I-Treatment
occurred	O
in	O
an	I-Background
infant	I-Background
boy	I-Background
who	I-Background
had	I-Background
a	I-Background
complicated	I-Background
illness	I-Background
with	I-Background
chronic	I-Problem
bilateral	I-Problem
subdural	I-Problem
hematomas	I-Problem
and	I-Background
sepsis	I-Problem
.	I-Background

cholestatic	I-Problem
liver	I-Problem
disease	I-Problem
with	I-Problem
ductopenia	I-Problem
(	I-Problem
vanishing	I-Problem
bile	I-Problem
duct	I-Problem
syndrome	I-Problem
)	I-Problem
after	O
administration	O
of	O
clindamycin	I-Treatment
and	I-Treatment
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
.	O

the	O
authors	O
suggest	O
that	O
in	O
the	O
absence	O
of	O
any	O
proven	O
benefit	O
of	O
itraconazole	I-Treatment
prophylaxis	O
,	O
and	O
given	O
the	O
interaction	O
of	O
this	O
drug	O
with	O
vincristine	I-Treatment
leading	O
to	O
severe	I-Problem
and	I-Problem
even	I-Problem
potentially	I-Problem
fatal	I-Problem
toxicities	I-Problem
,	O
the	O
combination	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

the	O
determinant	O
role	O
of	O
individual	O
pharmacogenetic	O
profile	O
in	O
the	O
occurrence	O
of	O
tacrolimus	I-Treatment
nephrotoxicity	I-Problem
is	O
presented	O
and	O
discussed	O
.	O

these	O
findings	O
suggest	O
that	O
bicytopenia	I-Problem
in	O
this	O
patient	I-Background
was	O
caused	O
by	O
d	I-Treatment
-	I-Treatment
pen	I-Treatment
and	O
may	O
be	O
due	O
to	O
different	O
sensitivities	O
in	O
the	O
hematopoietic	O
lineage	O
.	O

we	O
strongly	O
suspect	O
that	O
this	O
lethal	I-Problem
anuria	I-Problem
was	O
mainly	O
due	O
to	O
ifosfamide	I-Treatment
,	O
occurring	O
in	O
a	I-Background
patient	I-Background
having	I-Treatment
received	I-Treatment
previous	I-Treatment
cisplatin	I-Treatment
chemotherapy	I-Treatment
and	I-Background
with	I-Background
poor	I-Problem
kidney	I-Problem
perfusion	I-Problem
due	I-Background
to	I-Background
transient	I-Background
hypotension	I-Background
.	O

clinicians	O
have	O
been	O
aware	O
of	O
lithium	O
toxicity	O
for	O
many	O
years	O
and	O
traditionally	O
have	O
administered	O
thiazide	I-Treatment
diuretics	I-Treatment
for	O
lithium	O
-	O
induced	O
polyuria	I-Problem
and	O
nephrogenic	I-Problem
diabetes	I-Problem
insipidus	I-Problem
.	O

we	O
report	O
the	O
first	O
case	O
of	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
with	I-Problem
hyperkalemia	I-Problem
associated	O
with	O
the	O
recently	O
marketed	O
direct	O
renin	I-Treatment
inhibitor	I-Treatment
aliskiren	I-Treatment
.	O

the	O
authors	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
hemiparesis	I-Problem
who	O
developed	O
the	O
syndrome	O
of	O
irreversible	I-Problem
lithium	I-Problem
-	I-Problem
effectuated	I-Problem
neurotoxicity	I-Problem
(	I-Problem
silent	I-Problem
)	I-Problem
while	O
being	O
treated	O
with	O
lithium	I-Treatment
for	I-Treatment
a	I-Treatment
manic	I-Problem
episode	I-Problem
.	O

over	O
the	O
past	O
3	O
years	O
there	O
have	O
been	O
several	O
reports	O
of	O
uveitis	I-Problem
associated	O
with	O
rifabutin	I-Treatment
therapy	I-Treatment
.	O

propylthiouracil	I-Treatment
-	O
induced	O
cutaneous	I-Problem
vasculitis	I-Problem
.	O

it	O
has	O
been	O
reported	O
that	O
fluoroquinolone	I-Treatment
antimicrobials	I-Treatment
prolong	O
the	O
corrected	I-Problem
qt	I-Problem
interval	I-Problem
but	I-Problem
rarely	I-Problem
cause	I-Problem
torsade	I-Problem
de	I-Problem
pointes	I-Problem
.	O

succinylcholine	I-Treatment
-	O
induced	O
hyperkalemia	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
mucositis	I-Problem
secondary	O
to	O
chemotherapy	O
.	O

to	O
our	O
knowledge	O
,	O
this	O
is	O
the	I-Background
first	I-Background
case	I-Background
of	O
spontaneous	O
remission	O
of	O
mtx	I-Treatment
-	O
associated	O
gastric	I-Problem
lpd	I-Problem
after	O
discontinuation	O
of	O
mtx	I-Treatment
therapy	O
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
acute	I-Problem
myeloblastic	I-Problem
leukemia	I-Problem
(	I-Background
aml	I-Background
)	I-Background
who	O
developed	O
nephrotic	I-Problem
syndrome	I-Problem
after	O
receiving	O
several	I-Treatment
courses	I-Treatment
of	I-Treatment
chemotherapy	I-Treatment
,	I-Treatment
including	I-Treatment
macrophage	I-Treatment
-	I-Treatment
colony	I-Treatment
-	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
(	I-Treatment
m	I-Treatment
-	I-Treatment
csf	I-Treatment
)	I-Treatment
.	O

actinomycin	I-Treatment
d	I-Treatment
associated	O
hepatic	I-Problem
veno	I-Problem
-	I-Problem
occlusive	I-Problem
disease	I-Problem
-	O
-	O
a	O
report	O
of	O
2	O
cases	O
.	O

our	O
patient	I-Background
developed	O
both	O
nephrogenic	I-Problem
diabetes	I-Problem
insipidus	I-Problem
and	I-Problem
renal	I-Problem
tubular	I-Problem
acidosis	I-Problem
with	O
a	O
temporal	O
pattern	O
that	O
demonstrated	O
a	O
link	O
between	O
foscarnet	I-Treatment
therapy	O
and	O
these	O
abnormalities	O
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
acne	I-Problem
fulminans	I-Problem
occurring	O
during	O
treatment	O
with	O
13	I-Treatment
-	I-Treatment
cis	I-Treatment
-	I-Treatment
retinoic	I-Treatment
acid	I-Treatment
for	O
cystic	I-Problem
acne	I-Problem
.	O

verapamil	I-Treatment
is	O
widely	O
used	O
for	O
the	O
termination	O
of	O
paroxysmal	I-Problem
supraventricular	I-Problem
tachycardia	I-Problem
(	O
psvt	O
)	O
with	O
little	O
proarrhythmic	I-Problem
effect	I-Problem
.	O

acute	O
kidney	O
injury	O
caused	O
by	O
zonisamide	I-Treatment
-	O
induced	O
hypersensitivity	I-Problem
syndrome	I-Problem
.	O

our	O
findings	O
suggest	O
that	O
hyperkalemia	I-Problem
can	O
develop	O
with	O
the	O
use	O
of	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
heparin	I-Treatment
,	I-Treatment
within	I-Other
seven	I-Other
days	I-Other
of	I-Treatment
initiating	I-Treatment
heparin	I-Treatment
therapy	I-Treatment
,	O
and	O
that	O
patients	I-Background
with	I-Background
diabetes	I-Problem
mellitus	I-Problem
or	I-Background
chronic	I-Problem
renal	I-Problem
insufficiency	I-Problem
are	O
especially	O
predisposed	O
to	O
this	O
complication	O
.	O

we	O
report	O
a	O
case	O
of	O
zidovudine	I-Treatment
induced	O
anaemia	I-Problem
and	I-Problem
bone	I-Problem
marrow	I-Problem
aplasia	I-Problem
in	O
a	I-Background
patient	I-Background
infected	I-Background
with	I-Background
hiv	I-Problem
.	O

we	O
present	O
the	O
case	O
of	O
an	O
adult	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
patient	I-Background
with	O
a	I-Problem
parvovirus	I-Problem
b19	I-Problem
infection	I-Problem
and	I-Problem
leukopenia	I-Problem
during	O
long	I-Other
-	I-Other
term	I-Other
aza	I-Treatment
therapy	I-Treatment
.	O

pathogenesis	O
of	O
methotrexate	I-Treatment
-	O
induced	O
papular	I-Problem
eruption	I-Problem
in	I-Problem
psoriasis	I-Problem
may	O
involve	O
immune	O
mechanisms	O
other	O
than	O
those	O
of	O
methotrexate	O
-	O
induced	O
cutaneous	I-Problem
vasculitis	I-Problem
in	I-Problem
collagen	I-Problem
vascular	I-Problem
disease	I-Problem
.	O

cases	O
:	O
two	O
postmenopausal	I-Background
women	I-Background
treated	O
with	O
tamoxifen	I-Treatment
and	I-Treatment
progestational	I-Treatment
agents	O
for	O
breast	I-Problem
carcinoma	I-Problem
developed	O
uterine	I-Problem
enlargement	I-Problem
and	I-Problem
intermittent	I-Problem
spotting	I-Problem
.	O

tumor	I-Problem
lysis	I-Problem
syndrome	I-Problem
after	O
transcatheter	I-Treatment
arterial	I-Treatment
infusion	I-Treatment
of	I-Treatment
cisplatin	I-Treatment
and	I-Treatment
embolization	I-Treatment
therapy	O
for	O
liver	I-Problem
metastases	I-Problem
of	I-Problem
melanoma	I-Problem
.	O

oxcarbazepine	I-Treatment
-	O
induced	O
drug	O
reaction	O
with	O
eosinophilia	I-Problem
and	I-Problem
systemic	I-Problem
symptoms	I-Problem
(	I-Problem
dress	I-Problem
)	I-Problem
.	O

worsening	I-Problem
of	I-Problem
neurologic	I-Problem
syndrome	I-Problem
in	O
patients	I-Background
with	I-Background
wilson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
with	O
initial	O
penicillamine	I-Treatment
therapy	I-Treatment
.	O

patient	I-Background
a	I-Background
reported	O
right	I-Problem
leg	I-Problem
weakness	I-Problem
(	O
foot	O
drop	O
)	O
during	O
week	I-Other
4	I-Other
of	I-Treatment
cap	I-Treatment
-	I-Treatment
xrt	I-Treatment
(	I-Treatment
1600	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
)	I-Treatment
.	O

a	I-Background
child	I-Background
in	O
whom	O
a	O
phenobarbital	I-Treatment
hypersensitivity	I-Problem
drug	I-Problem
reaction	I-Problem
developed	O
which	I-Problem
consisted	I-Problem
of	I-Problem
fever	I-Problem
,	I-Problem
a	I-Problem
pruritic	I-Problem
desquamating	I-Problem
erythrodermic	I-Problem
rash	I-Problem
,	I-Problem
alopecia	I-Problem
,	I-Problem
icterus	I-Problem
,	I-Problem
protein	I-Problem
-	I-Problem
losing	I-Problem
enteropathy	I-Problem
,	I-Problem
myositis	I-Problem
,	I-Problem
and	I-Problem
nephritis	I-Problem
,	O
is	O
described	O
.	O

detection	O
of	O
activated	O
eosinophils	O
in	O
nasal	O
polyps	O
of	O
an	O
aspirin	I-Treatment
-	O
induced	O
asthma	I-Problem
patient	O
.	O

we	O
recommend	O
that	O
clinicians	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
pancreatitis	I-Problem
,	I-Problem
including	I-Problem
abdominal	I-Problem
pain	I-Problem
,	O
during	O
treatment	O
with	O
tigecycline	I-Treatment
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	O
experienced	O
a	O
lichenoid	I-Problem
eruption	I-Problem
after	O
the	I-Treatment
initiation	I-Other
of	I-Treatment
salsalate	I-Treatment
for	O
relief	O
of	O
arthritic	I-Problem
pain	I-Problem
.	O

concomitant	O
administration	O
of	O
lithium	I-Treatment
with	O
olanzapine	I-Treatment
may	O
place	O
patients	I-Background
at	O
risk	O
for	O
nms	I-Problem
.	O

we	O
report	O
the	O
case	O
of	O
an	I-Background
87	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
woman	I-Background
with	I-Background
myasthenia	I-Problem
gravis	I-Problem
who	O
presented	O
with	O
nausea	I-Problem
,	I-Problem
shortness	I-Problem
of	I-Problem
breath	I-Problem
,	I-Problem
azotemia	I-Problem
,	I-Problem
and	I-Problem
hyperkalemia	I-Problem
shortly	O
after	O
completing	O
a	O
course	O
of	O
intravenous	I-Treatment
immunoglobulin	I-Treatment
(	O
ivig	O
)	O
.	O

linezolid	I-Treatment
should	O
be	O
discontinued	O
immediately	O
in	O
patients	I-Background
experiencing	O
these	O
adverse	I-Problem
effects	I-Problem
.	O

purpose	O
:	O
symptomatic	I-Problem
visual	I-Problem
field	I-Problem
constriction	I-Problem
thought	O
to	O
be	O
associated	O
with	O
vigabatrin	I-Treatment
has	O
been	O
reported	O
.	O

clinically	I-Problem
significant	I-Problem
adverse	O
events	O
from	O
a	O
drug	O
interaction	I-Treatment
between	I-Treatment
quetiapine	I-Treatment
and	I-Treatment
atazanavir	I-Treatment
-	I-Treatment
ritonavir	I-Treatment
in	O
two	O
patients	I-Background
.	O

objective	O
:	O
to	O
report	O
two	O
cases	I-Background
of	O
fixed	I-Problem
drug	I-Problem
eruption	I-Problem
induced	O
by	O
methylphenidate	I-Treatment
.	O

linezolid	I-Treatment
is	O
an	O
oxazolidinone	O
antibacterial	O
agent	O
indicated	O
for	O
serious	I-Problem
gram	I-Problem
-	I-Problem
positive	I-Problem
infections	I-Problem
.	O

a	O
search	I-Test
of	O
the	O
united	O
states	O
food	O
and	O
drug	O
administration	O
'	O
s	O
adverse	O
event	O
reporting	O
system	O
identified	O
nine	O
cases	O
of	O
oxcarbazepine	I-Treatment
-	O
associated	O
angioedema	I-Problem
in	O
pediatric	I-Problem
patients	I-Background
aged	I-Background
16	I-Background
years	I-Background
and	I-Background
younger	I-Background
.	O

monitoring	O
of	I-Test
liver	I-Test
function	I-Test
tests	I-Test
should	O
be	O
mandatory	O
in	O
patients	I-Background
receiving	I-Treatment
high	I-Treatment
doses	I-Treatment
of	I-Treatment
cyproterone	I-Treatment
acetate	I-Treatment
;	O
the	O
drug	O
should	O
be	O
withdrawn	O
immediately	O
if	O
abnormal	I-Problem
liver	I-Problem
function	I-Problem
tests	O
are	O
found	O
.	O

in	O
six	O
cases	I-Background
ct	I-Problem
scans	I-Test
did	I-Problem
not	I-Problem
return	I-Problem
to	I-Problem
their	I-Problem
original	I-Problem
state	I-Problem
after	O
acth	I-Treatment
therapy	O
.	O

this	O
report	O
describes	O
a	O
probable	O
case	O
of	O
infliximab	I-Treatment
-	O
induced	O
membranous	I-Problem
nephropathy	I-Problem
.	O

thrombotic	I-Problem
thrombocytopenic	I-Problem
purpura	I-Problem
during	O
penicillamine	I-Treatment
therapy	O
in	O
rheumatoid	I-Problem
arthritis	I-Problem
.	O

objective	O
:	O
the	O
purpose	O
of	O
this	O
study	I-Test
was	O
to	O
determine	O
whether	O
desensitization	I-Treatment
to	I-Treatment
nph	I-Treatment
insulin	I-Treatment
,	I-Treatment
as	I-Treatment
well	I-Treatment
as	I-Treatment
standard	I-Treatment
insulin	I-Treatment
desensitization	I-Treatment
,	O
could	O
control	O
allergic	I-Problem
symptoms	I-Problem
in	I-Problem
a	I-Problem
patient	I-Problem
allergic	I-Problem
to	I-Problem
both	I-Problem
nph	I-Problem
and	I-Problem
regular	I-Problem
insulin	I-Problem
.	O

fulminant	I-Problem
hepatic	I-Problem
failure	I-Problem
developed	O
in	O
a	I-Background
24	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
black	I-Background
woman	I-Background
who	O
had	O
been	O
treated	O
with	O
propylthiouracil	I-Treatment
and	I-Treatment
propranolol	I-Treatment
for	O
hyperthyroidism	I-Problem
.	O

however	O
,	O
as	O
the	O
use	O
of	O
hepatitis	I-Treatment
b	I-Treatment
vaccination	I-Treatment
is	O
growing	O
,	O
adverse	O
side	O
effects	O
,	O
including	O
mental	I-Problem
nerve	I-Problem
neuropathy	I-Problem
,	O
should	O
be	O
observed	O
with	O
an	O
increased	O
frequency	O
.	O

acute	I-Problem
coronary	I-Problem
events	I-Problem
following	O
cisplatin	I-Treatment
-	I-Treatment
based	I-Treatment
chemotherapy	I-Treatment
.	O

capecitabine	O
(	O
cap	O
)	O
is	O
a	O
pro	O
-	O
drug	O
of	O
5	O
-	O
fu	O
and	O
peripheral	I-Problem
neuropathy	I-Problem
associated	O
with	O
cap	I-Treatment
has	O
not	O
been	O
reported	O
.	O

purpose	O
:	O
to	O
report	O
a	O
case	I-Problem
of	I-Problem
angiographically	I-Problem
documented	I-Problem
cystoid	I-Problem
macula	I-Problem
edema	I-Problem
occurring	O
after	O
switching	O
a	I-Background
pseudophakic	I-Problem
patient	I-Background
from	I-Treatment
latanoprost	I-Treatment
to	I-Treatment
bimatoprost	I-Treatment
.	I-Treatment

the	O
clinical	O
picture	O
was	O
identical	O
to	O
that	O
of	O
chloroquine	I-Treatment
and	I-Treatment
hydroxychloroquine	I-Treatment
maculopathy	I-Problem
.	O

conclusion	O
:	O
a	I-Background
woman	I-Background
receiving	O
enoxaparin	I-Treatment
every	I-Other
12	I-Other
hours	I-Other
developed	O
signs	I-Problem
and	I-Problem
symptoms	I-Problem
of	I-Problem
hepatotoxicity	I-Problem
after	I-Treatment
the	I-Treatment
second	I-Treatment
dose	I-Treatment
.	I-Treatment

a	O
case	O
of	O
liver	I-Problem
damage	I-Problem
following	O
treatment	O
with	O
danazol	I-Treatment
for	O
fibrocystic	I-Problem
breast	I-Problem
disease	I-Problem
is	O
reported	O
.	O

antacid	I-Treatment
and	I-Treatment
sucralfate	I-Treatment
-	O
induced	O
hypophosphatemic	I-Problem
osteomalacia	I-Problem
:	O
a	I-Background
case	I-Background
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
senna	I-Treatment
-	O
induced	O
cholestatic	I-Problem
hepatitis	I-Problem
which	O
was	O
not	O
diagnosed	O
at	O
presentation	O
.	O

five	O
patients	I-Background
are	O
described	O
in	O
whom	O
only	O
gentamicin	I-Treatment
sulfate	I-Treatment
appeared	O
responsible	O
for	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
.	O

however	O
,	O
in	O
order	O
to	O
avoid	O
neuropathic	I-Problem
side	I-Problem
effects	I-Problem
,	O
patients	I-Background
under	O
thalidomide	I-Treatment
therapy	I-Treatment
should	O
be	O
monitored	O
every	O
6	O
months	O
with	O
nerve	O
conduction	I-Test
studies	I-Test
while	O
taking	O
the	O
drug	O
.	O

videopolysomnographic	O
and	I-Test
pharmacokinetic	I-Test
studies	I-Test
with	O
monitoring	O
of	I-Test
plasma	O
levodopa	I-Test
levels	I-Test
demonstrated	O
marked	I-Problem
motor	I-Problem
hyperactivity	I-Problem
during	I-Problem
augmentation	I-Problem
,	I-Problem
with	I-Problem
anarchic	I-Problem
discharges	I-Problem
of	I-Problem
motor	I-Problem
unit	I-Problem
potentials	I-Problem
,	I-Problem
tonic	I-Problem
grouped	I-Problem
discharges	I-Problem
and	I-Problem
flexor	I-Problem
spasms	I-Problem
,	I-Problem
associated	I-Problem
with	I-Problem
painful	I-Problem
dysesthesia	I-Problem
.	O

antibiotic	I-Problem
-	I-Problem
associated	I-Problem
colitis	I-Problem
(	I-Problem
pseudomembranous	I-Problem
colitis	I-Problem
)	I-Problem
developed	O
in	O
four	O
patients	I-Background
with	I-Background
spinal	I-Problem
cord	I-Problem
injury	I-Problem
and	O
taking	O
oral	I-Treatment
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
27	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
indian	I-Background
woman	I-Background
who	O
developed	O
maculopapular	I-Problem
rash	I-Problem
and	I-Problem
angioedema	I-Problem
secondary	O
to	O
carbamazepine	I-Treatment
administration	I-Treatment
.	O

we	O
reviewed	O
the	O
literature	O
in	O
an	O
attempt	O
to	O
characterize	O
the	O
pattern	O
and	O
predictors	O
of	O
tmp	I-Treatment
/	I-Treatment
smx	I-Treatment
-	O
induced	O
aseptic	I-Problem
meningitis	I-Problem
.	O

mean	O
time	O
between	O
initiation	O
of	O
gemcitabine	O
therapy	O
and	O
onset	O
of	O
hus	I-Problem
was	O
7	I-Other
.	I-Other
4	I-Other
+	I-Other
/	I-Other
-	I-Other
3	I-Other
.	I-Other
5	I-Other
months	I-Other
,	I-Other
or	I-Other
21	I-Treatment
.	I-Treatment
9	I-Treatment
+	I-Treatment
/	I-Treatment
-	I-Treatment
10	I-Treatment
.	I-Treatment
9	I-Treatment
doses	I-Treatment
of	I-Treatment
gemcitabine	I-Treatment
.	O

aluminum	I-Treatment
intoxication	I-Treatment
,	O
along	O
with	O
other	O
factors	O
,	O
was	O
considered	O
to	O
be	O
the	O
cause	O
of	O
tc	I-Problem
development	I-Problem
.	O

agranulocytosis	I-Problem
during	O
clozapine	I-Treatment
therapy	I-Treatment
.	O

it	O
was	O
highly	O
suspected	O
that	O
finasteride	I-Treatment
was	O
associated	O
with	O
the	O
anterior	I-Problem
subcapsular	I-Problem
opacity	I-Problem
on	I-Problem
the	I-Problem
lens	I-Problem
,	O
and	O
the	I-Background
patient	I-Background
therefore	O
discontinued	O
use	O
of	O
finasteride	O
.	O

life	O
-	O
threatening	O
cranial	I-Problem
dystonia	I-Problem
following	O
trihexyphenidyl	I-Treatment
withdrawal	I-Treatment
.	O

the	O
risk	O
of	O
cardiac	I-Problem
decompensation	I-Problem
in	O
infants	I-Background
with	I-Background
supraventricular	I-Problem
tachycardia	I-Problem
and	I-Background
congestive	I-Problem
cardiac	I-Problem
failure	I-Problem
should	O
be	O
kept	O
in	O
mind	O
prior	O
to	O
administration	O
of	O
verapamil	I-Treatment
.	O

we	O
describe	O
serotonin	I-Problem
syndrome	I-Problem
after	O
concomitant	I-Treatment
use	I-Treatment
of	I-Treatment
linezolid	I-Treatment
and	I-Treatment
meperidine	I-Treatment
in	O
a	I-Background
27	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
acute	I-Problem
leukemia	I-Problem
.	O

recent	O
studies	O
have	O
shown	O
that	O
under	O
experimental	O
conditions	O
ferrous	I-Treatment
sulfate	I-Treatment
may	O
reduce	I-Problem
the	I-Problem
gastrointestinal	I-Problem
absorption	I-Problem
of	I-Problem
orally	I-Treatment
administered	I-Treatment
levothyroxine	I-Treatment
sodium	I-Treatment
in	O
patients	I-Background
with	I-Background
primary	I-Problem
hypothyroidism	I-Problem
.	O

we	O
report	O
here	O
a	O
case	O
of	O
cardiovascular	I-Problem
and	I-Problem
neurological	I-Problem
depression	I-Problem
induced	O
by	O
oxymetalzoline	I-Treatment
in	O
a	I-Background
toddler	I-Background
.	O

the	O
association	O
between	O
heparin	I-Treatment
and	O
priapism	I-Problem
is	O
often	O
recognized	O
;	O
abnormal	O
platelet	O
aggregation	O
could	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
side	O
effect	O
.	O

posterior	I-Problem
leukoencephalopathy	I-Problem
following	O
cisplatin	I-Treatment
,	I-Treatment
bleomycin	I-Treatment
and	I-Treatment
vinblastine	I-Treatment
therapy	I-Treatment
for	I-Treatment
germ	I-Problem
cell	I-Problem
tumor	I-Problem
of	I-Problem
the	I-Problem
ovary	I-Problem
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
cutaneous	I-Problem
and	I-Problem
hematologic	I-Problem
toxicity	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
il	I-Treatment
-	I-Treatment
2	I-Treatment
.	O

flecainide	I-Treatment
is	O
a	O
rare	O
cause	O
of	O
hypersensitivity	I-Problem
pneumonitis	I-Problem
,	O
and	O
few	O
cases	O
have	O
been	O
reported	O
.	O

the	O
patient	O
developed	O
grade	O
3	O
capecitabine	I-Treatment
-	O
induced	O
headache	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
biopsy	I-Problem
-	I-Problem
proven	I-Problem
acute	I-Problem
tubulointerstitial	I-Problem
nephritis	I-Problem
associated	O
with	O
a	I-Treatment
second	I-Other
course	I-Other
of	I-Treatment
flurbiprofen	I-Treatment
,	O
a	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
of	O
the	O
propionic	O
acid	O
class	O
.	O

although	O
an	O
association	O
between	O
exposure	O
to	O
bleomycin	I-Treatment
and	O
the	O
development	O
of	O
scleroderma	I-Problem
has	O
been	O
suspected	O
,	O
few	I-Background
cases	I-Background
are	O
reported	O
.	O

a	I-Background
74	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
received	O
oral	I-Treatment
administration	I-Treatment
of	I-Treatment
pilsicainide	I-Treatment
,	O
a	O
pure	O
sodium	O
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics	O
,	O
to	O
convert	O
paroxysmal	I-Problem
atrial	I-Problem
fibrillation	I-Problem
to	O
sinus	O
rhythm	O
and	O
developed	O
loss	I-Problem
of	I-Problem
consciousness	I-Problem
two	I-Other
days	I-Other
later	I-Other
.	O

aggressive	I-Problem
endometrial	I-Problem
carcinoma	I-Problem
in	O
a	O
breast	I-Problem
cancer	I-Problem
patient	I-Background
treated	O
with	O
tamoxifen	I-Treatment
with	I-Background
normal	I-Background
transvaginal	I-Background
ultrasonography	I-Test
.	O

less	O
common	O
adverse	O
events	O
to	O
dapsone	I-Treatment
include	O
the	I-Problem
idiosyncratic	I-Problem
reactions	I-Problem
of	I-Problem
leukopenia	I-Problem
and	I-Problem
agranulocytosis	I-Problem
,	I-Problem
cutaneous	I-Problem
eruptions	I-Problem
,	I-Problem
peripheral	I-Problem
neuropathy	I-Problem
,	I-Problem
psychosis	I-Problem
,	I-Problem
toxic	I-Problem
hepatitis	I-Problem
,	I-Problem
cholestatic	I-Problem
jaundice	I-Problem
,	I-Problem
nephrotic	I-Problem
syndrome	I-Problem
,	I-Problem
renal	I-Problem
papillary	I-Problem
necrosis	I-Problem
,	I-Problem
severe	I-Problem
hypoalbuminemia	I-Problem
without	I-Problem
proteinuria	I-Problem
,	I-Problem
an	I-Problem
infectious	I-Problem
mononucleosis	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
,	I-Problem
and	I-Problem
minor	I-Problem
neurological	I-Problem
and	I-Problem
gastrointestinal	I-Problem
complaints	I-Problem
.	O

the	O
association	O
of	O
venlafaxine	I-Treatment
treatment	I-Treatment
with	O
ischaemic	I-Problem
events	I-Problem
could	O
be	O
explained	O
by	O
its	O
unique	O
pharmacological	O
and	O
haemodynamic	O
properties	O
.	O

this	O
selective	O
closure	O
of	O
the	O
ductus	O
arteriosus	O
suggests	O
that	O
the	O
affected	O
twin	O
was	O
predisposed	O
to	O
hypoxia	O
and	O
thus	O
was	O
more	O
susceptible	O
to	O
ductal	I-Problem
closure	I-Problem
in	O
response	O
to	O
indomethacin	I-Treatment
exposure	I-Treatment
.	O

this	O
pattern	O
is	O
suggestive	O
of	O
renal	I-Problem
toxicity	I-Problem
due	O
to	O
tobramycin	I-Treatment
.	O

objective	O
:	O
to	O
evaluate	O
the	O
efficacy	O
of	O
the	O
administration	O
of	O
insulin	O
by	O
a	O
jet	O
-	O
injector	O
device	O
in	O
stopping	O
and	O
reversing	O
severe	I-Problem
human	I-Problem
insulin	I-Treatment
-	O
induced	O
lipoatrophy	I-Problem
.	O

this	O
is	O
a	I-Background
unique	I-Background
autopsy	I-Background
case	I-Background
of	O
hepatocellular	I-Problem
carcinoma	I-Problem
closely	O
related	O
to	O
diethylstilbestrol	I-Treatment
(	I-Treatment
des	I-Treatment
)	I-Treatment
therapy	O
for	O
prostatic	I-Problem
cancer	I-Problem
.	O

argatroban	I-Treatment
for	O
heparin	O
-	O
induced	O
thrombocytopenia	O
in	O
hepato	I-Problem
-	I-Problem
renal	I-Problem
failure	I-Problem
and	O
cvvhd	O
.	O

falling	I-Problem
backward	I-Problem
in	O
two	O
elderly	I-Background
patients	I-Background
taking	O
bupropion	I-Treatment
.	O

methods	O
:	O
three	O
patients	I-Background
with	O
apparent	O
itraconazole	I-Treatment
-	O
induced	O
liver	I-Problem
injury	I-Problem
were	O
studied	O
.	O

to	O
our	O
knowledge	O
,	O
four	O
cases	O
of	O
interstitial	I-Problem
pneumonitis	I-Problem
associated	O
with	O
fludarabine	I-Treatment
have	O
been	O
reported	O
in	O
medical	O
literature	O
.	O

normalization	I-Problem
of	I-Problem
generalized	I-Problem
retinal	I-Problem
function	I-Problem
and	I-Problem
progression	I-Problem
of	I-Problem
maculopathy	I-Problem
after	O
cessation	I-Treatment
of	I-Treatment
therapy	I-Treatment
in	O
a	I-Background
case	I-Background
of	I-Background
severe	I-Background
hydroxychloroquine	I-Treatment
retinopathy	I-Problem
with	O
19	I-Other
years	I-Other
follow	O
-	O
up	O
.	O

interferon	I-Treatment
-	O
induced	O
psychosis	I-Problem
as	O
a	O
"	O
psychiatric	O
contraindication	O
"	O
to	O
hepatitis	I-Problem
c	I-Problem
treatment	O
:	O
a	O
review	O
and	O
case	O
-	O
based	O
discussion	O
.	O

prolongation	I-Problem
of	I-Problem
the	I-Problem
qt	I-Problem
interval	I-Problem
and	I-Problem
ventricular	I-Problem
tachyarrhymias	I-Problem
have	O
been	O
described	O
in	O
patients	I-Background
on	O
amiodarone	I-Treatment
therapy	I-Treatment
.	O

aripiprazole	I-Treatment
,	O
5	I-Treatment
mg	I-Treatment
daily	I-Other
,	O
was	O
initiated	O
in	O
november	O
2004	O
as	O
an	O
augmentation	O
strategy	O
for	O
the	O
diagnosis	O
of	O
ocd	I-Problem
.	O

serious	I-Problem
adverse	I-Problem
events	I-Problem
experienced	O
by	O
patients	I-Background
with	I-Background
chronic	I-Problem
heart	I-Problem
failure	I-Problem
taking	O
spironolactone	I-Treatment
.	O

review	O
of	O
the	O
literature	O
relating	O
to	O
methicillin	I-Treatment
-	O
induced	O
nephropathy	I-Problem
suggests	O
a	O
hypersensitivity	I-Problem
origin	O
for	O
this	O
disorder	O
,	O
but	O
immunologic	O
and	I-Test
ultrastructural	I-Test
investigation	I-Test
to	O
date	O
has	O
failed	O
to	O
elucidate	O
pathogenesis	O
.	O

ards	I-Problem
has	O
been	O
associated	O
with	O
the	I-Treatment
administration	I-Treatment
of	I-Treatment
other	I-Treatment
monoclonal	I-Treatment
antibodies	I-Treatment
,	I-Treatment
such	I-Treatment
as	I-Treatment
infliximab	I-Treatment
,	I-Treatment
gemtuzumab	I-Treatment
ozogamicin	I-Treatment
,	I-Treatment
and	I-Treatment
okt3	I-Treatment
and	O
is	O
believed	O
to	O
be	O
directly	O
mediated	O
by	O
release	O
of	O
proinflammatory	O
cytokines	O
.	O

case	O
report	O
:	O
soon	O
after	O
initiation	O
of	O
amiodarone	I-Treatment
hcl	I-Treatment
(	I-Treatment
200	I-Treatment
mg	I-Treatment
/	O
day	I-Other
)	O
,	O
a	I-Background
76	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
came	O
to	O
us	O
with	O
symptoms	I-Problem
of	I-Problem
visual	I-Problem
"	I-Problem
shining	I-Problem
,	I-Problem
"	I-Problem
glare	I-Problem
,	I-Problem
color	I-Problem
vision	I-Problem
anomalies	I-Problem
,	I-Problem
and	I-Problem
gradually	I-Problem
decreased	I-Problem
vision	I-Problem
.	O

an	I-Background
insulin	I-Background
-	I-Background
dependent	I-Background
diabetic	I-Problem
patient	I-Background
with	I-Background
nephropathy	I-Problem
developed	O
severe	I-Problem
acidosis	I-Problem
after	O
treatment	O
with	O
acetazolamide	I-Treatment
for	I-Treatment
glaucoma	I-Problem
.	O

severe	O
hypo	I-Problem
-	I-Problem
alpha	I-Problem
-	I-Problem
lipoproteinemia	I-Problem
during	O
treatment	O
with	O
rosiglitazone	I-Treatment
.	O

peripheral	I-Problem
neuropathy	I-Problem
and	I-Problem
cerebellar	I-Problem
syndrome	I-Problem
associated	O
with	O
amiodarone	I-Treatment
therapy	O
.	O

conclusions	O
:	O
we	O
report	O
this	O
case	I-Background
of	O
the	O
concomitant	O
appearance	O
of	O
multiple	I-Problem
skin	I-Problem
cancers	I-Problem
and	I-Problem
nail	I-Problem
changes	I-Problem
associated	O
with	O
hydroxyurea	I-Treatment
use	O
.	O

itraconazole	I-Treatment
-	O
related	O
increased	I-Problem
vincristine	I-Treatment
neurotoxicity	I-Problem
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
.	O

a	I-Background
62	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
caucasian	I-Background
man	I-Background
with	I-Background
atrial	I-Problem
fibrillation	I-Problem
who	O
was	O
taking	O
warfarin	I-Treatment
reported	O
an	O
episode	O
of	O
hematochezia	I-Problem
;	O
his	O
international	I-Test
normalized	I-Test
ratio	I-Test
(	O
inr	O
)	O
was	O
1	O
.	O
74	O
.	O

severe	O
anaemia	I-Problem
related	O
to	O
oseltamivir	I-Treatment
during	I-Treatment
treatment	I-Treatment
of	I-Treatment
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
:	O
a	O
new	O
drug	O
interaction	O
?	O

background	O
:	O
how	O
to	O
best	O
treat	O
psychotic	I-Problem
patients	I-Background
who	O
have	O
had	O
past	O
clozapine	I-Treatment
-	O
induced	O
agranulocytosis	I-Problem
or	I-Problem
granulocytopenia	I-Problem
remains	O
a	O
problem	O
.	O

cystoid	I-Problem
macular	I-Problem
edema	I-Problem
in	O
a	O
low	I-Background
-	I-Background
risk	I-Background
patient	I-Background
after	O
switching	I-Treatment
from	I-Treatment
latanoprost	I-Treatment
to	I-Treatment
bimatoprost	I-Treatment
.	O

physicians	O
should	O
therefore	O
be	O
aware	O
of	O
its	O
occurrence	O
and	O
carefully	O
monitor	O
serum	O
levels	I-Test
of	O
cpk	O
,	O
got	O
and	O
gpt	O
during	O
the	O
treatment	O
of	O
diabetes	I-Problem
insipidus	I-Problem
with	O
clofibrate	I-Treatment
,	O
especially	O
in	O
patients	I-Background
with	I-Background
associated	I-Background
hypothyroidism	I-Problem
,	I-Background
latent	I-Problem
or	I-Background
overt	I-Problem
,	O
which	O
possibly	O
favors	O
the	O
development	O
of	O
myopathy	I-Problem
.	I-Problem

flurbiprofen	I-Treatment
-	O
associated	O
acute	I-Problem
tubulointerstitial	I-Problem
nephritis	I-Problem
.	O

conclusion	O
:	O
we	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
rhgh	I-Treatment
-	O
induced	O
hypercalcemia	I-Problem
in	O
an	I-Background
hiv	I-Problem
-	I-Background
infected	I-Background
patient	I-Background
.	O

a	O
case	O
of	O
basilar	I-Problem
invagination	I-Problem
which	O
is	O
thought	O
to	O
have	O
arisen	O
from	O
the	O
patient	O
'	O
s	O
intrauterine	O
exposure	O
to	O
phenytoin	I-Treatment
is	O
presented	O
.	O

methotrexate	I-Problem
pneumonitis	I-Problem
in	O
nonsurgical	I-Treatment
treatment	I-Treatment
of	O
ectopic	I-Problem
pregnancy	I-Problem
.	O

two	O
patients	I-Background
who	O
were	O
receiving	I-Treatment
tolazoline	I-Treatment
by	I-Treatment
infusion	I-Treatment
developed	O
duodenal	I-Problem
ulceration	I-Problem
and	I-Problem
subsequent	I-Problem
intestinal	I-Problem
perforation	I-Problem
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
14	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
with	I-Background
acute	I-Problem
promyelocytic	I-Problem
leukemia	I-Problem
who	O
developed	O
symptomatic	I-Problem
cardiomyopathy	I-Problem
only	O
4	I-Other
months	I-Other
into	I-Treatment
treatment	I-Treatment
with	I-Treatment
a	I-Treatment
combination	I-Treatment
of	I-Treatment
daunomycin	I-Treatment
and	I-Treatment
all	I-Treatment
-	I-Treatment
trans	I-Treatment
retinoic	I-Treatment
acid	I-Treatment
(	I-Treatment
atra	I-Treatment
)	I-Treatment
.	O

hepatotoxicity	I-Problem
seen	O
with	O
erlotinib	I-Treatment
,	O
a	O
small	O
molecule	O
tyrosine	O
kinase	O
inhibitor	O
to	O
egfr	O
,	O
is	O
usually	O
transient	I-Problem
with	I-Problem
mild	I-Problem
elevation	I-Problem
of	I-Problem
transaminases	I-Problem
.	O

results	O
:	O
a	I-Background
previously	I-Background
healthy	I-Background
42	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
presented	O
with	O
acute	I-Problem
-	I-Problem
onset	I-Problem
delirium	I-Problem
with	I-Problem
psychotic	I-Problem
features	I-Problem
as	O
a	O
consequence	O
of	O
levofloxacin	I-Treatment
therapy	I-Treatment
.	O

although	O
limb	O
dyskinesia	O
after	O
methylphenidate	I-Treatment
is	O
a	O
commonly	O
reported	O
side	O
effect	O
,	O
to	O
the	O
authors	O
'	O
knowledge	O
this	O
is	O
only	O
the	I-Background
second	I-Background
reported	I-Background
case	I-Background
to	O
develop	O
both	O
orofacial	I-Problem
and	I-Problem
limb	I-Problem
dyskinesia	I-Problem
in	O
the	O
acute	O
period	O
after	O
the	O
first	O
dose	O
of	O
methylphenidate	I-Treatment
.	O

phenylpropanolamine	I-Treatment
-	O
induced	O
psychosis	I-Problem
.	O

graft	I-Problem
versus	I-Problem
host	I-Problem
-	I-Problem
like	I-Problem
illness	I-Problem
in	O
a	I-Background
child	I-Background
with	O
phenobarbital	I-Treatment
hypersensitivity	I-Problem
.	O

the	O
wide	O
use	O
of	O
phenytoin	I-Treatment
during	O
the	O
recent	O
tuberculosis	I-Other
epidemic	O
makes	O
it	O
imperative	O
to	O
suspect	O
this	O
drug	O
interaction	O
in	O
patients	I-Background
exhibiting	O
clinical	O
features	O
that	O
might	O
be	O
related	O
to	O
phenytoin	I-Problem
toxicity	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
mmc	I-Treatment
-	O
related	O
hemolytic	I-Problem
uremic	I-Problem
syndrome	I-Problem
,	O
and	O
discuss	O
the	O
etiologic	O
parameters	O
,	O
clinical	O
aspects	O
,	O
prognosis	O
and	O
treatment	O
modalities	O
of	O
this	O
severe	O
syndrome	O
.	O

myasthenic	I-Problem
patients	I-Background
receiving	O
ampicillin	I-Treatment
should	O
be	O
closely	O
monitored	O
for	O
possible	O
acute	I-Problem
exacerbations	I-Problem
.	O

the	I-Background
male	I-Background
patient	I-Background
was	O
treated	O
with	O
225	I-Treatment
-	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
clozapine	I-Treatment
and	O
the	O
time	O
to	O
the	O
diagnosis	O
of	O
agranulocytosis	I-Problem
was	O
6	I-Other
weeks	I-Other
.	O

alprazolam	I-Problem
withdrawal	I-Problem
delirium	I-Problem
unresponsive	O
to	O
diazepam	I-Treatment
:	O
case	O
report	O
.	O

these	O
findings	O
support	O
previous	O
studies	I-Test
that	O
showed	O
that	O
the	O
use	O
of	O
aspirin	I-Treatment
during	O
the	I-Problem
antecedent	I-Problem
illness	I-Problem
may	O
be	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
rs	I-Problem
.	O

chloroquine	I-Treatment
-	O
induced	O
bilateral	I-Problem
ptosis	I-Problem
.	O

discussion	O
:	O
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
tuberculous	I-Problem
uveitis	I-Problem
following	O
treatment	O
with	O
etanercept	I-Treatment
.	O

hyponatremia	I-Problem
is	O
a	O
known	O
adverse	O
effect	O
of	O
duloxetine	I-Treatment
,	O
and	O
it	O
can	O
lead	O
to	O
potentially	I-Problem
life	I-Problem
-	I-Problem
threatening	I-Problem
complications	I-Problem
.	O

a	I-Background
22	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
drug	I-Problem
-	I-Problem
abuser	I-Problem
injected	I-Treatment
flunitrazepam	I-Treatment
tablets	I-Treatment
dissolved	I-Treatment
in	I-Treatment
tap	I-Treatment
water	I-Treatment
into	I-Treatment
her	I-Treatment
left	I-Treatment
femoral	I-Treatment
artery	I-Treatment
and	O
presented	O
with	O
clinical	O
signs	O
of	O
acute	I-Problem
ischaemia	I-Problem
of	I-Problem
the	I-Problem
left	I-Problem
leg	I-Problem
.	O

a	I-Background
patient	I-Background
with	I-Background
parkinson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
,	O
initially	I-Treatment
treated	I-Treatment
with	I-Treatment
bromocriptine	I-Treatment
and	I-Treatment
subsequently	I-Treatment
with	I-Treatment
cabergoline	I-Treatment
,	O
developed	O
progressive	I-Problem
pleuropulmonary	I-Problem
abnormalities	I-Problem
during	I-Problem
the	I-Problem
latter	I-Problem
therapy	I-Problem
.	O

camptocormia	I-Problem
,	O
a	O
new	O
side	O
effect	O
of	O
sodium	I-Treatment
valproate	I-Treatment
.	O

many	I-Background
patients	I-Background
with	I-Background
cardiac	I-Problem
arrhythmias	I-Problem
require	O
concomitant	I-Treatment
therapy	I-Treatment
with	I-Treatment
warfarin	I-Treatment
and	I-Treatment
amiodarone	I-Treatment
.	O

we	O
report	O
the	O
case	O
histories	O
of	O
two	O
patients	I-Background
with	I-Background
histologically	I-Background
confirmed	I-Background
adenocarcinoma	I-Problem
of	I-Problem
the	I-Problem
prostate	I-Problem
,	O
both	O
of	O
whom	O
had	O
been	O
treated	O
with	O
steroidal	I-Treatment
anti	I-Treatment
-	I-Treatment
androgen	I-Treatment
therapy	I-Treatment
in	I-Treatment
the	I-Treatment
form	I-Treatment
of	I-Treatment
cyproterone	I-Treatment
acetate	I-Treatment
prior	I-Treatment
to	I-Treatment
radical	I-Treatment
or	I-Treatment
palliative	I-Treatment
pelvic	I-Treatment
irradiation	I-Treatment
,	O
and	O
who	O
subsequently	O
developed	O
femoral	I-Problem
head	I-Problem
avascular	I-Problem
necrosis	I-Problem
.	I-Problem

thus	O
,	O
the	O
possible	O
in	O
vivo	O
effects	O
of	O
insulin	O
on	O
adipocytes	O
were	O
clearly	O
observed	O
in	O
this	O
case	O
of	O
insulin	I-Treatment
-	O
induced	O
lipohypertrophy	I-Problem
.	O

after	O
the	O
addition	O
of	O
citalopram	I-Treatment
,	O
a	O
desmethylclomipramine	I-Problem
plasma	I-Test
level	I-Problem
increase	I-Problem
and	I-Problem
an	I-Problem
8	I-Problem
-	I-Problem
hydroacy	I-Problem
-	I-Problem
desmethylclomipramine	I-Problem
plasma	I-Problem
level	I-Problem
decrease	I-Problem
were	O
observed	O
.	O

here	O
we	O
present	O
the	O
case	O
of	O
a	I-Background
woman	I-Background
who	O
received	O
high	I-Treatment
doses	I-Treatment
of	I-Treatment
methylprednisolone	I-Treatment
(	I-Treatment
1	I-Treatment
g	I-Treatment
iv	I-Treatment
daily	I-Other
)	I-Treatment
for	O
active	I-Problem
graves	I-Problem
'	I-Problem
ophthalmopathy	I-Problem
,	O
and	O
developed	O
severe	I-Problem
hypertension	I-Problem
followed	I-Problem
by	I-Problem
myocardial	I-Problem
infarction	I-Problem
on	I-Problem
the	I-Problem
fifth	I-Problem
day	I-Problem
of	I-Problem
treatment	I-Problem
.	I-Problem

severe	O
cardiomyopathy	I-Problem
following	O
treatment	I-Treatment
with	I-Treatment
the	I-Treatment
tumour	I-Treatment
necrosis	I-Treatment
factor	I-Treatment
-	I-Treatment
alpha	I-Treatment
inhibitor	I-Treatment
adalimumab	I-Treatment
for	O
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
.	O

there	O
are	O
now	O
reports	O
of	O
liver	I-Problem
failure	I-Problem
following	O
treatment	O
of	O
childhood	I-Background
cancers	I-Problem
with	O
amd	I-Treatment
.	O

imatinib	I-Treatment
mesylate	I-Treatment
-	O
related	O
fatal	I-Problem
acute	I-Problem
hepatic	I-Problem
failure	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
chronic	I-Problem
myeloid	I-Problem
leukaemia	I-Problem
and	I-Background
chronic	I-Problem
hepatitis	I-Problem
b	I-Problem
infection	I-Problem
.	O

this	O
phase	O
3	O
,	O
randomized	I-Test
,	O
double	I-Test
-	I-Test
blind	I-Test
1	I-Test
-	I-Test
yr	I-Test
study	I-Test
assessed	O
the	O
effects	O
of	O
combined	I-Treatment
rlx	I-Treatment
and	I-Treatment
aln	I-Treatment
in	O
331	O
postmenopausal	I-Background
women	I-Background
with	I-Background
osteoporosis	I-Problem
(	I-Background
femoral	I-Background
neck	I-Test
bmd	I-Test
t	I-Test
-	I-Test
score	I-Test
,	I-Background
less	I-Background
than	I-Background
-	I-Background
2	I-Background
)	I-Background
.	O

phenytoin	I-Treatment
toxicity	I-Problem
due	O
to	O
concomitant	I-Treatment
antituberculosis	I-Treatment
therapy	I-Treatment
.	I-Treatment

amiodarone	I-Treatment
is	O
well	O
recognized	O
as	O
an	O
anti	O
-	O
arrhythmic	O
drug	O
containing	O
a	O
high	O
dose	O
of	O
iodine	O
with	O
considerable	O
potential	I-Problem
to	I-Problem
cause	I-Problem
thyroid	I-Problem
dysfunction	I-Problem
.	O

pulmonary	I-Problem
infiltrates	I-Problem
and	I-Problem
skin	I-Problem
pigmentation	I-Problem
associated	O
with	O
sulfasalazine	I-Treatment
.	O

lithium	I-Treatment
treatment	I-Treatment
was	O
terminated	O
in	O
1975	O
because	O
of	O
lithium	I-Problem
intoxication	I-Problem
with	I-Problem
a	I-Problem
diabetes	I-Problem
insipidus	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
.	O

the	O
authors	O
report	O
a	O
longitudinal	I-Test
case	I-Test
study	I-Test
of	O
a	I-Background
woman	I-Background
with	I-Background
a	I-Background
history	I-Background
of	I-Background
bipolar	I-Problem
affective	I-Problem
disorder	I-Problem
in	O
which	O
l	I-Treatment
-	I-Treatment
dopa	I-Treatment
shortened	I-Problem
the	I-Problem
manic	I-Problem
-	I-Problem
depressive	I-Problem
cycle	I-Problem
length	I-Problem
when	O
administered	O
in	O
a	O
double	O
-	O
blind	I-Test
trial	I-Test
.	O

isoniazid	I-Treatment
causing	O
breast	I-Problem
tissue	I-Problem
enlargement	I-Problem
has	O
been	O
very	O
rarely	O
reported	O
.	O

the	O
induction	O
of	O
hypoglycaemia	I-Problem
with	O
pas	I-Treatment
in	O
this	I-Background
patient	I-Background
suggests	O
a	O
potential	O
role	O
for	O
pas	O
in	O
the	O
treatment	O
of	O
diabetes	I-Problem
mellitus	I-Problem
.	O

acute	I-Problem
dystonia	I-Problem
during	O
pegylated	I-Treatment
interferon	I-Treatment
alpha	I-Treatment
therapy	O
in	O
a	O
case	O
with	O
chronic	I-Problem
hepatitis	I-Problem
b	I-Problem
infection	I-Problem
.	O

i	O
saw	O
two	O
patients	I-Background
with	I-Background
kala	I-Problem
-	I-Problem
azar	I-Problem
resistant	I-Problem
to	I-Problem
sodium	I-Problem
stibogluconate	I-Problem
who	O
developed	O
cardiac	I-Problem
arrest	I-Problem
after	O
amphotericin	I-Treatment
infusion	I-Treatment
(	O
in	O
spite	O
of	O
tolerating	O
a	O
test	I-Test
dose	O
)	O
.	O

conclusions	O
:	O
anastrozole	I-Treatment
may	O
be	O
the	O
causative	O
factor	O
in	O
patients	I-Background
with	O
sclerosing	I-Problem
glomerulonephritis	I-Problem
.	O

we	O
describe	O
two	I-Background
cases	I-Background
of	O
acute	I-Problem
pancreatitis	I-Problem
that	O
occurred	O
after	O
long	O
term	O
mesalamine	I-Treatment
therapy	O
for	O
ulcerative	I-Problem
colitis	I-Problem
.	O

amphotericin	I-Treatment
b	I-Treatment
(	I-Treatment
amb	I-Treatment
)	I-Treatment
is	O
effective	O
,	O
but	O
its	O
use	O
is	O
limited	O
by	O
toxicity	I-Problem
:	I-Problem
renal	I-Problem
impairment	I-Problem
,	I-Problem
anaemia	I-Problem
,	I-Problem
fever	I-Problem
,	I-Problem
malaise	I-Problem
,	I-Problem
and	I-Problem
hypokalaemia	I-Problem
are	O
common	O
.	O

we	O
believe	O
that	O
a	I-Treatment
drug	I-Treatment
interaction	I-Treatment
between	I-Treatment
terfenadine	I-Treatment
and	I-Treatment
ketoconazole	I-Treatment
resulted	O
in	O
the	I-Problem
elevated	I-Problem
terfenadine	I-Problem
levels	I-Problem
in	I-Problem
plasma	I-Problem
and	I-Problem
in	I-Problem
the	I-Problem
cardiotoxicity	I-Problem
previously	O
seen	O
only	O
in	O
cases	O
of	O
terfenadine	O
overdose	O
.	O

a	O
case	O
of	O
halothane	I-Treatment
induced	O
hepatitis	I-Problem
is	O
reported	O
in	O
a	I-Background
middle	I-Background
aged	I-Background
woman	I-Background
who	O
underwent	O
gastric	I-Treatment
surgery	I-Treatment
for	I-Treatment
morbid	I-Problem
obesity	I-Problem
.	O

carbonic	I-Treatment
anhydrase	I-Treatment
inhibitors	I-Treatment
used	O
in	O
the	O
treatment	O
of	O
glaucoma	I-Problem
,	I-Problem
seizure	I-Problem
disorders	I-Problem
,	I-Problem
and	I-Problem
hypertension	I-Problem
are	O
rarely	O
associated	O
with	O
blood	I-Problem
dyscrasias	I-Problem
.	O

administration	I-Treatment
of	I-Treatment
intrathecal	I-Treatment
ara	I-Treatment
-	I-Treatment
c	I-Treatment
in	I-Treatment
the	I-Treatment
same	I-Treatment
dose	I-Treatment
over	I-Treatment
longer	I-Other
intervals	I-Other
within	I-Other
3	I-Other
-	I-Other
5	I-Other
days	I-Other
between	I-Other
consecutive	I-Other
doses	I-Other
resulted	O
in	O
mild	O
,	O
transient	O
neurological	I-Problem
symptoms	I-Problem
(	O
paresthesias	O
)	O
in	O
only	O
one	O
of	O
30	O
patients	I-Background
so	O
treated	O
.	O

anaphylaxis	I-Problem
from	O
isoniazid	I-Treatment
is	O
a	O
possible	O
side	O
effect	O
to	O
this	O
commonly	I-Treatment
prescribed	I-Treatment
antibiotic	I-Treatment
.	O

among	O
12	O
thyrotoxic	O
patients	O
,	O
a	I-Background
patient	I-Background
with	I-Background
arrhythmogenic	I-Problem
right	I-Problem
ventricular	I-Problem
dysplasia	I-Problem
,	O
who	O
had	O
been	O
taking	O
amiodarone	I-Treatment
for	I-Treatment
4	I-Other
years	I-Other
,	O
developed	O
thyrotoxicosis	I-Problem
with	I-Problem
subacute	I-Problem
onset	I-Problem
,	I-Problem
accompanied	I-Problem
by	I-Problem
transiently	I-Problem
positive	I-Problem
thyrotropin	I-Problem
(	I-Problem
tsh	I-Problem
)	I-Problem
receptor	I-Problem
antibody	I-Problem
(	I-Problem
trab	I-Problem
)	I-Problem
,	I-Problem
or	I-Problem
thyrotropin	I-Problem
-	I-Problem
binding	I-Problem
inhibiting	I-Problem
immunoglobulin	I-Problem
(	I-Problem
tbii	I-Problem
)	I-Problem
.	O

methotrexate	I-Treatment
-	O
induced	O
papular	I-Problem
eruption	I-Problem
following	O
treatment	O
of	O
psoriasis	I-Problem
.	O

sexual	I-Problem
dysfunction	I-Problem
associated	O
with	O
intrathecal	I-Treatment
baclofen	I-Treatment
use	O
:	O
a	O
report	O
of	O
two	O
cases	I-Background
.	O

patients	I-Background
treated	O
with	O
l	I-Treatment
-	I-Treatment
asparaginase	I-Treatment
may	O
present	O
with	O
hemorrhagic	I-Problem
and	I-Problem
thrombotic	I-Problem
cerebrovascular	I-Problem
events	I-Problem
.	O

since	O
imiquimod	I-Treatment
induces	O
large	I-Problem
amounts	I-Problem
of	I-Problem
type	I-Problem
i	I-Problem
interferon	I-Problem
production	I-Problem
from	O
tlr7	O
-	O
expressing	O
plasmacytoid	O
dendritic	O
cell	O
precursors	O
(	O
pdcs	O
)	O
,	O
the	O
natural	O
interferon	O
-	O
producing	O
cells	O
of	O
the	O
peripheral	O
blood	O
,	O
we	O
asked	O
whether	O
pdcs	O
are	O
present	O
in	O
psoriatic	O
skin	O
.	O

ptosis	I-Problem
occurring	O
24	I-Other
h	I-Other
after	O
chloroquine	I-Treatment
therapy	I-Treatment
,	O
with	O
full	I-Problem
recovery	I-Problem
48	I-Problem
h	I-Problem
after	I-Problem
cessation	I-Problem
of	I-Problem
chloroquine	I-Problem
,	O
has	O
not	O
been	O
described	O
previously	O
.	O

hypersensitivity	I-Problem
pneumonitis	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
associated	O
with	O
the	O
use	O
of	O
lenalidomide	I-Treatment
.	O

incidence	O
of	O
seizures	I-Problem
in	O
pediatric	I-Background
cancer	I-Problem
patients	I-Background
treated	O
with	O
imipenem	I-Treatment
/	I-Treatment
cilastatin	I-Treatment
.	O

one	O
of	O
these	O
was	O
clofazimine	I-Treatment
,	O
an	O
aniline	O
aposafranine	O
derivative	O
known	O
to	O
produce	O
a	I-Problem
ceroid	I-Problem
-	I-Problem
like	I-Problem
pigment	I-Problem
in	O
the	O
tissues	O
of	O
patients	I-Background
treated	I-Background
with	I-Background
this	I-Background
drug	I-Background
or	I-Background
lepromatous	I-Problem
leprosy	I-Problem
.	O

deposits	I-Problem
of	I-Problem
plasma	I-Problem
proteins	I-Problem
in	I-Problem
the	I-Problem
skin	I-Problem
during	O
treatment	O
with	O
carbamazepine	I-Treatment
and	I-Treatment
diphenylhydantoin	I-Treatment
.	O

2	I-Treatment
-	I-Treatment
chloro	I-Treatment
-	I-Treatment
deoxyadenosine	I-Treatment
induces	O
durable	O
complete	O
remission	O
in	O
castleman	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
but	O
may	O
accelerate	O
its	O
transformation	O
to	O
non	I-Problem
-	I-Problem
hodgkin	I-Problem
'	I-Problem
s	I-Problem
lymphoma	I-Problem
.	O

hypersensitivity	I-Problem
to	O
aspirin	I-Treatment
can	O
be	O
manifested	O
as	O
acute	I-Problem
asthma	I-Problem
,	O
urticaria	I-Problem
and	O
/	O
or	O
angioedema	I-Problem
,	O
or	O
a	O
systemic	I-Problem
anaphylactoid	I-Problem
reaction	I-Problem
.	O

only	O
one	O
patient	O
,	O
the	I-Background
youngest	I-Background
,	O
did	O
well	O
on	O
risperidone	I-Treatment
therapy	O
.	O

two	O
elderly	I-Background
women	I-Background
suffered	O
an	O
acute	I-Problem
deterioration	I-Problem
of	I-Problem
renal	I-Problem
function	I-Problem
after	O
treatment	I-Treatment
with	I-Treatment
cefoxitin	I-Treatment
sodium	I-Treatment
.	O

physicians	O
should	O
suspect	O
pulmonary	I-Problem
toxicity	I-Problem
in	O
patients	I-Background
with	I-Background
respiratory	I-Problem
distress	I-Problem
after	O
gemcitabine	I-Treatment
chemotherapy	I-Treatment
,	O
mainly	I-Background
in	I-Background
elderly	I-Background
patients	I-Background
.	O

delay	I-Problem
of	I-Problem
corneal	I-Problem
wound	I-Problem
healing	I-Problem
in	O
patients	I-Background
treated	O
with	O
colchicine	I-Treatment
.	O

amiodarone	I-Treatment
-	O
induced	O
thyrotoxicosis	I-Problem
associated	O
with	O
thyrotropin	O
receptor	I-Test
antibody	I-Test
.	O

conclusion	O
:	O
all	O
doctors	O
need	O
to	O
be	O
aware	O
of	O
the	O
need	O
to	O
review	O
the	O
indications	O
for	O
gabapentin	I-Treatment
use	O
during	O
periods	O
of	O
acute	I-Problem
illness	I-Problem
,	O
especially	O
with	O
regard	O
to	O
renal	I-Problem
impairment	I-Problem
.	O

ea	I-Problem
signs	I-Test
were	O
observed	O
in	O
all	I-Background
7	O
patients	I-Background
in	O
association	O
with	O
propofol	I-Treatment
tiva	I-Treatment
but	O
did	O
not	O
recur	O
in	O
any	O
of	O
123	O
subsequent	O
anesthetics	O
sessions	O
during	O
which	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
ketamine	I-Treatment
was	I-Treatment
added	I-Treatment
to	I-Treatment
propofol	I-Treatment
.	O

the	O
cause	O
of	O
death	O
was	O
multiple	I-Problem
drug	I-Problem
intoxication	I-Problem
following	O
acute	O
use	O
of	O
sertraline	I-Treatment
,	O
the	O
manner	O
of	O
death	O
was	O
suicide	O
,	O
and	O
the	O
mechanism	O
of	O
death	O
is	O
an	O
unexplained	O
drug	O
interaction	O
and	O
/	O
or	O
toxicity	O
.	O

on	I-Treatment
the	I-Treatment
next	I-Treatment
day	I-Treatment
,	I-Treatment
after	I-Treatment
a	I-Treatment
total	I-Treatment
dose	I-Treatment
of	I-Treatment
only	I-Treatment
600	I-Treatment
mg	I-Treatment
of	I-Treatment
danazol	I-Treatment
,	O
gingival	I-Problem
bleeding	I-Problem
and	I-Problem
purpura	I-Problem
occurred	O
.	O

sle	I-Problem
receded	O
after	O
withdrawal	I-Treatment
of	I-Treatment
carbamazepine	I-Treatment
and	I-Treatment
treatment	I-Treatment
with	I-Treatment
anti	I-Treatment
-	I-Treatment
inflammatory	I-Treatment
drugs	I-Treatment
.	O

a	I-Background
67	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
bipolar	I-Problem
disorder	I-Problem
developed	O
a	O
creutzfeldt	I-Problem
-	I-Problem
jakob	I-Problem
like	I-Problem
syndrome	I-Problem
during	O
lithium	I-Treatment
carbonate	I-Treatment
treatment	O
.	O

a	O
42	I-Background
year	I-Background
old	I-Background
man	I-Background
,	O
treated	O
for	O
testicular	I-Problem
carcinoma	I-Problem
with	O
combination	I-Treatment
chemotherapy	I-Treatment
that	I-Treatment
included	I-Treatment
bleomycin	I-Treatment
,	I-Treatment
developed	O
life	O
threatening	O
interstitial	I-Problem
pneumonitis	I-Problem
.	O

disseminated	I-Problem
eruptive	I-Problem
giant	I-Problem
mollusca	I-Problem
contagiosa	I-Problem
in	O
an	I-Background
adult	I-Background
psoriasis	I-Problem
patient	I-Background
during	O
efalizumab	I-Treatment
therapy	I-Treatment
.	O

significant	O
clinical	O
improvement	O
of	O
the	O
porphyria	I-Problem
followed	O
withdrawal	I-Treatment
of	I-Treatment
the	I-Treatment
diphenylhydantoin	I-Treatment
.	O

temozolomide	I-Treatment
was	O
restarted	O
2	O
months	O
later	O
;	O
the	I-Background
patient	I-Background
again	O
developed	O
a	O
fever	I-Problem
.	O

the	I-Background
patient	I-Background
'	I-Background
s	I-Background
previous	I-Background
rash	I-Problem
and	O
the	O
temporal	O
relation	O
of	O
this	O
event	O
and	O
the	O
ingestion	I-Treatment
of	I-Treatment
phenolphthalein	I-Treatment
,	O
as	O
well	O
as	O
the	O
similarity	O
of	O
this	O
case	O
to	O
other	O
reports	O
,	O
point	O
to	O
phenolphthalein	O
as	O
the	O
cause	O
of	O
ten	I-Problem
in	O
this	O
patient	O
.	O

ciprofloxacin	I-Treatment
greatly	O
elevates	O
plasma	I-Problem
concentrations	I-Test
of	I-Problem
tizanidine	I-Treatment
and	I-Problem
dangerously	I-Problem
potentiates	I-Problem
its	I-Problem
hypotensive	I-Problem
and	I-Problem
sedative	I-Problem
effects	I-Problem
,	O
mainly	O
by	O
inhibiting	O
its	O
cyp1a2	O
-	O
mediated	O
metabolism	O
,	O
at	O
least	O
when	O
administered	O
1	O
hour	O
before	O
tizanidine	I-Treatment
.	O

results	O
:	O
the	I-Background
patient	I-Background
,	I-Background
a	I-Background
27	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
married	I-Background
japanese	I-Background
woman	I-Background
with	I-Background
borderline	I-Problem
personality	I-Problem
disorder	I-Problem
,	O
developed	O
an	O
increased	I-Problem
libido	I-Problem
with	O
the	O
administration	I-Treatment
of	I-Treatment
fluvoxamine	I-Treatment
.	O

acute	I-Problem
renal	I-Problem
failure	I-Problem
with	I-Problem
severe	I-Problem
tubulointerstitial	I-Problem
changes	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
minimal	I-Problem
change	I-Problem
nephrotic	I-Problem
syndrome	I-Problem
treated	O
with	O
enalapril	I-Treatment
.	O

purpose	O
:	O
a	I-Background
case	I-Background
of	O
carbamazepine	I-Treatment
-	O
induced	O
hyperammonemia	I-Problem
is	O
presented	O
.	O

the	O
cough	I-Problem
continued	O
for	O
the	O
duration	O
of	O
therapy	O
with	O
quinapril	I-Treatment
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
carbamazepine	I-Treatment
toxicity	I-Problem
following	O
the	O
administration	O
of	O
oxybutynin	I-Treatment
and	I-Treatment
dantrolene	I-Treatment
.	O

danazol	I-Treatment
induced	O
thrombocytopenia	I-Problem
.	O

four	O
elderly	I-Background
ltcf	I-Problem
residents	I-Background
treated	O
with	O
serotonergic	I-Treatment
antidepressants	I-Treatment
including	I-Treatment
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitor	I-Treatment
(	I-Treatment
ssri	I-Treatment
)	I-Treatment
or	I-Treatment
mirtazapine	I-Treatment
and	I-Treatment
opioids	I-Treatment
.	O

detection	O
of	O
antineutrophil	O
cytoplasmic	O
antibody	O
in	O
a	O
patient	I-Background
with	O
l	I-Treatment
-	I-Treatment
tryptophan	I-Treatment
induced	O
eosinophilia	I-Problem
-	I-Problem
myalgia	I-Problem
syndrome	I-Problem
.	O

his	O
impaired	I-Problem
memory	I-Problem
was	O
found	O
to	O
be	O
due	O
to	O
the	O
atenolol	I-Treatment
he	I-Background
was	O
on	O
and	O
he	O
made	O
a	O
complete	O
recovery	O
on	O
withdrawing	O
the	O
beta	O
-	O
blocker	O
.	O

tiagabine	I-Treatment
overdose	I-Treatment
causes	O
an	I-Problem
unusual	I-Problem
array	I-Problem
of	I-Problem
neurological	I-Problem
symptoms	I-Problem
,	O
many	O
similar	O
to	O
reported	O
adverse	O
effects	O
during	O
therapeutic	O
use	O
.	O

this	O
paper	O
reports	O
on	O
a	O
6	I-Background
.	I-Background
9	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
autistic	I-Problem
male	I-Background
who	O
developed	O
repeated	I-Problem
episodes	I-Problem
of	I-Problem
acute	I-Problem
dystonic	I-Problem
reactions	I-Problem
associated	O
with	O
pimozide	I-Treatment
administration	I-Treatment
at	I-Treatment
the	I-Treatment
doses	I-Treatment
of	I-Treatment
0	I-Treatment
.	I-Treatment
096	I-Treatment
mg	I-Treatment
/	I-Treatment
kg	I-Treatment
/	I-Treatment
day	I-Treatment
and	I-Treatment
0	I-Other
.	I-Treatment
032	I-Treatment
mg	I-Treatment
/	I-Treatment
kg	I-Treatment
/	I-Treatment
day	I-Other
and	I-Treatment
32	I-Treatment
hours	I-Treatment
following	I-Treatment
pimozide	I-Treatment
withdrawal	I-Treatment
,	I-Treatment
as	I-Treatment
well	I-Treatment
as	I-Treatment
during	I-Treatment
subsequent	I-Treatment
thioridazine	I-Treatment
administration	I-Treatment
.	O

cephalexin	I-Treatment
rash	I-Problem
in	O
infectious	I-Problem
mononucleosis	I-Problem
.	O

he	O
developed	O
recurrent	I-Problem
skin	I-Problem
rash	I-Problem
,	I-Problem
fever	I-Problem
,	I-Problem
hypereosinophilia	I-Problem
,	I-Problem
and	I-Problem
acute	I-Problem
renal	I-Problem
failure	I-Problem
after	O
rechallenge	I-Treatment
with	I-Treatment
chlorambucil	I-Treatment
.	O

lower	I-Problem
extremity	I-Problem
arterial	I-Problem
insufficiency	I-Problem
after	O
long	I-Other
-	I-Other
term	I-Other
methysergide	I-Treatment
maleate	I-Treatment
therapy	I-Treatment
.	O

hepatolithiasis	I-Problem
(	I-Problem
intrahepatic	I-Problem
stone	I-Problem
)	I-Problem
during	O
octreotide	I-Treatment
therapy	O
for	O
acromegaly	I-Problem
:	O
a	O
case	O
report	O
.	O

acute	I-Problem
unilateral	I-Problem
total	I-Problem
visual	I-Problem
loss	I-Problem
after	O
retrogasserian	I-Treatment
phenol	I-Treatment
injection	I-Treatment
for	O
the	O
treatment	O
of	O
trigeminal	I-Problem
neuralgia	I-Problem
:	O
a	O
case	O
report	O
.	O

objective	O
:	O
clozapine	I-Treatment
causes	O
few	I-Problem
extrapyramidal	I-Problem
symptoms	I-Problem
and	O
is	O
recommended	O
as	O
a	O
treatment	O
drug	O
for	O
severe	O
tardive	O
dyskinesia	O
(	O
td	O
)	O
.	O

methylphenidate	I-Treatment
-	O
induced	O
acute	I-Problem
orofacial	I-Problem
and	I-Problem
extremity	I-Problem
dyskinesia	I-Problem
.	O

basilar	I-Problem
invagination	I-Problem
and	I-Problem
mid	I-Problem
-	I-Problem
line	I-Problem
skeletal	I-Problem
abnormalities	I-Problem
due	O
to	O
in	O
utero	I-Treatment
exposure	I-Treatment
to	I-Treatment
phenytoin	I-Treatment
.	O

discussion	O
:	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
illustrating	O
neuralgic	I-Problem
amyotrophy	I-Problem
triggered	O
by	O
exposure	O
to	O
the	O
antibiotics	I-Treatment
vancomycin	I-Treatment
,	I-Treatment
tobramycin	I-Treatment
,	I-Treatment
and	I-Treatment
piperacillin	I-Treatment
/	I-Treatment
tazobactam	I-Treatment
.	O

alveolar	I-Problem
-	I-Problem
interstitial	I-Problem
pneumopathy	I-Problem
after	O
gold	I-Treatment
-	I-Treatment
salts	I-Treatment
compounds	I-Treatment
administration	I-Treatment
,	O
requiring	O
mechanical	O
ventilation	O
.	O

this	O
study	I-Test
revealed	O
that	O
ketoconazole	I-Treatment
affected	O
the	O
disposition	O
of	O
rosiglitazone	O
in	O
humans	I-Background
,	O
probably	O
by	O
the	O
inhibition	O
of	O
cyp2c8	O
and	O
cyp2c9	O
,	O
leading	O
to	O
increasing	I-Problem
rosiglitazone	I-Problem
concentrations	I-Problem
that	I-Problem
could	I-Problem
increase	I-Problem
the	I-Problem
efficacy	I-Problem
of	I-Problem
rosiglitazone	I-Problem
or	I-Problem
its	I-Problem
adverse	I-Problem
events	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
duloxetine	I-Treatment
-	O
induced	O
hyponatremia	I-Problem
in	O
an	I-Background
elderly	I-Background
patient	I-Background
treated	O
with	O
thiazide	I-Treatment
diuretics	I-Treatment
.	O

protamine	I-Treatment
-	O
induced	O
fatal	O
anaphylaxis	I-Problem
.	O

we	O
diagnosed	O
this	I-Background
case	I-Background
as	O
danazol	I-Treatment
induced	O
thrombocytopenia	I-Problem
.	O

nms	I-Problem
is	O
a	O
drug	O
-	O
related	O
response	O
to	O
various	O
medications	O
,	O
such	O
as	O
haloperidol	I-Treatment
,	O
which	O
the	O
patient	I-Background
was	O
receiving	O
.	O

in	O
addition	O
,	O
ethambutol	I-Treatment
rarely	O
causes	O
visual	I-Problem
loss	I-Problem
during	I-Treatment
the	I-Treatment
early	I-Other
period	I-Other
or	I-Treatment
when	I-Treatment
given	I-Treatment
at	I-Treatment
lower	I-Treatment
doses	I-Treatment
.	O

the	O
day	I-Treatment
after	I-Treatment
clozapine	I-Treatment
was	I-Treatment
stopped	I-Treatment
,	I-Treatment
while	I-Treatment
he	I-Treatment
was	I-Treatment
still	I-Treatment
receiving	I-Treatment
clomipramine	I-Treatment
150	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
,	O
he	I-Background
began	O
behaving	I-Problem
oddly	I-Problem
,	I-Problem
started	I-Problem
sweating	I-Problem
profusely	I-Problem
,	I-Problem
shivering	I-Problem
,	I-Problem
and	I-Problem
became	I-Problem
tremulous	I-Problem
,	I-Problem
agitated	I-Problem
,	I-Problem
and	I-Problem
confused	I-Problem
.	O

conclusions	O
:	O
hypersensitivity	I-Problem
reactions	I-Problem
to	I-Problem
cyclosporine	I-Problem
are	O
due	O
to	O
cremophor	I-Treatment
el	I-Treatment
.	O

there	O
are	O
few	O
reports	O
in	O
the	O
literature	O
related	O
to	O
sulfonylurea	I-Treatment
-	O
induced	O
hepatotoxicity	I-Problem
.	O

radiation	I-Problem
recall	I-Problem
pneumonitis	I-Problem
induced	O
by	O
gemcitabine	I-Treatment
.	O

four	O
days	O
after	O
the	O
initial	O
injection	I-Treatment
of	I-Treatment
3	I-Treatment
.	I-Treatment
6	I-Treatment
mg	I-Treatment
of	I-Treatment
goserelin	I-Treatment
acetate	I-Treatment
,	O
severe	I-Problem
dyspnea	I-Problem
developed	O
due	O
to	O
worsening	I-Problem
pleuritis	I-Problem
carcinomatosa	I-Problem
,	O
which	O
was	O
considered	O
as	O
a	O
flare	O
-	O
up	O
.	O

ropinirole	I-Treatment
was	O
added	O
to	O
his	O
current	O
therapy	O
for	O
parkinson	I-Problem
disease	I-Problem
,	O
with	O
a	I-Treatment
corresponding	I-Treatment
decrease	I-Treatment
in	I-Treatment
the	I-Treatment
dose	I-Treatment
of	I-Treatment
levodopa	I-Treatment
/	I-Treatment
carbidopa	I-Treatment
to	I-Treatment
allow	I-Treatment
levodopa	I-Treatment
sparing	I-Treatment
.	O

recognizing	O
early	O
signs	O
of	O
hmsn	I-Problem
,	O
such	O
as	O
areflexia	O
and	O
pes	O
cavus	O
deformity	O
,	O
can	O
prevent	O
severe	I-Problem
neurotoxicity	I-Problem
of	I-Problem
polychemotherapy	I-Problem
by	O
avoiding	O
vincristine	I-Treatment
.	O

this	O
is	O
the	O
first	O
report	O
of	O
pulmonary	I-Problem
hypertension	I-Problem
in	O
an	I-Background
adult	I-Background
patient	I-Background
during	O
lithium	I-Treatment
therapy	I-Treatment
.	I-Treatment

in	O
this	O
report	O
,	O
we	O
present	O
a	O
case	O
of	O
hypoglycaemic	I-Problem
coma	I-Problem
associated	O
with	O
sp	I-Treatment
,	O
an	I-Problem
adverse	I-Problem
reaction	I-Problem
that	I-Problem
is	I-Problem
likely	I-Problem
to	I-Problem
be	I-Problem
underreported	I-Problem
and	I-Problem
expected	I-Problem
to	I-Problem
occur	I-Problem
with	I-Problem
greater	I-Problem
frequency	I-Problem
as	I-Problem
the	I-Problem
use	I-Problem
of	I-Problem
sp	I-Problem
increases	I-Problem
.	O

however	O
,	O
we	O
have	O
recently	O
had	O
four	O
cases	I-Background
of	O
clofibrate	I-Treatment
-	O
induced	O
myopathy	I-Problem
in	O
patients	O
with	O
diabetes	I-Problem
insipidus	I-Problem
due	I-Background
to	I-Background
hypothalamic	I-Background
lesions	I-Background
.	O

one	O
patient	I-Background
had	O
mri	I-Problem
t2	I-Problem
abnormalities	I-Problem
compatible	O
with	O
cyclosporin	I-Treatment
neurotoxicity	I-Problem
.	O

post	O
-	O
exposure	O
prophylaxis	O
for	O
h1n1	I-Problem
with	O
oseltamivir	I-Treatment
in	O
renal	I-Problem
allograft	I-Problem
recipient	I-Background
-	O
-	O
safe	I-Problem
and	I-Problem
effective	I-Problem
without	I-Problem
any	I-Problem
immunosuppresive	I-Problem
drug	I-Problem
interaction	I-Problem
.	O

seven	I-Other
days	I-Other
after	I-Other
the	I-Treatment
introduction	I-Treatment
of	I-Treatment
amoxycillin	I-Treatment
(	I-Treatment
500	I-Treatment
mg	I-Treatment
/	I-Treatment
8	I-Treatment
h	I-Treatment
)	I-Treatment
for	O
a	I-Problem
probable	I-Problem
respiratory	I-Problem
infection	I-Problem
,	O
the	I-Background
patient	I-Background
developed	O
spontaneous	I-Problem
bruising	I-Problem
,	I-Problem
with	I-Problem
an	I-Problem
inr	I-Test
of	I-Problem
7	I-Problem
.	I-Problem
1	I-Problem
.	O

to	O
report	O
a	I-Background
case	I-Background
in	O
which	O
significant	O
hypotension	I-Problem
occurred	O
after	O
initiation	I-Treatment
of	I-Treatment
tizanidine	I-Treatment
in	O
a	I-Background
patient	I-Background
using	O
the	O
antihypertensive	O
agent	O
lisinopril	I-Treatment
.	O

we	O
herein	O
describe	O
a	O
case	O
of	O
severe	I-Problem
hyponatremia	I-Problem
complicated	O
by	O
seizure	I-Problem
and	I-Problem
coma	I-Problem
due	O
to	O
the	O
intake	I-Treatment
of	I-Treatment
non	I-Treatment
-	I-Treatment
steroidal	I-Treatment
anti	I-Treatment
-	I-Treatment
inflammatory	I-Treatment
drugs	I-Treatment
(	I-Treatment
nsaids	I-Treatment
)	I-Treatment
in	O
a	I-Background
patient	I-Background
on	I-Treatment
ddavp	I-Treatment
replacement	I-Treatment
therapy	I-Treatment
for	I-Background
central	I-Problem
diabetes	I-Problem
insipidus	I-Problem
(	I-Background
di	I-Background
)	I-Background
.	O

each	I-Background
subject	I-Background
was	O
treated	O
according	O
to	O
the	O
following	O
sequence	O
:	O
baseline	I-Treatment
;	I-Treatment
phase	I-Treatment
1	I-Treatment
(	I-Treatment
days	I-Treatment
1	I-Treatment
-	I-Treatment
6	I-Treatment
)	I-Treatment
:	I-Treatment
cisapride	I-Treatment
10	I-Treatment
mg	I-Treatment
4	I-Other
times	I-Other
/	I-Other
day	I-Other
;	I-Treatment
washout	I-Treatment
(	I-Treatment
days	I-Treatment
7	I-Treatment
-	I-Treatment
13	I-Treatment
)	I-Treatment
;	I-Treatment
phase	I-Treatment
2	I-Treatment
(	I-Treatment
days	I-Treatment
14	I-Treatment
-	I-Treatment
44	I-Treatment
)	I-Treatment
:	I-Treatment
fluoxetine	I-Treatment
20	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
;	I-Treatment
and	I-Treatment
phase	I-Treatment
3	I-Treatment
(	I-Treatment
days	I-Treatment
45	I-Treatment
-	I-Treatment
52	I-Treatment
)	I-Treatment
:	I-Treatment
cisapride	I-Treatment
10	I-Treatment
mg	I-Treatment
4	I-Other
times	I-Other
/	I-Other
day	I-Other
(	I-Treatment
days	I-Treatment
45	I-Treatment
-	I-Treatment
51	I-Treatment
)	I-Treatment
plus	I-Treatment
fluoxetine	I-Treatment
20	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
(	I-Treatment
days	I-Treatment
45	I-Treatment
-	I-Treatment
52	I-Treatment
)	I-Treatment
.	O

these	O
findings	O
are	O
consistent	O
with	O
an	O
immune	O
-	O
complex	O
form	O
of	O
glomerulopathy	O
in	O
which	O
gold	O
is	O
neither	O
the	O
antigen	O
nor	O
a	O
hapten	O
in	O
the	O
glomerular	O
deposits	O
,	O
and	O
they	O
suggest	O
the	O
hypothesis	O
that	O
antibodies	O
to	O
tubular	O
epithelial	O
antigens	O
induced	O
by	O
gold	O
therapy	O
may	O
be	O
a	O
causative	O
factor	O
in	O
the	O
renal	I-Problem
disease	I-Problem
associated	O
with	O
gold	I-Treatment
therapy	I-Treatment
in	I-Treatment
rheumatoid	I-Problem
arthritis	I-Problem
.	O

induction	O
of	O
rapid	I-Problem
mood	I-Problem
cycling	I-Problem
during	O
l	I-Treatment
-	I-Treatment
dopa	I-Treatment
treatment	O
in	O
a	I-Background
bipolar	I-Problem
patient	I-Background
.	O

to	O
report	O
a	O
patient	I-Background
having	O
a	O
first	O
-	O
time	O
seizure	I-Problem
after	O
receiving	O
venlafaxine	I-Treatment
and	I-Treatment
trimipramine	I-Treatment
for	O
depression	I-Problem
.	O

paraplegia	I-Problem
following	O
prophylactic	I-Treatment
intrathecal	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
(	I-Treatment
ara	I-Treatment
-	I-Treatment
c	I-Treatment
)	I-Treatment
is	O
described	O
in	O
a	I-Background
patient	I-Background
with	I-Background
acute	I-Problem
myelogenous	I-Problem
leukemia	I-Problem
in	I-Problem
remission	I-Problem
who	O
received	O
doses	I-Treatment
of	I-Treatment
100	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
/	I-Treatment
d	I-Treatment
for	I-Treatment
5	I-Other
consecutive	I-Other
days	I-Other
.	O

isoniazid	I-Treatment
induced	O
gynaecomastia	I-Problem
:	O
a	O
case	O
report	O
.	O

one	O
previous	O
study	O
of	O
four	O
transplant	I-Problem
patients	I-Background
whose	O
immediate	I-Treatment
post	I-Problem
-	I-Problem
transplantation	I-Problem
immunosuppression	I-Problem
utilized	I-Treatment
corticosteroids	I-Treatment
,	I-Treatment
cyclosporine	I-Treatment
,	I-Treatment
mmf	I-Treatment
,	I-Treatment
and	I-Treatment
anti	I-Treatment
-	I-Treatment
t	I-Treatment
-	I-Treatment
lymphocyte	I-Treatment
globulin	I-Treatment
noted	O
anemia	I-Problem
in	O
13	O
%	O
of	O
them	O
.	O

pleuropulmonary	I-Problem
changes	I-Problem
during	O
treatment	O
of	O
parkinson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
with	O
a	O
long	O
-	O
acting	O
ergot	O
derivative	O
,	O
cabergoline	I-Treatment
.	O

however	O
,	O
each	I-Background
infant	I-Background
demonstrated	O
hemodynamic	I-Problem
decompensation	I-Problem
shortly	O
after	O
verapamil	I-Treatment
administration	O
and	O
required	O
cardiopulmonary	O
resuscitation	O
.	O

long	O
-	O
term	I-Test
studies	I-Test
are	O
needed	O
to	O
determine	O
whether	O
the	O
insulin	O
-	O
sensitizing	O
effects	O
of	O
the	O
glitazones	I-Treatment
can	O
prevent	O
or	O
delay	O
premature	I-Problem
atherosclerotic	I-Problem
cardiovascular	I-Problem
disease	I-Problem
,	I-Problem
morbidity	I-Problem
,	I-Problem
and	I-Problem
death	I-Problem
.	O

probable	O
propafenone	I-Treatment
-	O
induced	O
transient	I-Problem
global	I-Problem
amnesia	I-Problem
.	O

the	O
patient	O
continued	O
to	O
have	O
fever	I-Problem
and	I-Problem
autonomic	I-Problem
instability	I-Problem
without	I-Problem
evidence	I-Problem
of	I-Problem
infection	I-Problem
which	I-Problem
entirely	I-Problem
resolved	I-Problem
within	O
24	I-Other
hours	I-Other
of	I-Treatment
reinstitution	I-Treatment
of	I-Treatment
full	I-Treatment
preadmission	I-Treatment
dosing	I-Treatment
of	I-Treatment
oral	I-Treatment
baclofen	I-Treatment
.	O

traumatic	I-Problem
late	I-Problem
flap	I-Problem
dehiscence	I-Problem
and	I-Problem
enterobacter	I-Problem
keratitis	I-Problem
following	O
lasik	I-Treatment
.	O

we	O
report	O
on	O
a	O
patient	I-Background
with	I-Background
subarachnoid	I-Problem
haemorrhage	I-Problem
who	O
developed	O
an	O
acute	O
life	O
-	O
threatening	O
pseudo	I-Problem
-	I-Problem
obstruction	I-Problem
of	I-Problem
the	I-Problem
colon	I-Problem
,	O
a	O
variant	O
of	O
adynamic	O
ileus	O
,	O
while	O
being	O
treated	O
with	O
intravenous	I-Treatment
nimodipine	I-Treatment
.	O

a	I-Background
73	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
presented	O
with	O
fever	I-Problem
and	I-Problem
cough	I-Problem
2	I-Other
weeks	I-Other
after	I-Treatment
completing	I-Treatment
the	I-Treatment
third	I-Treatment
cycle	I-Treatment
of	I-Treatment
fludarabine	I-Treatment
for	I-Treatment
chronic	I-Problem
lymphocytic	I-Problem
leukemia	I-Problem
(	I-Problem
cll	I-Problem
)	I-Problem
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
myoclonus	I-Problem
induced	O
by	O
quetiapine	I-Treatment
.	O

a	I-Background
21	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
suffering	I-Background
from	I-Background
bipolar	I-Problem
affective	I-Problem
disorder	I-Problem
developed	O
systemic	I-Problem
lupus	I-Problem
erythematosus	I-Problem
(	I-Problem
sle	I-Problem
)	I-Problem
with	O
characteristic	O
laboratory	O
findings	O
,	O
18	I-Other
months	I-Other
after	I-Treatment
starting	I-Treatment
carbamazepine	I-Treatment
maintenance	I-Treatment
treatment	I-Treatment
.	O

acyclovir	I-Treatment
produces	O
neurologic	I-Problem
symptoms	I-Problem
that	O
resemble	O
extension	O
of	O
viral	O
infection	O
into	O
the	O
central	O
nervous	O
system	O
.	O

subcutaneous	I-Treatment
il	I-Test
-	I-Test
2	I-Test
is	O
safe	O
and	O
well	O
tolerated	O
,	O
with	O
a	O
mortality	I-Problem
rate	I-Problem
<	I-Problem
3	I-Problem
%	I-Problem
.	O

two	O
patients	I-Background
with	I-Background
hlh	I-Problem
developed	O
etoposide	I-Treatment
-	O
related	O
secondary	I-Problem
acute	I-Problem
myeloid	I-Problem
leukemia	I-Problem
(	I-Problem
saml	I-Problem
)	I-Problem
following	O
therapy	O
for	O
hlh	O
.	O

we	O
report	O
a	O
case	O
of	O
secondary	I-Problem
glaucoma	I-Problem
caused	O
by	O
epithelial	I-Problem
downgrowth	I-Problem
in	O
which	O
filtration	I-Treatment
surgery	I-Treatment
was	I-Treatment
performed	I-Treatment
with	I-Treatment
adjunctive	I-Treatment
use	I-Treatment
of	I-Treatment
subconjunctival	I-Treatment
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
.	O

mild	O
serotonin	I-Problem
syndrome	I-Problem
associated	O
with	O
concurrent	I-Treatment
linezolid	I-Treatment
and	I-Treatment
fluoxetine	I-Treatment
.	O

risperidone	I-Treatment
versus	I-Treatment
clozapine	I-Treatment
in	O
the	O
treatment	O
of	O
psychosis	I-Problem
in	O
six	O
patients	I-Background
with	I-Background
parkinson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
and	I-Background
other	I-Background
akinetic	I-Problem
-	I-Problem
rigid	I-Problem
syndromes	I-Problem
.	O

hydroxyurea	I-Treatment
associated	O
with	O
concomitant	I-Problem
occurrence	I-Problem
of	I-Problem
diffuse	I-Problem
longitudinal	I-Problem
melanonychia	I-Problem
and	I-Problem
multiple	I-Problem
squamous	I-Problem
cell	I-Problem
carcinomas	I-Problem
in	O
an	I-Background
elderly	I-Background
subject	I-Background
.	O

women	I-Background
(	I-Background
aged	I-Background
<	I-Background
or	I-Background
=	I-Background
75	I-Background
yr	I-Background
;	I-Background
>	I-Background
or	I-Background
=	I-Background
2	I-Background
yr	I-Background
since	I-Background
their	I-Background
last	I-Background
menstrual	I-Background
period	I-Background
)	I-Background
received	O
placebo	O
,	O
rlx	I-Treatment
60	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
,	I-Treatment
aln	I-Treatment
10	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
,	I-Treatment
or	I-Treatment
rlx	I-Treatment
60	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
and	I-Treatment
aln	I-Treatment
10	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
combined	I-Treatment
.	O

myoclonus	I-Problem
and	I-Problem
seizures	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
parkinsonism	I-Problem
:	O
induction	O
by	O
levodopa	I-Treatment
and	O
its	O
confirmation	O
on	O
seps	O
.	O

objective	O
:	O
to	O
describe	O
a	O
probable	O
case	O
of	O
transient	I-Problem
global	I-Problem
amnesia	I-Problem
caused	O
by	O
propafenone	I-Treatment
.	O

we	O
report	O
the	O
development	O
of	O
squamous	I-Problem
-	I-Problem
cell	I-Problem
carcinoma	I-Problem
within	I-Problem
a	I-Problem
basal	I-Problem
-	I-Problem
cell	I-Problem
epithelioma	I-Problem
that	O
was	O
treated	O
with	O
intralesional	I-Treatment
injections	I-Treatment
of	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
.	O

here	O
,	O
we	O
describe	O
levofloxacin	I-Treatment
-	O
induced	O
delirium	I-Problem
with	I-Problem
psychotic	I-Problem
features	I-Problem
in	O
a	O
relatively	I-Background
young	I-Background
,	I-Background
otherwise	I-Background
healthy	I-Background
female	I-Background
.	O

ticlopidine	I-Treatment
-	O
induced	O
phenytoin	I-Treatment
toxicity	I-Problem
.	O

pancreatitis	O
has	O
been	O
associated	O
with	O
the	O
tetracycline	O
class	O
of	O
antibiotics	O
and	O
concerns	O
about	O
tigecycline	I-Treatment
-	O
induced	O
acute	I-Problem
pancreatitis	I-Problem
have	O
recently	O
been	O
raised	O
.	O

abrupt	I-Treatment
,	I-Treatment
accidental	I-Treatment
withdrawal	I-Treatment
of	I-Treatment
trihexyphenidyl	I-Treatment
triggered	O
severe	O
exacerbation	I-Problem
of	I-Problem
the	I-Problem
cranial	I-Problem
dystonia	I-Problem
associated	I-Problem
with	I-Problem
inspiratory	I-Problem
stridor	I-Problem
and	I-Problem
acute	I-Problem
respiratory	I-Problem
difficulties	I-Problem
,	O
prompting	O
emergency	O
admission	O
.	O

we	O
report	O
two	O
patients	I-Background
with	O
anhedonic	I-Problem
ejaculation	I-Problem
(	I-Problem
ejaculation	I-Problem
without	I-Problem
orgasm	I-Problem
)	I-Problem
associated	O
with	O
initiation	O
of	O
treatment	O
with	O
desipramine	I-Treatment
.	O

a	I-Background
45	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
steroid	I-Problem
-	I-Problem
dependent	I-Problem
crohn	I-Problem
'	I-Problem
s	I-Problem
colitis	I-Problem
,	O
successfully	O
managed	O
with	O
maintenance	I-Treatment
infliximab	I-Treatment
infusions	I-Treatment
and	I-Treatment
methotrexate	I-Treatment
,	O
developed	O
a	O
lupus	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
eight	I-Other
months	I-Other
after	I-Treatment
her	I-Treatment
initial	I-Treatment
infusion	I-Treatment
.	O

severe	O
neurotoxicity	I-Problem
with	O
methyl	I-Treatment
g	I-Test
:	O
calgb	O
experience	O
.	O

we	O
report	O
a	O
case	O
of	O
a	O
60	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
affected	I-Background
by	I-Background
squamous	I-Problem
lung	I-Problem
carcinoma	I-Problem
,	I-Problem
who	O
developed	O
paroxysmal	I-Problem
supraventricular	I-Problem
tachycardia	I-Problem
during	O
cisplatin	I-Treatment
and	I-Treatment
etoposide	I-Treatment
combination	I-Treatment
chemotherapy	O
.	O

the	O
authors	O
report	O
a	O
case	O
of	O
acute	I-Problem
pancreatitis	I-Problem
(	O
ap	O
)	O
occurring	O
in	O
a	I-Background
patient	I-Background
under	O
treatment	O
with	O
carbamazepine	I-Treatment
(	O
cbz	O
)	O
for	O
post	I-Problem
-	I-Problem
traumatic	I-Problem
petit	I-Problem
mal	I-Problem
epilepsy	I-Problem
,	O
and	O
review	O
the	O
current	O
literature	O
of	O
drug	O
-	O
induced	O
ap	O
.	O

acute	I-Problem
ocular	I-Problem
ischemic	I-Problem
change	I-Problem
may	O
be	O
associated	O
with	O
intravitreal	I-Treatment
injection	I-Treatment
of	I-Treatment
bevacizumab	I-Treatment
in	O
patients	I-Background
with	I-Background
vascular	I-Problem
compromised	I-Problem
diabetic	I-Problem
retinopathy	I-Problem
and	I-Background
/	I-Background
or	I-Background
underlying	I-Problem
stenosis	I-Problem
of	I-Problem
the	I-Problem
carotid	I-Problem
artery	I-Problem
.	O

all	I-Treatment
-	I-Treatment
trans	I-Treatment
-	I-Treatment
retinoic	I-Treatment
acid	I-Treatment
(	I-Treatment
atra	I-Treatment
)	I-Treatment
has	O
been	O
proved	O
to	O
be	O
an	O
effective	O
treatment	O
for	O
acute	I-Problem
promyelocytic	I-Problem
leukemia	I-Problem
(	I-Problem
apl	I-Problem
)	I-Problem
,	O
inducing	O
remission	O
in	O
more	O
than	O
90	O
%	O
of	I-Background
cases	I-Background
.	O

vanishing	I-Problem
bile	I-Problem
duct	I-Problem
and	I-Problem
stevens	I-Problem
-	I-Problem
johnson	I-Problem
syndrome	I-Problem
associated	O
with	O
ciprofloxacin	I-Treatment
treated	O
with	O
tacrolimus	O
.	O

antiasthmatic	I-Treatment
medications	I-Treatment
were	I-Treatment
prescribed	I-Treatment
,	O
but	O
the	O
asthma	I-Problem
symptoms	O
did	O
not	O
improve	O
.	O

both	O
6	I-Treatment
-	I-Treatment
mp	I-Treatment
and	I-Treatment
aza	I-Treatment
are	O
widely	O
used	O
and	O
are	O
known	O
to	O
cause	O
hepatotoxicity	I-Problem
in	O
a	I-Background
proportion	I-Background
of	I-Background
patients	I-Background
.	O

both	I-Treatment
raloxifene	I-Treatment
(	I-Treatment
rlx	I-Treatment
)	I-Treatment
and	I-Treatment
alendronate	I-Treatment
(	I-Treatment
aln	I-Treatment
)	I-Treatment
can	O
treat	O
and	O
prevent	O
new	O
vertebral	I-Problem
fractures	I-Problem
,	O
increase	I-Problem
bone	I-Problem
mineral	I-Problem
density	I-Test
(	I-Problem
bmd	I-Problem
)	I-Problem
,	O
and	O
decrease	I-Problem
biochemical	I-Problem
markers	I-Test
of	I-Problem
bone	I-Problem
turnover	I-Problem
in	O
postmenopausal	I-Background
women	I-Background
with	I-Background
osteoporosis	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
severe	O
respiratory	I-Problem
failure	I-Problem
due	O
to	O
gold	I-Treatment
salt	I-Treatment
toxicity	O
in	O
a	I-Background
patient	I-Background
suffering	I-Background
from	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
requiring	O
mechanical	O
ventilation	O
.	O

we	O
describe	O
rupture	I-Problem
of	I-Problem
a	I-Problem
cerebral	I-Problem
arterial	I-Problem
aneurysm	I-Problem
in	O
a	I-Background
32	I-Background
year	I-Background
old	I-Background
hypertensive	I-Problem
woman	I-Background
following	O
the	O
introduction	O
of	O
nifedipine	I-Treatment
treatment	I-Treatment
.	O

factors	O
that	O
suggested	O
an	O
association	O
between	O
the	O
severe	I-Problem
angioedematous	I-Problem
reaction	I-Problem
and	O
bp	I-Treatment
topical	I-Treatment
application	I-Treatment
include	O
the	O
strong	O
reaction	O
to	O
bp	O
in	O
the	O
patch	I-Test
-	I-Test
test	I-Test
,	O
the	O
temporal	O
relationship	O
,	O
the	O
complete	O
resolution	O
of	O
symptoms	O
after	O
the	O
drug	O
was	O
withdrawn	O
and	O
the	O
absence	O
of	O
other	O
identified	O
explanations	O
.	O

rlx	I-Treatment
+	I-Treatment
aln	I-Treatment
reduced	O
bone	I-Problem
turnover	I-Problem
more	I-Problem
than	I-Problem
either	I-Problem
drug	I-Problem
alone	I-Problem
,	I-Problem
resulting	I-Problem
in	I-Problem
greater	I-Problem
bmd	I-Problem
increment	I-Problem
,	O
but	O
whether	O
this	O
difference	O
reflects	O
better	O
fracture	O
risk	O
reduction	O
was	O
not	O
assessed	O
in	O
this	O
study	I-Test
.	O

hepatotoxicity	I-Problem
related	O
to	O
itraconazole	I-Treatment
:	O
report	O
of	O
three	O
cases	I-Background
.	O

this	O
report	O
presents	O
a	O
case	O
of	O
colon	I-Problem
perforation	I-Problem
which	O
occurred	O
4	I-Other
months	I-Other
after	O
treatment	O
with	O
intraperitoneal	I-Treatment
chromic	I-Treatment
phosphate	I-Treatment
for	O
stage	I-Problem
ib	I-Problem
ovarian	I-Problem
papillary	I-Problem
serous	I-Problem
cystadenocarcinoma	I-Problem
.	O

flutamide	O
withdrawal	O
syndrome	O
is	O
characterized	O
by	O
a	O
decrease	I-Problem
in	I-Problem
prostate	I-Problem
-	I-Problem
specific	I-Problem
antigen	I-Problem
(	I-Problem
psa	I-Problem
)	I-Problem
after	O
flutamide	I-Treatment
withdrawal	O
in	O
a	O
subset	I-Background
of	I-Background
patients	I-Background
with	I-Background
progressing	I-Problem
metastatic	I-Problem
carcinoma	I-Problem
of	I-Problem
the	I-Problem
prostate	I-Problem
.	O

bradycardia	I-Problem
and	I-Problem
congestive	I-Problem
heart	I-Problem
failure	I-Problem
associated	O
with	O
ocular	I-Treatment
timolol	I-Treatment
maleate	I-Treatment
.	O

conclusions	O
:	O
patients	O
receiving	O
intravitreal	I-Treatment
injections	I-Treatment
of	I-Treatment
bevacizumab	I-Treatment
should	O
be	O
evaluated	O
for	O
potential	O
systemic	O
risk	O
factors	O
such	O
as	O
carotid	I-Problem
insufficiency	I-Problem
,	I-Problem
coagulopathy	I-Problem
and	I-Problem
poorly	I-Problem
controlled	I-Problem
diabetes	I-Problem
mellitus	I-Problem
.	O

severe	O
serotonin	I-Problem
toxicity	I-Problem
may	O
result	O
from	O
metaxalone	I-Treatment
abuse	I-Treatment
in	O
individuals	O
using	I-Treatment
a	I-Treatment
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitor	I-Treatment
therapeutically	I-Treatment
.	O

the	O
purpose	O
of	O
this	O
article	O
is	O
to	O
present	O
the	O
first	O
case	O
-	O
series	O
of	O
posterior	I-Problem
reversible	I-Problem
encephalopathy	I-Problem
syndrome	I-Problem
(	I-Problem
pres	I-Problem
)	I-Problem
associated	O
with	O
l	I-Treatment
-	I-Treatment
asparaginase	I-Treatment
treatment	I-Treatment
.	O

eruptive	I-Problem
epidermoid	I-Problem
cysts	I-Problem
resulting	O
from	O
treatment	O
with	O
imiquimod	I-Treatment
.	O

carbamazepine	I-Treatment
-	O
related	O
hyponatremia	I-Problem
following	O
cardiopulmonary	O
bypass	O
.	O

fulminant	I-Problem
hepatic	I-Problem
failure	I-Problem
is	O
a	O
rare	O
complication	O
of	O
disulfiram	I-Treatment
treatment	O
for	O
alcoholism	I-Problem
.	O

implications	O
:	O
clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
increased	O
toxicity	I-Problem
of	O
ropivacaine	I-Treatment
when	O
used	O
together	O
with	O
inhibitors	I-Treatment
of	I-Treatment
cyp1a2	I-Treatment
.	O

evidence	O
obtained	O
indicated	O
that	O
the	O
reye	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
might	O
be	O
caused	O
by	O
calcium	I-Treatment
hopantenate	I-Treatment
possibly	O
due	O
to	O
the	O
induction	O
of	O
pantothenic	O
acid	O
deficiency	O
.	O

hepatopathy	I-Problem
subsided	I-Problem
after	O
the	O
cessation	I-Treatment
of	O
carbamazepine	I-Treatment
and	O
lynestrenol	I-Treatment
.	O

this	O
article	O
presents	O
a	I-Background
patient	I-Background
with	I-Background
hypoparathyroidism	I-Problem
who	O
was	O
treated	O
with	O
calcium	I-Treatment
carbonate	I-Treatment
and	I-Treatment
calcitriol	I-Treatment
resulting	O
in	O
two	I-Problem
admissions	I-Problem
to	I-Problem
the	I-Problem
hospital	I-Problem
for	I-Problem
milk	I-Problem
-	I-Problem
alkali	I-Problem
syndrome	I-Problem
.	O

recurrent	I-Problem
hyponatremia	I-Problem
associated	O
with	O
citalopram	I-Treatment
and	I-Treatment
mirtazapine	I-Treatment
.	O

a	O
case	O
report	O
of	O
a	I-Problem
sharp	I-Problem
rise	I-Problem
in	I-Problem
international	I-Problem
normalized	I-Test
ratio	I-Test
(	I-Problem
inr	I-Problem
)	I-Problem
values	I-Problem
during	O
a	I-Background
patient	I-Background
'	O
s	O
concomitant	I-Treatment
use	I-Treatment
of	I-Treatment
warfarin	I-Treatment
and	I-Treatment
the	I-Treatment
antineoplastic	I-Treatment
agent	I-Treatment
vismodegib	I-Treatment
is	O
presented	O
.	O

in	O
this	O
report	O
we	O
described	O
a	I-Background
case	I-Background
of	I-Background
juvenile	I-Background
idiopathic	I-Problem
arthritis	I-Problem
patient	I-Background
who	O
developed	O
thymic	I-Problem
enlargement	I-Problem
(	I-Problem
true	I-Problem
thymic	I-Problem
hyperplasia	I-Problem
)	I-Problem
,	I-Problem
mediastinal	I-Problem
lymphadenopathy	I-Problem
and	I-Problem
pleurisy	I-Problem
associated	I-Problem
with	I-Problem
systemic	I-Problem
symptoms	I-Problem
under	O
etanercept	I-Treatment
treatment	O
.	O

a	I-Background
52	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
developed	O
symmetric	I-Problem
sensorimotor	I-Problem
polyneuropathy	I-Problem
and	O
cerebellar	I-Problem
syndrome	I-Problem
after	O
24	I-Other
months	I-Other
of	O
amiodarone	I-Treatment
treatment	O
.	O

the	O
case	O
of	O
a	I-Background
patient	I-Background
under	I-Treatment
tibolone	I-Treatment
therapy	I-Treatment
for	O
two	O
years	O
who	O
developed	O
a	I-Problem
mixed	I-Problem
-	I-Problem
type	I-Problem
liver	I-Problem
injury	I-Problem
with	I-Problem
prolonged	I-Problem
cholestasis	I-Problem
and	I-Problem
features	I-Problem
of	I-Problem
the	I-Problem
vanishing	I-Problem
bile	I-Problem
duct	I-Problem
syndrome	I-Problem
following	O
a	I-Treatment
ten	I-Other
weeks	I-Other
treatment	I-Treatment
with	I-Treatment
st	I-Treatment
.	I-Treatment
john	I-Treatment
wort	I-Treatment
(	I-Treatment
hypericum	I-Treatment
perforatum	I-Treatment
)	I-Treatment
infusions	I-Treatment
is	O
reported	O
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
a	O
diffuse	I-Problem
papular	I-Problem
eruption	I-Problem
following	O
treatment	O
of	O
psoriasis	I-Problem
with	O
methotrexate	I-Treatment
injections	I-Treatment
.	O

prolonged	O
severe	O
5	I-Treatment
-	I-Treatment
fluorouracil	I-Treatment
-	O
associated	O
neurotoxicity	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
dihydropyrimidine	I-Problem
dehydrogenase	I-Problem
deficiency	I-Problem
.	O

life	I-Problem
-	I-Problem
threatening	I-Problem
interstitial	I-Problem
lung	I-Problem
disease	I-Problem
associated	O
with	O
trastuzumab	I-Treatment
:	O
case	I-Background
report	O
.	O

thalidomide	I-Treatment
neuropathy	I-Problem
is	O
often	O
associated	O
with	O
proximal	I-Problem
weakness	I-Problem
and	O
may	O
progress	O
even	O
after	O
discontinuation	O
of	O
treatment	O
,	O
in	O
the	O
phenomenon	O
of	O
'	O
coasting	O
'	O
.	O

results	O
:	O
our	O
patient	I-Background
developed	O
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
while	O
on	O
copaxone	I-Treatment
treatment	O
as	O
a	O
consequence	O
of	O
long	I-Problem
-	I-Problem
term	I-Problem
immunosuppression	I-Problem
.	O

acute	I-Problem
vision	I-Problem
loss	I-Problem
after	O
intravitreal	I-Treatment
injection	I-Treatment
of	I-Treatment
bevacizumab	I-Treatment
(	I-Treatment
avastin	I-Treatment
)	I-Treatment
associated	O
with	O
ocular	I-Problem
ischemic	I-Problem
syndrome	I-Problem
.	O

development	O
of	O
persistent	I-Problem
late	I-Problem
onset	I-Problem
asthma	I-Problem
following	O
treatment	O
with	O
captopril	I-Treatment
.	O

herein	O
,	O
we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
aids	I-Problem
who	O
presented	O
to	O
medical	I-Problem
attention	I-Problem
with	I-Problem
pancytopenia	I-Problem
48	I-Other
months	I-Other
postchemotherapy	I-Treatment
with	I-Treatment
etoposide	I-Treatment
,	I-Treatment
prednisone	I-Treatment
,	I-Treatment
vincristine	I-Treatment
,	I-Treatment
cyclophosphamide	I-Treatment
,	I-Treatment
doxorubicin	I-Treatment
,	I-Treatment
and	I-Treatment
rituximab	I-Treatment
(	I-Treatment
r	I-Treatment
-	I-Treatment
epoch	I-Treatment
)	I-Treatment
for	O
diffuse	I-Problem
large	I-Problem
b	I-Problem
-	I-Problem
cell	I-Problem
lymphoma	I-Problem
.	O

however	O
,	O
prolongation	I-Problem
of	I-Problem
5	I-Problem
-	I-Problem
fu	I-Problem
half	I-Problem
-	I-Problem
life	I-Problem
and	I-Problem
an	I-Problem
increase	I-Problem
in	I-Problem
inr	I-Problem
have	O
been	O
reported	O
with	O
the	I-Treatment
concurrent	I-Treatment
use	I-Treatment
of	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
and	I-Treatment
warfarin	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
acute	I-Problem
generalized	I-Problem
exanthematous	I-Problem
pustulosis	I-Problem
(	I-Problem
agep	I-Problem
)	I-Problem
in	O
a	I-Background
50	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
that	O
was	O
attributed	O
to	O
the	O
ingestion	I-Treatment
of	I-Treatment
nimesulide	I-Treatment
.	O

this	O
case	O
demonstrates	O
the	O
value	O
of	O
dwi	O
in	O
evaluation	O
and	O
diagnosis	O
of	O
sub	I-Problem
-	I-Problem
acute	I-Problem
toxic	I-Problem
leukoencephalopathy	I-Problem
in	O
patients	I-Background
being	O
treated	O
with	O
methotrexate	I-Treatment
.	O

we	O
report	O
the	O
first	O
histopathologically	O
documented	O
case	O
of	O
oral	I-Problem
mucosa	I-Problem
pigmentation	I-Problem
after	O
olp	I-Problem
treatment	O
with	O
topical	I-Treatment
tacrolimus	I-Treatment
.	O

progressive	I-Problem
hypoxemia	I-Problem
mandated	O
endotracheal	O
intubation	O
1	I-Other
week	I-Other
after	O
rituximab	I-Treatment
administration	I-Treatment
and	O
led	I-Problem
to	I-Problem
death	I-Problem
4	O
weeks	O
after	O
admission	O
.	O

angiotensin	I-Treatment
converting	I-Treatment
enzyme	I-Treatment
blockers	I-Treatment
and	O
their	O
influence	O
on	O
the	O
endothelial	O
dysfunction	O
,	O
but	O
the	O
risk	O
of	O
hyperpotassemia	I-Problem
are	O
showed	O
.	O

this	O
is	O
the	O
first	O
report	O
of	O
a	O
fatal	O
outcome	O
from	O
serotonin	I-Problem
toxicity	I-Problem
,	O
precipitated	O
by	O
an	O
interaction	O
between	O
methylene	I-Treatment
blue	I-Treatment
and	O
venlafaxine	I-Treatment
.	O

a	O
helicoidal	I-Test
ct	I-Test
scan	I-Test
showed	O
diffuse	I-Problem
and	I-Problem
severe	I-Problem
interstitial	I-Problem
pneumonitis	I-Problem
,	O
and	O
lung	O
biopsy	I-Test
confirmed	O
accelerated	I-Problem
usual	I-Problem
interstitial	I-Problem
pneumonia	I-Problem
consistent	O
with	O
drug	I-Treatment
-	O
induced	O
toxicity	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
severe	O
hypotension	I-Problem
associated	O
with	O
intravenous	I-Treatment
valproate	I-Treatment
used	O
to	O
treat	O
status	I-Problem
epilepticus	I-Problem
in	O
an	I-Background
11	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
.	O

the	O
results	O
of	O
the	O
ultrasound	I-Test
examination	I-Test
combined	O
with	O
clinical	O
anamnesis	O
allowed	O
diagnosis	O
of	O
gastric	I-Problem
mucosa	I-Problem
foveolar	I-Problem
hyperplasia	I-Problem
due	O
to	O
prolonged	I-Other
pge1	I-Treatment
therapy	I-Treatment
.	O

to	O
our	O
knowledge	O
,	O
no	O
prior	O
cases	O
of	O
penicillamine	I-Treatment
-	O
induced	O
ttp	I-Problem
in	O
ra	O
have	O
been	O
reported	O
.	O

alternating	I-Problem
sinus	I-Problem
rhythm	I-Problem
and	I-Problem
intermittent	I-Problem
sinoatrial	I-Problem
block	I-Problem
induced	O
by	O
propranolol	I-Treatment
.	O

the	O
noted	O
increase	I-Problem
in	I-Problem
the	I-Problem
theophylline	I-Test
level	I-Problem
after	O
zafirlukast	I-Treatment
administration	I-Treatment
is	O
in	O
contrast	O
to	O
the	O
original	O
reports	O
by	O
the	O
manufacturer	O
.	O

the	O
cause	O
is	O
presumed	O
to	O
be	O
secondary	O
to	O
hypercoagulability	O
due	O
to	O
asparaginase	I-Treatment
-	O
induced	O
antithrombin	I-Problem
iii	I-Problem
deficiency	I-Problem
.	O

troglitazone	I-Treatment
-	O
induced	O
fulminant	I-Problem
hepatic	I-Problem
failure	I-Problem
.	O

a	I-Background
sixty	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
advanced	I-Problem
breast	I-Problem
cancer	I-Problem
,	I-Background
previously	I-Background
treated	I-Background
with	I-Background
cisplatin	I-Background
,	O
developed	O
an	I-Problem
irreversible	I-Problem
lethal	I-Problem
renal	I-Problem
failure	I-Problem
with	I-Problem
anuria	I-Problem
,	O
the	I-Other
day	I-Other
after	I-Other
5	I-Treatment
g	I-Treatment
/	I-Treatment
m2	I-Treatment
bolus	I-Treatment
ifosfamide	I-Treatment
.	O

with	O
the	O
negative	O
viral	O
serologies	I-Test
,	O
the	O
clinical	O
picture	O
was	O
most	O
consistent	O
with	O
an	O
infectious	I-Problem
mononucleosis	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
produced	O
by	O
the	O
minocycline	I-Treatment
ingestion	I-Treatment
.	O

high	I-Problem
-	I-Problem
grade	I-Problem
endometrial	I-Problem
stromal	I-Problem
sarcoma	I-Problem
after	O
tamoxifen	I-Treatment
therapy	O
for	O
breast	I-Problem
cancer	I-Problem
.	O

we	O
report	O
here	O
two	O
cases	O
of	O
dyserythropoietic	I-Problem
anaemia	I-Problem
associated	O
with	O
long	I-Other
-	I-Other
term	I-Other
linezolid	I-Treatment
use	O
that	O
share	O
striking	O
similarities	O
to	O
chloramphenicol	O
-	O
associated	O
myelotoxicity	O
.	O

dipyrone	I-Treatment
-	O
induced	O
granulocytopenia	I-Problem
:	O
a	I-Background
case	I-Background
for	O
awareness	O
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
patient	I-Background
with	I-Background
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
infection	I-Problem
who	O
developed	O
severe	I-Problem
anaemia	I-Problem
during	O
antiviral	O
treatment	O
with	O
peginterferon	I-Treatment
alfa	I-Treatment
/	I-Treatment
ribavirin	I-Treatment
when	O
oseltamivir	I-Treatment
was	O
added	O
to	O
treat	O
influenza	I-Problem
.	O

both	I-Background
patients	I-Background
were	O
then	O
treated	O
with	O
a	O
carboplatin	I-Treatment
alternative	O
to	O
cisplatin	O
in	O
the	O
following	O
courses	O
,	O
which	O
resulted	O
in	O
neither	I-Problem
a	I-Problem
relapse	I-Problem
of	I-Problem
the	I-Problem
colitis	I-Problem
nor	I-Problem
a	I-Problem
recurrence	I-Problem
of	I-Problem
the	I-Problem
malignancies	I-Problem
up	O
to	O
this	O
time	O
.	O

it	O
is	O
rare	O
to	O
develop	O
simultaneous	O
toxicities	I-Problem
while	O
on	O
anticonvulsants	I-Treatment
.	O

because	O
of	O
serious	O
side	O
effects	O
of	O
an	O
increase	O
in	O
the	O
qt	I-Problem
interval	I-Problem
causing	I-Problem
torsades	I-Problem
de	I-Problem
pointes	I-Problem
,	O
dofetilide	I-Treatment
must	O
be	O
initiated	O
with	O
close	O
monitoring	I-Test
of	O
the	I-Test
qt	I-Test
interval	I-Test
in	O
an	O
inpatient	O
setting	O
.	O

it	O
should	O
be	O
emphasized	O
that	O
the	O
recurrence	O
of	O
nephrotic	I-Problem
syndrome	I-Problem
was	O
observed	O
after	O
the	O
following	O
chemotherapy	I-Treatment
,	I-Treatment
including	I-Treatment
m	I-Treatment
-	I-Treatment
csf	I-Treatment
,	O
whereas	O
the	I-Problem
bone	I-Problem
marrow	I-Problem
still	I-Problem
remained	I-Problem
completely	I-Problem
remitted	I-Problem
.	O

we	O
present	O
a	I-Background
patient	I-Background
with	I-Background
human	I-Problem
immunodeficiency	I-Problem
virus	I-Problem
infection	I-Problem
under	O
treatment	O
with	O
foscarnet	I-Treatment
for	O
cmv	I-Problem
retinitis	I-Problem
who	O
complained	O
of	O
thirst	I-Problem
and	I-Problem
polyuria	I-Problem
.	O

this	O
represents	O
the	O
first	O
report	O
of	O
nonconvulsive	I-Problem
status	I-Problem
epilepticus	I-Problem
induced	O
by	O
ifosfamide	I-Treatment
.	O

background	O
:	O
headaches	I-Problem
have	O
been	O
reported	O
as	O
a	O
potential	O
side	O
effect	O
of	O
capecitabine	I-Treatment
therapy	O
.	O

when	O
dscg	I-Treatment
was	I-Treatment
withdrawn	I-Treatment
,	O
urticaria	I-Problem
vanished	I-Problem
and	O
the	I-Background
child	I-Background
remained	O
symptom	I-Problem
-	I-Problem
free	I-Problem
.	O

hepatotoxic	I-Problem
effects	I-Problem
in	O
a	I-Background
child	I-Background
receiving	O
valproate	I-Treatment
and	I-Treatment
carnitine	I-Treatment
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
graves	I-Problem
'	I-Problem
hyperthyroidism	I-Problem
induced	O
by	O
long	I-Other
-	I-Other
term	I-Other
interferon	I-Treatment
(	I-Treatment
ifn	I-Treatment
)	I-Treatment
therapy	I-Treatment
.	O

bleomycin	I-Treatment
and	I-Treatment
cyclophosphamide	I-Treatment
toxicity	I-Treatment
simulating	O
metastatic	I-Problem
nodules	I-Problem
to	I-Problem
the	I-Problem
lungs	I-Problem
in	O
childhood	I-Background
cancer	I-Problem
.	O

the	I-Background
patient	I-Background
presented	O
with	O
fulminant	I-Problem
microangiopathic	I-Problem
hemolytic	I-Problem
anemia	I-Problem
and	I-Problem
thrombocytopenia	I-Problem
within	I-Treatment
48	I-Other
hr	I-Other
of	I-Treatment
initiating	I-Treatment
therapy	I-Treatment
with	I-Treatment
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
.	O

pneumocystis	I-Problem
pneumonia	I-Problem
should	O
be	O
considered	O
in	O
asthmatic	I-Problem
patients	I-Background
taking	O
methotrexate	I-Treatment
who	O
present	O
with	O
fever	I-Problem
,	I-Problem
pulmonary	I-Problem
infiltrates	I-Problem
,	I-Problem
and	I-Problem
hypoxia	I-Problem
.	O

acute	I-Problem
respiratory	I-Problem
distress	I-Problem
syndrome	I-Problem
after	O
rituximab	I-Treatment
infusion	I-Treatment
.	O

conclusion	O
:	O
gemcitabine	I-Treatment
-	O
induced	O
recall	I-Problem
pneumonitis	I-Problem
is	O
a	O
rarely	O
reported	O
phenomenon	O
and	O
should	O
be	O
taken	O
into	O
account	O
even	O
after	O
extended	O
time	O
interval	O
to	O
the	O
previous	O
radiotherapy	O
.	O

in	O
a	I-Background
61	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
receiving	O
chronic	I-Treatment
low	I-Treatment
-	I-Treatment
dosage	I-Treatment
amiodarone	I-Treatment
an	O
interstitial	I-Problem
pneumopathy	I-Problem
was	O
observed	O
.	O

a	I-Background
75	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
bilateral	I-Problem
lower	I-Problem
leg	I-Problem
edema	I-Problem
6	I-Treatment
months	I-Treatment
after	I-Treatment
switching	I-Treatment
from	I-Treatment
troglitazone	I-Treatment
to	I-Treatment
pioglitazone	I-Treatment
.	O

an	I-Problem
acute	I-Problem
ischaemic	I-Problem
event	I-Problem
associated	O
with	O
the	O
use	O
of	O
venlafaxine	I-Treatment
:	O
a	I-Background
case	I-Background
report	O
and	O
proposed	O
pathophysiological	O
mechanisms	O
.	O

oseltamivir	I-Treatment
was	O
effective	O
for	O
post	O
-	O
exposure	O
prophylaxis	O
of	O
h1n1	I-Problem
in	O
close	O
contact	O
.	O

herein	O
,	O
we	O
present	O
a	I-Background
patient	I-Background
with	O
severe	I-Problem
and	I-Problem
prolonged	I-Problem
hypoglycemia	I-Problem
after	O
long	I-Treatment
-	I-Treatment
acting	I-Treatment
octreotide	I-Treatment
treatment	I-Treatment
.	O

worsening	I-Problem
pneumonitis	I-Problem
due	O
to	O
a	O
pharmacokinetic	I-Treatment
drug	I-Treatment
-	I-Treatment
drug	I-Treatment
interaction	I-Treatment
between	I-Treatment
everolimus	I-Treatment
and	I-Treatment
voriconazole	I-Treatment
in	O
a	I-Background
renal	I-Problem
transplant	I-Problem
patient	I-Background
.	O

vocal	I-Problem
cord	I-Problem
paralysis	I-Problem
as	O
a	O
consequence	O
of	O
peritonsillar	I-Treatment
infiltration	I-Treatment
with	I-Treatment
bupivacaine	I-Treatment
.	O

the	O
sulfonamides	I-Treatment
are	O
the	O
best	O
verified	O
drug	O
-	O
trigger	O
for	O
erythema	I-Problem
multiforme	I-Problem
and	I-Problem
stevens	I-Problem
-	I-Problem
johnson	I-Problem
syndrome	I-Problem
.	O

edema	I-Problem
associated	O
with	O
ibuprofen	I-Treatment
therapy	O
.	O

a	I-Background
patient	I-Background
is	I-Background
presented	I-Background
with	I-Background
typical	I-Problem
hyperthyroidism	I-Problem
,	O
who	O
developed	O
a	O
severe	I-Problem
proximal	I-Problem
muscle	I-Problem
weakness	I-Problem
and	I-Problem
a	I-Problem
raised	I-Problem
creatine	I-Problem
phosphokinase	I-Problem
after	O
treatment	I-Treatment
for	I-Treatment
hyperthyroidism	I-Problem
with	I-Treatment
propylthiouracil	I-Treatment
(	I-Treatment
100	I-Treatment
mg	I-Treatment
orally	I-Treatment
,	I-Treatment
three	I-Other
times	I-Other
a	I-Other
day	I-Other
)	I-Treatment
.	O

atorvastatin	I-Treatment
is	O
the	O
most	I-Problem
potent	I-Problem
of	O
this	O
class	O
of	O
agents	O
currently	O
available	O
and	O
is	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
hyperlipidemia	I-Problem
.	O

however	O
,	O
there	O
are	O
few	O
reports	O
in	O
the	O
literature	O
of	O
ampicillin	I-Treatment
as	O
a	O
cause	O
of	O
acute	I-Problem
interstitial	I-Problem
nephritis	I-Problem
.	O

optic	I-Problem
neuropathy	I-Problem
in	O
ethambutol	I-Treatment
-	O
treated	O
renal	I-Problem
tuberculosis	I-Problem
.	O

this	O
case	I-Test
study	I-Test
describes	O
an	O
atypical	O
case	O
of	O
refractory	O
,	O
sodium	I-Treatment
warfarin	I-Treatment
-	O
induced	O
necrotizing	I-Problem
fasciitis	I-Problem
and	I-Problem
myonecrosis	I-Problem
.	O

objective	O
:	O
to	O
report	O
a	I-Background
case	I-Background
of	O
possible	O
foscarnet	I-Treatment
-	O
induced	O
severe	I-Problem
hypomagnesemia	I-Problem
and	I-Problem
other	I-Problem
electrolyte	I-Problem
disorders	I-Problem
.	O

however	O
,	O
the	O
occurrence	O
and	O
management	O
of	O
akathisia	I-Problem
induced	O
by	O
fluvoxamine	I-Treatment
have	O
not	O
been	O
described	O
.	O

nephrotic	I-Problem
syndrome	I-Problem
associated	O
with	O
interferon	I-Treatment
-	I-Treatment
beta	I-Treatment
-	I-Treatment
1b	I-Treatment
therapy	I-Treatment
for	O
multiple	I-Problem
sclerosis	I-Problem
.	I-Problem

observations	O
:	O
a	I-Background
48	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
presented	O
with	O
disfiguring	I-Problem
facial	I-Problem
edema	I-Problem
10	I-Other
weeks	I-Other
after	O
she	O
began	O
antiviral	I-Treatment
therapy	I-Treatment
with	I-Treatment
peginterferon	I-Treatment
alfa	I-Treatment
-	I-Treatment
2a	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
for	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
infection	I-Problem
.	O

two	O
of	I-Background
these	I-Background
patients	I-Background
,	O
who	O
also	O
received	O
the	O
anti	I-Treatment
-	I-Treatment
emetic	I-Treatment
prochlorperazine	I-Treatment
,	O
lost	I-Problem
consciousness	I-Problem
for	I-Problem
48	I-Problem
-	I-Problem
72	I-Problem
h	I-Problem
and	I-Problem
then	I-Problem
fully	I-Problem
recovered	I-Problem
.	O

we	O
present	O
a	O
depressive	I-Problem
patient	I-Background
who	O
developed	O
mild	I-Problem
parkinsonian	I-Problem
signs	I-Problem
and	I-Problem
camptocormia	I-Problem
after	O
the	O
introduction	I-Treatment
of	I-Treatment
olanzapine	I-Treatment
.	O

the	O
case	O
report	O
discussed	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
third	O
of	O
its	O
kind	O
regarding	O
bone	I-Problem
fluorosis	I-Problem
resulting	O
from	O
use	O
of	O
this	O
nicotinic	I-Treatment
derivative	I-Treatment
.	O

we	O
report	O
a	O
case	O
of	O
thrombotic	I-Problem
thrombocytopenic	I-Problem
purpura	I-Problem
occurring	O
as	O
an	O
allergic	I-Problem
response	I-Problem
to	O
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
therapy	O
(	O
bactrim	O
,	O
septra	O
)	O
in	O
a	O
jehovah	I-Background
'	I-Background
s	I-Background
witness	I-Background
patient	I-Background
.	O

a	I-Background
25	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
woman	I-Background
with	I-Background
chronic	I-Problem
depression	I-Problem
was	O
treated	O
with	O
venlafaxine	I-Treatment
150	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
and	I-Treatment
trimipramine	I-Treatment
50	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
.	O

a	I-Background
31	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
developed	O
multiple	I-Problem
episodes	I-Problem
of	I-Problem
grand	I-Problem
mal	I-Problem
seizures	I-Problem
after	O
combination	I-Treatment
chemotherapy	I-Treatment
with	I-Treatment
cisplatin	I-Treatment
,	I-Treatment
vinblastine	I-Treatment
and	I-Treatment
bleomycin	I-Treatment
for	O
germ	I-Problem
cell	I-Problem
ovarian	I-Problem
cancer	I-Problem
stage	I-Problem
ic	I-Problem
.	O

nephrogenic	I-Problem
diabetes	I-Problem
insipidus	I-Problem
and	I-Problem
renal	I-Problem
tubular	I-Problem
acidosis	I-Problem
secondary	O
to	O
foscarnet	I-Treatment
therapy	O
.	O

purpose	O
:	O
topiramate	I-Treatment
-	O
induced	O
angle	I-Problem
-	I-Problem
closure	I-Problem
glaucoma	I-Problem
(	I-Problem
tiacg	I-Problem
)	I-Problem
is	O
believed	O
to	O
be	O
related	O
to	O
its	O
sulfonamide	O
moiety	O
.	O

these	O
toxicities	O
resolved	O
after	O
the	O
cessation	O
of	O
anticonvulsants	O
,	O
and	O
her	O
seizures	I-Problem
were	O
managed	O
acutely	O
with	O
scheduled	O
lorazepam	I-Treatment
.	O

this	O
article	O
reports	O
the	O
occurrence	O
of	O
rifampin	I-Treatment
-	O
associated	O
thrombocytopenia	I-Problem
in	O
an	I-Background
indigent	I-Background
patient	I-Background
after	I-Treatment
a	I-Treatment
four	I-Other
-	I-Other
month	I-Other
lapse	I-Treatment
in	I-Treatment
therapy	I-Treatment
for	I-Treatment
pulmonary	I-Problem
tuberculosis	I-Problem
.	O

drug	O
-	O
induced	O
psychosis	I-Problem
resulted	I-Problem
from	O
the	O
administration	I-Treatment
of	I-Treatment
quinacrine	I-Treatment
hydrochloride	I-Treatment
at	I-Treatment
a	I-Treatment
dosage	I-Treatment
of	I-Treatment
100	I-Treatment
mg	I-Treatment
twice	I-Other
daily	I-Other
for	O
the	O
treatment	O
of	O
discoid	I-Problem
lupus	I-Problem
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
a	I-Problem
scleroderma	I-Problem
-	I-Problem
like	I-Problem
reaction	I-Problem
induced	O
by	O
long	I-Other
-	I-Other
term	I-Other
administration	I-Treatment
of	I-Treatment
uft	I-Treatment
.	O

we	O
report	O
four	O
cases	O
of	O
hemodynamically	I-Problem
significant	I-Problem
pericardial	I-Problem
effusion	I-Problem
in	O
patients	O
with	O
refractory	I-Problem
lymphoma	I-Problem
who	O
were	O
receiving	O
gemcitabine	I-Treatment
,	O
all	O
of	O
whom	O
had	I-Background
a	I-Background
history	I-Background
of	I-Background
mediastinal	I-Problem
radiation	I-Problem
without	I-Problem
subcarinal	I-Problem
blocking	I-Problem
.	O

both	O
had	I-Background
impaired	I-Problem
lung	I-Problem
function	I-Problem
and	I-Background
abnormal	I-Problem
computed	I-Problem
tomographic	I-Problem
scans	I-Problem
,	O
and	O
their	O
condition	O
improved	O
when	O
nitrofurantoin	I-Treatment
was	I-Treatment
withdrawn	I-Treatment
and	I-Treatment
corticosteroid	I-Treatment
treatment	I-Treatment
commenced	I-Treatment
.	O

objective	O
:	O
the	O
purpose	O
of	O
this	O
study	I-Test
was	O
to	O
report	O
the	O
concomitant	O
occurrence	O
of	O
multiple	I-Problem
squamous	I-Problem
cell	I-Problem
carcinomas	I-Problem
and	I-Problem
diffuse	I-Problem
nail	I-Problem
hyperpigmentation	I-Problem
associated	O
with	O
hydroxyurea	I-Treatment
treatment	O
,	O
and	O
to	O
describe	O
a	O
successful	O
therapeutic	O
approach	O
using	O
imiquimod	O
5	O
%	O
.	O

we	O
present	O
a	O
case	O
report	O
of	O
a	I-Background
patient	I-Background
who	O
developed	O
a	O
prolonged	I-Problem
qt	I-Problem
while	O
being	O
treated	O
with	O
oral	I-Treatment
methadone	I-Treatment
for	O
a	O
chronic	I-Problem
pain	I-Problem
syndrome	I-Problem
.	O

in	O
this	O
article	O
,	O
we	O
describe	O
a	I-Background
japanese	I-Background
patient	I-Background
with	O
severe	I-Problem
interstitial	I-Problem
pneumonia	I-Problem
probably	O
caused	O
by	O
sorafenib	I-Treatment
treatment	O
for	O
metastatic	I-Problem
renal	I-Problem
cell	I-Problem
carcinoma	I-Problem
.	O

neurotoxicity	I-Problem
occurs	O
most	O
often	O
with	O
intermittent	I-Treatment
high	I-Treatment
dose	I-Treatment
5	I-Treatment
-	I-Treatment
fu	I-Treatment
as	I-Treatment
bolus	I-Treatment
injection	I-Treatment
or	I-Treatment
24	I-Treatment
-	I-Treatment
to	I-Treatment
48	I-Treatment
-	I-Treatment
h	I-Treatment
infusions	I-Treatment
.	O

lovastatin	I-Treatment
also	O
reportedly	O
has	O
caused	O
increases	I-Problem
in	I-Problem
inr	I-Problem
when	O
coadministered	O
with	O
warfarin	O
.	O

pravastatin	I-Treatment
does	O
not	O
appear	O
to	O
interact	O
with	O
warfarin	O
but	O
has	O
caused	O
an	O
increased	I-Problem
inr	I-Problem
when	O
combined	I-Treatment
with	I-Treatment
the	I-Treatment
anticoagulant	I-Treatment
fluindione	I-Treatment
.	O

bromocriptine	I-Treatment
-	O
induced	O
schizophrenia	I-Problem
.	O

pulmonary	I-Problem
toxicity	I-Problem
associated	O
with	O
erlotinib	I-Treatment
.	O

multicentric	I-Problem
hepatocellular	I-Problem
carcinoma	I-Problem
following	O
phosphate	I-Treatment
diethylstilbestrol	I-Treatment
therapy	O
for	O
prostatic	I-Problem
cancer	I-Problem
.	O

rapid	O
onset	O
of	O
quetiapine	I-Treatment
-	O
induced	O
diabetic	I-Problem
ketoacidosis	I-Problem
in	O
an	I-Background
elderly	I-Background
patient	I-Background
:	O
a	O
case	O
report	O
.	O

a	O
57	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
developed	O
pulmonary	I-Problem
sarcoidosis	I-Problem
during	O
therapy	O
with	O
interferon	I-Treatment
beta	I-Treatment
for	I-Treatment
advanced	I-Problem
renal	I-Problem
cell	I-Problem
carcinoma	I-Problem
metastatic	I-Problem
to	I-Problem
mediastinal	I-Problem
lymph	I-Problem
nodes	I-Problem
.	O

mesalamine	I-Treatment
-	O
induced	O
hypersensitivity	I-Problem
pneumonitis	I-Problem
.	O

a	I-Background
girl	I-Background
with	I-Background
cystic	I-Problem
fibrosis	I-Problem
and	I-Background
cyclic	I-Problem
neutropenia	I-Problem
developed	O
an	O
erythematous	I-Problem
papular	I-Problem
eruption	I-Problem
without	I-Problem
fever	I-Problem
or	I-Problem
neutrophilia	I-Problem
7	I-Other
months	I-Other
after	I-Treatment
commencing	I-Treatment
therapy	I-Treatment
with	I-Treatment
g	I-Treatment
-	I-Treatment
csf	I-Treatment
.	I-Treatment

lichen	I-Problem
planus	I-Problem
and	I-Problem
acne	I-Problem
provoked	O
by	O
gold	I-Treatment
.	O

to	O
the	O
best	O
of	O
our	O
knowledge	O
only	O
two	O
previous	O
cases	O
of	O
aml	I-Problem
have	O
been	O
linked	O
to	O
treatment	O
of	O
hcl	I-Problem
with	O
purine	I-Treatment
analogs	I-Treatment
,	I-Treatment
both	I-Treatment
with	I-Treatment
2	I-Treatment
-	I-Treatment
chlorodeoxyadenosine	I-Treatment
.	O

there	O
are	O
no	O
previous	O
reports	O
in	O
the	O
literature	O
about	O
the	O
emergence	O
of	O
cml	I-Problem
during	O
treatment	I-Treatment
with	I-Treatment
hydroxyurea	I-Treatment
.	O

intravenous	I-Treatment
valproate	I-Treatment
associated	O
with	O
significant	I-Problem
hypotension	I-Problem
in	O
the	O
treatment	O
of	O
status	I-Problem
epilepticus	I-Problem
.	O

torsade	I-Problem
de	I-Problem
pointes	I-Problem
associated	O
with	O
moxifloxacin	I-Treatment
:	O
a	O
rare	O
but	O
potentially	O
fatal	O
adverse	O
event	O
.	O

we	O
report	O
serious	I-Problem
adverse	I-Problem
effects	I-Problem
due	O
to	O
interaction	I-Treatment
between	I-Treatment
orally	I-Treatment
administered	I-Treatment
voriconazole	I-Treatment
and	I-Treatment
everolimus	I-Treatment
in	O
a	I-Background
renal	I-Problem
transplant	I-Problem
recipient	I-Background
.	O

horner	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
and	I-Problem
demyelinating	I-Problem
peripheral	I-Problem
neuropathy	I-Problem
caused	O
by	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
.	O

fatal	O
radiation	I-Problem
myelopathy	I-Problem
after	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
busulfan	I-Treatment
and	O
melphalan	I-Treatment
chemotherapy	O
and	O
radiotherapy	O
for	O
ewing	I-Problem
'	I-Problem
s	I-Problem
sarcoma	I-Problem
:	I-Problem
a	O
review	O
of	O
the	O
literature	O
and	O
implications	O
for	O
practice	O
.	O

this	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
ductopenia	I-Problem
apparently	O
caused	O
by	O
clindamycin	I-Treatment
.	O

mefloquine	I-Treatment
-	O
associated	O
hypoglycaemia	I-Problem
in	O
a	O
cachectic	I-Problem
aids	I-Problem
patient	I-Background
.	O

patients	I-Background
who	O
commonly	O
require	O
linezolid	I-Treatment
as	I-Treatment
an	I-Treatment
antimicrobial	I-Treatment
are	O
those	O
with	O
complex	I-Problem
infections	I-Problem
where	O
other	O
antibiotic	O
treatment	O
has	O
failed	O
.	O

in	O
three	O
of	I-Background
these	I-Background
patients	I-Background
the	O
infection	O
was	O
clinically	O
unsuspected	O
;	O
in	O
the	O
fourth	O
,	O
cutaneous	I-Problem
herpes	I-Problem
zoster	I-Problem
developed	O
after	O
administration	O
of	O
300	I-Treatment
mg	I-Treatment
of	I-Treatment
cytarabine	I-Treatment
daily	I-Other
for	I-Treatment
the	I-Treatment
preceding	I-Other
five	I-Other
days	I-Other
.	O

patients	I-Background
receiving	O
linezolid	I-Treatment
for	I-Treatment
more	I-Treatment
than	I-Treatment
28	I-Other
days	I-Other
should	O
be	O
monitored	O
for	O
signs	O
of	O
peripheral	I-Problem
and	I-Problem
optic	I-Problem
neuropathy	I-Problem
.	O

atrioventricular	I-Problem
block	I-Problem
complicating	O
amiodarone	I-Treatment
-	O
induced	O
hypothyroidism	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
pre	I-Problem
-	I-Problem
excitation	I-Problem
and	I-Background
rate	I-Problem
-	I-Problem
dependent	I-Problem
bilateral	I-Problem
bundle	I-Problem
branch	I-Problem
block	I-Problem
.	O

lithium	I-Treatment
is	O
known	O
to	O
cause	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
and	I-Problem
tubulo	I-Problem
-	I-Problem
interstitial	I-Problem
disease	I-Problem
,	O
but	O
the	O
recently	O
described	O
association	O
with	O
proteinuria	I-Problem
or	I-Problem
nephrotic	I-Problem
syndrome	I-Problem
is	O
little	O
recognized	O
.	O

a	O
40	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
advanced	I-Background
hiv	I-Problem
infection	I-Problem
and	I-Background
mycobacterium	I-Problem
avium	I-Problem
complex	I-Problem
infection	I-Problem
experienced	O
rapid	I-Problem
cognitive	I-Problem
decline	I-Problem
after	O
commencement	I-Treatment
of	I-Treatment
ethambutol	I-Treatment
,	O
and	O
symptoms	O
fully	O
resolved	O
with	O
cessation	O
.	O

ciprofloxacin	I-Treatment
-	O
induced	O
hemorrhagic	I-Problem
vasculitis	I-Problem
is	O
a	O
rare	O
side	O
effect	O
.	O

given	O
that	O
significant	I-Problem
thyroid	I-Problem
disorders	I-Problem
may	O
be	O
only	O
mildly	O
symptomatic	O
and	O
thus	O
may	O
escape	O
clinical	O
detection	O
,	O
we	O
suggest	O
that	O
thyroid	O
function	O
should	O
be	O
tested	O
in	O
any	O
patient	O
with	O
otherwise	O
unexplained	O
changes	O
in	O
warfarin	I-Treatment
dose	O
requirements	O
,	O
particularly	O
if	O
concomitantly	O
treated	O
with	I-Treatment
amiodarone	I-Treatment
.	O

myotonia	I-Problem
associated	O
with	O
sarcoidosis	I-Problem
:	O
marked	O
exacerbation	I-Problem
with	O
pravastatin	I-Treatment
.	O

this	O
observation	O
questions	O
the	O
suitability	O
of	O
aspirin	I-Treatment
as	O
prophylaxis	O
for	O
vascular	I-Problem
disease	I-Problem
in	O
patients	I-Background
with	I-Background
meningiomas	I-Problem
.	O

delayed	I-Problem
neurotoxicity	I-Problem
of	O
intraventricular	I-Treatment
interleukin	I-Test
-	I-Treatment
2	I-Treatment
:	O
a	I-Background
case	I-Background
report	I-Background
.	O

we	O
stress	O
the	O
potential	O
of	O
benzarone	I-Treatment
to	O
cause	O
hepatotoxicity	I-Problem
,	O
which	O
usually	O
resembles	O
severe	I-Problem
chronic	I-Problem
active	I-Problem
hepatitis	I-Problem
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
wilson	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
who	I-Background
presented	I-Background
with	I-Background
neurologic	I-Problem
disease	I-Problem
,	O
was	O
treated	O
with	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
,	O
and	O
suffered	O
sudden	I-Problem
neurologic	I-Problem
deterioration	I-Problem
coincident	O
with	O
therapy	O
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
21	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
patient	I-Background
with	O
dapsone	I-Treatment
hypersensitivity	I-Problem
syndrome	I-Problem
.	O

the	O
adverse	I-Problem
events	I-Problem
related	O
to	O
ribavirin	I-Treatment
and	O
drug	O
-	O
drug	O
interactions	O
during	O
therapy	O
for	O
hepatitis	I-Problem
c	I-Problem
are	O
discussed	O
.	O

insulin	I-Problem
-	I-Problem
dependent	I-Problem
diabetes	I-Problem
mellitus	I-Problem
developed	O
in	O
a	I-Background
young	I-Background
woman	I-Background
8	I-Other
weeks	I-Other
after	I-Treatment
the	I-Treatment
initiation	I-Treatment
of	I-Treatment
danazol	I-Treatment
for	O
treatment	O
of	O
pelvic	I-Problem
endometriosis	I-Problem
.	O

four	I-Background
cases	I-Background
of	O
fat	I-Problem
embolism	I-Problem
are	O
described	O
in	O
infants	I-Background
receiving	O
prolonged	I-Treatment
intravenous	I-Treatment
infusion	I-Treatment
of	I-Treatment
fat	I-Treatment
(	I-Treatment
intralipid	I-Treatment
20	I-Treatment
%	I-Treatment
)	I-Treatment
.	O

oral	O
adverse	I-Problem
effects	I-Problem
due	O
to	O
the	O
use	O
of	O
nevirapine	I-Treatment
.	O

purpose	O
:	O
a	O
case	O
of	O
probable	O
enoxaparin	I-Treatment
-	O
induced	O
hepatotoxicity	I-Problem
is	O
described	O
.	O

tizanidine	I-Treatment
was	O
used	O
again	O
after	O
her	O
bp	I-Test
had	O
stabilized	O
,	O
but	O
did	O
not	O
produce	O
similar	O
problems	I-Problem
.	O

it	O
is	O
suggested	O
therefore	O
that	O
methotrexate	I-Treatment
be	O
added	O
to	O
the	O
list	O
of	O
agents	O
capable	O
of	O
inducing	O
diffuse	I-Problem
interstitial	I-Problem
pulmonary	I-Problem
fibrosis	I-Problem
.	O

the	O
delayed	I-Problem
encephalopathy	I-Problem
developed	O
9	I-Other
and	I-Other
22	I-Other
months	I-Other
respectively	O
after	O
the	O
first	O
dose	O
of	O
intrathecal	I-Treatment
methotrexate	I-Treatment
.	O

severe	I-Problem
systemic	I-Problem
hypersensitivity	I-Problem
reaction	I-Problem
to	O
ibuprofen	I-Treatment
occurring	O
after	O
prolonged	I-Other
therapy	I-Other
.	O

in	O
patients	I-Background
with	I-Background
chronic	I-Problem
heart	I-Problem
failure	I-Problem
,	O
spironolactone	I-Treatment
added	O
to	O
conventional	O
treatment	O
may	O
lead	O
to	O
serious	I-Problem
and	I-Problem
,	I-Problem
occasionally	I-Problem
,	I-Problem
fatal	I-Problem
hyperkalaemia	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
acute	I-Problem
hyperphosphatemia	I-Problem
secondary	O
to	O
rectal	I-Treatment
administration	I-Treatment
of	I-Treatment
sodium	I-Treatment
phosphate	I-Treatment
and	I-Treatment
sodium	I-Treatment
biphosphate	I-Treatment
(	I-Treatment
fleet	I-Treatment
enema	I-Treatment
)	I-Treatment
.	O

visual	I-Problem
changes	I-Problem
secondary	O
to	O
initiation	O
of	O
amiodarone	I-Treatment
:	O
a	I-Background
case	I-Background
report	O
and	O
review	O
involving	O
ocular	O
management	O
in	O
cardiac	O
polypharmacy	O
.	O

this	O
is	O
the	O
first	O
case	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
onset	O
of	O
prolonged	I-Other
infliximab	I-Treatment
-	O
induced	O
lupus	I-Problem
.	O

a	I-Background
patient	I-Background
with	I-Background
developmental	I-Problem
disabilities	I-Problem
who	I-Background
had	I-Background
no	I-Background
history	I-Background
of	I-Background
movement	I-Background
disorders	I-Background
developed	O
eps	I-Problem
following	O
initiation	I-Treatment
of	I-Treatment
aripiprazole	I-Treatment
.	O

case	I-Background
report	O
:	O
life	I-Problem
-	I-Problem
threatening	I-Problem
hypoglycaemia	I-Problem
associated	O
with	O
sulfadoxine	I-Treatment
-	I-Treatment
pyrimethamine	I-Treatment
,	O
a	O
commonly	O
used	O
antimalarial	O
drug	O
.	O

diphenhydramine	I-Treatment
-	I-Problem
induced	I-Problem
wide	I-Problem
complex	I-Problem
dysrhythmia	I-Problem
responds	O
to	O
treatment	I-Treatment
with	I-Treatment
sodium	I-Treatment
bicarbonate	I-Treatment
.	O

prenatal	I-Problem
cytomegalovirus	I-Problem
(	I-Problem
cmv	I-Problem
)	I-Problem
infection	I-Problem
associated	I-Problem
with	I-Problem
severe	I-Problem
brain	I-Problem
damage	I-Problem
was	O
detected	O
in	O
an	I-Background
infant	I-Background
whose	I-Background
mother	I-Background
had	I-Background
been	I-Background
treated	I-Background
with	I-Background
prednisolone	I-Treatment
and	I-Treatment
azathioprine	I-Treatment
for	I-Background
systemic	I-Background
lupus	I-Background
erythematosus	I-Background
(	I-Background
sle	I-Background
)	I-Background
.	O

methotrexate	I-Treatment
may	O
rarely	O
provoke	O
serositis	I-Problem
,	O
even	O
with	O
low	O
doses	O
and	O
after	O
just	O
a	O
few	O
weeks	O
of	O
therapy	O
.	O

prescription	O
analyses	I-Test
by	O
pharmacists	O
and	O
literature	O
research	O
have	O
permitted	O
us	O
to	O
suggest	O
that	O
a	O
drug	O
-	O
drug	O
interaction	O
between	O
methotrexate	I-Treatment
and	I-Treatment
proton	I-Treatment
pump	I-Treatment
inhibitors	I-Treatment
(	I-Treatment
ppi	I-Treatment
)	I-Treatment
was	O
responsible	O
for	O
this	O
renal	I-Problem
failure	I-Problem
.	O

asthma	I-Problem
and	I-Problem
urticaria	I-Problem
during	O
disodium	I-Treatment
cromoglycate	I-Treatment
treatment	I-Treatment
.	O

we	O
suggest	O
that	O
the	O
previous	O
classification	O
of	O
nitrofurantoin	I-Treatment
induced	O
lung	I-Problem
injury	I-Problem
into	O
"	O
acute	O
"	O
and	O
"	O
chronic	O
"	O
injury	O
is	O
an	O
oversimplification	O
in	O
view	O
of	O
the	O
wide	O
variety	O
of	O
pathological	O
entities	O
that	O
have	O
subsequently	O
emerged	O
.	O

hepatitis	I-Problem
with	I-Problem
bridging	I-Problem
fibrosis	I-Problem
and	I-Problem
reversible	I-Problem
hepatic	I-Problem
insufficiency	I-Problem
in	O
a	I-Background
woman	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
taking	O
methotrexate	I-Treatment
.	O

primary	I-Problem
cns	I-Problem
lymphoma	I-Problem
regressed	O
on	O
withdrawal	I-Treatment
of	I-Treatment
mm	I-Treatment
.	O

pemphigus	I-Problem
foliaceus	I-Problem
induced	O
by	O
rifampicin	I-Treatment
.	O

l	I-Treatment
-	I-Treatment
t4	I-Treatment
stimulated	O
lymphocyte	I-Problem
transformation	I-Problem
in	O
this	I-Background
patient	I-Background
.	O

a	I-Background
53	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
lower	I-Problem
leg	I-Problem
edema	I-Problem
4	I-Other
weeks	I-Other
after	I-Treatment
rosiglitazone	I-Treatment
was	I-Treatment
increased	I-Treatment
from	I-Treatment
4	I-Treatment
mg	I-Treatment
once	I-Treatment
/	I-Treatment
day	I-Treatment
to	I-Treatment
4	I-Treatment
mg	I-Treatment
twice	I-Other
/	I-Other
day	I-Other
.	O

a	I-Background
mentally	I-Problem
retarded	I-Problem
23	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
myoclonic	I-Problem
astatic	I-Problem
epilepsy	I-Problem
developed	O
an	O
abnormal	I-Problem
posture	I-Problem
of	I-Problem
extreme	I-Problem
forward	I-Problem
flexion	I-Problem
,	I-Problem
called	I-Problem
camptocormia	I-Problem
,	I-Problem
during	O
valproate	I-Treatment
monotherapy	O
.	O

after	I-Other
5	I-Other
days	I-Other
of	I-Treatment
treatment	I-Treatment
with	I-Treatment
il	I-Treatment
-	I-Treatment
2	I-Treatment
,	O
the	O
patient	I-Background
developed	O
a	I-Problem
hemorrhagic	I-Problem
lesion	I-Problem
that	I-Problem
progressed	I-Problem
to	I-Problem
toxic	I-Problem
epidermal	I-Problem
necrolysis	I-Problem
,	I-Problem
as	I-Problem
well	I-Problem
as	I-Problem
grade	I-Problem
4	I-Problem
pancytopenia	I-Problem
.	O

acute	I-Problem
pancreatitis	I-Problem
after	O
long	I-Other
-	I-Other
term	I-Other
5	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
therapy	I-Treatment
.	O

physicians	O
should	O
be	O
aware	O
that	O
plp	I-Problem
can	O
occur	O
after	O
initiation	O
of	O
paclitaxel	I-Treatment
.	O

heparin	O
-	O
dependent	O
antibodies	O
and	O
thrombosis	O
without	O
heparin	I-Treatment
-	O
induced	O
thrombocytopenia	I-Problem
.	O

treatment	O
of	O
lithium	I-Treatment
tremor	I-Problem
with	O
metoprolol	I-Treatment
.	O

a	I-Background
54	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
,	O
treated	O
with	O
amiodarone	I-Treatment
,	O
developed	O
thyrotoxicosis	I-Problem
.	O

gynaecomastia	I-Problem
is	O
a	O
rarely	O
reported	O
adverse	O
drug	O
reaction	O
due	O
to	O
isoniazid	I-Treatment
therapy	I-Treatment
.	O

the	O
authors	O
performed	O
a	O
literature	I-Test
search	I-Test
using	O
pubmed	O
and	O
the	O
search	O
terms	O
"	O
gemcitabine	O
"	O
and	O
"	O
radiation	O
recall	O
"	O
to	O
find	O
prior	I-Background
cases	I-Background
of	O
radiation	I-Problem
recall	I-Problem
attributed	O
to	O
gemcitabine	I-Treatment
.	O

carbamazepine	I-Treatment
-	O
induced	O
diabetes	I-Problem
mellitus	I-Problem
.	O

she	I-Background
displayed	O
symptoms	I-Problem
of	I-Problem
st	I-Problem
8	I-Other
days	I-Other
after	I-Treatment
the	I-Treatment
introduction	I-Treatment
of	I-Treatment
linezolid	I-Treatment
.	O

naproxen	I-Treatment
is	O
a	O
commonly	O
used	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
nsaid	O
)	O
whose	O
side	O
effects	O
include	O
tinnitus	I-Problem
and	I-Problem
transient	I-Problem
hearing	I-Problem
loss	I-Problem
.	O

the	O
allopurinol	I-Treatment
hypersensitivity	I-Problem
syndrome	I-Problem
is	O
a	O
rare	O
adverse	O
drug	O
reaction	O
.	O

the	O
pulmonary	I-Problem
toxicity	I-Problem
is	O
probably	O
induced	O
by	O
piritrexim	I-Treatment
.	O

background	O
:	O
interferon	I-Treatment
(	I-Treatment
ifn	I-Treatment
)	I-Treatment
-	O
associated	O
retinopathy	I-Problem
is	I-Problem
typically	I-Problem
characterized	I-Problem
by	I-Problem
retinal	I-Problem
hemorrhages	I-Problem
and	I-Problem
cotton	I-Problem
wool	I-Problem
spots	I-Problem
at	I-Problem
the	I-Problem
posterior	I-Problem
fundus	I-Problem
,	O
but	O
visual	O
function	O
is	O
usually	O
maintained	O
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
a	I-Background
liver	I-Problem
abscess	I-Problem
due	I-Background
to	I-Background
entamoeba	I-Problem
histolytica	I-Problem
,	O
in	O
whom	O
metronidazole	I-Treatment
therapy	I-Treatment
(	I-Treatment
total	I-Treatment
dose	I-Treatment
,	I-Treatment
21	I-Treatment
g	I-Treatment
over	I-Treatment
14	I-Other
days	I-Other
)	I-Treatment
was	O
complicated	O
by	O
reversible	I-Problem
deafness	I-Problem
,	I-Problem
tinnitus	I-Problem
,	I-Problem
and	I-Problem
ataxia	I-Problem
and	I-Problem
who	I-Problem
relapsed	I-Problem
5	I-Problem
months	I-Problem
later	I-Problem
with	I-Problem
a	I-Problem
splenic	I-Problem
abscess	I-Problem
.	O

we	O
present	O
a	I-Background
japanese	I-Background
male	I-Background
patient	I-Background
who	I-Background
underwent	I-Background
a	I-Background
living	I-Background
-	I-Background
donor	I-Background
kidney	I-Problem
transplantation	I-Problem
having	O
received	O
tacrolimus	I-Treatment
,	I-Treatment
mycophenolate	I-Treatment
mofetil	I-Treatment
,	I-Treatment
and	I-Treatment
prednisolone	I-Treatment
for	O
immunosuppression	I-Problem
.	O

gold	I-Treatment
nephropathy	I-Problem
due	O
to	O
auranofin	I-Treatment
obscured	O
by	O
tolmetin	I-Treatment
pseudoproteinuria	O
.	O

we	O
report	O
three	O
cases	I-Background
of	O
amiodarone	I-Treatment
-	O
induced	O
torsades	I-Problem
de	I-Problem
pointe	I-Problem
.	O

torsades	I-Problem
de	I-Problem
pointes	I-Problem
due	O
to	O
drug	I-Treatment
interaction	I-Treatment
between	I-Treatment
disopyramide	I-Treatment
and	I-Treatment
clarithromycin	I-Treatment
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	O
developed	O
hus	I-Problem
after	O
treatment	O
with	O
mitomycin	I-Treatment
c	I-Treatment
(	I-Treatment
total	I-Treatment
dose	I-Treatment
144	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
)	I-Treatment
due	O
to	O
a	O
carcinoma	I-Problem
of	I-Problem
the	I-Problem
ascending	I-Problem
colon	I-Problem
.	O

in	O
this	O
case	O
,	O
5	I-Treatment
-	I-Treatment
fu	I-Treatment
increased	I-Treatment
pht	I-Treatment
,	I-Treatment
which	I-Treatment
in	I-Treatment
turn	I-Treatment
may	I-Treatment
have	I-Treatment
increased	I-Treatment
the	I-Treatment
pb	I-Test
concentration	I-Test
,	O
suggesting	O
that	O
when	O
fluoropyrimidine	O
antitumor	O
agents	O
are	O
administered	O
to	O
patients	I-Background
receiving	O
pht	O
in	O
combination	O
with	O
other	O
drugs	O
,	O
some	O
measures	O
should	O
be	O
taken	O
in	O
consideration	O
of	O
secondary	I-Problem
effects	I-Problem
of	I-Problem
antitumor	I-Problem
agents	I-Problem
on	I-Problem
other	I-Problem
drugs	I-Problem
that	O
may	O
possibly	O
interact	O
with	O
pht	O
,	O
including	O
frequent	O
monitoring	I-Test
of	I-Test
blood	O
drug	I-Test
concentration	I-Test
.	O

severe	I-Problem
loss	I-Problem
of	I-Problem
vision	I-Problem
after	O
removal	O
of	O
cataract	O
caused	O
by	O
intravitreal	I-Treatment
triamcinolone	I-Treatment
in	O
combination	O
with	O
photodynamic	I-Treatment
therapy	O
for	O
exudative	I-Problem
age	I-Problem
-	I-Problem
related	I-Problem
macular	I-Problem
degeneration	I-Problem
.	O

the	O
catapult	I-Test
i	I-Test
study	I-Test
shows	O
that	O
tirapazamine	I-Treatment
enhances	I-Problem
the	I-Problem
activity	I-Problem
of	I-Problem
cisplatin	I-Problem
in	O
patients	I-Background
with	I-Background
advanced	I-Problem
nsclc	I-Problem
and	O
confirms	O
that	O
hypoxia	O
is	O
an	O
exploitable	O
therapeutic	O
target	O
in	O
human	O
malignancies	O
.	O

cardiac	I-Problem
arrest	I-Problem
associated	O
with	O
sulprostone	I-Treatment
use	O
during	O
caesarean	O
section	O
.	O

linear	I-Problem
iga	I-Problem
bullous	I-Problem
dermatosis	I-Problem
occurring	O
after	O
carbamazepine	I-Treatment
.	O

hypothyroidism	I-Problem
,	O
occurring	O
in	O
up	O
to	O
11	O
percent	O
of	I-Background
patients	I-Background
treated	O
with	O
amiodarone	I-Treatment
,	O
can	O
also	O
alter	O
drug	O
metabolism	O
and	O
sensitize	O
the	O
central	O
nervous	O
system	O
,	O
thus	O
increasing	O
the	O
potential	O
for	O
toxicity	O
.	O

we	O
report	O
the	O
first	O
case	O
of	O
herpes	I-Problem
esophagitis	I-Problem
in	O
a	I-Background
renal	I-Problem
transplant	I-Problem
patient	I-Background
treated	O
with	O
cyclosporine	I-Treatment
a	I-Treatment
while	I-Treatment
on	I-Treatment
chronic	I-Treatment
steroid	I-Treatment
therapy	I-Treatment
.	O

severe	I-Problem
hepatocellular	I-Problem
dysfunction	I-Problem
following	O
cyproterone	I-Treatment
acetate	I-Treatment
therapy	O
.	O

it	O
is	O
thought	O
that	O
the	O
clinico	O
-	O
pathological	O
features	O
and	O
chronology	O
of	O
this	O
case	O
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3	I-Problem
-	I-Problem
week	I-Problem
sulphasalazine	I-Problem
syndrome	I-Problem
"	O
,	O
a	O
rare	O
,	O
but	O
often	O
fatal	O
,	O
immunoallergic	O
reaction	O
to	O
sulphasalazine	I-Treatment
.	O

two	O
patients	I-Background
with	I-Background
bipolar	I-Problem
affective	I-Problem
disorder	I-Problem
and	I-Background
a	I-Problem
history	I-Problem
of	I-Problem
bronchospastic	I-Problem
phenomena	I-Problem
experienced	O
tremor	I-Problem
during	O
lithium	I-Treatment
carbonate	I-Treatment
therapy	I-Treatment
.	O

acute	I-Problem
renal	I-Problem
failure	I-Problem
most	O
likely	O
was	O
secondary	O
to	O
the	O
nephrotoxic	O
effect	O
of	O
captopril	I-Treatment
on	O
chronically	I-Problem
hypoperfused	I-Problem
kidneys	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
radiotherapy	I-Treatment
-	I-Treatment
enhanced	I-Treatment
aminoglutethimide	I-Treatment
skin	I-Problem
toxicity	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
metastatic	I-Problem
breast	I-Problem
cancer	I-Problem
.	O

clinicians	O
should	O
also	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
serotonin	I-Problem
syndrome	I-Problem
when	O
encountering	O
a	I-Background
patient	I-Background
taking	O
serotonergic	I-Treatment
drugs	I-Treatment
who	O
presents	O
with	O
characteristic	O
symptoms	O
of	O
serotonin	O
syndrome	O
.	O

such	O
a	O
rapid	O
and	O
relentless	O
progression	O
of	O
methyldopa	I-Treatment
-	O
induced	O
liver	I-Problem
injury	I-Problem
is	O
undoubtedly	O
rare	O
,	O
but	O
it	O
may	O
be	O
prevented	O
by	O
careful	O
supervision	O
of	O
patients	O
who	O
exhibit	O
liver	O
function	O
abnormalities	O
early	O
in	O
the	O
course	O
of	O
therapy	O
.	O

in	O
eight	O
patients	I-Background
,	O
a	O
mean	I-Problem
decrease	I-Problem
in	I-Problem
serum	I-Problem
na	I-Test
+	I-Test
of	I-Problem
8	I-Problem
.	I-Problem
25	I-Problem
+	I-Problem
/	I-Problem
-	I-Problem
3	I-Problem
.	I-Problem
2	I-Problem
meq	I-Problem
/	I-Problem
l	I-Problem
was	O
observed	O
after	O
a	I-Treatment
single	I-Treatment
200	I-Treatment
mg	I-Treatment
intravenous	I-Treatment
dose	I-Treatment
of	I-Treatment
lorcainide	I-Treatment
.	O

nitrendipine	I-Treatment
-	O
induced	O
gingival	I-Problem
hyperplasia	I-Problem
.	O

extensive	O
immunological	I-Test
investigations	I-Test
were	O
performed	O
in	O
a	I-Background
patient	I-Background
with	I-Background
definite	I-Background
seronegative	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
who	O
developed	O
hypogammaglobulinemia	I-Problem
in	O
the	O
course	O
of	O
gold	I-Treatment
therapy	I-Treatment
.	O

one	O
case	O
of	O
tacrolimus	I-Treatment
-	O
induced	O
hepatic	I-Problem
vod	I-Problem
developing	O
after	I-Treatment
lung	I-Treatment
transplantation	I-Treatment
(	I-Treatment
lt	I-Treatment
)	I-Treatment
has	O
been	O
recently	O
reported	O
.	O

we	O
describe	O
a	O
case	O
of	O
an	I-Background
nhl	I-Problem
patient	I-Background
who	O
received	O
rituximab	I-Treatment
and	O
developed	O
symptomatic	I-Problem
,	I-Problem
biopsy	I-Problem
-	I-Problem
proven	I-Problem
multinodular	I-Problem
bronchiolitis	I-Problem
obliterans	I-Problem
with	I-Problem
organizing	I-Problem
pneumonia	I-Problem
(	I-Problem
boop	I-Problem
)	I-Problem
.	O

we	O
describe	O
a	O
case	O
of	O
tdp	I-Problem
caused	O
by	O
a	O
drug	O
interaction	O
in	O
a	O
76	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
taking	O
long	I-Treatment
-	I-Treatment
term	I-Treatment
disopyramide	I-Treatment
after	O
she	O
was	O
given	O
clarithromycin	I-Treatment
concomitantly	O
for	O
chronic	I-Problem
bronchitis	I-Problem
.	O

thus	O
,	O
clinical	O
recognition	O
of	O
sleep	I-Problem
disordered	I-Problem
breathing	I-Problem
should	O
be	O
taken	O
into	O
account	O
when	O
rheumatoid	I-Problem
arthritis	I-Problem
patients	I-Background
are	O
to	O
be	O
treated	O
with	O
infliximab	I-Treatment
.	O

we	O
present	O
a	O
case	O
of	O
a	O
sustained	I-Problem
monomorphic	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
following	O
adenosine	I-Treatment
infusion	I-Treatment
.	O

provocation	O
of	O
non	I-Problem
-	I-Problem
convulsive	I-Problem
status	I-Problem
epilepticus	I-Problem
by	O
tiagabine	I-Treatment
in	O
three	O
adolescent	I-Background
patients	I-Background
.	O

we	O
recommend	O
that	O
a	O
tma	I-Test
in	O
association	O
with	O
quinine	O
be	O
consistently	O
referred	O
to	O
as	O
quinine	I-Treatment
-	I-Problem
associated	I-Problem
thrombotic	I-Problem
microangiopathy	I-Problem
(	I-Problem
quinine	I-Problem
-	I-Problem
tma	I-Problem
)	I-Problem
to	O
better	O
distinguish	O
this	O
entity	O
from	O
idiopathic	O
ttp	O
.	O

the	O
authors	O
describe	O
a	O
case	O
of	O
oral	I-Problem
-	I-Problem
facial	I-Problem
dyskinesia	I-Problem
that	O
occurred	O
after	O
discontinuation	I-Treatment
of	I-Treatment
amoxapine	I-Treatment
,	I-Treatment
and	I-Treatment
antidepressant	I-Treatment
which	I-Treatment
may	I-Treatment
also	I-Treatment
have	I-Treatment
neuroleptic	I-Treatment
effects	I-Treatment
.	O

a	I-Background
34	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
hiv	I-Problem
-	I-Background
infected	I-Background
man	I-Background
who	O
had	O
recently	O
initiated	I-Treatment
efavirenz	I-Treatment
-	I-Treatment
based	I-Treatment
antiretroviral	I-Treatment
therapy	I-Treatment
was	O
diagnosed	O
with	O
disseminated	I-Problem
histoplasma	I-Problem
capsulatum	I-Problem
infection	I-Problem
.	O

aminoglutethimide	I-Treatment
was	I-Treatment
discontinued	I-Treatment
until	I-Treatment
completion	I-Treatment
of	I-Treatment
radiotherapy	I-Treatment
,	O
and	O
the	I-Problem
rash	I-Problem
resolved	I-Problem
.	O

we	O
explored	O
ophthalmic	I-Problem
and	I-Problem
neurologic	I-Problem
findings	I-Problem
in	O
two	O
children	I-Background
who	O
have	O
been	O
exposed	I-Treatment
prenatally	I-Treatment
to	I-Treatment
vgb	I-Treatment
.	O

two	O
cases	I-Background
are	O
described	O
of	O
chronic	I-Problem
schizophrenic	I-Problem
patients	O
maintained	O
on	O
depot	I-Treatment
neuroleptics	I-Treatment
,	O
who	O
developed	O
severe	I-Problem
extrapyramidal	I-Problem
symptoms	I-Problem
following	O
a	O
period	O
of	O
heavy	I-Treatment
betel	I-Treatment
nut	I-Treatment
consumption	I-Treatment
.	O

five	O
personal	O
observations	O
of	O
an	O
acute	I-Problem
amnestic	I-Problem
episode	I-Problem
in	O
younger	I-Background
individuals	I-Background
after	O
intake	I-Treatment
of	I-Treatment
clioquinol	I-Treatment
are	O
described	O
together	O
with	O
three	O
observations	O
from	O
the	O
medical	O
literature	O
.	O

in	O
a	I-Background
patient	I-Background
with	I-Background
severe	I-Background
renovascular	I-Problem
hypertension	I-Problem
,	O
nonoliguric	I-Problem
acute	I-Problem
renal	I-Problem
failure	I-Problem
developed	O
after	O
she	I-Background
received	O
captopril	I-Treatment
treatment	O
.	O

a	I-Background
30	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
pharmacist	I-Background
suffered	O
from	O
acute	I-Problem
allergic	I-Problem
contact	I-Problem
dermatitis	I-Problem
due	O
to	O
4	I-Treatment
-	I-Treatment
chloro	I-Treatment
-	I-Treatment
7	I-Treatment
-	I-Treatment
nitrobenzofurazan	I-Treatment
(	I-Treatment
nbd	I-Treatment
-	I-Treatment
cl	I-Treatment
)	I-Treatment
.	O

conclusion	O
:	O
this	O
rare	O
case	O
of	O
ptu	I-Treatment
-	O
induced	O
anca	I-Problem
-	I-Problem
associated	I-Problem
vasculitis	I-Problem
manifested	I-Problem
with	I-Problem
ototoxicity	I-Problem
in	I-Problem
combination	I-Problem
with	I-Problem
systemic	I-Problem
involvement	I-Problem
.	O

a	O
15	I-Other
-	I-Other
year	I-Other
follow	O
-	O
up	O
of	O
phenytoin	I-Treatment
-	O
induced	O
unilateral	I-Problem
gingival	I-Problem
hyperplasia	I-Problem
:	O
a	O
case	O
report	O
.	O

we	O
describe	O
two	O
patients	I-Background
with	I-Background
rheumatoid	I-Problem
factor	I-Problem
-	I-Problem
positive	I-Problem
,	I-Problem
polyarticular	I-Problem
-	I-Problem
onset	I-Problem
juvenile	I-Problem
rheumatoid	I-Problem
arthritis	I-Problem
in	O
whom	O
accelerated	I-Problem
nodulosis	I-Problem
developed	O
during	O
methotrexate	I-Treatment
therapy	I-Treatment
.	O

the	O
clinical	I-Test
data	O
suggest	O
that	O
anterior	I-Problem
lumbosacral	I-Problem
radiculopathy	I-Problem
is	O
also	O
a	O
type	O
of	O
neurologic	O
complication	O
associated	O
with	O
intrathecal	I-Treatment
methotrexate	I-Treatment
treatment	O
.	O

at	O
admission	O
simvastatin	I-Treatment
and	I-Treatment
all	I-Treatment
antiviral	I-Treatment
drugs	I-Treatment
were	O
discontinued	O
because	O
toxicity	I-Problem
due	O
to	O
a	O
drug	O
-	O
drug	O
interaction	O
was	O
suspected	O
.	O

a	O
major	O
limitation	O
in	O
the	O
use	O
of	O
amphotericin	I-Treatment
b	I-Treatment
is	O
its	O
potential	O
to	O
cause	O
nephrotoxicity	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
hyperpigmentation	I-Problem
due	O
to	O
bleomycin	I-Treatment
treatment	O
in	O
a	I-Background
patient	I-Background
with	I-Background
acquired	I-Problem
immune	I-Problem
deficiency	I-Problem
syndrome	I-Problem
(	I-Background
aids	I-Background
)	I-Background
.	O

azathioprine	I-Treatment
-	O
induced	O
myelosuppression	I-Problem
due	O
to	O
thiopurine	I-Problem
methyltransferase	I-Problem
deficiency	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
autoimmune	I-Problem
hepatitis	I-Problem
.	O

captopril	I-Treatment
-	O
associated	O
"	O
pseudocholangitis	I-Problem
'	O
.	O

a	O
case	O
of	O
toxic	I-Problem
hepatitis	I-Problem
caused	O
by	O
combination	I-Treatment
therapy	I-Treatment
with	I-Treatment
methotrexate	I-Treatment
and	I-Treatment
etretinate	I-Treatment
in	O
the	O
treatment	O
of	O
severe	I-Problem
psoriasis	I-Problem
is	O
presented	O
in	O
a	I-Background
47	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
.	O

carboplatin	I-Treatment
hypersensitivity	O
presenting	O
as	O
coronary	I-Problem
vasospasm	I-Problem
-	O
a	O
case	O
report	O
.	O

severe	I-Problem
hypoglycemia	I-Problem
from	O
helicobacter	I-Treatment
pylori	I-Treatment
triple	I-Treatment
-	I-Treatment
drug	I-Treatment
therapy	I-Treatment
and	I-Treatment
insulin	I-Treatment
detemir	I-Treatment
drug	I-Treatment
interaction	I-Treatment
.	O

the	O
aim	O
of	O
this	O
study	I-Test
was	O
to	O
describe	O
the	O
occurrence	O
of	O
acute	I-Problem
coronary	I-Problem
syndromes	I-Problem
in	O
3	O
cases	O
of	O
rituximab	I-Treatment
infusions	I-Treatment
.	O

acute	I-Treatment
pharmacokinetic	I-Treatment
and	I-Treatment
pharmacodynamic	I-Treatment
interactions	I-Treatment
between	I-Treatment
phenytoin	I-Treatment
and	I-Treatment
isradipine	I-Treatment
were	O
probably	O
responsible	O
for	O
the	I-Problem
lethargy	I-Problem
,	I-Problem
dysarthria	I-Problem
,	I-Problem
ataxia	I-Problem
,	I-Problem
and	I-Problem
weakness	I-Problem
our	O
patient	O
developed	O
.	O

a	I-Background
patient	I-Background
suffering	I-Background
from	I-Background
a	I-Background
rare	I-Background
enzyme	I-Problem
deficiency	I-Problem
developed	O
a	O
malignant	I-Problem
neuroleptic	I-Problem
syndrome	I-Problem
after	O
having	O
been	O
treated	O
with	O
one	I-Treatment
single	I-Treatment
dose	I-Treatment
of	I-Treatment
haloperidol	I-Treatment
.	O

captopril	I-Treatment
is	O
known	O
to	O
be	O
associated	O
with	O
dermatologic	I-Problem
,	I-Problem
hematologic	I-Problem
,	I-Problem
and	I-Problem
pulmonary	I-Problem
adverse	I-Problem
effects	I-Problem
.	O

other	O
upper	I-Problem
tract	I-Problem
neoplasms	I-Problem
after	O
cyclophosphamide	I-Treatment
are	O
reviewed	O
.	O

four	O
patients	I-Background
receiving	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
tamoxifen	I-Treatment
for	I-Treatment
greater	I-Treatment
than	I-Treatment
1	I-Other
year	I-Other
have	O
demonstrated	O
similar	O
retinal	I-Problem
changes	I-Problem
.	O

retinal	I-Problem
dysfunction	I-Problem
and	I-Problem
anterior	I-Problem
segment	I-Problem
deposits	I-Problem
in	O
a	O
patient	I-Background
treated	O
with	O
rifabutin	I-Treatment
.	O

carbamazepine	I-Treatment
induced	O
right	I-Problem
bundle	I-Problem
branch	I-Problem
block	I-Problem
in	O
a	O
greenlandic	I-Background
patient	I-Background
.	O

results	O
:	O
both	I-Background
cases	I-Background
presented	O
here	O
describe	O
corneal	I-Problem
ulcers	I-Problem
that	I-Problem
persisted	I-Problem
and	O
showed	O
signs	O
of	O
worsening	O
during	O
weeks	I-Treatment
of	I-Treatment
frequent	I-Other
topical	I-Treatment
dosing	I-Treatment
with	I-Treatment
moxifloxacin	I-Treatment
.	O

we	O
describe	O
a	I-Background
case	I-Background
of	O
poisoning	I-Problem
with	O
3	I-Treatment
,	I-Treatment
4	I-Treatment
-	I-Treatment
methylenedioxymet	I-Treatment
-	I-Treatment
amphetamine	I-Treatment
ecstasy	I-Treatment
that	O
presented	O
with	O
all	O
the	O
features	O
suggestive	O
of	O
a	O
fatal	O
outcome	O
,	O
including	O
a	O
creatinine	I-Test
phosphokinase	I-Test
level	I-Test
markedly	I-Problem
higher	I-Problem
than	O
any	O
previously	O
reported	O
.	O

ramipril	I-Treatment
-	O
induced	O
cutaneous	I-Problem
vasculitis	I-Problem
is	O
particularly	O
rare	O
and	O
our	O
case	O
was	O
atypical	O
because	O
the	I-Background
patient	I-Background
had	I-Background
tolerated	I-Problem
lisinopril	I-Problem
before	I-Background
.	O

to	O
date	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
what	O
appears	O
to	O
be	O
isolated	I-Problem
thrombocytopenia	I-Problem
associated	O
with	O
lansoprazole	I-Treatment
.	O

a	I-Background
7	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
developed	O
diabetes	I-Problem
mellitus	I-Problem
and	I-Problem
exocrine	I-Problem
pancreatic	I-Problem
insufficiency	I-Problem
after	O
3	I-Other
.	I-Other
5	I-Other
years	I-Other
of	I-Treatment
almost	I-Treatment
continuous	I-Treatment
treatment	I-Treatment
with	I-Treatment
azathioprine	I-Treatment
and	I-Treatment
/	I-Treatment
or	I-Treatment
prednisone	I-Treatment
for	O
idiopathic	I-Problem
auto	I-Problem
-	I-Problem
immune	I-Problem
haemolytic	I-Problem
anaemia	I-Problem
.	O

the	O
human	O
immunodeficiency	O
virus	O
protease	O
inhibitor	O
ritonavir	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
cytochrome	O
p450	O
3a4	O
enzyme	O
,	O
and	O
ritonavir	I-Treatment
'	I-Treatment
s	I-Treatment
concomitant	I-Treatment
administration	I-Treatment
with	I-Treatment
the	I-Treatment
substrates	I-Treatment
of	I-Treatment
this	I-Treatment
enzyme	I-Treatment
may	O
lead	O
to	O
dangerous	O
drug	I-Problem
interactions	I-Problem
.	O

there	O
remains	O
a	O
paucity	O
of	O
information	O
pertaining	O
to	O
alternative	O
anticoagulation	O
strategies	O
for	O
use	O
during	O
cardiopulmonary	O
bypass	O
concomitant	O
with	O
heparin	I-Treatment
-	O
induced	O
thrombocytopenia	I-Problem
,	O
especially	O
in	O
children	I-Background
.	O

unintended	I-Treatment
exposure	I-Treatment
to	I-Treatment
acyclovir	I-Treatment
early	O
in	O
pregnancy	O
,	O
which	O
is	O
not	O
uncommon	O
,	O
may	O
cause	O
excessive	I-Problem
maternal	I-Problem
and	I-Problem
physician	I-Problem
anxiety	I-Problem
.	O

the	O
ace	I-Treatment
inhibitors	I-Treatment
can	O
cause	O
various	O
skin	I-Problem
side	I-Problem
effects	I-Problem
;	O
however	O
,	O
it	O
rarely	O
causes	O
cutaneous	O
vasculitis	O
.	O

salicylate	O
intoxication	O
was	O
excluded	O
,	O
and	O
theophylline	I-Treatment
was	O
finally	O
incriminated	O
.	O

we	O
present	O
a	O
case	O
of	O
stroke	I-Problem
after	O
ppa	I-Treatment
ingestion	O
that	O
occurred	O
4	I-Other
months	I-Other
after	O
the	O
recall	O
in	O
an	I-Background
8	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
on	I-Background
chronic	I-Background
peritoneal	I-Background
dialysis	I-Background
.	O

cerebral	I-Problem
infarcts	I-Problem
in	O
a	O
pediatric	I-Background
patient	I-Background
secondary	O
to	O
phenylpropanolamine	I-Treatment
,	O
a	O
recalled	O
medication	O
.	O

to	O
our	O
knowledge	O
,	O
our	O
report	O
is	O
one	O
of	O
the	O
first	O
on	O
shock	I-Problem
and	I-Problem
angio	I-Problem
-	I-Problem
oedema	I-Problem
from	O
irbesartan	I-Treatment
.	O

clinical	O
course	O
of	O
macular	I-Problem
edema	I-Problem
in	O
two	O
cases	I-Background
of	O
interferon	I-Treatment
-	O
associated	O
retinopathy	I-Problem
observed	O
by	O
optical	O
coherence	I-Test
tomography	I-Test
.	O

this	O
report	O
describes	O
a	I-Background
13	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
with	I-Background
a	I-Background
right	I-Problem
frontal	I-Problem
high	I-Problem
-	I-Problem
grade	I-Problem
glioma	I-Problem
and	I-Background
complex	I-Problem
partial	I-Problem
seizures	I-Problem
who	O
developed	O
localized	I-Problem
purpura	I-Problem
after	O
23	I-Problem
months	I-Problem
of	I-Treatment
lamotrigine	I-Treatment
monotherapy	I-Treatment
.	O

patient	I-Background
1	I-Background
presented	O
bilateral	I-Problem
ballism	I-Problem
1	O
week	O
after	O
intravenous	I-Treatment
heroin	I-Treatment
injection	I-Treatment
.	O

he	I-Background
became	O
hyperkalemic	I-Problem
on	O
rechallenge	O
with	O
timolol	I-Treatment
and	O
normokalemic	O
following	O
its	O
withdrawal	O
.	O

ischaemic	I-Problem
colitis	I-Problem
in	O
a	I-Background
patient	I-Background
taking	O
meloxicam	I-Treatment
.	O

leflunomide	I-Treatment
-	O
associated	O
infections	I-Problem
in	O
rheumatoid	I-Problem
arthritis	I-Problem
.	O

cutaneous	I-Problem
sarcoidosis	I-Problem
during	O
interferon	I-Treatment
alfa	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
treatment	I-Treatment
of	I-Treatment
hepatitis	I-Problem
c	I-Problem
virus	I-Problem
infection	I-Problem
:	O
two	O
cases	I-Background
.	O

acute	I-Problem
renal	I-Problem
failure	I-Problem
in	O
a	I-Background
child	I-Background
associated	O
with	O
acyclovir	I-Treatment
.	O

bevacizumab	I-Treatment
is	I-Treatment
a	I-Treatment
recently	I-Treatment
developed	I-Treatment
monoclonal	I-Treatment
antibody	I-Treatment
against	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
used	O
to	O
inhibit	O
angiogenesis	I-Problem
.	O

two	O
patients	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
developed	O
evidence	O
of	O
hepatotoxicity	I-Problem
while	O
receiving	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
.	O

fatal	I-Problem
venous	I-Problem
thrombembolism	I-Problem
complicating	O
imatinib	I-Treatment
therapy	O
in	O
a	I-Background
patient	I-Background
with	I-Background
metastatic	I-Problem
gastrointestinal	I-Problem
stromal	I-Problem
tumor	I-Problem
.	O

however	O
,	O
acute	I-Problem
cardiomyopathy	I-Problem
and	I-Problem
pericarditis	I-Problem
secondary	O
to	O
methylphenidate	I-Treatment
use	O
has	O
been	O
rarely	O
reported	O
.	O

propoxyphene	I-Treatment
-	O
induced	O
wide	I-Problem
qrs	I-Problem
complex	I-Problem
dysrhythmia	I-Problem
responsive	O
to	O
sodium	O
bicarbonate	O
-	O
-	O
a	O
case	O
report	O
.	O

simvastatin	I-Problem
plasma	I-Test
concentration	I-Test
increased	I-Problem
30	I-Problem
times	I-Problem
in	I-Background
this	I-Background
patient	I-Background
and	O
statin	I-Treatment
induced	O
muscle	I-Problem
toxicity	I-Problem
is	O
related	O
to	O
the	O
concentration	O
of	O
the	O
statin	O
in	I-Test
blood	I-Test
.	O

poorly	I-Problem
controlled	I-Problem
hypertension	I-Problem
in	O
a	I-Background
painter	I-Background
with	O
chronic	O
lead	I-Treatment
toxicity	O
.	O

it	O
was	O
concluded	O
that	O
anca	O
is	O
closely	O
related	O
to	O
the	O
pathogenesis	O
of	O
crescentic	O
glomerulonephritis	O
and	O
that	O
treatment	O
with	O
ptu	I-Treatment
appeared	O
to	O
induce	O
anca	I-Problem
.	O

gelatinous	I-Problem
transformation	I-Problem
of	I-Problem
bone	I-Problem
marrow	I-Problem
following	O
chemotherapy	I-Treatment
for	O
myeloma	I-Problem
.	O

we	O
discuss	O
a	I-Background
case	I-Background
with	O
significant	I-Problem
progressive	I-Problem
peripheral	I-Problem
neurological	I-Problem
deterioration	I-Problem
following	O
administration	O
of	O
both	O
fludarabine	I-Treatment
and	I-Treatment
cytarabine	I-Treatment
as	O
part	O
of	O
the	O
fla	I-Treatment
(	I-Treatment
fludarabine	I-Treatment
and	I-Treatment
cytarabine	I-Treatment
)	I-Treatment
regime	I-Treatment
.	O

the	O
course	O
of	O
delirium	I-Problem
due	O
to	O
lithium	I-Treatment
intoxication	I-Treatment
.	O

preadmission	I-Treatment
warfarin	I-Treatment
use	O
was	O
not	O
associated	O
with	O
any	I-Problem
secondary	I-Problem
intracerebral	I-Problem
hemorrhage	I-Problem
(	I-Problem
or	I-Problem
,	I-Problem
1	I-Problem
.	I-Problem
2	I-Problem
;	I-Problem
95	I-Problem
%	I-Problem
ci	I-Problem
,	I-Problem
0	I-Problem
.	I-Problem
7	I-Problem
to	I-Problem
2	I-Problem
.	I-Problem
2	I-Problem
)	I-Problem
,	I-Problem
symptomatic	I-Problem
intracerebral	I-Problem
hemorrhage	I-Problem
(	I-Problem
or	I-Problem
,	I-Problem
1	I-Problem
.	I-Problem
1	I-Problem
;	I-Problem
95	I-Problem
%	I-Problem
ci	I-Problem
,	I-Problem
0	I-Problem
.	I-Problem
5	I-Problem
to	I-Problem
2	I-Problem
.	I-Problem
3	I-Problem
)	I-Problem
,	I-Problem
or	I-Problem
gastrointestinal	I-Problem
hemorrhage	I-Problem
(	I-Problem
or	I-Problem
,	I-Problem
1	I-Problem
.	I-Problem
1	I-Problem
;	I-Problem
95	I-Problem
%	I-Problem
ci	I-Problem
,	I-Problem
0	I-Problem
.	I-Problem
2	I-Problem
to	I-Problem
5	I-Problem
.	I-Problem
6	I-Problem
)	I-Problem
.	O

in	O
this	O
case	O
of	O
a	O
possible	O
drug	O
-	O
drug	O
interaction	O
between	O
ifn	I-Treatment
alfa	I-Treatment
11	I-Treatment
mu	I-Treatment
tiw	I-Treatment
and	O
gemfibrozil	I-Treatment
600	I-Treatment
mg	I-Treatment
bid	I-Treatment
in	O
a	I-Background
patient	I-Background
undergoing	I-Background
treatment	I-Background
for	I-Background
ifn	I-Problem
-	I-Problem
induced	I-Problem
hypertriglyceridemia	I-Problem
,	O
the	O
naranjo	I-Problem
adverse	I-Problem
drug	I-Problem
reactions	I-Problem
(	O
adr	O
)	I-Test
probability	I-Test
scale	I-Test
score	I-Test
was	O
7	O
(	O
ie	O
,	O
adr	O
possibly	O
related	O
to	O
treatment	O
)	O
.	O

stupor	I-Problem
from	O
lamotrigine	I-Treatment
toxicity	O
.	O

autopsy	O
findings	O
were	O
consistent	O
with	O
bleomycin	I-Treatment
and	I-Treatment
oxygen	I-Treatment
-	O
induced	O
pulmonary	I-Problem
damage	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
vitiligo	I-Problem
that	O
occurred	O
during	I-Treatment
the	I-Other
second	I-Other
month	I-Other
of	I-Treatment
interferon	I-Treatment
alpha	I-Treatment
2a	I-Treatment
therapy	I-Treatment
for	O
chronic	I-Problem
active	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

vardenafil	I-Treatment
is	I-Treatment
a	I-Treatment
new	I-Treatment
oral	I-Treatment
phosphodiesterase	I-Treatment
inhibitor	I-Treatment
used	O
for	O
erectile	I-Problem
dysfunction	I-Problem
.	O

conclusion	O
:	O
a	I-Background
patient	I-Background
with	I-Background
chf	I-Problem
and	I-Background
esrd	I-Problem
developed	O
myoclonic	I-Problem
muscle	I-Problem
spasms	I-Problem
after	O
receiving	O
dobutamine	I-Treatment
by	I-Treatment
continuous	I-Other
i	I-Treatment
.	I-Treatment
v	I-Treatment
.	O

nail	I-Problem
-	I-Problem
changes	I-Problem
induced	O
by	O
penicillamine	I-Treatment
.	O

the	I-Background
fourth	I-Background
patient	I-Background
showed	O
rls	I-Problem
symptoms	I-Problem
that	O
were	O
initially	O
caused	O
by	O
a	O
20	I-Treatment
-	I-Treatment
mg	I-Treatment
daily	I-Other
olanzapine	I-Treatment
dosage	I-Treatment
and	O
were	O
later	O
mitigated	O
when	O
olanzapine	O
was	O
reduced	O
and	O
ropinirole	O
was	O
administered	O
.	O

naproxen	I-Treatment
-	O
associated	O
sudden	I-Problem
sensorineural	I-Problem
hearing	I-Problem
loss	I-Problem
.	O

retinoic	I-Treatment
acid	I-Treatment
may	O
increase	O
the	O
risk	O
of	O
bone	I-Problem
marrow	I-Problem
transplant	I-Problem
nephropathy	I-Problem
.	O

a	O
review	O
of	O
published	O
case	O
reports	O
showed	O
a	I-Problem
short	I-Problem
time	I-Problem
to	I-Problem
onset	I-Problem
of	I-Problem
symptoms	I-Problem
following	O
the	O
introduction	I-Treatment
of	I-Treatment
linezolid	I-Treatment
,	I-Treatment
generally	I-Treatment
within	I-Other
1	I-Other
-	I-Other
3	I-Other
days	I-Other
.	O

intrathecal	I-Treatment
chemotherapy	I-Treatment
with	I-Treatment
methotrexate	I-Treatment
or	I-Treatment
cytosine	I-Treatment
arabinoside	I-Treatment
is	O
the	O
standard	O
approach	O
to	O
prophylaxis	O
and	O
treatment	O
of	O
central	I-Problem
nervous	I-Problem
system	I-Problem
leukemia	I-Problem
in	O
children	I-Background
.	O

the	O
following	O
day	O
,	O
the	O
patient	I-Background
developed	O
anxiety	I-Problem
,	I-Problem
panic	I-Problem
attacks	I-Problem
,	I-Problem
tremors	I-Problem
,	I-Problem
tachycardia	I-Problem
,	I-Problem
and	I-Problem
hypertension	I-Problem
that	O
persisted	O
throughout	O
linezolid	I-Treatment
treatment	O
.	O

although	O
transient	I-Problem
increases	I-Problem
in	I-Problem
ectopy	I-Problem
after	O
bretylium	I-Treatment
therapy	O
have	O
been	O
described	O
,	O
presumably	O
due	O
to	O
catecholamine	O
release	O
,	O
the	O
occurrence	O
of	O
life	I-Problem
-	I-Problem
threatening	I-Problem
ventricular	I-Problem
arrhythmia	I-Problem
leading	I-Problem
to	I-Problem
cardiac	I-Problem
arrest	I-Problem
has	O
not	O
previously	O
been	O
emphasized	O
.	O

we	O
report	O
three	O
cases	I-Background
of	O
ifn	I-Treatment
beta	I-Treatment
induced	O
hepatitis	I-Problem
in	I-Problem
ms	I-Problem
and	O
discuss	O
the	O
pathology	I-Test
findings	O
and	O
possible	O
mechanisms	O
of	O
drug	O
-	O
induced	O
liver	O
injury	O
.	O

rta	I-Problem
is	O
one	O
type	O
of	O
nephrotoxicity	I-Problem
induced	O
by	O
fk506	I-Treatment
,	O
and	O
it	O
is	O
reversible	O
in	O
mild	O
cases	O
when	O
appropriately	O
treated	O
.	O

the	O
most	O
common	O
side	O
effects	O
associated	O
with	O
amifostine	I-Treatment
are	O
nausea	I-Problem
,	I-Problem
vomiting	I-Problem
,	I-Problem
hypotension	I-Problem
,	I-Problem
hypocalcemia	I-Problem
and	O
allergic	I-Problem
reactions	I-Problem
.	I-Problem

nonconvulsive	I-Problem
status	I-Problem
epilepticus	I-Problem
due	O
to	O
ifosfamide	I-Treatment
.	O

clinical	O
experience	O
in	O
infectious	I-Problem
patients	I-Background
has	O
shown	O
that	O
oral	I-Treatment
telithromycin	I-Treatment
800	I-Treatment
mg	I-Treatment
once	I-Other
daily	I-Other
for	I-Treatment
5	I-Other
-	I-Other
10	I-Other
days	I-Other
is	O
effective	O
for	O
the	O
treatment	O
of	O
community	I-Problem
-	I-Problem
acquired	I-Problem
upper	I-Problem
and	I-Problem
lower	I-Problem
respiratory	I-Problem
tract	I-Problem
infections	I-Problem
.	O

five	O
patients	I-Background
receiving	O
fluoxetine	I-Treatment
for	O
the	O
treatment	O
of	O
obsessive	O
compulsive	O
disorder	O
or	O
major	O
depression	O
developed	O
akathisia	I-Problem
.	O

this	O
fourth	O
type	O
of	O
cutaneous	O
minocycline	I-Treatment
hyperpigmentation	I-Problem
may	O
be	O
a	O
variant	O
of	O
type	O
i	O
,	O
but	O
based	O
on	O
clinical	O
,	O
pathological	O
and	O
microanalytical	O
differences	O
,	O
appears	O
to	O
be	O
a	O
new	O
entity	O
.	O

phenytoin	I-Treatment
/	I-Treatment
isradipine	I-Treatment
interaction	I-Treatment
causing	O
severe	O
neurologic	I-Problem
toxicity	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
torsade	I-Problem
de	I-Problem
pointes	I-Problem
following	O
a	I-Treatment
single	I-Treatment
oral	I-Treatment
dose	I-Treatment
of	I-Treatment
amiodarone	I-Treatment
(	I-Treatment
1400	I-Treatment
mg	I-Treatment
or	I-Treatment
30	I-Treatment
mg	I-Treatment
kg	I-Treatment
-	I-Treatment
1	I-Treatment
)	I-Treatment
administered	O
after	O
short	O
intravenous	O
loading	O
for	O
prevention	I-Problem
of	I-Problem
paroxysmal	I-Problem
atrial	I-Problem
flutter	I-Problem
.	O

traditionally	O
,	O
children	I-Background
with	I-Background
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
receive	O
prednisone	I-Treatment
,	O
as	O
part	O
of	O
multiagent	O
remission	O
-	O
induction	O
chemotherapy	O
.	O

propylthiouracil	I-Treatment
-	O
induced	O
sensorineural	I-Problem
hearing	I-Problem
loss	I-Problem
associated	I-Problem
with	I-Problem
antineutrophil	I-Problem
cytoplasmic	I-Problem
antibodies	I-Problem
.	O

acute	I-Problem
respiratory	I-Problem
depression	I-Problem
as	O
a	O
complication	O
of	O
nebulised	I-Treatment
morphine	I-Treatment
.	O

we	O
report	O
on	O
a	I-Background
patient	I-Background
with	I-Background
an	I-Background
embryonal	I-Problem
teratocarcinoma	I-Problem
of	I-Problem
the	I-Problem
testicle	I-Problem
who	O
had	O
the	O
syndrome	I-Problem
of	I-Problem
inappropriate	I-Problem
secretion	I-Problem
of	I-Problem
antidiuretic	I-Problem
hormone	I-Problem
after	O
receiving	O
a	I-Treatment
high	I-Treatment
dose	I-Treatment
of	I-Treatment
vinblastine	I-Treatment
.	O

methotrexate	I-Treatment
-	O
induced	O
liver	I-Problem
cirrhosis	I-Problem
.	O

a	O
case	O
of	O
oculogyric	I-Problem
crisis	I-Problem
induced	O
by	O
metoclopramide	I-Treatment
is	O
described	O
in	O
this	O
paper	O
.	O

early	I-Problem
-	I-Problem
onset	I-Problem
acute	I-Problem
transverse	I-Problem
myelitis	I-Problem
following	O
hepatitis	I-Treatment
b	I-Treatment
vaccination	I-Treatment
and	O
respiratory	O
infection	O
:	O
case	I-Background
report	O
.	O

the	O
pro	I-Problem
-	I-Problem
arrhythmic	I-Problem
effects	I-Problem
of	O
procainamide	I-Treatment
may	O
be	O
explained	O
on	O
the	O
basis	O
of	O
both	O
its	O
vagolytic	O
action	O
on	O
the	O
atrioventricular	O
node	O
as	O
well	O
as	O
by	O
prolongation	O
of	O
refractoriness	O
in	O
the	O
accessory	O
pathway	O
.	O

we	O
present	O
the	O
management	O
of	O
agranulocytosis	I-Problem
and	I-Problem
neutropenic	I-Problem
sepsis	I-Problem
secondary	O
to	O
carbimazole	I-Treatment
with	I-Treatment
recombinant	I-Treatment
human	I-Treatment
granulocyte	I-Treatment
colony	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
(	I-Treatment
g	I-Treatment
-	I-Treatment
csf	I-Treatment
)	I-Treatment
.	O

cutaneous	I-Problem
mycobacterial	I-Problem
infection	I-Problem
post	O
intravesical	I-Treatment
bcg	I-Treatment
installation	I-Treatment
.	O

on	O
day	O
4	O
,	O
following	O
3	I-Treatment
doses	I-Treatment
of	I-Treatment
dalteparin	I-Treatment
,	O
the	I-Background
patient	I-Background
developed	O
acute	I-Problem
respiratory	I-Problem
distress	I-Problem
attributable	I-Problem
to	I-Problem
a	I-Problem
massive	I-Problem
right	I-Problem
hemothorax	I-Problem
confirmed	O
by	O
computed	O
tomography	I-Test
pulmonary	O
angiography	I-Test
(	O
ctpa	I-Test
)	O
and	O
intercostal	O
drainage	O
of	O
1500	O
ml	O
of	O
frank	O
blood	O
.	O

a	O
4	O
-	O
month	O
regimen	O
of	O
gatifloxacin	I-Treatment
with	O
rifampin	I-Treatment
,	O
isoniazid	I-Treatment
,	O
and	O
pyrazinamide	I-Treatment
is	O
being	O
evaluated	O
for	O
the	O
treatment	O
of	O
tuberculosis	I-Problem
in	O
a	O
phase	O
3	O
randomized	O
controlled	O
trial	O
(	O
oflotub	O
)	O
.	O

we	O
postulate	O
that	O
the	O
bolus	O
of	O
sulprostone	I-Treatment
resulted	O
in	O
possible	O
coronary	I-Problem
spasm	I-Problem
that	I-Problem
resulted	I-Problem
in	I-Problem
cardiac	I-Problem
arrest	I-Problem
.	O

a	O
72	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
a	I-Background
history	I-Background
of	I-Background
thyrotoxicosis	I-Problem
presented	O
with	O
sore	I-Problem
throat	I-Problem
and	I-Problem
fever	I-Problem
two	I-Other
weeks	I-Other
after	I-Treatment
starting	I-Treatment
carbimazole	I-Treatment
.	O

without	O
other	O
causes	O
for	O
the	O
hyponatremia	I-Problem
,	O
she	I-Background
was	O
diagnosed	O
with	O
the	O
syndrome	I-Problem
of	I-Problem
inappropriate	I-Problem
antidiuretic	I-Problem
hormone	I-Problem
,	O
presumably	O
caused	O
by	O
desmopressin	I-Treatment
.	O

fatal	I-Problem
peripheral	I-Problem
neuropathy	I-Problem
following	O
fla	I-Treatment
chemotherapy	I-Treatment
.	O

rhabdomyolysis	I-Problem
caused	O
by	O
a	O
potential	I-Treatment
sitagliptin	I-Treatment
-	I-Treatment
lovastatin	I-Treatment
interaction	I-Treatment
.	O

a	I-Background
78	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
a	I-Background
history	I-Background
of	I-Background
congestive	I-Problem
heart	I-Problem
failure	I-Problem
and	I-Background
coronary	I-Problem
artery	I-Problem
disease	I-Problem
began	O
taking	O
amiodarone	I-Treatment
to	O
suppress	O
sustained	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
.	O

a	I-Background
patient	I-Background
with	O
severe	I-Problem
cholestatic	I-Problem
jaundice	I-Problem
induced	O
by	O
captopril	I-Treatment
is	O
presented	O
.	O

three	O
distinct	O
types	O
of	O
minocycline	I-Treatment
-	O
induced	O
cutaneous	I-Problem
pigmentation	I-Problem
have	O
been	O
described	O
.	O

the	O
occurrence	O
of	O
symptoms	O
that	O
could	O
be	O
ascribed	O
to	O
an	O
acute	I-Problem
coronary	I-Problem
syndrome	I-Problem
should	O
always	O
be	O
taken	O
seriously	O
during	O
the	O
first	I-Other
rituximab	I-Treatment
infusion	I-Treatment
and	O
investigated	O
aggressively	O
.	O

antineutrophil	I-Problem
cytoplasmic	I-Test
antibody	I-Test
-	I-Problem
positive	I-Problem
crescentic	I-Problem
glomerulonephritis	I-Problem
associated	O
with	O
propylthiouracil	I-Treatment
therapy	I-Treatment
.	O

heparin	I-Treatment
-	O
induced	O
thrombocytopenia	I-Problem
is	O
a	O
rare	O
and	O
serious	O
complication	O
of	O
anticoagulation	I-Treatment
therapy	I-Treatment
.	O

iatrogenic	I-Problem
cushing	I-Problem
syndrome	I-Problem
after	O
epidural	I-Treatment
triamcinolone	I-Treatment
injections	I-Treatment
in	O
an	I-Background
hiv	I-Problem
type	I-Problem
1	I-Problem
-	I-Background
infected	I-Background
patient	I-Background
receiving	I-Treatment
therapy	I-Treatment
with	I-Treatment
ritonavir	I-Treatment
-	I-Treatment
lopinavir	I-Treatment
.	O

otolaryngologists	O
should	O
be	O
made	O
aware	O
of	O
a	O
newer	O
cause	O
of	O
nasal	I-Problem
septal	I-Problem
perforations	I-Problem
resulting	O
from	O
the	I-Treatment
more	I-Treatment
recent	I-Treatment
antiangiogenic	I-Treatment
therapy	I-Treatment
used	O
to	O
treat	O
malignancies	I-Problem
.	O

following	O
several	O
of	O
these	O
courses	O
of	O
therapy	O
,	O
respiratory	I-Problem
distress	I-Problem
occurred	O
9	I-Other
to	I-Other
12	I-Other
days	I-Other
after	O
the	I-Treatment
chlorambucil	I-Treatment
was	O
given	O
.	O

possible	O
mechanisms	O
for	O
damage	I-Problem
to	I-Problem
the	I-Problem
urothelium	I-Problem
by	O
ketamine	I-Treatment
are	O
suggested	O
.	O

persistent	I-Problem
hypoglycemia	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
diabetes	I-Problem
taking	O
etanercept	I-Treatment
for	O
the	O
treatment	O
of	O
psoriasis	I-Problem
.	O

cutaneous	I-Problem
necrosis	I-Problem
after	O
injection	I-Treatment
of	I-Treatment
polyethylene	I-Treatment
glycol	I-Treatment
-	I-Treatment
modified	I-Treatment
interferon	I-Treatment
alfa	I-Treatment
.	I-Treatment

we	O
report	O
an	O
unusual	O
case	O
of	O
simultaneous	I-Problem
transitional	I-Problem
cell	I-Problem
carcinoma	I-Problem
of	I-Problem
the	I-Problem
renal	I-Problem
pelvis	I-Problem
and	I-Problem
distal	I-Problem
ureter	I-Problem
without	I-Problem
transitional	I-Problem
cell	I-Problem
carcinoma	I-Problem
of	I-Problem
the	I-Problem
bladder	I-Problem
occurring	O
after	O
chronic	I-Other
cyclophosphamide	I-Treatment
therapy	I-Treatment
for	O
nonhodgkin	I-Problem
'	I-Problem
s	I-Problem
lymphoma	I-Problem
.	O

in	O
the	O
present	O
paper	O
,	O
we	O
describe	O
two	O
patients	I-Background
with	I-Background
active	I-Problem
uc	I-Problem
who	O
developed	O
a	O
severe	I-Problem
systemic	I-Problem
cmv	I-Problem
infection	I-Problem
during	O
a	O
treatment	O
with	O
an	O
oral	I-Treatment
microemulsion	I-Treatment
form	I-Treatment
of	I-Treatment
cyclosporine	I-Treatment
.	O

prior	I-Treatment
to	I-Treatment
surgery	I-Treatment
,	O
the	I-Background
patient	I-Background
received	O
droperidol	I-Treatment
,	O
an	O
agent	O
known	O
to	O
prolong	O
the	O
qt	O
interval	O
.	O

objective	O
:	O
we	O
report	O
a	O
case	O
of	O
cutaneous	I-Problem
ks	I-Problem
lesions	I-Problem
in	O
a	I-Background
patient	I-Background
affected	I-Background
by	I-Background
cml	I-Problem
treated	O
with	O
imatinib	I-Treatment
.	O

the	I-Problem
fk	I-Problem
506	I-Problem
dose	I-Problem
was	I-Problem
constant	I-Problem
within	I-Problem
21	I-Problem
days	I-Problem
after	O
discontinuing	O
phenytoin	I-Treatment
in	O
patient	I-Background
1	O
who	O
had	O
36	I-Other
days	I-Other
of	O
phenytoin	I-Treatment
therapy	I-Treatment
.	O

in	O
patients	I-Background
receiving	O
antithrombin	I-Treatment
iii	I-Treatment
and	I-Treatment
concomitant	I-Treatment
heparin	I-Treatment
,	O
a	O
significantly	O
increased	O
bleeding	I-Problem
incidence	I-Problem
was	O
observed	O
(	O
23	O
.	O
8	O
%	O
for	O
antithrombin	O
iii	O
group	O
vs	O
13	O
.	O
5	O
%	O
for	O
placebo	O
group	O
;	O
p	O
<	O
.	O
001	O
)	O
.	O

bone	O
marrow	I-Test
chromosomes	I-Test
were	O
studied	O
in	O
2	O
patients	I-Background
with	I-Background
polycythaemia	I-Problem
vera	I-Problem
(	I-Problem
pv	I-Problem
)	I-Problem
at	O
the	O
time	O
of	O
diagnosis	O
and	O
several	O
times	O
subsequently	O
during	O
therapy	O
with	O
chlorambucil	I-Treatment
.	O

procainamide	I-Treatment
-	O
induced	O
incessant	I-Problem
supraventricular	I-Problem
tachycardia	I-Problem
in	O
the	O
wolff	I-Problem
-	I-Problem
parkinson	I-Problem
-	I-Problem
white	I-Problem
syndrome	I-Problem
.	O

to	O
our	O
knowledge	O
,	O
however	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
a	O
possible	O
sitagliptin	I-Treatment
-	I-Treatment
lovastatin	I-Treatment
interaction	I-Treatment
that	O
may	O
have	O
caused	O
rhabdomyolysis	I-Problem
.	O

a	I-Background
drug	I-Problem
addict	I-Problem
with	O
staphylococcal	I-Problem
endocarditis	I-Problem
treated	O
with	O
methicillin	I-Treatment
,	O
who	O
developed	O
massive	I-Problem
proteinuria	I-Problem
and	I-Problem
acute	I-Problem
nephritic	I-Problem
syndrome	I-Problem
is	O
described	O
.	O

although	O
inhibition	O
of	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
is	O
considered	O
to	O
be	O
efficient	O
treatment	O
for	O
hypertension	I-Problem
associated	I-Problem
with	I-Problem
chronic	I-Problem
renal	I-Problem
failure	I-Problem
,	O
care	O
should	O
be	O
taken	O
when	O
captopril	I-Treatment
is	O
administered	O
initially	O
to	O
a	I-Background
patient	I-Background
with	I-Background
decreased	I-Problem
renal	I-Problem
function	I-Problem
,	O
under	O
the	O
conditions	O
of	O
sodium	O
and	O
water	O
depletion	O
.	O

two	O
patients	I-Background
with	O
extrapyramidal	I-Problem
side	I-Problem
effects	I-Problem
after	O
the	O
use	O
of	O
fluphenazine	I-Treatment
decanoate	I-Treatment
were	O
evaluated	O
by	O
means	O
of	O
ibzm	O
-	O
spect	O
.	O

the	O
clinical	O
course	O
suggests	O
that	O
the	O
interstitial	I-Problem
pneumonitis	I-Problem
was	O
induced	O
by	O
hydroxyurea	I-Treatment
.	O

disulfiram	I-Treatment
-	O
induced	O
hepatitis	I-Problem
.	O

the	O
majority	O
of	O
radiation	I-Problem
recall	I-Problem
reactions	I-Problem
attributed	O
to	O
gemcitabine	I-Treatment
are	O
reported	O
to	O
affect	O
internal	O
tissue	O
or	O
organs	O
.	O

the	O
known	O
side	O
effects	O
of	O
sibutramine	I-Treatment
,	O
ie	O
,	O
hypertension	I-Problem
and	I-Problem
tachycardia	I-Problem
,	O
depend	O
on	O
its	O
adrenergic	O
and	O
serotoninergic	O
effects	O
.	O

because	O
at	O
the	O
end	O
of	O
the	O
first	O
month	O
the	O
patient	I-Test
'	I-Test
s	I-Test
platelet	I-Test
counts	I-Test
were	O
normal	O
and	O
the	O
thrombocytopenia	O
developed	O
after	O
the	O
co	O
-	O
medication	O
with	O
conventional	O
drugs	O
,	O
it	O
was	O
suspected	O
that	O
the	O
thrombocytopenia	I-Problem
might	O
not	O
be	O
attributed	O
to	O
the	O
use	O
of	O
fhp	I-Treatment
.	O

syndrome	I-Problem
of	I-Problem
inappropriate	I-Problem
secretion	I-Problem
of	I-Problem
adh	I-Problem
(	I-Problem
siadh	I-Problem
)	I-Problem
following	O
cisplatin	I-Treatment
administration	O
in	O
a	I-Background
pulmonary	I-Problem
adenocarcinoma	I-Problem
patient	I-Background
with	I-Background
a	I-Background
malignant	I-Problem
pleural	I-Problem
effusion	I-Problem
.	O

he	O
had	O
an	O
immediate	I-Other
hypersensitivity	I-Problem
reaction	I-Problem
during	O
the	O
initiation	O
of	O
the	O
mtx	I-Treatment
infusion	I-Treatment
with	I-Problem
diffuse	I-Problem
urticaria	I-Problem
,	I-Problem
facial	I-Problem
swelling	I-Problem
,	I-Problem
cough	I-Problem
,	I-Problem
and	I-Problem
chest	I-Problem
tightness	I-Problem
.	O

conclusions	O
:	O
we	O
present	O
a	O
case	O
of	O
a	I-Background
patient	I-Background
with	O
cml	O
who	O
developed	O
ks	I-Problem
12	I-Other
months	I-Other
after	O
starting	O
treatment	O
with	O
imatinib	I-Treatment
400	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
.	O

grade	I-Problem
3	I-Problem
hepatotoxicity	I-Problem
(	O
ast	O
and	O
alt	O
>	O
5	O
to	O
20	O
upper	O
limit	O
normal	O
)	O
or	O
higher	O
has	O
been	O
observed	O
in	O
as	O
many	O
as	O
1	O
.	O
4	O
%	O
of	I-Background
ms	I-Problem
patients	I-Background
on	O
ifn	I-Treatment
beta	I-Treatment
.	O

the	O
second	O
patient	O
was	O
a	I-Background
girl	I-Background
of	I-Background
6	I-Background
,	O
already	O
on	O
risperidone	I-Treatment
for	O
adhd	I-Problem
and	O
borderline	I-Problem
intellectual	I-Problem
functioning	I-Problem
when	O
referred	O
.	O

to	O
report	O
a	I-Background
young	I-Background
man	I-Background
on	O
phenytoin	I-Treatment
who	O
developed	O
acute	I-Problem
neurologic	I-Problem
symptoms	I-Problem
after	O
isradipine	I-Treatment
was	O
introduced	O
to	O
his	O
treatment	O
regimen	O
and	O
discuss	O
the	O
possible	O
causes	O
of	O
this	O
drug	O
interaction	O
.	O

reversible	O
sirolimus	I-Treatment
-	O
associated	O
pneumonitis	I-Problem
after	O
heart	O
transplantation	O
.	O

we	O
report	O
a	I-Background
girl	I-Background
with	O
the	O
rett	I-Problem
syndrome	I-Problem
who	O
had	O
acute	I-Problem
encephalopathy	I-Problem
probably	O
induced	O
by	O
calcium	I-Treatment
hopantenate	I-Treatment
(	I-Treatment
hopa	I-Treatment
)	I-Treatment
.	O

only	O
after	O
three	O
subsequent	O
episodes	O
of	O
severe	O
,	O
symptomatic	I-Problem
thrombocytopenia	I-Problem
over	I-Other
the	I-Other
next	I-Other
four	I-Other
weeks	I-Other
did	O
he	O
say	O
,	O
upon	O
repeat	O
questioning	O
,	O
that	O
he	I-Background
had	O
continued	I-Treatment
to	I-Treatment
take	I-Treatment
quinine	I-Treatment
for	O
night	I-Problem
leg	I-Problem
cramps	I-Problem
.	O

an	O
episode	O
of	O
subacute	I-Problem
encephalopathy	I-Problem
after	O
the	O
infusion	O
of	O
a	I-Treatment
moderate	I-Treatment
dose	I-Treatment
of	I-Treatment
methotrexate	I-Treatment
(	I-Treatment
1500	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
)	I-Treatment
(	I-Treatment
mtx	I-Treatment
)	I-Treatment
is	O
reported	O
in	O
a	I-Background
young	I-Background
adult	I-Background
with	I-Background
metastastic	I-Problem
gastric	I-Problem
cancer	I-Problem
.	O

rhabdomyolysis	I-Problem
in	O
a	O
hepatitis	I-Problem
c	I-Problem
virus	I-Problem
infected	I-Background
patient	I-Background
treated	O
with	O
telaprevir	I-Treatment
and	I-Treatment
simvastatin	I-Treatment
.	O

four	I-Other
days	I-Other
after	I-Other
intravenous	I-Treatment
zoledronic	I-Treatment
acid	I-Treatment
,	O
the	O
patient	I-Background
presented	O
to	O
emergency	O
room	O
with	O
complaints	O
of	O
carpopedal	I-Problem
spasm	I-Problem
and	I-Problem
bronchospasm	I-Problem
.	O

ulcerating	I-Problem
enteritis	I-Problem
associated	O
with	O
flucytosine	I-Treatment
therapy	I-Treatment
.	O

objectives	O
:	O
to	O
describe	O
clinical	O
and	O
pathologic	O
findings	O
in	O
patients	I-Background
noted	O
to	O
develop	O
lower	I-Problem
gastrointestinal	I-Problem
symptoms	I-Problem
when	O
exposed	O
to	O
rofecoxib	I-Treatment
.	O

our	O
findings	O
suggest	O
that	O
significant	I-Problem
progression	I-Problem
of	I-Problem
marrow	I-Problem
reticulin	I-Problem
fibrosis	I-Problem
during	O
imatinib	I-Treatment
therapy	O
can	O
be	O
an	O
indicator	O
for	O
a	O
return	O
or	O
progression	O
of	O
cml	O
and	O
,	O
in	O
some	O
patients	O
with	O
cml	O
,	O
imatinib	O
may	O
promote	O
cytogenetic	O
clonal	O
evolution	O
,	O
resulting	O
in	O
a	O
poor	O
response	O
to	O
treatment	O
.	O

metabolic	I-Problem
acidosis	I-Problem
induced	O
by	O
cetrimide	I-Treatment
-	I-Treatment
chlorhexidine	I-Treatment
solution	I-Treatment
in	O
hydatid	I-Problem
cyst	I-Problem
surgery	O
.	O

reversal	O
of	O
gold	I-Treatment
-	O
induced	O
neutropenia	I-Problem
with	O
granulocyte	I-Treatment
colony	I-Test
-	I-Test
stimulating	I-Test
factor	I-Test
(	I-Treatment
g	I-Test
-	I-Test
csf	I-Test
)	I-Treatment
.	O

methyldopa	I-Treatment
-	O
induced	O
liver	I-Problem
injury	I-Problem
.	O

after	O
infliximab	I-Treatment
treatment	O
,	O
additional	O
sleep	I-Test
studies	I-Test
revealed	O
an	O
increase	I-Problem
in	I-Problem
the	I-Problem
number	I-Problem
of	I-Problem
apneic	I-Problem
events	I-Problem
and	I-Problem
sao2	I-Problem
dips	I-Problem
suggesting	O
that	O
tnfalpha	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	I-Problem
of	I-Problem
sleep	I-Problem
apnea	I-Problem
.	O

one	O
patient	I-Background
developed	O
severe	I-Problem
hyponatremia	I-Problem
with	I-Problem
serum	I-Problem
na	I-Test
+	I-Test
of	I-Problem
108	I-Problem
meq	I-Problem
/	I-Problem
l	I-Problem
when	O
hydrochlorothiazide	I-Treatment
was	O
given	O
to	O
control	O
hypertension	I-Problem
.	O

thyroid	I-Problem
dysfunction	I-Problem
has	O
been	O
reported	O
in	O
patients	I-Background
with	I-Background
malignant	I-Problem
disease	I-Problem
treated	O
with	O
recombinant	I-Treatment
alpha	I-Treatment
interferon	I-Treatment
.	O

the	O
authors	O
also	O
determined	O
that	O
their	O
case	O
of	O
myositis	I-Problem
developing	I-Problem
in	I-Problem
the	I-Problem
rectus	I-Problem
abdominus	I-Problem
muscle	I-Problem
of	O
a	I-Background
patient	I-Background
with	I-Background
pancreatic	I-Problem
adenocarcinoma	I-Problem
was	O
the	O
manifestation	O
of	O
radiation	O
recall	O
,	O
thereby	O
bringing	O
the	O
number	O
of	O
patients	O
who	O
developed	O
radiation	I-Problem
recall	I-Problem
to	O
gemcitabine	I-Treatment
and	O
were	O
discussed	O
in	O
the	O
current	O
study	I-Test
to	O
13	O
.	O

even	O
after	O
a	O
strict	O
warning	O
,	O
he	O
took	O
another	O
quinine	I-Treatment
tablet	I-Treatment
that	O
evening	O
,	O
which	O
triggered	O
his	O
fifth	O
episode	O
of	O
severe	I-Problem
thrombocytopenia	I-Problem
,	O
and	O
confirmed	O
the	O
etiology	O
of	O
quinine	O
-	O
induced	O
thrombocytopenia	O
.	O

case	I-Background
1	O
presented	O
after	O
25	I-Other
months	I-Other
of	I-Treatment
myelosuppressive	I-Treatment
therapy	I-Treatment
a	I-Problem
deletion	I-Problem
of	I-Problem
chromosome	I-Problem
no	I-Problem
.	I-Problem
12	I-Problem
,	I-Problem
del	I-Problem
(	I-Problem
12	I-Problem
)	I-Problem
(	I-Problem
p11	I-Problem
)	I-Problem
,	I-Problem
in	I-Problem
60	I-Problem
%	I-Problem
of	I-Problem
the	I-Problem
diploid	I-Problem
cells	I-Problem
.	O

diabetes	I-Problem
mellitus	I-Problem
was	O
observed	O
in	O
a	I-Background
patient	I-Background
given	O
carbamazepine	I-Treatment
.	O

anxiety	I-Problem
is	O
common	O
in	O
patients	I-Background
with	I-Background
schizophrenia	I-Problem
and	O
pregabalin	I-Treatment
has	I-Treatment
been	I-Treatment
suggested	I-Treatment
as	I-Treatment
an	I-Treatment
off	I-Treatment
-	I-Treatment
label	I-Treatment
add	I-Treatment
-	I-Treatment
on	I-Treatment
treatment	I-Treatment
.	O

large	I-Problem
cerebral	I-Problem
infarction	I-Problem
during	O
praziquantel	I-Treatment
therapy	O
in	O
neurocysticercosis	I-Problem
.	O

we	O
report	O
a	I-Background
13	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
who	O
developed	O
life	O
-	O
threatening	O
anaphylaxis	I-Problem
early	O
in	O
the	O
course	O
of	O
increlex	I-Treatment
therapy	O
.	O

drug	O
induced	O
liver	I-Problem
injury	I-Problem
secondary	O
to	O
interferon	I-Treatment
-	I-Treatment
beta	I-Treatment
(	I-Treatment
ifn	I-Treatment
-	I-Treatment
beta	I-Test
)	I-Treatment
in	O
multiple	I-Problem
sclerosis	I-Problem
.	O

conclusion	O
:	O
lipoid	I-Problem
pneumonia	I-Problem
as	O
a	O
result	O
of	O
mineral	I-Treatment
oil	I-Treatment
aspiration	I-Treatment
still	O
occurs	O
in	O
the	O
pediatric	I-Background
population	O
.	O

the	O
results	O
from	O
the	O
present	I-Test
study	I-Test
suggest	O
that	O
tissue	I-Treatment
plasminogen	I-Treatment
activator	I-Treatment
treatment	I-Treatment
appears	O
to	O
be	O
safe	O
in	O
patients	I-Background
with	I-Background
acute	I-Problem
ischemic	I-Problem
stroke	I-Problem
taking	I-Treatment
warfarin	I-Treatment
with	I-Treatment
an	I-Treatment
international	I-Treatment
normalized	I-Treatment
ratio	I-Treatment
<	I-Treatment
1	I-Treatment
.	I-Treatment
7	I-Treatment
and	O
may	I-Problem
reduce	I-Problem
the	I-Problem
risk	I-Problem
of	I-Problem
poor	I-Problem
functional	I-Problem
outcome	I-Problem
.	O

an	O
episode	O
of	O
leukoencephalopathy	I-Problem
is	O
reported	O
in	O
a	O
13	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
who	I-Background
,	O
after	O
standard	I-Treatment
radiotherapy	I-Treatment
for	I-Treatment
a	I-Treatment
posterior	I-Treatment
fossa	I-Treatment
medulloblastoma	I-Treatment
,	I-Treatment
received	I-Treatment
8	I-Treatment
treatments	I-Treatment
with	I-Treatment
a	I-Treatment
protocol	I-Treatment
containing	I-Treatment
a	I-Treatment
4	I-Treatment
-	I-Treatment
hour	I-Treatment
infusion	I-Treatment
of	I-Treatment
500	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
methotrexate	I-Treatment
and	I-Treatment
12	I-Treatment
mg	I-Treatment
intrathecal	I-Treatment
methotrexate	I-Treatment
.	O

background	O
:	O
accutane	I-Treatment
a	O
teratogenic	O
prescription	O
drug	O
licensed	O
to	O
treat	O
severe	I-Problem
,	I-Problem
recalcitrant	I-Problem
nodular	I-Problem
acne	I-Problem
.	O

objective	O
:	O
to	O
report	O
the	O
safe	O
use	O
of	O
fluorouracil	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
breast	I-Problem
cancer	I-Problem
who	I-Background
had	I-Background
allergic	I-Problem
reactions	I-Problem
to	I-Problem
capecitabine	I-Problem
.	O

esophageal	I-Problem
candidiasis	I-Problem
following	O
omeprazole	I-Treatment
therapy	O
:	O
a	O
report	O
of	O
two	O
cases	I-Background
.	O

we	O
describe	O
a	I-Background
10	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
with	I-Background
ulcerative	I-Problem
colitis	I-Problem
who	O
developed	O
acute	I-Problem
pancreatitis	I-Problem
while	O
on	O
long	I-Other
-	I-Other
term	I-Other
treatment	I-Other
with	I-Treatment
5	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
.	O

the	O
mechanism	O
of	O
niacin	I-Treatment
-	O
induced	O
coagulopathy	I-Problem
is	O
theorized	O
to	O
be	O
related	O
to	O
diminished	O
coagulation	O
factors	O
,	O
and	O
limited	O
data	O
suggest	O
that	O
this	O
may	O
be	O
more	O
pronounced	O
with	O
extended	I-Treatment
-	I-Treatment
release	I-Treatment
niacin	I-Treatment
.	O

objective	O
:	O
to	O
report	O
2	O
cases	O
of	O
nonconvulsive	I-Problem
status	I-Problem
epilepticus	I-Problem
(	I-Problem
ncse	I-Problem
)	I-Problem
following	O
infusion	I-Treatment
of	I-Treatment
ifosfamide	I-Treatment
.	O

we	O
conclude	O
that	O
the	O
observed	O
toxicity	I-Problem
with	I-Problem
jaundice	I-Problem
was	O
probably	O
caused	O
by	O
an	O
interaction	O
of	O
this	O
popular	O
chinese	O
formula	O
and	O
temozolomide	I-Treatment
.	O

pigmentary	I-Problem
disorders	I-Problem
are	O
recognized	O
adverse	O
effects	O
of	O
the	O
semi	I-Treatment
-	I-Treatment
synthetic	I-Treatment
tetracycline	I-Treatment
derivative	I-Treatment
antibiotic	I-Treatment
,	I-Treatment
minocycline	I-Treatment
.	O

pregabalin	I-Treatment
is	I-Treatment
an	I-Treatment
antiepileptic	I-Treatment
drug	I-Treatment
with	I-Treatment
anti	I-Treatment
-	I-Treatment
anxiety	I-Treatment
properties	I-Treatment
and	O
is	O
approved	O
for	O
treatment	O
of	O
generalized	I-Problem
anxiety	I-Problem
disorder	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
chronic	I-Other
use	I-Treatment
of	I-Treatment
hcq	I-Treatment
associated	O
with	O
torsade	I-Problem
de	I-Problem
pointes	I-Problem
.	O

purpose	O
:	O
the	O
occurrence	O
of	O
myoclonus	I-Problem
associated	O
with	O
continuous	I-Treatment
i	I-Treatment
.	I-Treatment
v	I-Treatment
.	I-Treatment
infusion	I-Treatment
of	I-Treatment
dobutamine	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
end	I-Problem
-	I-Problem
stage	I-Problem
renal	I-Problem
disease	I-Problem
(	I-Problem
esrd	I-Problem
)	I-Problem
is	O
described	O
.	O

the	O
case	O
concerns	O
the	O
sudden	I-Problem
death	I-Problem
of	O
a	I-Background
29	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	O
during	O
clozapine	I-Treatment
therapy	O
started	O
2	I-Other
weeks	I-Other
before	I-Other
.	O

in	O
this	O
paper	O
,	O
we	O
report	O
a	O
case	O
of	O
3	I-Background
years	I-Background
-	I-Background
old	I-Background
boy	I-Background
who	O
developed	O
acute	I-Problem
onset	I-Problem
tetraparesia	I-Problem
following	O
a	I-Problem
viral	I-Problem
respiratory	I-Problem
infecction	I-Problem
and	O
hepatitis	I-Treatment
b	I-Treatment
vaccination	I-Treatment
.	O

treatment	O
of	O
elp	I-Problem
in	O
children	O
is	O
generally	O
supportive	O
,	O
with	O
the	O
symptoms	I-Problem
and	I-Problem
roentgenographic	I-Problem
abnormalities	I-Problem
resolving	I-Problem
within	O
months	O
after	O
stopping	I-Treatment
the	I-Treatment
use	I-Treatment
of	I-Treatment
mineral	I-Treatment
oil	I-Treatment
.	O

pet	O
scintigraphy	I-Test
of	O
etoposide	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
.	O

we	O
report	O
a	I-Background
patient	I-Background
who	O
experienced	I-Problem
labd	I-Problem
shortly	I-Problem
after	O
starting	I-Treatment
carbamazepine	I-Treatment
therapy	I-Treatment
.	O

fulminant	I-Treatment
metoclopramide	I-Treatment
induced	O
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
rapidly	O
responsive	O
to	O
intravenous	O
dantrolene	O
.	O

can	O
ketamine	I-Treatment
prescribed	O
for	O
pain	I-Problem
cause	O
damage	I-Problem
to	I-Problem
the	I-Problem
urinary	I-Problem
tract	I-Problem
?	O

sixteen	O
hours	O
after	O
the	O
first	O
administration	O
of	O
ifn	O
,	O
ifn	I-Treatment
was	O
suspended	O
by	O
the	O
symptoms	O
of	O
congestive	I-Problem
heart	I-Problem
failure	I-Problem
(	I-Problem
chf	I-Problem
)	I-Problem
.	O

we	O
believe	O
this	O
is	O
the	O
first	O
report	O
of	O
myocardial	I-Problem
infarction	I-Problem
due	O
to	O
coronary	I-Problem
spasm	I-Problem
,	O
demonstrated	O
by	O
angiography	O
associated	O
with	O
l	I-Treatment
-	I-Treatment
thyroxine	I-Treatment
therapy	O
.	O

a	O
58	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
(	I-Problem
ra	I-Problem
)	I-Problem
developed	O
fever	I-Problem
,	I-Problem
skin	I-Problem
eruptions	I-Problem
,	I-Problem
leukocytopenia	I-Problem
,	I-Problem
and	I-Problem
thrombocytopenia	I-Problem
,	O
3	I-Other
weeks	I-Other
after	I-Other
treatment	I-Treatment
with	I-Treatment
sulfasalazine	I-Treatment
.	O

gold	I-Treatment
-	O
induced	O
aplastic	I-Problem
anemia	I-Problem
.	O

one	I-Background
patient	I-Background
developed	O
large	I-Problem
intramural	I-Problem
esophageal	I-Problem
hematoma	I-Problem
as	O
a	I-Treatment
complication	I-Treatment
of	I-Treatment
heparin	I-Treatment
therapy	I-Treatment
.	O

mammary	I-Problem
gigantism	I-Problem
is	O
a	O
rare	O
complication	O
of	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
treatment	I-Treatment
.	O

cyclobenzaprine	I-Treatment
shares	O
anticholinergic	I-Problem
effects	I-Problem
,	I-Problem
tachycardia	I-Problem
,	I-Problem
and	I-Problem
dysrhythmic	I-Problem
potential	O
with	I-Treatment
the	I-Treatment
tricyclic	I-Treatment
antidepressants	I-Treatment
(	I-Treatment
tcas	I-Treatment
)	I-Treatment
.	O

the	O
autopsy	I-Test
findings	O
and	O
a	O
detailed	O
medical	O
history	O
supported	O
the	O
conclusion	O
that	O
clozapine	I-Treatment
-	O
induced	O
hypersensitivity	I-Problem
myocarditis	I-Problem
was	O
the	O
most	O
likely	O
cause	O
of	O
death	I-Problem
.	O

purpose	O
:	O
to	O
present	O
a	O
case	O
of	O
respiratory	I-Problem
depression	I-Problem
following	O
the	O
administration	O
of	O
nebulised	I-Treatment
morphine	I-Treatment
.	O

methods	O
:	O
a	I-Background
55	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
became	O
stuporous	I-Problem
after	O
overdose	I-Treatment
with	I-Treatment
lamotrigine	I-Treatment
(	I-Treatment
ltg	I-Treatment
)	I-Treatment
and	I-Treatment
valproic	I-Treatment
acid	I-Treatment
(	I-Treatment
vpa	I-Treatment
)	I-Treatment
tablets	I-Treatment
.	O

recrudescence	I-Problem
of	I-Problem
imported	I-Problem
falciparum	I-Problem
malaria	I-Problem
after	O
quinine	I-Treatment
therapy	O
:	O
potential	O
drug	O
interaction	O
with	O
phenytoin	I-Treatment
.	O

conclusions	O
:	O
clinicians	O
should	O
be	O
aware	O
of	O
the	O
possible	O
association	O
of	O
thrombocytopenia	I-Problem
with	O
lansoprazole	I-Treatment
and	O
discontinue	O
the	O
drug	O
if	O
thrombocytopenia	O
becomes	O
apparent	O
.	O

conclusion	O
:	O
long	O
-	O
term	O
treatment	O
with	O
rifabutin	I-Treatment
may	O
have	O
a	O
reversible	O
and	O
previously	O
undescribed	O
side	I-Problem
-	I-Problem
effect	I-Problem
on	I-Problem
retinal	I-Problem
function	I-Problem
.	O

toxic	I-Problem
hepatitis	I-Problem
due	O
to	O
combination	O
therapy	O
with	O
methotrexate	I-Treatment
and	I-Treatment
etretinate	I-Treatment
in	O
psoriasis	I-Problem
.	O

to	O
report	O
the	O
results	O
of	O
therapeutic	O
drug	I-Test
monitoring	I-Test
of	O
lopinavir	I-Treatment
/	I-Treatment
ritonavir	I-Treatment
and	I-Treatment
itraconazole	I-Treatment
concentrations	I-Test
in	O
an	I-Background
hiv	I-Problem
-	I-Background
infected	I-Background
male	I-Background
who	O
was	O
treated	O
for	O
histoplasmosis	I-Problem
.	O

ulcer	I-Problem
became	I-Problem
worse	I-Problem
after	O
tobramycin	I-Treatment
and	I-Treatment
gentamycin	I-Treatment
treatment	O
for	O
2	O
days	O
.	O

thalidomide	O
has	O
proven	O
activity	O
in	O
refractory	I-Problem
multiple	I-Problem
myeloma	I-Problem
(	I-Problem
mm	I-Problem
)	I-Problem
,	O
and	O
although	O
single	I-Treatment
-	I-Treatment
agent	I-Treatment
thalidomide	I-Treatment
has	O
minimal	O
prothrombogenic	O
activity	O
,	O
its	O
combination	I-Treatment
with	I-Treatment
cytotoxic	I-Treatment
chemotherapy	I-Treatment
is	O
associated	O
with	O
a	O
significantly	I-Problem
increased	I-Problem
risk	I-Problem
of	I-Problem
dvt	I-Problem
.	O

these	O
cases	O
indicate	O
that	O
sulpiride	I-Treatment
can	O
cause	O
tardive	I-Problem
dyskinesia	I-Problem
and	O
that	O
this	O
drug	O
should	O
be	O
administered	O
with	O
caution	O
.	O

well	I-Problem
-	I-Problem
differentiated	I-Problem
endometrial	I-Problem
adenocarcinoma	I-Problem
of	I-Problem
the	I-Problem
secretory	I-Problem
type	I-Problem
(	I-Problem
figo	I-Problem
grade	I-Problem
1	I-Problem
)	I-Problem
with	I-Problem
minimal	I-Problem
myometrial	I-Problem
invasion	I-Problem
occurred	O
in	O
a	I-Background
postmenopausal	I-Problem
patient	I-Background
on	O
tamoxifen	I-Treatment
therapy	I-Treatment
5	I-Treatment
years	I-Treatment
after	I-Treatment
mastectomy	I-Treatment
for	I-Treatment
breast	I-Problem
carcinoma	I-Problem
.	I-Treatment

secondary	I-Problem
hematologic	I-Problem
neoplasm	I-Problem
after	O
intravesical	I-Treatment
chemotherapy	I-Treatment
for	O
superficial	O
bladder	I-Problem
carcinoma	I-Problem
.	O

ciprofloxacin	I-Treatment
-	O
induced	O
renal	I-Problem
insufficiency	I-Problem
in	O
cystic	I-Problem
fibrosis	I-Problem
.	O

while	O
the	I-Treatment
introduction	I-Treatment
of	I-Treatment
carmustine	I-Treatment
wafers	I-Treatment
(	I-Treatment
gliadel	I-Treatment
wafers	I-Treatment
)	I-Treatment
into	I-Treatment
the	I-Treatment
tumor	I-Treatment
resection	I-Treatment
cavity	I-Treatment
has	O
been	O
shown	O
to	O
be	O
a	O
beneficial	O
therapy	O
for	O
malignant	I-Problem
glioma	I-Problem
,	O
it	O
is	O
recognized	O
that	O
clinically	O
significant	I-Problem
cerebral	I-Problem
edema	I-Problem
is	O
a	O
potential	O
adverse	O
effect	O
.	O

didanosine	I-Treatment
also	O
has	O
a	O
potential	O
for	O
inducing	O
seizures	I-Problem
.	O

obsessive	I-Problem
-	I-Problem
compulsive	I-Problem
symptoms	I-Problem
suddenly	O
emerged	O
10	O
days	O
after	O
starting	O
risperidone	I-Treatment
and	O
resolved	O
within	O
3	O
days	O
of	O
discontinuation	O
.	O

refractory	I-Problem
hypoglycemia	I-Problem
from	O
ciprofloxacin	I-Treatment
and	I-Treatment
glyburide	I-Treatment
interaction	I-Treatment
.	O

anaphylactic	I-Problem
reaction	I-Problem
to	O
recombinant	I-Treatment
insulin	I-Treatment
-	I-Treatment
like	I-Treatment
growth	I-Treatment
factor	I-Treatment
-	I-Treatment
i	I-Treatment
.	I-Treatment

subtherapeutic	I-Treatment
warfarin	I-Treatment
is	O
not	O
associated	O
with	O
increased	I-Problem
hemorrhage	I-Problem
rates	I-Problem
in	O
ischemic	I-Problem
strokes	I-Problem
treated	I-Treatment
with	I-Treatment
tissue	I-Treatment
plasminogen	I-Treatment
activator	I-Treatment
.	O

teicoplanin	I-Treatment
-	O
induced	O
agranulocytosis	I-Problem
that	O
followed	I-Treatment
vancomycin	I-Treatment
-	O
induced	O
agranulocytosis	O
suggests	O
a	O
possible	O
cross	O
-	O
reactivity	O
between	O
the	O
2	O
drugs	O
.	O

a	I-Background
55	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
developed	O
symptoms	O
suggestive	O
of	O
hepatitis	I-Problem
12	I-Other
weeks	I-Other
after	O
first	O
receiving	O
methyldopa	I-Treatment
for	O
hypertension	I-Problem
.	O

cyclophosphamide	I-Treatment
can	O
rarely	O
cause	O
interstitial	I-Problem
pneumonitis	I-Problem
and	I-Problem
fibrosis	I-Problem
.	O

flucytosine	I-Treatment
-	O
associated	O
diarrhea	I-Problem
has	O
been	O
previously	O
described	O
in	O
6	O
%	O
-	O
10	O
%	O
of	I-Background
patients	I-Background
receiving	O
the	O
drug	O
.	O

iv	I-Treatment
propranolol	I-Treatment
was	O
used	O
as	O
the	O
initial	O
treatment	O
for	O
his	I-Background
hyperadrenergic	I-Problem
state	I-Problem
,	O
resulting	O
in	O
a	O
decrease	I-Problem
in	I-Problem
heart	I-Problem
rate	I-Problem
but	I-Problem
a	I-Problem
paroxsymal	I-Problem
increase	I-Problem
in	I-Problem
blood	I-Problem
pressure	I-Test
.	O

we	O
believe	O
that	O
this	O
is	O
the	O
first	O
report	O
of	O
secretory	I-Problem
carcinoma	I-Problem
of	I-Problem
the	I-Problem
endometrium	I-Problem
associated	O
with	O
tamoxifen	I-Treatment
use	O
.	O

herpes	I-Problem
simplex	I-Problem
esophagitis	I-Problem
in	O
a	O
renal	I-Problem
transplant	I-Problem
patient	I-Background
treated	O
with	O
cyclosporine	I-Treatment
a	O
:	O
a	O
case	O
report	O
.	O

this	O
clinical	O
course	O
suggests	O
that	O
the	O
sensorimotor	I-Problem
polyneuropathy	I-Problem
may	O
have	O
been	O
caused	O
by	O
5	I-Treatment
-	I-Treatment
asa	I-Treatment
.	O

spontaneous	I-Problem
nasal	I-Problem
septal	I-Problem
perforation	I-Problem
with	O
antiangiogenic	I-Treatment
bevacizumab	I-Treatment
therapy	I-Treatment
.	O

there	O
are	O
a	O
few	O
case	O
reports	O
on	O
hair	I-Problem
loss	I-Problem
associated	O
with	O
tricyclic	I-Treatment
antidepressants	I-Treatment
and	I-Treatment
serotonin	I-Treatment
selective	I-Treatment
reuptake	I-Treatment
inhibitors	I-Treatment
(	O
ssris	O
)	O
,	O
but	O
none	O
deal	O
specifically	O
with	O
paroxetine	O
.	O

there	O
have	O
been	O
more	I-Problem
than	I-Problem
20	I-Problem
observations	I-Problem
of	I-Problem
the	I-Problem
appearance	I-Problem
or	I-Problem
aggravation	I-Problem
of	I-Problem
this	I-Problem
granulomatosis	I-Problem
with	O
interferon	I-Treatment
alfa	I-Treatment
and	I-Treatment
more	I-Treatment
recently	I-Treatment
with	I-Treatment
the	I-Treatment
combination	I-Treatment
of	I-Treatment
interferon	I-Treatment
alfa	I-Treatment
plus	I-Treatment
ribavirin	I-Treatment
.	O

conclusion	O
:	O
a	I-Background
37	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
african	I-Background
-	I-Background
american	I-Background
man	I-Background
with	I-Background
g6pd	I-Problem
deficiency	I-Problem
developed	O
hemolytic	I-Problem
anemia	I-Problem
,	I-Problem
hepatitis	I-Problem
,	I-Problem
orthostatic	I-Problem
hypotension	I-Problem
,	I-Problem
and	I-Problem
aseptic	I-Problem
meningitis	I-Problem
simultaneously	O
after	O
using	O
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
.	O

all	I-Treatment
-	I-Treatment
trans	I-Treatment
retinoic	I-Treatment
acid	I-Treatment
-	O
induced	O
focal	I-Problem
myositis	I-Problem
,	I-Problem
synovitis	I-Problem
,	I-Problem
and	I-Problem
mononeuritis	I-Problem
.	O

oxygen	I-Treatment
potentiation	I-Treatment
of	I-Treatment
bleomycin	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
is	O
discussed	O
.	O

conclusions	O
:	O
ltg	I-Treatment
overdose	I-Treatment
may	O
result	O
in	O
a	O
severe	O
but	O
reversible	I-Problem
encephalopathy	I-Problem
,	O
a	O
previously	O
undescribed	O
phenomenon	O
.	O

in	O
this	O
report	O
,	O
we	O
describe	O
a	O
case	O
of	O
rhabdomyolysis	I-Problem
and	I-Problem
acute	I-Problem
renal	I-Problem
failure	I-Problem
secondary	O
to	O
the	O
interaction	I-Treatment
between	I-Treatment
danazol	I-Treatment
and	I-Treatment
simvastatin	I-Treatment
.	O

infectious	I-Problem
toxicity	I-Problem
of	O
dexamethasone	I-Treatment
during	O
all	I-Treatment
remission	I-Treatment
-	I-Treatment
induction	I-Treatment
chemotherapy	I-Treatment
:	O
report	O
of	O
two	O
cases	I-Background
and	O
literature	O
review	O
.	O

a	I-Background
56	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
male	I-Background
had	O
been	O
receiving	O
chronic	I-Treatment
warfarin	I-Treatment
therapy	I-Treatment
for	I-Treatment
11	I-Treatment
years	I-Treatment
after	I-Treatment
mechanical	I-Treatment
heart	I-Treatment
valve	I-Treatment
replacement	I-Treatment
.	O

isoniazid	I-Treatment
associated	O
,	O
painful	I-Problem
,	I-Problem
bilateral	I-Problem
gynaecomastia	I-Problem
.	O

electrocardiographic	O
findings	I-Test
and	O
laboratory	O
data	O
indicated	O
a	O
diagnosis	O
of	O
acute	I-Problem
myocardial	I-Problem
infarction	I-Problem
due	O
to	O
the	I-Treatment
l	I-Treatment
-	I-Treatment
thyroxine	I-Treatment
therapy	I-Treatment
.	I-Treatment

combining	I-Treatment
methylephedrine	I-Treatment
and	I-Treatment
chinese	I-Treatment
herbal	I-Treatment
drugs	I-Treatment
might	O
carry	O
a	O
risk	I-Problem
of	I-Problem
stroke	I-Problem
.	O

coadministration	I-Treatment
of	I-Treatment
200	I-Treatment
mg	I-Treatment
bid	I-Treatment
voriconazole	I-Treatment
with	I-Treatment
400	I-Treatment
mg	I-Treatment
(	I-Treatment
or	I-Treatment
higher	I-Treatment
)	I-Treatment
qd	I-Treatment
efavirenz	I-Treatment
is	O
contraindicated	O
due	O
to	O
the	O
clinically	I-Problem
significant	I-Problem
effect	I-Problem
of	O
efavirenz	I-Treatment
on	I-Treatment
voriconazole	I-Treatment
pharmacokinetics	O
.	O

an	O
interaction	I-Treatment
between	I-Treatment
niacin	I-Treatment
and	I-Treatment
warfarin	I-Treatment
likely	O
elevated	I-Problem
the	I-Problem
inr	I-Problem
in	O
this	I-Background
patient	I-Background
because	O
of	O
synergistic	O
coagulopathy	O
and	O
pharmacokinetic	O
effects	O
of	O
niacin	O
.	O

we	O
present	O
two	O
cases	I-Background
in	I-Background
which	I-Background
both	I-Background
patients	I-Background
suffered	I-Background
with	I-Background
cls	I-Problem
,	O
which	O
we	O
believe	O
was	O
caused	O
following	O
administration	O
of	O
granulocyte	I-Treatment
colony	I-Treatment
-	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
,	O
to	O
our	O
knowledge	O
not	O
described	O
in	O
the	O
intensive	O
care	O
patient	O
previously	O
.	O

capecitabine	I-Problem
was	I-Problem
discontinued	I-Problem
and	I-Problem
the	I-Problem
allergic	I-Problem
reactions	I-Problem
resolved	I-Problem
after	O
the	O
woman	I-Background
took	O
diphenhydramine	I-Treatment
for	I-Treatment
1	I-Other
week	I-Other
.	O

intravenous	I-Treatment
fluconazole	I-Treatment
400	I-Treatment
mg	I-Treatment
,	I-Treatment
followed	I-Treatment
by	I-Treatment
100	I-Treatment
mg	I-Treatment
every	I-Treatment
24	I-Treatment
hours	I-Treatment
according	O
to	O
impaired	O
renal	O
function	O
,	O
was	O
immediately	O
started	O
;	O
to	O
avoid	O
further	O
nephrotoxicity	I-Problem
,	O
immunosuppressant	I-Treatment
therapy	I-Treatment
was	I-Treatment
switched	I-Treatment
from	I-Treatment
cyclosporine	I-Treatment
plus	I-Treatment
mycophenolate	I-Treatment
mofetil	I-Treatment
to	I-Treatment
oral	I-Treatment
everolimus	I-Treatment
0	I-Treatment
.	I-Treatment
75	I-Treatment
mg	I-Treatment
every	I-Treatment
12	I-Treatment
hours	I-Treatment
.	O

soon	O
after	O
introduction	O
of	O
insulin	I-Treatment
therapy	O
,	O
she	I-Background
developed	O
severe	O
anasarca	I-Problem
,	I-Problem
including	I-Problem
marked	I-Problem
peripheral	I-Problem
oedema	I-Problem
,	I-Problem
ascites	I-Problem
and	I-Problem
pleural	I-Problem
effusion	I-Problem
.	O

we	O
describe	O
a	I-Background
continuous	I-Problem
ambulatory	I-Problem
peritoneal	I-Problem
dialysis	I-Problem
(	I-Problem
capd	I-Problem
)	I-Problem
patient	I-Background
that	O
developed	O
vancomycin	I-Treatment
-	O
induced	O
agranulocytosis	I-Problem
during	O
treatment	O
for	O
methicillin	I-Problem
-	I-Problem
resistant	I-Problem
staphylococcus	I-Problem
aureus	I-Problem
(	I-Problem
mrsa	I-Problem
)	I-Problem
-	I-Problem
associated	I-Problem
external	I-Problem
cuff	I-Problem
infection	I-Problem
and	I-Problem
pneumonia	I-Problem
.	O

in	I-Background
both	O
cases	I-Background
,	O
we	O
believe	O
that	O
serotonin	I-Problem
syndrome	I-Problem
was	O
produced	O
by	O
a	I-Treatment
combination	I-Treatment
of	I-Treatment
an	I-Treatment
antidepressant	I-Treatment
and	I-Treatment
an	I-Treatment
atypical	I-Treatment
antipsychotic	I-Treatment
.	O

cyclosporin	I-Treatment
side	O
effects	O
included	O
hirsutism	I-Problem
,	I-Problem
hypertension	I-Problem
,	I-Problem
increased	I-Problem
blood	I-Problem
levels	I-Problem
of	I-Problem
urea	I-Problem
and	I-Problem
creatinine	I-Problem
,	I-Problem
and	I-Problem
abnormalities	I-Problem
in	I-Problem
liver	I-Problem
function	I-Problem
tests	I-Problem
.	I-Problem

she	O
displayed	O
severe	O
hyperactivity	I-Problem
,	I-Problem
agitation	I-Problem
and	I-Problem
irritability	I-Problem
upon	O
switching	I-Treatment
to	I-Treatment
methylphenidate	I-Treatment
medication	O
.	O

to	O
date	O
,	O
only	O
three	O
cases	I-Background
of	O
seizures	I-Problem
associated	O
with	O
amphotericin	I-Treatment
b	I-Treatment
have	O
been	O
reported	O
in	O
the	O
literature	O
,	O
but	O
healthcare	O
providers	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
this	O
rare	O
adverse	O
effect	O
.	O

heparin	I-Treatment
-	O
induced	O
thrombocytopenia	I-Problem
complicated	I-Problem
with	I-Problem
massive	I-Problem
thrombosis	I-Problem
of	I-Problem
the	I-Problem
inferior	I-Problem
vena	I-Problem
cava	I-Problem
after	I-Problem
filter	I-Problem
placement	I-Problem
.	O

pharmacokinetics	O
of	O
methadone	I-Treatment
in	O
human	I-Problem
-	I-Problem
immunodeficiency	I-Problem
-	I-Problem
virus	I-Problem
-	I-Background
infected	I-Background
patients	I-Background
receiving	O
nevirapine	I-Treatment
once	I-Other
daily	I-Other
.	O

three	O
patients	I-Background
receiving	O
gold	I-Treatment
salt	I-Treatment
treatment	O
for	O
rheumatoid	I-Problem
arthritis	I-Problem
developed	O
severe	I-Problem
aplastic	I-Problem
anemia	I-Problem
.	O

a	O
case	O
of	O
anaphylactoid	I-Problem
reaction	O
due	O
solely	O
to	O
the	O
use	O
of	O
gelofusine	I-Treatment
in	O
a	O
patient	I-Background
with	I-Background
non	I-Problem
-	I-Problem
haemorrhagic	I-Problem
hypovolaemia	I-Problem
is	O
presented	O
,	O
with	O
a	O
discussion	O
on	O
the	O
management	O
and	O
the	O
use	O
of	O
allergy	O
identification	O
jewellery	O
.	O

nonoliguric	I-Problem
acute	I-Problem
renal	I-Problem
failure	I-Problem
after	O
captopril	I-Treatment
therapy	O
.	O

we	O
report	O
a	I-Background
patient	I-Background
with	I-Background
type	I-Problem
2	I-Problem
diabetes	I-Problem
mellitus	I-Problem
who	O
,	O
while	O
treated	O
with	O
the	I-Treatment
antitumor	I-Treatment
necrosis	I-Treatment
factor	I-Treatment
-	I-Treatment
alpha	I-Treatment
blocking	I-Treatment
agent	I-Treatment
etanercept	I-Treatment
for	O
severe	I-Problem
plaque	I-Problem
psoriasis	I-Problem
,	O
experienced	O
persistent	I-Problem
hypoglycemia	I-Problem
requiring	O
the	O
lowering	O
and	O
eventual	O
elimination	O
of	O
his	O
previous	I-Treatment
insulin	I-Treatment
regimen	I-Treatment
.	O

we	O
report	O
the	O
first	O
case	O
of	O
doxycycline	I-Treatment
-	O
induced	O
hypoglycemia	I-Problem
in	O
a	I-Background
young	I-Background
nondiabetic	I-Problem
man	I-Background
.	O

the	O
time	O
course	O
of	O
events	O
suggested	O
that	O
amphotericin	I-Treatment
b	I-Treatment
was	O
the	O
cause	O
of	O
the	O
seizures	I-Problem
in	O
this	O
aids	I-Problem
patient	I-Background
.	O

allergic	I-Problem
contact	I-Problem
dermatitis	I-Problem
from	O
4	I-Treatment
-	I-Treatment
chloro	I-Treatment
-	I-Treatment
7	I-Treatment
-	I-Treatment
nitrobenzofurazan	I-Treatment
.	O

we	O
describe	O
a	I-Background
5	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
showed	O
recovery	I-Problem
of	I-Problem
vincristine	I-Problem
induced	I-Problem
cranial	I-Problem
polyneuropathy	I-Problem
with	O
pyridoxine	I-Treatment
and	I-Treatment
pyridostigmine	I-Treatment
treatment	I-Treatment
.	O

lipoid	I-Problem
pneumonia	I-Problem
:	O
a	O
silent	O
complication	O
of	O
mineral	I-Treatment
oil	I-Treatment
aspiration	I-Treatment
.	O

seizures	I-Problem
associated	O
with	O
fluoxetine	I-Treatment
therapy	I-Treatment
.	O

sustained	I-Problem
monomorphic	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
after	O
adenosine	I-Treatment
infusion	I-Treatment
.	I-Treatment

a	I-Background
9	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
boy	I-Background
developed	O
acute	I-Problem
renal	I-Problem
failure	I-Problem
following	O
intravenous	I-Treatment
acyclovir	I-Treatment
(	O
30	I-Treatment
mg	I-Treatment
/	I-Treatment
kg	I-Treatment
per	I-Other
day	I-Other
)	O
administered	O
for	O
6	I-Other
days	I-Other
to	O
treat	O
herpetic	I-Problem
encephalitis	I-Problem
.	O

we	O
report	O
a	I-Background
4	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
who	O
presented	O
with	O
acute	I-Problem
bilateral	I-Problem
blindness	I-Problem
,	I-Problem
a	I-Problem
focal	I-Problem
seizure	I-Problem
and	I-Problem
hypertension	I-Problem
10	I-Other
days	I-Other
after	O
commencing	O
oxybutynin	I-Treatment
to	O
treat	O
enuresis	I-Problem
.	O

severe	I-Problem
arrhythmia	I-Problem
as	O
a	O
result	O
of	O
the	O
interaction	I-Treatment
of	I-Treatment
cetirizine	I-Treatment
and	I-Treatment
pilsicainide	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
renal	I-Problem
insufficiency	I-Problem
:	O
first	O
case	O
presentation	O
showing	O
competition	O
for	O
excretion	O
via	O
renal	O
multidrug	O
resistance	O
protein	O
1	O
and	O
organic	O
cation	O
transporter	O
2	O
.	O

reported	O
are	O
three	O
children	I-Background
who	O
developed	O
progressive	O
paraparesis	I-Problem
after	O
intrathecal	I-Treatment
methotrexate	I-Treatment
administration	O
followed	O
by	O
complete	O
or	O
partial	O
recovery	O
.	O

we	O
observed	O
ventricular	I-Problem
fibrillation	I-Problem
in	O
2	O
patients	I-Background
who	I-Background
presented	I-Background
to	I-Background
the	I-Background
emergency	I-Background
department	I-Background
with	I-Background
pre	I-Problem
-	I-Problem
excited	I-Problem
atrial	I-Problem
fibrillation	I-Problem
and	O
were	O
given	O
12	I-Treatment
mg	I-Treatment
of	I-Treatment
adenosine	I-Treatment
.	O

during	O
administration	O
of	O
chemotherapy	I-Treatment
,	O
the	O
patient	I-Background
progressively	O
developed	O
a	I-Problem
complex	I-Problem
association	I-Problem
of	I-Problem
beau	I-Problem
'	I-Problem
s	I-Problem
lines	I-Problem
,	I-Problem
transverse	I-Problem
melanonychia	I-Problem
,	I-Problem
muehrcke	I-Problem
'	I-Problem
s	I-Problem
lines	I-Problem
,	I-Problem
and	I-Problem
diffuse	I-Problem
hyperpigmentation	I-Problem
of	I-Problem
the	I-Problem
skin	I-Problem
.	O

distinct	I-Problem
patterns	I-Problem
of	I-Problem
chromonychia	I-Problem
,	I-Problem
beau	I-Problem
'	I-Problem
s	I-Problem
lines	I-Problem
,	I-Problem
and	I-Problem
melanoderma	I-Problem
seen	O
with	O
vincristine	I-Treatment
,	I-Treatment
adriamycin	I-Treatment
,	I-Treatment
dexamethasone	I-Treatment
therapy	O
for	O
multiple	I-Problem
myeloma	I-Problem
.	O

theophylline	I-Treatment
intoxication	I-Problem
mimicking	O
diabetic	O
ketoacidosis	O
in	O
a	I-Background
child	I-Background
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	O
,	O
after	O
receiving	O
his	O
first	O
dose	O
of	O
pregabalin	I-Treatment
to	O
relieve	O
neuropathic	I-Problem
pain	I-Problem
,	O
presented	O
with	O
a	O
negative	I-Problem
myoclonus	I-Problem
.	O

conclusions	O
:	O
the	O
use	O
of	O
fluorouracil	I-Treatment
treatment	I-Treatment
with	I-Treatment
careful	I-Treatment
monitoring	I-Test
can	O
be	O
considered	O
in	O
a	I-Background
patient	I-Background
with	I-Background
mild	I-Background
allergic	I-Problem
reactions	I-Problem
to	I-Problem
capecitabine	I-Problem
.	O

symptomatic	I-Problem
hypocalcaemia	I-Problem
and	I-Problem
renal	I-Problem
impairment	I-Problem
associated	O
with	O
bisphosphonate	I-Treatment
treatment	I-Treatment
in	O
patients	I-Background
with	I-Background
multiple	I-Problem
myeloma	I-Problem
.	O

although	O
this	O
g	I-Treatment
-	I-Treatment
csf	I-Treatment
-	O
driven	O
leucocytosis	I-Problem
was	O
alarming	O
it	O
did	O
not	O
appear	O
to	O
have	O
adversely	O
affected	O
the	O
patient	O
'	O
s	O
prognosis	O
.	O

a	I-Background
case	I-Background
of	O
pyridoxine	I-Treatment
-	O
dependent	O
seizures	I-Problem
is	O
reported	O
.	O

a	I-Background
case	I-Background
of	I-Background
a	I-Background
53	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
who	O
developed	O
acute	I-Problem
pneumonitis	I-Problem
after	O
bleomycin	I-Treatment
and	I-Treatment
moderate	I-Treatment
oxygen	I-Treatment
administration	O
is	O
presented	O
.	O

renal	I-Problem
tubular	I-Problem
acidosis	I-Problem
secondary	O
to	O
fk506	I-Treatment
in	O
living	O
donor	O
liver	O
transplantation	O
:	O
a	I-Background
case	I-Background
report	O
.	O

retinopathy	I-Problem
in	O
hepatitis	I-Problem
c	I-Problem
patients	I-Background
due	O
to	O
combination	O
therapy	O
with	O
pegylated	I-Treatment
interferon	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
.	O

after	O
excluding	O
other	O
causes	O
of	O
long	O
qt	O
syndrome	O
,	O
the	O
hcq	I-Test
was	O
suspected	O
as	O
the	O
cause	O
of	O
her	I-Background
ventricular	I-Problem
tachycardia	I-Problem
.	O

phantom	I-Problem
limb	I-Problem
pain	I-Problem
as	O
a	O
manifestation	O
of	O
paclitaxel	I-Treatment
neurotoxicity	O
.	O

a	O
case	O
of	O
allopurinol	I-Treatment
hypersensitivity	I-Problem
,	O
possibly	O
the	O
first	O
in	O
a	I-Background
black	I-Background
african	I-Background
,	O
is	O
reported	O
.	O

ramipril	O
was	O
stopped	O
and	O
he	I-Background
required	O
a	I-Treatment
course	I-Treatment
of	I-Treatment
steroids	I-Treatment
after	O
which	O
the	I-Problem
rash	I-Problem
improved	I-Problem
slowly	I-Problem
.	O

late	O
development	O
of	O
diabetes	I-Problem
mellitus	I-Problem
after	O
interferon	I-Treatment
-	I-Treatment
alfa	I-Treatment
and	O
ribavirin	I-Treatment
therapy	O
for	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
:	O
a	O
case	O
report	O
.	O

second	I-Problem
cancers	I-Problem
including	I-Problem
various	I-Problem
types	I-Problem
of	I-Problem
hematological	I-Problem
malignancy	I-Problem
have	O
been	O
reported	O
in	O
patients	I-Background
with	I-Background
hairy	I-Problem
cell	I-Problem
leukemia	I-Problem
treated	O
with	O
chemotherapy	I-Treatment
or	I-Treatment
interferon	I-Treatment
alfa	I-Treatment
.	O

a	I-Background
patient	I-Background
with	I-Background
a	I-Problem
large	I-Problem
hydatid	I-Problem
cyst	I-Problem
of	I-Problem
the	I-Problem
left	I-Problem
lobe	I-Problem
of	I-Problem
the	I-Problem
liver	I-Problem
developed	O
metabolic	I-Problem
acidosis	I-Problem
following	O
rather	I-Treatment
liberal	I-Treatment
use	I-Treatment
of	I-Treatment
cetrimide	I-Treatment
-	I-Treatment
chlorhexidine	I-Treatment
solution	I-Treatment
as	I-Treatment
a	I-Treatment
scolicidal	I-Treatment
agent	I-Treatment
.	O

interventions	O
and	O
results	O
:	O
cardiac	I-Problem
complications	I-Problem
were	O
observed	O
in	O
five	O
pediatric	I-Background
patients	I-Background
who	O
received	O
between	I-Treatment
4	I-Treatment
.	I-Treatment
6	I-Treatment
and	I-Treatment
40	I-Treatment
.	I-Treatment
8	I-Treatment
mg	I-Treatment
/	I-Treatment
kg	I-Treatment
/	I-Treatment
d	I-Treatment
of	I-Treatment
amphotericin	I-Treatment
b	I-Treatment
.	I-Treatment

in	O
this	O
case	O
report	O
,	O
we	O
have	O
described	O
a	I-Background
patient	I-Background
with	I-Background
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
who	O
developed	O
subfulminant	I-Problem
hepatitis	I-Problem
b	I-Problem
after	O
the	O
fourth	I-Other
infusion	I-Treatment
of	I-Treatment
infliximab	I-Treatment
due	O
to	O
an	O
unrecognized	O
hbs	O
-	O
antigen	O
carrier	O
state	O
.	O

we	O
analyzed	O
the	O
incidence	O
of	O
dvt	I-Problem
in	O
232	O
mm	I-Problem
patients	I-Background
who	O
received	O
a	O
combination	O
of	O
chemotherapy	I-Treatment
and	O
thalidomide	I-Treatment
on	O
2	O
protocols	O
that	O
differed	O
only	O
by	O
the	O
inclusion	O
of	O
doxorubicin	O
in	O
one	O
.	O

valvular	I-Problem
heart	I-Problem
disease	I-Problem
in	O
a	I-Background
patient	I-Background
taking	O
benfluorex	I-Treatment
.	O

the	I-Background
fifth	I-Background
patient	I-Background
exhibited	O
paraesthesia	I-Problem
and	I-Problem
agitation	I-Problem
caused	O
by	O
olanzapine	I-Treatment
that	O
was	O
misdiagnosed	O
as	O
psychotic	O
agitation	O
.	O

a	O
review	O
of	O
the	O
literature	O
found	O
11	O
children	I-Background
and	I-Background
2	O
adults	I-Background
in	O
whom	O
intranasal	I-Treatment
desmopressin	I-Treatment
was	O
associated	O
with	O
hyponatremia	I-Problem
,	O
all	O
of	O
whom	O
experienced	O
seizures	I-Problem
or	I-Problem
altered	I-Problem
mental	I-Problem
status	I-Problem
.	O

hepatotoxicity	I-Problem
associated	O
with	O
use	O
of	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
in	O
rheumatoid	I-Problem
arthritis	I-Problem
.	O

accelerated	I-Problem
nodulosis	I-Problem
during	O
methotrexate	I-Treatment
therapy	O
for	O
juvenile	I-Problem
rheumatoid	I-Problem
arthritis	I-Problem
.	O

amiodarone	I-Treatment
is	O
a	O
class	O
iii	O
antiarrhythmic	O
with	O
an	I-Problem
adverse	I-Problem
-	I-Problem
effect	I-Problem
profile	I-Problem
involving	I-Problem
many	I-Problem
different	I-Problem
organ	I-Problem
systems	I-Problem
.	O

nail	I-Problem
and	I-Problem
skin	I-Problem
alterations	I-Problem
associated	O
with	O
the	O
use	O
of	O
chemotherapy	I-Treatment
have	O
been	O
described	O
in	O
the	O
last	O
decade	O
involving	O
various	O
combinations	O
of	O
two	O
different	O
types	O
of	O
nail	O
changes	O
.	O

this	O
report	O
describes	O
a	O
case	O
of	O
flucytosine	I-Treatment
-	O
associated	O
ulcerating	I-Problem
enteritis	I-Problem
in	I-Problem
which	I-Problem
the	I-Problem
small	I-Test
bowel	I-Test
x	I-Test
-	I-Test
ray	I-Test
demonstrated	I-Problem
severe	I-Problem
luminal	I-Problem
narrowing	I-Problem
,	I-Problem
ulceration	I-Problem
,	I-Problem
and	I-Problem
marked	I-Problem
separation	I-Problem
of	I-Problem
loops	I-Problem
of	I-Problem
bowel	I-Problem
.	O

chromosome	I-Problem
abnormalities	I-Problem
after	O
chlorambucil	I-Treatment
therapy	I-Treatment
of	O
polycythaemia	I-Problem
vera	I-Problem
.	O

with	O
the	O
use	O
of	O
optical	O
coherence	I-Test
tomography	I-Test
(	O
oct	O
)	O
,	O
two	O
patients	O
with	O
ifn	I-Treatment
-	O
associated	O
retinopathy	I-Problem
who	O
had	O
developed	O
macular	I-Problem
edema	I-Problem
and	I-Problem
reduced	I-Problem
visual	I-Problem
acuity	I-Problem
during	O
the	O
clinical	O
course	O
of	O
ifn	O
therapy	O
were	O
observed	O
.	O

atrial	I-Problem
fibrillation	I-Problem
after	O
vardenafil	I-Treatment
therapy	I-Treatment
.	O

in	O
phase	O
iii	O
clinical	O
trials	O
,	O
the	O
telithromycin	I-Treatment
800	I-Treatment
mg	I-Treatment
once	I-Other
-	I-Other
daily	I-Other
dose	I-Treatment
has	O
been	O
shown	O
to	O
provide	O
close	O
to	O
the	O
maximum	O
antimicrobial	O
activity	O
against	O
s	I-Problem
.	I-Problem
pneumoniae	I-Problem
,	O
haemophilus	I-Problem
influenzae	I-Problem
and	O
staphylococcus	I-Problem
aureus	I-Problem
in	O
patients	I-Background
with	I-Background
community	I-Background
-	I-Background
acquired	I-Background
pneumonia	I-Problem
.	O

we	O
suggest	O
that	O
meloxicam	I-Treatment
might	O
have	O
intestinal	I-Problem
toxic	I-Problem
effects	I-Problem
when	O
taken	O
in	O
high	I-Treatment
doses	I-Treatment
,	O
because	O
of	O
reduced	O
cox	O
-	O
2	O
selectivity	O
.	O

atrial	I-Problem
fibrillation	I-Problem
following	O
methylprednisolone	I-Treatment
pulse	I-Treatment
therapy	I-Treatment
.	O

subglottic	I-Problem
stenosis	I-Problem
in	I-Problem
wegener	I-Problem
'	I-Problem
s	I-Problem
granulomatosis	I-Problem
:	O
development	O
during	O
cyclophosphamide	I-Treatment
treatment	I-Treatment
with	I-Treatment
response	I-Treatment
to	I-Treatment
carbon	I-Treatment
dioxide	I-Treatment
laser	I-Treatment
therapy	I-Treatment
.	O

pregabalin	I-Treatment
-	O
induced	O
cortical	I-Problem
negative	I-Problem
myoclonus	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
neuropathic	I-Problem
pain	I-Problem
.	O

the	O
mechanism	O
of	O
rta	I-Problem
induced	O
by	O
fk506	I-Treatment
has	O
not	O
yet	O
been	O
clearly	O
elucidated	O
.	O

the	O
risk	O
of	O
new	I-Problem
-	I-Problem
onset	I-Problem
diabetic	I-Problem
ketoacidosis	I-Problem
in	O
patients	I-Background
with	I-Background
diabetic	I-Problem
risk	I-Problem
factors	I-Problem
who	O
are	O
taking	O
perospirone	I-Treatment
hydrochloride	I-Treatment
or	I-Treatment
other	I-Treatment
atypical	I-Treatment
antipsychotics	I-Treatment
should	O
be	O
kept	O
in	O
mind	O
.	O

severe	I-Problem
symptomatic	I-Problem
hyponatremia	I-Problem
during	O
sibutramine	I-Treatment
therapy	O
:	O
a	O
case	O
report	O
.	O

zoledronic	I-Treatment
acid	I-Treatment
-	O
induced	O
severe	I-Problem
hypocalcaemia	I-Problem
in	O
a	O
prostate	I-Problem
cancer	I-Problem
patient	I-Background
with	I-Background
extensive	I-Problem
osteoblastic	I-Problem
bone	I-Problem
metastases	I-Problem
.	O

mm	I-Problem
patients	I-Background
treated	O
with	O
thalidomide	I-Treatment
and	I-Treatment
doxorubicin	I-Treatment
have	O
a	I-Problem
high	I-Problem
risk	I-Problem
of	I-Problem
developing	I-Problem
dvt	I-Problem
.	O

these	O
two	O
cases	O
highlight	O
the	O
importance	O
of	O
considering	O
lopinavir	I-Treatment
/	I-Treatment
ritonavir	I-Treatment
induced	O
arrhythmias	I-Problem
when	O
dealing	O
with	O
hiv	I-Problem
-	I-Background
positive	I-Background
individuals	I-Background
.	O

atrial	I-Problem
fibrillation	I-Problem
occurring	O
in	O
a	I-Background
patient	I-Background
taking	O
etanercept	I-Treatment
plus	I-Treatment
methotrexate	I-Treatment
for	I-Treatment
rheumatoid	I-Problem
arthritis	I-Problem
.	O

we	O
describe	O
a	I-Background
52	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
diagnosed	O
with	O
stage	I-Problem
iii	I-Problem
multiple	I-Problem
myeloma	I-Problem
,	O
who	O
was	O
treated	O
with	O
5	I-Other
-	I-Other
monthly	I-Other
cycles	I-Treatment
of	I-Treatment
vad	I-Treatment
(	I-Treatment
vincristine	I-Treatment
,	I-Treatment
adriamycin	I-Treatment
and	I-Treatment
dexamathasone	I-Treatment
)	I-Treatment
.	O

we	O
review	O
the	O
literature	O
on	O
previously	O
reported	O
cases	O
of	O
cutaneous	I-Problem
necrosis	I-Problem
after	O
injection	O
of	O
standard	I-Treatment
interferon	I-Treatment
alfa	I-Treatment
or	O
pegylated	I-Treatment
interferon	I-Treatment
alfa	I-Treatment
-	I-Treatment
2b	I-Treatment
and	O
discuss	O
the	O
different	O
pathophysiologic	O
mechanisms	O
that	O
might	O
be	O
involved	O
.	O

used	I-Treatment
injudiciously	I-Treatment
,	I-Treatment
naloxone	I-Treatment
can	O
lead	O
to	O
withdrawal	I-Problem
syndrome	I-Problem
,	I-Problem
return	I-Problem
of	I-Problem
severe	I-Problem
pain	I-Problem
,	I-Problem
and	I-Problem
other	I-Problem
adverse	I-Problem
effects	I-Problem
.	O

when	O
vague	I-Problem
symptoms	I-Problem
develop	O
during	O
desmopressin	I-Treatment
therapy	O
,	O
hyponatremia	I-Problem
must	O
be	O
considered	O
as	O
part	O
of	O
the	O
differential	O
diagnosis	O
.	O

intravesical	I-Treatment
chemotherapy	I-Treatment
may	O
be	O
associated	O
with	O
a	O
risk	O
of	O
secondary	I-Problem
malignancy	I-Problem
.	O

discontinuation	O
of	O
methicillin	I-Treatment
therapy	O
and	O
appropriate	O
antibiotic	I-Treatment
treatment	O
of	O
endocarditis	I-Problem
led	O
to	O
clinical	O
improvement	O
,	O
emphasizing	O
the	O
need	O
to	O
promptly	O
discontinue	O
potential	O
nephrotoxic	I-Treatment
agents	I-Treatment
when	O
abnormalities	I-Problem
in	I-Problem
renal	I-Problem
function	I-Problem
appear	O
.	O

conclusions	O
:	O
this	O
study	I-Test
confirmed	O
that	O
in	O
most	I-Background
patients	I-Background
mtx	I-Treatment
-	O
induced	O
liver	I-Problem
cirrhosis	I-Problem
is	I-Problem
not	I-Problem
aggressive	I-Problem
.	O

we	O
report	O
the	O
case	O
of	O
severe	I-Problem
liver	I-Problem
toxicity	I-Problem
with	I-Problem
jaundice	I-Problem
during	O
radiochemotherapy	O
with	O
temozolomide	I-Treatment
likely	O
due	O
to	O
interaction	O
with	O
a	I-Treatment
popular	I-Treatment
chinese	I-Treatment
herbal	I-Treatment
formula	I-Treatment
after	O
surgery	O
for	O
glioblastoma	I-Problem
.	O

he	I-Background
was	O
started	O
on	O
oral	I-Treatment
lansoprazole	I-Treatment
60	I-Treatment
mg	I-Treatment
twice	I-Other
daily	I-Other
and	O
,	O
on	O
hospital	O
day	I-Other
2	I-Other
,	O
his	O
platelet	I-Test
count	I-Test
decreased	I-Problem
to	O
102	O
x	O
10	O
(	O
3	O
)	O
/	O
mm	O
(	O
3	O
)	O
;	O
on	O
hospital	O
day	O
3	O
,	O
the	O
platelet	I-Test
count	I-Test
was	O
36	O
x	O
10	O
(	O
3	O
)	O
/	O
mm	O
(	O
3	O
)	O
.	O

she	I-Background
received	O
an	O
accidental	O
450	I-Treatment
-	I-Treatment
mg	I-Treatment
bolus	I-Treatment
injection	I-Treatment
of	I-Treatment
morphine	I-Treatment
intrathecally	O
and	O
developed	O
hypertension	I-Problem
,	I-Problem
status	I-Problem
epilepticus	I-Problem
,	I-Problem
intracerebral	I-Problem
hemorrhage	I-Problem
,	I-Problem
and	I-Problem
respiratory	I-Problem
failure	I-Problem
.	O

we	O
describe	O
six	O
patients	I-Background
who	O
developed	O
tardive	I-Problem
dyskinesia	I-Problem
after	O
treatment	O
with	O
sulpiride	I-Treatment
for	O
depression	I-Problem
or	O
gastrointestinal	I-Problem
symptoms	I-Problem
.	O

hepatotoxicity	I-Problem
of	O
hycanthone	I-Treatment
in	O
patients	I-Background
with	I-Background
metastatic	I-Problem
breast	I-Problem
cancer	I-Problem
.	O

the	O
authors	O
report	O
five	O
additional	O
cases	O
of	O
capecitabine	I-Treatment
-	O
induced	O
multifocal	I-Problem
leukoencephalopathy	I-Problem
.	O

chlormadinone	I-Treatment
acetate	I-Treatment
withdrawal	O
syndrome	O
under	O
combined	O
androgen	I-Treatment
blockade	I-Treatment
for	O
advanced	I-Problem
prostate	I-Problem
cancer	I-Problem
.	O

restless	I-Problem
legs	I-Problem
syndrome	I-Problem
and	O
periodic	I-Problem
limb	I-Problem
movements	I-Problem
during	I-Problem
sleep	I-Problem
probably	O
associated	O
with	O
olanzapine	I-Treatment
.	O

evaluation	O
of	I-Test
the	I-Test
literature	I-Test
provides	O
substantial	O
evidence	O
for	O
the	O
use	O
of	O
hydrocortisone	I-Treatment
in	O
prevention	O
of	O
cardiac	I-Problem
arrhythmias	I-Problem
.	O

we	O
report	O
a	I-Background
case	I-Background
of	I-Background
rta	I-Problem
secondary	O
to	O
fk506	I-Treatment
administration	I-Treatment
in	I-Treatment
liver	I-Treatment
transplantation	I-Treatment
.	O

myoclonus	I-Problem
associated	O
with	O
continuous	I-Treatment
dobutamine	I-Treatment
infusion	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
end	I-Problem
-	I-Problem
stage	I-Problem
renal	I-Problem
disease	I-Problem
.	O

amphotericin	I-Problem
b	I-Problem
nephrotoxicity	I-Problem
in	I-Problem
humans	I-Problem
decreased	I-Problem
by	O
salt	I-Treatment
repletion	I-Treatment
.	O

only	O
a	O
few	O
reports	O
of	O
overt	I-Problem
jaundice	I-Problem
are	O
associated	O
with	O
streptokinase	I-Treatment
.	O

possible	O
heart	I-Problem
failure	I-Problem
exacerbation	I-Problem
associated	O
with	O
rosiglitazone	I-Treatment
:	O
case	O
report	O
and	O
literature	O
review	O
.	O

we	O
report	O
the	I-Background
first	I-Background
case	I-Background
of	O
polymorphic	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
with	I-Problem
normal	I-Problem
qt	I-Problem
interval	I-Problem
associated	O
with	O
the	O
oral	I-Treatment
use	I-Treatment
of	I-Treatment
levofloxacin	I-Treatment
in	O
the	O
absence	O
of	O
other	O
etiologies	O
known	O
to	O
cause	O
these	O
arrhythmias	I-Problem
.	O

reversible	I-Problem
leukopenia	I-Problem
was	O
documented	O
in	O
an	I-Background
81	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
treated	O
with	O
adjunctive	I-Treatment
ibopamine	I-Treatment
100	I-Treatment
mg	I-Treatment
t	I-Treatment
.	I-Treatment
i	I-Treatment
.	I-Treatment
d	I-Treatment
.	I-Treatment
for	O
chronic	I-Problem
congestive	I-Problem
heart	I-Problem
failure	I-Problem
.	O

we	O
conjectured	O
that	O
the	O
side	O
effects	O
of	O
insulin	I-Treatment
,	O
such	O
as	O
anti	I-Problem
-	I-Problem
natriuresis	I-Problem
and	I-Problem
increased	I-Problem
vascular	I-Problem
permeability	I-Problem
,	O
might	O
be	O
pronounced	O
in	O
the	O
presence	O
of	O
the	O
hepatic	O
dysfunction	O
that	O
accompanies	O
insulin	O
insensitivity	O
,	O
hyperinsulinaemia	O
and	O
hypoalbuminaemia	O
.	O

acute	I-Problem
myelogenous	I-Problem
leukemia	I-Problem
in	O
patients	I-Background
receiving	I-Treatment
chlorambucil	I-Treatment
as	I-Treatment
long	I-Treatment
-	I-Treatment
term	I-Treatment
adjuvant	I-Treatment
chemotherapy	I-Treatment
for	O
stage	I-Problem
ii	I-Problem
breast	I-Problem
cancer	I-Problem
.	I-Problem

we	O
report	O
a	O
case	O
of	O
generalized	I-Problem
cutaneous	I-Problem
sclerosis	I-Problem
associated	I-Problem
with	I-Problem
muscle	I-Problem
and	I-Problem
oesophageal	I-Problem
involvement	I-Problem
in	O
a	O
patient	O
exposed	O
to	O
herbicides	I-Treatment
containing	I-Treatment
bromocil	I-Treatment
,	I-Treatment
diuron	I-Treatment
and	I-Treatment
aminotriazole	I-Treatment
.	O

only	O
3	O
cases	O
of	O
imatinib	I-Treatment
-	O
induced	O
tumor	I-Problem
lysis	I-Problem
syndrome	I-Problem
have	O
been	O
reported	O
.	O

a	I-Background
61	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
patient	I-Background
who	I-Background
had	I-Background
been	I-Background
treated	I-Background
with	I-Background
lisinopril	I-Background
in	I-Background
the	I-Background
past	I-Background
without	I-Background
any	I-Background
problems	I-Background
was	O
commenced	O
on	O
ramipril	I-Treatment
for	O
left	I-Problem
ventricular	I-Problem
dysfunction	I-Problem
.	O

however	O
,	O
repeated	I-Treatment
intracameral	I-Treatment
tpa	I-Treatment
injections	I-Treatment
may	O
cause	O
unwanted	I-Problem
complications	I-Problem
such	I-Problem
as	I-Problem
vitreous	I-Problem
hemorrhage	I-Problem
.	O

in	O
this	O
article	O
,	O
we	O
present	O
the	O
case	O
of	O
a	I-Background
vitiligo	I-Problem
patient	I-Background
who	O
was	O
admitted	O
to	O
our	O
facility	O
with	O
an	O
intense	I-Problem
burn	I-Problem
after	O
the	O
topical	I-Treatment
use	I-Treatment
of	I-Treatment
8	I-Treatment
-	I-Treatment
methoxypsoralen	I-Treatment
solution	I-Treatment
as	I-Treatment
a	I-Treatment
suntanning	I-Treatment
agent	I-Treatment
.	O

the	O
frequency	O
and	O
relationship	O
of	O
granulocytopenia	I-Problem
caused	O
by	O
sustained	O
-	O
release	O
procainamide	I-Treatment
in	O
patients	I-Background
with	I-Background
tachyarrhythmias	I-Problem
are	O
briefly	O
discussed	O
,	O
and	O
prior	O
reported	O
cases	O
are	O
reviewed	O
.	O

cicatricial	I-Problem
entropion	I-Problem
associated	O
with	O
chronic	I-Treatment
dipivefrin	I-Treatment
application	I-Treatment
.	O

nine	O
delirious	I-Problem
patients	I-Background
suffering	O
from	O
lithium	I-Treatment
intoxication	I-Problem
were	O
examined	O
with	O
the	O
mini	I-Test
-	I-Test
mental	I-Test
state	I-Test
exam	I-Test
(	O
mms	O
)	O
to	O
describe	O
the	O
clinical	O
course	O
of	O
the	O
disorder	O
.	O

cryptococcus	I-Problem
neoformans	I-Problem
fatal	I-Problem
sepsis	I-Problem
in	O
a	I-Background
chronic	I-Problem
lymphocytic	I-Problem
leukemia	I-Problem
patient	I-Background
treated	O
with	O
alemtuzumab	I-Treatment
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

cholestyramine	I-Treatment
induced	O
hyperchloremic	I-Problem
metabolic	I-Problem
acidosis	I-Problem
.	I-Problem

methadone	O
is	O
recommended	O
as	O
being	O
free	O
of	O
some	O
of	O
the	O
neuropsychological	I-Problem
side	I-Problem
effects	I-Problem
noticed	O
with	O
morphine	I-Treatment
,	O
which	O
are	O
attributed	O
to	O
active	O
metabolites	O
.	O

this	O
is	O
the	O
first	O
reported	O
case	O
of	O
boop	I-Problem
associated	O
with	O
single	I-Treatment
-	I-Treatment
agent	I-Treatment
rituximab	I-Treatment
,	O
and	O
along	O
with	O
two	O
other	O
patients	O
we	O
describe	O
,	O
as	O
well	O
as	O
two	O
prior	O
reports	O
of	O
boop	O
in	O
nhl	O
patients	O
receiving	O
rituximab	O
-	O
based	O
combinations	O
,	O
strengthens	O
the	O
possibility	O
of	O
a	O
causal	O
relationship	O
.	O

the	O
treatment	O
for	O
acidosis	I-Problem
and	I-Problem
hyperkalaemia	I-Problem
should	O
be	O
started	O
as	O
soon	O
as	O
rta	I-Problem
is	O
diagnosed	O
,	O
and	O
the	O
dosage	O
of	O
fk506	I-Treatment
should	O
also	O
be	O
reduced	O
if	O
possible	O
.	O

a	I-Background
62	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
treated	I-Treatment
with	I-Treatment
pranlukast	I-Treatment
for	I-Treatment
2	I-Other
months	I-Other
developed	O
interstitial	I-Problem
pneumonitis	I-Problem
with	I-Problem
a	I-Problem
high	I-Problem
fever	I-Problem
.	O

neurotoxicity	I-Problem
of	O
valacyclovir	I-Treatment
in	I-Treatment
peritoneal	I-Treatment
dialysis	I-Treatment
:	O
a	O
pharmacokinetic	I-Test
study	I-Test
.	O

he	I-Background
had	O
been	O
taking	O
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
for	I-Treatment
approximately	I-Treatment
eight	I-Other
days	I-Other
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headaches	I-Problem
,	I-Problem
dizziness	I-Problem
,	I-Problem
difficulty	I-Problem
with	I-Problem
speech	I-Problem
,	I-Problem
weakness	I-Problem
,	I-Problem
and	I-Problem
itching	I-Problem
on	I-Problem
the	I-Problem
trunk	I-Problem
of	I-Problem
his	I-Problem
body	I-Problem
and	I-Problem
legs	I-Problem
,	O
where	O
a	O
maculopapular	I-Problem
rash	I-Problem
was	O
noted	O
.	O

we	O
present	O
an	I-Background
aids	I-Problem
patient	I-Background
with	O
severe	I-Problem
and	I-Problem
prolonged	I-Problem
lactic	I-Problem
acidosis	I-Problem
on	O
stavudine	I-Treatment
and	I-Treatment
lamivudine	I-Treatment
.	O

sudden	I-Problem
cardiac	I-Problem
death	I-Problem
due	I-Problem
to	I-Problem
hypersensitivity	I-Problem
myocarditis	I-Problem
during	O
clozapine	I-Treatment
treatment	O
.	O

it	O
also	O
highlights	O
a	O
current	O
major	O
etiologic	O
question	O
,	O
that	O
is	O
,	O
whether	O
and	O
to	O
what	O
degree	O
lead	I-Treatment
exposure	I-Treatment
contributes	O
to	O
the	O
development	O
of	O
hypertension	I-Problem
,	O
and	O
raises	O
the	O
issue	O
of	O
whether	O
lead	O
-	O
induced	O
hypertension	O
constitutes	O
a	O
subset	O
of	O
hypertension	O
that	O
is	O
especially	O
amenable	O
to	O
therapy	O
with	O
dietary	O
calcium	O
.	O

we	O
report	O
an	O
allogeneic	I-Problem
bone	I-Problem
marrow	I-Problem
transplant	I-Problem
recipient	I-Background
who	O
developed	O
cmv	I-Problem
infection	I-Problem
refractory	O
to	O
sequential	I-Treatment
therapy	I-Treatment
with	I-Treatment
ganciclovir	I-Treatment
,	I-Treatment
foscarnet	I-Treatment
,	I-Treatment
and	I-Treatment
cidofovir	I-Treatment
.	O

acute	I-Problem
interstitial	I-Problem
pneumonia	I-Problem
induced	O
by	O
ono	I-Treatment
-	I-Treatment
1078	I-Treatment
(	I-Treatment
pranlukast	I-Treatment
)	I-Treatment
,	O
a	O
leukotriene	O
receptor	O
antagonist	O
.	O

conclusion	O
:	O
significant	O
ocular	O
complications	O
such	O
as	O
an	O
irreversible	I-Problem
decrease	I-Problem
of	I-Problem
visual	I-Problem
acuity	I-Problem
may	O
develop	O
in	O
patients	I-Background
treated	O
with	O
pegylated	I-Treatment
interferon	I-Treatment
.	O

conclusions	O
:	O
this	O
case	O
report	O
showed	O
that	O
the	O
clinical	I-Problem
appearance	I-Problem
of	I-Problem
hashimoto	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
after	O
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
therapy	O
for	O
chronic	I-Problem
c	I-Problem
hepatitis	I-Problem
in	O
our	I-Background
patient	I-Background
was	O
associated	O
with	O
a	I-Problem
specific	I-Problem
genetic	I-Problem
predisposition	I-Problem
(	I-Problem
dr5	I-Problem
)	I-Problem
for	I-Problem
this	I-Problem
pathology	I-Problem
.	O

we	O
present	O
here	O
a	I-Background
female	I-Background
patient	I-Background
who	O
developed	O
acute	I-Problem
bilateral	I-Problem
parotitis	I-Problem
within	I-Other
minutes	I-Other
of	O
i	I-Treatment
.	I-Treatment
v	I-Treatment
.	I-Treatment
enalaprilat	I-Treatment
injection	I-Treatment
and	O
recovered	O
within	O
24	O
hours	O
of	O
stopping	O
the	O
drug	O
and	O
with	O
symptomatic	O
treatment	O
.	O

we	O
describe	O
2	O
patients	I-Background
with	I-Background
prior	I-Problem
amputation	I-Problem
who	O
experienced	O
phantom	I-Problem
limb	I-Problem
pain	I-Problem
(	I-Problem
plp	I-Problem
)	I-Problem
after	O
receiving	O
paclitaxel	I-Treatment
therapy	I-Treatment
.	O

there	O
is	O
evidence	O
that	O
the	O
angiotensin	I-Treatment
ii	I-Treatment
receptor	I-Treatment
antagonist	I-Treatment
,	I-Treatment
losartan	I-Treatment
,	O
increases	I-Problem
urate	I-Problem
excretion	I-Problem
by	O
reducing	I-Problem
reabsorption	I-Problem
of	I-Problem
urate	I-Problem
in	I-Problem
the	I-Problem
renal	I-Problem
proximal	I-Problem
tubule	I-Problem
.	I-Problem

although	O
no	O
coagulation	O
study	I-Test
was	O
done	O
and	O
the	O
meckel	O
'	O
s	O
diverticulum	O
is	O
normally	O
associated	O
with	O
bleeding	O
,	O
the	O
particular	O
intensity	O
of	O
the	O
following	O
hemorrhage	I-Problem
may	O
have	O
been	O
favored	O
by	O
metformin	I-Treatment
.	O

upper	I-Problem
tract	I-Problem
urothelial	I-Problem
malignancy	I-Problem
after	O
cyclophosphamide	I-Treatment
therapy	I-Treatment
:	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O

background	O
:	O
methotrexate	I-Treatment
(	I-Treatment
mtx	I-Treatment
)	I-Treatment
may	O
induce	O
liver	I-Problem
damage	I-Problem
,	I-Problem
which	I-Problem
in	I-Problem
some	I-Problem
psoriatics	I-Problem
will	I-Problem
lead	I-Problem
to	I-Problem
fibrosis	I-Problem
or	I-Problem
cirrhosis	I-Problem
.	O

the	O
infection	I-Problem
proceeded	I-Problem
even	O
after	O
treatment	O
with	O
fluconazole	I-Treatment
.	O

we	O
report	O
the	O
case	O
of	O
intoxication	I-Problem
of	O
a	I-Background
41	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
patient	I-Background
suffering	O
from	O
major	I-Problem
depression	I-Problem
with	O
mirtazapine	I-Treatment
complicated	O
by	O
severe	O
hypothermia	I-Problem
.	O

the	O
bilateral	O
ptosis	O
markedly	O
improved	O
after	O
7	I-Other
days	I-Other
of	O
pyridoxine	I-Treatment
and	I-Treatment
pyridostigmine	I-Treatment
treatment	I-Treatment
and	O
completely	O
resolved	O
after	O
two	O
weeks	O
.	O

purpose	O
:	O
the	O
case	O
of	O
a	I-Background
patient	I-Background
who	O
developed	O
aseptic	I-Problem
meningitis	I-Problem
,	I-Problem
hemolytic	I-Problem
anemia	I-Problem
,	I-Problem
hepatitis	I-Problem
,	I-Problem
and	I-Problem
orthostatic	I-Problem
hypotension	I-Problem
simultaneously	O
during	O
treatment	O
with	O
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
is	O
described	O
.	O

seizures	I-Problem
and	I-Problem
extrapyramidal	I-Problem
symptoms	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
tourette	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
,	I-Background
asperger	I-Problem
'	I-Problem
s	I-Problem
syndrome	I-Problem
,	I-Background
and	I-Background
multiple	I-Problem
sclerosis	I-Problem
treated	O
with	O
interferon	I-Treatment
beta	I-Treatment
-	I-Treatment
1a	I-Treatment
and	I-Treatment
clomipramine	I-Treatment
.	O

psychotic	I-Problem
disorder	I-Problem
associated	O
with	O
isoniazid	I-Treatment
.	O

the	I-Treatment
azathioprine	I-Treatment
dose	I-Treatment
was	I-Treatment
low	I-Treatment
(	I-Treatment
1	I-Treatment
mg	I-Treatment
/	I-Treatment
kg	I-Treatment
)	I-Treatment
and	O
pancytopenia	I-Problem
occurred	O
after	O
56	I-Other
days	I-Other
therapy	I-Treatment
.	O

findings	O
on	O
discontinuation	O
and	O
rechallenge	O
supported	O
the	O
assumption	O
that	O
the	O
hair	I-Problem
loss	I-Problem
was	O
a	O
side	O
effect	O
of	O
the	O
paroxetine	I-Treatment
.	I-Treatment

the	O
successful	O
development	O
and	O
implementation	O
of	O
this	O
protocol	O
will	O
have	O
impact	O
on	O
patients	I-Background
who	O
have	O
anaphylactic	I-Problem
reactions	I-Problem
to	O
mtx	I-Treatment
but	O
require	O
this	O
medication	O
for	O
specific	O
diseases	O
.	O

clomiphene	I-Treatment
is	O
a	O
first	O
line	O
treatment	O
for	O
anovulation	I-Problem
,	O
a	O
common	O
cause	O
of	O
infertility	O
.	O

a	I-Background
new	I-Background
case	I-Background
of	O
creutzfeldt	I-Problem
-	I-Problem
jakob	I-Problem
disease	I-Problem
associated	O
with	O
human	I-Treatment
growth	I-Treatment
hormone	I-Treatment
therapy	O
in	O
new	O
zealand	O
.	O

this	O
case	I-Test
study	I-Test
is	O
the	O
second	O
report	O
of	O
localized	I-Problem
purpura	I-Problem
after	O
prolonged	I-Other
lamotrigine	O
treatment	O
suggesting	O
this	O
may	O
be	O
an	O
atypical	O
lamotrigine	I-Treatment
-	O
induced	O
drug	I-Problem
reaction	I-Problem
.	O

extrapyramidal	I-Problem
symptoms	I-Problem
are	O
well	O
-	O
documented	O
complications	O
of	O
therapy	O
with	O
haloperidol	I-Treatment
,	O
even	O
when	O
small	I-Treatment
doses	I-Treatment
are	O
used	O
.	O

although	O
cetirizine	I-Treatment
has	O
less	O
potential	O
for	O
causing	O
arrhythmias	I-Problem
than	O
other	O
histamine	O
1	O
blockers	O
,	O
such	O
an	O
interaction	O
should	O
be	O
considered	O
,	O
especially	O
in	O
patients	I-Background
with	I-Background
renal	I-Problem
insufficiency	I-Problem
who	O
are	O
receiving	O
pilsicainide	O
.	O

bronchiolitis	I-Problem
obliterans	I-Problem
with	I-Problem
organizing	I-Problem
pneumonia	I-Problem
after	O
rituximab	I-Treatment
therapy	I-Treatment
for	O
non	I-Problem
-	I-Problem
hodgkin	I-Problem
'	I-Problem
s	I-Problem
lymphoma	I-Problem
.	O

the	O
case	O
demonstrates	O
that	O
hypersensitivity	I-Problem
reaction	I-Problem
to	O
pranlukast	I-Treatment
and	O
resultant	O
atin	O
is	O
possible	O
,	O
and	O
that	O
periodic	O
urine	I-Test
testing	I-Test
in	O
patients	O
receiving	O
pranlukast	I-Treatment
should	O
be	O
considered	O
.	O

the	O
patient	O
'	O
s	O
clinical	O
presentation	O
,	O
histologic	O
features	O
on	O
liver	O
biopsy	I-Test
and	O
favorable	O
course	O
after	O
stopping	O
the	O
drug	O
suggest	O
that	O
barbiturates	I-Treatment
can	O
be	O
added	O
to	O
the	O
list	O
of	O
agents	O
which	O
can	O
cause	O
submassive	I-Problem
hepatic	I-Problem
necrosis	I-Problem
.	O

although	O
there	O
have	O
been	O
numerous	O
reports	O
of	O
effusions	O
,	O
none	O
have	O
provided	O
complete	O
pleural	I-Test
fluid	I-Test
analysis	I-Test
;	O
therefore	O
,	O
we	O
report	O
2	O
patients	I-Background
with	O
dasatinib	I-Treatment
-	O
induced	O
pleural	I-Problem
effusion	I-Problem
with	O
complete	O
pleural	I-Test
fluid	I-Test
analysis	I-Test
.	O

morphea	I-Problem
after	O
bromocriptine	I-Treatment
therapy	I-Treatment
.	O

purpose	O
:	O
to	O
describe	O
the	O
clinical	O
and	O
electrophysiological	O
findings	O
in	O
a	I-Background
young	I-Background
boy	I-Background
with	O
decreased	I-Problem
vision	I-Problem
possibly	O
due	O
to	O
retinal	I-Problem
damage	I-Problem
by	O
rifabutin	I-Treatment
.	O

we	O
reported	O
a	I-Background
case	I-Background
of	O
disulfiram	I-Treatment
-	O
induced	O
hepatitis	I-Problem
with	O
unique	O
clinical	O
features	O
and	O
compared	O
our	O
case	O
with	O
others	O
in	O
the	O
literature	O
.	O

we	O
report	O
a	O
patient	I-Background
receiving	O
chronic	I-Other
lithium	I-Treatment
therapy	I-Treatment
who	O
presented	O
with	O
a	O
transient	I-Problem
cdi	I-Problem
occurring	O
in	O
the	O
setting	O
of	O
underlying	I-Problem
chronic	I-Problem
ndi	I-Problem
.	O

here	O
we	O
report	O
a	I-Background
patient	I-Background
with	I-Background
newly	I-Background
diagnosed	I-Background
acute	I-Problem
promyelocytic	I-Problem
leukemia	I-Problem
who	O
developed	O
acute	I-Problem
focal	I-Problem
myositis	I-Problem
,	I-Problem
synovitis	I-Problem
,	I-Problem
and	I-Problem
possible	I-Problem
vasculitis	I-Problem
,	O
after	O
receiving	O
all	I-Treatment
-	I-Treatment
trans	I-Treatment
retinoic	I-Treatment
acid	I-Treatment
therapy	O
.	O

we	O
report	O
a	O
case	O
of	O
methotrexate	I-Problem
toxicity	I-Problem
potentially	O
induced	O
by	O
a	O
drug	O
interaction	O
between	O
methotrexate	I-Treatment
and	I-Treatment
omeprazole	I-Treatment
in	O
a	I-Background
25	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
osteosarcoma	I-Problem
.	O

increasing	I-Treatment
the	I-Treatment
olanzapine	I-Treatment
dosage	I-Treatment
severely	O
aggravated	O
the	O
symptoms	I-Problem
of	I-Problem
rls	I-Problem
.	O

we	O
report	O
a	I-Background
case	I-Background
of	I-Background
48	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
seizure	I-Problem
disorder	I-Problem
on	O
divalproex	I-Treatment
sodium	I-Treatment
(	I-Treatment
depakote	I-Treatment
)	I-Treatment
who	O
presented	O
with	O
dyspnea	I-Problem
.	O

to	O
report	O
a	O
probable	O
interaction	I-Treatment
between	I-Treatment
warfarin	I-Treatment
and	I-Treatment
marijuana	I-Treatment
smoking	I-Treatment
,	O
resulting	O
in	O
increased	I-Problem
international	I-Problem
normalized	I-Problem
ratio	I-Problem
(	I-Problem
inr	I-Problem
)	I-Problem
values	I-Problem
and	I-Problem
bleeding	I-Problem
complications	I-Problem
.	O

transient	I-Problem
cardiac	I-Problem
arrhythmias	I-Problem
related	O
to	O
lopinavir	I-Treatment
/	I-Treatment
ritonavir	I-Treatment
in	O
two	O
patients	I-Background
with	I-Background
hiv	I-Problem
infection	I-Problem
.	O

interestingly	O
,	O
the	O
use	O
of	O
carboplatin	O
(	O
cbdca	O
)	O
and	O
vds	O
in	O
the	O
subsequent	O
treatment	O
course	O
was	O
well	O
tolerated	O
indicating	O
that	O
the	O
siadh	I-Problem
was	O
most	O
likely	O
to	O
have	O
been	O
induced	O
by	O
administration	O
of	O
cddp	I-Treatment
.	O

although	O
heparin	I-Treatment
-	I-Test
dependent	I-Treatment
antibodies	I-Test
(	I-Treatment
hdas	I-Treatment
)	I-Treatment
typically	O
manifest	O
with	O
thrombocytopenia	I-Problem
as	O
in	O
heparin	O
-	O
induced	O
thrombocytopenia	O
(	O
hit	O
)	O
,	O
they	O
may	O
also	O
manifest	O
with	O
preserved	O
platelet	I-Test
counts	I-Test
.	O

a	O
69	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
female	I-Background
whose	O
anticoagulation	I-Treatment
treatment	I-Treatment
had	I-Treatment
been	I-Treatment
stable	I-Treatment
for	I-Treatment
18	I-Treatment
months	I-Treatment
with	I-Treatment
warfarin	I-Treatment
2	I-Treatment
.	I-Treatment
5	I-Treatment
mg	I-Treatment
daily	I-Other
(	I-Other
17	I-Other
.	I-Treatment
5	I-Treatment
mg	I-Treatment
/	I-Treatment
wk	I-Treatment
)	I-Treatment
presented	O
to	O
an	O
anticoagulation	O
clinic	O
with	O
a	O
critically	O
elevated	I-Problem
inr	I-Problem
of	I-Problem
greater	I-Problem
than	I-Problem
12	I-Problem
.	I-Problem
3	I-Problem
after	O
a	O
dose	I-Treatment
increase	I-Treatment
in	I-Treatment
extended	I-Treatment
-	I-Treatment
release	I-Treatment
niacin	I-Treatment
(	I-Treatment
niaspan	I-Treatment
)	I-Treatment
from	I-Treatment
500	I-Treatment
mg	I-Treatment
to	I-Treatment
1000	I-Treatment
mg	I-Treatment
daily	I-Other
the	I-Treatment
previous	I-Treatment
week	I-Treatment
.	O

the	O
most	O
serious	O
dental	O
side	O
effect	O
of	O
bisphosphonate	I-Treatment
treatment	I-Treatment
(	I-Treatment
particularly	I-Treatment
when	I-Treatment
it	I-Treatment
is	I-Treatment
administered	I-Treatment
intravenously	I-Treatment
)	I-Treatment
is	O
,	O
paradoxically	O
,	O
osteonecrosis	I-Problem
of	I-Problem
the	I-Problem
mandible	I-Problem
or	I-Problem
the	I-Problem
maxilla	I-Problem
represented	I-Problem
by	I-Problem
exposed	I-Problem
nonhealing	I-Problem
bone	I-Problem
.	O

pericardial	I-Problem
hemorrhage	I-Problem
due	O
to	O
acetylsalicylic	I-Treatment
acid	I-Treatment
in	O
a	O
patient	O
with	O
essential	O
thrombocythemia	O
.	O

these	I-Background
cases	I-Background
and	O
a	O
review	O
of	O
the	O
literature	O
suggested	O
that	O
hepatotoxicity	I-Problem
,	O
though	O
rare	O
,	O
should	O
be	O
added	O
to	O
the	O
list	O
of	O
adverse	O
reactions	O
to	O
d	I-Treatment
-	I-Treatment
penicillamine	I-Treatment
.	O

after	I-Other
four	I-Other
months	I-Other
,	O
while	O
receiving	I-Treatment
rh	I-Treatment
,	O
he	O
developed	O
painful	I-Problem
bilateral	I-Problem
gynaecomastia	I-Problem
.	O

the	O
plasma	I-Test
concentrations	I-Test
of	O
both	O
drugs	O
were	O
significantly	O
increased	O
during	O
the	O
coadministration	O
,	O
and	O
the	O
cetirizine	I-Test
concentration	I-Test
decreased	O
on	O
cessation	O
of	O
pilsicainide	I-Treatment
despite	O
the	O
fact	O
that	O
treatment	O
with	O
cetirizine	I-Treatment
was	O
continued	O
,	O
which	O
suggested	O
that	O
the	O
fainting	I-Problem
was	O
induced	O
by	O
the	O
pharmacokinetic	O
drug	O
interaction	O
.	O

objective	O
:	O
to	O
report	O
a	O
case	O
of	O
multiple	I-Problem
episodes	I-Problem
of	I-Problem
seizure	I-Problem
activity	I-Problem
in	O
an	I-Background
aids	I-Problem
patent	I-Background
following	O
amphotericin	I-Treatment
b	I-Treatment
infusion	I-Treatment
.	O

the	O
vomiting	I-Problem
occurred	O
on	O
switching	O
to	O
different	I-Treatment
pancreatic	I-Treatment
enzymes	I-Treatment
preparations	I-Treatment
,	I-Treatment
ie	I-Treatment
,	I-Treatment
creon	I-Treatment
10	I-Treatment
,	I-Treatment
viokase	I-Treatment
,	I-Treatment
and	I-Treatment
pancrease	I-Treatment
mt	I-Test
16	I-Treatment
.	O

although	O
tardive	I-Problem
dyskinesia	I-Problem
is	O
a	O
known	O
adverse	O
reaction	O
of	O
sustained	O
treatment	O
with	O
traditional	O
neuroleptic	O
agents	O
,	O
it	O
was	O
only	O
rarely	O
reported	O
in	O
association	O
with	O
sulpiride	I-Treatment
,	O
a	O
selective	O
d2	O
-	O
receptor	O
antagonist	O
.	O

this	O
report	O
highlights	O
a	O
case	O
of	O
drug	O
-	O
induced	O
dysphagia	I-Problem
in	O
a	I-Background
patient	I-Background
receiving	O
haloperidol	I-Treatment
for	O
obsessive	I-Problem
nocturnal	I-Problem
thoughts	I-Problem
and	I-Problem
auditory	I-Problem
disturbances	I-Problem
.	O

in	O
addition	O
to	O
disease	O
refractoriness	O
,	O
rare	O
instances	O
of	O
disease	I-Problem
progression	I-Problem
from	I-Problem
chronic	I-Problem
phase	I-Problem
to	I-Problem
blast	I-Problem
crisis	I-Problem
during	O
imatinib	I-Treatment
therapy	I-Treatment
have	O
recently	O
been	O
anecdotally	O
reported	O
.	O

we	O
report	O
a	I-Background
typical	I-Background
case	I-Background
of	O
transient	I-Problem
serotonin	I-Problem
syndrome	I-Problem
secondary	O
to	O
tramadol	I-Treatment
-	I-Treatment
citalopram	I-Treatment
combination	I-Treatment
.	O

although	O
use	O
of	O
the	O
naranjo	O
adverse	O
reaction	I-Test
probability	I-Test
scale	I-Test
indicated	O
a	O
probable	O
relationship	O
(	O
score	O
of	O
6	O
)	O
between	O
the	I-Background
patient	I-Background
'	O
s	O
development	O
of	O
methotrexate	I-Treatment
toxicity	I-Problem
and	I-Treatment
omeprazole	I-Treatment
use	I-Treatment
,	O
we	O
believe	O
this	O
was	O
a	O
drug	O
-	O
drug	O
interaction	O
case	O
consistent	O
with	O
previous	O
reports	O
in	O
the	O
literature	O
.	O

systemic	I-Treatment
cyclosporin	I-Treatment
(	I-Treatment
10	I-Treatment
mg	I-Treatment
/	I-Treatment
kg	I-Treatment
/	I-Treatment
day	I-Treatment
)	I-Treatment
resulted	O
in	O
resolution	I-Problem
of	I-Problem
the	I-Problem
corneal	I-Problem
ulceration	I-Problem
within	O
two	O
weeks	O
of	O
beginning	O
treatment	O
,	O
and	O
the	O
patient	I-Background
has	O
remained	O
in	O
remission	O
after	O
15	O
months	O
of	O
therapy	O
.	O

we	O
report	O
a	I-Background
59	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
patient	I-Background
with	I-Background
chronic	I-Problem
myeloid	I-Problem
leukemia	I-Problem
,	O
who	O
developed	O
severe	O
interstitial	I-Problem
lung	I-Problem
fibrosis	I-Problem
after	O
short	I-Other
term	I-Other
and	I-Treatment
sequential	I-Treatment
treatment	I-Treatment
with	I-Treatment
melphalan	I-Treatment
and	I-Treatment
busulfan	I-Treatment
.	O

does	O
the	O
use	O
of	O
insulin	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
liver	I-Problem
dysfunction	I-Problem
increase	I-Problem
water	I-Problem
retention	I-Problem
in	I-Problem
the	I-Problem
body	I-Problem
,	I-Problem
i	I-Problem
.	I-Problem
e	I-Problem
.	I-Problem
cause	I-Problem
insulin	I-Problem
oedema	I-Problem
?	I-Problem

sustained	I-Problem
hypothyroidism	I-Problem
induced	O
by	O
recombinant	I-Treatment
alpha	I-Treatment
interferon	I-Treatment
in	O
patients	I-Background
with	I-Background
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

withdrawal	I-Treatment
of	I-Treatment
depakote	I-Treatment
resulted	O
in	O
resolution	I-Problem
of	I-Problem
the	I-Problem
effusion	I-Problem
.	O

adenosine	I-Treatment
-	O
induced	O
ventricular	I-Problem
fibrillation	I-Problem
.	O

evaluation	O
of	O
initial	O
and	I-Test
steady	O
-	I-Test
state	I-Test
gatifloxacin	I-Treatment
pharmacokinetics	I-Test
and	O
dose	O
in	O
pulmonary	I-Problem
tuberculosis	I-Problem
patients	I-Background
by	O
using	O
monte	O
carlo	I-Test
simulations	I-Test
.	O

we	O
report	O
two	O
patients	I-Background
with	I-Background
acne	I-Problem
vulgaris	I-Problem
with	O
a	O
fourth	I-Problem
type	I-Problem
of	I-Problem
minocycline	I-Treatment
-	O
induced	O
cutaneous	I-Problem
pigmentation	I-Problem
.	O

budesonide	I-Treatment
is	O
a	O
synthetic	O
glucocorticosteroid	O
that	O
is	O
commonly	O
used	O
in	O
topical	O
treatment	O
of	O
asthma	I-Problem
and	I-Problem
rhinitis	I-Problem
.	I-Problem

cyclosporin	I-Treatment
therapy	O
in	O
mooren	I-Problem
'	I-Problem
s	I-Problem
ulcer	I-Problem
.	O

she	I-Background
developed	O
neurotoxicity	I-Problem
with	O
an	O
adjustment	I-Treatment
dosage	I-Treatment
of	I-Treatment
valacyclovir	I-Treatment
for	O
a	O
cutaneous	I-Problem
zoster	I-Problem
infection	I-Problem
.	O

nine	I-Background
eyes	I-Background
from	I-Background
6	O
patients	I-Background
,	I-Background
74	I-Background
years	I-Background
to	I-Background
90	I-Background
years	I-Background
of	I-Background
age	I-Background
,	O
referred	O
by	O
ophthalmologists	O
for	O
repair	O
of	O
cicatricial	I-Problem
entropion	I-Problem
after	O
at	I-Treatment
least	I-Treatment
2	I-Other
years	I-Other
of	I-Treatment
twice	I-Other
-	I-Other
a	I-Other
-	I-Other
day	I-Other
application	I-Treatment
of	I-Treatment
dipivefrin	I-Treatment
.	O

artemether	I-Treatment
-	I-Treatment
lumefantrine	I-Treatment
(	I-Treatment
al	I-Treatment
)	I-Treatment
is	O
first	O
-	O
line	O
treatment	O
for	O
uncomplicated	I-Problem
malaria	I-Problem
in	O
many	O
african	O
countries	O
.	O

functional	O
regulation	I-Test
of	O
certain	O
neuroreceptors	O
during	O
risperidone	I-Treatment
treatment	O
may	O
lead	O
to	O
altered	I-Problem
behavioural	I-Problem
responses	I-Problem
upon	O
switching	I-Treatment
to	I-Treatment
methylphenidate	I-Treatment
.	O

transient	I-Problem
leucopenia	I-Problem
and	I-Problem
thrombocytopenia	I-Problem
associated	O
with	O
sodium	I-Treatment
nitroprusside	I-Treatment
infusion	I-Treatment
.	O

this	O
unusual	I-Problem
pattern	I-Problem
of	I-Problem
low	I-Problem
-	I-Problem
grade	I-Problem
endometrial	I-Problem
carcinoma	I-Problem
adds	I-Problem
to	I-Problem
the	I-Problem
spectrum	I-Problem
of	I-Problem
uterine	I-Problem
neoplasia	I-Problem
associated	O
with	O
tamoxifen	I-Treatment
therapy	O
.	O

inappropriate	I-Problem
antidiuretic	I-Problem
hormone	I-Problem
secretion	I-Problem
after	O
high	I-Treatment
dose	I-Treatment
vinblastine	I-Treatment
.	O

osteomyelitis	I-Problem
occurring	O
during	O
infliximab	I-Treatment
treatment	O
of	O
severe	I-Problem
psoriasis	I-Problem
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
transitional	I-Problem
cell	I-Problem
carcinoma	I-Problem
of	I-Problem
the	I-Problem
renal	I-Problem
pelvis	I-Problem
who	O
developed	O
respiratory	I-Problem
dysfunction	I-Problem
and	I-Problem
an	I-Problem
abnormal	I-Problem
chest	I-Problem
x	I-Problem
-	I-Problem
ray	I-Problem
with	I-Problem
diffuse	I-Problem
interstitial	I-Problem
opacities	I-Problem
while	O
on	O
chemotherapy	I-Treatment
with	I-Treatment
piritrexim	I-Treatment
,	I-Treatment
a	I-Treatment
methotrexate	I-Treatment
analog	I-Treatment
.	O

amiodarone	I-Treatment
induced	O
torsades	I-Problem
de	I-Problem
pointe	I-Problem
.	O

a	I-Background
patient	I-Background
with	I-Background
wegener	I-Problem
'	I-Problem
s	I-Problem
granulomatosis	I-Problem
rapidly	O
developed	O
a	O
circumferential	I-Problem
subglottic	I-Problem
stenosis	I-Problem
while	O
on	O
a	O
cyclophosphamide	I-Treatment
regimen	I-Treatment
that	O
had	O
caused	O
resolution	I-Problem
of	I-Problem
systemic	I-Problem
symptoms	I-Problem
and	I-Problem
pulmonary	I-Problem
infiltrates	I-Problem
.	O

a	I-Background
case	I-Background
is	O
presented	O
which	O
illustrates	O
a	O
probably	O
fatal	I-Problem
interaction	I-Problem
between	O
minoxidil	I-Treatment
and	O
a	O
coagulation	I-Problem
disorder	I-Problem
.	O

methadone	I-Treatment
-	O
induced	O
myoclonus	I-Problem
in	O
advanced	I-Problem
cancer	I-Problem
.	O

life	I-Problem
-	I-Problem
threatening	I-Problem
anaphylactoid	I-Problem
reaction	I-Problem
to	O
amifostine	I-Treatment
used	I-Treatment
with	I-Treatment
concurrent	I-Treatment
chemoradiotherapy	I-Treatment
for	O
nasopharyngeal	I-Problem
cancer	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
dermatomyositis	I-Problem
:	O
a	O
case	O
report	O
with	O
literature	O
review	O
.	O

we	O
conclude	O
that	O
while	O
thrombocytopenia	I-Problem
and	I-Problem
schistocytosis	I-Problem
can	O
be	O
seen	O
in	O
quinine	I-Treatment
-	O
associated	O
ttp	I-Problem
/	I-Problem
hus	I-Problem
,	O
the	O
pathophysiology	O
seems	O
to	O
be	O
distinct	O
from	O
that	O
seen	O
in	O
most	O
cases	O
of	O
idiopathic	O
ttp	O
(	O
i	O
.	O
e	O
.	O
,	O
severely	O
decreased	O
adamts13	O
with	O
an	O
inhibitor	O
)	O
.	O

conclusions	O
:	O
spontaneous	I-Problem
hemothorax	I-Problem
is	O
a	O
rare	O
phenomenon	O
in	O
conjunction	O
with	O
lmwh	I-Treatment
but	O
should	O
be	O
considered	O
in	O
cases	O
of	O
acute	I-Problem
respiratory	I-Problem
distress	I-Problem
following	O
commencement	O
of	O
lmwh	O
.	O

conclusion	O
:	O
these	I-Background
cases	I-Background
suggest	O
that	O
moxifloxacin	I-Treatment
may	O
interfere	I-Problem
with	I-Problem
the	I-Problem
healing	I-Problem
of	I-Problem
corneal	I-Problem
ulcers	I-Problem
.	O

reinstitution	O
of	O
penicillamine	I-Treatment
treatment	O
caused	O
a	O
recurrence	O
thus	O
proving	O
a	O
causal	O
relationship	O
between	O
penicillamine	I-Treatment
and	O
the	O
described	O
nail	I-Problem
-	I-Problem
changes	I-Problem
.	O

a	I-Background
34	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
lady	I-Background
developed	O
a	I-Problem
constellation	I-Problem
of	I-Problem
dermatitis	I-Problem
,	I-Problem
fever	I-Problem
,	I-Problem
lymphadenopathy	I-Problem
and	I-Problem
hepatitis	I-Problem
,	O
beginning	O
on	O
the	O
17th	I-Other
day	I-Other
of	O
a	I-Treatment
course	I-Treatment
of	I-Treatment
oral	I-Treatment
sulphasalazine	I-Treatment
for	O
sero	I-Problem
-	I-Problem
negative	I-Problem
rheumatoid	I-Problem
arthritis	I-Problem
.	O

he	O
had	O
been	O
commenced	O
on	O
a	I-Treatment
course	I-Treatment
of	I-Treatment
fusidic	I-Treatment
acid	I-Treatment
at	I-Treatment
discharge	I-Treatment
in	I-Treatment
addition	I-Treatment
to	I-Treatment
his	I-Treatment
ongoing	I-Treatment
statin	I-Treatment
prescription	I-Treatment
and	O
presented	O
4	I-Other
weeks	I-Other
later	I-Other
with	O
symptoms	I-Problem
consistent	I-Problem
with	I-Problem
rhabdomyolysis	I-Problem
.	O

1	O
.	O
artelinic	I-Treatment
acid	I-Treatment
(	I-Treatment
al	I-Treatment
)	I-Treatment
,	I-Treatment
a	I-Treatment
water	I-Treatment
-	I-Treatment
soluble	I-Treatment
artemisinin	I-Treatment
analogue	I-Treatment
for	O
treatment	O
of	O
multidrug	I-Problem
resistant	I-Problem
malaria	I-Problem
,	O
is	O
metabolized	O
to	O
the	O
active	O
metabolite	O
dihydroqinghaosu	O
(	O
dqhs	O
)	O
solely	O
by	O
cyp3a4	O
/	O
5	O
.	O

inhaled	I-Treatment
tobramycin	I-Treatment
solution	O
-	O
associated	O
recurrent	I-Problem
eosinophilia	I-Problem
and	I-Problem
severe	I-Problem
persistent	I-Problem
bronchospasm	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
cystic	I-Problem
fibrosis	I-Problem
:	O
a	O
case	O
report	O
.	O

the	O
occurrence	O
of	O
bmtn	I-Problem
in	O
two	O
children	I-Background
treated	O
with	O
ra	I-Treatment
in	O
our	O
unit	O
is	O
unlikely	O
to	O
be	O
coincidental	O
.	O

comeoscleral	I-Problem
perforation	I-Problem
after	O
pterygium	I-Treatment
excision	I-Treatment
and	I-Treatment
intraoperative	I-Treatment
mitomycin	I-Treatment
c	I-Treatment
.	I-Treatment

capecitabine	I-Treatment
-	O
induced	O
multifocal	I-Problem
leukoencephalopathy	I-Problem
:	O
a	O
report	O
of	O
five	O
cases	I-Background
.	O

vigabatrin	I-Treatment
-	O
induced	O
visual	I-Problem
field	I-Problem
defects	I-Problem
are	O
at	O
present	O
the	O
most	O
important	O
safety	O
issue	O
in	O
the	O
use	O
of	O
the	O
drug	O
.	O

serotonin	I-Problem
syndrome	I-Problem
in	O
elderly	I-Background
patients	I-Background
treated	O
for	O
psychotic	I-Problem
depression	I-Problem
with	O
atypical	I-Treatment
antipsychotics	I-Treatment
and	O
antidepressants	I-Treatment
:	O
two	O
case	O
reports	O
.	O

we	O
report	O
two	O
new	O
cases	O
of	O
sarcoidosis	I-Problem
in	O
two	O
patients	I-Background
with	I-Background
hepatitis	I-Problem
c	I-Problem
virus	I-Problem
infection	I-Problem
treated	O
with	O
interferon	I-Treatment
alfa	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
.	O

a	I-Background
57	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
morphea	I-Problem
while	O
taking	O
bromocriptine	I-Treatment
.	O

potential	O
mechanisms	O
regarding	O
the	O
pathophysiology	O
of	O
lithium	I-Treatment
-	O
associated	O
cdi	I-Problem
are	O
discussed	O
.	O

acute	I-Problem
coronary	I-Problem
syndromes	I-Problem
complicating	O
the	I-Treatment
first	I-Treatment
infusion	I-Treatment
of	I-Treatment
rituximab	I-Treatment
.	O

spontaneous	I-Problem
hemothorax	I-Problem
following	I-Problem
anticoagulation	I-Problem
with	O
low	I-Treatment
-	I-Treatment
molecular	I-Treatment
-	I-Treatment
weight	I-Treatment
heparin	I-Treatment
.	O

there	O
were	O
no	I-Problem
incremental	I-Problem
increases	I-Problem
in	I-Problem
myelosuppression	I-Problem
,	I-Problem
peripheral	I-Problem
neuropathy	I-Problem
,	I-Problem
or	I-Problem
renal	I-Problem
,	I-Problem
hepatic	I-Problem
,	I-Problem
or	I-Problem
cardiac	I-Problem
toxicity	I-Problem
and	I-Problem
no	I-Problem
deaths	I-Problem
related	O
to	O
tirapazamine	I-Treatment
.	O

a	O
phase	O
iii	O
trial	O
,	O
cisplatin	O
and	O
tirapazamine	O
in	O
subjects	O
with	O
advanced	O
previously	O
untreated	O
non	O
-	O
small	O
-	O
cell	O
lung	O
tumors	O
(	O
catapult	O
i	O
)	O
,	O
was	O
designed	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
tirapazamine	I-Treatment
plus	I-Treatment
cisplatin	I-Treatment
for	O
the	O
treatment	O
of	O
non	I-Problem
-	I-Problem
small	I-Problem
-	I-Problem
cell	I-Problem
lung	I-Problem
cancer	I-Problem
(	I-Problem
nsclc	I-Problem
)	I-Problem
.	O

combination	I-Treatment
antimicrobial	I-Treatment
regimens	I-Treatment
(	I-Treatment
e	I-Treatment
.	I-Treatment
g	I-Treatment
.	I-Treatment
,	I-Treatment
linezolid	I-Treatment
with	I-Treatment
rifampin	I-Treatment
)	I-Treatment
aimed	O
at	O
improving	I-Problem
bacterial	I-Problem
eradication	I-Problem
and	I-Problem
preventing	I-Problem
resistance	I-Problem
are	O
often	O
used	O
;	O
however	O
,	O
most	O
data	O
supporting	O
this	O
treatment	O
strategy	O
are	O
not	O
from	O
randomized	O
controlled	I-Test
trials	I-Test
.	O

clinicians	O
treating	O
elderly	I-Background
patients	I-Background
with	O
a	I-Treatment
combination	I-Treatment
of	I-Treatment
serotonergic	I-Treatment
antidepressants	I-Treatment
and	I-Treatment
atypical	I-Treatment
antipsychotics	I-Treatment
for	I-Treatment
psychotic	I-Problem
depression	I-Problem
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
serotonin	I-Problem
syndrome	I-Problem
.	O

enalaprilat	I-Treatment
induced	O
acute	I-Problem
parotitis	I-Problem
.	O

we	O
believe	O
the	O
most	O
likely	O
cause	O
was	O
hepatic	O
inhibition	O
of	O
the	O
cyp3a4	O
hepatic	O
isoenzyme	O
by	O
fusidic	I-Treatment
acid	I-Treatment
resulting	O
in	O
an	I-Problem
acute	I-Problem
severe	I-Problem
rise	I-Problem
in	I-Problem
plasma	I-Problem
simvastatin	I-Problem
level	I-Problem
and	I-Problem
extensive	I-Problem
myocellular	I-Problem
damage	I-Problem
.	O

the	O
authors	O
describe	O
pericardial	I-Problem
hemorrhage	I-Problem
,	O
which	O
is	O
related	O
to	O
the	O
use	O
of	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
acetylsalicylic	I-Treatment
acid	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
essential	I-Problem
thrombocythemia	I-Problem
.	O

this	O
complex	I-Problem
pattern	I-Problem
of	I-Problem
nail	I-Problem
and	I-Problem
skin	I-Problem
changes	I-Problem
is	O
accounted	O
by	O
synergy	O
or	O
an	O
additive	O
effect	O
of	O
chemotherapy	I-Treatment
agents	I-Treatment
on	O
cellular	O
proliferation	O
of	O
nail	O
compartments	O
.	O

akathisia	I-Problem
is	O
a	O
relatively	O
rare	O
side	O
effect	O
with	O
the	O
newer	O
atypical	O
antipsychotic	O
agents	O
,	O
particularly	O
clozapine	I-Treatment
,	O
and	O
is	O
easily	O
misdiagnosed	O
in	O
children	I-Background
.	O

in	O
this	O
case	O
,	O
discontinuing	I-Treatment
piroxicam	I-Treatment
,	I-Treatment
a	I-Treatment
nonsteroidal	I-Treatment
anti	I-Treatment
-	I-Treatment
inflammatory	I-Treatment
drug	I-Treatment
,	I-Treatment
and	I-Treatment
starting	I-Treatment
a	I-Treatment
palliative	I-Treatment
treatment	I-Treatment
plan	O
helped	O
resolve	O
a	I-Background
patient	I-Background
'	I-Background
s	I-Background
ulcers	I-Problem
.	O

eosinophilia	I-Problem
has	O
been	O
encountered	O
from	O
0	O
.	O
2	O
to	O
61	O
.	O
7	O
%	O
in	O
clozapine	I-Treatment
-	O
treated	O
patients	I-Background
,	O
mostly	O
with	O
a	O
transient	O
course	O
and	O
spontaneous	O
remission	O
.	O

we	O
presented	O
a	I-Background
patient	I-Background
with	I-Background
status	I-Problem
asthmaticus	I-Problem
treated	O
with	O
a	O
combination	O
of	O
theophylline	I-Treatment
and	I-Treatment
prednisone	I-Treatment
who	O
developed	O
a	O
perforated	I-Problem
gastric	I-Problem
ulcer	I-Problem
.	O

we	O
speculate	O
on	O
a	O
causal	O
relationship	O
between	O
the	O
assumption	O
of	O
the	O
additives	O
and	O
the	I-Problem
fatal	I-Problem
hepatitis	I-Problem
and	O
envisage	O
a	O
synergy	O
between	O
the	O
additives	O
and	O
montelukast	I-Treatment
,	O
which	O
per	O
se	O
has	O
well	O
been	O
studied	O
as	O
a	O
hepatotoxic	O
drug	O
.	O

fatal	I-Problem
liver	I-Problem
failure	I-Problem
following	O
food	I-Treatment
supplements	I-Treatment
during	I-Treatment
chronic	I-Treatment
treatment	I-Treatment
with	I-Treatment
montelukast	I-Treatment
.	O

treatment	O
of	O
carbimazole	I-Problem
-	I-Problem
induced	I-Problem
agranulocytosis	I-Problem
and	I-Problem
sepsis	I-Problem
with	O
granulocyte	I-Treatment
colony	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
.	O

a	O
study	O
following	O
large	I-Background
patient	I-Background
groups	I-Background
on	O
theophylline	I-Treatment
and	I-Treatment
a	I-Treatment
combination	I-Treatment
of	I-Treatment
theophylline	I-Treatment
and	I-Treatment
steroids	I-Treatment
might	O
clarify	O
the	O
risk	O
of	O
ulcer	I-Problem
formation	O
in	O
patients	O
being	O
treated	O
with	O
these	O
medications	O
for	O
asthma	I-Problem
.	O

the	I-Treatment
combination	I-Treatment
of	I-Treatment
cyclobenzaprine	I-Treatment
and	I-Treatment
fluoxetine	I-Treatment
resulted	O
in	O
significant	I-Problem
qt	I-Problem
prolongation	I-Problem
in	O
our	I-Background
patient	I-Background
that	O
progressed	I-Problem
to	I-Problem
torsade	I-Problem
de	I-Problem
pointes	I-Problem
after	O
preoperative	I-Other
droperidol	I-Treatment
administration	I-Treatment
.	O

introduction	O
-	O
the	O
aim	O
of	O
this	O
case	O
report	O
is	O
to	O
present	O
a	O
15	O
-	O
year	O
follow	O
-	O
up	O
of	O
a	I-Background
patient	I-Background
with	O
phenytoin	I-Treatment
(	I-Problem
pht	I-Problem
)	I-Problem
intoxication	I-Problem
with	I-Problem
unilateral	I-Problem
gingival	I-Problem
hyperplasia	I-Problem
(	I-Problem
gh	I-Problem
)	I-Problem
.	O

this	O
severe	I-Problem
illness	I-Problem
was	O
likely	O
caused	O
by	O
minocycline	I-Treatment
,	O
and	O
we	O
speculate	O
that	O
minocycline	O
may	O
have	O
acted	O
as	O
a	O
superantigen	O
,	O
causing	O
lymphocyte	O
over	O
-	O
activation	O
and	O
massive	O
cytokine	O
release	O
.	O

results	O
:	O
three	O
patients	I-Background
who	O
developed	O
symptoms	I-Problem
of	I-Problem
inflammatory	I-Problem
bowel	I-Problem
disease	I-Problem
(	I-Problem
ibd	I-Problem
)	I-Problem
during	O
rofecoxib	I-Treatment
exposure	I-Treatment
are	O
described	O
along	O
with	O
pathology	O
findings	O
.	O

radiation	I-Problem
recall	I-Test
refers	O
to	O
inflammatory	I-Problem
reactions	I-Problem
triggered	O
by	O
cytotoxic	I-Treatment
agents	I-Treatment
and	O
develops	O
in	O
previously	O
irradiated	O
areas	O
.	O

herein	O
,	O
we	O
describe	O
2	O
patients	I-Background
who	O
developed	O
unusual	O
cd8	I-Problem
+	I-Problem
cutaneous	I-Problem
lymphoproliferative	I-Problem
disorders	O
after	O
treatment	O
with	O
efalizumab	I-Treatment
and	I-Treatment
infliximab	I-Treatment
.	O

intrathecal	O
methotrexate	I-Treatment
-	O
induced	O
acute	I-Problem
cerebellar	I-Problem
syndrome	I-Problem
.	O

barbiturate	I-Treatment
-	O
induced	O
submassive	I-Problem
hepatic	I-Problem
necrosis	I-Problem
.	O

the	O
possible	O
effects	O
of	O
tamoxifen	O
upon	O
the	O
uterus	O
are	O
discussed	O
in	O
this	O
article	O
,	O
in	O
view	O
of	O
reports	O
of	O
tamoxifen	I-Treatment
associated	O
with	O
endometrial	I-Problem
carcinoma	I-Problem
and	I-Problem
endometriosis	I-Problem
.	O

intranasal	I-Treatment
desmopressin	I-Treatment
-	O
induced	O
hyponatremia	I-Problem
.	O

sunburn	I-Problem
may	O
sometimes	O
be	O
a	O
major	O
injury	O
in	O
psoralen	I-Treatment
users	I-Treatment
because	I-Treatment
high	I-Treatment
doses	I-Treatment
or	I-Treatment
inappropriate	I-Treatment
use	I-Treatment
of	O
the	O
drug	O
may	O
render	O
the	O
skin	I-Problem
extremely	I-Problem
sensitive	I-Problem
.	O

we	O
reviewed	O
the	O
records	O
of	O
3	O
patients	I-Background
with	I-Background
lymphoproliferative	I-Problem
disorders	I-Problem
who	O
experienced	O
acute	I-Problem
coronary	I-Problem
syndromes	I-Problem
associated	O
with	O
their	I-Treatment
initial	I-Treatment
infusion	I-Treatment
of	I-Treatment
rituximab	I-Treatment
.	O

previous	O
successful	O
treatment	O
with	O
one	O
ace	I-Treatment
inhibitor	I-Treatment
does	O
not	O
rule	O
out	O
the	O
vasculitis	I-Problem
caused	O
by	O
the	O
drug	O
from	O
the	O
same	O
group	O
.	O

we	O
report	O
a	I-Background
patient	I-Background
with	I-Background
pulmonary	I-Problem
adenocarcinoma	I-Problem
complicated	O
by	O
the	I-Problem
syndrome	I-Problem
of	I-Problem
inappropriate	I-Problem
secretion	I-Problem
of	I-Problem
antidiuretic	I-Problem
hormone	I-Problem
(	I-Problem
siadh	I-Problem
)	I-Problem
following	O
systemic	I-Treatment
chemotherapy	I-Treatment
with	I-Treatment
cisplatin	I-Treatment
(	I-Treatment
cddp	I-Treatment
)	I-Treatment
and	I-Treatment
vindesine	I-Treatment
(	I-Treatment
vds	I-Treatment
)	I-Treatment
.	O

our	O
patient	O
had	O
headache	I-Problem
,	I-Problem
mild	I-Problem
fever	I-Problem
,	I-Problem
nausea	I-Problem
,	I-Problem
vomiting	I-Problem
,	I-Problem
rash	I-Problem
,	I-Problem
and	I-Problem
eosinophilia	I-Problem
after	I-Other
3	I-Other
weeks	I-Other
of	I-Treatment
disulfiram	I-Treatment
therapy	O
.	O

decreased	I-Problem
serum	I-Problem
linezolid	I-Problem
levels	I-Problem
in	O
a	I-Background
critically	I-Problem
ill	I-Problem
patient	I-Background
receiving	O
concomitant	I-Treatment
linezolid	I-Treatment
and	I-Treatment
rifampin	I-Treatment
.	O

objective	O
:	O
to	O
report	O
the	O
first	I-Background
five	O
cases	I-Background
of	I-Background
amphotericin	I-Treatment
b	I-Treatment
overdose	I-Treatment
with	O
secondary	O
cardiac	I-Problem
complications	I-Problem
in	O
a	I-Background
pediatric	I-Background
population	I-Background
.	O

conclusions	O
:	O
amphotericin	I-Treatment
b	I-Treatment
seems	O
to	O
be	O
the	O
probable	O
cause	O
of	O
the	O
seizures	I-Problem
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	O
developed	O
acute	I-Problem
cerebellar	I-Problem
syndrome	I-Problem
after	O
prophylactic	I-Treatment
intrathecal	I-Treatment
methotrexate	I-Treatment
administration	I-Treatment
and	O
recovered	O
spontaneously	O
.	O

levofloxacin	I-Treatment
induced	O
polymorphic	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
with	I-Problem
normal	I-Problem
qt	I-Problem
interval	I-Problem
.	O

most	O
physicians	O
are	O
aware	O
of	O
serotonin	I-Problem
syndrome	I-Problem
secondary	O
to	O
antidepressants	I-Treatment
but	O
do	O
not	O
think	O
about	O
other	O
classes	O
of	O
medications	O
such	O
as	O
analgesics	I-Treatment
.	O

we	O
describe	O
two	O
patients	I-Background
with	O
aspergillus	I-Problem
arthritis	I-Problem
of	I-Problem
the	I-Problem
knee	I-Problem
joint	I-Problem
following	O
fludarabine	I-Treatment
-	I-Treatment
based	I-Treatment
non	I-Treatment
-	I-Treatment
myeloablative	I-Treatment
stem	I-Treatment
cell	I-Treatment
transplantation	I-Treatment
.	O

a	O
case	O
of	O
fluoxetine	I-Treatment
induced	O
seizures	I-Problem
,	O
in	O
a	I-Background
person	I-Background
with	I-Background
down	I-Problem
syndrome	I-Problem
,	O
is	O
described	O
.	O

we	O
report	O
a	O
case	O
of	O
acute	I-Problem
generalized	I-Problem
exanthematous	I-Problem
pustulosis	I-Problem
(	I-Problem
agep	I-Problem
)	I-Problem
induced	O
by	O
salazosulfapyridine	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
ulcerative	I-Problem
colitis	I-Problem
.	O

diclofenac	I-Treatment
-	O
associated	O
hepatitis	I-Problem
.	O

angioimmunoblastic	I-Problem
lymphadenopathy	I-Problem
with	I-Problem
dysproteinemia	I-Problem
following	O
doxycycline	I-Treatment
administration	I-Treatment
.	O

doxycycline	I-Treatment
-	O
induced	O
hypoglycemia	I-Problem
in	O
a	I-Background
nondiabetic	I-Background
young	I-Background
man	I-Background
.	O

case	I-Background
2	I-Background
demonstrated	O
after	O
40	I-Other
months	I-Other
on	I-Treatment
chlorambucil	I-Treatment
the	O
presence	O
of	O
a	I-Problem
balanced	I-Problem
translocation	I-Problem
,	I-Problem
t	I-Problem
(	I-Problem
1	I-Problem
;	I-Problem
5	I-Problem
)	I-Problem
(	I-Problem
p36	I-Problem
;	I-Problem
q31	I-Problem
)	I-Problem
in	I-Problem
90	I-Problem
%	I-Problem
of	I-Problem
the	I-Problem
cells	I-Problem
.	O

within	O
6	I-Other
months	I-Other
of	O
pranlukast	I-Treatment
withdrawal	O
,	O
anemia	I-Problem
resolved	I-Problem
and	I-Problem
urinary	I-Problem
sediment	I-Problem
and	I-Problem
renal	I-Problem
function	I-Problem
normalized	I-Problem
.	O

sirolimus	I-Treatment
-	O
associated	O
hepatotoxicity	I-Problem
in	O
the	O
kidney	I-Problem
graft	I-Problem
recipient	I-Problem
.	I-Background

although	O
vasculitis	I-Problem
has	O
been	O
reported	O
in	O
the	O
course	O
of	O
hairy	I-Problem
cell	I-Problem
leukaemia	I-Problem
,	O
it	O
has	O
only	O
rarely	O
been	O
reported	O
as	O
the	O
consequence	O
of	O
cladribine	I-Treatment
treatment	O
.	O

despite	O
aggressive	O
medical	O
management	O
,	O
including	O
intravenous	I-Treatment
hydration	I-Treatment
and	I-Treatment
broad	I-Treatment
-	I-Treatment
spectrum	I-Treatment
antibiotics	I-Treatment
,	O
the	O
patient	I-Background
continued	O
to	O
become	I-Problem
more	I-Problem
confused	I-Problem
,	I-Problem
agitated	I-Problem
,	I-Problem
and	I-Problem
despondent	I-Problem
over	I-Problem
the	I-Problem
subsequent	I-Problem
24	I-Problem
hours	I-Problem
.	O

cyclosporine	I-Treatment
is	I-Treatment
a	I-Treatment
potent	I-Treatment
inhibitor	I-Treatment
of	I-Treatment
simvastatin	I-Treatment
metabolism	I-Treatment
,	O
and	O
may	O
therefore	O
facilitate	O
simvastatin	O
-	O
induced	O
rhabdomyolysis	O
.	O

the	O
effect	O
of	O
food	O
consumption	O
on	O
lumefantrine	O
bioavailability	O
in	O
african	I-Background
children	I-Background
receiving	O
artemether	I-Treatment
-	I-Treatment
lumefantrine	I-Treatment
crushed	I-Treatment
or	I-Treatment
dispersible	I-Treatment
tablets	I-Treatment
(	I-Treatment
coartem	I-Treatment
)	I-Treatment
for	O
acute	I-Problem
uncomplicated	I-Problem
plasmodium	I-Problem
falciparum	I-Problem
malaria	I-Problem
.	O

to	O
report	O
2	O
cases	I-Background
of	O
serotonin	I-Problem
toxicity	I-Problem
(	I-Problem
st	I-Problem
)	I-Problem
associated	O
with	O
concomitant	I-Treatment
use	I-Treatment
of	I-Treatment
linezolid	I-Treatment
and	I-Treatment
serotonergic	I-Treatment
drugs	I-Treatment
and	O
review	O
previously	O
published	O
case	O
reports	O
.	O

this	O
case	O
illustrates	O
that	O
the	I-Problem
hemophagocytic	I-Problem
syndrome	I-Problem
associated	I-Problem
with	I-Problem
reactivation	I-Problem
of	I-Problem
ebv	I-Problem
can	O
occur	O
as	O
part	O
of	O
drug	O
hypersensitivity	O
reactions	O
in	O
ra	O
patients	O
taking	O
sulfasalazine	I-Treatment
.	O

tardive	I-Problem
dyskinesia	I-Problem
induced	O
by	O
sulpiride	I-Treatment
.	O

seizures	I-Problem
occurred	O
in	O
two	O
patients	I-Background
with	I-Background
probable	I-Background
alzheimer	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
who	O
were	O
receiving	O
long	I-Treatment
-	I-Treatment
term	I-Treatment
treatment	I-Treatment
with	I-Treatment
metrifonate	I-Treatment
,	O
an	O
irreversible	O
acetylcholinesterase	O
inhibitor	O
.	O

high	I-Treatment
-	I-Treatment
dose	I-Treatment
antithrombin	I-Treatment
iii	I-Treatment
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
hemorrhage	I-Problem
when	O
administered	O
with	O
heparin	I-Treatment
.	O

with	O
the	O
increasing	O
use	O
of	O
cyclosporine	I-Treatment
a	I-Treatment
in	O
transplant	I-Problem
patients	I-Background
,	O
the	O
incidence	O
of	O
herpes	I-Problem
esophagitis	I-Problem
may	I-Problem
increase	I-Problem
.	I-Problem

after	O
starting	O
nevirapine	I-Treatment
treatment	O
,	O
nine	O
out	O
of	O
ten	O
patients	I-Background
experienced	O
symptoms	O
of	O
abstinence	I-Problem
syndrome	I-Problem
,	O
and	O
methadone	O
dose	O
had	O
to	O
be	O
increased	O
by	O
20	O
%	O
on	O
average	O
during	O
the	O
course	O
of	O
the	O
study	I-Test
.	O

treatment	O
was	O
begun	O
with	O
amphotericin	I-Treatment
b	I-Treatment
-	I-Treatment
deoxycholate	I-Treatment
but	O
renal	I-Problem
toxicity	I-Problem
signs	O
led	O
to	O
its	O
substitution	O
by	O
fluconazole	I-Treatment
.	O

post	O
marketing	O
studies	I-Test
of	O
interferon	I-Treatment
-	I-Treatment
beta	I-Treatment
(	I-Treatment
ifn	I-Treatment
beta	I-Treatment
)	I-Treatment
therapy	O
in	O
multiple	O
sclerosis	O
(	O
ms	O
)	O
have	O
demonstrated	O
surprisingly	O
high	O
rates	O
of	O
hepatotoxicity	I-Problem
.	O

we	O
describe	O
the	O
first	O
case	O
of	O
disseminated	I-Problem
salmonellosis	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
temozolomide	I-Treatment
.	O

objective	O
:	O
to	O
describe	O
a	O
case	O
of	O
exacerbated	I-Problem
mania	I-Problem
potentially	O
related	O
to	O
an	O
interaction	I-Treatment
between	I-Treatment
lopinavir	I-Treatment
/	I-Treatment
ritonavir	I-Treatment
and	I-Treatment
valproic	I-Treatment
acid	I-Treatment
(	O
vpa	O
)	O
and	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
this	O
interaction	O
.	O

the	O
first	O
reported	O
case	O
,	O
in	O
an	O
adult	O
,	O
of	O
cholestyramine	I-Treatment
induced	O
hyperchloremic	I-Problem
metabolic	I-Problem
acidosis	I-Problem
is	O
a	I-Background
70	I-Background
year	I-Background
old	I-Background
female	I-Background
with	I-Background
a	I-Background
two	I-Background
year	I-Background
history	I-Background
of	I-Background
primary	I-Problem
biliary	I-Problem
cirrhosis	I-Problem
confirmed	O
by	O
histologic	O
and	O
immunologic	I-Test
criteria	I-Test
.	O

we	O
report	O
a	O
case	O
of	O
fatal	I-Problem
c	I-Problem
.	I-Problem
neoformans	I-Problem
fungemia	I-Problem
in	O
a	I-Background
neutropenic	I-Background
patient	I-Background
with	I-Background
a	I-Background
history	I-Background
of	I-Background
chronic	I-Problem
lymphocytic	I-Problem
leukemia	I-Problem
treated	O
with	O
alemtuzumab	I-Treatment
.	O

aggressive	I-Treatment
hydration	I-Treatment
,	I-Treatment
urinary	I-Treatment
alkalinization	I-Treatment
,	I-Treatment
and	I-Treatment
leucovorin	I-Treatment
were	O
continued	O
during	O
the	O
period	O
of	O
elevated	I-Treatment
methotrexate	I-Treatment
levels	O
,	O
with	O
the	I-Background
patient	I-Background
receiving	O
a	O
course	I-Treatment
of	I-Treatment
hemodialysis	I-Treatment
and	I-Treatment
a	I-Treatment
dose	I-Treatment
of	I-Treatment
carboxypeptidase	I-Treatment
g2	I-Treatment
.	O

acute	I-Problem
myocardial	I-Problem
infarction	I-Problem
due	I-Problem
to	I-Problem
coronary	I-Problem
spasm	I-Problem
associated	O
with	O
l	I-Treatment
-	I-Treatment
thyroxine	I-Treatment
therapy	O
.	O

only	O
patients	I-Background
on	O
dt	I-Treatment
-	I-Treatment
pace	I-Treatment
but	I-Treatment
not	I-Treatment
dcep	I-Treatment
-	I-Treatment
t	I-Treatment
experienced	O
an	I-Problem
increased	I-Problem
incidence	I-Problem
of	I-Problem
dvt	I-Problem
.	O

to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
published	O
report	O
of	O
a	O
possible	O
drug	I-Problem
interaction	I-Problem
in	O
a	I-Background
critically	I-Problem
ill	I-Problem
patient	I-Background
receiving	O
concomitant	I-Treatment
linezolid	I-Treatment
and	I-Treatment
rifampin	I-Treatment
.	O

within	O
24	I-Other
hours	I-Other
of	I-Treatment
fluid	I-Treatment
restriction	I-Treatment
and	I-Treatment
cessation	I-Treatment
of	I-Treatment
desmopressin	I-Treatment
,	O
her	I-Background
symptoms	I-Problem
and	I-Problem
hyponatremia	I-Problem
resolved	O
.	O

an	O
adverse	O
reaction	O
to	O
ifn	I-Treatment
was	O
strongly	O
suspected	O
as	O
the	O
cause	O
of	O
chf	I-Problem
.	O

a	I-Background
51	I-Background
-	I-Background
year	I-Background
old	I-Background
physically	I-Background
fit	I-Background
woman	I-Background
experienced	O
angio	I-Problem
-	I-Problem
oedema	I-Problem
and	I-Problem
hypotensive	I-Problem
shock	I-Problem
after	O
irbesartan	I-Treatment
ingestion	I-Treatment
requiring	O
noradrenaline	O
infusion	O
.	O

our	O
report	O
suggested	O
that	O
cbdca	I-Problem
hypersensitivity	I-Problem
was	O
correlated	O
with	O
the	O
total	I-Treatment
dose	I-Treatment
of	I-Treatment
previously	I-Treatment
administered	I-Treatment
platinum	I-Treatment
agents	I-Treatment
and	O
that	O
cbdca	O
should	O
be	O
excluded	O
in	O
patients	O
who	O
have	O
received	O
multiple	O
platinum	O
-	O
based	O
chemotherapy	O
,	O
even	O
in	O
platinum	O
-	O
sensitive	O
cases	O
,	O
because	O
cbdca	O
hypersensitivity	O
can	O
occur	O
even	O
with	O
low	O
-	O
dose	O
cbdca	O
administration	O
.	O

lansoprazole	I-Treatment
-	O
induced	O
thrombocytopenia	I-Problem
.	O

cutaneous	I-Problem
necrosis	I-Problem
as	O
a	O
result	O
of	O
interferon	I-Treatment
alfa	I-Treatment
is	O
an	O
infrequent	O
complication	O
with	O
unknown	O
pathogenesis	O
,	O
in	O
which	O
a	O
cutaneous	O
local	O
immune	O
-	O
mediated	O
inflammatory	O
process	O
might	O
be	O
involved	O
.	O

torsade	I-Problem
de	I-Problem
pointes	I-Problem
resulting	O
from	O
the	O
addition	O
of	O
droperidol	I-Treatment
to	O
an	O
existing	O
cytochrome	I-Treatment
p450	I-Treatment
drug	O
interaction	O
.	O

sulfasalazine	I-Treatment
-	O
induced	O
hypersensitivity	I-Problem
syndrome	I-Problem
and	I-Problem
hemophagocytic	I-Problem
syndrome	I-Problem
associated	O
with	O
reactivation	O
of	O
epstein	O
-	O
barr	O
virus	O
.	O

objectives	O
:	O
the	O
authors	O
described	O
a	O
case	O
of	O
hashimoto	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
during	O
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
(	I-Treatment
ifn	I-Treatment
-	I-Treatment
alpha	I-Treatment
)	I-Treatment
treatment	I-Treatment
for	O
chronic	I-Problem
viral	I-Problem
c	I-Problem
hepatitis	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
the	I-Background
specific	I-Problem
genetic	I-Problem
susceptibility	I-Problem
associated	I-Background
with	I-Background
the	I-Background
thyroid	I-Background
disease	I-Background
.	O

nephrogenic	I-Problem
diabetes	I-Problem
insipidus	I-Problem
(	I-Problem
ndi	I-Problem
)	I-Problem
is	O
a	O
well	O
-	O
documented	O
complication	O
of	O
lithium	I-Treatment
use	O
.	O

serotonin	I-Treatment
toxicity	I-Problem
associated	O
with	O
concomitant	I-Treatment
use	I-Treatment
of	I-Treatment
linezolid	I-Treatment
.	O

we	O
report	O
the	I-Background
case	I-Background
of	I-Background
a	I-Background
30	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
after	O
kidney	I-Treatment
transplantation	I-Treatment
,	I-Treatment
treated	I-Treatment
with	I-Treatment
steroids	I-Treatment
,	I-Treatment
cyclosporin	I-Treatment
a	I-Treatment
and	I-Treatment
srl	I-Treatment
,	O
with	O
steroid	I-Problem
-	I-Problem
resistant	I-Problem
acute	I-Problem
rejection	I-Problem
in	O
anamnesis	O
.	O

infants	I-Background
are	O
particularly	O
susceptible	O
to	O
chronic	O
nitrate	I-Treatment
-	O
induced	O
methemoglobinemia	I-Problem
because	O
of	O
their	O
low	O
stomach	O
acid	O
production	O
,	O
large	O
numbers	O
of	O
nitrite	O
-	O
reducing	O
bacteria	O
,	O
and	O
the	O
relatively	O
easy	O
oxidation	O
of	O
fetal	O
hemoglobin	I-Test
.	O

a	I-Background
72	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
renal	I-Problem
insufficiency	I-Problem
who	O
was	O
taking	I-Treatment
oral	I-Treatment
pilsicainide	I-Treatment
(	I-Treatment
150	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
)	I-Treatment
complained	O
of	O
feeling	I-Problem
faint	I-Problem
3	I-Other
days	I-Other
after	I-Treatment
she	I-Treatment
was	I-Treatment
prescribed	I-Treatment
oral	I-Treatment
cetirizine	I-Treatment
(	I-Treatment
20	I-Treatment
mg	I-Treatment
/	I-Treatment
d	I-Treatment
)	I-Treatment
.	O

chronic	I-Treatment
hydroxychloroquine	I-Treatment
use	O
associated	O
with	O
qt	I-Problem
prolongation	I-Problem
and	I-Problem
refractory	I-Problem
ventricular	I-Problem
arrhythmia	I-Problem
.	O

this	O
increase	O
when	O
clozapine	I-Treatment
was	I-Treatment
switched	I-Treatment
to	I-Treatment
risperidone	I-Treatment
and	I-Treatment
vice	I-Treatment
versa	I-Treatment
is	O
consistent	O
with	O
our	O
previous	O
report	O
of	O
elevated	I-Problem
serum	I-Problem
triglyceride	I-Problem
levels	I-Problem
in	O
clozapine	O
-	O
treated	O
patients	I-Background
.	O

sensorimotor	I-Problem
polyneuropathy	I-Problem
with	O
5	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
:	O
a	I-Background
case	I-Background
report	O
.	O

hydrocortisone	I-Treatment
prophylaxis	I-Treatment
and	I-Treatment
verapamil	I-Treatment
therapy	I-Treatment
were	O
the	O
primary	O
therapies	O
used	O
in	O
patient	I-Background
1	I-Background
(	I-Background
the	I-Background
only	I-Background
survivor	I-Background
)	I-Background
.	O

the	O
clinical	O
aspect	O
closely	O
resembled	O
classical	I-Problem
transient	I-Problem
global	I-Problem
amnesia	I-Problem
but	O
the	O
episode	O
after	O
clioquinol	I-Treatment
lasted	O
longer	O
(	O
24	O
hours	O
to	O
three	O
days	O
)	O
and	O
a	I-Problem
more	I-Problem
or	I-Problem
less	I-Problem
extensive	I-Problem
retrograde	I-Problem
amnesia	I-Problem
persisted	O
permanently	O
.	O

we	O
report	O
a	I-Background
case	I-Background
of	I-Background
aild	I-Problem
in	I-Background
an	I-Background
80	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
who	O
presented	O
with	O
a	O
generalized	I-Problem
pruritic	I-Problem
maculopapular	I-Problem
eruption	I-Problem
and	I-Problem
fever	I-Problem
following	O
doxycycline	I-Treatment
administration	I-Treatment
.	O

objective	O
:	O
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
published	O
case	O
report	O
of	O
an	I-Background
adolescent	I-Background
girl	I-Background
with	I-Background
a	I-Background
mitochondrial	I-Problem
disorder	I-Problem
and	I-Background
depression	I-Problem
who	O
displayed	O
both	O
new	I-Problem
-	I-Problem
onset	I-Problem
psychotic	I-Problem
and	I-Problem
increased	I-Problem
mood	I-Problem
symptoms	I-Problem
during	O
treatment	O
with	O
risperidone	I-Treatment
.	O

young	I-Background
children	I-Background
undergoing	I-Treatment
cisplatin	I-Treatment
chemotherapy	I-Treatment
are	O
known	O
to	O
be	O
at	O
risk	O
for	O
progressive	I-Problem
sensorineural	I-Problem
hearing	I-Problem
loss	I-Problem
.	O

systemic	I-Problem
capillary	I-Problem
leak	I-Problem
syndrome	I-Problem
after	O
granulocyte	I-Treatment
colony	I-Test
-	I-Test
stimulating	I-Test
factor	I-Test
(	I-Test
g	I-Test
-	I-Test
csf	I-Treatment
)	I-Treatment
.	O

case	O
summaries	O
:	O
two	O
patients	I-Background
who	O
received	O
ifosfamide	I-Treatment
-	I-Treatment
containing	I-Treatment
chemotherapy	I-Treatment
developed	O
ncse	I-Problem
.	O

one	O
of	O
the	O
monohydroxy	O
-	O
metabolites	O
has	O
been	O
incriminated	O
with	O
tacrine	I-Treatment
-	O
induced	O
hepatotoxicity	I-Problem
.	O

background	O
:	O
to	O
assess	O
the	O
nature	O
,	O
incidence	O
,	O
and	O
risk	O
factors	O
of	O
retinopathy	I-Problem
associated	O
with	O
pegylated	I-Treatment
interferon	I-Treatment
and	I-Treatment
ribavirin	I-Treatment
combination	I-Treatment
therapy	I-Treatment
in	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
patients	I-Background
.	O

thrombogenic	I-Problem
activity	I-Problem
of	O
doxorubicin	I-Treatment
in	O
myeloma	I-Problem
patients	I-Background
receiving	O
thalidomide	I-Treatment
:	O
implications	O
for	O
therapy	O
.	O

agranulocytosis	I-Problem
is	O
a	O
rare	O
adverse	O
effect	O
associated	O
with	O
prolonged	I-Other
vancomycin	I-Treatment
therapy	I-Treatment
,	O
and	O
is	O
potentially	O
serious	O
,	O
especially	O
in	O
end	I-Problem
stage	I-Problem
renal	I-Problem
disease	I-Problem
(	I-Problem
esrd	I-Problem
)	I-Problem
patients	I-Background
.	O

thiopurine	O
methyltransferase	O
deficiency	O
occurs	O
at	O
a	O
frequency	O
of	O
one	O
in	O
300	O
and	O
is	O
associated	O
with	O
profound	I-Problem
myelosuppression	I-Problem
after	O
a	I-Other
short	I-Other
course	I-Other
of	I-Treatment
azathioprine	I-Treatment
.	O

hypotension	I-Problem
and	I-Problem
sinus	I-Problem
arrest	I-Problem
with	O
nifedipine	I-Treatment
in	O
pulmonary	I-Problem
hypertension	I-Problem
.	O

we	O
describe	O
children	I-Background
and	I-Background
adolescents	I-Background
with	I-Background
chronic	I-Problem
hematologic	I-Problem
and	I-Problem
oncologic	I-Problem
diseases	I-Problem
who	O
exhibited	O
drug	I-Problem
-	I-Problem
seeking	I-Problem
behavior	I-Problem
or	I-Problem
anticholinergic	I-Problem
symptoms	I-Problem
with	O
the	O
use	O
of	O
diphenhydramine	I-Treatment
.	O

transient	I-Problem
central	I-Problem
diabetes	I-Problem
insipidus	I-Problem
in	O
the	O
setting	O
of	O
underlying	O
chronic	I-Problem
nephrogenic	I-Problem
diabetes	I-Problem
insipidus	I-Problem
associated	O
with	O
lithium	I-Treatment
use	O
.	O

a	O
macrophage	I-Problem
activation	I-Problem
syndrome	I-Problem
,	O
possibly	O
related	O
to	O
methotrexate	I-Treatment
toxicity	I-Treatment
,	O
developed	O
in	O
a	I-Background
boy	I-Background
with	I-Background
systemic	I-Problem
juvenile	I-Problem
rheumatoid	I-Problem
arthritis	I-Problem
.	O

hyponatremia	I-Problem
in	O
patients	I-Background
treated	O
with	O
lorcainide	I-Treatment
,	O
a	O
new	O
antiarrhythmic	O
drug	O
.	O

electrical	I-Problem
proarrhythmia	I-Test
with	O
procainamide	I-Treatment
:	O
a	O
new	O
icd	O
-	O
drug	O
interaction	O
.	O

it	O
is	O
presumed	O
that	O
her	O
hyperchloremic	I-Problem
metabolic	I-Problem
acidosis	I-Problem
was	O
secondary	O
to	O
cholestyramine	I-Treatment
because	O
of	O
the	O
similarity	O
to	O
pediatric	O
reports	O
;	O
the	O
rapid	O
and	O
lasting	O
response	O
to	O
intravenous	O
sodium	O
bicarbonate	O
;	O
the	O
absence	O
of	O
another	O
etiology	O
;	O
normal	O
serum	O
potassium	O
,	O
chloride	O
and	O
bicarbonate	O
despite	O
continued	O
spironolactone	O
therapy	O
after	O
recovery	O
.	O

azathioprine	I-Treatment
can	O
cause	O
severe	I-Problem
myelosuppression	I-Problem
.	O

secretory	I-Problem
endometrial	I-Problem
adenocarcinoma	I-Problem
in	O
a	I-Background
patient	I-Background
on	O
tamoxifen	I-Treatment
for	I-Treatment
breast	I-Problem
cancer	I-Problem
:	O
a	O
report	O
of	O
a	O
case	O
.	O

it	O
was	O
postulated	O
that	O
the	O
allergic	I-Problem
reaction	I-Problem
was	O
most	O
likely	O
caused	O
by	O
capecitabine	I-Treatment
or	I-Treatment
the	I-Treatment
intermediate	I-Treatment
metabolites	I-Treatment
based	O
on	O
the	O
immediate	O
reappearance	O
of	O
symptoms	O
from	O
the	O
rechallenge	O
,	O
pharmacokinetic	O
data	I-Test
,	O
and	O
well	O
-	O
tolerance	O
of	O
fluorouracil	O
.	O

anterior	I-Problem
lumbosacral	I-Problem
radiculopathy	I-Problem
after	O
intrathecal	I-Treatment
methotrexate	I-Treatment
treatment	O
.	O

divalproex	I-Treatment
sodium	I-Treatment
-	O
induced	O
eosinophilic	I-Problem
pleural	I-Problem
effusion	I-Problem
.	O

a	I-Background
26	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
japanese	I-Background
man	I-Background
,	I-Background
who	I-Background
had	I-Background
been	I-Background
receiving	I-Background
medical	I-Background
attention	I-Background
for	I-Background
ulcerative	I-Problem
colitis	I-Problem
for	I-Background
one	I-Background
year	I-Background
,	O
presented	O
with	O
diffuse	I-Problem
erythema	I-Problem
and	I-Problem
pustules	I-Problem
on	I-Problem
his	I-Problem
face	I-Problem
and	I-Problem
trunk	I-Problem
,	I-Problem
malaise	I-Problem
,	I-Problem
and	I-Problem
fever	I-Problem
up	I-Problem
to	I-Problem
39	I-Problem
degrees	I-Problem
c	I-Problem
one	I-Other
day	I-Other
after	O
the	O
administration	O
of	O
salazosulfapyridine	I-Treatment
.	O

amphotericin	I-Treatment
b	I-Treatment
-	O
induced	O
seizures	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
aids	I-Problem
.	O

concomitant	I-Treatment
irradiation	I-Treatment
apparently	O
enhanced	O
the	O
skin	I-Problem
toxicity	I-Problem
of	O
aminoglutethimide	I-Treatment
or	O
possibly	O
aminoglutethimide	O
had	O
a	O
radiosensitizing	O
role	O
in	O
this	I-Background
patient	I-Background
.	O

case	O
description	O
:	O
a	I-Background
59	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
known	I-Background
neurocysticercosis	I-Problem
developed	O
a	I-Problem
large	I-Problem
cerebral	I-Problem
infarction	I-Problem
during	I-Treatment
praziquantel	I-Treatment
therapy	I-Treatment
.	O

we	O
describe	O
a	I-Background
73	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
who	O
developed	O
serious	O
systemic	I-Problem
vasculitis	I-Problem
with	I-Problem
associated	I-Problem
thrombocytopenia	I-Problem
in	O
the	O
course	O
of	O
treatment	O
with	O
cladribine	I-Treatment
.	O

all	I-Problem
changes	I-Problem
disappeared	O
4	O
months	O
after	O
the	O
discontinuation	O
of	O
vad	O
chemotherapy	O
,	O
which	O
further	O
pointed	O
out	O
towards	O
adriamycin	I-Treatment
and	I-Treatment
vincristine	I-Treatment
as	O
possible	O
etiologic	O
agents	O
.	O

because	O
of	O
further	O
progression	O
combination	O
treatment	O
of	O
bevacizumab	I-Treatment
and	I-Treatment
irinotecan	I-Treatment
was	O
started	O
and	O
again	O
no	O
liver	I-Problem
toxicity	I-Problem
was	O
observed	O
.	O

torsade	I-Problem
de	I-Problem
pointes	I-Problem
represents	O
a	O
potential	O
complication	O
of	O
chronic	I-Treatment
amiodarone	I-Treatment
therapy	I-Treatment
.	O

eosinophilia	I-Problem
caused	O
by	O
clozapine	I-Treatment
was	O
observed	O
in	O
challenge	O
,	O
preceded	I-Problem
by	I-Problem
a	I-Problem
faster	I-Problem
neutrophil	I-Problem
production	I-Problem
and	I-Problem
consecutive	I-Problem
decrease	I-Problem
(	I-Problem
z	I-Problem
=	I-Problem
2	I-Problem
.	I-Problem
27	I-Problem
,	I-Problem
p	I-Problem
=	I-Problem
0	I-Problem
.	I-Problem
01	I-Problem
)	I-Problem
.	O

the	O
first	O
case	O
is	O
a	I-Background
69	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
who	I-Background
was	I-Background
admitted	I-Background
for	I-Background
depression	I-Problem
with	I-Problem
psychosis	I-Problem
and	O
treated	O
with	O
trazodone	I-Treatment
,	I-Treatment
risperidone	I-Treatment
,	I-Treatment
and	I-Treatment
sertraline	I-Treatment
.	O

multiple	O
complications	O
of	O
propylthiouracil	I-Treatment
treatment	O
:	O
granulocytopenia	I-Problem
,	I-Problem
eosinophilia	I-Problem
,	I-Problem
skin	I-Problem
reaction	I-Problem
and	I-Problem
hepatitis	I-Problem
with	I-Problem
lymphocyte	I-Problem
sensitization	I-Problem
.	O

severe	I-Problem
hyperkalemia	I-Problem
occurred	O
in	O
a	I-Background
patient	I-Background
with	I-Background
radiation	I-Problem
pneumonitis	I-Problem
and	I-Background
glaucoma	I-Problem
shortly	O
after	O
beginning	O
prednisone	I-Treatment
therapy	O
.	O

she	O
was	O
treated	O
with	O
pancrease	I-Treatment
mt	I-Treatment
16	I-Treatment
,	O
but	O
had	O
consistent	O
vomiting	I-Problem
1	I-Other
to	I-Other
2	I-Other
hours	I-Other
after	O
administration	O
of	O
enzymes	I-Treatment
.	O

following	O
are	O
two	O
clinical	I-Background
case	I-Background
reports	O
demonstrating	O
profound	I-Problem
cerebral	I-Problem
edema	I-Problem
associated	O
with	O
implantation	I-Treatment
of	I-Treatment
gliadel	I-Treatment
wafers	I-Treatment
.	O

at	O
this	O
point	O
,	O
a	I-Treatment
new	I-Treatment
antifungal	I-Treatment
agent	I-Treatment
had	O
been	O
commenced	O
,	O
suggesting	O
a	I-Problem
possible	I-Problem
drug	I-Problem
interaction	I-Problem
enhancing	I-Problem
the	I-Problem
risk	I-Problem
of	I-Problem
known	I-Problem
neurological	I-Problem
toxicity	I-Problem
with	I-Problem
this	I-Problem
regime	I-Problem
.	O

the	O
knowledge	O
concerning	O
vgb	I-Treatment
-	O
associated	O
visual	I-Problem
dysfunction	I-Problem
in	O
pediatric	I-Background
patients	I-Background
,	O
particularly	O
in	O
those	O
who	O
have	O
been	O
exposed	O
to	O
vgb	O
in	O
utero	O
is	O
limited	O
.	O

we	O
herein	O
described	O
an	O
additional	O
patient	I-Background
with	I-Background
bcr	I-Problem
-	I-Problem
abl	I-Problem
(	I-Problem
ela2	I-Problem
)	I-Problem
positive	I-Problem
acute	I-Problem
lymphoblastic	I-Problem
leukemia	I-Problem
who	O
developed	O
tumor	I-Problem
lysis	I-Problem
syndrome	I-Problem
after	O
10	I-Other
-	I-Other
day	I-Other
treatment	I-Treatment
with	I-Treatment
imatinib	I-Treatment
.	O

tubulointerstitial	I-Problem
nephritis	I-Problem
induced	O
by	O
the	O
leukotriene	O
receptor	O
antagonist	O
pranlukast	I-Treatment
.	O

two	O
drugs	O
commonly	O
used	O
in	O
triple	O
-	O
drug	O
therapy	O
for	O
treatment	O
of	O
a	I-Problem
helicobacter	I-Problem
pylori	I-Problem
infection	I-Problem
,	O
clarithromycin	I-Treatment
and	I-Treatment
omeprazole	I-Treatment
,	O
have	O
rarely	O
been	O
associated	O
with	O
hypoglycemia	I-Problem
when	O
given	O
alone	O
.	O

we	O
describe	O
the	O
infectious	I-Problem
toxicities	I-Problem
experienced	O
by	O
the	O
first	I-Background
two	I-Background
patients	I-Background
in	I-Background
our	I-Background
institution	I-Background
treated	I-Treatment
with	I-Treatment
dexamethasone	I-Treatment
(	I-Treatment
10	I-Treatment
mg	I-Treatment
/	I-Treatment
m	I-Treatment
(	I-Treatment
2	I-Treatment
)	I-Treatment
/	I-Treatment
day	I-Treatment
for	I-Treatment
4	I-Other
weeks	I-Other
with	I-Treatment
gradual	I-Treatment
tapering	I-Treatment
)	I-Treatment
during	I-Treatment
induction	I-Treatment
according	I-Treatment
to	I-Treatment
the	I-Treatment
dexamethasone	I-Treatment
arm	I-Treatment
of	I-Treatment
bfm	I-Treatment
2000	I-Treatment
and	O
review	O
the	O
relevant	O
literature	O
that	O
suggests	O
an	O
increased	O
risk	O
of	O
infectious	O
complications	O
with	O
dexamethasone	O
.	O

this	O
case	O
demonstrates	O
that	O
there	O
is	O
no	O
cross	O
reactivity	O
between	O
glyburide	I-Treatment
and	I-Treatment
chlorpropamide	I-Treatment
in	O
producing	O
hemolytic	I-Problem
anemia	I-Problem
.	O

codeine	I-Treatment
intoxication	I-Problem
in	O
the	O
neonate	I-Background
.	O

however	O
,	O
1	I-Problem
eye	I-Problem
had	I-Problem
vitreous	I-Problem
hemorrhage	I-Problem
after	O
repeated	I-Treatment
injections	I-Treatment
of	I-Treatment
tpa	I-Treatment
.	O

dilated	I-Problem
cardiomyopathy	I-Problem
associated	O
with	O
chronic	I-Treatment
overuse	I-Treatment
of	I-Treatment
an	I-Treatment
adrenaline	I-Treatment
inhaler	I-Treatment
.	O

surgeons	O
and	O
physicians	O
should	O
therefore	O
be	O
aware	O
of	O
the	O
potential	O
for	O
rta	I-Problem
to	O
occur	O
with	O
fk506	I-Treatment
after	I-Treatment
any	I-Treatment
organ	I-Treatment
transplantation	I-Treatment
.	O

thirty	O
patients	I-Background
with	O
hepatic	I-Problem
reactions	O
to	O
cyclofenil	I-Treatment
,	O
a	O
non	O
-	O
steroidal	O
drug	O
with	O
a	O
stimulating	O
effect	O
on	O
ovulation	O
,	O
are	O
reviewed	O
.	O

though	O
serotonin	I-Problem
syndrome	I-Problem
is	O
most	O
often	O
associated	O
with	O
ingestion	I-Treatment
of	I-Treatment
more	I-Treatment
than	I-Treatment
one	I-Treatment
serotonergic	I-Treatment
drug	I-Treatment
,	O
many	O
other	O
mechanisms	O
have	O
been	O
associated	O
with	O
serotonergic	O
excess	O
.	O

because	O
of	O
a	O
hypersensitivity	I-Problem
reaction	I-Problem
,	O
initial	O
therapy	O
with	O
penicillin	I-Treatment
g	I-Treatment
and	O
gentamicin	I-Treatment
was	O
stopped	O
and	O
substituted	O
with	O
cefazolin	I-Treatment
.	O

ophthalmologists	O
should	O
be	O
aware	O
of	O
the	O
ocular	I-Problem
side	I-Problem
effects	I-Problem
of	O
ifn	I-Treatment
therapy	O
and	O
carefully	O
monitor	O
patients	I-Background
for	O
the	O
possible	O
occurrence	O
of	O
hypoalbuminemia	I-Problem
and	I-Problem
thrombocytopenia	I-Problem
.	O

chlorpropamide	I-Treatment
-	O
induced	O
hemolytic	I-Problem
anemia	I-Problem
.	O

we	O
report	O
recrudescence	O
of	O
imported	O
plasmodium	I-Problem
falciparum	I-Problem
malaria	I-Problem
following	O
quinine	I-Treatment
treatment	I-Treatment
in	I-Treatment
the	I-Treatment
context	I-Treatment
of	I-Treatment
concurrent	I-Treatment
phenytoin	I-Treatment
use	I-Treatment
.	O

it	O
is	O
likely	O
that	O
ra	I-Treatment
contributed	O
to	O
the	O
deterioration	I-Problem
in	I-Problem
renal	I-Problem
function	I-Problem
in	O
these	O
patients	O
.	O

marked	I-Problem
sinus	I-Problem
tachycardia	I-Problem
resulting	O
from	O
the	O
synergistic	O
effects	O
of	O
marijuana	I-Treatment
and	I-Treatment
nortriptyline	I-Treatment
.	O

infliximab	I-Treatment
and	O
its	O
serious	O
adverse	O
effects	O
are	O
discussed	O
,	O
and	O
other	O
cases	O
of	O
osteomyelitis	I-Problem
with	O
infliximab	I-Treatment
use	O
are	O
also	O
reviewed	O
.	O

a	O
new	O
type	O
of	O
minocycline	I-Treatment
-	O
induced	O
cutaneous	I-Problem
hyperpigmentation	I-Problem
.	O

stroke	I-Problem
is	O
an	O
infrequent	O
but	O
recognized	O
complication	O
of	O
heroin	I-Treatment
addiction	I-Treatment
.	O

although	O
this	O
type	O
of	O
hyperpigmentation	O
has	O
been	O
previously	O
seen	O
in	O
patients	O
with	O
cancer	O
who	O
are	O
receiving	O
bleomycin	O
,	O
this	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
reported	O
case	O
of	O
bleomycin	I-Treatment
-	O
induced	O
hyperpigmentation	I-Problem
in	O
an	I-Background
aids	I-Problem
patient	I-Background
and	O
should	O
be	O
added	O
to	O
the	O
growing	O
list	O
of	O
cutaneous	O
eruptions	O
seen	O
in	O
these	O
patients	O
.	O

case	I-Background
report	O
of	O
withdrawal	I-Problem
dyskinesia	I-Problem
associated	O
with	O
amoxapine	I-Treatment
.	O

concern	O
exists	O
that	O
preadmission	I-Treatment
warfarin	I-Treatment
use	O
may	O
be	O
associated	O
with	O
an	O
increased	I-Problem
risk	I-Problem
of	I-Problem
intracerebral	I-Problem
hemorrhage	I-Problem
in	O
patients	I-Background
with	I-Background
ischemic	I-Problem
stroke	I-Problem
receiving	I-Treatment
intravenous	I-Treatment
tissue	I-Treatment
plasminogen	I-Treatment
activator	I-Treatment
,	O
even	O
in	O
those	O
with	O
an	O
international	O
normalized	O
ratio	O
<	O
1	O
.	O
7	O
.	O

development	O
of	O
essential	I-Problem
thrombocythemia	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
interferon	I-Treatment
alfa	I-Treatment
and	I-Treatment
pentostatin	I-Treatment
for	O
hairy	I-Problem
cell	I-Problem
leukemia	I-Problem
.	O

a	I-Background
case	I-Background
of	O
siadh	I-Problem
induced	O
by	O
mizoribin	I-Treatment
administration	I-Treatment
.	O

the	O
agranulocytosis	I-Problem
was	O
rapidly	O
resolved	O
by	O
granulocyte	I-Treatment
colony	I-Treatment
-	I-Treatment
stimulating	I-Treatment
factor	I-Treatment
(	I-Treatment
g	I-Treatment
-	I-Treatment
csf	I-Treatment
)	I-Treatment
therapy	I-Treatment
and	I-Treatment
by	I-Treatment
the	I-Treatment
discontinuation	I-Treatment
of	I-Treatment
vancomycin	I-Treatment
.	O

a	I-Background
patient	I-Background
that	O
received	O
methadone	I-Treatment
for	O
cancer	I-Problem
-	I-Problem
associated	I-Problem
pain	I-Problem
developed	O
myoclonus	I-Problem
as	O
a	O
side	O
effect	O
.	O

these	O
cases	O
were	O
considered	O
unusual	O
in	O
light	O
of	O
the	O
short	O
delay	O
of	O
their	O
onset	O
after	O
initiation	O
of	O
immunosuppressive	O
therapy	O
and	O
their	O
fulminant	O
course	O
:	O
3	O
of	I-Background
these	I-Background
patients	I-Background
died	O
of	O
pcp	I-Problem
occurring	O
during	O
the	O
first	I-Other
month	I-Other
of	I-Treatment
treatment	I-Treatment
with	I-Treatment
prednisone	I-Treatment
.	O

five	I-Other
days	I-Other
after	I-Treatment
the	I-Treatment
fourth	I-Treatment
dose	I-Treatment
of	I-Treatment
vincristine	I-Treatment
,	O
she	I-Background
presented	O
with	O
bilateral	I-Problem
ptosis	I-Problem
.	O

as	O
it	O
had	O
been	O
10	O
months	O
since	O
her	O
last	O
dosage	O
adjustment	O
of	O
diltiazem	O
,	O
it	O
was	O
unlikely	O
that	O
the	O
statin	I-Problem
-	I-Problem
induced	I-Problem
rhabdomyolysis	I-Problem
was	O
precipitated	O
by	O
diltiazem	I-Treatment
.	O

after	O
the	O
chlorambucil	I-Treatment
was	O
discontinued	O
,	O
the	O
wbc	I-Test
count	I-Test
began	I-Problem
to	I-Problem
slowly	I-Problem
rise	I-Problem
and	O
the	I-Background
patient	I-Background
developed	O
clinical	I-Problem
aml	I-Problem
.	O

she	I-Background
received	O
3	I-Treatment
.	I-Treatment
8	I-Treatment
mg	I-Treatment
cumulative	I-Treatment
dose	I-Treatment
of	I-Treatment
vincristin	I-Treatment
before	O
development	O
of	O
ptosis	I-Problem
.	O

in	O
addition	O
,	O
the	O
tachycardia	I-Problem
persisted	I-Problem
and	I-Problem
was	I-Problem
repeatedly	I-Problem
spontaneously	I-Problem
reinitiated	I-Problem
for	I-Problem
prolonged	I-Problem
periods	I-Problem
after	O
procainamide	I-Treatment
.	O

a	I-Background
third	I-Background
patient	I-Background
experienced	O
disabling	I-Problem
neurotoxicity	I-Problem
in	I-Problem
the	I-Problem
extremity	I-Problem
of	I-Problem
a	I-Problem
prior	I-Problem
ulnar	I-Problem
nerve	I-Problem
and	I-Problem
tendon	I-Problem
transposition	I-Problem
after	O
receiving	O
paclitaxel	I-Treatment
.	O

acute	I-Problem
renal	I-Problem
insufficiency	I-Problem
is	O
known	O
to	O
occur	O
in	O
patients	I-Background
who	O
are	O
taking	O
ciprofloxacin	I-Treatment
,	O
particularly	O
the	O
elderly	I-Background
.	O

a	O
61	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
clinical	I-Problem
lupus	I-Problem
syndrome	I-Problem
with	I-Problem
positive	I-Problem
antinuclear	I-Problem
antibody	I-Problem
,	I-Problem
positive	I-Problem
lupus	I-Problem
erythematosus	I-Problem
(	I-Problem
le	I-Problem
)	I-Problem
cell	I-Problem
preparation	I-Problem
,	I-Problem
and	I-Problem
diffuse	I-Problem
proliferative	I-Problem
glomerulonephritis	I-Problem
following	O
26	I-Other
months	I-Other
of	I-Treatment
procainamide	I-Treatment
therapy	I-Treatment
.	O

laryngeal	I-Problem
dyspnea	I-Problem
in	O
relation	O
to	O
an	O
interaction	O
between	O
acenocoumarol	I-Treatment
and	O
topical	I-Treatment
econazole	I-Treatment
lotion	I-Treatment
.	O

a	I-Background
46	I-Background
-	I-Background
year	I-Background
old	I-Background
man	I-Background
with	I-Background
a	I-Problem
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
virus	I-Problem
infection	I-Problem
received	O
triple	I-Treatment
therapy	I-Treatment
with	I-Treatment
ribavirin	I-Treatment
,	I-Treatment
pegylated	I-Treatment
interferon	I-Treatment
and	I-Treatment
telaprevir	I-Treatment
.	O

leishmania	I-Problem
infantum	I-Problem
leishmaniasis	I-Problem
in	O
corticosteroid	I-Treatment
-	O
-	O
treated	O
patients	O
.	O

the	I-Background
patient	I-Background
developed	O
occipital	I-Problem
infarcts	I-Problem
and	O
was	O
found	O
to	O
have	O
extremely	I-Treatment
elevated	I-Treatment
levels	I-Treatment
of	I-Treatment
ppa	I-Treatment
in	O
his	O
blood	I-Test
and	O
dialysis	O
fluid	I-Test
.	O

as	O
atypical	I-Treatment
antipsychotics	I-Treatment
are	O
increasingly	O
used	O
in	O
the	O
treatment	O
of	O
childhood	I-Problem
behavioural	I-Problem
disorders	I-Problem
either	O
as	I-Treatment
monotherapy	I-Treatment
or	I-Treatment
in	I-Treatment
combination	I-Treatment
with	I-Treatment
other	I-Treatment
medications	I-Treatment
,	O
there	O
is	O
a	O
need	O
to	O
know	O
more	O
about	O
their	O
safety	O
,	O
in	O
particular	O
during	O
switching	O
to	O
and	O
from	O
methylphenidate	O
treatment	O
,	O
as	O
antipsychotics	O
and	O
methylphenidate	O
have	O
opposing	O
effects	O
on	O
dopaminergic	O
neurotransmission	O
.	O

sensory	I-Problem
neuropathy	I-Problem
revealing	I-Problem
necrotizing	I-Problem
vasculitis	I-Problem
during	O
infliximab	I-Treatment
therapy	I-Treatment
for	O
rheumatoid	I-Problem
arthritis	I-Problem
.	O

because	O
etoposide	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
is	O
an	O
uncommon	O
but	O
serious	O
adverse	O
event	O
,	O
clinicians	O
must	O
be	O
vigilant	O
about	O
the	O
possibility	O
of	O
it	O
,	O
so	O
that	O
the	O
optimal	O
treatment	O
can	O
start	O
as	O
soon	O
as	O
possible	O
.	O

on	O
march	O
13	O
the	I-Background
patient	I-Background
was	I-Background
again	I-Background
admitted	I-Background
for	I-Background
worsening	I-Background
chf	I-Background
and	O
was	O
started	O
on	O
continuous	I-Other
dobutamine	I-Treatment
infusion	I-Treatment
.	O

we	O
report	O
a	I-Background
53	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
-	I-Background
man	I-Background
who	O
developed	O
rippling	I-Problem
muscle	I-Problem
disease	I-Problem
(	I-Problem
rmd	I-Problem
)	I-Problem
2	I-Other
months	I-Other
after	I-Treatment
starting	I-Treatment
simvastatin	I-Treatment
therapy	I-Treatment
for	O
hypercholesterolemia	I-Problem
.	O

after	O
taking	O
cholestyramine	I-Treatment
ii	I-Treatment
sachets	I-Treatment
twice	I-Other
daily	I-Other
for	I-Treatment
two	I-Other
months	I-Other
she	I-Background
presented	O
with	O
lethargy	I-Problem
,	I-Problem
confusion	I-Problem
and	I-Problem
drowsiness	I-Problem
.	O

escape	O
atrial	O
complexes	O
,	O
which	O
occurred	O
following	O
junctional	O
premature	O
complexes	O
,	O
failed	O
to	O
initiate	O
tachycardia	O
in	O
the	O
control	O
state	O
but	O
tachycardia	I-Problem
was	O
always	O
reinitiated	O
by	O
an	O
identical	O
escape	O
sequence	O
after	O
procainamide	I-Treatment
.	O

ten	O
percent	O
of	O
newly	O
diagnosed	O
myeloma	I-Problem
patients	I-Background
treated	O
with	O
any	I-Treatment
type	I-Treatment
of	I-Treatment
chemotherapy	I-Treatment
develop	O
deep	I-Problem
venous	I-Problem
thrombosis	I-Problem
(	I-Problem
dvt	I-Problem
)	I-Problem
.	O

in	O
summary	O
,	O
we	O
report	O
herein	O
the	I-Background
first	I-Background
case	I-Background
of	O
siadh	I-Problem
believed	O
to	O
be	O
an	O
adverse	O
effect	O
of	O
mizoribin	I-Treatment
,	O
which	O
may	O
therefore	O
needed	O
to	O
be	O
added	O
to	O
the	O
list	O
of	O
drugs	O
which	O
can	O
induce	O
siadh	O
.	O

isoniazid	I-Treatment
and	I-Treatment
ethambutol	I-Treatment
as	O
a	O
cause	O
of	O
optic	I-Problem
neuropathy	I-Problem
.	O

administration	O
of	O
pyridoxine	I-Treatment
to	O
an	I-Background
infant	I-Background
after	O
a	O
long	O
period	O
of	O
convulsions	I-Problem
was	O
followed	O
by	O
acute	I-Problem
hypotonia	I-Problem
.	O

acute	I-Problem
pancreatitis	I-Problem
in	O
a	I-Background
child	I-Background
with	I-Background
idiopathic	I-Problem
ulcerative	I-Problem
colitis	I-Problem
on	O
long	I-Other
-	I-Other
term	I-Other
5	I-Treatment
-	I-Treatment
aminosalicylic	I-Treatment
acid	I-Treatment
therapy	I-Treatment
.	O

high	I-Treatment
-	I-Treatment
dose	I-Treatment
antithrombin	I-Treatment
iii	I-Treatment
in	O
severe	I-Problem
sepsis	I-Problem
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

fatal	I-Problem
interstitial	I-Problem
pneumonitis	I-Problem
following	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
intermittent	I-Treatment
chlorambucil	I-Treatment
therapy	I-Treatment
for	O
chronic	I-Problem
lymphocyte	I-Problem
leukemia	I-Problem
.	O

these	O
findings	O
suggest	O
that	O
the	O
corneal	I-Problem
and	I-Problem
retinal	I-Problem
changes	I-Problem
are	O
the	O
result	O
of	O
a	O
toxic	O
effect	O
of	O
tamoxifen	I-Treatment
when	O
used	O
in	O
the	O
doses	O
and	O
duration	O
described	O
.	O

common	O
adverse	O
events	O
(	O
frequency	O
10	O
%	O
)	O
of	O
lacosamide	I-Treatment
doses	I-Treatment
up	I-Treatment
to	I-Treatment
600	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
include	O
nonspecific	I-Problem
central	I-Problem
nervous	I-Problem
system	I-Problem
effects	I-Problem
(	I-Problem
e	I-Problem
.	I-Problem
g	I-Problem
.	I-Problem
,	I-Problem
dizziness	I-Problem
,	I-Problem
ataxia	I-Problem
,	I-Problem
diplopia	I-Problem
,	I-Problem
and	I-Problem
somnolence	I-Problem
)	I-Problem
.	O

we	O
report	O
two	O
cases	O
of	O
serotonin	I-Problem
syndrome	I-Problem
in	O
elderly	I-Background
patients	I-Background
during	O
treatment	O
of	O
psychotic	I-Problem
depression	I-Problem
with	O
atypical	I-Treatment
antipsychotics	I-Treatment
and	I-Treatment
antidepressants	I-Treatment
.	O

piritrexim	I-Treatment
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
.	O

progression	I-Problem
of	I-Problem
chronic	I-Problem
myeloid	I-Problem
leukemia	I-Problem
to	I-Problem
blast	I-Problem
crisis	I-Problem
during	O
treatment	O
with	O
imatinib	I-Treatment
mesylate	I-Treatment
.	O

presentation	O
of	O
three	O
palliative	I-Background
care	I-Background
patients	I-Background
who	O
were	O
given	O
ketamine	I-Treatment
as	O
an	O
analgesic	O
and	O
subsequently	O
developed	O
significant	O
and	O
debilitating	O
urological	I-Problem
symptoms	I-Problem
.	O

a	I-Background
52	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
patient	I-Background
diagnosed	I-Background
of	I-Background
ankylosing	I-Problem
spondylitis	I-Problem
presented	O
with	O
an	I-Problem
iron	I-Problem
deficiency	I-Problem
anemia	I-Problem
after	O
a	I-Treatment
ten	I-Other
-	I-Other
month	I-Other
treatment	I-Treatment
of	I-Treatment
methotrexate	I-Treatment
.	O

the	O
international	O
literature	O
regarding	O
opportunistic	I-Problem
infections	I-Problem
after	O
immunosuppressive	I-Treatment
therapy	I-Treatment
with	I-Treatment
alemtuzumab	I-Treatment
with	O
particular	O
attention	O
on	O
fungal	O
infections	O
has	O
also	O
been	O
reviewed	O
.	O

clinicians	O
should	O
be	O
aware	O
of	O
the	O
dysrhythmic	I-Problem
potential	O
of	O
cyclobenzaprine	I-Treatment
and	I-Treatment
fluoxetine	I-Treatment
,	O
monitor	O
for	O
other	O
cytochrome	O
p450	O
inhibitors	O
,	O
and	O
avoid	O
concomitant	O
drugs	O
known	O
to	O
prolong	O
the	O
qt	O
interval	O
.	O

acute	I-Problem
generalized	I-Problem
exanthematous	I-Problem
pustulosis	I-Problem
induced	O
by	O
salazosulfapyridine	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
ulcerative	I-Problem
colitis	I-Problem
.	O

conclusion	O
:	O
acetic	I-Treatment
acid	I-Treatment
is	O
corrosive	O
and	O
may	O
cause	O
vagina	I-Problem
bleeding	I-Problem
.	O

we	O
report	O
a	O
case	O
admitted	O
with	O
a	O
first	O
-	O
detected	O
,	O
symptomatic	I-Problem
paroxysmal	I-Problem
atrial	I-Problem
fibrillation	I-Problem
in	O
a	I-Background
healthy	I-Background
patient	I-Background
after	O
self	O
-	O
medication	O
with	O
vardenafil	I-Treatment
.	O

propranolol	I-Treatment
:	O
an	O
unrecognized	O
cause	O
of	O
central	I-Problem
nervous	I-Problem
system	I-Problem
dysfunction	I-Problem
in	O
patients	I-Background
undergoing	I-Background
cardiopulmonary	I-Problem
bypass	I-Problem
.	O

conclusions	O
:	O
symptoms	I-Problem
and	I-Problem
pathologic	I-Problem
changes	I-Problem
of	I-Problem
colitis	I-Problem
are	O
associated	O
with	O
exposure	O
to	O
rofecoxib	I-Treatment
.	O

a	O
possible	O
drug	I-Treatment
-	I-Treatment
drug	I-Treatment
interaction	I-Treatment
between	I-Treatment
ifn	I-Treatment
alfa	I-Treatment
11	I-Treatment
mu	I-Treatment
tiw	I-Other
and	I-Treatment
gemfibrozil	I-Treatment
600	I-Treatment
mg	I-Treatment
bid	I-Other
was	O
reported	O
in	O
a	I-Background
patient	I-Background
undergoing	O
treatment	O
for	O
ifn	I-Problem
-	I-Problem
induced	I-Problem
hypertriglyceridemia	I-Problem
.	O

systemic	I-Problem
vasculitis	I-Problem
complicating	O
hairy	I-Problem
cell	I-Problem
leukaemia	I-Problem
treatment	O
with	O
cladribine	I-Treatment
.	O

quinine	I-Treatment
is	O
universally	O
used	O
for	O
the	O
very	O
common	O
symptom	O
of	O
night	I-Problem
leg	I-Problem
cramps	I-Problem
.	O

however	O
,	O
continued	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
mtx	I-Treatment
led	O
,	O
in	O
spite	O
of	O
normal	O
liver	I-Test
tests	I-Test
,	O
8	O
years	O
after	O
the	O
last	I-Test
biopsy	I-Test
to	O
liver	I-Problem
failure	I-Problem
and	I-Problem
death	I-Problem
in	O
1	O
of	O
our	O
patients	O
.	O

antithrombin	I-Treatment
iii	I-Treatment
may	O
provide	O
protection	O
from	O
multiorgan	I-Problem
failure	I-Problem
and	O
improve	O
survival	O
in	O
severely	I-Problem
ill	I-Problem
patients	I-Background
.	O

in	I-Background
the	I-Background
second	I-Background
case	I-Background
,	O
five	I-Problem
cardiac	I-Problem
arrests	I-Problem
due	I-Problem
to	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
and	I-Problem
fibrillation	I-Problem
occurred	O
during	O
several	I-Other
hours	I-Other
after	I-Other
beginning	I-Treatment
a	I-Treatment
trial	I-Treatment
of	I-Treatment
bretylium	I-Treatment
maintenance	I-Treatment
therapy	I-Treatment
for	O
complex	I-Problem
ventricular	I-Problem
ectopy	I-Problem
.	O

the	O
association	O
of	O
central	I-Problem
diabetes	I-Problem
insipidus	I-Problem
(	I-Problem
cdi	I-Problem
)	I-Problem
with	O
lithium	I-Treatment
use	O
is	O
rare	O
.	O

however	O
,	O
a	O
new	O
episode	O
of	O
neutropenia	I-Problem
,	I-Problem
with	I-Problem
a	I-Problem
wbc	I-Test
count	I-Test
of	I-Problem
2	I-Problem
.	I-Problem
8	I-Problem
x	I-Problem
10	I-Problem
(	I-Problem
3	I-Problem
)	I-Problem
/	I-Problem
mm3	I-Problem
and	I-Problem
anc	I-Problem
of	I-Problem
0	I-Problem
.	I-Problem
448	I-Problem
x	I-Problem
10	I-Problem
(	I-Problem
3	I-Problem
)	I-Problem
/	I-Problem
mm3	I-Problem
,	O
occurred	O
11	I-Other
days	I-Other
after	I-Treatment
teicoplanin	I-Treatment
initiation	I-Treatment
.	O

in	O
a	O
phase	I-Test
ii	I-Test
study	I-Test
of	O
hycanthone	I-Treatment
in	O
patients	I-Background
with	I-Background
breast	I-Problem
cancer	I-Problem
we	O
have	O
recently	O
observed	O
severe	O
hepatotoxicity	I-Problem
,	O
even	O
at	O
lower	I-Treatment
doses	I-Treatment
,	O
which	O
resulted	O
in	O
two	O
drug	O
-	O
related	O
deaths	O
.	O

this	O
is	O
the	O
first	O
report	O
of	O
non	I-Problem
-	I-Problem
convulsive	I-Problem
status	I-Problem
epilepticus	I-Problem
provoked	O
by	O
tiagabine	I-Treatment
in	O
adolescent	I-Background
patients	I-Background
.	O

two	O
patients	I-Background
are	O
described	O
who	O
developed	O
sensory	I-Problem
neuropathy	I-Problem
after	O
the	I-Treatment
ingestion	I-Treatment
of	I-Treatment
30	I-Treatment
.	I-Treatment
6	I-Treatment
and	I-Treatment
114	I-Treatment
g	I-Treatment
metronidazole	I-Treatment
respectively	O
.	O

we	O
report	O
two	O
young	I-Background
patients	I-Background
with	I-Background
cystic	I-Problem
fibrosis	I-Problem
who	O
presented	O
with	O
acute	I-Problem
renal	I-Problem
insufficiency	I-Problem
after	O
2	I-Other
-	I-Other
3	I-Other
weeks	I-Other
of	I-Treatment
oral	I-Treatment
ciprofloxacin	I-Treatment
therapy	I-Treatment
.	O

a	I-Background
37	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
with	I-Background
multiple	I-Problem
myeloma	I-Problem
received	O
citalopram	I-Treatment
40	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
and	I-Treatment
trazodone	I-Treatment
150	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
for	O
anxiety	I-Problem
-	I-Problem
related	I-Problem
disorders	I-Problem
.	O

hashimoto	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
during	O
interferon	I-Treatment
-	I-Treatment
alpha	I-Treatment
therapy	O
in	O
a	I-Background
patient	I-Background
with	I-Background
pre	I-Background
-	I-Background
treatment	I-Background
negative	I-Background
anti	I-Background
-	I-Background
thyroid	I-Background
autoantibodies	I-Background
and	I-Background
with	I-Background
the	I-Background
specific	I-Problem
genetic	I-Problem
susceptibility	I-Problem
to	I-Problem
the	I-Problem
thyroid	I-Problem
disease	I-Problem
.	O

fever	I-Problem
,	I-Problem
lymphadenopathy	I-Problem
,	I-Problem
eosinophilia	I-Problem
,	I-Problem
lymphocytosis	I-Problem
,	I-Problem
hepatitis	I-Problem
,	I-Problem
and	I-Problem
dermatitis	I-Problem
:	O
a	O
severe	O
adverse	O
reaction	O
to	O
minocycline	I-Treatment
.	O

conclusions	O
:	O
this	O
observation	O
of	O
"	O
on	O
-	O
off	O
"	O
risperidone	O
treatment	O
suggests	O
that	O
risperidone	I-Treatment
may	O
have	O
worsened	O
both	O
psychiatric	I-Problem
and	I-Problem
physical	I-Problem
manifestations	I-Problem
of	O
the	O
mitochondrial	I-Problem
disorder	I-Problem
in	I-Background
this	I-Background
adolescent	I-Background
.	O

the	O
events	O
of	O
non	I-Problem
-	I-Problem
convulsive	I-Problem
status	I-Problem
epilepticus	I-Problem
subsided	I-Problem
following	O
reduction	I-Treatment
in	I-Treatment
tiagabine	I-Treatment
dosages	I-Treatment
.	O

conclusions	O
:	O
for	O
all	O
patients	I-Background
with	O
vancomycin	I-Treatment
-	O
induced	O
neutropenia	I-Problem
,	O
possible	O
cross	O
-	I-Test
reactivity	I-Test
of	O
teicoplanin	I-Treatment
should	O
be	O
monitored	O
.	O

methotrexate	I-Treatment
induced	O
sprue	I-Problem
-	I-Problem
like	I-Problem
syndrome	I-Problem
.	O

because	O
of	O
the	O
described	O
effects	O
of	O
niacin	I-Treatment
on	O
the	O
coagulation	I-Test
cascade	I-Test
and	O
the	O
possibility	O
for	O
pharmacokinetic	O
interactions	O
,	O
there	O
is	O
a	O
potential	O
for	O
synergistic	I-Problem
coagulopathy	I-Problem
when	O
combined	I-Treatment
with	I-Treatment
warfarin	I-Treatment
therapy	I-Treatment
.	O

the	O
failure	O
of	O
therapy	O
with	O
disopyramide	O
and	O
mexiletine	O
to	O
reproduce	O
this	O
observation	O
suggests	O
either	O
a	O
previously	O
unreported	O
electrophysiologic	I-Problem
effect	I-Problem
of	O
,	O
or	O
idiosyncratic	O
response	O
to	O
,	O
procainamide	I-Treatment
.	O

despite	O
administration	O
of	O
phenytoin	O
and	O
lorazepam	O
,	O
the	O
seizures	I-Problem
persisted	O
and	O
occurred	O
only	O
during	O
amphotercin	I-Treatment
b	I-Treatment
administration	O
.	O

we	O
describe	O
a	I-Background
patient	I-Background
who	I-Background
presented	I-Background
with	I-Background
bloody	I-Problem
diarrhoea	I-Problem
after	O
15	I-Treatment
mg	I-Treatment
meloxicam	I-Treatment
daily	I-Other
for	I-Treatment
10	I-Other
days	I-Other
for	O
osteoarthritis	I-Problem
.	O

in	O
the	O
first	I-Background
patient	I-Background
,	O
two	I-Problem
episodes	I-Problem
of	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
requiring	I-Problem
cardioversion	I-Problem
occurred	O
in	O
close	I-Other
temporal	I-Other
sequence	I-Other
with	I-Treatment
administering	I-Treatment
bretylium	I-Treatment
.	O

transient	O
phenytoin	I-Treatment
induced	O
iga	I-Problem
deficiency	I-Problem
and	I-Problem
permanent	I-Problem
ige	I-Problem
increase	I-Problem
.	O

cerebral	I-Problem
edema	I-Problem
associated	O
with	O
gliadel	I-Treatment
wafers	I-Treatment
:	O
two	O
case	O
studies	O
.	O

following	O
the	O
development	O
of	O
restless	I-Problem
leg	I-Problem
syndrome	I-Problem
,	O
therapy	O
with	O
clonazepam	I-Treatment
0	I-Treatment
.	I-Treatment
5	I-Treatment
mg	I-Treatment
qhs	I-Treatment
was	O
initiated	O
.	O

we	O
present	O
a	I-Background
case	I-Background
of	I-Background
a	I-Background
diabetic	I-Problem
patient	I-Background
taking	I-Background
glyburide	I-Treatment
who	O
was	O
prescribed	O
ciprofloxacin	I-Treatment
and	O
developed	O
prolonged	I-Problem
hypoglycemia	I-Problem
,	I-Problem
which	I-Problem
persisted	I-Problem
for	I-Problem
over	I-Problem
24	I-Problem
hours	I-Problem
.	O

we	O
describe	O
a	I-Background
74	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
(	I-Background
ra	I-Background
)	I-Background
who	O
developed	O
syndrome	I-Problem
of	I-Problem
inappropriate	I-Problem
secretion	I-Problem
of	I-Problem
antidiuretic	I-Problem
hormone	I-Problem
(	I-Problem
siadh	I-Problem
)	I-Problem
1	I-Other
.	I-Other
5	I-Other
months	I-Other
after	I-Other
commencement	I-Treatment
of	I-Treatment
mizoribin	I-Treatment
prescription	I-Treatment
when	O
his	O
arthritis	O
was	O
improved	O
.	O

to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
ivermectin	I-Treatment
-	O
induced	O
severe	I-Problem
liver	I-Problem
disease	I-Problem
published	O
in	O
the	O
literature	O
.	O

this	O
is	O
the	O
first	O
case	O
of	O
hydroxyurea	I-Treatment
-	O
induced	O
acute	I-Problem
interstitial	I-Problem
pneumonitis	I-Problem
reported	O
in	O
the	O
literature	O
.	O

a	I-Background
32	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
a	I-Background
family	I-Background
history	I-Background
of	I-Background
type	I-Problem
2	I-Problem
diabetes	I-Problem
mellitus	I-Problem
presented	O
with	O
circulatory	I-Problem
collapse	I-Problem
and	I-Problem
deep	I-Problem
coma	I-Problem
after	I-Other
9	I-Other
days	I-Other
of	I-Treatment
treatment	I-Treatment
with	I-Treatment
perospirone	I-Treatment
hydrochloride	I-Treatment
,	O
a	O
recently	O
developed	O
atypical	O
antipsychotic	O
agent	O
available	O
only	O
in	O
japan	O
.	O

conclusion	O
:	O
the	O
chronic	I-Other
use	I-Treatment
of	I-Treatment
hcq	I-Treatment
for	O
rheumatic	I-Problem
diseases	I-Problem
,	O
or	O
as	O
an	O
anti	O
-	O
malarial	O
drug	O
,	O
should	O
be	O
balanced	O
against	O
the	O
risk	O
of	O
developing	O
potentially	O
lethal	I-Problem
cardiac	I-Problem
arrhythmias	I-Problem
.	O

myoclonic	I-Problem
spasms	I-Problem
following	O
intrathecal	I-Treatment
morphine	I-Treatment
.	I-Treatment

this	O
is	O
the	O
first	O
report	O
of	O
a	O
disulfiram	I-Problem
-	I-Problem
like	I-Problem
reaction	I-Problem
with	O
cefmenoxime	I-Treatment
.	O

to	O
report	O
a	O
case	O
of	O
a	O
probable	O
interaction	O
between	O
warfarin	I-Treatment
and	I-Treatment
extended	I-Treatment
-	I-Treatment
release	I-Treatment
niacin	I-Treatment
that	O
may	O
have	O
led	O
to	O
synergistic	I-Problem
coagulopathy	I-Problem
and	O
to	O
inform	O
health	O
care	O
providers	O
of	O
a	O
need	O
for	O
more	O
frequent	I-Test
monitoring	I-Test
of	O
international	O
normalized	O
ratio	O
(	O
inr	O
)	O
in	O
patients	O
taking	O
these	O
drugs	O
concomitantly	O
.	O

dasatinib	I-Treatment
-	O
induced	O
pleural	I-Problem
effusions	I-Problem
:	O
a	O
lymphatic	O
network	O
disorder	O
?	O

this	O
article	O
reports	O
the	O
case	O
of	O
an	I-Background
otherwise	I-Background
healthy	I-Background
patient	I-Background
who	O
experienced	O
permanent	I-Problem
sensorineural	I-Problem
hearing	I-Problem
loss	I-Problem
after	O
a	I-Treatment
brief	I-Other
course	I-Other
of	I-Treatment
naproxen	I-Treatment
and	O
reviews	O
the	O
literature	O
on	O
nsaid	O
-	O
related	O
permanent	O
sensorineural	O
hearing	O
loss	O
.	O

administration	O
of	O
steroid	I-Treatment
and	O
decreasing	O
the	O
dose	O
of	O
ptu	I-Treatment
produced	O
a	I-Problem
good	I-Problem
clinical	I-Problem
response	I-Problem
and	I-Problem
the	I-Problem
anca	I-Problem
disappeared	I-Problem
.	O

the	I-Background
second	I-Background
patient	I-Background
exhibited	O
sudden	I-Problem
plms	I-Problem
following	O
olanzapine	I-Treatment
injection	I-Treatment
.	O

however	O
,	O
adenosine	I-Treatment
shortens	O
the	O
antegrade	O
refractoriness	O
of	O
accessory	O
atrioventricular	O
connections	O
and	O
may	O
cause	O
acceleration	I-Problem
of	I-Problem
the	I-Problem
ventricular	I-Problem
rate	I-Problem
during	I-Problem
atrial	I-Problem
fibrillation	I-Problem
.	O

a	O
cardiology	I-Test
consultation	I-Test
performed	O
on	O
the	O
day	O
of	O
admission	O
determined	O
that	O
a	O
markedly	O
elevated	I-Problem
creatine	I-Problem
kinase	I-Problem
-	I-Problem
myocardial	I-Problem
band	I-Test
isoenzyme	I-Test
level	I-Test
and	I-Problem
borderline	I-Problem
-	I-Test
high	I-Test
troponin	I-Test
i	I-Test
level	I-Test
were	O
diagnostic	O
of	O
rhabdomyolysis	I-Problem
secondary	O
to	O
statin	I-Treatment
use	O
.	O

methods	O
:	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
titrated	O
oral	O
challenges	O
with	O
pancreatic	O
enzymes	I-Test
resulted	O
in	O
definite	O
vomiting	I-Problem
within	O
1	O
to	O
1	O
.	O
5	O
hours	O
after	O
challenges	O
with	O
viokase	I-Treatment
and	I-Treatment
pancrease	I-Treatment
mt	I-Test
16	I-Treatment
,	O
but	O
not	O
with	O
placebo	O
.	O

abiraterone	I-Treatment
acetate	I-Treatment
,	I-Treatment
an	I-Treatment
androgen	I-Treatment
biosynthesis	I-Treatment
inhibitor	I-Treatment
,	O
prolongs	O
survival	O
in	O
men	I-Background
with	I-Background
metastatic	I-Problem
castration	I-Problem
-	I-Problem
resistant	I-Problem
prostate	I-Problem
cancer	I-Problem
(	I-Background
mcrpc	I-Background
)	I-Background
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
chemotherapy	O
setting	O
as	O
demonstrated	O
by	O
the	O
pivotal	O
phase	O
iii	I-Test
studies	I-Test
cou	O
-	I-Test
aa	I-Test
-	O
301	O
and	O
cou	O
-	O
aa	I-Test
-	O
302	O
.	O

reduction	I-Treatment
of	I-Treatment
methylprednisolone	I-Treatment
dosage	I-Treatment
rather	I-Treatment
than	I-Treatment
insulin	I-Treatment
therapy	I-Treatment
resulted	O
in	O
better	O
control	O
of	O
glycemia	I-Problem
.	O

here	O
,	O
we	O
report	O
a	O
case	O
of	O
rfp	I-Treatment
-	O
induced	O
hypothyroidism	I-Problem
without	I-Problem
underlying	I-Problem
thyroid	I-Problem
disease	I-Problem
.	O

here	O
we	O
report	O
ramipril	I-Treatment
-	O
induced	O
cutaneous	I-Problem
vasculitis	I-Problem
in	O
a	I-Background
patient	I-Background
who	O
required	O
steroid	O
therapy	O
to	O
control	O
it	O
.	O

a	I-Background
78	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
a	I-Problem
transvenous	I-Problem
cardioverter	I-Problem
defibrillator	I-Problem
system	I-Problem
developed	O
frequent	I-Problem
shocks	I-Problem
during	I-Treatment
oral	I-Treatment
procainamide	I-Treatment
therapy	I-Treatment
.	O

a	I-Background
53	I-Background
year	I-Background
old	I-Background
greenlandic	I-Background
male	I-Background
was	I-Problem
admitted	I-Problem
twice	I-Problem
over	I-Problem
a	I-Problem
period	I-Problem
of	I-Problem
4	I-Problem
years	I-Problem
with	I-Problem
a	I-Problem
new	I-Problem
complete	I-Problem
right	I-Problem
bundle	I-Problem
branch	I-Problem
block	I-Problem
after	O
ingestion	I-Treatment
of	I-Treatment
10	I-Treatment
g	I-Treatment
and	I-Treatment
4	I-Treatment
g	I-Treatment
of	I-Treatment
carbamazepine	I-Treatment
respectively	O
.	O

in	O
contrast	O
,	O
other	I-Treatment
common	I-Treatment
agents	I-Treatment
for	I-Treatment
the	I-Treatment
most	I-Treatment
part	I-Treatment
trigger	O
cutaneous	I-Problem
inflammation	I-Problem
.	O

in	O
both	O
patients	I-Background
the	O
rippling	I-Problem
phenomena	I-Problem
worsened	O
with	O
pyridostigmine	I-Treatment
treatment	O
but	O
markedly	O
improved	O
after	O
immunosuppression	O
with	O
azathioprine	O
.	O

we	O
present	O
findings	O
from	O
three	O
patients	I-Background
who	O
experienced	O
a	O
psoriasiform	I-Problem
eruption	I-Problem
apparently	O
due	O
to	O
the	O
antiepileptic	I-Treatment
agents	I-Treatment
sodium	I-Treatment
valproate	I-Treatment
and	I-Treatment
carbamazepine	I-Treatment
.	O

we	O
report	O
here	O
such	O
a	I-Background
case	I-Background
with	I-Background
bilateral	I-Problem
mooren	I-Problem
'	I-Problem
s	I-Problem
ulcer	I-Problem
that	O
failed	O
to	O
respond	O
to	O
local	I-Treatment
therapy	I-Treatment
with	I-Treatment
topical	I-Treatment
corticosteroids	I-Treatment
,	I-Treatment
silver	I-Treatment
nitrate	I-Treatment
,	I-Treatment
and	I-Treatment
conjunctival	I-Treatment
resection	I-Treatment
,	I-Treatment
as	I-Treatment
well	I-Treatment
as	I-Treatment
systemic	I-Treatment
immunosuppression	I-Treatment
with	I-Treatment
corticosteroids	I-Treatment
,	I-Treatment
cyclophosphamide	I-Treatment
,	I-Treatment
and	I-Treatment
azathioprine	I-Treatment
.	O

jaundice	I-Problem
induced	O
by	O
streptokinase	I-Treatment
.	O

when	O
thrombosis	I-Problem
develops	O
during	O
heparin	I-Treatment
treatment	O
,	O
it	O
is	O
important	O
to	O
suspect	O
hitts	I-Problem
and	O
to	O
assay	O
for	O
the	O
associated	O
antibodies	O
,	O
regardless	O
of	O
the	O
actual	I-Test
platelet	I-Test
count	I-Test
.	O

the	O
results	O
in	O
this	O
case	O
suggest	O
that	O
cyclosporin	I-Treatment
is	I-Problem
an	I-Problem
effective	I-Problem
agent	I-Problem
in	O
patients	I-Background
with	I-Background
severe	I-Background
sight	I-Background
threatening	I-Background
mooren	I-Problem
'	I-Problem
s	I-Problem
ulcer	I-Problem
.	O

conclusions	O
:	O
amphotericin	I-Treatment
b	I-Treatment
overdose	I-Treatment
can	O
be	O
fatal	O
in	O
children	I-Background
and	I-Background
infants	I-Background
.	O

five	O
and	O
one	O
-	O
half	O
years	O
after	O
the	O
diagnosis	I-Background
of	I-Background
myeloma	I-Problem
,	O
while	O
in	O
remission	O
on	O
cyclophosphamide	I-Treatment
therapy	I-Treatment
,	O
the	O
patient	I-Background
experienced	O
severe	I-Problem
abdominal	I-Problem
right	I-Problem
lower	I-Problem
quadrant	I-Problem
pain	I-Problem
due	O
to	O
a	O
large	I-Problem
cecal	I-Problem
lymphoma	I-Problem
.	O

leukaemoid	I-Problem
monocytosis	I-Problem
in	I-Problem
m4	I-Problem
aml	I-Problem
following	O
chemotherapy	I-Treatment
and	I-Treatment
g	I-Treatment
-	I-Treatment
csf	I-Treatment
.	O

vitiligo	I-Problem
associated	O
with	O
alpha	I-Treatment
-	I-Treatment
interferon	I-Treatment
in	O
a	I-Background
patient	I-Background
with	I-Background
chronic	I-Problem
active	I-Problem
hepatitis	I-Problem
c	I-Problem
.	I-Problem

we	O
report	O
a	O
case	O
of	O
fulminant	I-Problem
neuroleptic	I-Problem
malignant	I-Problem
syndrome	I-Problem
in	O
a	I-Background
man	I-Background
aged	I-Background
70	I-Background
developing	O
within	I-Other
12	I-Other
hours	I-Other
of	O
starting	O
six	I-Other
-	I-Other
hourly	I-Other
intravenous	I-Treatment
metoclopramide	I-Treatment
.	O

case	O
presentation	O
:	O
we	O
report	O
a	I-Background
patient	I-Background
with	I-Background
cf	I-Problem
who	O
developed	O
recurrent	I-Problem
eosinophilia	I-Problem
and	I-Problem
severe	I-Problem
persistent	I-Problem
bronchospasm	I-Problem
following	O
repeated	I-Treatment
administration	I-Treatment
of	I-Treatment
preservative	I-Treatment
-	I-Treatment
free	I-Treatment
tobramycin	I-Treatment
by	I-Treatment
inhalation	I-Treatment
,	O
beginning	I-Background
at	I-Background
16	I-Background
months	I-Background
of	I-Background
age	I-Background
.	O

ballistic	I-Problem
movements	I-Test
due	I-Problem
to	I-Problem
ischemic	I-Problem
infarcts	I-Problem
after	O
intravenous	I-Treatment
heroin	I-Treatment
overdose	I-Treatment
:	O
report	O
of	O
two	O
cases	I-Background
.	O

a	I-Background
case	I-Background
of	O
barbiturate	I-Treatment
-	O
induced	O
submassive	I-Problem
hepatic	I-Problem
necrosis	I-Problem
is	O
presented	O
and	O
the	O
literature	O
is	O
reviewed	O
.	O

with	O
combined	O
use	O
,	O
clinicians	O
should	O
be	O
aware	O
,	O
when	O
phenytoin	I-Treatment
is	I-Treatment
added	I-Treatment
,	O
of	O
the	O
potential	O
for	O
reexacerbation	I-Problem
of	I-Problem
pulmonary	I-Problem
symptomatology	I-Problem
due	O
to	O
lowered	O
serum	O
theophylline	I-Treatment
concentrations	O
.	O

fluoxetine	I-Treatment
-	O
induced	O
akathisia	I-Problem
:	O
clinical	O
and	O
theoretical	O
implications	O
.	O

lansoprazole	I-Treatment
-	O
associated	O
collagenous	I-Problem
colitis	I-Problem
:	O
a	O
case	O
report	O
.	O

we	O
discuss	O
a	I-Problem
variety	I-Problem
of	I-Problem
bronchopulmonary	I-Problem
complications	I-Problem
of	I-Problem
ibd	I-Problem
and	O
their	O
association	O
with	O
sulfasalazine	I-Treatment
.	O

objective	O
:	O
to	O
report	O
the	I-Problem
late	I-Problem
development	I-Problem
of	I-Problem
immune	I-Problem
-	I-Problem
mediated	I-Problem
diabetes	I-Problem
mellitus	I-Problem
after	O
completion	O
of	O
alfa	I-Treatment
-	I-Treatment
interferon	I-Treatment
therapy	O
for	O
hepatitis	I-Problem
c	I-Problem
in	O
an	I-Background
asian	I-Background
patient	I-Background
.	O

the	O
tirapazamine	I-Treatment
-	I-Treatment
plus	I-Treatment
-	I-Treatment
cisplatin	I-Treatment
regimen	I-Treatment
was	O
associated	O
with	O
mild	I-Problem
to	I-Problem
moderate	I-Problem
adverse	I-Problem
events	I-Problem
,	I-Problem
including	I-Problem
acute	I-Problem
,	I-Problem
reversible	I-Problem
hearing	I-Problem
loss	I-Problem
,	I-Problem
reversible	I-Problem
,	I-Problem
intermittent	I-Problem
muscle	I-Problem
cramping	I-Problem
,	I-Problem
diarrhea	I-Problem
,	I-Problem
skin	I-Problem
rash	I-Problem
,	I-Problem
nausea	I-Problem
,	I-Problem
and	I-Problem
vomiting	I-Problem
.	O

to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
corneoscleral	I-Problem
melting	I-Problem
in	O
the	O
first	O
postoperative	O
week	O
after	O
a	I-Treatment
single	I-Treatment
intraoperative	I-Treatment
application	I-Treatment
of	I-Treatment
mitomycin	I-Treatment
c	I-Treatment
has	O
not	O
been	O
reported	O
.	O

thrombo	I-Problem
-	I-Problem
embolic	I-Problem
complication	I-Problem
after	O
streptokinase	I-Treatment
therapy	O
of	O
pulmonary	I-Problem
emboli	I-Problem
.	I-Problem

amebic	I-Problem
abscess	I-Problem
of	I-Problem
the	I-Problem
spleen	I-Problem
complicated	I-Problem
by	O
metronidazole	I-Treatment
-	O
induced	O
neurotoxicity	I-Problem
:	O
case	I-Background
report	O
.	O

subfulminant	I-Problem
hepatitis	I-Problem
b	I-Problem
after	O
infliximab	I-Treatment
in	O
crohn	I-Problem
'	I-Problem
s	I-Problem
disease	I-Problem
:	O
need	O
for	O
hbv	O
-	O
screening	I-Test
?	O

disseminated	I-Problem
salmonellosis	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
temozolomide	I-Treatment
.	O

the	O
aim	O
of	O
our	O
paper	O
was	O
to	O
describe	O
hepatotoxicity	I-Problem
of	O
sirolimus	I-Treatment
(	I-Treatment
srl	I-Treatment
)	I-Treatment
in	O
a	I-Background
kidney	I-Problem
graft	I-Problem
recipient	I-Background
.	O

idiosyncratic	I-Problem
pulmonary	I-Problem
reactions	I-Problem
to	O
nitrofurantoin	I-Treatment
are	O
not	O
unusual	O
,	O
often	O
presenting	O
as	O
eosinophilic	I-Problem
pneumonia	I-Problem
.	O

the	O
nz	O
pharmacovigilance	O
centre	O
has	O
received	O
7	O
additional	O
reports	O
of	O
severe	I-Problem
infections	I-Problem
in	O
patients	I-Background
with	I-Background
ra	I-Problem
taking	O
leflunomide	I-Treatment
.	O

in	O
addition	O
,	O
loading	O
with	O
one	I-Treatment
low	I-Treatment
oral	I-Treatment
dose	I-Treatment
of	I-Treatment
serine	I-Treatment
produced	O
psychotic	I-Problem
symptoms	I-Problem
5	I-Other
h	I-Other
later	I-Treatment
which	O
lasted	O
3	O
-	O
6	O
h	O
.	O

localized	I-Problem
purpura	I-Problem
associated	O
with	O
lamotrigine	I-Treatment
.	O

aseptic	I-Problem
meningitis	I-Problem
,	I-Problem
hemolytic	I-Problem
anemia	I-Problem
,	I-Problem
hepatitis	I-Problem
,	I-Problem
and	I-Problem
orthostatic	I-Problem
hypotension	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
trimethoprim	I-Treatment
-	I-Treatment
sulfamethoxazole	I-Treatment
.	O

torsemide	I-Treatment
appears	O
to	O
also	O
be	O
a	O
part	O
of	O
a	O
long	O
list	O
of	O
agents	O
that	O
can	O
cause	O
pancreatitis	I-Problem
.	O

sulfasalazine	I-Treatment
has	O
been	O
associated	O
with	O
bronchopulmonary	I-Problem
complications	I-Problem
of	I-Problem
inflammatory	I-Problem
bowel	I-Problem
disease	I-Problem
(	I-Problem
ibd	I-Problem
)	I-Problem
in	O
adults	I-Background
.	O

hydroxyurea	I-Treatment
-	O
induced	O
acute	O
interstitial	I-Problem
pneumonitis	I-Problem
in	O
a	I-Background
patient	I-Background
with	I-Background
essential	I-Problem
thrombocythemia	I-Problem
.	O

the	O
reported	O
case	O
represents	O
an	O
unusual	O
association	O
between	O
medication	O
with	O
the	O
proton	I-Treatment
pump	I-Treatment
inhibitor	I-Treatment
lansoprazole	I-Treatment
and	O
the	O
development	O
of	O
collagenous	I-Problem
colitis	I-Problem
suggesting	O
the	O
importance	O
of	O
evaluation	O
of	O
drug	O
use	O
in	O
patients	I-Background
with	I-Background
microscopic	I-Problem
colitis	I-Problem
.	O

the	O
temporal	O
sequence	O
of	O
the	O
respiratory	O
insufficiency	O
and	O
the	O
histopathology	I-Test
,	O
when	O
compared	O
to	O
the	O
previous	O
examples	O
in	O
the	O
literature	O
,	O
suggest	O
that	O
cyclophosphamide	I-Treatment
was	O
aetiologically	O
responsible	O
for	O
the	O
lung	I-Problem
disease	I-Problem
.	O

a	O
57	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
developed	O
chronic	I-Problem
,	I-Problem
watery	I-Problem
diarrhea	I-Problem
four	I-Other
weeks	I-Other
after	I-Treatment
helicobacter	I-Treatment
pylori	I-Treatment
eradication	I-Treatment
therapy	I-Treatment
including	I-Treatment
lansoprazole	I-Treatment
followed	I-Treatment
by	I-Treatment
lansoprazole	I-Treatment
monotherapy	I-Treatment
for	I-Treatment
gastroesophageal	I-Problem
reflux	I-Problem
disease	I-Problem
.	O

we	O
believe	O
that	O
this	O
represents	O
an	O
unusual	O
case	O
of	O
moderate	I-Treatment
-	I-Treatment
dose	I-Treatment
mtx	I-Treatment
-	O
induced	O
neurotoxicity	I-Problem
in	O
a	O
patient	I-Background
with	I-Background
gastric	I-Problem
cancer	I-Problem
,	O
which	O
has	O
not	O
previously	O
been	O
reported	O
.	O

the	I-Background
patient	I-Background
expired	I-Problem
after	O
seven	I-Other
cycles	I-Other
of	I-Treatment
treatment	I-Treatment
had	O
been	O
completed	O
because	O
of	O
pulmonary	O
fibrosis	O
and	O
the	O
drug	I-Treatment
toxicity	I-Treatment
of	I-Treatment
bleomycin	I-Treatment
.	O

a	O
statistical	O
association	O
between	O
the	O
incidence	O
of	O
dvt	I-Problem
and	O
combination	I-Treatment
chemotherapy	I-Treatment
including	I-Treatment
doxorubicin	I-Treatment
(	I-Treatment
p	I-Treatment
=	I-Treatment
.	I-Treatment
02	I-Treatment
)	I-Treatment
was	O
observed	O
;	O
this	O
association	O
was	O
confirmed	O
on	O
multivariate	O
analysis	I-Test
.	O

bleomycin	I-Problem
pneumonitis	I-Problem
potentiated	O
by	O
oxygen	I-Treatment
administration	I-Treatment
.	O

after	I-Other
five	I-Other
and	I-Other
six	I-Other
weeks	I-Other
of	I-Treatment
continuous	I-Treatment
oral	I-Treatment
administration	I-Treatment
of	I-Treatment
methylprednisolone	I-Treatment
,	O
the	O
boys	I-Background
developed	O
steroid	I-Problem
diabetes	I-Problem
.	O

conclusion	O
:	O
this	O
report	O
describes	O
a	O
case	O
of	O
a	I-Treatment
probable	I-Treatment
interaction	I-Treatment
between	I-Treatment
topical	I-Treatment
econazole	I-Treatment
lotion	I-Treatment
1	I-Treatment
%	I-Treatment
and	I-Treatment
acenocoumarol	I-Treatment
that	O
resulted	O
in	O
overanticoagulation	I-Problem
and	I-Problem
a	I-Problem
life	I-Problem
-	I-Problem
threatening	I-Problem
laryngeal	I-Problem
hematoma	I-Problem
in	O
this	O
elderly	I-Background
patient	I-Background
.	O

pulmonary	I-Problem
lymphohistiocytic	I-Problem
reactions	I-Problem
temporally	O
related	O
to	O
etanercept	I-Treatment
therapy	O
.	O

disseminated	I-Problem
tuberculous	I-Problem
lesions	I-Problem
post	O
intravesical	O
bcg	I-Treatment
therapy	O
are	O
rare	O
but	O
need	O
to	O
be	O
identified	O
and	O
treated	O
quickly	O
.	O

rhabdomyolysis	I-Problem
can	O
occur	O
with	O
all	O
statins	I-Treatment
when	O
used	O
alone	O
and	O
particularly	O
when	O
combined	O
with	O
other	I-Treatment
drugs	I-Treatment
that	I-Treatment
are	I-Treatment
themselves	I-Treatment
myotoxic	I-Treatment
or	I-Treatment
that	I-Treatment
elevate	I-Treatment
the	I-Treatment
concentration	I-Treatment
of	I-Treatment
the	I-Treatment
statin	I-Treatment
.	O

amiodarone	I-Treatment
-	O
induced	O
dysthyroidism	I-Problem
.	O

acute	I-Problem
coronary	I-Problem
syndromes	I-Problem
can	O
be	O
associated	O
with	O
the	O
infusion	I-Treatment
of	I-Treatment
rituximab	I-Treatment
.	O

approximately	O
15	I-Other
min	I-Other
after	O
the	O
first	O
administration	O
of	O
nebulised	I-Treatment
morphine	I-Treatment
the	O
patient	I-Background
became	O
markedly	I-Problem
bradypneic	I-Problem
(	I-Problem
respiratory	I-Problem
rate	I-Test
:	I-Problem
4	I-Problem
-	I-Problem
5	I-Problem
bpm	I-Problem
)	I-Problem
,	I-Problem
hypotensive	I-Problem
(	I-Problem
bp	I-Problem
70	I-Problem
/	I-Problem
40	I-Problem
mmhg	I-Problem
)	I-Problem
,	I-Problem
and	I-Problem
responded	I-Problem
only	I-Problem
partially	I-Problem
to	I-Problem
command	I-Problem
.	O

akathisia	I-Problem
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	I-Treatment
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta	I-Treatment
-	I-Treatment
adrenergic	I-Treatment
antagonist	I-Treatment
propranolol	I-Treatment
,	O
dose	O
reduction	O
,	O
or	O
both	O
.	O

an	O
unusual	O
cause	O
of	O
burn	I-Problem
injury	I-Problem
:	O
unsupervised	O
use	I-Treatment
of	I-Treatment
drugs	I-Treatment
that	I-Treatment
contain	I-Treatment
psoralens	I-Treatment
.	I-Treatment

the	O
patient	I-Background
suffered	O
a	O
life	I-Problem
-	I-Problem
threatening	I-Problem
anaphylactoid	I-Problem
reaction	I-Problem
to	O
amifostine	I-Treatment
.	O

we	O
report	O
three	O
cases	O
of	O
severe	I-Problem
hypocalcaemia	I-Problem
associated	O
with	O
i	I-Treatment
.	I-Treatment
v	I-Treatment
.	I-Treatment
bisphosphonate	I-Treatment
treatment	I-Treatment
in	O
patients	I-Background
with	I-Background
multiple	I-Problem
myeloma	I-Problem
.	O

we	O
report	O
a	I-Background
case	I-Background
of	O
exfoliative	I-Problem
dermatitis	I-Problem
clearly	O
linked	O
to	O
intravenous	I-Treatment
and	I-Treatment
intraperitoneal	I-Treatment
administration	I-Treatment
of	I-Treatment
tobramycin	I-Treatment
.	O

glomerulonephritis	I-Problem
in	O
procainamide	I-Treatment
induced	O
lupus	I-Problem
erythematosus	I-Problem
:	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O

patients	I-Background
treated	O
with	O
captopril	I-Treatment
who	O
develop	O
"	O
atypical	I-Problem
cholangitis	I-Problem
"	O
should	O
be	O
suspected	O
of	O
having	O
captopril	I-Treatment
-	O
associated	O
liver	I-Problem
damage	I-Problem
.	O

we	O
report	O
a	O
case	O
of	O
codeine	I-Treatment
intoxication	I-Problem
in	I-Background
the	I-Background
neonate	I-Background
,	O
in	O
which	O
the	O
drug	O
was	O
prescribed	O
for	I-Background
cough	I-Problem
control	I-Background
during	I-Background
an	I-Background
emergency	I-Background
department	I-Background
visit	I-Background
.	O

discontinuation	I-Treatment
of	I-Treatment
simvastatin	I-Treatment
and	I-Treatment
cyclosporine	I-Treatment
resulted	O
in	O
resolution	O
of	O
rhabdomyolysis	I-Problem
and	O
normalization	I-Problem
of	I-Problem
renal	I-Problem
function	I-Problem
.	O

phenylpropanolamine	I-Treatment
(	I-Treatment
ppa	I-Treatment
)	I-Treatment
recently	O
has	O
been	O
publicly	O
implicated	O
as	O
a	O
cause	O
of	O
stroke	I-Problem
and	I-Problem
other	I-Problem
neurologic	I-Problem
events	I-Problem
.	O

critically	O
elevated	I-Problem
inr	I-Problem
in	O
a	I-Background
patient	I-Background
on	O
warfarin	I-Treatment
after	O
increase	I-Treatment
in	I-Treatment
extended	I-Treatment
-	I-Treatment
release	I-Treatment
niacin	I-Treatment
dose	I-Treatment
.	O

he	I-Background
developed	O
severe	O
hyperactivity	I-Problem
and	I-Problem
agitation	I-Problem
on	O
taking	O
methylphenidate	I-Treatment
after	I-Treatment
the	I-Treatment
discontinuation	I-Treatment
of	I-Treatment
risperidone	I-Treatment
treatment	O
.	O

we	O
suggest	O
that	O
objective	O
evaluation	I-Test
of	I-Test
retinal	I-Test
function	I-Test
with	O
electrophysiological	O
methods	I-Test
should	O
be	O
performed	O
in	O
patients	O
with	O
visual	I-Problem
disturbance	I-Problem
during	O
treatment	O
with	O
rifabutin	I-Treatment
.	O

a	O
clinically	O
atypical	O
,	O
neuropathologically	O
verified	O
case	O
of	O
creutzfeldt	I-Problem
-	I-Problem
jakob	I-Problem
disease	I-Problem
is	O
described	O
in	O
a	I-Background
32	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
new	I-Background
zealand	I-Background
woman	I-Background
with	I-Background
idiopathic	I-Problem
hypopituitarism	I-Problem
who	O
had	O
been	O
treated	O
in	O
late	O
adolescence	O
(	O
1970	O
to	O
1973	O
)	O
with	O
human	I-Treatment
growth	I-Treatment
hormone	I-Treatment
processed	O
from	O
pooled	O
cadaveric	O
pituitary	O
glands	O
.	O

quinine	I-Treatment
remains	O
a	O
reliable	O
treatment	O
for	O
falciparum	I-Problem
malaria	I-Problem
in	O
most	O
parts	O
of	O
the	O
world	O
.	O

severe	O
corneal	I-Problem
toxicity	I-Problem
after	O
topical	I-Treatment
fluoroquinolone	I-Treatment
therapy	I-Treatment
:	O
report	O
of	O
two	O
cases	O
.	O

she	O
developed	O
a	I-Problem
generalized	I-Problem
rash	I-Problem
and	I-Problem
itching	I-Problem
,	I-Problem
sore	I-Problem
throat	I-Problem
,	I-Problem
and	I-Problem
dizziness	I-Problem
approximately	I-Treatment
4	I-Other
hours	I-Other
after	I-Treatment
the	I-Treatment
first	I-Treatment
dose	I-Treatment
of	I-Treatment
capecitabine	I-Treatment
.	O

seizures	I-Problem
associated	O
with	O
fluoxetine	I-Treatment
therapy	I-Treatment
are	O
uncommon	O
.	O

a	I-Background
14	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
with	I-Background
newly	I-Background
diagnosed	I-Background
sle	I-Problem
developed	O
a	I-Problem
pruritic	I-Problem
bullous	I-Problem
eruption	I-Problem
while	O
on	O
prednisone	I-Treatment
.	O

sodium	I-Treatment
valproate	I-Treatment
and	I-Treatment
carbamazepine	I-Treatment
,	O
antiepileptic	O
drugs	O
that	O
are	O
associated	O
with	O
a	O
relatively	O
low	O
rate	O
of	O
adverse	I-Problem
cutaneous	I-Problem
reactions	I-Problem
,	O
should	O
be	O
added	O
to	O
the	O
growing	O
list	O
of	O
drugs	O
that	O
produce	O
psoriasiform	O
eruptions	O
.	O

tirapazamine	I-Treatment
plus	I-Treatment
cisplatin	I-Treatment
versus	O
cisplatin	O
in	O
advanced	I-Problem
non	I-Problem
-	I-Problem
small	I-Problem
-	I-Problem
cell	I-Problem
lung	I-Problem
cancer	I-Problem
:	O
a	O
report	O
of	O
the	O
international	O
catapult	O
i	O
study	O
group	O
.	O

exfoliative	I-Problem
dermatitis	I-Problem
secondary	O
to	O
tobramycin	I-Treatment
sulfate	I-Treatment
.	I-Treatment

kaposi	I-Problem
'	I-Problem
s	I-Problem
sarcoma	I-Problem
in	O
a	I-Background
patient	I-Background
treated	O
with	O
imatinib	I-Treatment
mesylate	I-Treatment
for	O
chronic	I-Problem
myeloid	I-Problem
leukemia	I-Problem
.	O

a	O
young	I-Background
patient	I-Background
experienced	O
marked	O
sinus	I-Problem
tachycardia	I-Problem
while	O
smoking	O
marijuana	O
and	O
receiving	O
therapeutic	O
doses	O
of	O
nortriptyline	I-Treatment
.	O

hypogammaglobulinemia	I-Problem
associated	O
with	O
gold	I-Treatment
therapy	I-Treatment
:	O
evidence	O
for	O
a	I-Problem
partial	I-Problem
maturation	I-Problem
blockade	I-Problem
of	I-Problem
b	I-Problem
cells	I-Problem
.	O

experience	O
with	O
five	O
patients	I-Background
in	O
whom	O
impaired	I-Problem
renal	I-Problem
function	I-Problem
developed	O
early	O
during	O
amphotericin	I-Treatment
b	I-Treatment
therapy	I-Treatment
is	O
reported	O
.	O

this	O
report	O
details	O
the	O
pulmonary	O
pathologic	O
findings	O
in	O
four	O
patients	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
,	O
who	O
developed	I-Problem
new	I-Problem
onset	I-Problem
of	I-Problem
pulmonary	I-Problem
signs	I-Problem
and	I-Problem
symptoms	I-Problem
with	I-Problem
alveolar	I-Problem
infiltrates	I-Problem
temporally	O
related	O
to	O
the	O
institution	I-Treatment
of	I-Treatment
etanercept	I-Treatment
therapy	I-Treatment
.	O

conclusion	O
:	O
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
in	O
patients	I-Background
who	O
develop	O
recurrent	I-Problem
eosinophilia	I-Problem
and	I-Problem
deterioration	I-Problem
of	I-Problem
pulmonary	I-Problem
function	I-Problem
following	O
the	O
use	I-Treatment
of	I-Treatment
tobramycin	I-Treatment
by	I-Treatment
inhalation	I-Treatment
or	I-Treatment
by	I-Treatment
intravenous	I-Treatment
administration	I-Treatment
.	O

ncse	I-Problem
,	O
an	O
epileptic	O
disorder	O
in	O
which	O
typical	O
convulsive	O
activity	O
is	O
absent	O
,	O
has	O
previously	O
been	O
reported	O
in	O
only	O
4	O
patients	I-Background
receiving	O
ifosfamide	I-Treatment
.	O

we	O
describe	O
a	O
case	O
of	O
life	O
-	O
threatening	O
hyponatremia	I-Problem
associated	O
with	O
sibutramine	I-Treatment
use	O
in	O
an	O
obese	I-Problem
woman	I-Background
.	O

polymyoclonus	I-Problem
seizure	I-Problem
resulting	O
from	O
accidental	I-Treatment
injection	I-Treatment
of	I-Treatment
tranexamic	I-Treatment
acid	I-Treatment
in	I-Treatment
spinal	I-Treatment
anesthesia	I-Treatment
.	O

hydroxymethylglutaryl	I-Treatment
coenzyme	I-Treatment
a	I-Treatment
reductase	I-Treatment
inhibitors	I-Treatment
(	I-Treatment
statins	I-Treatment
)	I-Treatment
have	O
been	O
associated	O
with	O
myopathy	I-Problem
and	I-Problem
rhabdomyolysis	I-Problem
.	O

propranolol	I-Treatment
-	O
induced	O
hypertension	I-Problem
in	O
treatment	O
of	O
cocaine	O
intoxication	O
.	O

this	O
is	O
the	O
second	O
report	O
of	O
lactic	I-Problem
acidosis	I-Problem
in	O
a	I-Background
patient	I-Background
on	O
stavudine	I-Treatment
and	I-Treatment
lamivudine	I-Treatment
.	O

we	O
report	O
on	O
a	I-Background
patient	I-Background
with	I-Background
renal	I-Problem
artery	I-Problem
stenosis	I-Problem
who	I-Problem
had	I-Problem
only	I-Problem
1	I-Problem
kidney	I-Problem
and	O
in	O
whom	O
acute	I-Problem
renal	I-Problem
impairment	I-Problem
developed	I-Problem
with	I-Problem
transient	I-Problem
anuria	I-Problem
after	O
the	I-Treatment
administration	I-Treatment
of	I-Treatment
captopril	I-Treatment
.	O

however	O
,	O
in	O
the	O
mid	O
-	O
to	O
-	O
late	O
1980s	O
,	O
a	O
series	O
of	O
letters	O
to	O
the	O
editor	O
and	O
case	O
reports	O
announced	O
an	O
association	O
between	O
tamoxifen	I-Treatment
therapy	O
in	O
women	I-Background
with	I-Background
breast	I-Problem
cancer	I-Problem
and	O
the	O
development	O
of	O
endometrial	I-Problem
carcinoma	I-Problem
.	O

simvastatin	I-Treatment
-	O
induced	O
rhabdomyolysis	I-Problem
following	O
cyclosporine	I-Treatment
treatment	I-Treatment
for	O
uveitis	I-Problem
.	O

based	O
on	O
our	O
previous	O
demonstration	O
that	O
quinine	I-Treatment
could	O
be	O
used	O
clinically	O
to	O
reverse	I-Problem
p	I-Problem
-	I-Problem
glycoprotein	I-Problem
-	I-Problem
mediated	I-Problem
resistance	I-Problem
,	O
we	O
designed	O
a	O
multicenter	O
,	O
randomized	O
trial	O
aiming	O
to	O
determine	O
whether	O
quinine	O
would	O
improve	O
the	O
survival	O
of	O
adult	I-Background
patients	I-Background
(	I-Background
15	I-Background
-	I-Background
60	I-Background
years	I-Background
old	I-Background
)	I-Background
with	O
de	I-Problem
novo	I-Problem
acute	I-Problem
myelogenous	I-Problem
leukemia	I-Problem
(	I-Problem
aml	I-Problem
)	I-Problem
.	O

vincristine	I-Treatment
induced	O
cranial	I-Problem
polyneuropathy	I-Problem
.	O

here	O
we	O
describe	O
another	O
case	O
of	O
vod	I-Problem
occurring	O
after	O
lt	O
,	O
but	O
in	O
which	O
the	O
causative	O
role	O
was	O
played	O
by	O
azathioprine	I-Treatment
.	O

a	O
retrospective	O
review	O
of	O
ttp	I-Problem
patients	I-Background
with	O
quinine	I-Treatment
-	O
associated	O
thrombotic	I-Problem
microangiopathy	I-Problem
(	I-Problem
tma	I-Problem
)	I-Problem
for	O
whom	O
adamts13	O
was	O
measured	O
before	O
plasma	O
exchange	I-Test
was	O
performed	O
.	O

rituximab	I-Treatment
-	I-Treatment
chop	I-Treatment
induced	O
interstitial	I-Problem
pneumonitis	I-Problem
in	O
patients	I-Background
with	I-Background
disseminated	I-Problem
extranodal	I-Problem
marginal	I-Problem
zone	I-Problem
b	I-Problem
cell	I-Problem
lymphoma	I-Problem
.	O

nitrendipine	I-Treatment
is	I-Treatment
an	I-Treatment
experimental	I-Treatment
calcium	I-Treatment
channel	I-Treatment
blocking	I-Treatment
agent	I-Treatment
that	O
also	O
appears	O
to	O
cause	O
the	O
side	O
effect	O
of	O
drug	O
-	O
induced	O
gingival	I-Problem
hyperplasia	I-Problem
.	O

the	O
present	O
study	I-Test
describes	O
a	O
patient	I-Background
who	O
had	O
unusual	I-Problem
weight	I-Problem
fluctuation	I-Problem
under	O
corticosteroid	I-Treatment
and	I-Treatment
psychotropic	I-Treatment
treatment	I-Treatment
such	I-Treatment
as	I-Treatment
mianserin	I-Treatment
and	I-Treatment
aripiprazole	I-Treatment
.	O

clozapine	I-Treatment
-	O
induced	O
akathisia	I-Problem
in	O
children	I-Background
with	I-Background
schizophrenia	I-Problem
.	O

patients	I-Background
with	I-Background
previously	I-Background
untreated	I-Background
nsclc	I-Problem
were	O
randomized	O
to	O
receive	O
either	I-Treatment
tirapazamine	I-Treatment
(	I-Treatment
390	I-Treatment
mg	I-Treatment
/	I-Treatment
m	I-Treatment
(	I-Treatment
2	I-Treatment
)	I-Treatment
infused	I-Treatment
over	I-Other
2	I-Other
hours	I-Other
)	I-Treatment
followed	I-Treatment
1	I-Treatment
hour	I-Treatment
later	I-Treatment
by	I-Treatment
cisplatin	I-Treatment
(	I-Treatment
75	I-Treatment
mg	I-Treatment
/	I-Treatment
m	I-Treatment
(	I-Treatment
2	I-Treatment
)	I-Treatment
over	I-Other
1	I-Other
hour	I-Other
)	I-Treatment
or	I-Treatment
75	I-Treatment
mg	I-Treatment
/	I-Treatment
m	I-Treatment
(	I-Treatment
2	I-Treatment
)	I-Treatment
of	I-Treatment
cisplatin	I-Treatment
alone	I-Treatment
,	I-Treatment
every	I-Other
3	I-Other
weeks	I-Other
for	I-Other
a	I-Other
maximum	I-Other
of	I-Other
eight	I-Other
cycles	I-Other
.	O

drug	I-Treatment
interactions	I-Treatment
between	I-Treatment
macrolide	I-Treatment
antibiotics	I-Treatment
such	I-Treatment
as	I-Treatment
erythomycin	I-Treatment
and	I-Treatment
pharmacologic	I-Treatment
agents	I-Treatment
that	I-Treatment
prolong	I-Treatment
the	I-Treatment
qt	I-Treatment
interval	I-Treatment
have	O
been	O
known	O
to	O
cause	O
tdp	I-Problem
.	I-Problem
however	O
,	O
clarithromycin	O
is	O
thought	O
to	O
be	O
less	O
frequently	O
associated	O
with	O
drug	O
induced	O
tdp	O
,	O
because	O
it	O
inactivates	O
hepatic	O
cytochrome	I-Test
p	I-Test
-	O
450	O
to	O
a	O
lesser	O
extent	O
than	O
erythromycin	O
.	O

in	O
a	O
randomised	O
,	O
investigator	O
-	O
blinded	O
,	O
multicentre	O
phase	O
iii	O
efficacy	O
trial	O
,	O
899	O
infants	I-Background
and	I-Background
children	I-Background
with	I-Background
acute	I-Background
uncomplicated	I-Background
plasmodium	I-Problem
falciparum	I-Problem
malaria	I-Problem
received	O
six	I-Treatment
doses	I-Treatment
of	I-Treatment
al	I-Treatment
according	I-Treatment
to	I-Treatment
body	I-Treatment
weight	I-Treatment
over	I-Treatment
3	I-Other
days	I-Other
either	I-Treatment
as	I-Treatment
crushed	I-Treatment
tablets	I-Treatment
(	I-Treatment
coartem	I-Treatment
)	I-Treatment
or	I-Treatment
as	I-Treatment
dispersible	I-Treatment
tablets	I-Treatment
.	O

a	I-Background
patient	I-Background
presented	O
with	O
dilated	I-Problem
cardiomyopathy	I-Problem
after	O
many	I-Treatment
years	I-Treatment
of	I-Treatment
overusing	I-Treatment
an	I-Treatment
adrenaline	I-Treatment
inhaler	I-Treatment
.	O

occurrence	O
of	O
withdrawal	I-Problem
dyskinesia	I-Problem
indicates	O
that	O
the	O
neuroleptic	O
effects	O
of	O
amoxapine	I-Treatment
may	O
be	O
clinically	O
significant	O
.	O

hair	I-Problem
loss	I-Problem
associated	O
with	O
paroxetine	I-Treatment
treatment	O
:	O
a	I-Background
case	I-Background
report	O
.	O

results	O
:	O
in	O
a	I-Background
22	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
thai	I-Background
woman	I-Background
with	I-Background
graves	I-Problem
'	I-Problem
disease	I-Problem
,	O
tinnitus	I-Problem
,	I-Problem
hearing	I-Problem
impairment	I-Problem
in	I-Problem
the	I-Problem
left	I-Problem
ear	I-Problem
(	I-Problem
with	I-Problem
progression	I-Problem
to	I-Problem
the	I-Problem
right	I-Problem
ear	I-Problem
)	I-Problem
,	I-Problem
and	I-Problem
vertigo	I-Problem
developed	O
after	I-Other
3	I-Other
years	I-Other
of	I-Treatment
therapy	I-Treatment
with	I-Treatment
ptu	I-Treatment
.	O

additive	I-Problem
pulmonary	I-Problem
toxicity	I-Problem
with	O
melphalan	I-Treatment
and	I-Treatment
busulfan	I-Treatment
therapy	I-Treatment
.	O

we	O
report	O
the	O
case	O
of	O
a	O
20	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
originally	I-Background
from	I-Background
cameroon	I-Background
who	I-Background
was	I-Background
infected	I-Problem
by	I-Problem
the	I-Problem
l	I-Problem
.	I-Problem
loa	I-Problem
parasite	I-Problem
and	O
developed	O
severe	I-Problem
hepatitis	I-Problem
,	O
identified	O
1	I-Other
month	I-Other
after	I-Treatment
a	I-Treatment
single	I-Treatment
dose	I-Treatment
of	I-Treatment
ivermectin	I-Treatment
.	O

to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
lithium	I-Treatment
-	O
associated	O
cdi	I-Problem
and	I-Problem
ndi	I-Problem
presenting	O
concurrently	O
.	O

in	O
this	O
healthy	I-Background
population	I-Background
,	O
the	O
relative	O
risk	O
of	O
developing	O
endometrial	I-Problem
carcinoma	I-Problem
in	O
the	O
tamoxifen	I-Treatment
arm	O
was	O
2	O
.	O
54	O
,	O
although	O
when	O
stratified	O
by	O
age	O
,	O
in	O
women	O
over	O
50	O
,	O
the	O
risk	O
grew	O
to	O
4	O
.	O
01	O
.	O

paradoxical	I-Problem
ventricular	I-Problem
tachycardia	I-Problem
and	I-Problem
fibrillation	I-Problem
after	O
intravenous	I-Treatment
bretylium	I-Treatment
therapy	O
.	O

objective	O
:	O
to	O
describe	O
a	I-Background
case	I-Background
of	O
thrombocytopenia	I-Problem
associated	O
with	O
the	O
administration	O
of	O
lansoprazole	I-Treatment
.	O

a	I-Background
patient	I-Background
developed	O
optic	I-Problem
neuropathy	I-Problem
while	O
being	O
treated	O
with	O
isoniazid	I-Treatment
and	I-Treatment
ethambutol	I-Treatment
.	O

this	O
case	O
describes	O
a	I-Background
52	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
white	I-Background
woman	I-Background
who	O
developed	O
a	I-Problem
spontaneous	I-Problem
nasal	I-Problem
septal	I-Problem
perforation	I-Problem
after	O
given	O
the	O
antiangiogenic	I-Treatment
drug	I-Treatment
,	I-Treatment
bevacizumab	I-Treatment
,	O
for	O
metastatic	O
ovarian	O
cancer	O
treatment	O
.	O

eleven	O
patients	I-Background
developed	O
infection	I-Problem
requiring	O
hospitalization	O
while	O
taking	O
leflunomide	I-Treatment
including	O
:	O
lower	I-Problem
respiratory	I-Problem
tract	I-Problem
infections	I-Problem
(	I-Problem
3	I-Problem
)	I-Problem
,	I-Problem
cellulitis	I-Problem
(	I-Problem
2	I-Problem
)	I-Problem
,	I-Problem
disseminated	I-Problem
herpes	I-Problem
zoster	I-Problem
(	I-Problem
2	I-Problem
)	I-Problem
,	I-Problem
probable	I-Problem
tb	I-Problem
liver	I-Problem
(	I-Problem
1	I-Problem
)	I-Problem
,	I-Problem
abdominal	I-Problem
sepsis	I-Problem
(	I-Problem
1	I-Problem
)	I-Problem
,	I-Problem
mycotic	I-Problem
aneurysm	I-Problem
(	I-Problem
1	I-Problem
)	I-Problem
and	I-Problem
gastroenteritis	I-Problem
(	I-Problem
1	I-Problem
)	I-Problem
.	O

symptoms	I-Problem
and	I-Problem
endoscopic	I-Problem
lesions	I-Problem
quickly	O
regressed	O
within	I-Treatment
1	I-Other
week	I-Other
of	I-Treatment
meloxicam	I-Treatment
withdrawal	I-Treatment
.	O

potential	O
drug	I-Treatment
interaction	I-Treatment
between	I-Treatment
simvastatin	I-Treatment
and	I-Treatment
danazol	I-Treatment
causing	O
rhabdomyolysis	I-Problem
.	O

multiple	I-Problem
myeloma	I-Problem
complicated	I-Problem
by	I-Problem
congestive	I-Problem
heart	I-Problem
failure	I-Problem
following	O
first	I-Treatment
administration	I-Treatment
of	I-Treatment
recombinant	I-Treatment
alpha	I-Treatment
-	I-Treatment
interferon	I-Treatment
.	O

carboplatin	I-Problem
hypersensitivity	I-Problem
induced	O
by	O
low	I-Treatment
-	I-Treatment
dose	I-Treatment
paclitaxel	I-Treatment
/	I-Treatment
carboplatin	I-Treatment
in	O
multiple	I-Background
platinum	I-Treatment
-	I-Background
treated	I-Background
patients	I-Background
with	I-Background
recurrent	I-Problem
ovarian	I-Problem
cancer	I-Problem
.	O

case	O
summary	O
:	O
a	I-Background
46	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
african	I-Background
-	I-Background
american	I-Background
man	I-Background
experienced	O
recurrent	I-Problem
grand	I-Problem
mal	I-Problem
seizures	I-Problem
during	O
intravenous	I-Treatment
infusion	I-Treatment
of	I-Treatment
amphotericin	I-Treatment
b	I-Treatment
,	O
then	O
petit	O
mal	O
seizures	O
as	O
the	O
infusion	O
was	O
stopped	O
and	O
the	O
drug	I-Test
concentrations	I-Test
decreased	O
with	O
time	O
.	O

moreover	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
incidence	O
of	O
boop	I-Problem
following	O
rituximab	I-Treatment
therapy	I-Treatment
may	O
be	O
higher	O
than	O
has	O
been	O
previously	O
appreciated	O
.	O

two	O
cases	I-Background
of	O
hypothyroidism	I-Problem
in	O
patients	O
with	O
chronic	I-Problem
hepatitis	I-Problem
c	I-Problem
treated	O
with	O
recombinant	I-Treatment
alpha	I-Treatment
interferon	I-Treatment
are	O
reported	O
.	O

objective	O
:	O
to	O
report	O
the	O
case	O
of	O
a	O
young	I-Background
woman	I-Background
with	I-Background
graves	I-Problem
'	I-Problem
disease	I-Problem
in	O
whom	O
ototoxicity	I-Problem
developed	I-Problem
because	O
of	O
propylthiouracil	I-Treatment
(	I-Treatment
ptu	I-Treatment
)	I-Treatment
-	O
induced	O
antineutrophil	O
cytoplasmic	O
antibody	I-Test
(	O
anca	O
)	I-Test
-	O
associated	O
vasculitis	O
.	O

an	I-Background
obese	I-Problem
patient	I-Background
,	I-Background
not	I-Background
diabetic	I-Background
,	O
treated	O
with	O
metformin	I-Treatment
for	I-Treatment
some	I-Other
weeks	I-Other
,	O
was	O
referred	O
to	O
us	O
with	O
severe	I-Problem
inferior	I-Problem
digestive	I-Problem
hemorrhage	I-Problem
,	O
diagnosed	O
with	O
meckel	I-Problem
'	I-Problem
s	I-Problem
diverticulum	I-Problem
.	O

although	O
a	O
lot	O
of	O
amiodarone	I-Treatment
-	O
induced	O
torsades	I-Problem
de	I-Problem
pointe	I-Problem
have	O
been	O
published	O
,	O
a	O
review	O
of	O
all	O
these	O
cases	O
and	O
the	O
underlying	O
risk	O
-	O
factors	O
has	O
never	O
been	O
made	O
.	O

this	O
report	O
is	O
about	O
three	O
cases	I-Background
of	I-Background
children	I-Background
who	O
developed	O
severe	O
adverse	I-Problem
reactions	I-Problem
during	I-Treatment
switching	I-Treatment
from	I-Treatment
risperidone	I-Treatment
to	I-Treatment
methylphenidate	I-Treatment
.	O

this	I-Background
patient	I-Background
,	I-Background
who	I-Background
had	I-Background
a	I-Background
history	I-Background
of	I-Background
osteoarthritis	I-Background
,	O
had	O
severe	O
hepatitis	I-Problem
5	I-Other
weeks	I-Other
after	I-Treatment
being	I-Treatment
started	I-Treatment
on	I-Treatment
diclofenac	I-Treatment
for	O
increasing	I-Problem
pain	I-Problem
in	I-Problem
the	I-Problem
joints	I-Problem
.	O

she	I-Background
received	O
chemotherapy	I-Treatment
according	O
to	O
the	O
previously	O
described	O
modified	O
st	O
.	O
jude	O
total	O
therapy	O
studies	I-Test
xiii	O
.	O

a	I-Background
17	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
patient	I-Background
who	O
had	O
been	O
taking	O
oral	I-Treatment
minocycline	I-Treatment
(	I-Treatment
50	I-Treatment
mg	I-Treatment
twice	I-Other
daily	I-Other
)	I-Treatment
for	I-Treatment
3	I-Other
weeks	I-Other
for	O
acne	I-Problem
developed	O
an	O
eruption	I-Problem
that	O
progressed	O
to	O
an	I-Problem
exfoliative	I-Problem
dermatitis	I-Problem
.	O

risperidone	I-Treatment
-	O
induced	O
obsessive	I-Problem
-	I-Problem
compulsive	I-Problem
symptoms	I-Problem
in	O
two	O
children	I-Background
.	O

conclusions	O
:	O
cicatrization	O
in	O
the	O
substantia	O
propria	O
of	O
the	O
conjunctiva	O
by	O
excessive	O
lymphocytic	O
infiltration	O
after	O
topically	O
administered	O
antiglaucoma	I-Treatment
drugs	I-Treatment
including	I-Treatment
dipivefrin	I-Treatment
is	O
a	O
possible	O
mechanism	O
of	O
action	O
for	O
entropion	I-Problem
.	O

a	I-Background
patient	I-Background
with	I-Background
the	I-Background
wolff	I-Problem
-	I-Problem
parkinson	I-Problem
-	I-Problem
white	I-Problem
syndrome	I-Problem
presented	O
with	O
incessant	I-Problem
orthodromic	I-Problem
atrioventricular	I-Problem
tachycardia	I-Problem
following	O
initiation	I-Treatment
of	I-Treatment
procainamide	I-Treatment
therapy	I-Treatment
.	O

hypersensitivity	I-Problem
to	I-Problem
carboplatin	I-Problem
is	O
a	O
rare	O
but	O
real	O
complication	O
of	O
therapy	O
and	O
should	O
be	O
considered	O
in	O
patients	I-Background
presenting	I-Background
with	I-Background
hyperacute	I-Problem
changes	I-Problem
on	I-Problem
ecg	I-Problem
whilst	O
receiving	O
carboplatin	I-Treatment
therapy	I-Treatment
.	O

purpose	O
:	O
to	O
report	O
that	O
acute	I-Treatment
lamotrigine	I-Treatment
poisoning	I-Treatment
may	O
result	O
in	O
severe	I-Problem
encephalopathy	I-Problem
.	O

reversal	O
of	O
ergotamine	I-Treatment
-	O
induced	O
arteriospasm	I-Problem
by	O
mechanical	O
intra	O
-	O
arterial	O
dilatation	O
.	O

there	O
have	O
been	O
several	O
case	O
reports	O
of	O
serotonin	I-Problem
syndrome	I-Problem
from	O
similar	O
combinations	I-Treatment
of	I-Treatment
antidepressant	I-Treatment
and	I-Treatment
atypical	I-Treatment
antipsychotic	I-Treatment
treatment	I-Treatment
.	O

we	O
report	O
the	O
first	O
case	O
of	O
a	I-Background
human	I-Problem
immunodeficiency	I-Problem
virus	I-Problem
type	I-Problem
1	I-Problem
(	I-Background
hiv	I-Background
-	I-Background
1	I-Background
)	I-Background
-	I-Background
infected	I-Background
individual	I-Background
receiving	O
combination	I-Treatment
antiretroviral	I-Treatment
therapy	I-Treatment
,	I-Treatment
which	I-Treatment
included	I-Treatment
ritonavir	I-Treatment
,	O
who	O
developed	O
cushing	I-Problem
syndrome	I-Problem
with	O
profound	O
complications	O
after	O
epidural	I-Treatment
triamcinolone	I-Treatment
injections	I-Treatment
.	O

disulfiram	I-Problem
-	I-Problem
like	I-Problem
reactions	I-Problem
with	O
newer	O
cephalosporins	O
:	O
cefmenoxime	I-Treatment
.	O

we	O
recommend	O
routine	I-Treatment
follow	I-Treatment
up	I-Treatment
by	I-Treatment
ecg	I-Treatment
of	O
patients	I-Background
over	I-Background
the	I-Background
age	I-Background
of	I-Background
50	I-Background
treated	O
with	O
carbamazepine	I-Treatment
.	O

a	I-Background
10	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
with	I-Background
lennox	I-Problem
-	I-Problem
gastaut	I-Problem
syndrome	I-Problem
who	O
received	O
intravenous	I-Treatment
lorazepam	I-Treatment
for	O
atypical	I-Problem
absence	I-Problem
status	I-Problem
seizures	I-Problem
is	O
reported	O
.	O

ritonavir	I-Treatment
can	O
inhibit	O
the	O
metabolism	I-Problem
of	I-Problem
fentanyl	I-Problem
significantly	I-Problem
,	O
so	O
caution	O
should	O
be	O
exercised	O
if	O
fentanyl	I-Treatment
is	O
given	O
to	O
patients	I-Background
receiving	I-Background
ritonavir	I-Background
medication	I-Background
.	O

this	I-Background
case	I-Background
emphasizes	O
the	O
importance	O
of	O
the	O
evaluation	I-Test
of	O
lithium	I-Treatment
-	O
associated	O
polyuria	I-Problem
with	O
a	O
direct	I-Test
measurement	I-Test
of	O
plasma	O
vasopressin	I-Test
,	O
interpreted	O
with	O
simultaneous	O
plasma	O
and	I-Test
urine	I-Test
osmolality	I-Test
to	O
secure	O
the	O
correct	O
diagnosis	O
and	O
ensure	O
appropriate	O
therapeutic	O
management	O
.	O

a	I-Background
patient	I-Background
with	I-Background
chronic	I-Problem
myelomonocytic	I-Problem
leukemia	I-Problem
developed	O
drug	O
-	O
induced	O
pulmonary	I-Problem
toxicity	I-Problem
after	O
using	I-Treatment
low	I-Treatment
dose	I-Treatment
oral	I-Treatment
etoposide	I-Treatment
.	O

alopecia	I-Problem
and	I-Problem
hair	I-Problem
loss	I-Problem
are	O
rare	O
side	O
effects	O
of	O
psychotropic	I-Treatment
drugs	I-Treatment
.	O

occult	O
quinine	I-Treatment
-	O
induced	O
thrombocytopenia	I-Problem
.	O

we	O
report	O
the	O
case	O
of	O
a	I-Background
17	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
male	I-Background
who	O
developed	O
chest	I-Problem
pain	I-Problem
,	I-Problem
elevated	I-Problem
cardiac	I-Problem
biomarkers	I-Problem
,	I-Problem
and	I-Problem
acute	I-Problem
left	I-Problem
ventricular	I-Problem
dysfunction	I-Problem
following	O
a	I-Treatment
single	I-Treatment
dose	I-Treatment
of	I-Treatment
methylphenidate	I-Treatment
.	O

in	I-Background
patients	I-Background
with	I-Background
swallowing	I-Background
dysfunction	I-Background
and	I-Background
pneumonia	I-Background
,	O
a	I-Treatment
history	I-Treatment
of	I-Treatment
mineral	I-Treatment
oil	I-Treatment
use	I-Treatment
should	O
be	O
obtained	O
and	O
a	O
diagnosis	O
of	O
elp	I-Problem
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnoses	O
if	O
mineral	O
oil	O
use	O
has	O
occurred	O
.	O

agranulocytosis	I-Problem
induced	O
by	O
vancomycin	I-Treatment
in	O
an	O
esrd	I-Problem
patient	I-Background
on	I-Background
capd	I-Background
.	O

first	O
case	O
of	O
ivermectin	I-Treatment
-	O
induced	O
severe	I-Problem
hepatitis	I-Problem
.	I-Problem

the	O
authors	O
suggest	O
that	O
fluoxetine	I-Treatment
-	O
induced	O
akathisia	I-Problem
may	I-Problem
be	I-Problem
caused	I-Problem
by	I-Problem
serotonergically	I-Problem
mediated	I-Problem
inhibition	I-Problem
of	I-Problem
dopaminergic	I-Problem
neurotransmission	I-Problem
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine	O
-	O
induced	O
akathisia	O
and	O
tricyclic	O
antidepressant	O
-	O
induced	O
"	O
jitteriness	O
"	O
may	O
be	O
identical	O
.	O

the	O
use	O
of	O
telithromycin	I-Treatment
in	O
patients	I-Background
receiving	I-Background
multiple	I-Background
doses	I-Background
of	I-Background
oxycodone	I-Background
for	I-Background
pain	I-Background
relief	I-Background
may	O
increase	O
the	O
risk	O
of	O
opioid	I-Problem
adverse	I-Problem
effects	I-Problem
.	O

a	O
case	O
of	O
metoclopramide	I-Treatment
-	O
induced	O
oculogyric	I-Problem
crisis	I-Problem
in	O
a	I-Background
16	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
girl	I-Background
with	I-Background
cystic	I-Problem
fibrosis	I-Problem
.	O

supported	O
by	O
a	O
subtherapeutic	I-Test
quinine	I-Test
level	I-Test
,	O
we	O
hypothesise	O
that	O
a	O
drug	O
interaction	O
with	O
phenytoin	I-Treatment
may	O
compromise	O
the	O
efficacy	I-Problem
of	I-Problem
quinine	I-Treatment
in	O
the	O
treatment	O
of	O
malaria	I-Problem
.	O

sporadic	I-Problem
rippling	I-Problem
muscle	I-Problem
disease	I-Problem
unmasked	O
by	O
simvastatin	I-Treatment
.	O

an	O
objective	I-Test
causality	I-Test
assessment	I-Test
by	O
use	O
of	O
the	O
naranjo	I-Test
probability	I-Test
scale	I-Test
revealed	O
that	O
ncse	I-Problem
due	O
to	O
ifosfamide	I-Treatment
was	O
probable	O
.	O

cis	I-Treatment
-	I-Treatment
retinoic	I-Treatment
acid	I-Treatment
(	I-Test
ra	I-Test
)	I-Test
may	O
further	O
increase	O
the	O
risk	O
of	O
developing	O
bmtn	I-Problem
.	O

he	I-Background
was	O
later	O
skin	O
tested	I-Test
to	O
confirm	O
allergy	I-Problem
to	O
mtx	I-Treatment
.	O

indolent	I-Problem
aspergillus	I-Problem
arthritis	I-Problem
complicating	O
fludarabine	I-Treatment
-	O
based	O
non	O
-	O
myeloablative	O
stem	O
cell	O
transplantation	O
.	O

a	O
case	O
of	O
acute	I-Problem
cardiomyopathy	I-Problem
and	I-Problem
pericarditis	I-Problem
associated	O
with	O
methylphenidate	I-Treatment
.	O

study	O
design	O
:	O
case	O
reports	O
are	O
presented	O
of	O
three	O
premature	I-Background
infants	I-Background
(	I-Background
mean	I-Background
gestational	I-Background
age	I-Background
27	I-Background
weeks	I-Background
)	I-Background
cared	I-Background
for	I-Background
in	I-Background
the	I-Background
intensive	I-Background
care	I-Background
nursery	I-Background
in	O
whom	O
clinically	I-Problem
significant	I-Problem
septal	I-Problem
hypertrophy	I-Problem
and	I-Problem
left	I-Problem
ventricular	I-Problem
outflow	I-Problem
tract	I-Problem
obstruction	I-Problem
developed	O
during	I-Treatment
dexamethasone	I-Treatment
treatment	I-Treatment
for	I-Treatment
bronchopulmonary	I-Problem
dysplasia	I-Problem
.	I-Problem

a	I-Background
case	I-Background
of	I-Background
the	I-Background
rett	I-Problem
syndrome	I-Problem
with	O
acute	I-Problem
encephalopathy	I-Problem
induced	O
during	O
calcium	I-Treatment
hopantenate	I-Treatment
treatment	I-Treatment
.	O

transient	I-Problem
serotonin	I-Problem
syndrome	I-Problem
caused	O
by	O
concurrent	I-Treatment
use	I-Treatment
of	I-Treatment
tramadol	I-Treatment
and	I-Treatment
selective	I-Treatment
serotonin	I-Treatment
reuptake	I-Treatment
inhibitor	I-Treatment
.	O

adverse	O
events	O
associated	O
with	O
ifn	I-Treatment
alfa	I-Treatment
-	I-Treatment
2b	I-Treatment
use	O
are	O
primarily	I-Problem
constitutional	I-Problem
symptoms	I-Problem
.	O

sustained	I-Treatment
-	I-Treatment
release	I-Treatment
procainamide	I-Treatment
-	O
induced	O
reversible	I-Problem
granulocytopenia	I-Problem
after	O
myocardial	O
infarction	O
.	O

we	O
describe	O
a	I-Background
patient	I-Background
with	I-Background
m4	I-Problem
aml	I-Problem
treated	O
with	O
standard	I-Treatment
chemotherapy	I-Treatment
followed	I-Treatment
by	I-Treatment
g	I-Treatment
-	I-Treatment
csf	I-Treatment
who	O
developed	O
marked	I-Problem
monocytosis	I-Problem
on	O
day	I-Other
8	I-Other
of	O
g	O
-	O
csf	O
therapy	O
.	O

esophageal	I-Problem
candidiasis	I-Problem
was	O
diagnosed	O
at	O
endoscopy	O
in	O
two	O
patients	I-Background
receiving	O
omeprazole	I-Treatment
therapy	I-Treatment
.	O

bisphosphonate	I-Treatment
induced	O
osteochemonecrosis	I-Problem
of	I-Problem
the	I-Problem
jaw	I-Problem
mimicking	O
a	O
tumour	O
.	O

objectives	O
:	O
to	O
describe	O
the	O
clinicopathologic	O
features	O
of	O
3	O
patients	I-Background
with	I-Background
cml	I-Problem
who	O
rapidly	O
progressed	O
from	I-Problem
chronic	I-Problem
phase	I-Problem
to	I-Problem
blast	I-Problem
crisis	I-Problem
while	O
taking	O
imatinib	I-Treatment
and	O
to	O
perform	O
a	O
review	O
of	O
the	O
literature	O
.	O

although	O
they	O
had	O
only	O
a	I-Problem
few	I-Problem
nodules	I-Problem
at	I-Background
diagnosis	I-Background
,	O
the	I-Problem
nodules	I-Problem
increased	I-Problem
in	I-Problem
number	I-Problem
and	I-Problem
size	I-Problem
3	I-Other
to	I-Other
4	I-Other
months	I-Other
after	O
the	O
start	O
of	O
methotrexate	I-Treatment
therapy	I-Treatment
in	O
both	O
patients	O
.	O

conclusions	O
:	O
among	O
the	O
many	O
presentations	O
of	O
ifosfamide	I-Treatment
neurotoxicity	I-Problem
,	O
clinicians	O
should	O
consider	O
ncse	I-Problem
as	O
a	O
possible	O
explanation	O
for	O
changes	I-Problem
in	I-Problem
consciousness	I-Problem
in	O
a	I-Background
patient	I-Background
receiving	O
this	O
agent	O
.	O

it	O
is	O
concluded	O
that	O
siadh	I-Problem
is	O
an	O
important	O
side	O
effect	O
of	O
lorcainide	I-Treatment
therapy	I-Treatment
.	O

hepatoxicity	I-Problem
is	O
a	O
rare	O
complication	O
of	O
srl	I-Treatment
therapy	I-Treatment
and	O
may	O
be	O
connected	O
with	O
some	O
diagnostic	O
and	O
/	O
or	O
therapeutic	O
problems	O
.	O

a	O
previous	I-Test
study	I-Test
of	O
patients	O
with	O
"	O
quinine	I-Treatment
-	O
associated	O
ttp	I-Problem
/	I-Problem
hus	I-Problem
"	O
found	O
that	O
adamts13	I-Problem
activities	I-Problem
were	I-Problem
not	I-Problem
abnormal	I-Problem
in	O
12	O
/	O
12	O
patients	I-Background
.	O

a	I-Background
teenage	I-Background
girl	I-Background
with	I-Background
crescentic	I-Problem
glomerulonephritis	I-Problem
had	O
antineutrophil	I-Problem
cytoplasmic	I-Test
antibody	I-Test
(	I-Problem
anca	I-Problem
)	I-Problem
detected	O
after	O
she	O
had	O
received	O
propylthiouracil	I-Treatment
(	I-Treatment
ptu	I-Treatment
)	I-Treatment
for	O
hyperthyroidism	I-Problem
without	I-Problem
cutaneous	I-Problem
vasculitis	I-Problem
.	O

digestive	I-Problem
hemorrhage	I-Problem
caused	I-Problem
by	I-Problem
a	I-Problem
meckel	I-Problem
'	I-Problem
s	I-Problem
diverticulum	I-Problem
in	O
a	O
metformin	I-Treatment
-	O
treated	O
patient	I-Background
:	O
is	O
there	O
any	O
connection	O
?	O

our	O
findings	O
reveal	O
that	O
even	O
in	O
patients	I-Background
without	I-Background
a	I-Background
history	I-Background
of	I-Background
seizures	I-Background
,	O
pregabalin	I-Treatment
can	O
cause	O
a	O
cortical	I-Problem
negative	I-Problem
myoclonus	I-Problem
.	O

we	O
describe	O
the	O
first	O
documented	O
case	O
of	O
azathioprine	I-Treatment
-	O
induced	O
severe	I-Problem
myelosuppression	I-Problem
due	O
to	O
thiopurine	O
methyltransferase	O
deficiency	O
in	O
autoimmune	O
liver	O
disease	O
.	O

we	O
report	O
five	O
cases	O
of	O
carboplatin	I-Treatment
(	I-Problem
cbdca	I-Problem
)	I-Problem
hypersensitivity	I-Problem
after	O
weekly	I-Other
low	I-Treatment
-	I-Treatment
dose	I-Treatment
paclitaxel	I-Treatment
(	I-Treatment
60	I-Treatment
mg	I-Treatment
/	I-Treatment
m2	I-Treatment
)	I-Treatment
/	I-Treatment
cbdca	I-Treatment
(	I-Treatment
area	I-Treatment
under	I-Treatment
the	I-Treatment
concentration	I-Treatment
curve	I-Treatment
=	I-Treatment
2	I-Treatment
)	I-Treatment
therapy	I-Treatment
in	O
patients	I-Background
with	I-Background
recurrent	I-Problem
ovarian	I-Problem
cancer	I-Problem
receiving	O
multiple	I-Treatment
platinum	I-Treatment
-	I-Treatment
based	I-Treatment
chemotherapy	I-Treatment
.	O

the	I-Background
patient	I-Background
was	O
placed	O
on	O
omeprazole	I-Treatment
after	O
his	O
first	O
cycle	O
of	O
high	I-Treatment
-	I-Treatment
dose	I-Treatment
methotrexate	I-Treatment
for	O
stress	I-Problem
ulcer	I-Problem
prophylaxis	O
,	O
and	O
it	O
was	O
discontinued	O
before	O
the	O
start	O
of	O
the	O
first	O
day	O
of	O
the	O
patient	O
'	O
s	O
second	O
round	O
of	O
high	O
-	O
dose	O
methotrexate	I-Treatment
.	O

because	O
the	I-Background
patient	I-Background
had	O
been	O
taking	O
lovastatin	I-Treatment
for	O
the	O
past	O
12	I-Other
years	I-Other
,	O
the	O
possibility	O
that	O
the	O
rhabdomyolysis	I-Problem
may	O
have	O
been	O
caused	O
by	O
a	O
drug	O
interaction	O
between	O
lovastatin	I-Treatment
and	O
a	O
concomitant	O
drug	O
was	O
evaluated	O
.	O

ibopamine	I-Treatment
-	O
induced	O
reversible	O
leukopenia	I-Problem
during	O
treatment	O
for	O
congestive	I-Problem
heart	I-Problem
failure	I-Problem
.	O

a	I-Background
71	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
man	I-Background
with	I-Background
paroxysmal	I-Problem
atrial	I-Problem
fibrillation	I-Problem
who	I-Background
had	I-Background
a	I-Background
previous	I-Background
anterior	I-Problem
myocardial	I-Problem
infarction	I-Problem
exhibited	O
granulocytopenia	I-Problem
8	I-Other
days	I-Other
following	O
the	O
administration	O
of	O
oral	I-Treatment
sustained	I-Treatment
-	I-Treatment
release	I-Treatment
procainamide	I-Treatment
(	I-Treatment
750	I-Treatment
mg	I-Treatment
/	I-Treatment
day	I-Treatment
)	I-Treatment
.	O

clinicians	O
should	O
be	O
cognizant	O
of	O
this	O
possibility	O
and	O
consider	O
a	O
diagnosis	O
of	O
hdas	I-Problem
in	O
patients	I-Background
with	O
ongoing	O
thrombosis	I-Problem
who	O
are	O
receiving	O
heparin	I-Treatment
therapy	O
.	O

rifampin	I-Treatment
-	O
induced	O
hypothyroidism	I-Problem
without	I-Problem
underlying	I-Problem
thyroid	I-Problem
disease	I-Problem
.	O

paradoxical	I-Problem
precipitation	I-Problem
of	I-Problem
tonic	I-Problem
seizures	I-Problem
by	O
lorazepam	I-Treatment
in	O
a	O
child	I-Background
with	I-Background
atypical	I-Background
absence	I-Problem
seizures	I-Problem
.	O

peculiar	I-Problem
nail	I-Problem
-	I-Problem
changes	I-Problem
in	O
a	I-Background
70	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
woman	I-Background
with	I-Background
rheumatoid	I-Problem
arthritis	I-Problem
occurring	O
after	O
approximately	O
1	I-Other
year	I-Other
of	O
penicillamine	I-Treatment
treatment	O
are	O
described	O
.	O

cutaneous	I-Problem
vasculitis	I-Problem
secondary	O
to	O
ramipril	I-Treatment
.	O

multiple	O
mechanisms	O
for	O
ciprofloxacin	I-Treatment
-	O
induced	O
nephrotoxicity	I-Problem
have	O
been	O
proposed	O
.	O

pregabalin	I-Treatment
was	I-Treatment
added	I-Treatment
to	I-Treatment
clozapine	I-Treatment
in	O
2	O
patients	I-Background
with	I-Background
schizophrenia	I-Problem
,	I-Background
who	I-Background
both	I-Background
suffered	I-Background
from	I-Background
severe	I-Background
anxiety	I-Problem
symptoms	I-Problem
.	O

severe	I-Problem
hyperkalemia	I-Problem
as	O
a	O
complication	O
of	O
timolol	I-Treatment
,	O
a	I-Treatment
topically	I-Treatment
applied	I-Treatment
beta	I-Treatment
-	I-Treatment
adrenergic	I-Treatment
antagonist	I-Treatment
.	O

amphotericin	I-Treatment
b	I-Treatment
overdose	I-Treatment
in	O
pediatric	I-Background
patients	I-Background
with	O
associated	O
cardiac	I-Problem
arrest	I-Problem
.	O

of	O
particular	O
interest	O
is	O
that	O
toxicity	I-Problem
only	O
occurred	O
during	O
the	O
second	I-Treatment
course	I-Treatment
of	I-Treatment
fla	I-Treatment
and	I-Treatment
sixth	I-Other
course	I-Other
of	I-Treatment
ara	I-Treatment
-	I-Treatment
c	I-Treatment
containing	I-Treatment
chemotherapy	I-Treatment
.	O

the	O
literature	I-Test
search	I-Test
found	O
12	O
cases	I-Background
of	O
radiation	I-Problem
recall	I-Problem
caused	O
by	O
gemcitabine	I-Treatment
.	O

two	O
heroin	I-Problem
addicts	I-Problem
,	I-Background
aged	I-Background
34	I-Background
and	I-Background
19	I-Background
years	I-Background
,	O
developed	O
ballistic	I-Problem
movements	I-Problem
after	O
intravenous	I-Treatment
heroin	I-Treatment
overdose	I-Treatment
.	O

successful	O
challenge	O
with	O
clozapine	I-Treatment
in	O
a	O
history	O
of	O
eosinophilia	I-Problem
.	O

case	O
summary	O
:	O
a	I-Background
57	I-Background
-	I-Background
year	I-Background
-	I-Background
old	I-Background
female	I-Background
with	I-Background
cardiomyopathy	I-Problem
and	I-Background
"	I-Problem
sulfa	I-Problem
"	I-Problem
(	I-Problem
trimethoprim	I-Problem
/	I-Problem
sulfamethoxazole	I-Problem
)	I-Problem
allergy	I-Problem
documented	O
as	O
pancreatitis	I-Problem
presented	O
with	O
symptoms	O
consistent	O
with	O
pancreatitis	O
after	O
use	O
of	O
furosemide	I-Treatment
.	O

acute	I-Problem
intravascular	I-Problem
hemolysis	I-Problem
developed	O
when	O
a	I-Background
diabetic	I-Problem
patient	I-Background
,	O
previously	O
treated	O
with	O
glyburide	O
,	O
was	O
started	O
on	O
another	O
oral	O
sulfonylurea	O
drug	O
,	O
chlorpropamide	I-Treatment
.	O

intravitreal	I-Treatment
triamcinolone	I-Treatment
may	O
have	O
had	O
an	O
influence	O
on	O
the	O
exacerbation	I-Problem
of	I-Problem
retinochoroiditis	I-Problem
in	I-Problem
the	I-Problem
posterior	I-Problem
pole	I-Problem
of	O
the	I-Background
patient	I-Background
.	O

we	O
evaluated	O
a	O
patient	I-Background
who	O
developed	O
a	O
psychotic	I-Problem
disorder	I-Problem
after	O
4	I-Other
months	I-Other
of	I-Treatment
isoniazid	I-Treatment
prophylaxis	I-Treatment
for	O
a	O
positive	O
tuberculosis	I-Problem
tine	O
test	O
.	O

